Comparison	O
of	O
the	O
backbone	O
dynamics	O
of	O
the	O
apo	O
-	O
and	O
holo	O
-	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
biotin	B-PRGE
carboxyl	I-PRGE
carrier	I-PRGE
subunit	I-PRGE
of	O
Escherichia	O
coli	O
acetyl	O
-	O
CoA	O
carboxylase	O
.	O

The	O
biotin	B-PRGE
carboxyl	I-PRGE
carrier	I-PRGE
protein	I-PRGE
(	O
BCCP	B-PRGE
)	O
is	O
a	O
subunit	O
of	O
acetyl	O
-	O
CoA	O
carboxylase	O
,	O
a	O
biotin	O
-	O
dependent	O
enzyme	O
that	O
catalyzes	O
the	O
first	O
committed	O
step	O
of	O
fatty	O
acid	O
biosynthesis	O
.	O

In	O
its	O
functional	O
cycle	O
,	O
this	O
protein	O
engages	O
in	O
heterologous	O
protein	O
-	O
protein	O
interactions	O
with	O
three	O
distinct	O
partners	O
,	O
depending	O
on	O
its	O
state	O
of	O
post	O
-	O
translational	O
modification	O
.	O

Apo	O
-	O
BCCP	B-PRGE
interacts	O
specifically	O
with	O
the	O
biotin	O
holoenzyme	O
synthetase	O
,	O
BirA	B-PRGE
,	O
which	O
results	O
in	O
the	O
post	O
-	O
translational	O
attachment	O
of	O
biotin	O
to	O
a	O
single	O
lysine	O
residue	O
on	O
BCCP	B-PRGE
.	O

Holo	O
-	O
BCCP	B-PRGE
then	O
interacts	O
with	O
the	O
biotin	B-PRGE
carboxylase	I-PRGE
subunit	I-PRGE
of	I-PRGE
acetyl	I-PRGE
-	I-PRGE
CoA	I-PRGE
carboxylase	I-PRGE
,	O
which	O
leads	O
to	O
the	O
addition	O
of	O
the	O
carboxylate	O
group	O
of	O
bicarbonate	O
to	O
biotin	O
.	O

Finally	O
,	O
the	O
carboxy	O
-	O
biotinylated	O
form	O
of	O
BCCP	B-PRGE
interacts	O
with	O
transcarboxylase	B-PRGE
in	O
the	O
transfer	O
of	O
the	O
carboxylate	O
to	O
acetyl	O
-	O
CoA	O
to	O
form	O
malonyl	O
-	O
CoA	O
.	O

The	O
determinants	O
of	O
protein	O
-	O
protein	O
interaction	O
specificity	O
in	O
this	O
system	O
are	O
unknown	O
.	O

The	O
NMR	O
solution	O
structure	O
of	O
the	O
unbiotinylated	O
form	O
of	O
an	O
87	O
residue	O
C	O
-	O
terminal	O
domain	O
fragment	O
(	O
residue	O
70	O
-	O
156	O
)	O
of	O
BCCP	B-PRGE
(	O
holoBCCP87	B-PRGE
)	O
and	O
the	O
crystal	O
structure	O
of	O
the	O
biotinylated	O
form	O
of	O
a	O
C	O
-	O
terminal	O
fragment	O
(	O
residue	O
77	O
-	O
156	O
)	O
of	O
BCCP	B-PRGE
from	O
Escherichia	O
coli	O
acetyl	O
-	O
CoA	O
carboxylase	O
have	O
previously	O
been	O
determined	O
.	O

Comparative	O
analysis	O
of	O
these	O
structures	O
provided	O
evidence	O
for	O
small	O
,	O
localized	O
conformational	O
changes	O
in	O
the	O
biotin	O
-	O
binding	O
region	O
upon	O
biotinylation	O
of	O
the	O
protein	O
.	O

These	O
structural	O
changes	O
may	O
be	O
important	O
for	O
regulating	O
specific	O
protein	O
-	O
protein	O
interactions	O
.	O

Since	O
the	O
dynamic	O
properties	O
of	O
proteins	O
are	O
correlated	O
with	O
local	O
structural	O
environments	O
,	O
we	O
have	O
determined	O
the	O
relaxation	O
parameters	O
of	O
the	O
backbone	O
15N	O
nuclear	O
spins	O
of	O
holoBCCP87	B-PRGE
,	O
and	O
compared	O
these	O
with	O
the	O
data	O
obtained	O
for	O
the	O
apo	O
protein	O
.	O

The	O
results	O
indicate	O
that	O
upon	O
biotinylation	O
,	O
the	O
inherent	O
mobility	O
of	O
the	O
biotin	O
-	O
binding	O
region	O
and	O
the	O
protruding	O
thumb	O
,	O
with	O
which	O
the	O
biotin	O
group	O
interacts	O
in	O
the	O
holo	O
protein	O
,	O
are	O
significantly	O
reduced	O
.	O

Correlation	O
of	O
activity	O
regulation	O
and	O
substrate	O
recognition	O
of	O
the	O
ADP	O
-	O
ribosyltransferase	O
that	O
regulates	O
nitrogenase	O
activity	O
in	O
Rhodospirillum	O
rubrum	O
.	O

In	O
Rhodospirillum	O
rubrum	O
,	O
nitrogenase	O
activity	O
is	O
regulated	O
posttranslationally	O
through	O
the	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-PRGE
reductase	I-PRGE
by	O
dinitrogenase	B-PRGE
reductase	I-PRGE
ADP	I-PRGE
-	I-PRGE
ribosyltransferase	I-PRGE
(	O
DRAT	B-PRGE
)	O
.	O

Several	O
DRAT	B-PRGE
variants	O
that	O
are	O
altered	O
both	O
in	O
the	O
posttranslational	O
regulation	O
of	O
DRAT	B-PRGE
activity	O
and	O
in	O
the	O
ability	O
to	O
recognize	O
variants	O
of	O
dinitrogenase	B-PRGE
reductase	I-PRGE
have	O
been	O
found	O
.	O

This	O
correlation	O
suggests	O
that	O
these	O
two	O
properties	O
are	O
biochemically	O
connected	O
.	O

Mass	O
spectral	O
study	O
of	O
polymorphism	O
of	O
the	O
apolipoproteins	O
of	O
very	O
low	O
density	O
lipoprotein	O
.	O

New	O
isoforms	O
of	O
apolipoprotein	B-PRGE
(	I-PRGE
apo	I-PRGE
)	I-PRGE
C	I-PRGE
-	I-PRGE
I	I-PRGE
and	O
apoC	B-PRGE
-	I-PRGE
III	I-PRGE
have	O
been	O
detected	O
in	O
delipidated	O
fractions	O
from	O
very	O
low	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
(	O
MALDI	O
)	O
and	O
electrospray	O
ionization	O
(	O
ESI	O
)	O
mass	O
spectrometry	O
(	O
MS	O
)	O
.	O

The	O
cleavage	O
sites	O
of	O
truncated	O
apoC	B-PRGE
-	I-PRGE
III	I-PRGE
isoforms	O
have	O
also	O
been	O
identified	O
.	O

The	O
VLDL	O
fractions	O
were	O
isolated	O
by	O
fixed	O
-	O
angle	O
single	O
-	O
spin	O
ultracentrifugation	O
using	O
a	O
self	O
-	O
generating	O
sucrose	O
density	O
gradient	O
and	O
delipidated	O
using	O
a	O
newly	O
developed	O
C18	O
solid	O
phase	O
extraction	O
protocol	O
.	O

Fifteen	O
apoC	O
isoforms	O
and	O
apoE	B-PRGE
were	O
identified	O
in	O
the	O
MALDI	O
spectra	O
and	O
the	O
existence	O
of	O
the	O
more	O
abundant	O
species	O
was	O
verified	O
by	O
ESI	O
-	O
MS	O
.	O

The	O
relative	O
intensities	O
of	O
the	O
apoCs	O
are	O
closely	O
correlated	O
in	O
three	O
normolipidemic	O
subjects	O
.	O

A	O
fourth	O
subject	O
with	O
type	O
V	O
hyperlipidemia	O
exhibited	O
an	O
elevated	O
apoC	B-PRGE
-	I-PRGE
III	I-PRGE
level	O
and	O
a	O
suppressed	O
level	O
of	O
the	O
newly	O
discovered	O
truncated	O
apoC	B-PRGE
-	I-PRGE
I	I-PRGE
isoform	O
.	O

ApoC	B-PRGE
-	I-PRGE
II	I-PRGE
was	O
found	O
to	O
be	O
particularly	O
sensitive	O
to	O
in	O
vitro	O
oxidation	O
.	O

The	O
dynamic	O
range	O
and	O
specificity	O
of	O
the	O
MALDI	O
assay	O
shows	O
that	O
the	O
complete	O
apoC	O
isoform	O
profile	O
and	O
apoE	B-PRGE
phenotype	O
can	O
be	O
obtained	O
in	O
a	O
single	O
measurement	O
from	O
the	O
delipidated	O
VLDL	O
fraction	O
.	O

Evidence	O
that	O
halogenated	O
furanones	O
from	O
Delisea	O
pulchra	O
inhibit	O
acylated	O
homoserine	O
lactone	O
(	O
AHL	O
)	O
-	O
mediated	O
gene	O
expression	O
by	O
displacing	O
the	O
AHL	O
signal	O
from	O
its	O
receptor	O
protein	O
.	O

Acylated	O
homoserine	O
lactone	O
(	O
AHL	O
)	O
-	O
mediated	O
gene	O
expression	O
controls	O
phenotypes	O
involved	O
in	O
colonization	O
,	O
often	O
specifically	O
of	O
higher	O
organisms	O
,	O
in	O
both	O
marine	O
and	O
terrestrial	O
environments	O
.	O

The	O
marine	O
red	O
alga	O
Delisea	O
pulchra	O
produces	O
halogenated	O
furanones	O
which	O
resemble	O
AHLs	O
structurally	O
and	O
show	O
inhibitory	O
activity	O
at	O
ecologically	O
realistic	O
concentrations	O
in	O
AHL	O
bioassays	O
.	O

Evidence	O
is	O
presented	O
that	O
halogenated	O
furanones	O
displace	O
tritiated	O
OHHL	O
[	O
N	O
-	O
3	O
-	O
(	O
oxohexanoyl	O
)	O
-	O
L	O
-	O
homoserine	O
lactone	O
]	O
from	O
Escherichia	O
coli	O
cells	O
overproducing	O
LuxR	B-PRGE
with	O
potencies	O
corresponding	O
to	O
their	O
respective	O
inhibitory	O
activities	O
in	O
an	O
AHL	O
-	O
regulated	O
bioluminescence	O
assay	O
,	O
indicating	O
that	O
this	O
is	O
the	O
mechanism	O
by	O
which	O
furanones	O
inhibit	O
AHL	O
-	O
dependent	O
phenotypes	O
.	O

Alternative	O
mechanisms	O
for	O
this	O
phenomenon	O
are	O
also	O
addressed	O
.	O

General	O
metabolic	O
disruption	O
was	O
assessed	O
with	O
two	O
-	O
dimensional	O
PAGE	O
,	O
revealing	O
limited	O
non	O
-	O
AHL	O
-	O
related	O
effects	O
.	O

A	O
direct	O
chemical	O
interaction	O
between	O
the	O
algal	O
compounds	O
and	O
AHLs	O
,	O
as	O
monitored	O
by	O
1H	O
NMR	O
spectroscopy	O
,	O
was	O
shown	O
not	O
to	O
occur	O
in	O
vitro	O
.	O

These	O
results	O
support	O
the	O
contention	O
that	O
furanones	O
,	O
at	O
the	O
concentrations	O
produced	O
by	O
the	O
alga	O
,	O
can	O
control	O
bacterial	O
colonization	O
of	O
surfaces	O
by	O
specifically	O
interfering	O
with	O
AHL	O
-	O
mediated	O
gene	O
expression	O
at	O
the	O
level	O
of	O
the	O
LuxR	B-PRGE
protein	O
.	O

Activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
by	O
oxidized	O
LDL	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
:	O
mediation	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
and	O
association	O
with	O
oxidized	O
LDL	O
-	O
induced	O
cytotoxicity	O
.	O

Oxidized	O
low	O
-	O
density	O
lipoproteins	O
(	O
oxLDL	O
)	O
have	O
been	O
shown	O
to	O
play	O
a	O
crucial	O
role	O
in	O
atherosclerosis	O
,	O
but	O
the	O
underlying	O
molecular	O
mechanisms	O
have	O
not	O
been	O
fully	O
understood	O
.	O

The	O
present	O
study	O
showed	O
that	O
oxLDL	O
strongly	O
evoked	O
phosphorylation	O
and	O
activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
in	O
rat	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
in	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manners	O
,	O
reaching	O
the	O
maximal	O
activation	O
at	O
100	O
microg	O
/	O
mL	O
within	O
5	O
minutes	O
.	O

The	O
results	O
from	O
immunofluorescence	O
staining	O
also	O
revealed	O
that	O
p38	O
MAPK	O
was	O
activated	O
by	O
oxLDL	O
in	O
5	O
minutes	O
,	O
and	O
the	O
activated	O
p38	O
MAPK	O
was	O
translocated	O
from	O
cytoplasm	O
to	O
nucleus	O
of	O
VSMCs	O
in	O
15	O
minutes	O
.	O

Activation	O
of	O
p38	O
MAPK	O
by	O
oxLDL	O
was	O
apparently	O
not	O
mediated	O
by	O
their	O
classical	O
scavenger	O
receptors	O
and	O
was	O
not	O
affected	O
by	O
tyrosine	O
kinase	O
inhibitors	O
.	O

However	O
,	O
activation	O
of	O
p38	O
MAPK	O
was	O
effectively	O
blocked	O
by	O
pretreatment	O
with	O
pertussis	O
toxin	O
and	O
was	O
significantly	O
reduced	O
by	O
phospholipase	O
C	O
inhibitor	O
U	O
-	O
73122	O
.	O

OxLDL	O
also	O
inhibited	O
forskolin	O
-	O
stimulated	O
cAMP	O
accumulation	O
and	O
increased	O
inositol	O
phosphate	O
formation	O
.	O

More	O
interestingly	O
,	O
inhibition	O
of	O
p38	O
MAPK	O
by	O
its	O
specific	O
inhibitor	O
SB203580	O
significantly	O
blocked	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
(	O
increased	O
leakage	O
of	O
cytoplasmic	O
lactate	O
dehydrogenase	O
to	O
the	O
culture	O
medium	O
,	O
reduced	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
and	O
attenuated	O
mitochondrial	O
metabolism	O
of	O
tetrazolium	O
salt	O
,	O
(	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
5	O
-	O
(	O
3	O
-	O
carboxymethoxyphenyl	O
)	O
-	O
2	O
-	O
(	O
4	O
-	O
s	O
ulfophenyl	O
)	O
-	O
2H	O
-	O
tetrazolium	O
)	O
,	O
MTS	O
)	O
in	O
VSMCs	O
,	O
and	O
pretreatment	O
with	O
pertussis	O
toxin	O
also	O
inhibited	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
.	O

Taken	O
together	O
,	O
our	O
data	O
clearly	O
demonstrated	O
that	O
oxLDL	O
effectively	O
activated	O
p38	O
MAPK	O
in	O
VSMCs	O
,	O
which	O
was	O
likely	O
mediated	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
,	O
and	O
the	O
p38	O
activation	O
was	O
functionally	O
associated	O
with	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
in	O
VSMCs	O
.	O

Characterization	O
of	O
residues	O
in	O
human	O
IgE	O
and	O
IgG	O
binding	O
site	O
by	O
chemical	O
modification	O
of	O
ovomucoid	O
third	O
domain	O
.	O

Chemical	O
modification	O
of	O
ovomucoid	O
third	O
domain	O
(	O
DIII	O
)	O
has	O
been	O
conducted	O
to	O
characterize	O
the	O
binding	O
site	O
residues	O
that	O
determine	O
antigenecity	O
and	O
allergenecity	O
of	O
DIII	O
.	O

Nitration	O
of	O
Tyr	O
,	O
ethoxyformylation	O
of	O
His	O
and	O
succinylation	O
of	O
Lys	O
residues	O
led	O
to	O
a	O
decrease	O
of	O
alpha	O
-	O
helix	O
content	O
of	O
DIII	O
.	O

Modification	O
of	O
His	O
,	O
Tyr	O
,	O
Glu	O
,	O
Asp	O
and	O
Lys	O
residues	O
on	O
DIII	O
resulted	O
in	O
a	O
reduction	O
of	O
human	O
IgG	O
binding	O
activity	O
,	O
but	O
little	O
effect	O
on	O
IgE	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
hydrophilic	O
residues	O
appear	O
to	O
be	O
more	O
critical	O
for	O
human	O
IgG	O
binding	O
site	O
,	O
whereas	O
hydrophobic	O
residues	O
may	O
be	O
more	O
important	O
for	O
IgG	O
binding	O
site	O
.	O

A	O
new	O
30	O
-	O
kDa	O
ubiquitin	B-PRGE
-	O
related	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
hydrolase	O
from	O
bovine	O
brain	O
.	O

SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
functioning	O
as	O
an	O
important	O
reversible	O
protein	O
modifier	O
.	O

To	O
date	O
there	O
is	O
no	O
report	O
on	O
a	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
hydrolase	O
/	O
isopeptidase	O
catalyzing	O
the	O
release	O
of	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
from	O
its	O
precursor	O
or	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
ligated	O
proteins	O
in	O
mammalian	O
tissues	O
.	O

Here	O
we	O
found	O
multiple	O
activities	O
that	O
cleave	O
the	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
moiety	O
from	O
two	O
model	O
substrates	O
,	O
(	O
125	O
)	O
I	O
-	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
alphaNH	O
-	O
HSTVGSMHISPPEPESEEEEEHYC	O
and	O
/	O
or	O
GST	B-PRGE
-	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
(	O
35	O
)	O
S	O
-	O
RanGAP1	B-PRGE
conjugate	O
,	O
in	O
bovine	O
brain	O
extracts	O
.	O

Of	O
them	O
,	O
a	O
major	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
C	O
-	O
terminal	O
hydrolase	O
had	O
been	O
partially	O
purified	O
by	O
successive	O
chromatographic	O
operations	O
.	O

The	O
enzyme	O
had	O
the	O
ability	O
to	O
cleave	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
not	O
only	O
from	O
its	O
precursor	O
but	O
also	O
from	O
a	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
ligated	O
RanGAP1	B-PRGE
but	O
did	O
not	O
exhibit	O
any	O
significant	O
cleavage	O
of	O
the	O
ubiquitin	B-PRGE
-	O
and	O
NEDD8	B-PRGE
-	O
precursor	O
.	O

The	O
activity	O
of	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
hydrolase	O
was	O
almost	O
completely	O
inhibited	O
by	O
N	O
-	O
ethylmaleimide	O
,	O
but	O
not	O
by	O
phenylmethanesulfonyl	O
fluoride	O
,	O
EDTA	O
,	O
and	O
ubiquitin	B-PRGE
-	O
aldehyde	O
known	O
as	O
a	O
potent	O
inhibitor	O
of	O
deubiquitinylating	O
enzymes	O
.	O

Intriguingly	O
,	O
the	O
apparent	O
molecular	O
mass	O
of	O
the	O
isolated	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
hydrolase	O
was	O
approximately	O
30	O
kDa	O
,	O
which	O
is	O
significantly	O
smaller	O
than	O
the	O
recently	O
identified	O
yeast	O
Smt3	B-PRGE
/	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
specific	O
protease	O
Ulp1	B-PRGE
.	O

These	O
results	O
indicate	O
that	O
there	O
are	O
multiple	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
hydrolase	O
/	O
isopeptidases	O
in	O
mammalian	O
cells	O
and	O
that	O
the	O
30	O
-	O
kDa	O
small	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
hydrolase	O
plays	O
a	O
central	O
role	O
in	O
processing	O
of	O
the	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
precursor	O
.	O

Cell	O
cycle	O
-	O
regulated	O
attachment	O
of	O
the	O
ubiquitin	B-PRGE
-	O
related	O
protein	O
SUMO	O
to	O
the	O
yeast	O
septins	O
.	O

SUMO	O
is	O
a	O
ubiquitin	B-PRGE
-	O
related	O
protein	O
that	O
functions	O
as	O
a	O
posttranslational	O
modification	O
on	O
other	O
proteins	O
.	O

SUMO	O
conjugation	O
is	O
essential	O
for	O
viability	O
in	O
Saccharomyces	O
cerevisiae	O
and	O
is	O
required	O
for	O
entry	O
into	O
mitosis	O
.	O

We	O
have	O
found	O
that	O
SUMO	O
is	O
attached	O
to	O
the	O
septins	B-PRGE
Cdc3	I-PRGE
,	O
Cdc11	B-PRGE
,	O
and	O
Shs1	B-PRGE
/	O
Sep7	B-PRGE
specifically	O
during	O
mitosis	O
,	O
with	O
conjugates	O
appearing	O
shortly	O
before	O
anaphase	O
onset	O
and	O
disappearing	O
abruptly	O
at	O
cytokinesis	O
.	O

Septins	O
are	O
components	O
of	O
a	O
belt	O
of	O
10	O
-	O
nm	O
filaments	O
encircling	O
the	O
yeast	O
bud	O
neck	O
.	O

Intriguingly	O
,	O
only	O
septins	O
on	O
the	O
mother	O
cell	O
side	O
of	O
the	O
bud	O
neck	O
are	O
sumoylated	O
.	O

We	O
have	O
identified	O
four	O
major	O
SUMO	O
attachment	O
-	O
site	O
lysine	O
residues	O
in	O
Cdc3	B-PRGE
,	O
one	O
in	O
Cdc11	B-PRGE
,	O
and	O
two	O
in	O
Shs1	B-PRGE
,	O
all	O
within	O
the	O
consensus	O
sequence	O
(	O
IVL	O
)	O
KX	O
(	O
ED	O
)	O
.	O

Mutating	O
these	O
sites	O
eliminated	O
the	O
vast	O
majority	O
of	O
bud	O
neck	O
-	O
associated	O
SUMO	O
,	O
as	O
well	O
as	O
the	O
bulk	O
of	O
total	O
SUMO	O
conjugates	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
-	O
arrested	O
cells	O
,	O
indicating	O
that	O
sumoylated	O
septins	O
are	O
the	O
most	O
abundant	O
SUMO	O
conjugates	O
at	O
this	O
point	O
in	O
the	O
cell	O
cycle	O
.	O

This	O
mutant	O
has	O
a	O
striking	O
defect	O
in	O
disassembly	O
of	O
septin	O
rings	O
,	O
resulting	O
in	O
accumulation	O
of	O
septin	O
rings	O
marking	O
previous	O
division	O
sites	O
.	O

Thus	O
,	O
SUMO	O
conjugation	O
plays	O
a	O
role	O
in	O
regulating	O
septin	O
ring	O
dynamics	O
during	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
a	O
prenylation	O
-	O
deficient	O
Rab4	B-PRGE
interferes	O
with	O
propagation	O
of	O
insulin	B-PRGE
signaling	O
through	O
insulin	B-PRGE
receptor	I-PRGE
substrate	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Rab	O
proteins	O
are	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
the	O
Ras	O
superfamily	O
that	O
function	O
in	O
the	O
regulation	O
of	O
vesicle	O
transport	O
processes	O
.	O

The	O
Rab4	B-PRGE
isoform	O
has	O
been	O
implicated	O
in	O
insulin	B-PRGE
action	O
.	O

For	O
instance	O
,	O
overexpression	O
of	O
a	O
prenylation	O
-	O
deficient	O
form	O
of	O
Rab4	B-PRGE
has	O
been	O
shown	O
to	O
inhibit	O
insulin	B-PRGE
-	O
dependent	O
GLUT4	B-PRGE
translocation	O
.	O

Other	O
steps	O
affected	O
by	O
Rab4	B-PRGE
in	O
the	O
cascade	O
of	O
events	O
resulting	O
from	O
insulin	B-PRGE
receptor	I-PRGE
activation	O
have	O
not	O
been	O
elucidated	O
.	O

In	O
the	O
present	O
studies	O
,	O
we	O
measured	O
effects	O
on	O
insulin	B-PRGE
-	O
signaling	O
proteins	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
transiently	O
expressing	O
cytoplasmic	O
forms	O
of	O
Rab4	B-PRGE
and	O
Rab5	B-PRGE
.	O

Expression	O
of	O
a	O
mutant	O
Rab4	B-PRGE
lacking	O
a	O
prenylation	O
site	O
resulted	O
in	O
reduced	O
insulin	B-PRGE
-	O
dependent	O
phosphorylation	O
ofcytoplasmic	O
and	O
internal	O
membrane	O
-	O
associated	O
insulin	B-PRGE
receptor	I-PRGE
substrate	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
leading	O
to	O
decreased	O
insulin	B-PRGE
receptor	I-PRGE
substrate	I-PRGE
-	I-PRGE
1	I-PRGE
-	O
associated	O
phosphatidylinositol	O
3	O
'	O
-	O
OH	O
kinase	O
activation	O
and	O
decreased	O
Akt	O
activation	O
.	O

These	O
effects	O
were	O
not	O
observed	O
upon	O
introduction	O
of	O
a	O
similar	O
mutant	O
form	O
of	O
Rab5	B-PRGE
.	O

These	O
data	O
indicate	O
that	O
Rab4	B-PRGE
or	O
a	O
Rab4	B-PRGE
-	O
associated	O
protein	O
is	O
involved	O
at	O
one	O
or	O
more	O
steps	O
in	O
propagating	O
the	O
insulin	B-PRGE
signal	O
,	O
in	O
addition	O
to	O
any	O
role	O
it	O
may	O
play	O
in	O
the	O
regulation	O
of	O
GLUT4	B-PRGE
vesicle	O
translocation	O
.	O

Our	O
results	O
support	O
models	O
of	O
insulin	B-PRGE
signaling	O
in	O
which	O
regulation	O
of	O
internal	O
membrane	O
trafficking	O
plays	O
a	O
role	O
in	O
transduction	O
of	O
the	O
insulin	B-PRGE
signal	O
.	O

Structural	O
determinants	O
of	O
post	O
-	O
translational	O
modification	O
and	O
catalytic	O
specificity	O
for	O
the	O
lipoyl	O
domains	O
of	O
the	O
pyruvate	O
dehydrogenase	O
multienzyme	O
complex	O
of	O
Escherichia	O
coli	O
.	O

The	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	O
acyltransferase	O
(	O
E2p	B-PRGE
,	O
E2o	B-PRGE
)	O
components	O
of	O
the	O
pyruvate	O
and	O
2	O
-	O
oxoglutarate	O
dehydrogenase	O
multienzyme	O
complexes	O
are	O
specifically	O
recognised	O
by	O
their	O
cognate	O
2	O
-	O
oxo	O
acid	O
decarboxylase	O
(	O
E1p	B-PRGE
,	O
E1o	B-PRGE
)	O
.	O

A	O
prominent	O
surface	O
loop	O
links	O
the	O
first	O
and	O
second	O
beta	O
-	O
strands	O
in	O
all	O
lipoyl	O
domains	O
,	O
close	O
in	O
space	O
to	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
.	O

This	O
loop	O
was	O
subjected	O
to	O
various	O
modifications	O
by	O
directed	O
mutagenesis	O
of	O
a	O
sub	O
-	O
gene	O
encoding	O
a	O
lipoyl	O
domain	O
of	O
Escherichia	O
coli	O
E2p	B-PRGE
.	O

Deletion	O
of	O
the	O
loop	O
(	O
four	O
residues	O
)	O
rendered	O
the	O
domain	O
incapable	O
of	O
reductive	O
acetylation	O
by	O
E	O
.	O
coli	O
E1p	B-PRGE
in	O
the	O
presence	O
of	O
pyruvate	O
,	O
but	O
insertion	O
of	O
a	O
new	O
loop	O
(	O
six	O
residues	O
)	O
corresponding	O
to	O
that	O
in	O
the	O
E2o	B-PRGE
lipoyl	O
domain	O
partly	O
restored	O
this	O
ability	O
,	O
albeit	O
with	O
a	O
much	O
lower	O
rate	O
.	O

However	O
,	O
the	O
modified	O
domain	O
remained	O
unable	O
to	O
undergo	O
reductive	O
succinylation	O
by	O
E1o	B-PRGE
in	O
the	O
presence	O
of	O
2	O
-	O
oxoglutarate	O
.	O

Additional	O
exchange	O
of	O
the	O
two	O
residues	O
on	O
the	O
C	O
-	O
terminal	O
side	O
of	O
the	O
loop	O
(	O
V14A	O
,	O
E15T	O
)	O
had	O
no	O
effect	O
.	O

Insertion	O
of	O
a	O
different	O
four	O
-	O
residue	O
loop	O
also	O
restored	O
a	O
limited	O
ability	O
to	O
undergo	O
reductive	O
acetylation	O
,	O
but	O
still	O
significantly	O
less	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
domain	O
.	O

Exchanging	O
the	O
residue	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
in	O
the	O
E2p	B-PRGE
and	O
E2o	B-PRGE
domains	O
(	O
G39T	O
)	O
,	O
both	O
singly	O
and	O
in	O
conjunction	O
with	O
the	O
loop	O
exchange	O
,	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
the	O
E2p	B-PRGE
domain	O
to	O
be	O
reductively	O
acetylated	O
but	O
did	O
confer	O
a	O
slight	O
increase	O
in	O
susceptibility	O
to	O
reductive	O
succinylation	O
.	O

All	O
mutant	O
E2p	B-PRGE
domains	O
,	O
apart	O
from	O
that	O
with	O
the	O
loop	O
deletion	O
(	O
LD	O
)	O
,	O
were	O
readily	O
lipoylated	O
in	O
vitro	O
by	O
E	O
.	O
coli	O
lipoate	B-PRGE
protein	I-PRGE
ligase	I-PRGE
A	I-PRGE
;	O
the	O
E2p	B-PRGE
LD	O
mutant	O
could	O
be	O
lipoylated	O
only	O
at	O
a	O
significantly	O
lower	O
rate	O
.	O

Likewise	O
,	O
this	O
domain	O
exhibited	O
1D	O
and	O
2D	O
NMR	O
spectra	O
characteristic	O
of	O
a	O
partially	O
folded	O
protein	O
,	O
whereas	O
the	O
spectra	O
of	O
mutants	O
with	O
modified	O
loops	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
domain	O
.	O

The	O
surface	O
loop	O
is	O
evidently	O
important	O
to	O
the	O
structural	O
integrity	O
of	O
the	O
domain	O
and	O
may	O
help	O
to	O
stabilize	O
the	O
thioester	O
bond	O
linking	O
the	O
acyl	O
group	O
to	O
the	O
reduced	O
lipoyl	O
-	O
lysine	O
swinging	O
arm	O
as	O
part	O
of	O
the	O
catalytic	O
mechanism	O
.	O

Recognition	O
of	O
the	O
lipoyl	O
domain	O
by	O
its	O
partner	O
E1	O
appears	O
to	O
be	O
a	O
complex	O
process	O
and	O
not	O
attributable	O
to	O
any	O
single	O
determinant	O
on	O
the	O
domain	O
.	O

Identification	O
of	O
a	O
novel	O
isopeptidase	O
with	O
dual	O
specificity	O
for	O
ubiquitin	B-PRGE
-	O
and	O
NEDD8	B-PRGE
-	O
conjugated	O
proteins	O
.	O

Covalent	O
conjugation	O
of	O
proteins	O
by	O
ubiquitin	B-PRGE
or	O
ubiquitin	B-PRGE
-	O
like	O
molecules	O
is	O
an	O
important	O
form	O
of	O
post	O
-	O
translational	O
modification	O
and	O
plays	O
a	O
critical	O
role	O
in	O
many	O
cellular	O
processes	O
.	O

Similar	O
to	O
the	O
concept	O
of	O
phosphorylation	O
and	O
dephosphorylation	O
,	O
these	O
conjugates	O
are	O
regulated	O
by	O
a	O
large	O
number	O
of	O
deconjugating	O
enzymes	O
.	O

Here	O
,	O
we	O
report	O
the	O
cloning	O
of	O
a	O
2	O
,	O
141	O
-	O
base	O
pair	O
DNA	O
fragment	O
from	O
human	O
placenta	O
cDNA	O
library	O
by	O
a	O
strategy	O
that	O
involves	O
expressed	O
sequence	O
tag	O
data	O
base	O
searching	O
,	O
polymerase	O
chain	O
reaction	O
,	O
and	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

Nucleotide	O
sequence	O
analysis	O
revealed	O
that	O
the	O
cloned	O
cDNA	O
contains	O
an	O
open	O
reading	O
frame	O
of	O
1	O
,	O
143	O
base	O
pairs	O
encoding	O
a	O
novel	O
protease	O
,	O
USP21	B-PRGE
,	O
which	O
is	O
composed	O
of	O
381	O
residues	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
43	O
kDa	O
.	O

The	O
human	O
USP21	B-PRGE
gene	O
is	O
located	O
on	O
chromosome	O
1q21	O
and	O
encodes	O
a	O
member	O
of	O
the	O
ubiquitin	B-PRGE
-	O
specific	O
protease	O
family	O
with	O
highly	O
conserved	O
Cys	O
and	O
His	O
domains	O
.	O

The	O
activity	O
and	O
specificity	O
of	O
USP21	B-PRGE
were	O
determined	O
by	O
using	O
a	O
COS	O
cell	O
expression	O
system	O
in	O
vivo	O
.	O

We	O
showed	O
that	O
USP21	B-PRGE
is	O
capable	O
of	O
removing	O
ubiquitin	B-PRGE
from	O
ubiquitinated	O
proteins	O
as	O
expected	O
.	O

Furthermore	O
,	O
USP21	B-PRGE
is	O
capable	O
of	O
removing	O
NEDD8	B-PRGE
from	O
NEDD8	B-PRGE
conjugates	O
but	O
has	O
no	O
effect	O
on	O
Sentrin	B-PRGE
-	I-PRGE
1	I-PRGE
conjugates	O
.	O

As	O
expected	O
from	O
its	O
biochemical	O
activity	O
,	O
overexpression	O
of	O
USP21	B-PRGE
has	O
a	O
profound	O
growth	O
inhibitory	O
effect	O
on	O
U2OS	O
cells	O
.	O

Thus	O
,	O
USP21	B-PRGE
is	O
the	O
first	O
ubiquitin	B-PRGE
-	O
specific	O
protease	O
shown	O
to	O
have	O
dual	O
specificity	O
for	O
both	O
ubiquitin	B-PRGE
and	O
NEDD8	B-PRGE
and	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
.	O

Activation	O
of	O
H	B-PRGE
-	I-PRGE
ras61L	I-PRGE
-	O
specific	O
signaling	O
pathways	O
does	O
not	O
require	O
posttranslational	O
processing	O
of	O
H	B-PRGE
-	I-PRGE
ras	I-PRGE
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
H	B-PRGE
-	I-PRGE
ras61L	I-PRGE
retained	O
transforming	O
activity	O
when	O
lacking	O
C	O
-	O
terminal	O
lipid	O
modifications	O
,	O
provided	O
that	O
plasma	O
membrane	O
localization	O
was	O
restored	O
by	O
an	O
N	O
-	O
terminal	O
transmembrane	O
domain	O
.	O

Since	O
several	O
ras	O
-	O
activated	O
pathways	O
contribute	O
to	O
the	O
transformed	O
phenotype	O
,	O
we	O
utilized	O
a	O
novel	O
set	O
of	O
transmembrane	O
domain	O
-	O
anchored	O
H	B-PRGE
-	I-PRGE
ras	I-PRGE
derivatives	O
to	O
examine	O
if	O
lipids	O
are	O
required	O
for	O
activation	O
of	O
any	O
specific	O
signaling	O
pathways	O
.	O

We	O
demonstrate	O
here	O
that	O
H	B-PRGE
-	I-PRGE
ras61L	I-PRGE
-	O
induced	O
activation	O
of	O
the	O
Raf	B-PRGE
/	O
MEK	O
/	O
MAPK	O
pathway	O
,	O
including	O
recruitment	O
of	O
Raf	B-PRGE
to	O
the	O
plasma	O
membrane	O
and	O
activation	O
of	O
Raf	B-PRGE
and	O
MAPK	O
,	O
does	O
not	O
require	O
C	O
-	O
terminal	O
processing	O
of	O
H	B-PRGE
-	I-PRGE
ras61L	I-PRGE
.	O

Biochemical	O
fractionation	O
experiments	O
confirm	O
the	O
localization	O
of	O
TM	O
-	O
ras	O
derivatives	O
to	O
the	O
plasma	O
membrane	O
,	O
as	O
well	O
as	O
the	O
ras	O
-	O
mediated	O
recruitment	O
of	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Changes	O
in	O
the	O
actin	O
cytoskeleton	O
,	O
controlled	O
by	O
H	B-PRGE
-	I-PRGE
ras61L	I-PRGE
-	O
mediated	O
activation	O
of	O
the	O
Rac	O
/	O
Rho	O
pathway	O
,	O
as	O
well	O
as	O
PI	O
3	O
-	O
kinase	O
activation	O
,	O
can	O
also	O
occur	O
in	O
the	O
absence	O
of	O
C	O
-	O
terminal	O
lipid	O
modifications	O
.	O

Finally	O
,	O
downstream	O
events	O
,	O
such	O
as	O
the	O
induction	O
of	O
the	O
immediate	O
-	O
early	O
gene	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
or	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
are	O
stimulated	O
by	O
the	O
expression	O
of	O
plasma	O
membrane	O
-	O
anchored	O
,	O
nonlipidated	O
H	B-PRGE
-	I-PRGE
ras6lL	I-PRGE
.	O

These	O
results	O
demonstrate	O
that	O
H	B-PRGE
-	I-PRGE
ras	I-PRGE
can	O
be	O
functionally	O
targeted	O
to	O
the	O
plasma	O
membrane	O
using	O
a	O
transmembrane	O
domain	O
sequence	O
and	O
that	O
several	O
signal	O
transduction	O
pathways	O
downstream	O
of	O
H	B-PRGE
-	I-PRGE
ras	I-PRGE
can	O
be	O
activated	O
without	O
the	O
presence	O
of	O
normal	O
lipid	O
modifications	O
.	O

Membrane	O
pore	O
architecture	O
of	O
a	O
cytolytic	O
toxin	O
from	O
Bacillus	O
thuringiensis	O
.	O

To	O
investigate	O
the	O
membrane	O
pore	O
structure	O
of	O
Cyt2Aa1	B-PRGE
toxin	O
from	O
Bacillus	O
thuringiensis	O
,	O
14	O
single	O
-	O
cysteine	O
substitutions	O
of	O
the	O
toxin	O
were	O
constructed	O
.	O

Five	O
of	O
these	O
mutants	O
(	O
L172C	O
,	O
V186C	O
,	O
L189C	O
,	O
E214C	O
and	O
L220C	O
)	O
yielded	O
characteristic	O
products	O
when	O
processed	O
by	O
proteinase	B-PRGE
K	I-PRGE
;	O
other	O
mutants	O
were	O
degraded	O
by	O
this	O
enzyme	O
.	O

Mutants	O
that	O
yielded	O
characteristic	O
proteolysed	O
products	O
and	O
wild	O
-	O
type	O
toxin	O
were	O
labelled	O
with	O
polarity	O
-	O
sensitive	O
acrylodan	O
(	O
6	O
-	O
acryloyl	O
-	O
2	O
-	O
dimethylaminonaphthalene	O
)	O
at	O
the	O
thiol	O
group	O
of	O
cysteine	O
residues	O
.	O

A	O
green	O
-	O
blue	O
shift	O
in	O
the	O
emission	O
spectra	O
was	O
observed	O
with	O
all	O
labelled	O
toxins	O
on	O
transfer	O
from	O
an	O
aqueous	O
solution	O
into	O
a	O
solution	O
containing	O
membranes	O
or	O
liposomes	O
from	O
red	O
blood	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
label	O
moved	O
into	O
the	O
hydrophobic	O
environment	O
of	O
the	O
membrane	O
or	O
became	O
buried	O
within	O
hydrophobic	O
regions	O
of	O
the	O
protein	O
oligomers	O
.	O

Digestion	O
of	O
membrane	O
-	O
bound	O
labelled	O
toxin	O
with	O
proteinase	B-PRGE
K	I-PRGE
did	O
not	O
cause	O
a	O
significant	O
decrease	O
in	O
emission	O
intensity	O
from	O
any	O
of	O
the	O
labelled	O
mutants	O
.	O

This	O
suggests	O
that	O
L172C	O
,	O
V186C	O
,	O
L189C	O
,	O
E214C	O
and	O
L220C	O
are	O
inserted	O
into	O
the	O
membrane	O
and	O
are	O
therefore	O
protected	O
from	O
proteolysis	O
.	O

In	O
contrast	O
,	O
a	O
marked	O
decrease	O
in	O
emission	O
intensity	O
was	O
observed	O
when	O
membrane	O
-	O
bound	O
labelled	O
wild	O
-	O
type	O
toxin	O
was	O
digested	O
with	O
proteinase	B-PRGE
K	I-PRGE
.	O

This	O
suggests	O
that	O
Cys	O
-	O
19	O
does	O
not	O
insert	O
into	O
the	O
membrane	O
.	O

Fluorimetric	O
analysis	O
of	O
delipidated	O
pore	O
complexes	O
suggests	O
that	O
L172C	O
,	O
V186C	O
,	O
L189C	O
and	O
E214C	O
point	O
towards	O
the	O
lipid	O
in	O
the	O
membrane	O
,	O
whereas	O
L220C	O
is	O
either	O
within	O
the	O
hydrophobic	O
environment	O
of	O
the	O
protein	O
oligomers	O
or	O
exposed	O
to	O
the	O
membrane	O
lipids	O
.	O

Most	O
of	O
the	O
Cys	O
-	O
19	O
from	O
wild	O
-	O
type	O
molecules	O
is	O
enclosed	O
within	O
the	O
hydrophobic	O
pockets	O
of	O
the	O
protein	O
oligomers	O
.	O

Escherichia	O
coli	O
alpha	B-PRGE
-	I-PRGE
hemolysin	I-PRGE
(	O
HlyA	B-PRGE
)	O
is	O
heterogeneously	O
acylated	O
in	O
vivo	O
with	O
14	O
-	O
,	O
15	O
-	O
,	O
and	O
17	O
-	O
carbon	O
fatty	O
acids	O
.	O

alpha	B-PRGE
-	I-PRGE
Hemolysin	I-PRGE
(	O
HlyA	B-PRGE
)	O
is	O
a	O
secreted	O
protein	O
virulence	O
factor	O
observed	O
in	O
certain	O
uropathogenic	O
strains	O
of	O
Escherichia	O
coli	O
.	O

The	O
active	O
,	O
mature	O
form	O
of	O
HlyA	B-PRGE
is	O
produced	O
by	O
posttranslational	O
modification	O
of	O
the	O
protoxin	O
that	O
is	O
mediated	O
by	O
acyl	O
carrier	O
protein	O
and	O
an	O
acyltransferase	O
,	O
HlyC	B-PRGE
.	O

We	O
have	O
now	O
shown	O
using	O
mass	O
spectrometry	O
that	O
these	O
modifications	O
,	O
when	O
observed	O
in	O
protein	O
isolated	O
in	O
vivo	O
,	O
consist	O
of	O
acylation	O
at	O
the	O
epsilon	O
-	O
amino	O
groups	O
of	O
two	O
internal	O
lysine	O
residues	O
,	O
at	O
positions	O
564	O
and	O
690	O
,	O
with	O
saturated	O
14	O
-	O
(	O
68	O
%	O
)	O
,	O
15	O
-	O
(	O
26	O
%	O
)	O
,	O
and	O
17	O
-	O
(	O
6	O
%	O
)	O
carbon	O
amide	O
-	O
linked	O
side	O
chains	O
.	O

Thus	O
,	O
HlyA	B-PRGE
activated	O
in	O
vivo	O
consists	O
of	O
a	O
heterogeneous	O
family	O
of	O
up	O
to	O
nine	O
different	O
covalent	O
structures	O
,	O
and	O
the	O
substrate	O
specificity	O
of	O
the	O
HlyC	B-PRGE
acyltransferase	O
appears	O
to	O
differ	O
from	O
that	O
of	O
the	O
closely	O
related	O
CyaC	B-PRGE
acyltransferase	O
expressed	O
by	O
Bordetella	O
pertussis	O
.	O

Association	O
of	O
prenylated	O
proteins	O
with	O
the	O
plasma	O
membrane	O
and	O
the	O
inner	B-PRGE
nuclear	I-PRGE
membrane	I-PRGE
is	O
mediated	O
by	O
the	O
same	O
membrane	O
-	O
targeting	O
motifs	O
.	O

Targeting	O
of	O
nuclear	O
lamins	O
to	O
the	O
inner	O
nuclear	O
envelope	O
membrane	O
requires	O
a	O
nuclear	O
localization	O
signal	O
and	O
CaaX	O
motif	O
-	O
dependent	O
posttranslational	O
modifications	O
,	O
including	O
isoprenylation	O
and	O
carboxyl	O
methylation	O
.	O

These	O
modifications	O
,	O
although	O
necessary	O
for	O
membrane	O
targeting	O
,	O
are	O
not	O
sufficient	O
to	O
mediate	O
stable	O
association	O
with	O
membranes	O
.	O

We	O
show	O
that	O
two	O
variants	O
of	O
lamin	B-PRGE
B3	I-PRGE
(	O
i	O
.	O
e	O
.	O
,	O
B3a	B-PRGE
and	O
B3b	B-PRGE
)	O
exist	O
in	O
Xenopus	O
oocytes	O
.	O

They	O
are	O
encoded	O
by	O
two	O
alternatively	O
spliced	O
,	O
developmentally	O
regulated	O
mRNAs	O
.	O

The	O
two	O
lamin	O
variants	O
differ	O
greatly	O
in	O
their	O
membrane	O
association	O
in	O
meiotically	O
matured	O
eggs	O
.	O

The	O
presence	O
of	O
an	O
extra	O
cysteine	O
residue	O
(	O
as	O
a	O
potential	O
palmitoylation	O
site	O
)	O
and	O
a	O
basic	O
cluster	O
in	O
conjunction	O
with	O
the	O
CaaX	O
motif	O
function	O
as	O
secondary	O
targeting	O
signals	O
responsible	O
for	O
the	O
stable	O
membrane	O
association	O
of	O
lamin	B-PRGE
B3b	I-PRGE
in	O
Xenopus	O
eggs	O
.	O

Moreover	O
,	O
transfection	O
experiments	O
with	O
Green	B-PRGE
Fluorescent	I-PRGE
Protein	I-PRGE
lamin	O
tail	O
chimeras	O
and	O
with	O
a	O
Green	B-PRGE
Fluorescent	I-PRGE
Protein	I-PRGE
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
chimera	O
show	O
that	O
these	O
secondary	O
motifs	O
are	O
sufficient	O
to	O
target	O
proteins	O
to	O
the	O
inner	O
nuclear	O
membrane	O
and	O
/	O
or	O
the	O
plasma	O
membrane	O
.	O

Implications	O
for	O
the	O
intracellular	O
trafficking	O
of	O
doubly	O
lipidated	O
proteins	O
are	O
discussed	O
.	O

TcRho1	B-PRGE
,	O
a	O
farnesylated	O
Rho	O
family	O
homologue	O
from	O
Trypanosoma	O
cruzi	O
:	O
cloning	O
,	O
trans	O
-	O
splicing	O
,	O
and	O
prenylation	O
studies	O
.	O

Rho	O
GTPases	O
are	O
members	O
of	O
the	O
Ras	O
superfamily	O
and	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
,	O
including	O
maintenance	O
of	O
cell	O
morphology	O
and	O
motility	O
,	O
cell	O
cycle	O
progression	O
,	O
and	O
transcription	O
activation	O
.	O

We	O
report	O
the	O
molecular	O
identification	O
in	O
trypanosomatids	O
(	O
Trypanosoma	O
cruzi	O
)	O
of	O
the	O
first	O
member	O
of	O
the	O
Rho	O
family	O
.	O

The	O
cloned	O
Rho	O
protein	O
,	O
TcRho1	B-PRGE
,	O
shares	O
approximately	O
40	O
%	O
homology	O
with	O
other	O
members	O
of	O
the	O
Rho	O
family	O
.	O

Southern	O
blot	O
analysis	O
revealed	O
that	O
TcRHO1	B-PRGE
is	O
a	O
single	O
copy	O
gene	O
per	O
haploid	O
genome	O
,	O
and	O
Northern	O
blot	O
assays	O
showed	O
a	O
transcript	O
of	O
1200	O
nucleotides	O
in	O
length	O
.	O

Mapping	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
TcRHO1	B-PRGE
transcripts	O
revealed	O
at	O
least	O
five	O
different	O
transcripts	O
derived	O
from	O
differential	O
trans	O
-	O
splicing	O
.	O

Three	O
of	O
the	O
five	O
transcripts	O
contain	O
the	O
trans	O
-	O
splicing	O
site	O
within	O
the	O
coding	O
region	O
of	O
the	O
TcRHO1	B-PRGE
gene	O
.	O

TcRho1	B-PRGE
also	O
contains	O
the	O
C	O
-	O
terminal	O
sequence	O
CQLF	O
(	O
CAAX	O
motif	O
)	O
,	O
which	O
is	O
predicted	O
to	O
direct	O
post	O
-	O
translation	O
prenylation	O
of	O
the	O
cysteine	O
residue	O
.	O

A	O
synthetic	O
peptide	O
containing	O
this	O
C	O
-	O
terminal	O
motif	O
,	O
when	O
tested	O
against	O
Q	O
-	O
Sepharose	O
chromatography	O
fractions	O
from	O
T	O
.	O
cruzi	O
cytosol	O
,	O
was	O
shown	O
to	O
be	O
efficiently	O
farnesylated	O
,	O
but	O
not	O
geranylgeranylated	O
,	O
despite	O
the	O
fact	O
that	O
the	O
CAAX	O
motif	O
with	O
X	O
=	O
Phe	O
specifies	O
geranylgeranylation	O
by	O
mammalian	O
protein	O
geranylgeranyltransferase	O
I	O
.	O

Furthermore	O
,	O
immunoblot	O
analyses	O
of	O
epimastigote	O
protein	O
with	O
anti	O
-	O
S	O
-	O
farnesylcysteine	O
methyl	O
ester	O
and	O
anti	O
-	O
TcRho1	B-PRGE
antisera	O
strongly	O
suggested	O
that	O
TcRho1	B-PRGE
is	O
farnesylated	O
in	O
vivo	O
.	O

The	O
farnesylation	O
of	O
proteins	O
such	O
as	O
Rho	O
GTPases	O
could	O
be	O
the	O
basis	O
for	O
the	O
selective	O
cytotoxic	O
action	O
of	O
protein	O
farnesyltransferase	O
inhibitors	O
on	O
trypanosomatids	O
versus	O
mammalian	O
cells	O
.	O

Thiopalmitoylation	O
of	O
myelin	B-PRGE
proteolipid	I-PRGE
protein	I-PRGE
epitopes	O
enhances	O
immunogenicity	O
and	O
encephalitogenicity	O
.	O

Proteolipid	B-PRGE
protein	I-PRGE
(	O
PLP	B-PRGE
)	O
is	O
the	O
most	O
abundant	O
protein	O
of	O
CNS	O
myelin	O
,	O
and	O
is	O
posttranslationally	O
acylated	O
by	O
covalent	O
attachment	O
of	O
long	O
chain	O
fatty	O
acids	O
to	O
cysteine	O
residues	O
via	O
a	O
thioester	O
linkage	O
.	O

Two	O
of	O
the	O
acylation	O
sites	O
are	O
within	O
epitopes	O
of	O
PLP	B-PRGE
that	O
are	O
encephalitogenic	O
in	O
SJL	O
/	O
J	O
mice	O
(	O
PLP	B-PRGE
(	O
104	O
-	O
117	O
)	O
and	O
PLP	B-PRGE
(	O
139	O
-	O
151	O
)	O
)	O
and	O
against	O
which	O
increased	O
immune	O
responses	O
have	O
been	O
detected	O
in	O
some	O
multiple	O
sclerosis	O
patients	O
.	O

It	O
is	O
known	O
that	O
attachment	O
of	O
certain	O
types	O
of	O
lipid	O
side	O
chains	O
to	O
peptides	O
can	O
result	O
in	O
their	O
enhanced	O
immunogenicity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
thioacylated	O
PLP	B-PRGE
peptides	O
,	O
as	O
occur	O
in	O
the	O
native	O
protein	O
,	O
are	O
more	O
immunogenic	O
than	O
their	O
nonacylated	O
counterparts	O
,	O
and	O
whether	O
thioacylation	O
influences	O
the	O
development	O
of	O
autoreactivity	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

The	O
results	O
show	O
that	O
in	O
comparison	O
with	O
nonacylated	O
peptides	O
,	O
thioacylated	O
PLP	B-PRGE
lipopeptides	O
can	O
induce	O
greater	O
T	O
cell	O
and	O
Ab	O
responses	O
to	O
both	O
the	O
acylated	O
and	O
nonacylated	O
peptides	O
.	O

They	O
also	O
enhanced	O
the	O
development	O
and	O
chronicity	O
of	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Synthetic	O
peptides	O
in	O
which	O
the	O
fatty	O
acid	O
was	O
attached	O
via	O
an	O
amide	O
linkage	O
at	O
the	O
N	O
terminus	O
were	O
not	O
encephalitogenic	O
,	O
and	O
they	O
induced	O
greater	O
proportions	O
of	O
CD8	O
+	O
cells	O
in	O
initial	O
in	O
vitro	O
stimulation	O
.	O

Therefore	O
,	O
the	O
lability	O
and	O
the	O
site	O
of	O
the	O
linkage	O
between	O
the	O
peptide	O
and	O
fatty	O
acid	O
may	O
be	O
important	O
for	O
induction	O
of	O
encephalitogenic	O
CD4	B-PRGE
+	O
T	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
immune	O
responses	O
induced	O
by	O
endogenous	O
thioacylated	O
lipopeptides	O
may	O
contribute	O
to	O
the	O
immunopathogenesis	O
of	O
chronic	O
experimental	O
demyelinating	O
diseases	O
and	O
multiple	O
sclerosis	O
.	O

COP9	O
signalosome	O
revisited	O
:	O
a	O
novel	O
mediator	O
of	O
protein	O
degradation	O
.	O

The	O
COP9	O
signalosome	O
is	O
an	O
evolutionarily	O
conserved	O
multiprotein	O
complex	O
that	O
was	O
first	O
identified	O
as	O
an	O
essential	O
complex	O
that	O
represses	O
light	O
-	O
regulated	O
development	O
in	O
Arabidopsis	O
.	O

The	O
COP9	O
signalosome	O
has	O
similarity	O
to	O
the	O
lid	O
of	O
the	O
19S	O
regulatory	O
particle	O
of	O
the	O
26S	O
proteasome	O
and	O
has	O
recently	O
been	O
shown	O
to	O
interact	O
with	O
SCF	O
-	O
type	O
E3	O
ubiquitin	B-PRGE
ligases	O
.	O

Although	O
its	O
precise	O
role	O
in	O
the	O
process	O
of	O
protein	O
degradation	O
remains	O
to	O
be	O
established	O
,	O
the	O
COP9	O
signalosome	O
is	O
a	O
positive	O
regulator	O
of	O
E3	O
ubiquitin	B-PRGE
ligases	O
that	O
functions	O
at	O
least	O
in	O
part	O
by	O
mediating	O
the	O
deconjugation	O
of	O
the	O
NEDD8	B-PRGE
/	O
RUB	O
-	O
modification	O
from	O
the	O
cullin	O
subunit	O
of	O
SCF	O
-	O
type	O
E3	O
complexes	O
.	O

Here	O
,	O
we	O
discuss	O
these	O
recent	O
findings	O
,	O
which	O
add	O
an	O
additional	O
component	O
to	O
the	O
biology	O
of	O
substrate	O
-	O
specific	O
protein	O
degradation	O
.	O

Lovastatin	O
-	O
induced	O
cytoskeletal	O
reorganization	O
in	O
lens	O
epithelial	O
cells	O
:	O
role	O
of	O
Rho	O
GTPases	O
.	O

PURPOSE	O
:	O
To	O
understand	O
the	O
involvement	O
of	O
isoprenylated	O
small	O
guanosine	O
triphosphatases	O
(	O
GTPases	O
)	O
in	O
lovastatin	O
-	O
induced	O
cataractogenesis	O
,	O
Rho	O
-	O
and	O
Rac	O
-	O
mediated	O
cell	O
adhesion	O
and	O
actin	O
cytoskeletal	O
reorganization	O
were	O
investigated	O
in	O
lovastatin	O
-	O
treated	O
lens	O
epithelial	O
cells	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
lovastatin	O
on	O
F	O
-	O
actin	O
reorganization	O
(	O
phalloidin	O
staining	O
)	O
,	O
focal	O
adhesion	O
formation	O
(	O
paxillin	B-PRGE
or	O
vinculin	B-PRGE
)	O
,	O
cell	O
-	O
cell	O
adhesions	O
(	O
cadherin	O
and	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
)	O
,	O
and	O
protein	O
tyrosine	O
phosphorylation	O
were	O
evaluated	O
in	O
human	O
and	O
porcine	O
lens	O
epithelial	O
cells	O
by	O
immunocytochemical	O
staining	O
with	O
specific	O
antibodies	O
.	O

To	O
explore	O
the	O
involvement	O
of	O
the	O
Rho	O
and	O
Rac	O
GTPases	O
in	O
lovastatin	O
-	O
mediated	O
effects	O
,	O
changes	O
in	O
distribution	O
of	O
Rho	O
and	O
Rac	O
GTPases	O
were	O
analyzed	O
by	O
Western	O
blot	O
analysis	O
,	O
and	O
the	O
effects	O
of	O
C3	B-PRGE
-	I-PRGE
exoenzyme	I-PRGE
on	O
lovastatin	O
-	O
induced	O
cytoskeletal	O
changes	O
were	O
evaluated	O
by	O
immunocytochemical	O
analysis	O
.	O

RESULTS	O
:	O
Lovastatin	O
induced	O
drastic	O
changes	O
in	O
cell	O
shape	O
in	O
both	O
human	O
and	O
porcine	O
lens	O
epithelial	O
cells	O
,	O
including	O
a	O
profound	O
loss	O
of	O
actin	O
stress	O
fibers	O
,	O
focal	O
adhesions	O
,	O
protein	O
phosphotyrosine	O
,	O
and	O
cell	O
-	O
cell	O
adhesions	O
.	O

Lovastatin	O
treatment	O
also	O
led	O
to	O
the	O
accumulation	O
of	O
nonisoprenylated	O
Rho	O
and	O
Rac	O
GTPases	O
in	O
cytosolic	O
fraction	O
.	O

Supplementation	O
of	O
culture	O
media	O
with	O
geranylgeranyl	O
pyrophosphate	O
dramatically	O
reversed	O
the	O
lovastatin	O
-	O
induced	O
morphologic	O
and	O
cytoskeletal	O
changes	O
,	O
whereas	O
farnesyl	O
pyrophosphate	O
was	O
ineffective	O
.	O

Treatment	O
of	O
cells	O
with	O
C3	B-PRGE
-	I-PRGE
exoenzyme	I-PRGE
(	O
a	O
Rho	O
GTPase	O
-	O
specific	O
inhibitor	O
)	O
,	O
however	O
,	O
abolished	O
the	O
geranylgeranyl	O
-	O
supplementation	O
-	O
induced	O
recovery	O
from	O
the	O
morphologic	O
and	O
cytoskeletal	O
effects	O
of	O
lovastatin	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
inhibition	O
of	O
protein	O
prenylation	O
by	O
lovastatin	O
leads	O
to	O
disruption	O
of	O
actin	O
cytoskeletal	O
organization	O
,	O
and	O
to	O
loss	O
of	O
integrin	O
-	O
mediated	O
focal	O
adhesions	O
and	O
cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesions	O
in	O
lens	O
epithelial	O
cells	O
.	O

Based	O
on	O
isoprenoid	O
supplementation	O
studies	O
,	O
it	O
could	O
be	O
concluded	O
that	O
impairment	O
of	O
geranylgeranylated	O
Rho	O
and	O
Rac	O
GTPase	O
function	O
is	O
most	O
likely	O
responsible	O
for	O
lovastatin	O
-	O
induced	O
cytoskeletal	O
changes	O
in	O
lens	O
epithelial	O
cells	O
.	O

Impairment	O
of	O
mineralocorticoid	B-PRGE
receptor	I-PRGE
(	O
MR	B-PRGE
)	O
-	O
dependent	O
biological	O
response	O
by	O
oxidative	O
stress	O
and	O
aging	O
:	O
correlation	O
with	O
post	O
-	O
translational	O
modification	O
of	O
MR	B-PRGE
and	O
decreased	O
ADP	O
-	O
ribosylatable	O
level	O
of	O
elongating	B-PRGE
factor	I-PRGE
2	I-PRGE
in	O
kidney	O
cells	O
.	O

Acute	O
and	O
chronic	O
treatments	O
of	O
mice	O
with	O
the	O
glutathione	O
-	O
depleting	O
agent	O
,	O
L	O
-	O
buthionine	O
-	O
(	O
SR	O
)	O
-	O
sulfoximine	O
(	O
BSO	O
)	O
,	O
impaired	O
the	O
mineralocorticoid	B-PRGE
receptor	I-PRGE
(	O
MR	B-PRGE
)	O
-	O
dependent	O
biological	O
response	O
by	O
inhibiting	O
aldosterone	O
binding	O
.	O

This	O
steroid	O
-	O
binding	O
inhibition	O
was	O
fully	O
reversed	O
when	O
reducing	O
agents	O
were	O
added	O
to	O
kidney	O
cytosol	O
obtained	O
from	O
mice	O
treated	O
for	O
5	O
h	O
,	O
but	O
it	O
was	O
only	O
partially	O
reversed	O
in	O
cytosol	O
obtained	O
from	O
mice	O
treated	O
for	O
10	O
days	O
.	O

Although	O
the	O
oligomeric	O
structure	O
of	O
the	O
MR	B-PRGE
-	O
hsp90	B-PRGE
heterocomplex	O
was	O
always	O
unaffected	O
,	O
a	O
decreased	O
amount	O
of	O
MR	B-PRGE
protein	O
was	O
evidenced	O
after	O
the	O
long	O
term	O
treatment	O
.	O

Such	O
a	O
deleterious	O
effect	O
was	O
correlated	O
with	O
a	O
post	O
-	O
translational	O
modification	O
of	O
MR	B-PRGE
,	O
as	O
demonstrated	O
by	O
an	O
increased	O
level	O
of	O
receptor	O
carbonylation	O
.	O

In	O
addition	O
,	O
a	O
failure	O
at	O
the	O
elongation	O
/	O
termination	O
step	O
was	O
also	O
observed	O
during	O
the	O
receptor	O
translation	O
process	O
in	O
a	O
reticulocyte	O
lysate	O
system	O
.	O

Thus	O
,	O
a	O
high	O
polyribosomes	O
/	O
monomers	O
ratio	O
and	O
both	O
increased	O
proteolysis	O
and	O
decreased	O
ADP	O
-	O
ribosylatable	O
concentration	O
of	O
elongation	B-PRGE
factor	I-PRGE
2	I-PRGE
(	O
EF	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
were	O
shown	O
.	O

Importantly	O
,	O
similar	O
observations	O
were	O
also	O
performed	O
in	O
vivo	O
after	O
depletion	O
of	O
glutathione	O
.	O

Notwithstanding	O
the	O
EF	B-PRGE
-	I-PRGE
2	I-PRGE
functional	O
disruption	O
,	O
not	O
all	O
renal	O
proteins	O
were	O
equally	O
affected	O
as	O
the	O
MR	B-PRGE
.	O

Interestingly	O
,	O
both	O
EF	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
MR	B-PRGE
expressed	O
in	O
old	O
mice	O
were	O
similarly	O
affected	O
as	O
in	O
L	O
-	O
buthionine	O
-	O
(	O
SR	O
)	O
-	O
sulfoximine	O
-	O
treated	O
young	O
mice	O
.	O

We	O
therefore	O
propose	O
that	O
a	O
dramatic	O
depletion	O
of	O
glutathione	O
in	O
kidney	O
cells	O
mimics	O
the	O
cumulative	O
effect	O
of	O
aging	O
which	O
,	O
at	O
the	O
end	O
,	O
may	O
lead	O
to	O
a	O
renal	O
mineralocorticoid	O
dysfunction	O
.	O

Time	O
-	O
dependent	O
potentiation	O
of	O
the	O
beta	O
-	O
cell	O
is	O
a	O
Ca2	O
+	O
-	O
independent	O
phenomenon	O
.	O

When	O
isolated	O
rat	O
pancreatic	O
islets	O
are	O
treated	O
with	O
16	O
.	O
7	O
mM	O
glucose	O
,	O
a	O
time	O
-	O
dependent	O
potentiation	O
(	O
TDP	O
)	O
of	O
insulin	B-PRGE
release	O
occurs	O
that	O
can	O
be	O
detected	O
by	O
subsequent	O
treatment	O
with	O
50	O
mM	O
KCl	O
.	O

It	O
has	O
been	O
thought	O
that	O
TDP	O
by	O
glucose	O
is	O
a	O
Ca2	O
+	O
-	O
dependent	O
phenomenon	O
and	O
only	O
occurs	O
when	O
exposure	O
to	O
glucose	O
is	O
carried	O
out	O
in	O
the	O
presence	O
of	O
Ca2	O
+	O
.	O

In	O
contrast	O
to	O
this	O
,	O
we	O
now	O
demonstrate	O
TDP	O
under	O
stringent	O
Ca2	O
+	O
-	O
free	O
conditions	O
(	O
Ca2	O
+	O
-	O
free	O
buffer	O
containing	O
1	O
mM	O
EGTA	O
)	O
.	O

In	O
fact	O
,	O
under	O
these	O
Ca2	O
+	O
-	O
free	O
conditions	O
glucose	O
caused	O
an	O
even	O
stronger	O
TDP	O
than	O
in	O
the	O
presence	O
of	O
Ca2	O
+	O
.	O

TDP	O
induced	O
by	O
glucose	O
in	O
the	O
absence	O
of	O
extracellular	O
Ca2	O
+	O
was	O
unaffected	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

However	O
,	O
cerulenin	O
or	O
tunicamycin	O
,	O
two	O
inhibitors	O
of	O
protein	O
acylation	O
,	O
eradicated	O
TDP	O
without	O
affecting	O
glucose	O
metabolism	O
.	O

The	O
TDP	O
by	O
glucose	O
was	O
not	O
associated	O
with	O
an	O
increase	O
in	O
the	O
cytosolic	O
free	O
Ca2	O
+	O
concentration	O
(	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
during	O
subsequent	O
treatment	O
with	O
high	O
K	O
+	O
.	O

Exposure	O
of	O
islets	O
to	O
forskolin	O
under	O
Ca	O
(	O
2	O
+	O
)	O
-	O
free	O
conditions	O
did	O
not	O
cause	O
TDP	O
despite	O
a	O
large	O
increase	O
in	O
the	O
cellular	O
cAMP	O
levels	O
.	O

In	O
conclusion	O
,	O
glucose	O
alone	O
induces	O
TDP	O
under	O
stringent	O
Ca2	O
+	O
-	O
free	O
conditions	O
when	O
[	O
Ca2	O
+	O
]	O
i	O
was	O
significantly	O
lowered	O
.	O

Protein	O
acylation	O
is	O
implicated	O
in	O
the	O
underlying	O
mechanism	O
of	O
TDP	O
.	O

Sumoylation	O
of	O
topoisomerase	B-PRGE
I	I-PRGE
is	O
involved	O
in	O
its	O
partitioning	O
between	O
nucleoli	O
and	O
nucleoplasm	O
and	O
its	O
clearing	O
from	O
nucleoli	O
in	O
response	O
to	O
camptothecin	O
.	O

Previous	O
studies	O
identified	O
a	O
small	O
fraction	O
of	O
putatively	O
sumoylated	O
topoisomerase	B-PRGE
I	I-PRGE
(	O
TOP1	B-PRGE
)	O
under	O
basal	O
conditions	O
(	O
approximately	O
1	O
%	O
)	O
,	O
and	O
anticancer	O
camptothecins	O
that	O
trap	O
the	O
TOP1	B-PRGE
-	O
DNA	O
covalent	O
intermediate	O
markedly	O
increase	O
the	O
sumoylation	O
of	O
TOP1	B-PRGE
(	O
<	O
or	O
=	O
10	O
%	O
)	O
.	O

To	O
study	O
the	O
role	O
of	O
the	O
sumoylation	O
of	O
TOP1	B-PRGE
,	O
we	O
mutated	O
sites	O
on	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	B-PRGE
)	O
-	O
TOP1	B-PRGE
corresponding	O
to	O
the	O
consensus	O
sequence	O
for	O
protein	O
sumoylation	O
(	O
PsiKXE	O
,	O
where	O
Psi	O
is	O
a	O
hydrophobic	O
residue	O
)	O
and	O
assayed	O
the	O
mutants	O
for	O
basal	O
and	O
camptothecin	O
-	O
induced	O
sumoylation	O
.	O

Only	O
one	O
of	O
the	O
eight	O
mutants	O
,	O
K117R	O
,	O
located	O
in	O
the	O
highly	O
charged	O
NH2	O
-	O
terminal	O
region	O
,	O
showed	O
a	O
substantial	O
reduction	O
(	O
approximately	O
5	O
-	O
fold	O
)	O
in	O
basal	O
and	O
camptothecin	O
-	O
induced	O
sumoylation	O
;	O
thus	O
,	O
Lys	O
-	O
117	O
appears	O
to	O
be	O
the	O
major	O
sumoylation	O
site	O
.	O

A	O
triple	O
mutant	O
having	O
the	O
PsiKXE	O
sequences	O
flanking	O
K117R	O
additionally	O
mutated	O
(	O
K103R	O
/	O
K117R	O
/	O
K153R	O
)	O
showed	O
little	O
if	O
any	O
sumoylation	O
,	O
but	O
was	O
degraded	O
like	O
wild	O
-	O
type	O
GFP	B-PRGE
-	O
TOP1	B-PRGE
during	O
camptothecin	O
treatment	O
.	O

However	O
,	O
K103R	O
/	O
K117R	O
/	O
K153R	O
-	O
GFP	B-PRGE
-	O
TOP1	B-PRGE
was	O
markedly	O
concentrated	O
within	O
nucleoli	O
,	O
depleted	O
from	O
the	O
remainder	O
of	O
nucleus	O
,	O
and	O
failed	O
to	O
be	O
cleared	O
from	O
nucleoli	O
in	O
response	O
to	O
camptothecin	O
treatment	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
model	O
wherein	O
basal	O
transient	O
sumoylation	O
of	O
the	O
NH2	O
-	O
terminal	O
,	O
highly	O
charged	O
,	O
disordered	O
region	O
prevents	O
TOP1	B-PRGE
binding	O
to	O
sites	O
in	O
nucleoli	O
,	O
thus	O
driving	O
it	O
to	O
bind	O
in	O
the	O
nucleoplasm	O
;	O
and	O
camptothecin	O
treatment	O
,	O
which	O
increases	O
TOP1	B-PRGE
sumoylation	O
,	O
further	O
shifts	O
the	O
binding	O
resulting	O
in	O
delocalization	O
of	O
TOP1	B-PRGE
from	O
nucleoli	O
to	O
nucleoplasm	O
.	O

Age	O
-	O
related	O
changes	O
in	O
human	O
bone	O
proteoglycan	O
structure	O
.	O

Impact	O
of	O
osteogenesis	O
imperfecta	O
.	O

Proteoglycans	O
(	O
PGs	O
)	O
are	O
a	O
family	O
of	O
molecules	O
that	O
undergo	O
extensive	O
post	O
-	O
translational	O
modifications	O
that	O
include	O
addition	O
of	O
glycosaminoglycan	O
(	O
GAG	O
)	O
chains	O
as	O
well	O
as	O
N	O
-	O
and	O
O	O
-	O
linked	O
oligosaccharides	O
to	O
the	O
protein	O
core	O
.	O

PG	O
composition	O
and	O
structure	O
have	O
been	O
reported	O
to	O
alter	O
with	O
age	O
.	O

To	O
test	O
whether	O
the	O
post	O
-	O
translational	O
modifications	O
to	O
PGs	O
can	O
serve	O
as	O
in	O
vitro	O
surrogate	O
end	O
point	O
markers	O
for	O
chronological	O
age	O
,	O
the	O
extent	O
of	O
GAG	O
modifications	O
was	O
determined	O
for	O
PGs	O
derived	O
from	O
normal	O
human	O
bone	O
cells	O
of	O
14	O
donors	O
(	O
age	O
range	O
,	O
fetal	O
to	O
60	O
years	O
)	O
.	O

Isolated	O
cells	O
were	O
steady	O
state	O
radiolabeled	O
with	O
(	O
35	O
)	O
SO	O
(	O
4	O
)	O
(	O
2	O
-	O
)	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
GlcN	O
.	O

For	O
biglycan	B-PRGE
and	O
decorin	B-PRGE
,	O
iduronate	O
content	O
was	O
linearly	O
correlated	O
with	O
age	O
(	O
increased	O
1	O
.	O
5x	O
between	O
fetal	O
and	O
age	O
60	O
years	O
)	O
.	O

For	O
the	O
syndecan	O
-	O
like	O
heparan	O
sulfate	O
PG	O
,	O
the	O
N	O
-	O
sulfation	O
of	O
post	O
-	O
natal	O
cells	O
increased	O
over	O
3	O
.	O
5	O
-	O
fold	O
until	O
reaching	O
a	O
plateau	O
during	O
the	O
4th	O
decade	O
of	O
life	O
.	O

The	O
amount	O
of	O
O	O
-	O
linked	O
oligosaccharides	O
was	O
also	O
found	O
to	O
decrease	O
as	O
a	O
function	O
of	O
increasing	O
normal	O
donor	O
age	O
,	O
whereas	O
the	O
specific	O
activity	O
of	O
the	O
metabolic	O
precursor	O
pool	O
remained	O
constant	O
regardless	O
of	O
donor	O
age	O
.	O

These	O
age	O
-	O
related	O
changes	O
in	O
post	O
-	O
translational	O
modifications	O
were	O
then	O
used	O
to	O
demonstrate	O
that	O
osteoblasts	O
derived	O
from	O
patients	O
with	O
osteogenesis	O
imperfecta	O
did	O
not	O
exhibit	O
facets	O
of	O
a	O
pre	O
-	O
mature	O
aging	O
,	O
but	O
rather	O
were	O
arrested	O
in	O
a	O
fetal	O
-	O
like	O
phenotypic	O
state	O
.	O

A	O
growth	O
matrix	O
rich	O
in	O
thrombospondin	O
altered	O
PG	O
metabolism	O
in	O
osteoblastic	O
cells	O
,	O
resulting	O
in	O
the	O
production	O
and	O
secretion	O
of	O
the	O
fetal	O
-	O
like	O
(	O
rich	O
in	O
O	O
-	O
linked	O
oligosaccharides	O
)	O
forms	O
of	O
decorin	B-PRGE
and	O
biglycan	B-PRGE
.	O

This	O
effect	O
was	O
qualitatively	O
different	O
from	O
the	O
effect	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
,	O
which	O
predominantly	O
altered	O
GAGs	O
rather	O
than	O
O	O
-	O
linked	O
oligosaccharides	O
.	O

No	O
other	O
Arg	O
-	O
Gly	O
-	O
Asp	O
protein	O
(	O
fibronectin	B-PRGE
,	O
vitronectin	B-PRGE
,	O
type	O
I	O
collagen	O
,	O
osteopontin	B-PRGE
,	O
and	O
bone	O
sialoprotein	O
)	O
showed	O
any	O
detectable	O
effect	O
on	O
PG	O
metabolism	O
in	O
bone	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
a	O
proper	O
matrix	O
stoichiometry	O
is	O
critical	O
for	O
metabolism	O
of	O
PGs	O
.	O

Expression	O
and	O
characterization	O
of	O
recombinant	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
gamma	I-PRGE
-	I-PRGE
glutamyl	I-PRGE
carboxylase	I-PRGE
from	O
an	O
invertebrate	O
,	O
Conus	O
textile	O
.	O

The	O
marine	O
snail	O
Conus	O
is	O
the	O
sole	O
invertebrate	O
wherein	O
both	O
the	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
carboxylase	I-PRGE
and	O
its	O
product	O
,	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
have	O
been	O
identified	O
.	O

To	O
examine	O
its	O
biosynthesis	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
we	O
studied	O
the	O
carboxylase	B-PRGE
from	O
Conus	O
venom	O
ducts	O
.	O

The	O
carboxylase	B-PRGE
cDNA	O
from	O
Conus	O
textile	O
has	O
an	O
ORF	O
that	O
encodes	O
a	O
811	O
-	O
amino	O
-	O
acid	O
protein	O
which	O
exhibits	O
sequence	O
similarity	O
to	O
the	O
vertebrate	O
carboxylases	O
,	O
with	O
41	O
%	O
identity	O
and	O
approximately	O
60	O
%	O
sequence	O
similarity	O
to	O
the	O
bovine	O
carboxylase	O
.	O

Expression	O
of	O
this	O
cDNA	O
in	O
COS	O
cells	O
or	O
insect	O
cells	O
yielded	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
carboxylase	I-PRGE
activity	O
and	O
vitamin	O
K	O
-	O
dependent	O
epoxidase	O
activity	O
.	O

The	O
recombinant	O
carboxylase	B-PRGE
has	O
a	O
molecular	O
mass	O
of	O
approximately	O
130	O
kDa	O
.	O

The	O
recombinant	O
Conus	O
carboxylase	B-PRGE
carboxylated	O
Phe	O
-	O
Leu	O
-	O
Glu	O
-	O
Glu	O
-	O
Leu	O
and	O
the	O
28	O
-	O
residue	O
peptides	O
based	O
on	O
residues	O
-	O
18	O
to	O
+	O
10	O
of	O
human	O
proprothrombin	B-PRGE
and	O
proFactor	B-PRGE
IX	I-PRGE
with	O
Km	O
values	O
of	O
420	O
micro	O
m	O
,	O
1	O
.	O
7	O
micro	O
m	O
and	O
6	O
micro	O
m	O
,	O
respectively	O
;	O
the	O
Km	O
for	O
vitamin	O
K	O
is	O
52	O
micro	O
m	O
.	O

The	O
Km	O
values	O
for	O
peptides	O
based	O
on	O
the	O
sequence	O
of	O
the	O
conotoxin	B-PRGE
epsilon	I-PRGE
-	I-PRGE
TxIX	I-PRGE
and	O
two	O
precursor	O
analogs	O
containing	O
12	O
or	O
29	O
amino	O
acids	O
of	O
the	O
propeptide	O
region	O
are	O
565	O
micro	O
m	O
,	O
75	O
micro	O
m	O
and	O
74	O
micro	O
m	O
,	O
respectively	O
.	O

The	O
recombinant	O
Conus	O
carboxylase	B-PRGE
,	O
in	O
the	O
absence	O
of	O
endogenous	O
substrates	O
,	O
is	O
stimulated	O
up	O
to	O
fivefold	O
by	O
vertebrate	O
propeptides	O
but	O
not	O
by	O
Conus	O
propeptides	O
.	O

These	O
results	O
suggest	O
two	O
propeptide	O
-	O
binding	O
sites	O
in	O
the	O
carboxylase	B-PRGE
,	O
one	O
that	O
binds	O
the	O
Conus	O
and	O
vertebrate	O
propeptides	O
and	O
is	O
required	O
for	O
substrate	O
binding	O
,	O
and	O
the	O
other	O
that	O
binds	O
only	O
the	O
vertebrate	O
propeptide	O
and	O
is	O
required	O
for	O
enzyme	O
stimulation	O
.	O

The	O
marked	O
functional	O
and	O
structural	O
similarities	O
between	O
the	O
Conus	O
carboxylase	B-PRGE
and	O
vertebrate	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
gamma	I-PRGE
-	I-PRGE
carboxylases	I-PRGE
argue	O
for	O
conservation	O
of	O
a	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
carboxylase	I-PRGE
across	O
animal	O
species	O
and	O
the	O
importance	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
synthesis	O
in	O
diverse	O
biological	O
systems	O
.	O

Cholesterol	O
-	O
modulating	O
agents	O
kill	O
acute	O
myeloid	O
leukemia	O
cells	O
and	O
sensitize	O
them	O
to	O
therapeutics	O
by	O
blocking	O
adaptive	O
cholesterol	O
responses	O
.	O

The	O
mevalonate	O
pathway	O
produces	O
many	O
critical	O
substances	O
in	O
cells	O
,	O
including	O
sterols	O
essential	O
for	O
membrane	O
structure	O
and	O
isoprenoids	O
vital	O
to	O
the	O
function	O
of	O
many	O
membrane	O
proteins	O
.	O

3	B-PRGE
-	I-PRGE
Hydroxy	I-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
methylglutaryl	I-PRGE
coenzyme	I-PRGE
A	I-PRGE
(	I-PRGE
HMG	I-PRGE
-	I-PRGE
CoA	I-PRGE
)	I-PRGE
reductase	I-PRGE
is	O
a	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
mevalonate	O
pathway	O
.	O

Because	O
cholesterol	O
is	O
a	O
product	O
of	O
this	O
pathway	O
,	O
HMG	B-PRGE
-	I-PRGE
CoA	I-PRGE
reductase	I-PRGE
inhibitors	O
(	O
statins	O
)	O
are	O
used	O
to	O
treat	O
hypercholesterolemia	O
.	O

Statins	O
are	O
also	O
toxic	O
to	O
several	O
malignancies	O
,	O
including	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

Although	O
this	O
toxicity	O
has	O
been	O
attributed	O
to	O
the	O
inhibition	O
of	O
Ras	O
/	O
Rho	O
isoprenylation	O
,	O
we	O
have	O
previously	O
shown	O
that	O
statin	O
toxicity	O
in	O
primary	O
AML	O
cells	O
(	O
AMLs	O
)	O
does	O
not	O
correlate	O
with	O
Ras	O
isoprenylation	O
or	O
with	O
activating	O
Ras	O
mutations	O
.	O

In	O
other	O
studies	O
,	O
we	O
have	O
shown	O
that	O
hypoxic	O
and	O
oxidant	O
injuries	O
induce	O
cholesterol	O
increments	O
in	O
renal	O
tubule	O
cells	O
and	O
that	O
statins	O
sensitize	O
these	O
cells	O
to	O
injury	O
by	O
blocking	O
protective	O
cholesterol	O
responses	O
.	O

We	O
now	O
demonstrate	O
that	O
exposing	O
particular	O
AMLs	O
to	O
radiochemotherapy	O
induces	O
much	O
greater	O
cellular	O
cholesterol	O
increments	O
than	O
those	O
seen	O
in	O
similarly	O
treated	O
normal	O
bone	O
marrow	O
.	O

Treatment	O
of	O
these	O
AMLs	O
with	O
mevastatin	O
or	O
zaragozic	O
acid	O
(	O
which	O
inhibits	O
cholesterol	O
synthesis	O
but	O
not	O
isoprenoid	O
synthesis	O
)	O
attenuates	O
the	O
cholesterol	O
increments	O
and	O
sensitizes	O
cells	O
to	O
radiochemotherapy	O
.	O

The	O
extent	O
of	O
toxicity	O
is	O
affected	O
by	O
the	O
availability	O
of	O
extracellular	O
lipoproteins	O
,	O
further	O
suggesting	O
that	O
cellular	O
cholesterol	O
is	O
critical	O
to	O
cell	O
survival	O
in	O
particular	O
AMLs	O
.	O

Because	O
zaragozic	O
acid	O
does	O
not	O
inhibit	O
isoprenoid	O
synthesis	O
,	O
these	O
data	O
suggest	O
that	O
cholesterol	O
modulation	O
is	O
an	O
important	O
mechanism	O
whereby	O
statins	O
exert	O
toxic	O
effects	O
on	O
some	O
AMLs	O
and	O
that	O
cholesterol	O
modulators	O
may	O
improve	O
therapeutic	O
ratios	O
in	O
AML	O
by	O
impacting	O
cholesterol	O
-	O
dependent	O
cytoresistance	O
.	O

The	O
ABSCISIC	B-PRGE
ACID	I-PRGE
INSENSITIVE	I-PRGE
3	I-PRGE
(	O
ABI3	B-PRGE
)	O
gene	O
is	O
modulated	O
by	O
farnesylation	O
and	O
is	O
involved	O
in	O
auxin	O
signaling	O
and	O
lateral	O
root	O
development	O
in	O
Arabidopsis	O
.	O

Genetic	O
screens	O
have	O
identified	O
a	O
number	O
of	O
genes	O
that	O
regulate	O
abscisic	O
acid	O
(	O
ABA	O
)	O
responsiveness	O
in	O
Arabidopsis	O
.	O

Using	O
a	O
combination	O
of	O
suppressor	O
screens	O
and	O
double	O
mutant	O
analysis	O
,	O
we	O
have	O
determined	O
a	O
genetic	O
relationship	O
for	O
a	O
number	O
of	O
these	O
ABA	O
response	O
loci	O
.	O

Based	O
on	O
germination	O
in	O
the	O
presence	O
of	O
exogenous	O
ABA	O
,	O
the	O
ABI1	B-PRGE
and	O
ABI2	B-PRGE
phosphatases	O
act	O
at	O
or	O
upstream	O
of	O
the	O
ERA1	B-PRGE
farnesyl	O
transferase	O
and	O
the	O
ABI3	B-PRGE
and	O
ABI5	B-PRGE
transcription	O
factors	O
act	O
at	O
or	O
downstream	O
of	O
ERA1	B-PRGE
.	O

In	O
contrast	O
with	O
ABI3	B-PRGE
and	O
ABI5	B-PRGE
,	O
the	O
ABI4	B-PRGE
transcription	O
factor	O
appears	O
to	O
act	O
at	O
or	O
upstream	O
of	O
ERA1	B-PRGE
.	O

Based	O
on	O
reporter	O
gene	O
constructs	O
,	O
the	O
upstream	O
regulation	O
of	O
ABI3	B-PRGE
by	O
ERA1	B-PRGE
occurs	O
at	O
least	O
partially	O
at	O
the	O
level	O
of	O
transcription	O
,	O
suggesting	O
that	O
this	O
lipid	O
modification	O
is	O
required	O
to	O
attenuate	O
ABI3	B-PRGE
expression	O
.	O

Similar	O
experiments	O
also	O
indicate	O
that	O
ABI3	B-PRGE
is	O
auxin	O
inducible	O
in	O
lateral	O
root	O
primordia	O
.	O

Related	O
to	O
this	O
,	O
loss	O
-	O
of	O
-	O
function	O
abi3	B-PRGE
alleles	O
show	O
reduced	O
lateral	O
root	O
responsiveness	O
in	O
the	O
presence	O
of	O
auxin	O
and	O
an	O
auxin	O
transport	O
inhibitor	O
,	O
and	O
era1	B-PRGE
mutants	O
have	O
increased	O
numbers	O
of	O
lateral	O
roots	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
that	O
genes	O
identified	O
through	O
ABA	O
responsive	O
germination	O
screens	O
such	O
as	O
ERA1	B-PRGE
and	O
ABI3	B-PRGE
have	O
functions	O
in	O
auxin	O
action	O
in	O
Arabidopsis	O
.	O

The	O
COP9	O
signalosome	O
interacts	O
with	O
SCF	O
UFO	B-PRGE
and	O
participates	O
in	O
Arabidopsis	O
flower	O
development	O
.	O

The	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
is	O
involved	O
in	O
multiple	O
developmental	O
processes	O
.	O

It	O
interacts	O
with	O
SCF	O
ubiquitin	B-PRGE
ligases	O
and	O
deconjugates	O
Nedd8	B-PRGE
/	O
Rub1	B-PRGE
from	O
cullins	O
(	O
deneddylation	O
)	O
.	O

CSN	O
is	O
highly	O
expressed	O
in	O
Arabidopsis	O
floral	O
tissues	O
.	O

To	O
investigate	O
the	O
role	O
of	O
CSN	O
in	O
flower	O
development	O
,	O
we	O
examined	O
the	O
expression	O
pattern	O
of	O
CSN	O
in	O
developing	O
flowers	O
.	O

We	O
report	O
here	O
that	O
two	O
csn1	B-PRGE
partially	O
deficient	O
Arabidopsis	O
strains	O
exhibit	O
aberrant	O
development	O
of	O
floral	O
organs	O
,	O
decline	O
of	O
APETALA3	B-PRGE
(	O
AP3	B-PRGE
)	O
expression	O
,	O
and	O
low	O
fertility	O
in	O
addition	O
to	O
defects	O
in	O
shoot	O
and	O
inflorescence	O
meristems	O
.	O

We	O
show	O
that	O
UNUSUAL	B-PRGE
FLORAL	I-PRGE
ORGANS	I-PRGE
(	O
UFO	B-PRGE
)	O
forms	O
a	O
SCF	O
(	O
UFO	B-PRGE
)	O
complex	O
,	O
which	O
is	O
associated	O
with	O
CSN	O
in	O
vivo	O
.	O

Genetic	O
interaction	O
analysis	O
indicates	O
that	O
CSN	O
is	O
necessary	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
activity	O
of	O
the	O
F	O
-	O
box	O
protein	O
UFO	B-PRGE
in	O
AP3	B-PRGE
activation	O
and	O
in	O
floral	O
organ	O
transformation	O
.	O

Compared	O
with	O
the	O
previously	O
reported	O
csn5	B-PRGE
antisense	O
and	O
csn1	B-PRGE
null	O
mutants	O
,	O
partial	O
deficiency	O
of	O
CSN1	B-PRGE
causes	O
a	O
reduction	O
in	O
the	O
level	O
of	O
CUL1	B-PRGE
in	O
the	O
mutant	O
flowers	O
without	O
an	O
obvious	O
defect	O
in	O
CUL1	B-PRGE
deneddylation	O
.	O

We	O
conclude	O
that	O
CSN	O
is	O
an	O
essential	O
regulator	O
of	O
Arabidopsis	O
flower	O
development	O
and	O
suggest	O
that	O
CSN	O
regulates	O
Arabidopsis	O
flower	O
development	O
in	O
part	O
by	O
modulating	O
SCF	O
(	O
UFO	B-PRGE
)	O
-	O
mediated	O
AP3	B-PRGE
activation	O
.	O

A	O
comparative	O
kinetic	O
study	O
on	O
the	O
singlet	O
molecular	O
oxygen	O
-	O
mediated	O
photoxidation	O
of	O
alpha	B-PRGE
-	I-PRGE
and	O
beta	B-PRGE
-	I-PRGE
chymotrypsins	I-PRGE
.	O

Kinetic	O
aspects	O
of	O
the	O
sensitized	O
photooxidation	O
of	O
alpha	B-PRGE
-	I-PRGE
and	O
beta	B-PRGE
-	I-PRGE
chymotrypsins	I-PRGE
have	O
been	O
studied	O
at	O
pH	O
6	O
and	O
8	O
.	O

The	O
sensitization	O
,	O
employing	O
classical	O
O2	O
(	O
1Deltag	O
)	O
-	O
photogenerators	O
,	O
such	O
as	O
xanthene	O
dyes	O
,	O
is	O
a	O
kinetically	O
intricate	O
process	O
because	O
of	O
the	O
presence	O
of	O
ground	O
state	O
dye	O
-	O
protein	O
associations	O
and	O
to	O
the	O
simultaneous	O
participation	O
of	O
superoxide	O
ion	O
and	O
singlet	O
molecular	O
oxygen	O
[	O
O2	O
(	O
1Deltag	O
)	O
]	O
.	O

Both	O
proteins	O
,	O
that	O
possess	O
the	O
same	O
distribution	O
pattern	O
of	O
photooxidizable	O
amino	O
acids	O
,	O
suffer	O
a	O
pure	O
O2	O
(	O
1Deltag	O
)	O
-	O
mediated	O
photodynamic	O
attack	O
,	O
using	O
the	O
carbonylic	O
sensitizer	O
Perinaphthenone	O
.	O

Overall	O
and	O
reactive	O
rate	O
constants	O
for	O
the	O
O2	O
(	O
1Deltag	O
)	O
-	O
quenching	O
(	O
in	O
the	O
order	O
of	O
108	O
and	O
107	O
/	O
M	O
/	O
s	O
,	O
respectively	O
)	O
,	O
and	O
rates	O
of	O
oxygen	O
consumption	O
determined	O
by	O
time	O
-	O
resolved	O
,	O
spectroscopic	O
and	O
polarographic	O
methods	O
indicate	O
that	O
alpha	B-PRGE
-	I-PRGE
and	O
beta	B-PRGE
-	I-PRGE
chymotrypsins	I-PRGE
are	O
less	O
photooxidizable	O
at	O
pH	O
6	O
,	O
as	O
a	O
result	O
of	O
an	O
enhancement	O
of	O
the	O
O2	O
(	O
1Deltag	O
)	O
-	O
physical	O
quenching	O
component	O
.	O

In	O
general	O
terms	O
,	O
beta	B-PRGE
-	I-PRGE
chymotrypsin	I-PRGE
exhibits	O
the	O
greater	O
overall	O
proclivity	O
to	O
interact	O
with	O
O2	O
(	O
1Deltag	O
)	O
,	O
whereas	O
structural	O
factors	O
,	O
possibly	O
evidenced	O
by	O
a	O
higher	O
exposure	O
of	O
the	O
reactive	O
tryptophan	O
residues	O
,	O
impart	O
an	O
increased	O
photooxidation	O
degree	O
to	O
the	O
proteins	O
at	O
pH	O
8	O
,	O
specially	O
to	O
the	O
alpha	B-PRGE
-	I-PRGE
chymotrypsin	I-PRGE
.	O

Sequence	O
analysis	O
of	O
a	O
gene	O
product	O
synthesized	O
by	O
Xanthomonas	O
sp	O
.	O
during	O
growth	O
on	O
natural	O
rubber	O
latex	O
.	O

Xanthomonas	O
sp	O
.	O
secretes	O
an	O
extracellular	O
protein	O
(	O
Mr	O
approximately	O
70	O
+	O
/	O
-	O
5	O
kDa	O
)	O
during	O
growth	O
on	O
purified	O
natural	O
rubber	O
[	O
poly	O
(	O
1	O
,	O
4	O
-	O
cis	O
-	O
isoprene	O
)	O
]	O
but	O
not	O
during	O
growth	O
on	O
water	O
-	O
soluble	O
carbon	O
sources	O
such	O
as	O
glucose	O
or	O
gluconate	O
.	O

A	O
1	O
.	O
3	O
kbp	O
DNA	O
fragment	O
coding	O
for	O
an	O
internal	O
part	O
of	O
the	O
structural	O
gene	O
of	O
the	O
70	O
kDa	O
protein	O
was	O
amplified	O
by	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
amino	O
acid	O
sequence	O
information	O
obtained	O
after	O
Edman	O
degradation	O
of	O
selected	O
trypsin	O
-	O
generated	O
peptides	O
of	O
the	O
purified	O
70	O
kDa	O
protein	O
.	O

The	O
PCR	O
product	O
was	O
used	O
as	O
a	O
DNA	O
probe	O
to	O
clone	O
the	O
complete	O
structural	O
gene	O
from	O
genomic	O
DNA	O
of	O
Xanthomonas	O
sp	O
.	O

The	O
sequenced	O
DNA	O
contained	O
a	O
2037	O
bp	O
open	O
reading	O
frame	O
which	O
coded	O
for	O
a	O
polypeptide	O
of	O
678	O
amino	O
acids	O
(	O
Mr	O
74	O
.	O
6	O
kDa	O
)	O
and	O
which	O
included	O
the	O
features	O
of	O
the	O
N	O
-	O
terminal	O
signal	O
peptidase	O
cleavage	O
site	O
(	O
Mr	O
approximately	O
72	O
.	O
9	O
kDa	O
for	O
the	O
mature	O
protein	O
)	O
.	O

Analysis	O
of	O
the	O
amino	O
acid	O
sequence	O
revealed	O
the	O
presence	O
of	O
two	O
heme	O
binding	O
motifs	O
(	O
CXXCH	O
)	O
and	O
a	O
approximately	O
20	O
amino	O
acids	O
long	O
sequence	O
that	O
is	O
conserved	O
in	O
the	O
Paracoccus	O
denitrificans	O
and	O
Pseudomonas	O
aeruginosa	O
diheme	O
cytochrome	B-PRGE
c	I-PRGE
peroxidases	I-PRGE
(	O
CCPs	B-PRGE
)	O
.	O

This	O
region	O
includes	O
a	O
histidine	O
residue	O
(	O
H519	O
in	O
Xanthomonas	O
sp	O
.	O
and	O
H265	O
and	O
H271	O
in	O
the	O
Pseudomonas	O
strains	O
,	O
respectively	O
)	O
that	O
is	O
essential	O
for	O
activity	O
in	O
CCPs	B-PRGE
and	O
that	O
is	O
also	O
conserved	O
in	O
other	O
bacterial	O
oxidases	O
.	O

Blast	O
analysis	O
confirmed	O
the	O
relatedness	O
of	O
the	O
70	O
kDa	O
protein	O
to	O
heme	O
-	O
containing	O
oxidases	O
and	O
suggested	O
that	O
it	O
is	O
a	O
member	O
of	O
a	O
new	O
family	O
of	O
relatively	O
large	O
(	O
approximately	O
500	O
to	O
approximately	O
1000	O
amino	O
acids	O
)	O
extracellular	O
proteins	O
with	O
so	O
far	O
unknown	O
function	O
being	O
only	O
far	O
related	O
in	O
amino	O
acid	O
sequence	O
to	O
P	O
.	O
denitrificans	O
and	O
P	O
.	O
aeruginosa	O
CCPs	B-PRGE
.	O

High	O
affinity	O
for	O
farnesyltransferase	O
and	O
alternative	O
prenylation	O
contribute	O
individually	O
to	O
K	B-PRGE
-	I-PRGE
Ras4B	I-PRGE
resistance	O
to	O
farnesyltransferase	O
inhibitors	O
.	O

Farnesyltransferase	O
inhibitors	O
(	O
FTIs	O
)	O
block	O
Ras	O
farnesylation	O
,	O
subcellular	O
localization	O
and	O
activity	O
,	O
and	O
inhibit	O
the	O
growth	O
of	O
Ras	O
-	O
transformed	O
cells	O
.	O

Although	O
FTIs	O
are	O
ineffective	O
against	O
K	B-PRGE
-	I-PRGE
Ras4B	I-PRGE
,	O
the	O
Ras	O
isoform	O
most	O
commonly	O
mutated	O
in	O
human	O
cancers	O
,	O
they	O
can	O
inhibit	O
the	O
growth	O
of	O
tumors	O
containing	O
oncogenic	O
K	B-PRGE
-	I-PRGE
Ras4B	I-PRGE
,	O
implicating	O
other	O
farnesylated	O
proteins	O
or	O
suggesting	O
distinct	O
functions	O
for	O
farnesylated	O
and	O
for	O
geranylgeranylated	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
,	O
which	O
is	O
generated	O
when	O
farnesyltransferase	O
is	O
inhibited	O
.	O

In	O
addition	O
to	O
bypassing	O
FTI	O
blockade	O
through	O
geranylgeranylation	O
,	O
K	B-PRGE
-	I-PRGE
Ras4B	I-PRGE
resistance	O
to	O
FTIs	O
may	O
also	O
result	O
from	O
its	O
higher	O
affinity	O
for	O
farnesyltransferase	O
.	O

Using	O
chimeric	O
Ras	O
proteins	O
containing	O
all	O
combinations	O
of	O
Ras	O
background	O
,	O
CAAX	O
motif	O
,	O
and	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
polybasic	O
domain	O
,	O
we	O
show	O
that	O
either	O
a	O
polybasic	O
domain	O
or	O
an	O
alternatively	O
prenylated	O
CAAX	O
renders	O
Ras	O
prenylation	O
,	O
Ras	O
-	O
induced	O
Elk	B-PRGE
-	I-PRGE
1	I-PRGE
activation	O
,	O
and	O
anchorage	O
-	O
independent	O
cell	O
growth	O
FTI	O
-	O
resistant	O
.	O

The	O
polybasic	O
domain	O
alone	O
increases	O
the	O
affinity	O
of	O
Ras	O
for	O
farnesyltransferase	O
,	O
implying	O
independent	O
roles	O
for	O
each	O
K	B-PRGE
-	I-PRGE
Ras4B	I-PRGE
sequence	O
element	O
in	O
FTI	O
resistance	O
.	O

Using	O
microarray	O
analysis	O
and	O
colony	O
formation	O
assays	O
,	O
we	O
confirm	O
that	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
function	O
is	O
independent	O
of	O
the	O
identity	O
of	O
the	O
prenyl	O
group	O
and	O
,	O
therefore	O
,	O
that	O
FTI	O
inhibition	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
transformed	O
cells	O
is	O
likely	O
to	O
be	O
independent	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
inhibition	O
.	O

Our	O
results	O
imply	O
that	O
relevant	O
FTI	O
targets	O
will	O
lack	O
both	O
polybasic	O
and	O
potentially	O
geranylgeranylated	O
methionine	O
-	O
CAAX	O
motifs	O
.	O

Disruption	O
of	O
the	O
COP9	O
signalosome	O
Csn2	B-PRGE
subunit	O
in	O
mice	O
causes	O
deficient	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
p53	B-PRGE
and	O
cyclin	O
E	O
,	O
and	O
early	O
embryonic	O
death	O
.	O

Csn2	B-PRGE
(	O
Trip15	B-PRGE
/	O
Cops2	B-PRGE
/	O
Alien	B-PRGE
)	O
encodes	O
the	O
second	O
subunit	O
of	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
an	O
eight	O
-	O
subunit	O
heteromeric	O
complex	O
homologous	O
to	O
the	O
lid	O
subcomplex	O
of	O
the	O
26S	O
proteasome	O
.	O

CSN	O
is	O
a	O
regulator	O
of	O
SCF	O
(	O
Skp1	B-PRGE
-	O
cullin	O
-	O
F	O
-	O
box	O
protein	O
)	O
ubiquitin	B-PRGE
ligases	O
,	O
mostly	O
through	O
the	O
enzymatic	O
activity	O
that	O
deconjugates	O
the	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
Nedd8	B-PRGE
from	O
the	O
SCF	O
Cul1	B-PRGE
component	O
.	O

In	O
addition	O
,	O
CSN	O
associates	O
with	O
protein	O
kinase	O
activities	O
targeting	O
p53	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
and	O
IkappaB	O
for	O
phosphorylation	O
.	O

Csn2	B-PRGE
also	O
interacts	O
with	O
and	O
regulates	O
a	O
subset	O
of	O
nuclear	O
hormone	O
receptors	O
and	O
is	O
considered	O
a	O
novel	O
corepressor	O
.	O

We	O
report	O
that	O
targeted	O
disruption	O
of	O
Csn2	B-PRGE
in	O
mice	O
caused	O
arrest	O
of	O
embryo	O
development	O
at	O
the	O
peri	O
-	O
implantation	O
stage	O
.	O

Csn2	B-PRGE
(	O
-	O
/	O
-	O
)	O
blastocysts	O
failed	O
to	O
outgrow	O
in	O
culture	O
and	O
exhibited	O
a	O
cell	O
proliferation	O
defect	O
in	O
inner	O
cell	O
mass	O
,	O
accompanied	O
by	O
a	O
slight	O
decrease	O
in	O
Oct4	B-PRGE
.	O

In	O
addition	O
,	O
lack	O
of	O
Csn2	B-PRGE
disrupted	O
the	O
CSN	O
complex	O
and	O
resulted	O
in	O
a	O
drastic	O
increase	O
in	O
cyclin	O
E	O
,	O
supporting	O
a	O
role	O
for	O
CSN	O
in	O
cooperating	O
with	O
the	O
SCF	O
-	O
ubiquitin	B-PRGE
-	O
proteasome	O
system	O
to	O
regulate	O
protein	O
turnover	O
.	O

Furthermore	O
,	O
Csn2	B-PRGE
(	O
-	O
/	O
-	O
)	O
embryos	O
contained	O
elevated	O
levels	O
of	O
p53	B-PRGE
and	O
p21	B-PRGE
,	O
which	O
may	O
contribute	O
to	O
premature	O
cell	O
cycle	O
arrest	O
of	O
the	O
mutant	O
.	O

On	O
again	O
-	O
off	O
again	O
:	O
COP9	O
signalosome	O
turns	O
the	O
key	O
on	O
protein	O
degradation	O
.	O

The	O
COP9	O
signalosome	O
is	O
an	O
eight	O
-	O
subunit	O
protein	O
complex	O
that	O
regulates	O
protein	O
ubiquitination	O
and	O
protein	O
turnover	O
in	O
a	O
variety	O
of	O
plant	O
developmental	O
and	O
physiological	O
contexts	O
,	O
including	O
light	O
-	O
regulated	O
development	O
,	O
hormone	O
signaling	O
,	O
and	O
defense	O
against	O
pathogens	O
.	O

In	O
all	O
eukaryotes	O
tested	O
,	O
the	O
COP9	O
signalosome	O
is	O
able	O
to	O
posttranslationally	O
modify	O
the	O
cullin	O
subunit	O
of	O
E3	O
-	O
ubiquitin	B-PRGE
-	O
ligase	O
complexes	O
by	O
cleaving	O
off	O
the	O
covalently	O
coupled	O
peptide	O
,	O
Nedd8	B-PRGE
.	O

Two	O
contrasting	O
models	O
ascribe	O
stimulatory	O
or	O
inhibitory	O
roles	O
to	O
the	O
modification	O
of	O
cullin	O
/	O
E3	O
that	O
is	O
mediated	O
by	O
the	O
COP9	O
signalosome	O
.	O

There	O
is	O
considerable	O
disagreement	O
as	O
to	O
whether	O
Nedd8	B-PRGE
cleavage	O
underlies	O
all	O
of	O
the	O
COP9	O
signalosome	O
'	O
s	O
numerous	O
cellular	O
and	O
phenotypic	O
effects	O
.	O

This	O
is	O
because	O
macroscopic	O
phenotypes	O
do	O
not	O
always	O
correlate	O
with	O
biochemical	O
defects	O
in	O
COP9	O
signalosome	O
mutants	O
.	O

Additional	O
biochemical	O
activities	O
,	O
including	O
protein	O
interactions	O
with	O
the	O
cellular	O
machineries	O
for	O
protein	O
phosphorylation	O
,	O
protein	O
turnover	O
,	O
and	O
protein	O
translation	O
,	O
have	O
been	O
proposed	O
to	O
account	O
for	O
the	O
role	O
of	O
the	O
COP9	O
signalosome	O
in	O
development	O
and	O
disease	O
.	O

But1	B-PRGE
and	O
But2	B-PRGE
proteins	O
bind	O
to	O
Uba3	B-PRGE
,	O
a	O
catalytic	O
subunit	O
of	O
E1	O
for	O
neddylation	O
,	O
in	O
fission	O
yeast	O
.	O

NEDD8	B-PRGE
/	O
Rub1	B-PRGE
is	O
the	O
most	O
homologous	O
protein	O
to	O
ubiquitin	B-PRGE
among	O
the	O
ubiquitin	B-PRGE
-	O
like	O
proteins	O
,	O
and	O
it	O
is	O
covalently	O
linked	O
to	O
target	O
proteins	O
via	O
the	O
C	O
-	O
terminal	O
glycine	O
residue	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitylation	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
NEDD8	B-PRGE
ligation	O
pathway	O
remains	O
elusive	O
.	O

Using	O
the	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
isolated	O
novel	O
genes	O
from	O
the	O
Schizosaccharomyces	O
pombe	O
cDNA	O
library	O
whose	O
products	O
bind	O
to	O
Uba3	B-PRGE
,	O
which	O
is	O
a	O
catalytic	O
protein	O
for	O
E1	O
-	O
like	O
activity	O
of	O
the	O
NEDD8	B-PRGE
pathway	O
.	O

We	O
designated	O
these	O
genes	O
but1	B-PRGE
(	O
+	O
)	O
and	O
but2	B-PRGE
(	O
+	O
)	O
(	O
for	O
proteins	O
that	O
bind	O
to	O
Uba	B-PRGE
three	I-PRGE
)	O
.	O

But1	B-PRGE
is	O
a	O
nuclear	O
protein	O
and	O
its	O
overexpression	O
caused	O
cell	O
elongation	O
,	O
which	O
is	O
a	O
common	O
phenotype	O
of	O
the	O
NEDD8	B-PRGE
pathway	O
defective	O
mutant	O
in	O
S	O
.	O
pombe	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
but1	B-PRGE
(	O
+	O
)	O
in	O
ned8	B-PRGE
-	O
temperature	O
sensitive	O
mutant	O
had	O
a	O
deleterious	O
effect	O
even	O
under	O
permissive	O
temperatures	O
.	O

Our	O
results	O
suggest	O
that	O
But1	B-PRGE
may	O
have	O
an	O
inhibitory	O
role	O
in	O
the	O
NEDD8	B-PRGE
pathway	O
.	O

Rac	O
GTPase	O
instructs	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
by	O
conveying	O
the	O
SCF	O
complex	O
and	O
IkBalpha	B-PRGE
to	O
the	O
ruffling	O
membranes	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
ubiquitously	O
expressed	O
transcription	O
factor	O
that	O
plays	O
a	O
central	O
role	O
in	O
directing	O
a	O
vast	O
range	O
of	O
cellular	O
functions	O
.	O

Its	O
activation	O
is	O
controlled	O
by	O
the	O
Rac	O
GTPase	O
and	O
relies	O
on	O
the	O
coordinated	O
cooperation	O
of	O
the	O
E3	O
-	O
ligase	O
complex	O
SCF	O
(	O
betaTrCP	B-PRGE
)	O
,	O
composed	O
by	O
Skp	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
Cullin	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
Rbx	B-PRGE
/	O
Roc1	B-PRGE
,	O
and	O
the	O
beta	B-PRGE
-	I-PRGE
TrCP	I-PRGE
proteins	O
.	O

Recently	O
,	O
Cullin	B-PRGE
-	I-PRGE
1	I-PRGE
has	O
been	O
reported	O
to	O
form	O
a	O
complex	O
with	O
the	O
activated	O
Rac	O
GTPase	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
specific	O
activation	O
of	O
the	O
Rac	O
GTPase	O
,	O
besides	O
directing	O
its	O
own	O
positioning	O
,	O
induces	O
the	O
relocalization	O
of	O
the	O
SCF	O
component	O
Cullin	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
the	O
ruffling	O
membranes	O
.	O

This	O
occurred	O
only	O
if	O
the	O
ruffles	O
were	O
stimulated	O
by	O
the	O
Rac	O
GTPase	O
and	O
was	O
accompanied	O
by	O
the	O
repositioning	O
to	O
the	O
same	O
intracellular	O
compartment	O
of	O
the	O
SCF	O
protein	O
Skp	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
the	O
ubiquitin	B-PRGE
-	O
like	O
molecule	O
Nedd	B-PRGE
-	I-PRGE
8	I-PRGE
.	O

The	O
SCF	O
substrate	O
IkBalpha	B-PRGE
was	O
also	O
directed	O
to	O
the	O
ruffling	O
membranes	O
in	O
a	O
Rac	O
-	O
dependent	O
way	O
.	O

The	O
novelty	O
of	O
these	O
findings	O
is	O
in	O
respect	O
to	O
the	O
demonstration	O
that	O
the	O
correct	O
positioning	O
at	O
the	O
ruffling	O
membranes	O
is	O
crucial	O
for	O
the	O
subsequent	O
series	O
of	O
events	O
that	O
leads	O
to	O
IkBalpha	B-PRGE
proteasomal	O
degradation	O
and	O
the	O
resultant	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Consequently	O
,	O
this	O
points	O
to	O
the	O
role	O
of	O
Rac	O
as	O
a	O
docking	O
molecule	O
in	O
NF	O
-	O
kappaB	O
activation	O
.	O

PIASy	B-PRGE
-	O
mediated	O
repression	O
of	O
the	O
androgen	B-PRGE
receptor	I-PRGE
is	O
independent	O
of	O
sumoylation	O
.	O

PIASy	B-PRGE
,	O
a	O
member	O
of	O
the	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
(	O
PIAS	O
)	O
family	O
,	O
represses	O
the	O
transcriptional	O
activity	O
of	O
the	O
androgen	B-PRGE
receptor	I-PRGE
(	O
AR	B-PRGE
)	O
.	O

In	O
this	O
report	O
,	O
we	O
investigate	O
the	O
mechanism	O
of	O
PIASy	B-PRGE
-	O
mediated	O
repression	O
of	O
AR	B-PRGE
.	O

We	O
show	O
that	O
AR	B-PRGE
binds	O
to	O
the	O
RING	O
-	O
finger	O
like	O
domain	O
of	O
PIASy	B-PRGE
.	O

PIASy	B-PRGE
contains	O
two	O
transcriptional	O
repression	O
domains	O
,	O
RD1	O
and	O
RD2	O
.	O

RD1	O
,	O
but	O
not	O
RD2	O
,	O
is	O
required	O
for	O
PIASy	B-PRGE
-	O
mediated	O
repression	O
of	O
AR	B-PRGE
.	O

We	O
show	O
that	O
the	O
RD1	O
domain	O
binds	O
HDAC1	B-PRGE
and	O
HDAC2	B-PRGE
and	O
that	O
HDAC	O
activity	O
is	O
required	O
for	O
PIASy	B-PRGE
-	O
mediated	O
AR	B-PRGE
repression	O
.	O

PIAS	O
proteins	O
possess	O
small	O
ubiquitin	B-PRGE
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
E3	O
ligase	O
activity	O
.	O

Conjugation	O
of	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
AR	B-PRGE
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
AR	B-PRGE
activity	O
.	O

We	O
examine	O
if	O
the	O
SUMO	O
ligase	O
activity	O
of	O
PIASy	B-PRGE
is	O
required	O
for	O
PIASy	B-PRGE
to	O
repress	O
AR	B-PRGE
.	O

We	O
show	O
that	O
a	O
mutant	O
PIASy	B-PRGE
,	O
defective	O
in	O
promoting	O
sumoylation	O
,	O
retains	O
the	O
ability	O
to	O
repress	O
AR	B-PRGE
transcription	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
all	O
the	O
known	O
sumoylation	O
acceptor	O
sites	O
of	O
AR	B-PRGE
does	O
not	O
affect	O
the	O
transrepression	O
activity	O
of	O
PIASy	B-PRGE
on	O
AR	B-PRGE
.	O

Our	O
results	O
suggest	O
that	O
PIASy	B-PRGE
may	O
repress	O
AR	B-PRGE
by	O
recruiting	O
histone	O
deacetylases	O
,	O
independent	O
of	O
its	O
SUMO	O
ligase	O
activity	O
.	O

pVHL	B-PRGE
modification	O
by	O
NEDD8	B-PRGE
is	O
required	O
for	O
fibronectin	B-PRGE
matrix	O
assembly	O
and	O
suppression	O
of	O
tumor	O
development	O
.	O

Functional	O
inactivation	O
of	O
the	O
von	B-PRGE
Hippel	I-PRGE
-	I-PRGE
Lindau	I-PRGE
(	I-PRGE
VHL	I-PRGE
)	I-PRGE
tumor	I-PRGE
suppressor	I-PRGE
gene	O
is	O
the	O
cause	O
of	O
the	O
familial	O
VHL	O
disease	O
and	O
most	O
sporadic	O
renal	O
clear	O
-	O
cell	O
carcinomas	O
(	O
RCC	O
)	O
.	O

pVHL	B-PRGE
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
the	O
destruction	O
of	O
hypoxia	B-PRGE
-	I-PRGE
inducible	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
HIF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
subunits	O
via	O
ubiquitin	B-PRGE
-	O
mediated	O
proteolysis	O
and	O
in	O
the	O
regulation	O
of	O
fibronectin	B-PRGE
matrix	O
assembly	O
.	O

Although	O
most	O
disease	O
-	O
causing	O
pVHL	B-PRGE
mutations	O
hinder	O
the	O
regulation	O
of	O
the	O
HIF	O
pathway	O
,	O
every	O
disease	O
-	O
causing	O
pVHL	B-PRGE
mutant	O
tested	O
to	O
date	O
has	O
failed	O
to	O
promote	O
the	O
assembly	O
of	O
the	O
fibronectin	B-PRGE
matrix	O
,	O
underscoring	O
its	O
potential	O
importance	O
in	O
VHL	O
disease	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
ubiquitin	B-PRGE
-	O
like	O
molecule	O
called	O
NEDD8	B-PRGE
covalently	O
modifies	O
pVHL	B-PRGE
.	O

A	O
nonneddylateable	O
pVHL	B-PRGE
mutant	O
,	O
while	O
retaining	O
its	O
ability	O
to	O
ubiquitylate	O
HIF	O
,	O
failed	O
to	O
bind	O
to	O
and	O
promote	O
the	O
assembly	O
of	O
the	O
fibronectin	B-PRGE
matrix	O
.	O

Expression	O
of	O
the	O
neddylation	O
-	O
defective	O
pVHL	B-PRGE
in	O
RCC	O
cells	O
,	O
while	O
restoring	O
the	O
regulation	O
of	O
HIF	O
,	O
failed	O
to	O
promote	O
the	O
differentiated	O
morphology	O
in	O
a	O
three	O
-	O
dimensional	O
growth	O
assay	O
and	O
was	O
insufficient	O
to	O
suppress	O
the	O
formation	O
of	O
tumors	O
in	O
SCID	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
NEDD8	B-PRGE
modification	O
of	O
pVHL	B-PRGE
plays	O
an	O
important	O
role	O
in	O
fibronectin	B-PRGE
matrix	O
assembly	O
and	O
that	O
in	O
the	O
absence	O
of	O
such	O
regulation	O
,	O
an	O
intact	O
HIF	O
pathway	O
is	O
insufficient	O
to	O
prevent	O
VHL	B-PRGE
-	O
associated	O
tumorigenesis	O
.	O

Role	O
of	O
the	O
isoprenyl	O
pocket	O
of	O
the	O
G	O
protein	O
beta	O
gamma	O
subunit	O
complex	O
in	O
the	O
binding	O
of	O
phosducin	B-PRGE
and	O
phosducin	B-PRGE
-	I-PRGE
like	I-PRGE
protein	O
.	O

Phosducin	B-PRGE
(	O
Pdc	B-PRGE
)	O
and	O
phosducin	B-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
(	O
PhLP	B-PRGE
)	O
regulate	O
G	O
protein	O
-	O
mediated	O
signaling	O
by	O
binding	O
to	O
the	O
betagamma	O
subunit	O
complex	O
of	O
heterotrimeric	O
G	O
proteins	O
(	O
Gbetagamma	O
)	O
and	O
removing	O
the	O
dimer	O
from	O
cell	O
membranes	O
.	O

The	O
binding	O
of	O
Pdc	B-PRGE
induces	O
a	O
conformational	O
change	O
in	O
the	O
beta	O
-	O
propeller	O
structure	O
of	O
Gbetagamma	O
,	O
creating	O
a	O
pocket	O
between	O
blades	O
6	O
and	O
7	O
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
isoprenyl	O
group	O
of	O
Gbetagamma	O
inserts	O
into	O
this	O
pocket	O
,	O
stabilizing	O
the	O
Pdc	B-PRGE
.	O
Gbetagamma	O
structure	O
and	O
decreasing	O
the	O
affinity	O
of	O
the	O
complex	O
for	O
the	O
lipid	O
bilayer	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
the	O
binding	O
of	O
Pdc	B-PRGE
and	O
PhLP	B-PRGE
to	O
several	O
Gbetagamma	O
dimers	O
containing	O
variants	O
of	O
the	O
beta	O
or	O
gamma	O
subunit	O
was	O
measured	O
.	O

These	O
variants	O
included	O
modifications	O
of	O
the	O
isoprenyl	O
group	O
(	O
gamma	O
)	O
,	O
residues	O
involved	O
in	O
the	O
conformational	O
change	O
(	O
beta	O
)	O
,	O
and	O
residues	O
lining	O
the	O
proposed	O
prenyl	O
pocket	O
(	O
beta	O
)	O
.	O

Switching	O
prenyl	O
groups	O
from	O
farnesyl	O
to	O
geranylgeranyl	O
or	O
vice	O
versa	O
had	O
little	O
effect	O
on	O
binding	O
.	O

However	O
,	O
alanine	O
substitution	O
of	O
one	O
residue	O
in	O
the	O
beta	O
subunit	O
involved	O
in	O
the	O
conformational	O
change	O
(	O
W332	O
)	O
decreased	O
binding	O
5	O
-	O
fold	O
.	O

Alanine	O
substitution	O
of	O
certain	O
residues	O
within	O
the	O
prenyl	O
pocket	O
caused	O
only	O
minor	O
decreases	O
in	O
binding	O
,	O
while	O
a	O
lysine	O
substitution	O
of	O
T329	O
within	O
the	O
pocket	O
inhibited	O
binding	O
10	O
-	O
fold	O
.	O

Molecular	O
modeling	O
of	O
the	O
binding	O
energy	O
of	O
the	O
Pdc	B-PRGE
.	O
Gbeta	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
gamma	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
complex	O
required	O
insertion	O
of	O
the	O
geranylgeranyl	O
group	O
into	O
the	O
prenyl	O
pocket	O
in	O
order	O
to	O
accurately	O
predict	O
the	O
effects	O
of	O
prenyl	O
pocket	O
amino	O
acid	O
substitutions	O
.	O

Finally	O
,	O
a	O
dimer	O
containing	O
a	O
gamma	O
subunit	O
with	O
no	O
prenyl	O
group	O
(	O
gamma	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
-	O
C68S	O
)	O
decreased	O
binding	O
by	O
nearly	O
20	O
-	O
fold	O
.	O

These	O
results	O
support	O
the	O
structural	O
model	O
in	O
which	O
the	O
prenyl	O
group	O
escapes	O
contact	O
with	O
the	O
aqueous	O
milieu	O
by	O
inserting	O
into	O
the	O
prenyl	O
pocket	O
and	O
stabilizing	O
the	O
Pdc	B-PRGE
-	O
binding	O
conformation	O
of	O
Gbetagamma	O
.	O

Atg21	B-PRGE
is	O
a	O
phosphoinositide	O
binding	O
protein	O
required	O
for	O
efficient	O
lipidation	O
and	O
localization	O
of	O
Atg8	B-PRGE
during	O
uptake	O
of	O
aminopeptidase	B-PRGE
I	I-PRGE
by	O
selective	O
autophagy	O
.	O

Delivery	O
of	O
proteins	O
and	O
organelles	O
to	O
the	O
vacuole	O
by	O
autophagy	O
and	O
the	O
cytoplasm	O
to	O
vacuole	O
targeting	O
(	O
Cvt	O
)	O
pathway	O
involves	O
novel	O
rearrangements	O
of	O
membrane	O
resulting	O
in	O
the	O
formation	O
of	O
vesicles	O
that	O
fuse	O
with	O
the	O
vacuole	O
.	O

The	O
mechanism	O
of	O
vesicle	O
formation	O
and	O
the	O
origin	O
of	O
the	O
membrane	O
are	O
complex	O
issues	O
still	O
to	O
be	O
resolved	O
.	O

Atg18	B-PRGE
and	O
Atg21	B-PRGE
are	O
proteins	O
essential	O
to	O
vesicle	O
formation	O
and	O
together	O
with	O
Ygr223c	B-PRGE
form	O
a	O
novel	O
family	O
of	O
phosphoinositide	O
binding	O
proteins	O
that	O
are	O
associated	O
with	O
the	O
vacuole	O
and	O
perivacuolar	O
structures	O
.	O

Their	O
localization	O
requires	O
the	O
activity	O
of	O
Vps34	B-PRGE
,	O
suggesting	O
that	O
phosphatidylinositol	O
(	O
3	O
)	O
phosphate	O
may	O
be	O
essential	O
for	O
their	O
function	O
.	O

The	O
activity	O
of	O
Atg18	B-PRGE
is	O
vital	O
for	O
all	O
forms	O
of	O
autophagy	O
,	O
whereas	O
Atg21	B-PRGE
is	O
required	O
for	O
the	O
Cvt	O
pathway	O
but	O
not	O
for	O
nitrogen	O
starvation	O
-	O
induced	O
autophagy	O
.	O

The	O
loss	O
of	O
Atg21	B-PRGE
results	O
in	O
the	O
absence	O
of	O
Atg8	B-PRGE
from	O
the	O
pre	O
-	O
autophagosomal	O
structure	O
(	O
PAS	O
)	O
,	O
which	O
may	O
be	O
ascribed	O
to	O
a	O
reduced	O
rate	O
of	O
conjugation	O
of	O
Atg8	B-PRGE
to	O
phosphatidylethanolamine	O
.	O

A	O
similar	O
defect	O
in	O
localization	O
of	O
a	O
second	O
ubiquitin	B-PRGE
-	O
like	O
conjugate	O
,	O
Atg12	B-PRGE
-	O
Atg5	B-PRGE
,	O
suggests	O
that	O
Atg21	B-PRGE
may	O
be	O
involved	O
in	O
the	O
recruitment	O
of	O
membrane	O
to	O
the	O
PAS	O
.	O

Effect	O
of	O
the	O
statin	O
atorvastatin	O
on	O
intracellular	O
signalling	O
by	O
the	O
prostacyclin	B-PRGE
receptor	I-PRGE
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Prostacyclin	O
plays	O
a	O
central	O
role	O
within	O
the	O
vasculature	O
.	O

We	O
have	O
previously	O
established	O
that	O
the	O
prostacyclin	B-PRGE
receptor	I-PRGE
(	O
IP	B-PRGE
)	O
undergoes	O
isoprenylation	O
,	O
a	O
lipid	O
modification	O
obligate	O
for	O
its	O
function	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
hydroxy	O
methyl	O
glutaryl	O
co	O
-	O
enzyme	O
A	O
reductase	O
inhibitor	O
atorvastatin	O
on	O
signalling	O
and	O
function	O
of	O
the	O
IP	B-PRGE
expressed	O
in	O
mammalian	O
whole	O
cells	O
and	O
in	O
platelets	O
isolated	O
from	O
patients	O
undergoing	O
therapeutic	O
intervention	O
with	O
atorvastatin	O
.	O

Initially	O
,	O
the	O
effect	O
of	O
atorvastatin	O
on	O
signalling	O
by	O
the	O
human	O
(	O
h	O
)	O
and	O
mouse	O
(	O
m	O
)	O
IP	B-PRGE
overexpressed	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
and	O
the	O
hIP	B-PRGE
endogenously	O
expressed	O
in	O
human	O
erythroleukaemic	O
92	O
.	O
1	O
.	O
7	O
cells	O
was	O
investigated	O
.	O

Atorvastatin	O
significantly	O
reduced	O
IP	B-PRGE
-	O
mediated	O
cAMP	O
generation	O
(	O
IC	O
(	O
50	O
)	O
6	O
.	O
6	O
-	O
11	O
.	O
1	O
microm	O
)	O
and	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
mobilization	O
(	O
IC	O
(	O
50	O
)	O
7	O
.	O
2	O
-	O
16	O
.	O
4	O
microm	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
but	O
had	O
no	O
effect	O
on	O
signalling	O
by	O
the	O
nonisoprenylated	O
beta	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
adrenergic	I-PRGE
receptor	I-PRGE
or	O
the	O
alpha	O
or	O
beta	O
isoforms	O
of	O
the	O
human	O
thromboxane	B-PRGE
A	I-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
receptor	I-PRGE
(	O
TP	B-PRGE
)	O
.	O

Moreover	O
,	O
atorvastatin	O
significantly	O
reduced	O
IP	B-PRGE
-	O
mediated	O
crossdesensitization	O
of	O
signalling	O
by	O
TP	B-PRGE
alpha	I-PRGE
(	O
IC	O
(	O
50	O
)	O
10	O
.	O
4	O
microm	O
)	O
,	O
but	O
not	O
by	O
TP	B-PRGE
beta	I-PRGE
.	O

In	O
contrast	O
to	O
the	O
whole	O
-	O
cell	O
data	O
,	O
atorvastatin	O
therapy	O
did	O
not	O
interfere	O
with	O
IP	B-PRGE
-	O
mediated	O
cAMP	O
generation	O
or	O
IP	B-PRGE
-	O
induced	O
inhibition	O
of	O
TP	B-PRGE
-	O
mediated	O
aggregation	O
of	O
platelets	O
isolated	O
from	O
human	O
volunteers	O
undergoing	O
therapeutic	O
intervention	O
with	O
atorvastatin	O
(	O
10	O
-	O
80	O
mg	O
per	O
daily	O
dose	O
)	O
.	O

In	O
conclusion	O
,	O
while	O
data	O
generated	O
in	O
whole	O
cells	O
indicated	O
that	O
atorvastatin	O
significantly	O
impairs	O
signalling	O
by	O
both	O
the	O
hIP	B-PRGE
and	O
mP	O
,	O
the	O
in	O
vivo	O
clinical	O
data	O
indicated	O
that	O
,	O
at	O
the	O
administered	O
therapeutic	O
dose	O
,	O
atorvastatin	O
does	O
not	O
significantly	O
compromise	O
IP	B-PRGE
signalling	O
and	O
function	O
in	O
humans	O
.	O

Novel	O
role	O
of	O
ARF6	B-PRGE
in	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
induced	O
signaling	O
and	O
angiogenesis	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
stimulates	O
endothelial	O
cell	O
(	O
EC	O
)	O
migration	O
and	O
proliferation	O
primarily	O
through	O
the	O
VEGF	B-PRGE
receptor	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
VEGFR2	B-PRGE
)	O
.	O

We	O
have	O
shown	O
that	O
VEGF	O
stimulates	O
a	O
Rac1	B-PRGE
-	O
dependent	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
to	O
produce	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
that	O
are	O
involved	O
in	O
VEGFR2	B-PRGE
autophosphorylation	O
and	O
angiogenic	O
-	O
related	O
responses	O
in	O
ECs	O
.	O

The	O
small	O
GTPase	O
ARF6	B-PRGE
is	O
involved	O
in	O
membrane	O
trafficking	O
and	O
cell	O
motility	O
;	O
however	O
,	O
its	O
roles	O
in	O
VEGF	O
signaling	O
and	O
physiological	O
responses	O
in	O
ECs	O
are	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
dominant	O
-	O
negative	O
ARF6	B-PRGE
[	O
ARF6	B-PRGE
(	O
T27N	O
)	O
]	O
almost	O
completely	O
inhibits	O
VEGF	O
-	O
induced	O
Rac1	B-PRGE
activation	O
,	O
ROS	O
production	O
,	O
and	O
VEGFR2	B-PRGE
autophosphorylation	O
in	O
ECs	O
.	O

Fractionation	O
of	O
caveolae	O
/	O
lipid	O
raft	O
membranes	O
demonstrates	O
that	O
ARF6	B-PRGE
,	O
Rac1	B-PRGE
,	O
and	O
VEGFR2	B-PRGE
are	O
localized	O
in	O
caveolin	O
-	O
enriched	O
fractions	O
basally	O
.	O

VEGF	O
stimulation	O
results	O
in	O
the	O
release	O
of	O
VEGFR2	B-PRGE
from	O
caveolae	O
/	O
lipid	O
rafts	O
and	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
without	O
affecting	O
localization	O
of	O
ARF6	B-PRGE
,	O
Rac1	B-PRGE
,	O
or	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
these	O
fractions	O
.	O

The	O
egress	O
of	O
VEGFR2	B-PRGE
from	O
caveolae	O
/	O
lipid	O
rafts	O
is	O
contemporaneous	O
with	O
the	O
tyrosine	O
phosphorylation	O
of	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
Tyr14	O
)	O
and	O
VEGFR2	B-PRGE
and	O
with	O
their	O
association	O
with	O
each	O
other	O
.	O

ARF6	B-PRGE
(	O
T27N	O
)	O
significantly	O
inhibits	O
both	O
VEGF	O
-	O
induced	O
responses	O
.	O

Immunofluorescence	O
studies	O
show	O
that	O
activated	O
VEGFR2	B-PRGE
and	O
phosphocaveolin	O
colocalize	O
at	O
focal	O
complexes	O
/	O
adhesions	O
after	O
VEGF	O
stimulation	O
.	O

Both	O
overexpression	O
of	O
ARF6	B-PRGE
(	O
T27N	O
)	O
and	O
mutant	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
Y14F	O
)	O
,	O
which	O
cannot	O
be	O
phosphorylated	O
,	O
block	O
VEGF	O
-	O
stimulated	O
EC	O
migration	O
and	O
proliferation	O
.	O

Moreover	O
,	O
ARF6	B-PRGE
expression	O
is	O
markedly	O
upregulated	O
in	O
association	O
with	O
an	O
increase	O
in	O
capillary	O
density	O
in	O
a	O
mouse	O
hindlimb	O
ischemia	O
model	O
of	O
angiogenesis	O
.	O

Thus	O
,	O
ARF6	B-PRGE
is	O
involved	O
in	O
the	O
temporal	O
-	O
spatial	O
organization	O
of	O
caveolae	O
/	O
lipid	O
rafts	O
-	O
and	O
ROS	O
-	O
dependent	O
VEGF	O
signaling	O
in	O
ECs	O
as	O
well	O
as	O
in	O
angiogenesis	O
in	O
vivo	O
.	O

Golgi	O
targeting	O
of	O
human	O
guanylate	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
requires	O
nucleotide	O
binding	O
,	O
isoprenylation	O
,	O
and	O
an	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
inducible	O
cofactor	O
.	O

Human	O
guanylate	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
a	O
large	O
GTPase	O
,	O
similar	O
in	O
structure	O
to	O
the	O
dynamins	O
.	O

Like	O
many	O
smaller	O
GTPases	O
of	O
the	O
Ras	O
/	O
Rab	O
family	O
,	O
it	O
is	O
farnesylated	O
,	O
suggesting	O
it	O
may	O
dock	O
into	O
membranes	O
and	O
perhaps	O
play	O
a	O
role	O
in	O
intracellular	O
trafficking	O
.	O

To	O
date	O
,	O
however	O
,	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
has	O
never	O
been	O
associated	O
with	O
a	O
specific	O
intracellular	O
compartment	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
can	O
associate	O
with	O
the	O
Golgi	O
apparatus	O
.	O

Redistribution	O
from	O
the	O
cytosol	O
to	O
the	O
Golgi	O
was	O
observed	O
by	O
immunofluorescence	O
and	O
subcellular	O
fractionation	O
after	O
aluminum	O
fluoride	O
treatment	O
,	O
suggesting	O
that	O
it	O
occurs	O
when	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
in	O
its	O
GTP	O
-	O
bound	O
state	O
.	O

Relocalization	O
was	O
blocked	O
by	O
a	O
farnesyl	O
transferase	O
inhibitor	O
.	O

The	O
C589S	O
mutant	O
of	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
cannot	O
be	O
farnesylated	O
,	O
and	O
the	O
previously	O
uncharacterized	O
R48P	O
mutant	O
,	O
which	O
cannot	O
bind	O
GTP	O
,	O
both	O
failed	O
to	O
localize	O
to	O
the	O
Golgi	O
.	O

These	O
two	O
mutants	O
had	O
a	O
dominant	O
-	O
negative	O
effect	O
,	O
preventing	O
endogenous	O
wild	O
-	O
type	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
from	O
efficiently	O
redistributing	O
after	O
aluminum	O
fluoride	O
treatment	O
.	O

Furthermore	O
,	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
requires	O
another	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
factor	O
to	O
be	O
targeted	O
to	O
the	O
Golgi	O
,	O
because	O
constitutively	O
expressed	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
remained	O
cytosolic	O
in	O
cells	O
treated	O
with	O
aluminum	O
fluoride	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Finally	O
,	O
two	O
nonhydrolyzing	O
mutants	O
of	O
hGBP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
corresponding	O
to	O
active	O
mutants	O
of	O
Ras	O
family	O
proteins	O
,	O
failed	O
to	O
constitutively	O
associate	O
with	O
the	O
Golgi	O
;	O
we	O
propose	O
three	O
possible	O
explanations	O
for	O
this	O
surprising	O
result	O
.	O

Pc2	B-PRGE
-	O
mediated	O
sumoylation	O
of	O
Smad	B-PRGE
-	I-PRGE
interacting	I-PRGE
protein	I-PRGE
1	I-PRGE
attenuates	O
transcriptional	O
repression	O
of	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
.	O

Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
important	O
in	O
embryonic	O
development	O
and	O
tumorigenesis	O
.	O

Smad	B-PRGE
-	I-PRGE
interacting	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
SIP1	B-PRGE
)	O
can	O
induce	O
EMT	O
by	O
repressing	O
the	O
transcription	O
of	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
through	O
recruitment	O
of	O
the	O
corepressor	O
C	B-PRGE
-	I-PRGE
terminal	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
CtBP	B-PRGE
)	O
.	O

How	O
the	O
activity	O
of	O
SIP1	B-PRGE
is	O
regulated	O
still	O
remains	O
unclear	O
.	O

Here	O
we	O
show	O
in	O
vivo	O
and	O
in	O
vitro	O
that	O
SIP1	B-PRGE
is	O
covalently	O
modified	O
by	O
sumoylation	O
at	O
two	O
conserved	O
sites	O
,	O
Lys391	O
and	O
Lys866	O
.	O

The	O
polycomb	O
protein	O
Pc2	B-PRGE
,	O
but	O
not	O
the	O
PIAS	O
(	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
)	O
family	O
proteins	O
,	O
acts	O
as	O
a	O
Small	O
ubiquitin	O
-	O
like	O
modifier	O
E3	O
ligase	O
for	O
SIP1	B-PRGE
.	O

Sumoylation	O
of	O
SIP1	B-PRGE
does	O
not	O
affect	O
its	O
subcellular	O
localization	O
,	O
but	O
regulates	O
its	O
transcriptional	O
activity	O
.	O

Compared	O
with	O
the	O
wild	O
-	O
type	O
,	O
a	O
SIP1	B-PRGE
sumoylation	O
null	O
mutant	O
shows	O
more	O
potent	O
repression	O
on	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
transcription	O
but	O
similar	O
repression	O
on	O
two	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
beta	I-PRGE
-	O
responsive	O
reporter	O
genes	O
and	O
comparable	O
activation	O
on	O
vitamin	B-PRGE
D3	I-PRGE
receptor	I-PRGE
transcription	O
.	O

Coexpression	O
of	O
SIP1	B-PRGE
with	O
Pc2	B-PRGE
can	O
partially	O
relieve	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
repression	O
by	O
SIP1	B-PRGE
.	O

We	O
further	O
show	O
that	O
SIP1	B-PRGE
sumoylation	O
disrupts	O
the	O
recruitment	O
of	O
CtBP	B-PRGE
.	O

Thus	O
SIP1	B-PRGE
sumoylation	O
regulates	O
its	O
transcriptional	O
activity	O
in	O
a	O
promoter	O
context	O
-	O
dependent	O
manner	O
and	O
may	O
represent	O
an	O
important	O
intervention	O
target	O
to	O
modulate	O
EMT	O
in	O
tumorigenesis	O
.	O

Regulation	O
of	O
MEF2	B-PRGE
by	O
histone	B-PRGE
deacetylase	I-PRGE
4	I-PRGE
-	O
and	O
SIRT1	B-PRGE
deacetylase	O
-	O
mediated	O
lysine	O
modifications	O
.	O

The	O
class	O
II	O
deacetylase	O
histone	B-PRGE
deacetylase	I-PRGE
4	I-PRGE
(	O
HDAC4	B-PRGE
)	O
negatively	O
regulates	O
the	O
transcription	O
factor	O
MEF2	B-PRGE
.	O

HDAC4	B-PRGE
is	O
believed	O
to	O
repress	O
MEF2	B-PRGE
transcriptional	O
activity	O
by	O
binding	O
to	O
MEF2	B-PRGE
and	O
catalyzing	O
local	O
histone	B-PRGE
deacetylation	O
.	O

Here	O
we	O
report	O
that	O
HDAC4	B-PRGE
also	O
controls	O
MEF2	B-PRGE
by	O
a	O
novel	O
SUMO	O
E3	O
ligase	O
activity	O
.	O

We	O
show	O
that	O
HDAC4	B-PRGE
interacts	O
with	O
the	O
SUMO	O
E2	O
conjugating	O
enzyme	O
Ubc9	B-PRGE
and	O
is	O
itself	O
sumoylated	O
.	O

The	O
overexpression	O
of	O
HDAC4	B-PRGE
leads	O
to	O
prominent	O
MEF2	B-PRGE
sumoylation	O
in	O
vivo	O
,	O
whereas	O
recombinant	O
HDAC4	B-PRGE
stimulates	O
MEF2	B-PRGE
sumoylation	O
in	O
a	O
reconstituted	O
system	O
in	O
vitro	O
.	O

Importantly	O
,	O
HDAC4	B-PRGE
promotes	O
sumoylation	O
on	O
a	O
lysine	O
residue	O
that	O
is	O
also	O
subject	O
to	O
acetylation	O
by	O
a	O
MEF2	B-PRGE
coactivator	O
,	O
the	O
acetyltransferase	O
CBP	B-PRGE
,	O
suggesting	O
a	O
possible	O
interplay	O
between	O
acetylation	O
and	O
sumoylation	O
in	O
regulating	O
MEF2	B-PRGE
activity	O
.	O

Indeed	O
,	O
MEF2	B-PRGE
acetylation	O
is	O
correlated	O
with	O
MEF2	B-PRGE
activation	O
and	O
dynamically	O
induced	O
upon	O
muscle	O
cell	O
differentiation	O
,	O
while	O
sumoylation	O
inhibits	O
MEF2	B-PRGE
transcriptional	O
activity	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
HDAC4	B-PRGE
does	O
not	O
function	O
as	O
a	O
MEF2	B-PRGE
deacetylase	O
.	O

Instead	O
,	O
the	O
NAD	O
+	O
-	O
dependent	O
deacetylase	O
SIRT1	B-PRGE
can	O
potently	O
induce	O
MEF2	B-PRGE
deacetylation	O
.	O

Our	O
studies	O
reveal	O
a	O
novel	O
regulation	O
of	O
MEF2	B-PRGE
transcriptional	O
activity	O
by	O
two	O
distinct	O
classes	O
of	O
deacetylases	O
that	O
affect	O
MEF2	B-PRGE
sumoylation	O
and	O
acetylation	O
.	O

Different	O
transition	O
-	O
state	O
structures	O
for	O
the	O
reactions	O
of	O
beta	O
-	O
lactams	O
and	O
analogous	O
beta	O
-	O
sultams	O
with	O
serine	O
beta	O
-	O
lactamases	O
.	O

Beta	O
-	O
sultams	O
are	O
the	O
sulfonyl	O
analogues	O
of	O
beta	O
-	O
lactams	O
,	O
and	O
N	O
-	O
acyl	O
beta	O
-	O
sultams	O
are	O
novel	O
inactivators	O
of	O
the	O
class	O
C	O
beta	O
-	O
lactamase	O
of	O
Enterobacter	O
cloacae	O
P99	O
.	O

They	O
sulfonylate	O
the	O
active	O
site	O
serine	O
residue	O
to	O
form	O
a	O
sulfonate	O
ester	O
which	O
subsequently	O
undergoes	O
C	O
-	O
O	O
bond	O
fission	O
and	O
formation	O
of	O
a	O
dehydroalanine	O
residue	O
by	O
elimination	O
of	O
the	O
sulfonate	O
anion	O
as	O
shown	O
by	O
electrospray	O
ionization	O
mass	O
spectroscopy	O
.	O

The	O
analogous	O
N	O
-	O
acyl	O
beta	O
-	O
lactams	O
are	O
substrates	O
for	O
beta	O
-	O
lactamase	O
and	O
undergo	O
enzyme	O
-	O
catalyzed	O
hydrolysis	O
presumably	O
by	O
the	O
normal	O
acylation	O
-	O
deacylation	O
process	O
.	O

The	O
rates	O
of	O
acylation	O
of	O
the	O
enzyme	O
by	O
the	O
beta	O
-	O
lactams	O
,	O
measured	O
by	O
the	O
second	O
-	O
order	O
rate	O
constant	O
for	O
hydrolysis	O
,	O
kcat	O
/	O
K	O
(	O
m	O
)	O
,	O
and	O
those	O
of	O
sulfonylation	O
by	O
the	O
beta	O
-	O
sultams	O
,	O
measured	O
by	O
the	O
second	O
-	O
order	O
rate	O
constant	O
for	O
inactivation	O
,	O
k	O
(	O
i	O
)	O
,	O
both	O
show	O
a	O
similar	O
pH	O
dependence	O
to	O
that	O
exhibited	O
by	O
the	O
beta	O
-	O
lactamase	O
-	O
catalyzed	O
hydrolysis	O
of	O
beta	O
-	O
lactam	O
antibiotics	O
.	O

Electron	O
-	O
withdrawing	O
groups	O
in	O
the	O
aryl	O
residue	O
of	O
the	O
leaving	O
group	O
of	O
N	O
-	O
aroyl	O
beta	O
-	O
lactams	O
increase	O
the	O
rate	O
of	O
alkaline	O
hydrolysis	O
and	O
give	O
a	O
Bronsted	O
beta	O
(	O
lg	O
)	O
of	O
-	O
0	O
.	O
55	O
,	O
indicative	O
of	O
a	O
late	O
transition	O
state	O
for	O
rate	O
-	O
limiting	O
formation	O
of	O
the	O
tetrahedral	O
intermediate	O
.	O

Interestingly	O
,	O
the	O
corresponding	O
Bronsted	O
beta	O
(	O
lg	O
)	O
for	O
the	O
beta	O
-	O
lactamase	O
-	O
catalyzed	O
hydrolysis	O
of	O
the	O
same	O
substrates	O
is	O
-	O
0	O
.	O
06	O
,	O
indicative	O
of	O
an	O
earlier	O
transition	O
state	O
for	O
the	O
enzyme	O
-	O
catalyzed	O
reaction	O
.	O

By	O
contrast	O
,	O
although	O
the	O
Bronsted	O
beta	O
(	O
lg	O
)	O
for	O
the	O
alkaline	O
hydrolysis	O
of	O
N	O
-	O
aroyl	O
beta	O
-	O
sultams	O
is	O
-	O
0	O
.	O
73	O
,	O
similar	O
to	O
that	O
for	O
the	O
beta	O
-	O
lactams	O
,	O
that	O
for	O
the	O
sulfonylation	O
of	O
beta	O
-	O
lactamase	O
by	O
these	O
compounds	O
is	O
-	O
1	O
.	O
46	O
,	O
compatible	O
with	O
significant	O
amide	O
anion	O
expulsion	O
/	O
S	O
-	O
N	O
fission	O
in	O
the	O
transition	O
state	O
.	O

In	O
this	O
case	O
,	O
the	O
enzyme	O
reaction	O
displays	O
a	O
later	O
transition	O
state	O
compared	O
with	O
hydroxide	O
-	O
ion	O
-	O
catalyzed	O
hydrolysis	O
of	O
the	O
beta	O
-	O
sultam	O
.	O

Atorvastatin	O
desensitizes	O
beta	O
-	O
adrenergic	O
signaling	O
in	O
cardiac	O
myocytes	O
via	O
reduced	O
isoprenylation	O
of	O
G	O
-	O
protein	O
gamma	O
-	O
subunits	O
.	O

Statins	O
exert	O
pleiotropic	O
,	O
cholesterol	O
-	O
independent	O
effects	O
by	O
reducing	O
isoprenylation	O
of	O
monomeric	O
GTPases	O
.	O

Here	O
we	O
examined	O
whether	O
statins	O
also	O
reduce	O
isoprenylation	O
of	O
gamma	O
-	O
subunits	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
and	O
thereby	O
affect	O
beta	O
-	O
adrenergic	O
signaling	O
and	O
regulation	O
of	O
force	O
in	O
cardiac	O
myocytes	O
.	O

Neonatal	O
rat	O
cardiac	O
myocytes	O
(	O
NRCM	O
)	O
were	O
treated	O
with	O
atorvastatin	O
(	O
0	O
.	O
1	O
-	O
10	O
micromol	O
/	O
l	O
;	O
12	O
-	O
48	O
h	O
)	O
and	O
examined	O
for	O
adenylyl	O
cyclase	O
regulating	O
G	O
-	O
protein	O
alpha	O
-	O
(	O
Galpha	O
)	O
,	O
beta	O
-	O
(	O
Gbeta	O
)	O
,	O
and	O
gamma	O
-	O
(	O
Ggamma	O
)	O
subunits	O
and	O
cAMP	O
accumulation	O
.	O

Engineered	O
heart	O
tissue	O
(	O
EHT	O
)	O
from	O
NRCM	O
was	O
used	O
to	O
evaluate	O
contractile	O
consequences	O
.	O

In	O
atorvastatin	O
-	O
treated	O
NRCM	O
,	O
a	O
second	O
band	O
of	O
Ggamma3	B-PRGE
with	O
a	O
lower	O
apparent	O
molecular	O
weight	O
appeared	O
in	O
cytosol	O
and	O
particulate	O
fractions	O
that	O
was	O
absent	O
in	O
vehicle	O
-	O
treated	O
NRCM	O
,	O
but	O
also	O
seen	O
after	O
GGTI	O
-	O
298	O
,	O
a	O
geranylgeranyl	O
transferase	O
inhibitor	O
.	O

In	O
parallel	O
,	O
Gbeta	O
accumulated	O
in	O
the	O
cytosol	O
and	O
total	O
cellular	O
content	O
of	O
Galphas	O
was	O
reduced	O
.	O

In	O
atorvastatin	O
-	O
treated	O
NRCM	O
,	O
the	O
cAMP	O
-	O
increasing	O
effect	O
of	O
isoprenaline	O
was	O
reduced	O
.	O

Likewise	O
,	O
the	O
positive	O
inotropic	O
effect	O
of	O
isoprenaline	O
was	O
desensitized	O
and	O
reduced	O
after	O
treatment	O
with	O
atorvastatin	O
.	O

The	O
effects	O
of	O
atorvastatin	O
were	O
abolished	O
by	O
mevalonate	O
and	O
/	O
or	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
by	O
farnesyl	O
pyrophosphate	O
or	O
squalene	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
show	O
that	O
atorvastatin	O
desensitizes	O
NRCM	O
to	O
beta	O
-	O
adrenergic	O
stimulation	O
by	O
a	O
mechanism	O
that	O
involves	O
reduced	O
isoprenylation	O
of	O
Ggamma	O
and	O
subsequent	O
reductions	O
in	O
the	O
cellular	O
content	O
of	O
Galphas	O
.	O

The	O
proprotein	O
convertase	O
(	O
PC	O
)	O
PCSK9	B-PRGE
is	O
inactivated	O
by	O
furin	B-PRGE
and	O
/	O
or	O
PC5	B-PRGE
/	O
6A	B-PRGE
:	O
functional	O
consequences	O
of	O
natural	O
mutations	O
and	O
post	O
-	O
translational	O
modifications	O
.	O

PCSK9	B-PRGE
is	O
the	O
ninth	O
member	O
of	O
the	O
proprotein	O
convertase	O
(	O
PC	O
)	O
family	O
.	O

Some	O
of	O
its	O
natural	O
mutations	O
have	O
been	O
genetically	O
associated	O
with	O
the	O
development	O
of	O
a	O
dominant	O
form	O
of	O
familial	O
hyper	O
-	O
or	O
hypocholesterolemia	O
.	O

The	O
exact	O
mechanism	O
of	O
action	O
of	O
PCSK9	B-PRGE
is	O
not	O
clear	O
,	O
although	O
it	O
is	O
known	O
to	O
enhance	O
the	O
intracellular	O
degradation	O
of	O
the	O
low	B-PRGE
density	I-PRGE
lipoprotein	I-PRGE
(	I-PRGE
LDL	I-PRGE
)	I-PRGE
receptor	I-PRGE
in	O
acidic	O
compartments	O
,	O
likely	O
the	O
endosomes	O
/	O
lysosomes	O
.	O

We	O
analyzed	O
the	O
post	O
-	O
translational	O
modifications	O
of	O
PCSK9	B-PRGE
and	O
show	O
that	O
it	O
is	O
sulfated	O
within	O
its	O
prosegment	O
at	O
Tyr38	O
.	O

We	O
also	O
examined	O
the	O
susceptibility	O
of	O
PCSK9	B-PRGE
to	O
proteolytic	O
cleavage	O
by	O
the	O
other	O
members	O
of	O
the	O
PC	O
family	O
.	O

The	O
data	O
show	O
that	O
the	O
natural	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
R218S	O
,	O
F216L	O
,	O
and	O
D374Y	O
associated	O
with	O
hypercholesterolemia	O
result	O
in	O
total	O
or	O
partial	O
loss	O
of	O
furin	B-PRGE
/	O
PC5	B-PRGE
/	O
6A	B-PRGE
processing	O
at	O
the	O
motif	O
RFHR218	O
downward	O
arrow	O
.	O

In	O
contrast	O
,	O
the	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
A443T	O
and	O
C679X	O
lead	O
either	O
to	O
the	O
lack	O
of	O
trans	O
-	O
Golgi	O
network	O
/	O
recycling	O
endosome	O
localization	O
and	O
an	O
enhanced	O
susceptibility	O
to	O
furin	B-PRGE
cleavage	O
(	O
A443T	O
)	O
or	O
to	O
the	O
inability	O
of	O
PCSK9	B-PRGE
to	O
exit	O
the	O
endoplasmic	O
reticulum	O
(	O
C679X	O
)	O
.	O

Furthermore	O
,	O
we	O
report	O
the	O
presence	O
of	O
both	O
native	O
and	O
furin	B-PRGE
-	O
like	O
cleaved	O
forms	O
of	O
PCSK9	B-PRGE
in	O
circulating	O
human	O
plasma	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
PCSK9	B-PRGE
levels	O
are	O
finely	O
regulated	O
by	O
the	O
basic	O
amino	O
acid	O
convertases	O
furin	B-PRGE
and	O
PC5	B-PRGE
/	O
6A	O
.	O

The	O
latter	O
may	O
reduce	O
the	O
lifetime	O
of	O
this	O
proteinase	O
and	O
its	O
ability	O
to	O
degrade	O
the	O
cell	O
-	O
surface	O
LDL	B-PRGE
receptor	I-PRGE
,	O
thereby	O
regulating	O
the	O
levels	O
of	O
circulating	O
LDL	O
cholesterol	O
.	O

Identification	O
by	O
functional	O
proteomics	O
of	O
a	O
deubiquitinating	O
/	O
deNeddylating	O
enzyme	O
in	O
Plasmodium	O
falciparum	O
.	O

Ubiquitination	O
is	O
a	O
post	O
-	O
translational	O
modification	O
implicated	O
in	O
a	O
variety	O
of	O
cellular	O
functions	O
,	O
including	O
transcriptional	O
regulation	O
,	O
protein	O
degradation	O
and	O
membrane	O
protein	O
trafficking	O
.	O

Ubiquitin	B-PRGE
and	O
the	O
enzymes	O
that	O
act	O
on	O
it	O
,	O
although	O
conserved	O
and	O
essential	O
in	O
eukaryotes	O
,	O
have	O
not	O
been	O
well	O
studied	O
in	O
parasites	O
,	O
despite	O
sequencing	O
of	O
several	O
parasite	O
genomes	O
.	O

Several	O
putative	O
ubiquitin	B-PRGE
hydrolases	O
have	O
been	O
identified	O
in	O
Plasmodium	O
falciparum	O
based	O
on	O
sequence	O
homology	O
alone	O
,	O
with	O
no	O
evidence	O
of	O
expression	O
or	O
function	O
.	O

Here	O
we	O
identify	O
the	O
first	O
deubiquitinating	O
enzyme	O
in	O
P	O
.	O
falciparum	O
,	O
PfUCH54	B-PRGE
,	O
by	O
its	O
activity	O
.	O

We	O
show	O
that	O
PfUCH54	B-PRGE
also	O
has	O
deNeddylating	O
activity	O
,	O
as	O
assayed	O
by	O
a	O
mammalian	O
Nedd8	B-PRGE
-	O
based	O
probe	O
.	O

This	O
activity	O
is	O
absent	O
from	O
mammalian	O
homologues	O
of	O
PfUCH54	B-PRGE
.	O

Given	O
the	O
importance	O
of	O
parasitic	O
membrane	O
protein	O
trafficking	O
as	O
well	O
as	O
protein	O
degradation	O
in	O
the	O
virulence	O
of	O
this	O
parasite	O
,	O
this	O
family	O
of	O
enzymes	O
may	O
represent	O
a	O
target	O
for	O
pharmacological	O
intervention	O
with	O
this	O
disease	O
.	O

Ubiquitin	B-PRGE
and	O
ubiquitin	B-PRGE
-	O
like	O
modifications	O
of	O
the	O
p53	B-PRGE
family	O
.	O

Regulation	O
of	O
p53	B-PRGE
by	O
the	O
ubiquitin	B-PRGE
-	O
proteasomal	O
pathway	O
has	O
been	O
studied	O
considerably	O
.	O

Studies	O
have	O
also	O
demonstrated	O
that	O
the	O
ubiquitin	B-PRGE
-	O
like	O
proteins	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NEDD8	B-PRGE
modify	O
p53	B-PRGE
.	O

Similarly	O
,	O
p63	B-PRGE
and	O
p73	B-PRGE
are	O
subject	O
to	O
regulation	O
by	O
ubiquitin	B-PRGE
and	O
ubiquitin	B-PRGE
-	O
like	O
modifications	O
,	O
and	O
perturbations	O
of	O
these	O
pathways	O
in	O
the	O
regulation	O
of	O
the	O
p53	B-PRGE
family	O
have	O
been	O
implicated	O
in	O
tumorigenesis	O
and	O
developmental	O
abnormalities	O
.	O

Here	O
,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
regulation	O
of	O
the	O
p53	B-PRGE
family	O
by	O
covalent	O
modification	O
by	O
ubiquitin	B-PRGE
,	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
NEDD8	B-PRGE
.	O

Transport	O
and	O
assembly	O
of	O
gag	B-PRGE
proteins	O
into	O
Moloney	O
murine	O
leukemia	O
virus	O
.	O

We	O
have	O
studied	O
the	O
process	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
(	O
M	O
-	O
MuLV	O
)	O
assembly	O
by	O
characterization	O
of	O
core	O
(	O
gag	B-PRGE
)	O
protein	O
mutants	O
and	O
analysis	O
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
gag	B-PRGE
proteins	O
produced	O
by	O
cells	O
in	O
the	O
presence	O
of	O
the	O
ionophore	O
monensin	O
.	O

Our	O
genetic	O
studies	O
involved	O
examination	O
of	O
linker	O
insertion	O
mutants	O
of	O
a	O
Gag	B-PRGE
-	O
beta	B-PRGE
-	I-PRGE
galactosidase	I-PRGE
(	O
Gag	B-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
gal	I-PRGE
)	O
fusion	O
protein	O
,	O
GBG2051	O
,	O
which	O
is	O
incorporated	O
into	O
virus	O
particles	O
when	O
expressed	O
in	O
the	O
presence	O
of	O
wt	O
viral	O
proteins	O
.	O

Analysis	O
indicated	O
that	O
the	O
amino	O
-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
gag	B-PRGE
matrix	O
domain	O
is	O
essential	O
for	O
targeting	O
of	O
proteins	O
to	O
the	O
plasma	O
membrane	O
;	O
mutant	O
proteins	O
localized	O
to	O
the	O
cytoplasm	O
or	O
were	O
trapped	O
on	O
intracellular	O
membranes	O
.	O

Mutations	O
through	O
most	O
of	O
the	O
coding	O
region	O
of	O
the	O
gag	B-PRGE
capsid	O
domain	O
generated	O
proteins	O
which	O
were	O
released	O
from	O
cells	O
in	O
membrane	O
vesicles	O
but	O
not	O
in	O
virions	O
.	O

In	O
contrast	O
,	O
linker	O
insertions	O
into	O
p12gag	B-PRGE
or	O
carboxy	O
-	O
terminal	O
portions	O
of	O
the	O
matrix	O
or	O
capsid	O
coding	O
regions	O
did	O
not	O
affect	O
assembly	O
of	O
fusion	O
proteins	O
into	O
virus	O
particles	O
.	O

Monensin	O
,	O
which	O
blocks	O
vesicular	O
transport	O
,	O
inhibited	O
gag	B-PRGE
protein	O
intracellular	O
transport	O
and	O
release	O
from	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
significant	O
proportion	O
of	O
M	O
-	O
MuLV	O
myristylated	O
gag	B-PRGE
proteins	O
travel	O
via	O
vesicles	O
to	O
the	O
cell	O
surface	O
.	O

Specific	O
matrix	O
protein	O
polypeptide	O
regions	O
and	O
myristic	O
acid	O
modification	O
are	O
both	O
necessary	O
for	O
appropriate	O
gag	B-PRGE
protein	O
transport	O
,	O
while	O
capsid	O
protein	O
interactions	O
appear	O
to	O
mediate	O
the	O
final	O
phase	O
of	O
virion	O
formation	O
.	O

Endothelial	O
cell	O
response	O
to	O
lactate	O
:	O
implication	O
of	O
PAR	O
modification	O
of	O
VEGF	O
.	O

Angiogenesis	O
,	O
the	O
process	O
of	O
formation	O
of	O
new	O
blood	O
vessels	O
from	O
pre	O
-	O
existing	O
one	O
,	O
occurs	O
in	O
many	O
physiological	O
and	O
pathological	O
conditions	O
,	O
most	O
of	O
which	O
are	O
underlined	O
by	O
hypoxia	O
and	O
resultant	O
accumulation	O
of	O
lactate	O
.	O

Although	O
lactate	O
is	O
known	O
to	O
induce	O
angiogenesis	O
,	O
the	O
mechanism	O
of	O
its	O
action	O
on	O
endothelial	O
cells	O
(	O
ECs	O
)	O
is	O
not	O
known	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
response	O
of	O
ECs	O
to	O
lactate	O
.	O

Morphological	O
analysis	O
revealed	O
that	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
in	O
culture	O
respond	O
to	O
lactate	O
by	O
switching	O
over	O
to	O
angiogenic	O
phenotype	O
concomitant	O
with	O
upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
VEGFR2	B-PRGE
)	O
as	O
determined	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

Apart	O
from	O
increase	O
in	O
the	O
levels	O
of	O
VEGF	O
protein	O
as	O
determined	O
by	O
ELISA	O
,	O
chorio	O
allantoic	O
membrane	O
(	O
CAM	O
)	O
assay	O
using	O
the	O
cell	O
extracts	O
revealed	O
that	O
lactate	O
also	O
increased	O
the	O
angiogenic	O
potency	O
of	O
VEGF	O
.	O

Isolated	O
VEGF	O
,	O
when	O
blotted	O
and	O
subsequently	O
probed	O
with	O
anti	O
-	O
PAR	O
antibody	O
,	O
revealed	O
considerable	O
reduction	O
in	O
poly	O
-	O
adenosyl	O
ribosylation	O
of	O
VEGF	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
NAD	O
(	O
+	O
)	O
,	O
in	O
presence	O
of	O
lactate	O
.	O

Thus	O
it	O
appears	O
that	O
ECs	O
respond	O
to	O
lactate	O
by	O
increasing	O
the	O
production	O
of	O
VEGF	O
and	O
modulating	O
its	O
angiogenic	O
potency	O
through	O
poly	O
-	O
ADP	O
ribosylation	O
(	O
PAR	O
)	O
-	O
dependent	O
mechanism	O
and	O
thereby	O
switch	O
over	O
to	O
angiogenic	O
phenotype	O
.	O

Tyrosine	O
sulfation	O
of	O
statherin	B-PRGE
.	O

Tyrosylprotein	O
sulfotransferase	O
(	O
TPST	O
)	O
,	O
responsible	O
for	O
the	O
sulfation	O
of	O
a	O
variety	O
of	O
secretory	O
and	O
membrane	O
proteins	O
,	O
has	O
been	O
identified	O
and	O
characterized	O
in	O
submandibular	O
salivary	O
glands	O
(	O
William	O
et	O
al	O
.	O
Arch	O
Biochem	O
Biophys	O
1997	O
;	O
338	O
:	O
90	O
-	O
96	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
the	O
sulfation	O
of	O
a	O
salivary	O
secretory	O
protein	O
,	O
statherin	B-PRGE
,	O
by	O
the	O
tyrosylprotein	O
sulfotransferase	O
present	O
in	O
human	O
saliva	O
.	O

Optimum	O
statherin	B-PRGE
sulfation	O
was	O
observed	O
at	O
pH	O
6	O
.	O
5	O
and	O
at	O
20	O
mm	O
MnCl	O
(	O
2	O
)	O
.	O

Increase	O
in	O
the	O
level	O
of	O
total	O
sulfation	O
was	O
observed	O
with	O
increasing	O
statherin	B-PRGE
concentration	O
.	O

The	O
K	O
(	O
m	O
)	O
value	O
of	O
tyrosylprotein	O
sulfotransferase	O
for	O
statherin	B-PRGE
was	O
40	O
microM	O
.	O

Analysis	O
of	O
the	O
sulfated	O
statherin	B-PRGE
product	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
followed	O
by	O
autoradiography	O
revealed	O
(	O
35	O
)	O
S	O
-	O
labelling	O
of	O
a	O
5	O
kDa	O
statherin	B-PRGE
.	O

Further	O
analysis	O
of	O
the	O
sulfated	O
statherin	B-PRGE
revealed	O
the	O
sulfation	O
on	O
tyrosyl	O
residue	O
.	O

This	O
study	O
is	O
the	O
first	O
report	O
demonstrating	O
tyrosine	O
sulfation	O
of	O
a	O
salivary	O
secretory	O
protein	O
.	O

The	O
implications	O
of	O
this	O
sulfation	O
of	O
statherin	B-PRGE
in	O
hydroxyapatite	O
binding	O
and	O
Actinomyces	O
viscosus	O
interactions	O
are	O
discussed	O
.	O

Substrate	O
-	O
mediated	O
regulation	O
of	O
cullin	O
neddylation	O
.	O

Cullin	O
-	O
based	O
E3	O
ligases	O
are	O
a	O
large	O
family	O
of	O
multi	O
-	O
subunit	O
ubiquitin	B-PRGE
ligases	O
with	O
diverse	O
cellular	O
functions	O
,	O
including	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
,	O
of	O
the	O
DNA	O
damage	O
response	O
,	O
and	O
of	O
various	O
transcription	O
factors	O
.	O

These	O
ligases	O
are	O
composed	O
of	O
one	O
of	O
six	O
mammalian	O
cullin	O
homologs	O
(	O
Cul1	B-PRGE
,	O
Cul2	B-PRGE
,	O
Cul3	B-PRGE
,	O
Cul4a	B-PRGE
,	O
Cul4b	B-PRGE
,	O
and	O
Cul5	B-PRGE
)	O
,	O
the	O
Ring	O
finger	O
containing	O
protein	O
Roc1	B-PRGE
/	O
Rbx1	B-PRGE
,	O
and	O
cullin	O
homolog	O
-	O
specific	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
.	O

To	O
be	O
active	O
,	O
cullin	O
-	O
based	O
ligases	O
require	O
the	O
covalent	O
modification	O
of	O
a	O
conserved	O
lysine	O
residue	O
in	O
the	O
cullin	O
protein	O
with	O
the	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
Nedd8	B-PRGE
.	O

We	O
show	O
in	O
this	O
study	O
that	O
in	O
intact	O
cells	O
Cul1	B-PRGE
neddylation	O
is	O
dependent	O
on	O
binding	O
to	O
adaptor	O
proteins	O
and	O
substrate	O
recognition	O
subunits	O
.	O

Mutant	O
Cul1	B-PRGE
that	O
is	O
unable	O
to	O
recruit	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
exhibits	O
markedly	O
reduced	O
neddylation	O
,	O
and	O
inhibiting	O
binding	O
of	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
to	O
wild	O
type	O
Cul1	B-PRGE
reduces	O
Nedd8	B-PRGE
modification	O
.	O

This	O
regulatory	O
mechanism	O
also	O
extends	O
to	O
other	O
cullin	O
-	O
based	O
E3	O
ligases	O
,	O
including	O
Cul2	B-PRGE
,	O
Cul3	B-PRGE
,	O
and	O
Cul4a	B-PRGE
.	O

The	O
regulation	O
of	O
cullin	O
neddylation	O
by	O
adaptor	O
proteins	O
and	O
substrate	O
recognition	O
subunits	O
in	O
cells	O
was	O
found	O
to	O
be	O
independent	O
of	O
both	O
CAND1	B-PRGE
and	O
the	O
COP9	O
signalosome	O
,	O
two	O
negative	O
regulators	O
of	O
cullin	O
Nedd8	B-PRGE
modification	O
.	O

Using	O
hypoxia	B-PRGE
-	I-PRGE
inducible	I-PRGE
factor	I-PRGE
-	I-PRGE
1alpha	I-PRGE
(	O
HIF	B-PRGE
-	I-PRGE
1alpha	I-PRGE
)	O
,	O
a	O
substrate	O
of	O
the	O
Elongin	B-PRGE
B	I-PRGE
/	O
C	B-PRGE
-	O
Cul2	B-PRGE
-	O
VHL	B-PRGE
ligase	O
,	O
we	O
demonstrate	O
the	O
critical	O
role	O
of	O
substrate	O
binding	O
to	O
promote	O
Cul2	B-PRGE
neddylation	O
in	O
a	O
manner	O
that	O
does	O
not	O
require	O
substrate	O
ubiquitination	O
but	O
may	O
involve	O
a	O
conformational	O
change	O
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
through	O
which	O
availability	O
of	O
substrate	O
recognition	O
subunits	O
and	O
substrates	O
can	O
regulate	O
the	O
ubiquitin	B-PRGE
ligase	O
activity	O
.	O

Pro	O
-	O
oxidant	O
activity	O
of	O
histatin	B-PRGE
5	I-PRGE
related	O
Cu	O
(	O
II	O
)	O
-	O
model	O
peptide	O
probed	O
by	O
mass	O
spectrometry	O
.	O

Histatin	B-PRGE
5	I-PRGE
is	O
a	O
cationic	O
salivary	O
peptide	O
with	O
strong	O
candidacidal	O
and	O
bactericidal	O
activity	O
at	O
physiological	O
concentration	O
.	O

In	O
this	O
paper	O
we	O
demonstrate	O
by	O
optical	O
spectroscopy	O
and	O
ESI	O
-	O
IT	O
-	O
MS	O
experiments	O
that	O
a	O
synthetic	O
peptide	O
related	O
to	O
the	O
N	O
-	O
terminus	O
of	O
histatin	B-PRGE
5	I-PRGE
specifically	O
binds	O
copper	O
ions	O
in	O
vitro	O
and	O
that	O
the	O
complex	O
metal	O
-	O
peptide	O
generates	O
reactive	O
oxygen	O
species	O
at	O
physiological	O
concentration	O
of	O
ascorbate	O
,	O
leading	O
to	O
significant	O
auto	O
-	O
oxidation	O
of	O
the	O
peptide	O
within	O
short	O
reaction	O
time	O
.	O

The	O
oxidative	O
activity	O
of	O
this	O
peptide	O
is	O
associated	O
to	O
the	O
presence	O
of	O
a	O
specific	O
metal	O
binding	O
site	O
present	O
at	O
its	O
N	O
-	O
terminus	O
.	O

The	O
motif	O
is	O
constituted	O
by	O
the	O
amino	O
acid	O
sequence	O
NH	O
(	O
2	O
)	O
-	O
Asp	O
-	O
Ser	O
-	O
His	O
,	O
representing	O
a	O
copper	O
and	O
nickel	O
amino	O
terminal	O
binding	O
site	O
,	O
known	O
as	O
"	O
ATCUN	O
motif	O
"	O
.	O

The	O
results	O
of	O
the	O
study	O
suggest	O
that	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
can	O
be	O
an	O
intrinsic	O
property	O
of	O
histatin	B-PRGE
5	I-PRGE
connected	O
to	O
its	O
ability	O
to	O
bind	O
metals	O
.	O

Roles	O
for	O
negative	O
cell	O
regulator	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
in	O
control	O
of	O
MDM2	B-PRGE
activities	O
.	O

The	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
,	O
upregulated	O
by	O
p53	B-PRGE
in	O
response	O
to	O
DNA	O
damage	O
,	O
can	O
have	O
a	O
positive	O
-	O
feedback	O
impact	O
driving	O
p53	B-PRGE
activities	O
and	O
is	O
a	O
human	O
cancer	O
epithelial	O
marker	O
downregulated	O
in	O
various	O
tumors	O
.	O

However	O
,	O
the	O
precise	O
roles	O
of	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
during	O
tumorigenesis	O
are	O
not	O
well	O
characterized	O
.	O

Here	O
,	O
we	O
show	O
that	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
is	O
a	O
critical	O
regulator	O
of	O
murine	O
double	O
minute	O
oncogene	O
(	O
MDM2	B-PRGE
)	O
.	O

14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
interacts	O
with	O
MDM2	B-PRGE
at	O
the	O
RING	O
domain	O
.	O

The	O
C	O
-	O
terminal	O
region	O
of	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
binds	O
to	O
MDM2	B-PRGE
very	O
efficiently	O
.	O

Importantly	O
,	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
overexpression	O
leads	O
to	O
destabilization	O
of	O
MDM2	B-PRGE
through	O
enhancing	O
MDM2	B-PRGE
self	O
-	O
ubiquitination	O
and	O
accelerating	O
turnover	O
rate	O
.	O

Conversely	O
,	O
loss	O
of	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
results	O
in	O
a	O
significant	O
increase	O
in	O
MDM2	B-PRGE
protein	O
.	O

Moreover	O
,	O
live	O
-	O
cell	O
images	O
indicated	O
that	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
can	O
affect	O
the	O
location	O
of	O
MDM2	B-PRGE
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
and	O
that	O
MDM2	B-PRGE
-	O
mediated	O
cytoplasmic	O
localization	O
of	O
p53	B-PRGE
can	O
be	O
reversed	O
by	O
the	O
presence	O
of	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
.	O

Significantly	O
,	O
we	O
further	O
showed	O
that	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
causes	O
MDM2	B-PRGE
downregulation	O
,	O
thereby	O
stabilizing	O
p53	B-PRGE
and	O
inhibiting	O
tumor	O
growth	O
in	O
animal	O
tumors	O
.	O

Also	O
,	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
blocks	O
MDM2	B-PRGE
-	O
mediated	O
retinoblastoma	O
degradation	O
and	O
p53	B-PRGE
NEDDylation	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3sigma	I-PRGE
is	O
a	O
pivotal	O
MDM2	B-PRGE
regulator	O
involved	O
in	O
blocking	O
a	O
variety	O
of	O
activities	O
of	O
MDM2	B-PRGE
.	O

Caspase	B-PRGE
-	I-PRGE
3	I-PRGE
cleavage	O
of	O
GGA3	B-PRGE
stabilizes	O
BACE	B-PRGE
:	O
implications	O
for	O
Alzheimer	O
'	O
s	O
disease	O
.	O

BACE	B-PRGE
initiates	O
the	O
production	O
of	O
beta	B-PRGE
-	I-PRGE
amyloid	I-PRGE
(	O
Abeta	B-PRGE
)	O
,	O
the	O
likely	O
cause	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

In	O
this	O
issue	O
of	O
Neuron	O
,	O
Tesco	O
et	O
al	O
.	O
show	O
that	O
during	O
apoptosis	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
cleaves	O
the	O
adaptor	O
protein	O
GGA3	B-PRGE
,	O
which	O
is	O
required	O
for	O
BACE	B-PRGE
lysosomal	O
degradation	O
,	O
consequently	O
stabilizing	O
BACE	B-PRGE
and	O
elevating	O
Abeta	B-PRGE
generation	O
.	O

N	O
-	O
acylation	O
of	O
Aplysia	O
egg	B-PRGE
-	I-PRGE
laying	I-PRGE
hormone	I-PRGE
with	O
biotin	O
.	O

Characterization	O
of	O
bioactive	O
and	O
inactive	O
derivatives	O
.	O

Chemical	O
modification	O
of	O
the	O
egg	B-PRGE
-	I-PRGE
laying	I-PRGE
hormone	I-PRGE
(	O
ELH	B-PRGE
)	O
of	O
Aplysia	O
by	O
reaction	O
with	O
the	O
N	O
-	O
hydroxysuccinimide	O
ester	O
of	O
biotin	O
,	O
which	O
contained	O
6	O
-	O
aminohexanoic	O
acid	O
as	O
spacer	O
,	O
yielded	O
seven	O
distinct	O
derivatives	O
that	O
were	O
readily	O
separated	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

The	O
derivatives	O
were	O
chemically	O
characterized	O
by	O
amino	O
acid	O
compositional	O
analysis	O
,	O
sequence	O
analysis	O
,	O
and	O
mass	O
spectrometry	O
.	O

The	O
seven	O
derivatives	O
resulted	O
from	O
combinations	O
of	O
differential	O
modification	O
of	O
the	O
three	O
amino	O
groups	O
in	O
the	O
ELH	B-PRGE
molecule	O
located	O
at	O
Ile1	O
(	O
alpha	O
-	O
NH2	O
)	O
,	O
Lys8	O
,	O
and	O
Lys36	O
.	O

Of	O
the	O
seven	O
derivatives	O
formed	O
,	O
only	O
one	O
,	O
monobiotinyl	O
Lys36	O
-	O
ELH	B-PRGE
,	O
was	O
biologically	O
active	O
in	O
eliciting	O
egg	O
-	O
laying	O
activity	O
and	O
altering	O
the	O
electrophysiological	O
activity	O
of	O
the	O
abdominal	O
ganglion	O
neuron	O
R15	O
and	O
LB	O
and	O
LC	O
cluster	O
neurons	O
.	O

In	O
addition	O
,	O
evaluation	O
of	O
the	O
time	O
course	O
of	O
biotinylation	O
of	O
ELH	B-PRGE
revealed	O
that	O
the	O
relative	O
rate	O
of	O
amino	O
group	O
reactivity	O
was	O
epsilon	O
-	O
NH2	O
-	O
Lys36	O
greater	O
than	O
epsilon	O
-	O
NH2	O
-	O
Lys8	O
much	O
greater	O
than	O
alpha	O
-	O
NH2	O
-	O
Ile1	O
.	O

The	O
slow	O
rate	O
of	O
reaction	O
of	O
the	O
terminal	O
alpha	O
-	O
amino	O
group	O
suggested	O
that	O
it	O
was	O
relatively	O
inaccessible	O
to	O
biotinylation	O
,	O
possibly	O
due	O
to	O
conformational	O
factors	O
or	O
to	O
ion	O
-	O
pair	O
formation	O
with	O
an	O
unidentified	O
carboxyl	O
group	O
.	O

Loss	O
of	O
bioactivity	O
of	O
ELH	B-PRGE
monobiotinylated	O
on	O
the	O
alpha	O
-	O
amino	O
group	O
,	O
coupled	O
with	O
the	O
unusually	O
low	O
reactivity	O
of	O
the	O
alpha	O
-	O
amino	O
group	O
,	O
provided	O
strong	O
evidence	O
for	O
the	O
importance	O
of	O
the	O
alpha	O
-	O
amino	O
group	O
in	O
ELH	B-PRGE
function	O
.	O

Furthermore	O
,	O
the	O
development	O
and	O
availability	O
of	O
a	O
bioactive	O
ELH	B-PRGE
probe	O
should	O
greatly	O
facilitate	O
the	O
isolation	O
,	O
characterization	O
,	O
and	O
localization	O
of	O
the	O
ELH	B-PRGE
receptor	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
in	O
human	O
varicose	O
veins	O
:	O
involvement	O
of	O
matrix	B-PRGE
gla	I-PRGE
protein	I-PRGE
in	O
extracellular	O
matrix	O
remodeling	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
the	O
global	O
pattern	O
of	O
differentially	O
expressed	O
genes	O
in	O
human	O
varicose	O
veins	O
.	O

Using	O
suppressive	O
subtractive	O
hybridization	O
,	O
we	O
identified	O
overexpression	O
of	O
genes	O
known	O
to	O
be	O
associated	O
with	O
extracellular	O
matrix	O
remodeling	O
,	O
including	O
collagen	B-PRGE
III	I-PRGE
,	O
tissue	B-PRGE
inhibitor	I-PRGE
of	I-PRGE
metalloproteinases	I-PRGE
I	I-PRGE
,	O
dermatopontin	B-PRGE
,	O
matrix	B-PRGE
Gla	I-PRGE
protein	I-PRGE
(	O
MGP	B-PRGE
)	O
and	O
tenascin	B-PRGE
C	I-PRGE
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
confirmed	O
the	O
differential	O
expression	O
of	O
these	O
genes	O
.	O

The	O
overexpression	O
of	O
MGP	B-PRGE
transcript	O
was	O
associated	O
with	O
increased	O
MGP	B-PRGE
level	O
in	O
varicose	O
veins	O
,	O
in	O
particular	O
the	O
undercarboxylated	O
form	O
of	O
the	O
protein	O
.	O

Smooth	O
muscle	O
cells	O
from	O
varicose	O
veins	O
showed	O
increased	O
proliferation	O
rate	O
and	O
enhanced	O
matrix	O
mineralization	O
.	O

This	O
observation	O
correlated	O
with	O
the	O
presence	O
of	O
ectopic	O
mineralization	O
areas	O
in	O
the	O
varicose	O
vein	O
walls	O
.	O

The	O
use	O
of	O
warfarin	O
,	O
to	O
inhibit	O
MGP	B-PRGE
activity	O
,	O
or	O
siRNA	O
targeting	O
MGP	B-PRGE
transcript	O
induced	O
a	O
reduction	O
in	O
the	O
exacerbated	O
proliferation	O
of	O
varicose	O
vein	O
smooth	O
muscle	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
high	O
expression	O
of	O
MGP	B-PRGE
in	O
varicose	O
veins	O
may	O
contribute	O
to	O
venous	O
wall	O
remodeling	O
by	O
affecting	O
proliferation	O
and	O
mineralization	O
processes	O
probably	O
through	O
impaired	O
carboxylation	O
of	O
MGP	B-PRGE
.	O

In	O
addition	O
,	O
suppressive	O
subtractive	O
hybridization	O
results	O
also	O
produce	O
a	O
profile	O
of	O
differentially	O
expressed	O
genes	O
in	O
varicose	O
veins	O
,	O
in	O
particular	O
extracellular	O
matrix	O
components	O
.	O

Further	O
study	O
of	O
these	O
genes	O
will	O
provide	O
insights	O
into	O
their	O
specific	O
roles	O
in	O
the	O
etiology	O
of	O
venous	O
disease	O
.	O

Statins	O
reduce	O
amyloid	B-PRGE
-	I-PRGE
beta	I-PRGE
production	O
through	O
inhibition	O
of	O
protein	O
isoprenylation	O
.	O

Epidemiological	O
evidence	O
suggests	O
that	O
long	O
term	O
treatment	O
with	O
hydroxymethylglutaryl	O
-	O
CoA	O
reductase	O
inhibitors	O
,	O
or	O
statins	O
,	O
decreases	O
the	O
risk	O
for	O
developing	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

However	O
,	O
statin	O
-	O
mediated	O
AD	O
protection	O
cannot	O
be	O
fully	O
explained	O
by	O
reduction	O
of	O
cholesterol	O
levels	O
.	O

In	O
addition	O
to	O
their	O
cholesterol	O
lowering	O
effects	O
,	O
statins	O
have	O
pleiotropic	O
actions	O
and	O
act	O
to	O
lower	O
the	O
concentrations	O
of	O
isoprenoid	O
intermediates	O
,	O
such	O
as	O
geranylgeranyl	O
pyrophosphate	O
and	O
farnesyl	O
pyrophosphate	O
.	O

The	O
Rho	O
and	O
Rab	O
family	O
small	O
G	O
-	O
proteins	O
require	O
addition	O
of	O
these	O
isoprenyl	O
moieties	O
at	O
their	O
C	O
termini	O
for	O
normal	O
GTPase	O
function	O
.	O

In	O
neuroblastoma	O
cell	O
lines	O
,	O
treatment	O
with	O
statins	O
inhibits	O
the	O
membrane	O
localization	O
of	O
Rho	O
and	O
Rab	O
proteins	O
at	O
statin	O
doses	O
as	O
low	O
as	O
200	O
nm	O
,	O
without	O
affecting	O
cellular	O
cholesterol	O
levels	O
.	O

In	O
addition	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
at	O
low	O
,	O
physiologically	O
relevant	O
,	O
doses	O
statins	O
preferentially	O
inhibit	O
the	O
isoprenylation	O
of	O
a	O
subset	O
of	O
GTPases	O
.	O

The	O
amyloid	B-PRGE
precursor	I-PRGE
protein	I-PRGE
(	O
APP	B-PRGE
)	O
is	O
proteolytically	O
cleaved	O
to	O
generate	O
beta	B-PRGE
-	I-PRGE
amyloid	I-PRGE
(	O
Abeta	B-PRGE
)	O
,	O
which	O
is	O
the	O
major	O
component	O
of	O
senile	O
plaques	O
found	O
in	O
AD	O
.	O

We	O
show	O
that	O
inhibition	O
of	O
protein	O
isoprenylation	O
by	O
statins	O
causes	O
the	O
accumulation	O
of	O
APP	B-PRGE
within	O
the	O
cell	O
through	O
inhibition	O
of	O
Rab	O
family	O
proteins	O
involved	O
in	O
vesicular	O
trafficking	O
.	O

Moreover	O
,	O
inhibition	O
of	O
Rho	O
family	O
protein	O
function	O
reduces	O
levels	O
of	O
APP	B-PRGE
C	O
-	O
terminal	O
fragments	O
due	O
to	O
enhanced	O
lysosomal	O
dependent	O
degradation	O
.	O

Statin	O
inhibition	O
of	O
protein	O
isoprenylation	O
results	O
in	O
decreased	O
Abeta	B-PRGE
secretion	O
.	O

In	O
summary	O
,	O
we	O
show	O
that	O
statins	O
selectively	O
inhibit	O
GTPase	O
isoprenylation	O
at	O
clinically	O
relevant	O
doses	O
,	O
leading	O
to	O
reduced	O
Abeta	B-PRGE
production	O
in	O
an	O
isoprenoid	O
-	O
dependent	O
manner	O
.	O

These	O
studies	O
provide	O
insight	O
into	O
the	O
mechanisms	O
by	O
which	O
statins	O
may	O
reduce	O
AD	O
pathogenesis	O
.	O

Mint3	B-PRGE
/	O
X11gamma	B-PRGE
is	O
an	O
ADP	O
-	O
ribosylation	O
factor	O
-	O
dependent	O
adaptor	O
that	O
regulates	O
the	O
traffic	O
of	O
the	O
Alzheimer	O
'	O
s	O
Precursor	O
protein	O
from	O
the	O
trans	O
-	O
Golgi	O
network	O
.	O

Beta	B-PRGE
-	I-PRGE
amyloid	I-PRGE
peptides	O
(	O
Abeta	B-PRGE
)	O
are	O
the	O
major	O
component	O
of	O
plaques	O
in	O
brains	O
of	O
Alzheimer	O
'	O
s	O
patients	O
,	O
and	O
are	O
they	O
derived	O
from	O
the	O
proteolytic	O
processing	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
amyloid	I-PRGE
precursor	I-PRGE
protein	I-PRGE
(	O
APP	B-PRGE
)	O
.	O

The	O
movement	O
of	O
APP	B-PRGE
between	O
organelles	O
is	O
highly	O
regulated	O
,	O
and	O
it	O
is	O
tightly	O
connected	O
to	O
its	O
processing	O
by	O
secretases	O
.	O

We	O
proposed	O
previously	O
that	O
transport	O
of	O
APP	B-PRGE
within	O
the	O
cell	O
is	O
mediated	O
in	O
part	O
through	O
its	O
sorting	O
into	O
Mint	O
/	O
X11	O
-	O
containing	O
carriers	O
.	O

To	O
test	O
our	O
hypothesis	O
,	O
we	O
purified	O
APP	B-PRGE
-	O
containing	O
vesicles	O
from	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
,	O
and	O
we	O
showed	O
that	O
Mint2	B-PRGE
/	O
3	B-PRGE
are	O
specifically	O
enriched	O
and	O
that	O
Mint3	B-PRGE
and	O
APP	B-PRGE
are	O
present	O
in	O
the	O
same	O
vesicles	O
.	O

Increasing	O
cellular	O
APP	B-PRGE
levels	O
increased	O
the	O
amounts	O
of	O
both	O
APP	B-PRGE
and	O
Mint3	B-PRGE
in	O
purified	O
vesicles	O
.	O

Additional	O
evidence	O
supporting	O
an	O
obligate	O
role	O
for	O
Mint3	B-PRGE
in	O
traffic	O
of	O
APP	B-PRGE
from	O
the	O
trans	O
-	O
Golgi	O
network	O
to	O
the	O
plasma	O
membrane	O
include	O
the	O
observations	O
that	O
depletion	O
of	O
Mint3	B-PRGE
by	O
small	O
interference	O
RNA	O
(	O
siRNA	O
)	O
or	O
mutation	O
of	O
the	O
Mint	O
binding	O
domain	O
of	O
APP	B-PRGE
changes	O
the	O
export	O
route	O
of	O
APP	B-PRGE
from	O
the	O
basolateral	O
to	O
the	O
endosomal	O
/	O
lysosomal	O
sorting	O
route	O
.	O

Finally	O
,	O
we	O
show	O
that	O
increased	O
expression	O
of	O
Mint3	B-PRGE
decreased	O
and	O
siRNA	O
-	O
mediated	O
knockdowns	O
increased	O
the	O
secretion	O
of	O
the	O
neurotoxic	O
beta	B-PRGE
-	I-PRGE
amyloid	I-PRGE
peptide	O
,	O
Abeta	B-PRGE
(	O
1	O
-	O
40	O
)	O
.	O

Together	O
,	O
our	O
data	O
implicate	O
Mint3	B-PRGE
activity	O
as	O
a	O
critical	O
determinant	O
of	O
post	O
-	O
Golgi	O
APP	B-PRGE
traffic	O
.	O

Fbx8	B-PRGE
makes	O
Arf6	B-PRGE
refractory	O
to	O
function	O
via	O
ubiquitination	O
.	O

The	O
small	O
GTP	O
-	O
binding	O
protein	O
Arf6	B-PRGE
regulates	O
membrane	O
remodeling	O
at	O
cell	O
peripheries	O
and	O
plays	O
crucial	O
roles	O
in	O
higher	O
orders	O
of	O
cellular	O
functions	O
including	O
tumor	O
invasion	O
.	O

Here	O
we	O
show	O
that	O
Fbx8	B-PRGE
,	O
an	O
F	O
-	O
box	O
protein	O
bearing	O
the	O
Sec7	O
domain	O
,	O
mediates	O
ubiquitination	O
of	O
Arf6	B-PRGE
.	O

This	O
ubiquitination	O
did	O
not	O
appear	O
to	O
be	O
linked	O
to	O
immediate	O
proteasomal	O
degradation	O
of	O
Arf6	B-PRGE
,	O
whereas	O
Fbx8	B-PRGE
knockdown	O
caused	O
hyperactivation	O
of	O
Arf6	B-PRGE
.	O

Expression	O
of	O
Fbx8	B-PRGE
protein	O
was	O
substantially	O
lost	O
in	O
several	O
breast	O
tumor	O
cell	O
lines	O
,	O
in	O
which	O
Arf6	B-PRGE
activity	O
is	O
pivotal	O
for	O
their	O
invasion	O
.	O

Forced	O
expression	O
of	O
Fbx8	B-PRGE
in	O
these	O
cells	O
suppressed	O
their	O
Arf6	B-PRGE
activities	O
and	O
invasive	O
activities	O
,	O
in	O
which	O
the	O
F	O
-	O
box	O
and	O
Sec7	O
domains	O
of	O
Fbx8	B-PRGE
are	O
required	O
.	O

Together	O
with	O
the	O
possible	O
mechanism	O
as	O
to	O
how	O
Fbx8	B-PRGE
-	O
mediated	O
ubiquitination	O
interferes	O
with	O
the	O
functions	O
of	O
Arf6	B-PRGE
,	O
we	O
propose	O
that	O
Fbx8	B-PRGE
provides	O
a	O
novel	O
suppressive	O
control	O
of	O
Arf6	B-PRGE
activity	O
through	O
noncanonical	O
ubiquitination	O
.	O

Our	O
results	O
indicate	O
that	O
dysfunction	O
of	O
Fbx8	B-PRGE
expression	O
may	O
contribute	O
to	O
the	O
invasiveness	O
of	O
some	O
breast	O
cancer	O
cells	O
.	O

Acetylation	O
in	O
nuclear	O
receptor	O
signaling	O
and	O
the	O
role	O
of	O
sirtuins	O
.	O

It	O
has	O
been	O
known	O
since	O
the	O
early	O
1970s	O
that	O
nuclear	O
receptor	O
complexes	O
bind	O
DNA	O
in	O
association	O
with	O
coregulatory	O
proteins	O
.	O

Characterization	O
of	O
these	O
nuclear	O
receptor	O
coregulators	O
has	O
revealed	O
diverse	O
enzymatic	O
activities	O
that	O
temporally	O
and	O
spatially	O
coordinate	O
nuclear	O
receptor	O
activity	O
within	O
the	O
context	O
of	O
local	O
chromatin	O
in	O
response	O
to	O
diverse	O
hormone	O
signals	O
.	O

Chromatin	O
-	O
modifying	O
proteins	O
,	O
which	O
dictate	O
the	O
higher	O
-	O
order	O
chromatin	O
structure	O
in	O
which	O
DNA	O
is	O
packaged	O
,	O
in	O
turn	O
orchestrate	O
orderly	O
recruitment	O
of	O
nuclear	O
receptor	O
complexes	O
.	O

Modifications	O
of	O
histones	B-PRGE
include	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
,	O
ubiquitylation	O
,	O
sumoylation	O
,	O
ADP	O
ribosylation	O
,	O
deimination	O
,	O
and	O
proline	O
isomerization	O
.	O

At	O
this	O
time	O
,	O
we	O
understand	O
how	O
a	O
subset	O
of	O
these	O
modifications	O
regulates	O
nuclear	O
receptor	O
signaling	O
.	O

However	O
,	O
the	O
effects	O
,	O
particularly	O
of	O
acetylation	O
and	O
demethylation	O
,	O
are	O
profound	O
.	O

The	O
finding	O
that	O
nuclear	O
receptors	O
are	O
directly	O
acetylated	O
and	O
that	O
acetylation	O
in	O
turn	O
directly	O
regulates	O
contact	O
-	O
independent	O
growth	O
has	O
broad	O
therapeutic	O
implications	O
.	O

Studies	O
over	O
the	O
past	O
7	O
yr	O
have	O
led	O
to	O
the	O
understanding	O
that	O
nuclear	O
receptor	O
acetylation	O
is	O
a	O
conserved	O
function	O
,	O
regulating	O
diverse	O
nuclear	O
receptor	O
activity	O
.	O

Furthermore	O
,	O
we	O
now	O
know	O
that	O
acetylation	O
of	O
multiple	O
and	O
distinct	O
substrates	O
within	O
nuclear	O
receptor	O
signaling	O
pathways	O
,	O
form	O
an	O
acetylation	O
signaling	O
network	O
from	O
the	O
cell	O
surface	O
to	O
the	O
nucleus	O
.	O

The	O
finding	O
that	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
)	O
-	O
dependent	O
histone	B-PRGE
deacetylases	O
,	O
the	O
sirtuins	O
,	O
are	O
capable	O
of	O
deacetylating	O
nuclear	O
receptors	O
provides	O
a	O
new	O
level	O
of	O
complexity	O
in	O
the	O
control	O
of	O
nuclear	O
receptor	O
activity	O
in	O
which	O
local	O
intracellular	O
concentrations	O
of	O
NAD	O
may	O
regulate	O
nuclear	O
receptor	O
physiology	O
.	O

Trafficking	O
and	O
postsecretory	O
events	O
responsible	O
for	O
the	O
formation	O
of	O
secreted	O
human	O
salivary	O
peptides	O
:	O
a	O
proteomics	O
approach	O
.	O

To	O
elucidate	O
the	O
localization	O
of	O
post	O
-	O
translational	O
modifications	O
of	O
different	O
classes	O
of	O
human	O
salivary	O
proteins	O
and	O
peptides	O
(	O
acidic	O
and	O
basic	O
proline	O
-	O
rich	O
proteins	O
(	O
PRPs	O
)	O
,	O
Histatins	O
,	O
Statherin	B-PRGE
,	O
P	B-PRGE
-	I-PRGE
B	I-PRGE
peptide	O
,	O
and	O
"	O
S	O
type	O
"	O
Cystatins	O
)	O
a	O
comparative	O
reversed	O
phase	O
HPLC	O
-	O
ESI	O
-	O
MS	O
analysis	O
on	O
intact	O
proteins	O
of	O
enriched	O
granule	O
preparations	O
from	O
parotid	O
and	O
submandibular	O
glands	O
as	O
well	O
as	O
parotid	O
,	O
submandibular	O
/	O
sublingual	O
(	O
Sm	O
/	O
Sl	O
)	O
,	O
and	O
whole	O
saliva	O
was	O
performed	O
.	O

The	O
main	O
results	O
of	O
this	O
study	O
indicate	O
the	O
following	O
.	O

(	O
i	O
)	O
Phosphorylation	O
of	O
all	O
salivary	O
peptides	O
,	O
sulfation	O
of	O
Histatin	B-PRGE
1	I-PRGE
,	O
proteolytic	O
cleavages	O
of	O
acidic	O
and	O
precursor	O
basic	O
PRPs	O
occur	O
before	O
granule	O
storage	O
.	O

(	O
ii	O
)	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
basic	O
PRPs	O
are	O
secreted	O
by	O
the	O
parotid	O
gland	O
only	O
,	O
whereas	O
all	O
isoforms	O
of	O
acidic	O
PRPs	O
(	O
aPRPs	O
)	O
are	O
secreted	O
by	O
both	O
parotid	O
and	O
Sm	O
/	O
Sl	O
glands	O
.	O

(	O
iii	O
)	O
Phosphorylation	O
levels	O
of	O
aPRPs	O
,	O
Histatin	B-PRGE
1	I-PRGE
,	O
and	O
Statherin	B-PRGE
are	O
higher	O
in	O
the	O
parotid	O
gland	O
,	O
whereas	O
the	O
extent	O
of	O
cleavage	O
of	O
aPRP	O
is	O
higher	O
in	O
Sm	O
/	O
Sl	O
glands	O
.	O

(	O
iv	O
)	O
O	O
-	O
Sulfation	O
of	O
tyrosines	O
of	O
Histatin	B-PRGE
1	I-PRGE
is	O
a	O
post	O
-	O
translational	O
modification	O
specific	O
for	O
the	O
submandibular	O
gland	O
.	O

(	O
v	O
)	O
The	O
concentration	O
of	O
Histatin	B-PRGE
3	I-PRGE
,	O
Histatin	B-PRGE
5	I-PRGE
,	O
and	O
Histatin	B-PRGE
6	I-PRGE
,	O
but	O
not	O
Histatin	B-PRGE
1	I-PRGE
,	O
is	O
higher	O
in	O
parotid	O
saliva	O
.	O

(	O
vi	O
)	O
Histatin	B-PRGE
3	I-PRGE
is	O
submitted	O
to	O
the	O
first	O
proteolytic	O
cleavage	O
(	O
generating	O
Histatins	B-PRGE
6	I-PRGE
and	O
5	B-PRGE
)	O
during	O
granule	O
maturation	O
,	O
and	O
it	O
occurs	O
to	O
the	O
same	O
relative	O
extent	O
in	O
both	O
glands	O
.	O

(	O
vii	O
)	O
The	O
proteolytic	O
cleavages	O
of	O
Histatin	B-PRGE
5	I-PRGE
and	O
6	B-PRGE
,	O
generating	O
a	O
cascade	O
of	O
Histatin	B-PRGE
3	I-PRGE
fragments	O
,	O
take	O
place	O
after	O
granule	O
secretion	O
and	O
are	O
more	O
extensive	O
in	O
parotid	O
secretion	O
.	O

(	O
viii	O
)	O
Basic	O
PRPs	O
are	O
cleaved	O
in	O
the	O
oral	O
cavity	O
by	O
unknown	O
peptidases	O
,	O
generating	O
various	O
small	O
proline	O
-	O
rich	O
peptides	O
.	O

(	O
ix	O
)	O
C	O
-	O
terminal	O
removal	O
from	O
Statherin	B-PRGE
is	O
more	O
extensive	O
in	O
parotid	O
saliva	O
.	O

(	O
x	O
)	O
P	B-PRGE
-	I-PRGE
B	I-PRGE
peptide	O
is	O
secreted	O
by	O
both	O
glands	O
,	O
and	O
its	O
relative	O
quantity	O
is	O
higher	O
in	O
submandibular	O
/	O
sublingual	O
secretion	O
.	O

(	O
xi	O
)	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
S	O
type	O
Cystatins	O
are	O
mainly	O
the	O
product	O
of	O
Sm	O
/	O
Sl	O
glands	O
.	O

Functional	O
and	O
structural	O
roles	O
of	O
conserved	O
cysteine	O
residues	O
in	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
follicle	B-PRGE
-	I-PRGE
stimulating	I-PRGE
hormone	I-PRGE
receptor	I-PRGE
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

The	O
carboxyl	O
-	O
terminal	O
segment	O
of	O
G	O
protein	O
-	O
coupled	O
receptors	O
has	O
one	O
or	O
more	O
conserved	O
cysteine	O
residues	O
that	O
are	O
potential	O
sites	O
for	O
palmitoylation	O
.	O

This	O
posttranslational	O
modification	O
contributes	O
to	O
membrane	O
association	O
,	O
internalization	O
,	O
and	O
membrane	O
targeting	O
of	O
proteins	O
.	O

In	O
contrast	O
to	O
other	O
members	O
of	O
the	O
glycoprotein	O
hormone	O
receptor	O
family	O
(	O
the	O
LH	B-PRGE
and	O
thyroid	B-PRGE
-	I-PRGE
stimulating	I-PRGE
hormone	I-PRGE
receptors	I-PRGE
)	O
,	O
it	O
is	O
not	O
known	O
whether	O
the	O
follicle	B-PRGE
-	I-PRGE
stimulating	I-PRGE
hormone	I-PRGE
receptor	I-PRGE
(	O
FSHR	B-PRGE
)	O
is	O
palmitoylated	O
and	O
what	O
are	O
the	O
effects	O
of	O
abolishing	O
its	O
potential	O
palmitoylation	O
sites	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
functional	O
analysis	O
of	O
the	O
FSHR	B-PRGE
carboxyl	O
-	O
terminal	O
segment	O
cysteine	O
residues	O
was	O
carried	O
out	O
.	O

We	O
constructed	O
a	O
series	O
of	O
mutant	O
FSHRs	B-PRGE
by	O
substituting	O
cysteine	O
residues	O
with	O
alanine	O
,	O
serine	O
,	O
or	O
threonine	O
individually	O
and	O
together	O
at	O
positions	O
629	O
and	O
655	O
(	O
conserved	O
cysteines	O
)	O
and	O
627	O
(	O
nonconserved	O
)	O
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
cysteine	O
residues	O
are	O
palmitoylated	O
but	O
that	O
only	O
modification	O
at	O
Cys629	O
is	O
functionally	O
relevant	O
.	O

The	O
lack	O
of	O
palmitoylation	O
does	O
not	O
appear	O
to	O
greatly	O
impair	O
coupling	O
to	O
G	O
(	O
s	O
)	O
but	O
,	O
when	O
absent	O
at	O
position	O
629	O
,	O
does	O
significantly	O
impair	O
cell	O
surface	O
membrane	O
expression	O
of	O
the	O
partially	O
palmitoylated	O
receptor	O
.	O

All	O
FSHR	B-PRGE
Cys	O
mutants	O
were	O
capable	O
of	O
binding	O
agonist	O
with	O
the	O
same	O
affinity	O
as	O
the	O
wild	O
-	O
type	O
receptor	O
and	O
internalizing	O
on	O
agonist	O
stimulation	O
.	O

Molecular	O
dynamics	O
simulations	O
at	O
a	O
time	O
scale	O
of	O
approximately	O
100	O
nsec	O
revealed	O
that	O
replacement	O
of	O
Cys629	O
resulted	O
in	O
structures	O
that	O
differed	O
significantly	O
from	O
that	O
of	O
the	O
wild	O
-	O
type	O
receptor	O
.	O

Thus	O
,	O
deviations	O
from	O
wild	O
-	O
type	O
conformation	O
may	O
potentially	O
contribute	O
to	O
the	O
severe	O
impairment	O
in	O
plasma	O
membrane	O
expression	O
and	O
the	O
modest	O
effects	O
on	O
signaling	O
exhibited	O
by	O
the	O
receptors	O
modified	O
in	O
this	O
particular	O
position	O
.	O

Galectin	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
novel	O
structural	O
component	O
and	O
a	O
major	O
regulator	O
of	O
h	B-PRGE
-	I-PRGE
ras	I-PRGE
nanoclusters	O
.	O

The	O
organization	O
of	O
Ras	O
proteins	O
into	O
nanoclusters	O
on	O
the	O
inner	O
plasma	O
membrane	O
is	O
essential	O
for	O
Ras	O
signal	O
transduction	O
,	O
but	O
the	O
mechanisms	O
that	O
drive	O
nanoclustering	O
are	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
activation	O
stimulates	O
the	O
formation	O
of	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
.	O
GTP	O
-	O
Galectin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
Gal	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
complexes	O
on	O
the	O
plasma	O
membrane	O
that	O
are	O
then	O
assembled	O
into	O
transient	O
nanoclusters	O
.	O

Gal	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
therefore	O
an	O
integral	O
structural	O
component	O
of	O
the	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
-	O
signaling	O
nanocluster	O
.	O

Increasing	O
Gal	B-PRGE
-	I-PRGE
1	I-PRGE
levels	O
increases	O
the	O
stability	O
of	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
nanoclusters	O
,	O
leading	O
to	O
enhanced	O
effector	O
recruitment	O
and	O
signal	O
output	O
.	O

Elements	O
in	O
the	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
C	O
-	O
terminal	O
hypervariable	O
region	O
and	O
an	O
activated	O
G	O
-	O
domain	O
are	O
required	O
for	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
-	O
Gal	B-PRGE
-	I-PRGE
1	I-PRGE
interaction	O
.	O

Palmitoylation	O
is	O
not	O
required	O
for	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
-	O
Gal	B-PRGE
-	I-PRGE
1	I-PRGE
complex	O
formation	O
,	O
but	O
is	O
required	O
to	O
anchor	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
-	O
Gal	B-PRGE
-	I-PRGE
1	I-PRGE
complexes	O
to	O
the	O
plasma	O
membrane	O
.	O

Our	O
data	O
suggest	O
a	O
mechanism	O
for	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
nanoclustering	O
that	O
involves	O
a	O
dual	O
role	O
for	O
Gal	B-PRGE
-	I-PRGE
1	I-PRGE
as	O
a	O
critical	O
scaffolding	O
protein	O
and	O
a	O
molecular	O
chaperone	O
that	O
contributes	O
to	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
trafficking	O
by	O
returning	O
depalmitoylated	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
to	O
the	O
Golgi	O
complex	O
for	O
repalmitoylation	O
.	O

A	O
targeted	O
proteomic	O
analysis	O
of	O
the	O
ubiquitin	B-PRGE
-	O
like	O
modifier	O
nedd8	B-PRGE
and	O
associated	O
proteins	O
.	O

Nedd8	B-PRGE
is	O
a	O
small	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
that	O
can	O
be	O
conjugated	O
to	O
substrate	O
-	O
proteins	O
in	O
a	O
process	O
known	O
as	O
neddylation	O
.	O

Although	O
neddylation	O
plays	O
a	O
critical	O
regulatory	O
role	O
in	O
cell	O
proliferation	O
and	O
development	O
,	O
the	O
spectrum	O
of	O
Nedd8	B-PRGE
substrates	O
and	O
its	O
interaction	O
network	O
remain	O
poorly	O
understood	O
.	O

To	O
explore	O
the	O
neddylation	O
pathway	O
at	O
the	O
proteome	O
level	O
,	O
we	O
have	O
affinity	O
purified	O
Nedd8	B-PRGE
modified	O
and	O
associated	O
proteins	O
from	O
HEK293	O
cells	O
stably	O
expressing	O
GST	O
-	O
Nedd8	B-PRGE
and	O
employed	O
LC	O
-	O
MS	O
/	O
MS	O
for	O
subsequent	O
protein	O
identification	O
.	O

A	O
total	O
of	O
496	O
GST	O
-	O
Nedd8	B-PRGE
modified	O
and	O
associated	O
proteins	O
have	O
been	O
identified	O
,	O
including	O
all	O
of	O
the	O
eight	O
cullin	O
family	O
members	O
(	O
i	O
.	O
e	O
.	O
,	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
-	B-PRGE
2	I-PRGE
,	O
-	B-PRGE
3	I-PRGE
,	O
-	B-PRGE
4A	I-PRGE
,	O
-	B-PRGE
4B	I-PRGE
,	O
-	B-PRGE
5	I-PRGE
,	O
-	B-PRGE
7	I-PRGE
,	O
and	O
Parc	B-PRGE
)	O
that	O
are	O
involved	O
in	O
the	O
neddylation	O
and	O
ubiquitin	B-PRGE
-	O
proteasome	O
degradation	O
pathway	O
.	O

In	O
addition	O
,	O
a	O
group	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
DNA	O
repair	O
and	O
replication	O
,	O
cell	O
cycle	O
regulation	O
and	O
chromatin	O
organization	O
,	O
and	O
remodeling	O
have	O
been	O
copurified	O
and	O
identified	O
.	O

Apart	O
from	O
protein	O
identification	O
,	O
the	O
neddylation	O
sites	O
of	O
cullins	O
were	O
determined	O
by	O
MS	O
/	O
MS	O
analysis	O
,	O
which	O
agree	O
well	O
with	O
previous	O
mutagenesis	O
studies	O
.	O

Furthermore	O
,	O
MS	O
analyses	O
revealed	O
that	O
Nedd8	B-PRGE
K11	O
,	O
K22	O
,	O
K48	O
,	O
and	O
K60	O
can	O
form	O
chains	O
in	O
vivo	O
,	O
whereas	O
Nedd8	B-PRGE
K22	O
and	O
K48	O
can	O
be	O
neddylated	O
in	O
vitro	O
.	O

These	O
results	O
present	O
the	O
first	O
molecular	O
evidence	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
polyneddylation	O
,	O
suggesting	O
that	O
chain	O
formation	O
of	O
ubiquitin	B-PRGE
and	O
ubiquitin	B-PRGE
-	O
like	O
proteins	O
may	O
be	O
a	O
general	O
phenomenon	O
for	O
these	O
modifications	O
.	O

Although	O
much	O
remains	O
to	O
be	O
explored	O
for	O
the	O
biological	O
significance	O
of	O
the	O
observations	O
,	O
this	O
work	O
provides	O
critically	O
important	O
information	O
regarding	O
Nedd8	B-PRGE
chain	O
assembly	O
and	O
its	O
interaction	O
network	O
.	O

The	O
vast	O
amount	O
of	O
proteomic	O
information	O
obtained	O
here	O
can	O
provide	O
clues	O
on	O
the	O
biological	O
role	O
of	O
Nedd8	B-PRGE
and	O
lay	O
the	O
foundation	O
for	O
an	O
in	O
-	O
depth	O
analysis	O
of	O
the	O
regulation	O
of	O
the	O
Nedd8	B-PRGE
pathway	O
.	O

Docking	O
of	O
fatty	O
acids	O
into	O
the	O
WIF	O
domain	O
of	O
the	O
human	O
Wnt	B-PRGE
inhibitory	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Palmitoylated	O
Wnt	O
proteins	O
comprise	O
a	O
conserved	O
family	O
of	O
secreted	O
signaling	O
molecules	O
associated	O
with	O
variety	O
of	O
human	O
cancers	O
.	O

WIF	O
domain	O
of	O
the	O
human	O
WIF	B-PRGE
(	I-PRGE
Wnt	I-PRGE
inhibitory	I-PRGE
factor	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
is	O
sufficient	O
for	O
Wnt	O
binding	O
and	O
signaling	O
inhibition	O
.	O

Detailed	O
interactions	O
between	O
Wnt	O
and	O
WIF	B-PRGE
-	I-PRGE
1	I-PRGE
are	O
not	O
known	O
.	O

Computational	O
docking	O
was	O
employed	O
to	O
identify	O
a	O
possible	O
fatty	O
acid	O
binding	O
site	O
in	O
the	O
WIF	O
domain	O
.	O

A	O
putative	O
binding	O
site	O
was	O
identified	O
inside	O
the	O
domain	O
.	O

WIF	O
domain	O
exhibited	O
the	O
highest	O
affinity	O
for	O
C16	O
:	O
0	O
-	O
C18	O
:	O
0	O
(	O
-	O
22	O
kJ	O
/	O
mol	O
free	O
energy	O
of	O
binding	O
)	O
fatty	O
acids	O
.	O

The	O
results	O
suggest	O
a	O
role	O
of	O
the	O
WIF	O
domain	O
as	O
a	O
palmitoyl	O
binding	O
domain	O
required	O
for	O
WIF	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
to	O
palmitoylated	O
Wnt	O
and	O
signaling	O
inhibition	O
.	O

Palmitoylation	O
and	O
ubiquitination	O
regulate	O
exit	O
of	O
the	O
Wnt	O
signaling	O
protein	O
LRP6	B-PRGE
from	O
the	O
endoplasmic	O
reticulum	O
.	O

Canonical	O
Wnt	O
signaling	O
is	O
initiated	O
by	O
binding	O
of	O
Wnt	O
proteins	O
to	O
members	O
of	O
the	O
Frizzled	B-PRGE
family	O
and	O
subsequent	O
complex	O
formation	O
with	O
lipoprotein	B-PRGE
receptor	I-PRGE
-	I-PRGE
related	I-PRGE
proteins	I-PRGE
5	I-PRGE
/	O
6	B-PRGE
(	O
LRP5	B-PRGE
/	O
6	B-PRGE
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
LRP6	B-PRGE
is	O
palmitoylated	O
on	O
a	O
juxtamembranous	O
cysteine	O
and	O
that	O
palmitoylation	O
is	O
required	O
for	O
exit	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

We	O
propose	O
that	O
palmitoylation	O
serves	O
to	O
tilt	O
the	O
long	O
,	O
23	O
-	O
residue	O
transmembrane	O
domain	O
of	O
LRP6	B-PRGE
with	O
respect	O
to	O
the	O
plane	O
of	O
membrane	O
to	O
prevent	O
a	O
hydrophobic	O
mismatch	O
and	O
subsequent	O
recognition	O
by	O
the	O
ER	O
quality	O
control	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
a	O
palmitoylation	O
-	O
deficient	O
LRP6	B-PRGE
mutant	O
could	O
be	O
rescued	O
from	O
ER	O
retention	O
by	O
deletion	O
of	O
two	O
to	O
four	O
residues	O
in	O
the	O
transmembrane	O
domain	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
palmitoylation	O
-	O
deficient	O
LRP6	B-PRGE
was	O
retained	O
in	O
the	O
ER	O
by	O
a	O
completely	O
novel	O
monoubiquitination	O
-	O
dependent	O
ER	O
retention	O
mechanism	O
.	O

Mutation	O
of	O
a	O
specific	O
lysine	O
indeed	O
abolished	O
ubiquitination	O
of	O
palmitoylation	O
-	O
deficient	O
LRP6	B-PRGE
and	O
led	O
to	O
a	O
rescue	O
from	O
ER	O
retention	O
.	O

Finally	O
,	O
at	O
the	O
cell	O
surface	O
,	O
we	O
found	O
that	O
interplay	O
between	O
palmitoylation	O
and	O
ubiquitination	O
was	O
necessary	O
for	O
efficient	O
Wnt	O
signaling	O
.	O

Quantification	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
-	O
modified	O
proteins	O
in	O
cerebrospinal	O
fluid	O
from	O
infants	O
and	O
children	O
after	O
traumatic	O
brain	O
injury	O
.	O

Poly	O
-	O
ADP	O
-	O
ribosylation	O
(	O
PAR	O
)	O
of	O
proteins	O
by	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerases	O
(	O
PARP	O
)	O
occurs	O
after	O
experimental	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
and	O
modulates	O
neurologic	O
outcome	O
.	O

Several	O
promising	O
pharmacological	O
PARP	O
inhibitors	O
have	O
been	O
developed	O
for	O
use	O
in	O
humans	O
,	O
but	O
there	O
is	O
currently	O
no	O
clinically	O
relevant	O
means	O
of	O
monitoring	O
treatment	O
effects	O
.	O

We	O
therefore	O
used	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
to	O
measure	O
PAR	O
-	O
modified	O
proteins	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

Cerebrospinal	O
fluid	O
samples	O
from	O
17	O
pediatric	O
TBI	O
patients	O
and	O
15	O
controls	O
were	O
plated	O
overnight	O
and	O
then	O
incubated	O
with	O
polyclonal	O
antibody	O
against	O
PAR	O
.	O

Histone	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
PARP	O
substrate	O
,	O
was	O
incubated	O
with	O
active	O
PARP	O
,	O
NAD	O
,	O
and	O
nicked	O
DNA	O
,	O
and	O
served	O
as	O
the	O
standard	O
.	O

Both	O
peak	O
and	O
mean	O
CSF	O
PAR	O
-	O
modified	O
proteins	O
were	O
increased	O
in	O
TBI	O
patients	O
versus	O
controls	O
.	O

Peak	O
CSF	O
PAR	O
-	O
modified	O
protein	O
levels	O
occurred	O
on	O
day	O
1	O
and	O
levels	O
remained	O
increased	O
on	O
day	O
2	O
after	O
TBI	O
.	O

Increases	O
in	O
peak	O
CSF	O
PAR	O
-	O
modified	O
protein	O
concentrations	O
were	O
independently	O
associated	O
with	O
age	O
and	O
male	O
sex	O
,	O
but	O
not	O
initial	O
Glasgow	O
Coma	O
Scale	O
score	O
,	O
Glasgow	O
outcome	O
score	O
,	O
or	O
mechanism	O
of	O
injury	O
.	O

The	O
increase	O
in	O
PAR	O
-	O
modified	O
proteins	O
in	O
CSF	O
after	O
TBI	O
may	O
be	O
because	O
of	O
increased	O
PARP	O
activation	O
,	O
decreased	O
PAR	O
degradation	O
,	O
or	O
both	O
.	O

As	O
PAR	O
-	O
modified	O
protein	O
concentration	O
correlated	O
with	O
age	O
and	O
male	O
sex	O
,	O
developmental	O
and	O
sex	O
-	O
dependent	O
roles	O
for	O
PARP	O
after	O
TBI	O
are	O
implicated	O
.	O

Genetic	O
analysis	O
of	O
CAND1	B-PRGE
-	O
CUL1	B-PRGE
interactions	O
in	O
Arabidopsis	O
supports	O
a	O
role	O
for	O
CAND1	B-PRGE
-	O
mediated	O
cycling	O
of	O
the	O
SCFTIR1	B-PRGE
complex	O
.	O

SKP1	B-PRGE
-	O
Cullin1	B-PRGE
-	O
F	O
-	O
box	O
protein	O
(	O
SCF	O
)	O
ubiquitin	B-PRGE
-	O
ligases	O
regulate	O
numerous	O
aspects	O
of	O
eukaryotic	O
growth	O
and	O
development	O
.	O

Cullin	O
-	O
Associated	O
and	O
Neddylation	O
-	O
Dissociated	O
(	O
CAND1	B-PRGE
)	O
modulates	O
SCF	O
function	O
through	O
its	O
interactions	O
with	O
the	O
CUL1	B-PRGE
subunit	O
.	O

Although	O
biochemical	O
studies	O
with	O
human	O
CAND1	B-PRGE
suggested	O
that	O
CAND1	B-PRGE
plays	O
a	O
negative	O
regulatory	O
role	O
by	O
sequestering	O
CUL1	B-PRGE
and	O
preventing	O
SCF	O
complex	O
assembly	O
,	O
genetic	O
studies	O
in	O
Arabidopsis	O
have	O
shown	O
that	O
cand1	B-PRGE
mutants	O
exhibit	O
reduced	O
SCF	O
activity	O
,	O
demonstrating	O
that	O
CAND1	B-PRGE
is	O
required	O
for	O
optimal	O
SCF	O
function	O
in	O
vivo	O
.	O

Together	O
,	O
these	O
genetic	O
and	O
biochemical	O
studies	O
have	O
suggested	O
a	O
model	O
of	O
CAND1	B-PRGE
-	O
mediated	O
cycles	O
of	O
SCF	O
complex	O
assembly	O
and	O
disassembly	O
.	O

Here	O
,	O
using	O
the	O
SCF	O
(	O
TIR1	B-PRGE
)	O
complex	O
of	O
the	O
Arabidopsis	O
auxin	O
response	O
pathway	O
,	O
we	O
test	O
the	O
SCF	O
cycling	O
model	O
with	O
Arabidopsis	O
mutant	O
derivatives	O
of	O
CAND1	B-PRGE
and	O
CUL1	B-PRGE
that	O
have	O
opposing	O
effects	O
on	O
the	O
CAND1	B-PRGE
-	O
CUL1	B-PRGE
interaction	O
.	O

We	O
find	O
that	O
the	O
disruption	O
of	O
the	O
CAND1	B-PRGE
-	O
CUL1	B-PRGE
interaction	O
results	O
in	O
an	O
increased	O
abundance	O
of	O
assembled	O
SCF	O
(	O
TIR1	B-PRGE
)	O
complex	O
.	O

In	O
contrast	O
,	O
stabilization	O
of	O
the	O
CAND1	B-PRGE
-	O
CUL1	B-PRGE
interaction	O
diminishes	O
SCF	O
(	O
TIR1	B-PRGE
)	O
complex	O
abundance	O
.	O

The	O
fact	O
that	O
both	O
decreased	O
and	O
increased	O
CAND1	B-PRGE
-	O
CUL1	B-PRGE
interactions	O
result	O
in	O
reduced	O
SCF	O
(	O
TIR1	B-PRGE
)	O
activity	O
in	O
vivo	O
strongly	O
supports	O
the	O
hypothesis	O
that	O
CAND1	B-PRGE
-	O
mediated	O
cycling	O
is	O
required	O
for	O
optimal	O
SCF	O
function	O
.	O

Palmitoylation	O
and	O
membrane	O
interactions	O
of	O
the	O
neuroprotective	O
chaperone	O
cysteine	B-PRGE
-	I-PRGE
string	I-PRGE
protein	I-PRGE
.	O

Cysteine	B-PRGE
-	I-PRGE
string	I-PRGE
protein	I-PRGE
(	O
CSP	B-PRGE
)	O
is	O
an	O
extensively	O
palmitoylated	O
DnaJ	B-PRGE
-	O
family	O
chaperone	O
,	O
which	O
exerts	O
an	O
important	O
neuroprotective	O
function	O
.	O

Palmitoylation	O
is	O
required	O
for	O
the	O
intracellular	O
sorting	O
and	O
function	O
of	O
CSP	B-PRGE
,	O
and	O
thus	O
it	O
is	O
important	O
to	O
understand	O
how	O
this	O
essential	O
modification	O
of	O
CSP	B-PRGE
is	O
regulated	O
.	O

Recent	O
work	O
identified	O
23	O
putative	O
palmitoyl	O
transferases	O
containing	O
a	O
conserved	O
DHHC	O
domain	O
in	O
mammalian	O
cells	O
,	O
and	O
here	O
we	O
show	O
that	O
palmitoylation	O
of	O
CSP	B-PRGE
is	O
enhanced	O
specifically	O
by	O
co	O
-	O
expression	O
of	O
the	O
Golgi	O
-	O
localized	O
palmitoyl	O
transferases	O
DHHC3	B-PRGE
,	O
DHHC7	B-PRGE
,	O
DHHC15	B-PRGE
,	O
or	O
DHHC17	B-PRGE
.	O

Indeed	O
,	O
these	O
DHHC	O
proteins	O
promote	O
stable	O
membrane	O
attachment	O
of	O
CSP	B-PRGE
,	O
which	O
is	O
otherwise	O
cytosolic	O
.	O

An	O
inverse	O
correlation	O
was	O
identified	O
between	O
membrane	O
affinity	O
of	O
unpalmitoylated	O
CSP	B-PRGE
mutants	O
and	O
subsequent	O
palmitoylation	O
:	O
mutants	O
with	O
an	O
increased	O
membrane	O
affinity	O
localize	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
are	O
physically	O
separated	O
from	O
the	O
Golgi	O
-	O
localized	O
DHHC	O
proteins	O
.	O

Palmitoylation	O
of	O
an	O
ER	O
-	O
localized	O
mutant	O
could	O
be	O
rescued	O
by	O
brefeldin	O
A	O
treatment	O
,	O
which	O
promotes	O
the	O
mixing	O
of	O
ER	O
and	O
Golgi	O
membranes	O
.	O

Interestingly	O
though	O
,	O
the	O
palmitoylated	O
mutant	O
remained	O
at	O
the	O
ER	O
following	O
brefeldin	O
A	O
washout	O
and	O
did	O
not	O
traffic	O
to	O
more	O
distal	O
membrane	O
compartments	O
.	O

We	O
propose	O
that	O
CSP	B-PRGE
has	O
a	O
weak	O
membrane	O
affinity	O
that	O
allows	O
the	O
protein	O
to	O
locate	O
its	O
partner	O
Golgi	O
-	O
localized	O
DHHC	O
proteins	O
directly	O
by	O
membrane	O
"	O
sampling	O
.	O
"	O
Mutations	O
that	O
enhance	O
membrane	O
association	O
prevent	O
sampling	O
and	O
lead	O
to	O
accumulation	O
of	O
CSP	B-PRGE
on	O
cellular	O
membranes	O
such	O
as	O
the	O
ER	O
.	O

The	O
coupling	O
of	O
CSP	B-PRGE
palmitoylation	O
to	O
Golgi	O
membranes	O
may	O
thus	O
be	O
an	O
important	O
requirement	O
for	O
subsequent	O
sorting	O
.	O

The	O
HOOK	O
-	O
domain	O
between	O
the	O
SH3	O
and	O
the	O
GK	O
domains	O
of	O
Cavbeta	O
subunits	O
contains	O
key	O
determinants	O
controlling	O
calcium	O
channel	O
inactivation	O
.	O

Ca	O
(	O
v	O
)	O
beta	O
subunits	O
of	O
voltage	O
-	O
gated	O
calcium	O
channels	O
contain	O
two	O
conserved	O
domains	O
,	O
a	O
src	O
-	O
homology	O
-	O
3	O
(	O
SH3	O
)	O
-	O
domain	O
and	O
a	O
guanylate	O
kinase	O
-	O
like	O
(	O
GK	O
)	O
-	O
domain	O
.	O

The	O
SH3	O
-	O
domain	O
is	O
split	O
,	O
with	O
its	O
final	O
(	O
fifth	O
)	O
beta	O
-	O
strand	O
separated	O
from	O
the	O
rest	O
of	O
the	O
domain	O
by	O
an	O
intervening	O
sequence	O
termed	O
the	O
HOOK	O
-	O
domain	O
,	O
whose	O
sequence	O
varies	O
between	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
.	O

Here	O
we	O
have	O
been	O
guided	O
by	O
the	O
recent	O
structural	O
studies	O
of	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
in	O
the	O
design	O
of	O
specific	O
truncated	O
constructs	O
,	O
with	O
the	O
goal	O
of	O
investigating	O
the	O
role	O
of	O
the	O
HOOK	O
-	O
domain	O
of	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
in	O
the	O
modulation	O
of	O
inactivation	O
of	O
N	O
-	O
type	O
calcium	O
channels	O
.	O

We	O
have	O
coexpressed	O
the	O
beta	O
subunit	O
constructs	O
with	O
Ca	B-PRGE
(	I-PRGE
v	I-PRGE
)	I-PRGE
2	I-PRGE
.	I-PRGE
2	I-PRGE
and	O
alpha	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
delta	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
using	O
the	O
N	O
-	O
terminally	O
palmitoylated	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
subunit	O
,	O
because	O
it	O
supports	O
very	O
little	O
voltage	O
-	O
dependent	O
inactivation	O
,	O
and	O
made	O
comparisons	O
with	O
beta	B-PRGE
(	I-PRGE
1b	I-PRGE
)	I-PRGE
domains	O
.	O

Deletion	O
of	O
the	O
variable	O
region	O
of	O
the	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
HOOK	O
-	O
domain	O
resulted	O
in	O
currents	O
with	O
a	O
rapidly	O
inactivating	O
component	O
,	O
and	O
additional	O
mutation	O
of	O
the	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
palmitoylation	O
motif	O
further	O
enhanced	O
inactivation	O
.	O

The	O
isolated	O
GK	O
-	O
domain	O
of	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
alone	O
enhanced	O
current	O
amplitude	O
,	O
but	O
the	O
currents	O
were	O
rapidly	O
and	O
completely	O
inactivating	O
.	O

When	O
the	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
-	O
GK	O
-	O
domain	O
construct	O
was	O
extended	O
proximally	O
,	O
by	O
including	O
the	O
HOOK	O
-	O
domain	O
and	O
the	O
epsilon	O
-	O
strand	O
of	O
the	O
SH3	O
-	O
domain	O
,	O
inactivation	O
was	O
about	O
four	O
-	O
fold	O
slower	O
than	O
in	O
the	O
absence	O
of	O
the	O
HOOK	O
domain	O
.	O

When	O
the	O
SH3	O
-	O
domain	O
of	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
truncated	O
prior	O
to	O
the	O
HOOK	O
-	O
domain	O
was	O
coexpressed	O
with	O
the	O
(	O
HOOK	O
+	O
epsilonSH3	O
+	O
GK	O
)	O
-	O
domain	O
of	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
,	O
all	O
the	O
properties	O
of	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
were	O
restored	O
,	O
in	O
terms	O
of	O
loss	O
of	O
inactivation	O
.	O

Furthermore	O
,	O
removal	O
of	O
the	O
HOOK	O
sequence	O
from	O
the	O
(	O
HOOK	O
+	O
epsilonSH3	O
+	O
GK	O
)	O
-	O
beta	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
construct	O
increased	O
inactivation	O
.	O

Together	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
the	O
HOOK	O
domain	O
is	O
an	O
important	O
determinant	O
of	O
inactivation	O
.	O

Membrane	O
binding	O
of	O
lipidated	O
Ras	O
peptides	O
and	O
proteins	O
-	O
-	O
the	O
structural	O
point	O
of	O
view	O
.	O

Biological	O
membranes	O
are	O
interesting	O
interfaces	O
,	O
at	O
which	O
important	O
biological	O
processes	O
occur	O
.	O

In	O
addition	O
to	O
integral	O
membrane	O
proteins	O
,	O
a	O
number	O
of	O
proteins	O
bind	O
to	O
the	O
membrane	O
surface	O
and	O
associate	O
with	O
it	O
.	O

Posttranslational	O
lipid	O
modification	O
is	O
one	O
important	O
mechanism	O
,	O
by	O
which	O
soluble	O
molecules	O
develop	O
a	O
propensity	O
towards	O
the	O
membrane	O
and	O
reversibly	O
bind	O
to	O
it	O
.	O

Membrane	O
binding	O
by	O
insertion	O
of	O
hydrophobic	O
lipid	O
moieties	O
is	O
relevant	O
for	O
up	O
to	O
10	O
%	O
of	O
all	O
cellular	O
proteins	O
.	O

A	O
particular	O
interesting	O
lipid	O
-	O
modified	O
protein	O
is	O
the	O
small	O
GTPase	O
Ras	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
cellular	O
signal	O
transduction	O
.	O

Until	O
recently	O
,	O
the	O
structural	O
basis	O
for	O
membrane	O
binding	O
of	O
Ras	O
was	O
not	O
well	O
-	O
defined	O
.	O

However	O
,	O
with	O
the	O
advent	O
of	O
new	O
synthesis	O
techniques	O
and	O
the	O
advancement	O
of	O
several	O
biophysical	O
methods	O
,	O
a	O
number	O
of	O
structural	O
and	O
dynamical	O
features	O
about	O
membrane	O
binding	O
of	O
Ras	O
proteins	O
have	O
been	O
revealed	O
.	O

This	O
review	O
will	O
summarize	O
the	O
chemical	O
biology	O
of	O
Ras	O
and	O
discuss	O
in	O
more	O
detail	O
the	O
biophysical	O
and	O
structural	O
features	O
of	O
the	O
membrane	O
bound	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

RanBP2	B-PRGE
and	O
SENP3	B-PRGE
function	O
in	O
a	O
mitotic	O
SUMO2	B-PRGE
/	O
3	B-PRGE
conjugation	O
-	O
deconjugation	O
cycle	O
on	O
Borealin	B-PRGE
.	O

The	O
ubiquitin	B-PRGE
-	O
like	O
SUMO	O
system	O
controls	O
cellular	O
key	O
functions	O
,	O
and	O
several	O
lines	O
of	O
evidence	O
point	O
to	O
a	O
critical	O
role	O
of	O
SUMO	O
for	O
mitotic	O
progression	O
.	O

However	O
,	O
in	O
mammalian	O
cells	O
mitotic	O
substrates	O
of	O
sumoylation	O
and	O
the	O
regulatory	O
components	O
involved	O
are	O
not	O
well	O
defined	O
.	O

Here	O
,	O
we	O
identify	O
Borealin	B-PRGE
,	O
a	O
component	O
of	O
the	O
chromosomal	O
passenger	O
complex	O
(	O
CPC	O
)	O
,	O
as	O
a	O
mitotic	O
target	O
of	O
SUMO	O
.	O

The	O
CPC	O
,	O
which	O
additionally	O
comprises	O
INCENP	B-PRGE
,	O
Survivin	B-PRGE
,	O
and	O
Aurora	B-PRGE
B	I-PRGE
,	O
regulates	O
key	O
mitotic	O
events	O
,	O
including	O
chromosome	O
congression	O
,	O
the	O
spindle	O
assembly	O
checkpoint	O
,	O
and	O
cytokinesis	O
.	O

We	O
show	O
that	O
Borealin	B-PRGE
is	O
preferentially	O
modified	O
by	O
SUMO2	B-PRGE
/	O
3	B-PRGE
and	O
demonstrate	O
that	O
the	O
modification	O
is	O
dynamically	O
regulated	O
during	O
mitotic	O
progression	O
,	O
peaking	O
in	O
early	O
mitosis	O
.	O

Intriguingly	O
,	O
the	O
SUMO	O
ligase	O
RanBP2	B-PRGE
interacts	O
with	O
the	O
CPC	O
,	O
stimulates	O
SUMO	O
modification	O
of	O
Borealin	B-PRGE
in	O
vitro	O
,	O
and	O
is	O
required	O
for	O
its	O
modification	O
in	O
vivo	O
.	O

Moreover	O
,	O
the	O
SUMO	O
isopeptidase	O
SENP3	B-PRGE
is	O
a	O
specific	O
interaction	O
partner	O
of	O
Borealin	B-PRGE
and	O
catalyzes	O
the	O
removal	O
of	O
SUMO2	B-PRGE
/	O
3	B-PRGE
from	O
Borealin	B-PRGE
.	O

These	O
data	O
thus	O
delineate	O
a	O
mitotic	O
SUMO2	B-PRGE
/	O
3	B-PRGE
conjugation	O
-	O
deconjugation	O
cycle	O
of	O
Borealin	B-PRGE
and	O
further	O
assign	O
a	O
regulatory	O
function	O
of	O
RanBP2	B-PRGE
and	O
SENP3	B-PRGE
in	O
the	O
mitotic	O
SUMO	O
pathway	O
.	O

Structural	O
basis	O
and	O
specificity	O
of	O
human	O
otubain	B-PRGE
1	I-PRGE
-	O
mediated	O
deubiquitination	O
.	O

OTUB	B-PRGE
(	I-PRGE
otubain	I-PRGE
)	I-PRGE
1	I-PRGE
is	O
a	O
human	O
deubiquitinating	O
enzyme	O
that	O
is	O
implicated	O
in	O
mediating	O
lymphocyte	O
antigen	O
responsiveness	O
,	O
but	O
whose	O
molecular	O
function	O
is	O
generally	O
not	O
well	O
defined	O
.	O

A	O
structural	O
analysis	O
of	O
OTUB1	B-PRGE
shows	O
differences	O
in	O
accessibility	O
to	O
the	O
active	O
site	O
and	O
in	O
surface	O
properties	O
of	O
the	O
substrate	O
-	O
binding	O
regions	O
when	O
compared	O
with	O
its	O
close	O
homologue	O
,	O
OTUB2	B-PRGE
,	O
suggesting	O
variations	O
in	O
regulatory	O
mechanisms	O
and	O
substrate	O
specificity	O
.	O

Biochemical	O
analysis	O
reveals	O
that	O
OTUB1	B-PRGE
has	O
a	O
preference	O
for	O
cleaving	O
Lys	O
(	O
48	O
)	O
-	O
linked	O
polyubiquitin	B-PRGE
chains	O
over	O
Lys	O
(	O
63	O
)	O
-	O
linked	O
polyubiquitin	B-PRGE
chains	O
,	O
and	O
it	O
is	O
capable	O
of	O
cleaving	O
NEDD8	B-PRGE
(	O
neural	B-PRGE
-	I-PRGE
precursor	I-PRGE
-	I-PRGE
cell	I-PRGE
-	I-PRGE
expressed	I-PRGE
developmentally	I-PRGE
down	I-PRGE
-	I-PRGE
regulated	I-PRGE
8	I-PRGE
)	O
,	O
but	O
not	O
SUMO	B-PRGE
(	I-PRGE
small	I-PRGE
ubiquitin	I-PRGE
-	I-PRGE
related	I-PRGE
modifier	I-PRGE
)	I-PRGE
1	I-PRGE
/	O
2	B-PRGE
/	O
3	B-PRGE
and	O
ISG15	B-PRGE
(	O
interferon	O
-	O
stimulated	O
gene	O
15	O
)	O
conjugates	O
.	O

A	O
functional	O
comparison	O
of	O
OTUB1	B-PRGE
and	O
OTUB2	B-PRGE
indicated	O
a	O
differential	O
reactivity	O
towards	O
ubiquitin	B-PRGE
-	O
based	O
active	O
-	O
site	O
probes	O
carrying	O
a	O
vinyl	O
methyl	O
ester	O
,	O
a	O
2	O
-	O
chloroethyl	O
or	O
a	O
2	O
-	O
bromoethyl	O
group	O
at	O
the	O
C	O
-	O
terminus	O
.	O

Mutational	O
analysis	O
suggested	O
that	O
a	O
narrow	O
P1	O
'	O
site	O
,	O
as	O
observed	O
in	O
OTUB1	B-PRGE
,	O
correlates	O
with	O
its	O
ability	O
to	O
preferentially	O
cleave	O
Lys	O
(	O
48	O
)	O
-	O
linked	O
ubiquitin	B-PRGE
chains	O
.	O

Analysis	O
of	O
cellular	O
interaction	O
partners	O
of	O
OTUB1	B-PRGE
by	O
co	O
-	O
immunoprecipitation	O
and	O
MS	O
/	O
MS	O
(	O
tandem	O
mass	O
spectrometry	O
)	O
experiments	O
demonstrated	O
that	O
FUS	B-PRGE
[	O
fusion	B-PRGE
involved	I-PRGE
in	I-PRGE
t	I-PRGE
(	I-PRGE
12	I-PRGE
;	I-PRGE
6	I-PRGE
)	I-PRGE
in	I-PRGE
malignant	I-PRGE
liposarcoma	I-PRGE
;	O
also	O
known	O
as	O
TLS	B-PRGE
(	O
translocation	B-PRGE
in	I-PRGE
liposarcoma	I-PRGE
)	O
or	O
CHOP	B-PRGE
(	O
CCAAT	B-PRGE
/	I-PRGE
enhancer	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
homologous	I-PRGE
protein	I-PRGE
)	O
]	O
and	O
RACK1	B-PRGE
[	O
receptor	B-PRGE
for	I-PRGE
activated	I-PRGE
kinase	I-PRGE
1	I-PRGE
;	O
also	O
known	O
as	O
GNB2L1	B-PRGE
(	O
guanine	B-PRGE
-	I-PRGE
nucleotide	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
beta	I-PRGE
polypeptide	I-PRGE
2	I-PRGE
-	I-PRGE
like	I-PRGE
1	I-PRGE
)	O
]	O
are	O
part	O
of	O
OTUB1	B-PRGE
-	O
containing	O
complexes	O
,	O
pointing	O
towards	O
a	O
molecular	O
function	O
of	O
this	O
deubiquitinating	O
enzyme	O
in	O
RNA	O
processing	O
and	O
cell	O
adhesion	O
/	O
morphology	O
.	O

O	O
-	O
linked	O
GlcNAc	O
modification	O
of	O
cardiac	O
myofilament	O
proteins	O
:	O
a	O
novel	O
regulator	O
of	O
myocardial	O
contractile	O
function	O
.	O

In	O
addition	O
to	O
O	O
-	O
phosphorylation	O
,	O
O	O
-	O
linked	O
modifications	O
of	O
serine	O
and	O
threonine	O
by	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
D	O
-	O
glucosamine	O
(	O
GlcNAc	O
)	O
may	O
regulate	O
muscle	O
contractile	O
function	O
.	O

This	O
study	O
assessed	O
the	O
potential	O
role	O
of	O
O	O
-	O
GlcNAcylation	O
in	O
cardiac	O
muscle	O
contractile	O
activation	O
.	O

To	O
identify	O
specific	O
sites	O
of	O
O	O
-	O
GlcNAcylation	O
in	O
cardiac	O
myofilament	O
proteins	O
,	O
a	O
recently	O
developed	O
methodology	O
based	O
on	O
GalNAz	O
-	O
biotin	O
labeling	O
followed	O
by	O
dithiothreitol	O
replacement	O
and	O
light	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
site	O
mapping	O
was	O
adopted	O
.	O

Thirty	O
-	O
two	O
O	O
-	O
GlcNAcylated	O
peptides	O
from	O
cardiac	O
myofilaments	O
were	O
identified	O
on	O
cardiac	O
myosin	O
heavy	O
chain	O
,	O
actin	B-PRGE
,	O
myosin	B-PRGE
light	I-PRGE
chains	I-PRGE
,	O
and	O
troponin	B-PRGE
I	I-PRGE
.	O

To	O
assess	O
the	O
potential	O
physiological	O
role	O
of	O
the	O
GlcNAc	O
,	O
force	O
-	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
relationships	O
were	O
studied	O
in	O
skinned	O
rat	O
trabeculae	O
.	O

Exposure	O
to	O
GlcNAc	O
significantly	O
decreased	O
calcium	O
sensitivity	O
(	O
pCa50	O
)	O
,	O
whereas	O
maximal	O
force	O
(	O
F	O
(	O
max	O
)	O
)	O
and	O
Hill	O
coefficient	O
(	O
n	O
)	O
were	O
not	O
modified	O
.	O

Using	O
a	O
pan	O
-	O
specific	O
O	O
-	O
GlcNAc	O
antibody	O
,	O
it	O
was	O
determined	O
that	O
acute	O
exposure	O
of	O
myofilaments	O
to	O
GlcNAc	O
induced	O
a	O
significant	O
increase	O
in	O
actin	O
O	O
-	O
GlcNAcylation	O
.	O

This	O
study	O
provides	O
the	O
first	O
identification	O
of	O
O	O
-	O
GlcNAcylation	O
sites	O
in	O
cardiac	O
myofilament	O
proteins	O
and	O
demonstrates	O
their	O
potential	O
role	O
in	O
regulating	O
myocardial	O
contractile	O
function	O
.	O

Biochemical	O
characterization	O
of	O
plasma	O
-	O
derived	O
tissue	B-PRGE
factor	I-PRGE
pathway	I-PRGE
inhibitor	I-PRGE
:	O
post	O
-	O
translational	O
modification	O
of	O
free	O
,	O
full	O
-	O
length	O
form	O
with	O
particular	O
reference	O
to	O
the	O
sugar	O
chain	O
.	O

BACKGROUND	O
:	O
Tissue	B-PRGE
factor	I-PRGE
pathway	I-PRGE
inhibitor	I-PRGE
(	O
TFPI	B-PRGE
)	O
is	O
a	O
physiological	O
protease	O
inhibitor	O
that	O
inhibits	O
the	O
initial	O
reactions	O
of	O
the	O
extrinsic	O
blood	O
coagulation	O
pathway	O
.	O

Most	O
TFPI	B-PRGE
in	O
human	O
plasma	O
is	O
associated	O
with	O
lipoproteins	O
;	O
however	O
,	O
the	O
most	O
functionally	O
active	O
form	O
is	O
thought	O
to	O
be	O
the	O
free	O
,	O
full	O
-	O
length	O
form	O
(	O
f	O
-	O
pTFPI	B-PRGE
)	O
.	O

Cell	O
culture	O
derived	O
TFPI	B-PRGE
and	O
recombinant	O
TFPI	B-PRGE
(	O
rTFPI	B-PRGE
)	O
exhibit	O
variations	O
in	O
their	O
respective	O
anticoagulant	O
activity	O
,	O
which	O
may	O
be	O
caused	O
by	O
post	O
-	O
translational	O
modifications	O
,	O
such	O
as	O
the	O
frequent	O
differences	O
in	O
sugar	O
chain	O
structures	O
among	O
recombinant	O
proteins	O
.	O

Sugar	O
chain	O
structures	O
in	O
rTFPI	B-PRGE
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
have	O
been	O
reported	O
previously	O
,	O
but	O
those	O
of	O
plasma	O
TFPI	B-PRGE
have	O
not	O
been	O
.	O

OBJECTIVES	O
:	O
To	O
purify	O
f	O
-	O
pTFPI	B-PRGE
and	O
analyze	O
the	O
sugar	O
chain	O
structures	O
.	O

RESULTS	O
AND	O
CONCLUSION	O
:	O
f	O
-	O
pTFPI	B-PRGE
was	O
purified	O
to	O
homogeneity	O
from	O
blood	O
plasma	O
using	O
a	O
combination	O
of	O
anion	O
-	O
exchange	O
,	O
heparin	O
affinity	O
,	O
immunoaffinity	O
,	O
and	O
reversed	O
-	O
phase	O
chromatographies	O
,	O
resulting	O
in	O
a	O
yield	O
of	O
76	O
%	O
.	O

f	O
-	O
pTFPI	B-PRGE
showed	O
a	O
partially	O
phosphorylated	O
glycoprotein	O
comprising	O
a	O
total	O
of	O
276	O
amino	O
acids	O
by	O
peptide	O
mapping	O
.	O

The	O
sugar	O
chain	O
structures	O
were	O
analyzed	O
by	O
two	O
-	O
dimensional	O
sugar	O
mapping	O
combined	O
with	O
exoglycosidase	O
digestion	O
of	O
the	O
pyridylamino	O
sugar	O
chains	O
and	O
the	O
following	O
results	O
were	O
obtained	O
.	O

(	O
Sialyl	O
)	O
Galbeta1	O
-	O
3GalNAc	O
was	O
linked	O
to	O
Thr	O
(	O
175	O
)	O
,	O
partially	O
to	O
Thr	O
(	O
14	O
)	O
and	O
Ser	O
(	O
174	O
)	O
;	O
sialyl	O
complex	O
-	O
type	O
sugar	O
chains	O
to	O
Asn	O
(	O
117	O
)	O
and	O
Asn	O
(	O
167	O
)	O
,	O
whereas	O
Asn	O
(	O
228	O
)	O
was	O
not	O
glycosylated	O
.	O

Neuraminidase	O
-	O
resistant	O
acidic	O
sugar	O
chains	O
including	O
sulfated	O
sugar	O
chains	O
were	O
not	O
observed	O
significantly	O
.	O

The	O
protease	O
inhibitory	O
activities	O
of	O
f	O
-	O
pTFPI	B-PRGE
towards	O
activated	O
factor	B-PRGE
(	I-PRGE
F	I-PRGE
)	I-PRGE
X	I-PRGE
and	O
tissue	B-PRGE
factor	I-PRGE
-	O
activated	O
FVII	O
complex	O
were	O
identical	O
to	O
those	O
of	O
full	O
-	O
length	O
rTFPI	B-PRGE
expressed	O
in	O
CHO	O
cells	O
.	O

Site	O
-	O
specific	O
mutagenesis	O
identifies	O
three	O
cysteine	O
residues	O
in	O
the	O
cytoplasmic	O
tail	O
as	O
acylation	O
sites	O
of	O
influenza	O
virus	O
hemagglutinin	B-PRGE
.	O

The	O
hemagglutinin	B-PRGE
(	O
HA	B-PRGE
)	O
of	O
influenza	O
virus	O
is	O
a	O
type	O
I	O
transmembrane	O
glycoprotein	O
which	O
is	O
acylated	O
with	O
long	O
-	O
chain	O
fatty	O
acids	O
.	O

In	O
this	O
study	O
we	O
have	O
used	O
oligonucleotide	O
-	O
directed	O
mutagenesis	O
of	O
cloned	O
cDNA	O
and	O
a	O
simian	O
virus	O
40	O
expression	O
system	O
to	O
determine	O
the	O
fatty	O
acid	O
binding	O
site	O
in	O
HA	B-PRGE
and	O
to	O
examine	O
possible	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
.	O

The	O
results	O
show	O
that	O
the	O
HA	B-PRGE
is	O
acylated	O
through	O
thioester	O
linkages	O
at	O
three	O
highly	O
conserved	O
cysteine	O
residues	O
located	O
in	O
the	O
cytoplasmic	O
domain	O
and	O
at	O
the	O
carboxy	O
-	O
terminal	O
end	O
of	O
the	O
transmembrane	O
region	O
,	O
whereas	O
a	O
cysteine	O
located	O
in	O
the	O
middle	O
of	O
the	O
membrane	O
-	O
spanning	O
domain	O
is	O
not	O
acylated	O
.	O

Mutants	O
lacking	O
fatty	O
acids	O
at	O
individual	O
or	O
all	O
three	O
attachment	O
sites	O
acquire	O
endoglycosidase	B-PRGE
H	I-PRGE
-	O
resistant	O
oligosaccharide	O
side	O
chains	O
,	O
are	O
cleaved	O
into	O
HA1	B-PRGE
and	O
HA2	B-PRGE
subunits	O
,	O
and	O
are	O
transported	O
to	O
the	O
plasma	O
membrane	O
at	O
rates	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
HA	B-PRGE
.	O

All	O
mutants	O
are	O
membrane	O
bound	O
and	O
not	O
secreted	O
into	O
the	O
medium	O
.	O

These	O
results	O
exclude	O
transport	O
signal	O
and	O
membrane	O
-	O
anchoring	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
for	O
this	O
integral	O
membrane	O
glycoprotein	O
.	O

Furthermore	O
,	O
lack	O
of	O
acylation	O
has	O
no	O
obvious	O
influence	O
on	O
the	O
biological	O
activities	O
of	O
HA	B-PRGE
:	O
cells	O
expressing	O
fatty	O
acid	O
-	O
free	O
HA	B-PRGE
bind	O
to	O
and	O
,	O
after	O
brief	O
exposure	O
to	O
mildly	O
acidic	O
pH	O
,	O
fuse	O
with	O
erythrocytes	O
;	O
the	O
HA	B-PRGE
-	O
induced	O
polykaryon	O
formation	O
is	O
not	O
impaired	O
,	O
either	O
.	O

Other	O
possible	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
in	O
integral	O
membrane	O
glycoproteins	O
which	O
cannot	O
be	O
examined	O
in	O
conventional	O
cDNA	O
expression	O
systems	O
are	O
discussed	O
.	O

Subcellular	O
localization	O
directs	O
signaling	O
specificity	O
of	O
the	O
Cryptococcus	O
neoformans	O
Ras1	B-PRGE
protein	O
.	O

In	O
the	O
human	O
fungal	O
pathogen	O
Cryptococcus	O
neoformans	O
,	O
Ras	O
signaling	O
mediates	O
sexual	O
differentiation	O
,	O
morphogenesis	O
,	O
and	O
pathogenesis	O
.	O

By	O
studying	O
Ras	O
prenylation	O
and	O
palmitoylation	O
in	O
this	O
organism	O
,	O
we	O
have	O
found	O
that	O
the	O
subcellular	O
localization	O
of	O
this	O
protein	O
dictates	O
its	O
downstream	O
signaling	O
specificity	O
.	O

Inhibiting	O
C	O
.	O
neoformans	O
Ras1	B-PRGE
prenylation	O
results	O
in	O
the	O
defective	O
general	O
membrane	O
targeting	O
of	O
this	O
protein	O
and	O
the	O
loss	O
of	O
all	O
Ras	O
function	O
.	O

In	O
contrast	O
,	O
palmitoylation	O
mediates	O
localization	O
of	O
Ras1	B-PRGE
to	O
the	O
plasma	O
membrane	O
and	O
is	O
required	O
for	O
normal	O
morphogenesis	O
and	O
survival	O
at	O
high	O
temperatures	O
.	O

However	O
,	O
palmitoylation	O
and	O
plasma	O
membrane	O
localization	O
are	O
not	O
required	O
for	O
Ras	O
-	O
dependent	O
sexual	O
differentiation	O
.	O

Likely	O
as	O
a	O
result	O
of	O
its	O
effect	O
on	O
thermotolerance	O
,	O
Ras1	B-PRGE
palmitoylation	O
is	O
also	O
required	O
for	O
the	O
pathogenesis	O
of	O
C	O
.	O
neoformans	O
.	O

These	O
data	O
support	O
an	O
emerging	O
paradigm	O
of	O
compartmentalized	O
Ras	O
signaling	O
.	O

However	O
,	O
our	O
studies	O
also	O
demonstrate	O
fundamental	O
differences	O
between	O
the	O
Ras	O
pathways	O
in	O
different	O
organisms	O
that	O
emphasize	O
the	O
functional	O
flexibility	O
of	O
conserved	O
signaling	O
cascades	O
.	O

Both	O
FMNH2	O
and	O
FADH2	O
can	O
be	O
utilized	O
by	O
the	O
dibenzothiophene	B-PRGE
monooxygenase	I-PRGE
from	O
a	O
desulfurizing	O
bacterium	O
Mycobacterium	O
goodii	O
X7B	O
.	O

To	O
investigate	O
the	O
flavin	O
utilization	O
by	O
dibenzothiophene	B-PRGE
monooxygenase	I-PRGE
(	O
DszC	B-PRGE
)	O
,	O
DszC	B-PRGE
of	O
a	O
desulfurizing	O
bacterium	O
Mycobacterium	O
goodii	O
X7B	O
was	O
purified	O
from	O
the	O
recombinant	O
Escherichia	O
coli	O
.	O

It	O
was	O
shown	O
to	O
be	O
able	O
to	O
utilize	O
either	O
FMNH	O
(	O
2	O
)	O
or	O
FADH	O
(	O
2	O
)	O
when	O
coupled	O
with	O
a	O
flavin	B-PRGE
reductase	I-PRGE
that	O
reduces	O
either	O
FMN	O
or	O
FAD	O
.	O

Sequence	O
analysis	O
indicated	O
that	O
DszC	B-PRGE
was	O
similar	O
to	O
the	O
C	O
(	O
2	O
)	O
component	O
of	O
p	O
-	O
hydroxyphenylacetate	O
hydroxylase	O
from	O
Acinetobacter	O
baumannii	O
,	O
which	O
can	O
use	O
both	O
FADH	O
(	O
2	O
)	O
and	O
FMNH	O
(	O
2	O
)	O
as	O
substrates	O
.	O

Both	O
flavins	O
at	O
high	O
concentrations	O
could	O
inhibit	O
the	O
activity	O
of	O
DszC	B-PRGE
due	O
to	O
autocatalytic	O
oxidation	O
of	O
reduced	O
flavins	O
.	O

The	O
results	O
suggest	O
that	O
DszC	B-PRGE
should	O
be	O
reclassified	O
as	O
an	O
FMNH	O
(	O
2	O
)	O
and	O
FADH	O
(	O
2	O
)	O
both	O
-	O
utilizing	O
monooxygenase	O
component	O
and	O
the	O
flavins	O
should	O
be	O
controlled	O
at	O
properly	O
reduced	O
levels	O
to	O
obtain	O
optimal	O
biodesulfurization	O
results	O
.	O

Generation	O
of	O
branched	O
-	O
chain	O
fatty	O
acids	O
through	O
lipoate	O
-	O
dependent	O
metabolism	O
facilitates	O
intracellular	O
growth	O
of	O
Listeria	O
monocytogenes	O
.	O

The	O
gram	O
-	O
positive	O
bacterial	O
pathogen	O
Listeria	O
monocytogenes	O
has	O
evolved	O
mechanisms	O
to	O
rapidly	O
replicate	O
in	O
the	O
host	O
cytosol	O
,	O
implying	O
efficient	O
utilization	O
of	O
host	O
-	O
derived	O
nutrients	O
.	O

However	O
,	O
the	O
contribution	O
of	O
host	O
nutrient	O
scavenging	O
versus	O
that	O
of	O
bacterial	O
biosynthesis	O
toward	O
rapid	O
intracellular	O
growth	O
remains	O
unclear	O
.	O

Nutrients	O
that	O
contribute	O
to	O
growth	O
of	O
L	O
.	O
monocytogenes	O
include	O
branched	O
-	O
chain	O
fatty	O
acids	O
(	O
BCFAs	O
)	O
,	O
amino	O
acids	O
,	O
and	O
other	O
metabolic	O
intermediates	O
generated	O
from	O
acyl	O
-	O
coenzyme	O
A	O
,	O
which	O
is	O
synthesized	O
using	O
lipoylated	O
metabolic	O
enzyme	O
complexes	O
.	O

To	O
characterize	O
which	O
biosynthetic	O
pathways	O
support	O
replication	O
of	O
L	O
.	O
monocytogenes	O
inside	O
the	O
host	O
cytosol	O
,	O
we	O
impaired	O
lipoate	O
-	O
dependent	O
metabolism	O
by	O
disrupting	O
two	O
lipoate	O
ligase	O
genes	O
that	O
are	O
responsible	O
for	O
bacterial	O
protein	O
lipoylation	O
.	O

Interrupting	O
lipoate	O
-	O
dependent	O
metabolism	O
modestly	O
impaired	O
replication	O
in	O
rich	O
broth	O
medium	O
but	O
strongly	O
inhibited	O
growth	O
in	O
defined	O
medium	O
and	O
host	O
cells	O
and	O
impaired	O
the	O
generation	O
of	O
BCFAs	O
.	O

Addition	O
of	O
short	O
BCFAs	O
and	O
amino	O
acids	O
restored	O
growth	O
of	O
the	O
A1A2	O
-	O
deficient	O
(	O
A1A2	O
-	O
)	O
mutant	O
in	O
minimal	O
medium	O
,	O
implying	O
that	O
lipoate	O
-	O
dependent	O
metabolism	O
generates	O
amino	O
acids	O
and	O
BCFAs	O
.	O

BCFAs	O
alone	O
rescued	O
intracellular	O
growth	O
and	O
spread	O
in	O
L2	O
fibroblasts	O
of	O
the	O
A1A2	O
-	O
mutant	O
.	O

Lipoate	O
-	O
dependent	O
metabolism	O
was	O
also	O
required	O
in	O
vivo	O
,	O
as	O
a	O
wild	O
-	O
type	O
strain	O
robustly	O
outcompeted	O
the	O
lipoylation	O
-	O
deficient	O
mutant	O
in	O
a	O
murine	O
model	O
of	O
listeriosis	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
lipoate	O
-	O
dependent	O
metabolism	O
contributes	O
to	O
both	O
amino	O
acid	O
and	O
BCFA	O
biosynthesis	O
and	O
that	O
BCFA	O
biosynthesis	O
is	O
preferentially	O
required	O
for	O
intracellular	O
growth	O
of	O
L	O
.	O
monocytogenes	O
.	O

Eliminylation	O
:	O
a	O
post	O
-	O
translational	O
modification	O
catalyzed	O
by	O
phosphothreonine	O
lyases	O
.	O

We	O
propose	O
the	O
classification	O
of	O
a	O
protein	O
post	O
-	O
translational	O
modification	O
,	O
eliminylation	O
,	O
based	O
on	O
the	O
recently	O
delineated	O
mechanism	O
of	O
the	O
Shigella	O
OspF	B-PRGE
and	O
Salmonella	O
SpvC	B-PRGE
phosphothreonine	O
lyases	O
.	O

These	O
bacterial	O
type	O
-	O
III	O
secretion	O
-	O
system	O
virulence	O
factors	O
are	O
injected	O
into	O
eukaryotic	O
cells	O
and	O
inhibit	O
signalling	O
by	O
irreversibly	O
inactivating	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
.	O

Remarkably	O
,	O
they	O
employ	O
an	O
unusual	O
beta	O
-	O
elimination	O
reaction	O
,	O
removing	O
the	O
phosphate	O
from	O
phosphothreonine	O
and	O
converting	O
it	O
into	O
dehydrobutyrine	O
(	O
an	O
alkene	O
)	O
.	O

Eliminylated	O
cysteine	O
can	O
also	O
be	O
produced	O
by	O
decarboxylation	O
and	O
eliminylated	O
serine	O
and	O
threonine	O
by	O
dehydration	O
;	O
these	O
residues	O
are	O
found	O
in	O
the	O
eye	O
lens	O
and	O
in	O
bacterial	O
lantibiotics	O
.	O

We	O
postulate	O
that	O
eliminylation	O
might	O
be	O
a	O
widespread	O
regulatory	O
modification	O
,	O
and	O
we	O
propose	O
the	O
use	O
of	O
phosphothreonine	O
lyases	O
as	O
in	O
vivo	O
MAPK	O
inhibitors	O
both	O
therapeutically	O
and	O
to	O
investigate	O
MAPK	O
signalling	O
regulation	O
.	O

Antigenic	O
protein	O
modifications	O
in	O
Ehrlichia	O
.	O

To	O
develop	O
effective	O
vaccination	O
strategies	O
against	O
Ehrlichia	O
,	O
we	O
have	O
previously	O
reported	O
developing	O
an	O
animal	O
model	O
of	O
cross	O
-	O
protection	O
in	O
which	O
C57BL	O
/	O
6	O
mice	O
primed	O
with	O
E	O
.	O
muris	O
were	O
resistant	O
to	O
lethal	O
infection	O
with	O
Ixodes	O
ovatus	O
ehrlichia	O
(	O
IOE	O
)	O
.	O

Polyclonal	O
antibody	O
produced	O
in	O
mice	O
after	O
priming	O
with	O
E	O
.	O
muris	O
and	O
later	O
injected	O
with	O
IOE	O
-	O
detected	O
antigenic	O
proteins	O
in	O
E	O
.	O
muris	O
and	O
IOE	O
cell	O
lysates	O
.	O

Cross	O
-	O
reaction	O
of	O
antigenic	O
proteins	O
was	O
observed	O
when	O
we	O
probed	O
both	O
the	O
E	O
.	O
muris	O
and	O
IOE	O
cell	O
lysates	O
with	O
IOE	O
and	O
E	O
.	O
muris	O
-	O
specific	O
polyclonal	O
antibody	O
.	O

Analysis	O
of	O
the	O
total	O
proteins	O
of	O
E	O
.	O
muris	O
and	O
IOE	O
by	O
two	O
dimensional	O
electrophoresis	O
showed	O
that	O
both	O
E	O
.	O
muris	O
and	O
IOE	O
have	O
the	O
same	O
antigenic	O
proteins	O
.	O

Finally	O
,	O
studies	O
on	O
post	O
-	O
translational	O
protein	O
modifications	O
using	O
a	O
novel	O
technique	O
,	O
Eastern	O
blotting	O
,	O
showed	O
that	O
E	O
.	O
muris	O
proteins	O
are	O
more	O
lipoylated	O
and	O
glycosylated	O
than	O
those	O
of	O
IOE	O
.	O

Regulation	O
of	O
AMPA	O
receptor	O
extrasynaptic	O
insertion	O
by	O
4	B-PRGE
.	I-PRGE
1N	I-PRGE
,	O
phosphorylation	O
and	O
palmitoylation	O
.	O

The	O
insertion	O
of	O
AMPA	O
receptors	O
(	O
AMPARs	O
)	O
into	O
the	O
plasma	O
membrane	O
is	O
an	O
important	O
step	O
in	O
the	O
synaptic	O
delivery	O
of	O
AMPARs	O
during	O
the	O
expression	O
of	O
synaptic	O
plasticity	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
regulating	O
AMPAR	O
insertion	O
remain	O
elusive	O
.	O

By	O
directly	O
visualizing	O
individual	O
insertion	O
events	O
of	O
the	O
AMPAR	O
subunit	O
GluR1	B-PRGE
in	O
rodents	O
,	O
we	O
found	O
that	O
the	O
protein	O
4	B-PRGE
.	I-PRGE
1N	I-PRGE
was	O
required	O
for	O
activity	O
-	O
dependent	O
GluR1	B-PRGE
insertion	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
phosphorylation	O
of	O
the	O
serine	O
816	O
(	O
S816	O
)	O
and	O
S818	O
residues	O
of	O
GluR1	B-PRGE
enhanced	O
4	B-PRGE
.	I-PRGE
1N	I-PRGE
binding	O
to	O
GluR1	B-PRGE
and	O
facilitated	O
GluR1	B-PRGE
insertion	O
.	O

In	O
addition	O
,	O
palmitoylation	O
of	O
GluR1	B-PRGE
C811	O
residue	O
modulated	O
PKC	O
phosphorylation	O
and	O
GluR1	B-PRGE
insertion	O
.	O

Finally	O
,	O
disrupting	O
4	B-PRGE
.	I-PRGE
1N	I-PRGE
-	O
dependent	O
GluR1	B-PRGE
insertion	O
decreased	O
surface	O
expression	O
of	O
GluR1	B-PRGE
and	O
the	O
expression	O
of	O
long	O
-	O
term	O
potentiation	O
.	O

Our	O
study	O
uncovers	O
a	O
previously	O
unknown	O
mechanism	O
that	O
governs	O
activity	O
-	O
dependent	O
GluR1	B-PRGE
trafficking	O
,	O
reveals	O
an	O
interaction	O
between	O
AMPAR	O
palmitoylation	O
and	O
phosphorylation	O
,	O
and	O
underscores	O
the	O
functional	O
importance	O
of	O
4	B-PRGE
.	I-PRGE
1N	I-PRGE
in	O
AMPAR	O
trafficking	O
and	O
synaptic	O
plasticity	O
.	O

Using	O
RNA	O
interference	O
to	O
identify	O
specific	O
modifiers	O
of	O
a	O
temperature	O
-	O
sensitive	O
,	O
embryonic	O
-	O
lethal	O
mutation	O
in	O
the	O
Caenorhabditis	O
elegans	O
ubiquitin	B-PRGE
-	O
like	O
Nedd8	B-PRGE
protein	O
modification	O
pathway	O
E1	O
-	O
activating	O
gene	O
rfl	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
essential	O
Caenorhabditis	O
elegans	O
gene	O
rfl	B-PRGE
-	I-PRGE
1	I-PRGE
encodes	O
one	O
subunit	O
of	O
a	O
heterodimeric	O
E1	O
-	O
activating	O
enzyme	O
in	O
the	O
Nedd8	B-PRGE
ubiquitin	B-PRGE
-	O
like	O
protein	O
conjugation	O
pathway	O
.	O

This	O
pathway	O
modifies	O
the	O
Cullin	O
scaffolds	O
of	O
E3	O
ubiquitin	B-PRGE
ligases	O
with	O
a	O
single	O
Nedd8	B-PRGE
moiety	O
to	O
promote	O
ligase	O
function	O
.	O

To	O
identify	O
genes	O
that	O
influence	O
neddylation	O
,	O
we	O
used	O
a	O
synthetic	O
screen	O
to	O
identify	O
genes	O
that	O
,	O
when	O
depleted	O
with	O
RNAi	O
,	O
enhance	O
or	O
suppress	O
the	O
embryonic	O
lethality	O
caused	O
by	O
or198ts	O
,	O
a	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
mutation	O
in	O
rfl	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

We	O
identified	O
reproducible	O
suppressor	O
and	O
enhancer	O
genes	O
and	O
employed	O
a	O
systematic	O
specificity	O
analysis	O
for	O
each	O
modifier	O
using	O
four	O
unrelated	O
ts	O
embryonic	O
lethal	O
mutants	O
.	O

Results	O
of	O
this	O
analysis	O
highlight	O
the	O
importance	O
of	O
specificity	O
controls	O
in	O
identifying	O
genetic	O
interactions	O
relevant	O
to	O
a	O
particular	O
biological	O
process	O
because	O
8	O
/	O
14	O
enhancers	O
and	O
7	O
/	O
21	O
suppressors	O
modified	O
lethality	O
in	O
other	O
mutants	O
.	O

Depletion	O
of	O
the	O
strongest	O
specific	O
suppressors	O
rescued	O
the	O
early	O
embryonic	O
cell	O
division	O
defects	O
in	O
rfl	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
or198ts	O
)	O
mutants	O
.	O

RNAi	O
knockdown	O
of	O
some	O
specific	O
suppressors	O
partially	O
restored	O
Cullin	O
neddylation	O
in	O
rfl	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
or198ts	O
)	O
mutants	O
,	O
consistent	O
with	O
their	O
gene	O
products	O
normally	O
opposing	O
neddylation	O
,	O
and	O
GFP	B-PRGE
fusions	O
to	O
several	O
suppressors	O
were	O
detected	O
in	O
the	O
cytoplasm	O
or	O
the	O
nucleus	O
,	O
similar	O
in	O
pattern	O
to	O
Nedd8	B-PRGE
conjugation	O
pathway	O
components	O
in	O
early	O
embryonic	O
cells	O
.	O

In	O
contrast	O
,	O
depletion	O
of	O
the	O
two	O
strongest	O
specific	O
enhancers	O
did	O
not	O
affect	O
the	O
early	O
embryonic	O
cell	O
division	O
defects	O
observed	O
in	O
rfl	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
or198ts	O
)	O
mutants	O
,	O
suggesting	O
that	O
they	O
may	O
act	O
at	O
later	O
times	O
in	O
other	O
essential	O
processes	O
.	O

Many	O
of	O
the	O
specific	O
modifiers	O
are	O
conserved	O
in	O
other	O
organisms	O
,	O
and	O
most	O
are	O
nonessential	O
.	O

Thus	O
,	O
when	O
controlled	O
properly	O
for	O
specificity	O
,	O
modifier	O
screens	O
using	O
conditionally	O
lethal	O
C	O
.	O
elegans	O
mutants	O
can	O
identify	O
roles	O
for	O
nonessential	O
but	O
conserved	O
genes	O
in	O
essential	O
processes	O
.	O

Characterization	O
of	O
subcellular	O
localization	O
of	O
duck	O
enteritis	O
virus	O
UL51	B-PRGE
protein	O
.	O

BACKGROUND	O
:	O
Knowledge	O
of	O
the	O
subcellular	O
localization	O
of	O
a	O
protein	O
can	O
provide	O
useful	O
insights	O
about	O
its	O
function	O
.	O

While	O
the	O
subcellular	O
localization	O
of	O
many	O
alphaherpesvirus	O
UL51	B-PRGE
proteins	O
has	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
where	O
duck	O
enteritis	O
virus	O
(	O
DEV	O
)	O
UL51	B-PRGE
protein	O
(	O
pUL51	B-PRGE
)	O
is	O
targeted	O
to	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
we	O
investigated	O
the	O
subcellular	O
localization	O
and	O
distribution	O
of	O
DEV	O
pUL51	B-PRGE
by	O
computer	O
aided	O
analysis	O
,	O
as	O
well	O
as	O
indirect	O
immunofluorescence	O
(	O
IIF	O
)	O
and	O
transmission	O
immunoelectron	O
microscopy	O
(	O
TIEM	O
)	O
approaches	O
in	O
DEV	O
-	O
infected	O
cells	O
.	O

RESULTS	O
:	O
The	O
DEV	O
UL51	B-PRGE
gene	O
product	O
was	O
identified	O
as	O
an	O
approximate	O
34	O
kDa	O
protein	O
in	O
DEV	O
-	O
infected	O
cells	O
analyzed	O
by	O
western	O
blotting	O
.	O

Computer	O
aided	O
analysis	O
suggested	O
that	O
DEV	O
pUL51	B-PRGE
is	O
not	O
targeted	O
to	O
the	O
mitochondrial	O
,	O
extra	O
-	O
cellular	O
or	O
nucleus	O
,	O
but	O
be	O
targeted	O
to	O
the	O
cytoplasmic	O
in	O
host	O
cells	O
,	O
more	O
specifically	O
,	O
palmitoylation	O
of	O
the	O
pUL51	B-PRGE
through	O
the	O
N	O
-	O
terminal	O
cysteine	O
at	O
position	O
9	O
makes	O
membrane	O
association	O
and	O
Golgi	O
localization	O
possible	O
.	O

Using	O
IIF	O
analysis	O
,	O
we	O
found	O
that	O
DEV	O
pUL51	B-PRGE
was	O
first	O
detected	O
in	O
a	O
juxtanuclear	O
region	O
of	O
DEV	O
-	O
infected	O
cells	O
at	O
9	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.	O
)	O
,	O
and	O
then	O
was	O
detected	O
widely	O
distributed	O
in	O
the	O
cytoplasm	O
and	O
especially	O
was	O
stronger	O
in	O
the	O
juxtanuclear	O
region	O
from	O
12	O
to	O
60	O
h	O
p	O
.	O
i	O
.	O

TIEM	O
analysis	O
revealed	O
that	O
DEV	O
pUL51	B-PRGE
was	O
mainly	O
associated	O
with	O
cytoplasmic	O
virions	O
and	O
also	O
with	O
some	O
membranous	O
structure	O
near	O
the	O
pUL51	B-PRGE
-	O
specific	O
immuno	O
-	O
labeling	O
intracellular	O
virion	O
in	O
the	O
cytoplasmic	O
vesicles	O
;	O
moreover	O
,	O
the	O
pUL51	B-PRGE
efficiently	O
accumulated	O
in	O
the	O
Golgi	O
apparatus	O
at	O
first	O
,	O
and	O
then	O
was	O
sent	O
to	O
the	O
plasma	O
membrane	O
from	O
the	O
Golgi	O
by	O
some	O
unknown	O
mechanism	O
.	O

CONCLUSION	O
:	O
In	O
this	O
work	O
,	O
we	O
described	O
the	O
basic	O
characteristics	O
of	O
pUL51	B-PRGE
subcellular	O
localization	O
and	O
distribution	O
for	O
the	O
first	O
time	O
.	O

From	O
these	O
results	O
,	O
we	O
concluded	O
that	O
palmitoylation	O
at	O
the	O
N	O
-	O
terminal	O
cysteine	O
,	O
which	O
is	O
conserved	O
in	O
all	O
alphaherpesvirus	O
UL51	B-PRGE
homologs	O
,	O
is	O
required	O
for	O
its	O
membrane	O
association	O
and	O
Golgi	O
localization	O
,	O
and	O
the	O
pUL51	B-PRGE
mainly	O
localized	O
to	O
the	O
juxtanuclear	O
region	O
of	O
DEV	O
-	O
infected	O
cells	O
,	O
as	O
well	O
seemed	O
to	O
be	O
incorporated	O
into	O
mature	O
virions	O
as	O
a	O
component	O
of	O
the	O
tegument	O
.	O

The	O
research	O
will	O
provide	O
useful	O
clues	O
for	O
DEV	O
pUL51	B-PRGE
functional	O
analysis	O
,	O
and	O
will	O
be	O
usefull	O
for	O
further	O
understanding	O
the	O
localization	O
properties	O
of	O
alphaherpesvirus	O
UL51	B-PRGE
homologs	O
.	O

Palmitoylation	O
of	O
the	O
sphingosine	O
1	O
-	O
phosphate	O
receptor	O
S1P	O
is	O
involved	O
in	O
its	O
signaling	O
functions	O
and	O
internalization	O
.	O

The	O
lipid	O
mediator	O
sphingosine	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
regulates	O
several	O
cellular	O
processes	O
through	O
binding	O
to	O
its	O
receptors	O
(	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
-	O
S1P	B-PRGE
(	I-PRGE
5	I-PRGE
)	I-PRGE
)	O
,	O
which	O
are	O
heterotrimeric	O
G	O
protein	O
-	O
coupled	O
receptors	O
.	O

Here	O
,	O
we	O
report	O
that	O
all	O
S1P	O
receptors	O
are	O
palmitoylated	O
.	O

In	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
,	O
three	O
Cys	O
residues	O
in	O
the	O
cytoplasmic	O
tail	O
are	O
palmitoylated	O
.	O

We	O
examined	O
the	O
roles	O
of	O
palmitoylation	O
of	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
using	O
model	O
cells	O
in	O
which	O
wild	O
-	O
type	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
or	O
a	O
non	O
-	O
palmitoylated	O
mutant	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
was	O
overproduced	O
.	O

Compared	O
with	O
wild	O
-	O
type	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
,	O
the	O
non	O
-	O
palmitoylated	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
exhibited	O
binding	O
affinity	O
similar	O
to	O
the	O
natural	O
ligand	O
S1P	O
but	O
lower	O
to	O
the	O
synthetic	O
ligand	O
FTY720	O
phosphate	O
(	O
FTY720	O
-	O
P	O
)	O
,	O
the	O
active	O
form	O
of	O
the	O
immunomodulator	O
FTY720	O
.	O

However	O
,	O
downstream	O
signaling	O
of	O
non	O
-	O
palmitoylated	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
was	O
similarly	O
affected	O
by	O
S1P	O
and	O
FTY720	O
-	O
P	O
stimulation	O
.	O

Moreover	O
,	O
upon	O
stimulation	O
with	O
S1P	O
,	O
internalization	O
of	O
the	O
mutant	O
non	O
-	O
palmitoylated	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
was	O
retarded	O
,	O
compared	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O

This	O
effect	O
was	O
much	O
more	O
pronounced	O
with	O
FTY720	O
-	O
P	O
stimulation	O
.	O

Similar	O
differences	O
were	O
observed	O
for	O
the	O
phosphorylation	O
of	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
and	O
its	O
mutant	O
.	O

These	O
findings	O
may	O
provide	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
of	O
the	O
pharmacological	O
effects	O
of	O
FTY720	O
.	O

Finally	O
,	O
palmitoylation	O
of	O
wild	O
-	O
type	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
increased	O
upon	O
treatment	O
with	O
S1P	O
,	O
suggesting	O
that	O
S1P	B-PRGE
(	I-PRGE
1	I-PRGE
)	I-PRGE
undergoes	O
a	O
palmitoylation	O
/	O
depalmitoylation	O
cycle	O
after	O
stimulation	O
by	O
its	O
ligands	O
.	O

Tyrosine	O
sulfation	O
:	O
an	O
increasingly	O
recognised	O
post	O
-	O
translational	O
modification	O
of	O
secreted	O
proteins	O
.	O

The	O
post	O
-	O
translational	O
sulfation	O
of	O
tyrosine	O
residues	O
occurs	O
in	O
numerous	O
secreted	O
and	O
integral	O
membrane	O
proteins	O
and	O
,	O
in	O
many	O
cases	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
controlling	O
the	O
interactions	O
of	O
these	O
proteins	O
with	O
physiological	O
binding	O
partners	O
as	O
well	O
as	O
invading	O
pathogens	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
of	O
protein	O
tyrosine	O
sulfation	O
have	O
come	O
about	O
owing	O
to	O
the	O
cloning	O
of	O
two	O
human	O
tyrosylprotein	O
sulfotransferases	O
(	O
TPST	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
TPST	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
,	O
the	O
development	O
of	O
novel	O
analytical	O
and	O
synthetic	O
methodologies	O
and	O
detailed	O
studies	O
of	O
proteins	O
and	O
peptides	O
containing	O
sulfotyrosine	O
residues	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
TPST	O
enzymes	O
,	O
review	O
the	O
major	O
techniques	O
available	O
for	O
studying	O
the	O
presence	O
,	O
location	O
and	O
function	O
of	O
tyrosine	O
sulfation	O
in	O
proteins	O
and	O
discuss	O
the	O
biological	O
functions	O
and	O
biochemical	O
interactions	O
of	O
several	O
proteins	O
(	O
or	O
protein	O
families	O
)	O
in	O
which	O
tyrosine	O
sulfation	O
influences	O
the	O
protein	O
function	O
.	O

In	O
particular	O
,	O
we	O
describe	O
the	O
detailed	O
evidence	O
supporting	O
the	O
importance	O
of	O
tyrosine	O
sulfation	O
in	O
the	O
cellular	O
adhesion	O
function	O
of	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
glycoprotein	I-PRGE
ligand	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
the	O
leukocyte	O
trafficking	O
and	O
pathogen	O
invasion	O
functions	O
of	O
chemokine	O
receptors	O
and	O
the	O
ligand	O
binding	O
and	O
activation	O
of	O
other	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
by	O
complement	O
proteins	O
,	O
phospholipdis	O
and	O
glycoprotein	O
hormones	O
.	O

Detection	O
of	O
protein	O
ubiquitination	O
.	O

Ubiquitination	O
,	O
the	O
covalent	O
attachment	O
of	O
the	O
polypeptide	O
ubiquitin	B-PRGE
to	O
target	O
proteins	O
,	O
is	O
a	O
key	O
posttranslational	O
modification	O
carried	O
out	O
by	O
a	O
set	O
of	O
three	O
enzymes	O
.	O

They	O
include	O
ubiquitin	B-PRGE
-	O
activating	O
enzyme	O
E1	O
,	O
ubiquitin	B-PRGE
-	O
conjugating	O
enzyme	O
E2	B-PRGE
,	O
and	O
ubiquitin	B-PRGE
ligase	O
E3	O
.	O

Unlike	O
to	O
E1	O
and	O
E2	O
,	O
E3	O
ubiquitin	B-PRGE
ligases	O
display	O
substrate	O
specificity	O
.	O

On	O
the	O
other	O
hand	O
,	O
numerous	O
deubiquitylating	O
enzymes	O
have	O
roles	O
in	O
processing	O
polyubiquitinated	O
proteins	O
.	O

Ubiquitination	O
can	O
result	O
in	O
change	O
of	O
protein	O
stability	O
,	O
cellular	O
localization	O
,	O
and	O
biological	O
activity	O
.	O

Mutations	O
of	O
genes	O
involved	O
in	O
the	O
ubiquitination	O
/	O
deubiquitination	O
pathway	O
or	O
altered	O
ubiquitin	B-PRGE
system	O
function	O
are	O
associated	O
with	O
many	O
different	O
human	O
diseases	O
such	O
as	O
various	O
types	O
of	O
cancer	O
,	O
neurodegeneration	O
,	O
and	O
metabolic	O
disorders	O
.	O

The	O
detection	O
of	O
altered	O
or	O
normal	O
ubiquitination	O
of	O
target	O
proteins	O
may	O
provide	O
a	O
better	O
understanding	O
on	O
the	O
pathogenesis	O
of	O
these	O
diseases	O
.	O

Here	O
,	O
we	O
describe	O
protocols	O
to	O
detect	O
protein	O
ubiquitination	O
in	O
cultured	O
cells	O
in	O
vivo	O
and	O
test	O
tubes	O
in	O
vitro	O
.	O

These	O
protocols	O
are	O
also	O
useful	O
to	O
detect	O
other	O
ubiquitin	B-PRGE
-	O
like	O
small	O
molecule	O
modification	O
such	O
as	O
sumolyation	O
and	O
neddylation	O
.	O

Resolving	O
the	O
CSN	O
and	O
CAND1	B-PRGE
paradoxes	O
.	O

In	O
this	O
issue	O
of	O
Molecular	O
Cell	O
,	O
Schmidt	O
et	O
al	O
.	O

(	O
2009	O
)	O
untangle	O
the	O
interplay	O
between	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
cullin	B-PRGE
-	I-PRGE
associated	I-PRGE
and	I-PRGE
neddylation	I-PRGE
-	I-PRGE
dissociated	I-PRGE
1	I-PRGE
(	O
CAND1	B-PRGE
)	O
protein	O
,	O
and	O
cullin	O
-	O
RING	O
ubiquitin	B-PRGE
ligases	O
(	O
CRLs	O
)	O
.	O

PARP	B-PRGE
-	I-PRGE
1	I-PRGE
transcriptional	O
activity	O
is	O
regulated	O
by	O
sumoylation	O
upon	O
heat	O
shock	O
.	O

Heat	O
shock	O
and	O
other	O
environmental	O
stresses	O
rapidly	O
induce	O
transcriptional	O
responses	O
subject	O
to	O
regulation	O
by	O
a	O
variety	O
of	O
post	O
-	O
translational	O
modifications	O
.	O

Among	O
these	O
,	O
poly	O
(	O
ADP	O
-	O
ribosyl	O
)	O
ation	O
and	O
sumoylation	O
have	O
received	O
growing	O
attention	O
.	O

Here	O
we	O
show	O
that	O
the	O
SUMO	O
E3	O
ligase	O
PIASy	B-PRGE
interacts	O
with	O
the	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
that	O
PIASy	B-PRGE
mediates	O
heat	O
shock	O
-	O
induced	O
poly	O
-	O
sumoylation	O
of	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Furthermore	O
,	O
PIASy	B-PRGE
,	O
and	O
hence	O
sumoylation	O
,	O
appears	O
indispensable	O
for	O
full	O
activation	O
of	O
the	O
inducible	O
HSP70	B-PRGE
.	I-PRGE
1	I-PRGE
gene	O
.	O

Chromatin	O
immunoprecipitation	O
experiments	O
show	O
that	O
PIASy	B-PRGE
,	O
SUMO	O
and	O
the	O
SUMO	O
-	O
conjugating	O
enzyme	O
Ubc9	B-PRGE
are	O
rapidly	O
recruited	O
to	O
the	O
HSP70	B-PRGE
.	I-PRGE
1	I-PRGE
promoter	O
upon	O
heat	O
shock	O
,	O
and	O
that	O
they	O
are	O
subsequently	O
released	O
with	O
kinetics	O
similar	O
to	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
SUMO	O
-	O
targeted	O
ubiquitin	B-PRGE
ligase	O
RNF4	B-PRGE
mediates	O
heat	O
-	O
shock	O
-	O
inducible	O
ubiquitination	O
of	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
regulates	O
the	O
stability	O
of	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
,	O
like	O
PIASy	B-PRGE
,	O
is	O
a	O
positive	O
regulator	O
of	O
HSP70	B-PRGE
.	I-PRGE
1	I-PRGE
gene	O
activity	O
.	O

These	O
results	O
,	O
thus	O
,	O
point	O
to	O
a	O
novel	O
mechanism	O
for	O
regulating	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
function	O
,	O
and	O
suggest	O
crosstalk	O
between	O
sumoylation	O
and	O
RNF4	B-PRGE
-	O
mediated	O
ubiquitination	O
in	O
regulating	O
gene	O
expression	O
in	O
response	O
to	O
heat	O
shock	O
.	O

Distinct	O
domains	O
within	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
mediate	O
synaptic	O
incorporation	O
,	O
stabilization	O
,	O
and	O
activity	O
-	O
dependent	O
trafficking	O
.	O

The	O
postsynaptic	O
density	O
(	O
PSD	O
)	O
consists	O
of	O
a	O
lattice	O
-	O
like	O
array	O
of	O
interacting	O
proteins	O
that	O
organizes	O
and	O
stabilizes	O
receptors	O
,	O
ion	O
channels	O
,	O
structural	O
,	O
and	O
signaling	O
proteins	O
necessary	O
for	O
synaptic	O
function	O
.	O

To	O
study	O
the	O
stabilization	O
of	O
proteins	O
within	O
this	O
structure	O
and	O
the	O
contribution	O
of	O
these	O
proteins	O
to	O
the	O
integrity	O
of	O
the	O
PSD	O
,	O
we	O
tagged	O
synaptic	O
proteins	O
with	O
PAGFP	B-PRGE
(	O
photoactivatable	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
)	O
and	O
used	O
combined	O
two	O
-	O
photon	O
laser	O
-	O
scanning	O
microscopy	O
and	O
two	O
-	O
photon	O
laser	O
photoactivation	O
to	O
measure	O
their	O
rate	O
of	O
turnover	O
in	O
individual	O
spines	O
of	O
rat	O
CA1	O
pyramidal	O
neurons	O
.	O

We	O
find	O
that	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
is	O
highly	O
stable	O
within	O
the	O
spine	O
,	O
more	O
so	O
than	O
other	O
PSD	O
-	O
associated	O
proteins	O
such	O
as	O
CaMKIIalpha	B-PRGE
,	O
CaMKIIbeta	B-PRGE
,	O
GluR2	B-PRGE
,	O
and	O
Stargazin	B-PRGE
.	O

Analysis	O
of	O
a	O
series	O
of	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
mutants	O
revealed	O
that	O
distinct	O
domains	O
stabilize	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
within	O
the	O
PSD	O
and	O
contribute	O
to	O
PSD	O
formation	O
.	O

Stabilization	O
of	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
within	O
the	O
PSD	O
requires	O
N	O
-	O
terminal	O
palmitoylation	O
and	O
protein	O
interactions	O
mediated	O
by	O
the	O
first	O
and	O
second	O
PDZ	O
domains	O
,	O
whereas	O
formation	O
of	O
a	O
stable	O
lattice	O
of	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
molecules	O
within	O
the	O
PSD	O
additionally	O
requires	O
the	O
C	O
-	O
terminal	O
SH3	O
domain	O
.	O

Furthermore	O
,	O
in	O
a	O
PDZ	O
domain	O
1	O
and	O
2	O
dependent	O
manner	O
,	O
activation	O
of	O
NMDA	O
receptors	O
with	O
a	O
chemical	O
long	O
-	O
term	O
depression	O
protocol	O
rapidly	O
destabilizes	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
and	O
causes	O
a	O
subset	O
of	O
the	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
molecules	O
previously	O
anchored	O
in	O
the	O
spine	O
to	O
be	O
released	O
.	O

Thus	O
,	O
through	O
the	O
analysis	O
of	O
rates	O
of	O
exchange	O
of	O
synaptic	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
,	O
we	O
determine	O
separate	O
domains	O
of	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
that	O
play	O
specific	O
roles	O
in	O
establishing	O
a	O
stable	O
postsynaptic	O
lattice	O
,	O
in	O
allowing	O
proteins	O
to	O
enter	O
this	O
lattice	O
,	O
and	O
in	O
reorganizing	O
this	O
structure	O
in	O
response	O
to	O
plasticity	O
-	O
inducing	O
stimuli	O
.	O

Avidin	B-PRGE
acylation	O
prevents	O
the	O
complement	O
-	O
dependent	O
lysis	O
of	O
avidin	B-PRGE
-	O
carrying	O
erythrocytes	O
.	O

Non	O
-	O
covalent	O
binding	O
of	O
avidin	B-PRGE
to	O
biotinylated	O
erythrocytes	O
results	O
in	O
complement	O
-	O
dependent	O
haemolysis	O
.	O

Biotinylated	O
erythrocytes	O
,	O
as	O
well	O
as	O
native	O
cells	O
,	O
are	O
not	O
lysed	O
by	O
complement	O
.	O

Complement	O
activation	O
requires	O
a	O
tight	O
contact	O
between	O
avidin	B-PRGE
and	O
the	O
erythrocyte	O
membrane	O
,	O
since	O
avidin	B-PRGE
does	O
not	O
in	O
itself	O
activate	O
complement	O
and	O
does	O
not	O
inhibit	O
lysis	O
of	O
sensitized	O
sheep	O
erythrocytes	O
.	O

The	O
efficiency	O
of	O
haemolysis	O
depends	O
on	O
avidin	B-PRGE
'	O
s	O
surface	O
density	O
.	O

When	O
the	O
avidin	B-PRGE
concentration	O
in	O
the	O
reaction	O
mixture	O
is	O
less	O
than	O
15	O
micrograms	O
/	O
ml	O
,	O
erythrocyte	O
lysis	O
is	O
not	O
induced	O
.	O

However	O
,	O
the	O
attachment	O
of	O
biotinylated	O
antibodies	O
to	O
avidin	B-PRGE
-	O
carrying	O
erythrocytes	O
decreases	O
dramatically	O
.	O

Acylation	O
of	O
avidin	B-PRGE
with	O
succinic	O
anhydride	O
strongly	O
decreases	O
its	O
ability	O
to	O
induce	O
complement	O
-	O
dependent	O
haemolysis	O
.	O

However	O
,	O
the	O
ability	O
of	O
avidin	B-PRGE
to	O
cross	O
-	O
link	O
the	O
biotin	O
-	O
containing	O
structures	O
decreases	O
after	O
acylation	O
.	O

A	O
50	O
%	O
modification	O
of	O
avidin	B-PRGE
by	O
succinic	O
anhydride	O
(	O
pI	O
about	O
7	O
.	O
0	O
)	O
allows	O
preparation	O
of	O
'	O
immunoerythrocytes	O
'	O
,	O
which	O
retain	O
their	O
affinity	O
to	O
antigen	O
and	O
stability	O
in	O
the	O
presence	O
of	O
complement	O
.	O

NUB1	B-PRGE
promotes	O
cytoplasmic	O
localization	O
of	O
p53	B-PRGE
through	O
cooperation	O
of	O
the	O
NEDD8	B-PRGE
and	O
ubiquitin	B-PRGE
pathways	O
.	O

Non	O
-	O
covalent	O
recognition	O
of	O
ubiquitin	B-PRGE
(	O
Ub	B-PRGE
)	O
and	O
ubiquitin	B-PRGE
-	O
like	O
molecules	O
(	O
Ubls	O
)	O
by	O
interacting	O
proteins	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
protein	O
function	O
and	O
initiation	O
of	O
signalling	O
events	O
.	O

In	O
addition	O
,	O
growing	O
evidence	O
suggests	O
that	O
regulation	O
of	O
p53	B-PRGE
subcellular	O
localization	O
contributes	O
to	O
the	O
biological	O
outcome	O
of	O
the	O
p53	B-PRGE
response	O
.	O

Cytoplasmic	O
p53	B-PRGE
is	O
shown	O
to	O
promote	O
apoptosis	O
and	O
inhibit	O
the	O
induction	O
of	O
autophagy	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
NEDD8	B-PRGE
ultimate	I-PRGE
buster	I-PRGE
1	I-PRGE
(	O
NUB1	B-PRGE
)	O
,	O
a	O
non	O
-	O
covalent	O
interactor	O
of	O
the	O
Ubl	O
NEDD8	B-PRGE
(	O
neural	B-PRGE
precursor	I-PRGE
cell	I-PRGE
expressed	I-PRGE
,	I-PRGE
developmentally	I-PRGE
downregulated	I-PRGE
8	I-PRGE
)	O
,	O
controls	O
the	O
localization	O
of	O
p53	B-PRGE
.	O

Expression	O
of	O
NUB1	B-PRGE
leads	O
to	O
decreased	O
modification	O
of	O
p53	B-PRGE
with	O
NEDD8	B-PRGE
and	O
stimulation	O
of	O
p53	B-PRGE
ubiquitination	O
.	O

The	O
biological	O
outcome	O
is	O
the	O
cytoplasmic	O
localization	O
and	O
inhibition	O
of	O
the	O
transcriptional	O
activity	O
of	O
p53	B-PRGE
.	O

Although	O
the	O
effects	O
of	O
NUB1	B-PRGE
on	O
p53	B-PRGE
depend	O
on	O
NEDDylation	O
and	O
the	O
murine	B-PRGE
double	I-PRGE
minute	I-PRGE
2	I-PRGE
(	O
Mdm2	B-PRGE
)	O
E3	O
-	O
ligase	O
,	O
the	O
cooperation	O
of	O
NEDD8	B-PRGE
with	O
ubiquitin	B-PRGE
is	O
required	O
.	O

The	O
data	O
identify	O
a	O
role	O
for	O
NEDD8	B-PRGE
in	O
controlling	O
p53	B-PRGE
localization	O
and	O
suggest	O
that	O
NEDD8	B-PRGE
can	O
control	O
protein	O
function	O
through	O
its	O
non	O
-	O
covalent	O
recognition	O
by	O
interacting	O
proteins	O
.	O

Small	O
-	O
molecule	O
inhibition	O
of	O
APT1	B-PRGE
affects	O
Ras	O
localization	O
and	O
signaling	O
.	O

Cycles	O
of	O
depalmitoylation	O
and	O
repalmitoylation	O
critically	O
control	O
the	O
steady	O
-	O
state	O
localization	O
and	O
function	O
of	O
various	O
peripheral	O
membrane	O
proteins	O
,	O
such	O
as	O
Ras	O
proto	O
-	O
oncogene	O
products	O
.	O

Interference	O
with	O
acylation	O
using	O
small	O
molecules	O
is	O
a	O
strategy	O
to	O
modulate	O
cellular	O
localization	O
-	O
-	O
and	O
thereby	O
unregulated	O
signaling	O
-	O
-	O
caused	O
by	O
palmitoylated	O
Ras	O
proteins	O
.	O

We	O
present	O
the	O
knowledge	O
-	O
based	O
development	O
and	O
characterization	O
of	O
a	O
potent	O
inhibitor	O
of	O
acyl	B-PRGE
protein	I-PRGE
thioesterase	I-PRGE
1	I-PRGE
(	O
APT1	B-PRGE
)	O
,	O
a	O
bona	O
fide	O
depalmitoylating	O
enzyme	O
that	O
is	O
,	O
so	O
far	O
,	O
poorly	O
characterized	O
in	O
cells	O
.	O

The	O
inhibitor	O
,	O
palmostatin	O
B	O
,	O
perturbs	O
the	O
cellular	O
acylation	O
cycle	O
at	O
the	O
level	O
of	O
depalmitoylation	O
and	O
thereby	O
causes	O
a	O
loss	O
of	O
the	O
precise	O
steady	O
-	O
state	O
localization	O
of	O
palmitoylated	O
Ras	O
.	O

As	O
a	O
consequence	O
,	O
palmostatin	O
B	O
induces	O
partial	O
phenotypic	O
reversion	O
in	O
oncogenic	O
HRasG12V	B-PRGE
-	O
transformed	O
fibroblasts	O
.	O

We	O
identify	O
APT1	B-PRGE
as	O
one	O
of	O
the	O
thioesterases	O
in	O
the	O
acylation	O
cycle	O
and	O
show	O
that	O
this	O
protein	O
is	O
a	O
cellular	O
target	O
of	O
the	O
inhibitor	O
.	O

Ohr	O
(	O
organic	O
hydroperoxide	O
resistance	O
protein	O
)	O
possesses	O
a	O
previously	O
undescribed	O
activity	O
,	O
lipoyl	O
-	O
dependent	O
peroxidase	O
.	O

The	O
Ohr	O
(	O
organic	O
hydroperoxide	O
resistance	O
)	O
family	O
of	O
15	O
-	O
kDa	O
Cys	O
-	O
based	O
,	O
thiol	O
-	O
dependent	O
peroxidases	O
is	O
central	O
to	O
the	O
bacterial	O
response	O
to	O
stress	O
induced	O
by	O
organic	O
hydroperoxides	O
but	O
not	O
by	O
hydrogen	O
peroxide	O
.	O

Ohr	O
has	O
a	O
unique	O
three	O
-	O
dimensional	O
structure	O
and	O
requires	O
dithiols	O
,	O
but	O
not	O
monothiols	O
,	O
to	O
support	O
its	O
activity	O
.	O

However	O
,	O
the	O
physiological	O
reducing	O
system	O
of	O
Ohr	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Here	O
we	O
show	O
that	O
lipoylated	O
enzymes	O
present	O
in	O
the	O
bacterial	O
extracts	O
of	O
Xylella	O
fastidiosa	O
interacted	O
physically	O
and	O
functionally	O
with	O
this	O
Cys	O
-	O
based	O
peroxidase	O
,	O
whereas	O
thioredoxin	O
and	O
glutathione	O
systems	O
failed	O
to	O
support	O
Ohr	O
peroxidase	O
activity	O
.	O

Furthermore	O
,	O
we	O
could	O
reconstitute	O
in	O
vitro	O
three	O
lipoyl	O
-	O
dependent	O
systems	O
as	O
the	O
Ohr	O
physiological	O
reducing	O
systems	O
.	O

We	O
also	O
showed	O
that	O
OsmC	B-PRGE
from	O
Escherichia	O
coli	O
,	O
an	O
orthologue	O
of	O
Ohr	O
from	O
Xylella	O
fastidiosa	O
,	O
is	O
specifically	O
reduced	O
by	O
lipoyl	O
-	O
dependent	O
systems	O
.	O

These	O
results	O
represent	O
the	O
first	O
description	O
of	O
a	O
Cys	O
-	O
based	O
peroxidase	O
that	O
is	O
directly	O
reduced	O
by	O
lipoylated	O
enzymes	O
.	O

One	O
SUMO	O
is	O
sufficient	O
to	O
silence	O
the	O
dimeric	O
potassium	O
channel	O
K2P1	B-PRGE
.	O

Small	B-PRGE
ubiquitin	I-PRGE
modifier	I-PRGE
1	I-PRGE
(	O
SUMO1	B-PRGE
)	O
is	O
shown	O
to	O
regulate	O
K2P1	B-PRGE
background	O
channels	O
in	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
of	O
live	O
mammalian	O
cells	O
.	O

Confocal	O
microscopy	O
reveals	O
native	O
SUMO1	B-PRGE
,	O
SAE1	B-PRGE
,	O
and	O
Ubc9	B-PRGE
(	O
the	O
enzymes	O
that	O
activate	O
and	O
conjugate	O
SUMO1	B-PRGE
)	O
at	O
PM	O
where	O
SUMO1	B-PRGE
and	O
expressed	O
human	O
K2P1	B-PRGE
are	O
demonstrated	O
to	O
colocalize	O
.	O

Silent	O
K2P1	B-PRGE
channels	O
in	O
excised	O
PM	O
patches	O
are	O
activated	O
by	O
SUMO	O
isopeptidase	O
(	O
SENP1	B-PRGE
)	O
and	O
resilenced	O
by	O
SUMO1	B-PRGE
.	O

K2P1	B-PRGE
-	O
Lys274	O
is	O
crucial	O
:	O
when	O
mutated	O
to	O
Gln	O
,	O
Arg	O
,	O
Glu	O
,	O
Asp	O
,	O
Cys	O
,	O
or	O
Ala	O
,	O
the	O
channels	O
are	O
constitutively	O
active	O
and	O
insensitive	O
to	O
SUMO1	B-PRGE
and	O
SENP1	B-PRGE
.	O

Tandem	O
mass	O
spectrometry	O
confirms	O
conjugation	O
of	O
SUMO1	B-PRGE
to	O
the	O
epsilon	O
-	O
amino	O
group	O
of	O
Lys274	O
in	O
vitro	O
.	O

FRET	O
microscopy	O
shows	O
that	O
assembly	O
of	O
K2P1	B-PRGE
and	O
SUMO1	B-PRGE
requires	O
Lys274	O
.	O

Single	O
-	O
particle	O
TIRF	O
microscopy	O
shows	O
that	O
wild	O
-	O
type	O
channels	O
in	O
PM	O
have	O
two	O
K2P1	B-PRGE
subunits	O
and	O
assemble	O
with	O
two	O
SUMO1	B-PRGE
monomers	O
.	O

Although	O
channels	O
engineered	O
with	O
one	O
Lys274	O
site	O
carry	O
just	O
one	O
SUMO1	B-PRGE
they	O
are	O
activated	O
and	O
silenced	O
by	O
SENP1	B-PRGE
and	O
SUMO1	B-PRGE
like	O
wild	O
-	O
type	O
channels	O
.	O

Role	O
of	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
of	O
E1	O
in	O
SUMO	O
adenylation	O
.	O

Post	O
-	O
translational	O
modifications	O
by	O
ubiquitin	B-PRGE
-	O
like	O
proteins	O
are	O
among	O
the	O
most	O
important	O
mechanisms	O
for	O
regulating	O
a	O
wide	O
variety	O
of	O
cellular	O
functions	O
.	O

In	O
these	O
modifications	O
an	O
E1	O
enzyme	O
activates	O
each	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
(	O
Ubl	O
)	O
by	O
adenylation	O
of	O
the	O
Ubl	O
C	O
-	O
terminal	O
COOH	O
group	O
and	O
then	O
forms	O
a	O
thioester	O
bond	O
with	O
the	O
adenylated	O
C	O
-	O
terminal	O
COOH	O
group	O
of	O
the	O
Ubl	O
.	O

Previous	O
x	O
-	O
ray	O
crystallography	O
studies	O
revealed	O
a	O
conserved	O
zinc	O
motif	O
in	O
the	O
SUMO	O
and	O
NEDD8	B-PRGE
E1	O
;	O
however	O
,	O
the	O
function	O
of	O
this	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
unclear	O
.	O

In	O
this	O
study	O
,	O
using	O
quantitative	O
ATP	O
:	O
PPi	O
isotope	O
exchange	O
assays	O
in	O
combination	O
with	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
show	O
that	O
the	O
conserved	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
in	O
the	O
SUMO	O
E1	O
is	O
important	O
for	O
SUMO	O
adenylation	O
and	O
is	O
critical	O
for	O
the	O
E1	O
pseudo	O
-	O
ordered	O
substrate	O
binding	O
mechanism	O
.	O

Furthermore	O
,	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
mutants	O
showed	O
significantly	O
reduced	O
k	O
(	O
cat	O
)	O
values	O
for	O
ATP	O
:	O
PPi	O
isotope	O
exchange	O
assays	O
,	O
suggesting	O
that	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
important	O
in	O
binding	O
and	O
preventing	O
SUMO	O
adenylate	O
from	O
dissociating	O
from	O
E1	O
before	O
formation	O
of	O
the	O
thioester	O
conjugate	O
.	O

Because	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
located	O
in	O
a	O
cross	O
-	O
over	O
loop	O
that	O
is	O
known	O
to	O
have	O
conformational	O
flexibility	O
,	O
the	O
results	O
described	O
here	O
suggest	O
that	O
this	O
cross	O
-	O
over	O
loop	O
interacts	O
with	O
Ubl	O
in	O
the	O
multistep	O
,	O
dynamic	O
process	O
of	O
Ubl	O
activation	O
by	O
E1s	O
.	O

Transcriptional	O
repression	O
by	O
sumoylation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
BZLF1	B-PRGE
protein	O
correlates	O
with	O
association	O
of	O
histone	O
deacetylase	O
.	O

The	O
transition	O
from	O
latent	O
to	O
lytic	O
phases	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
life	O
cycle	O
is	O
triggered	O
by	O
expression	O
of	O
a	O
viral	O
transactivator	O
,	O
BZLF1	B-PRGE
,	O
that	O
then	O
induces	O
expression	O
of	O
the	O
viral	O
immediate	O
-	O
early	O
and	O
early	O
genes	O
.	O

The	O
BZLF1	B-PRGE
protein	O
is	O
post	O
-	O
translationally	O
modified	O
by	O
a	O
small	B-PRGE
ubiquitin	I-PRGE
-	I-PRGE
related	I-PRGE
modifier	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
.	O

Here	O
we	O
found	O
that	O
BZLF1	B-PRGE
is	O
conjugated	O
at	O
lysine	O
12	O
not	O
only	O
by	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
but	O
also	O
by	O
SUMO	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
3	B-PRGE
.	O

The	O
K12R	O
mutant	O
of	O
BZLF1	B-PRGE
,	O
which	O
no	O
longer	O
becomes	O
sumoylated	O
,	O
exhibits	O
stronger	O
transactivation	O
than	O
the	O
wild	O
-	O
type	O
BZLF1	B-PRGE
in	O
a	O
reporter	O
assay	O
system	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
virus	O
genome	O
with	O
nucleosomal	O
structures	O
.	O

Furthermore	O
,	O
exogenous	O
supply	O
of	O
a	O
SUMO	O
-	O
specific	O
protease	O
,	O
SENP	B-PRGE
,	O
caused	O
de	O
-	O
sumoylation	O
of	O
BZLF1	B-PRGE
and	O
enhanced	O
BZLF1	B-PRGE
-	O
mediated	O
transactivation	O
.	O

Immunoprecipitation	O
experiments	O
proved	O
that	O
histone	B-PRGE
deacetylase	I-PRGE
3	I-PRGE
preferentially	O
associated	O
with	O
the	O
sumoylated	O
form	O
of	O
BZLF1	B-PRGE
.	O

Levels	O
of	O
the	O
sumoylated	O
BZLF1	B-PRGE
increased	O
as	O
lytic	O
replication	O
progressed	O
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
conclude	O
that	O
sumoylation	O
of	O
BZLF1	B-PRGE
regulates	O
its	O
transcriptional	O
activity	O
through	O
histone	B-PRGE
modification	O
during	O
Epstein	O
-	O
Barr	O
virus	O
productive	O
replication	O
.	O

Sequential	O
and	O
gamma	O
-	O
secretase	O
-	O
dependent	O
processing	O
of	O
the	O
betacellulin	B-PRGE
precursor	O
generates	O
a	O
palmitoylated	O
intracellular	O
-	O
domain	O
fragment	O
that	O
inhibits	O
cell	O
growth	O
.	O

Betacellulin	B-PRGE
(	O
BTC	B-PRGE
)	O
belongs	O
to	O
the	O
family	O
of	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
EGF	B-PRGE
)	O
-	O
like	O
growth	O
factors	O
that	O
are	O
expressed	O
as	O
transmembrane	O
precursors	O
and	O
undergo	O
proteolytic	O
ectodomain	O
shedding	O
to	O
release	O
soluble	O
mature	O
ligands	O
.	O

BTC	B-PRGE
is	O
a	O
dual	O
-	O
specificity	O
ligand	O
for	O
ErbB1	B-PRGE
and	O
ErbB4	B-PRGE
receptors	O
,	O
and	O
can	O
activate	O
unique	O
signal	O
-	O
transduction	O
pathways	O
that	O
are	O
beneficial	O
for	O
the	O
function	O
,	O
survival	O
and	O
regeneration	O
of	O
pancreatic	O
beta	O
-	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
BTC	B-PRGE
precursor	O
(	O
proBTC	B-PRGE
)	O
is	O
cleaved	O
by	O
ADAM10	B-PRGE
to	O
generate	O
soluble	O
ligand	O
and	O
a	O
stable	O
,	O
transmembrane	O
remnant	O
(	O
BTC	B-PRGE
-	O
CTF	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
fate	O
of	O
the	O
BTC	B-PRGE
-	O
CTF	O
in	O
greater	O
detail	O
.	O

We	O
demonstrated	O
that	O
proBTC	B-PRGE
is	O
cleaved	O
by	O
ADAM10	B-PRGE
to	O
produce	O
BTC	B-PRGE
-	O
CTF	O
,	O
which	O
then	O
undergoes	O
intramembrane	O
processing	O
by	O
presenilin	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
and	O
/	O
or	O
presenilin	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
gamma	O
-	O
secretase	O
to	O
generate	O
an	O
intracellular	O
-	O
domain	O
fragment	O
(	O
BTC	B-PRGE
-	O
ICD	O
)	O
.	O

We	O
found	O
that	O
the	O
proBTC	B-PRGE
cytoplasmic	O
domain	O
is	O
palmitoylated	O
and	O
that	O
palmitoylation	O
is	O
not	O
required	O
for	O
ADAM10	B-PRGE
-	O
dependent	O
cleavage	O
but	O
is	O
necessary	O
for	O
the	O
stability	O
and	O
gamma	O
-	O
secretase	O
-	O
dependent	O
processing	O
of	O
BTC	B-PRGE
-	O
CTF	O
to	O
generate	O
BTC	B-PRGE
-	O
ICD	O
.	O

Additionally	O
,	O
palmitoylation	O
is	O
required	O
for	O
nuclear	O
-	O
membrane	O
localization	O
of	O
BTC	B-PRGE
-	O
ICD	O
,	O
as	O
demonstrated	O
by	O
the	O
redistribution	O
of	O
non	O
-	O
palmitoylated	O
BTC	B-PRGE
-	O
ICD	O
mutant	O
to	O
the	O
nucleoplasm	O
.	O

Importantly	O
,	O
a	O
novel	O
receptor	O
-	O
independent	O
role	O
for	O
BTC	B-PRGE
-	O
ICD	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
BTC	B-PRGE
-	O
ICD	O
to	O
inhibit	O
cell	O
growth	O
in	O
vitro	O
.	O

Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	B-PRGE
protein	I-PRGE
is	O
necessary	O
for	O
partitioning	O
into	O
detergent	O
-	O
resistant	O
membranes	O
and	O
cell	O
-	O
cell	O
fusion	O
but	O
not	O
interaction	O
with	O
M	B-PRGE
protein	I-PRGE
.	O

Coronaviruses	O
are	O
enveloped	O
RNA	O
viruses	O
that	O
generally	O
cause	O
mild	O
disease	O
in	O
humans	O
.	O

However	O
,	O
the	O
recently	O
emerged	O
coronavirus	O
that	O
caused	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
most	O
pathogenic	O
human	O
coronavirus	O
discovered	O
to	O
date	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
mediates	O
virus	O
entry	O
by	O
binding	O
cellular	O
receptors	O
and	O
inducing	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
the	O
host	O
cell	O
membrane	O
.	O

Coronavirus	O
S	O
proteins	O
are	O
palmitoylated	O
,	O
which	O
may	O
affect	O
function	O
.	O

Here	O
,	O
we	O
created	O
a	O
non	O
-	O
palmitoylated	O
SARS	O
-	O
CoV	O
S	B-PRGE
protein	I-PRGE
by	O
mutating	O
all	O
nine	O
cytoplasmic	O
cysteine	O
residues	O
.	O

Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	B-PRGE
was	O
required	O
for	O
partitioning	O
into	O
detergent	O
-	O
resistant	O
membranes	O
and	O
for	O
cell	O
-	O
cell	O
fusion	O
.	O

Surprisingly	O
,	O
however	O
,	O
palmitoylation	O
of	O
S	B-PRGE
was	O
not	O
required	O
for	O
interaction	O
with	O
SARS	O
-	O
CoV	O
M	B-PRGE
protein	I-PRGE
.	O

This	O
contrasts	O
with	O
the	O
requirement	O
for	O
palmitoylation	O
of	O
mouse	O
hepatitis	O
virus	O
S	B-PRGE
protein	I-PRGE
for	O
interaction	O
with	O
M	B-PRGE
protein	I-PRGE
and	O
may	O
point	O
to	O
important	O
differences	O
in	O
assembly	O
and	O
infectivity	O
of	O
these	O
two	O
coronaviruses	O
.	O

Elucidation	O
of	O
XA21	B-PRGE
-	O
mediated	O
innate	O
immunity	O
.	O

In	O
the	O
early	O
1970s	O
,	O
the	O
Xa21	B-PRGE
gene	O
from	O
the	O
wild	O
rice	O
species	O
Oryza	O
longistaminata	O
drew	O
attention	O
of	O
rice	O
breeders	O
because	O
of	O
its	O
broad	O
-	O
spectrum	O
resistance	O
to	O
diverse	O
strains	O
of	O
a	O
serious	O
bacterial	O
disease	O
of	O
rice	O
in	O
Asia	O
and	O
Africa	O
,	O
called	O
'	O
bacterial	O
blight	O
disease	O
'	O
,	O
caused	O
by	O
the	O
Gram	O
-	O
negative	O
bacterium	O
,	O
Xanthomonas	O
oryzae	O
pv	O
.	O
oryzae	O
(	O
Xoo	O
)	O
.	O

In	O
1995	O
,	O
we	O
isolated	O
the	O
gene	O
controlling	O
this	O
resistance	O
and	O
in	O
2009	O
demonstrated	O
that	O
XA21	B-PRGE
recognizes	O
a	O
highly	O
conserved	O
peptide	O
,	O
called	O
'	O
Ax21	B-PRGE
'	O
(	O
activator	B-PRGE
of	I-PRGE
XA21	I-PRGE
-	I-PRGE
mediated	I-PRGE
immunity	I-PRGE
)	O
.	O

Tyrosine	O
sulfation	O
of	O
Ax21	B-PRGE
is	O
required	O
for	O
recognition	O
by	O
rice	O
XA21	B-PRGE
.	O

A	O
decade	O
of	O
genetic	O
,	O
molecular	O
and	O
biochemical	O
studies	O
have	O
uncovered	O
key	O
components	O
of	O
the	O
XA21	B-PRGE
-	O
mediated	O
signalling	O
cascade	O
.	O

Ax21	B-PRGE
recognition	O
by	O
XA21	B-PRGE
at	O
the	O
cell	O
surface	O
induces	O
phosphorylation	O
-	O
mediated	O
events	O
,	O
which	O
are	O
predicted	O
to	O
alter	O
subcellular	O
localization	O
and	O
/	O
or	O
DNA	O
-	O
binding	O
activity	O
of	O
a	O
WRKY	O
family	O
of	O
transcription	O
factors	O
.	O

Because	O
XA21	B-PRGE
is	O
representative	O
of	O
the	O
large	O
number	O
of	O
predicted	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
in	O
rice	O
(	O
n	O
=	O
328	O
)	O
,	O
Arabidopsis	O
(	O
n	O
=	O
35	O
)	O
and	O
other	O
plant	O
species	O
,	O
further	O
characterization	O
of	O
XA21	B-PRGE
-	O
mediated	O
signalling	O
pathways	O
will	O
contribute	O
to	O
elucidation	O
of	O
these	O
important	O
defence	O
responses	O
.	O

dHIP14	B-PRGE
-	O
dependent	O
palmitoylation	O
promotes	O
secretion	O
of	O
the	O
BMP	O
antagonist	O
Sog	B-PRGE
.	O

Analysis	O
of	O
diverse	O
signaling	O
systems	O
has	O
revealed	O
that	O
one	O
important	O
level	O
of	O
control	O
is	O
regulation	O
of	O
membrane	O
trafficking	O
of	O
ligands	O
and	O
receptors	O
.	O

The	O
activities	O
of	O
some	O
ligands	O
are	O
also	O
regulated	O
by	O
whether	O
they	O
are	O
membrane	O
bound	O
or	O
secreted	O
.	O

In	O
Drosophila	O
,	O
several	O
morphogenetic	O
signals	O
that	O
play	O
critical	O
roles	O
in	O
development	O
have	O
been	O
found	O
to	O
be	O
subject	O
to	O
such	O
regulation	O
.	O

For	O
example	O
,	O
activity	O
of	O
the	O
Hedgehog	B-PRGE
(	O
Hh	B-PRGE
)	O
is	O
regulated	O
by	O
Raspberry	B-PRGE
,	O
which	O
palmitoylates	O
Hh	B-PRGE
.	O

Similarly	O
,	O
the	O
palmitoylases	O
Porcupine	B-PRGE
and	O
Raspberry	B-PRGE
increase	O
the	O
activities	O
of	O
Wingless	B-PRGE
(	O
Wg	B-PRGE
)	O
and	O
the	O
EGF	O
-	O
ligand	O
Spitz	B-PRGE
(	O
Spi	B-PRGE
)	O
,	O
respectively	O
.	O

In	O
contrast	O
to	O
its	O
vertebrate	O
homologues	O
,	O
which	O
have	O
typical	O
N	O
-	O
terminal	O
signal	O
sequences	O
,	O
the	O
precursor	O
form	O
of	O
Drosophila	O
Hh	B-PRGE
contains	O
an	O
internal	O
type	O
-	O
II	O
secretory	O
signal	O
motif	O
.	O

The	O
Short	B-PRGE
Gastrulation	I-PRGE
(	O
Sog	B-PRGE
)	O
protein	O
is	O
another	O
secreted	O
Drosophila	O
protein	O
that	O
contains	O
a	O
type	O
-	O
II	O
signal	O
and	O
differs	O
from	O
its	O
vertebrate	O
ortholog	O
Chordin	B-PRGE
which	O
contains	O
a	O
standard	O
signal	O
peptide	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
regulation	O
of	O
Sog	B-PRGE
secretion	O
and	O
regulation	O
by	O
dHIP14	B-PRGE
,	O
the	O
ortholog	O
of	O
a	O
mammalian	O
palmitoylase	O
first	O
identified	O
as	O
Huntington	O
Interacting	O
Protein	O
(	O
HIP	O
)	O
.	O

We	O
show	O
that	O
dHIP14	B-PRGE
binds	O
to	O
Sog	B-PRGE
and	O
that	O
Sog	B-PRGE
is	O
palmitoylated	O
.	O

In	O
S2	O
cells	O
,	O
dHIP14	B-PRGE
promotes	O
secretion	O
of	O
Sog	B-PRGE
as	O
well	O
as	O
stabilizing	O
a	O
membrane	O
associated	O
form	O
of	O
Sog	B-PRGE
.	O

We	O
examined	O
the	O
requirement	O
for	O
candidate	O
cysteine	O
residues	O
in	O
the	O
N	O
-	O
terminal	O
predicted	O
cytoplasmic	O
domain	O
of	O
Sog	B-PRGE
and	O
find	O
that	O
Cys27	O
,	O
one	O
of	O
two	O
adjacent	O
cysteines	O
(	O
Cys27	O
and	O
Cys28	O
)	O
,	O
is	O
essential	O
for	O
the	O
full	O
activity	O
of	O
dHIP14	B-PRGE
and	O
its	O
effect	O
on	O
Sog	B-PRGE
.	O

Finally	O
,	O
we	O
find	O
that	O
dHIP14	B-PRGE
promotes	O
the	O
activity	O
of	O
Sog	B-PRGE
in	O
vivo	O
.	O

These	O
studies	O
highlight	O
the	O
growing	O
importance	O
of	O
lipid	O
modification	O
in	O
regulating	O
signaling	O
at	O
the	O
level	O
of	O
ligand	O
production	O
and	O
localization	O
.	O

GlcNAcylation	O
plays	O
an	O
essential	O
role	O
in	O
breast	O
cancer	O
metastasis	O
.	O

GlcNAcylation	O
,	O
a	O
dynamic	O
posttranslational	O
modification	O
,	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
biological	O
processes	O
and	O
some	O
human	O
diseases	O
.	O

Although	O
there	O
is	O
emerging	O
evidence	O
that	O
some	O
tumor	O
-	O
associated	O
proteins	O
are	O
modified	O
by	O
GlcNAcylation	O
,	O
the	O
role	O
of	O
GlcNAcylation	O
in	O
tumor	O
progression	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
GlcNAcylation	O
enhances	O
the	O
migration	O
/	O
invasion	O
of	O
breast	O
cancer	O
cells	O
in	O
vitro	O
and	O
lung	O
metastasis	O
in	O
vivo	O
.	O

The	O
decrease	O
of	O
cell	O
surface	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
is	O
the	O
molecular	O
mechanism	O
underlying	O
GlcNAcylation	O
-	O
induced	O
breast	O
cancer	O
metastasis	O
.	O

p120	B-PRGE
and	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
,	O
but	O
not	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
,	O
are	O
GlcNAcylated	O
;	O
the	O
GlcNAcylation	O
of	O
p120	B-PRGE
and	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
might	O
play	O
roles	O
in	O
the	O
decrease	O
of	O
cell	O
surface	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
.	O

Moreover	O
,	O
immunohistochemistry	O
analysis	O
indicated	O
that	O
the	O
global	O
GlcNAcylation	O
level	O
in	O
breast	O
tumor	O
tissues	O
is	O
elevated	O
significantly	O
as	O
compared	O
with	O
that	O
in	O
the	O
corresponding	O
adjacent	O
tissues	O
;	O
further	O
,	O
GlcNAcylation	O
was	O
significantly	O
enhanced	O
in	O
metastatic	O
lymph	O
nodes	O
compared	O
with	O
their	O
corresponding	O
primary	O
tumor	O
tissues	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
clearly	O
elucidate	O
the	O
roles	O
and	O
mechanisms	O
whereby	O
GlcNAcylation	O
influences	O
the	O
malignant	O
properties	O
of	O
breast	O
cancer	O
cells	O
.	O

These	O
results	O
also	O
suggest	O
that	O
GlcNAcylation	O
might	O
be	O
a	O
potential	O
target	O
for	O
the	O
diagnosis	O
and	O
therapy	O
of	O
breast	O
cancer	O
.	O

C	O
.	O
elegans	O
CAND	B-PRGE
-	I-PRGE
1	I-PRGE
regulates	O
cullin	O
neddylation	O
,	O
cell	O
proliferation	O
and	O
morphogenesis	O
in	O
specific	O
tissues	O
.	O

Cullin	O
-	O
RING	O
ubiquitin	B-PRGE
ligases	O
(	O
CRLs	O
)	O
are	O
critical	O
regulators	O
of	O
multiple	O
developmental	O
and	O
cellular	O
processes	O
in	O
eukaryotes	O
.	O

CAND1	B-PRGE
is	O
a	O
biochemical	O
inhibitor	O
of	O
CRLs	O
,	O
yet	O
has	O
been	O
shown	O
to	O
promote	O
CRL	O
activity	O
in	O
plant	O
and	O
mammalian	O
cells	O
.	O

Here	O
we	O
analyze	O
CAND1	B-PRGE
function	O
in	O
the	O
context	O
of	O
a	O
developing	O
metazoan	O
organism	O
.	O

Caenorhabditis	O
elegans	O
CAND	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
capable	O
of	O
binding	O
to	O
all	O
of	O
the	O
cullins	O
,	O
and	O
we	O
show	O
that	O
it	O
physically	O
interacts	O
with	O
CUL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
CUL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
vivo	O
.	O

The	O
covalent	O
attachment	O
of	O
the	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
Nedd8	B-PRGE
is	O
required	O
for	O
cullin	O
activity	O
in	O
animals	O
and	O
plants	O
.	O

In	O
cand	B-PRGE
-	I-PRGE
1	I-PRGE
mutants	O
,	O
the	O
levels	O
of	O
the	O
neddylated	O
isoforms	O
of	O
CUL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
CUL	B-PRGE
-	I-PRGE
4	I-PRGE
are	O
increased	O
,	O
indicating	O
that	O
CAND	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
negative	O
regulator	O
of	O
cullin	O
neddylation	O
.	O

cand	B-PRGE
-	I-PRGE
1	I-PRGE
mutants	O
are	O
hypersensitive	O
to	O
the	O
partial	O
loss	O
of	O
cullin	O
activity	O
,	O
suggesting	O
that	O
CAND	B-PRGE
-	I-PRGE
1	I-PRGE
facilitates	O
CRL	O
functions	O
.	O

cand	B-PRGE
-	I-PRGE
1	I-PRGE
mutants	O
exhibit	O
impenetrant	O
phenotypes	O
,	O
including	O
developmental	O
arrest	O
,	O
morphological	O
defects	O
of	O
the	O
vulva	O
and	O
tail	O
,	O
and	O
reduced	O
fecundity	O
.	O

cand	B-PRGE
-	I-PRGE
1	I-PRGE
mutants	O
share	O
with	O
cul	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
lin	B-PRGE
-	I-PRGE
23	I-PRGE
mutants	O
the	O
phenotypes	O
of	O
supernumerary	O
seam	O
cell	O
divisions	O
,	O
defective	O
alae	O
formation	O
,	O
and	O
the	O
accumulation	O
of	O
the	O
SCF	O
(	O
LIN	B-PRGE
-	I-PRGE
23	I-PRGE
)	O
target	O
the	O
glutamate	O
receptor	O
GLR	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
observation	O
that	O
cand	B-PRGE
-	I-PRGE
1	I-PRGE
mutants	O
have	O
phenotypes	O
associated	O
with	O
the	O
loss	O
of	O
the	O
SCF	O
(	O
LIN	B-PRGE
-	I-PRGE
23	I-PRGE
)	O
complex	O
,	O
but	O
lack	O
phenotypes	O
associated	O
with	O
other	O
specific	O
CRL	O
complexes	O
,	O
suggests	O
that	O
CAND	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
differentially	O
required	O
for	O
the	O
activity	O
of	O
distinct	O
CRL	O
complexes	O
.	O

Engineering	O
a	O
protein	O
-	O
protein	O
interface	O
using	O
a	O
computationally	O
designed	O
library	O
.	O

Computational	O
algorithms	O
for	O
protein	O
design	O
can	O
sample	O
large	O
regions	O
of	O
sequence	O
space	O
,	O
but	O
suffer	O
from	O
undersampling	O
of	O
conformational	O
space	O
and	O
energy	O
function	O
inaccuracies	O
.	O

Experimental	O
screening	O
of	O
combinatorial	O
protein	O
libraries	O
avoids	O
the	O
need	O
for	O
accurate	O
energy	O
functions	O
,	O
but	O
has	O
limited	O
access	O
to	O
vast	O
amounts	O
of	O
sequence	O
space	O
.	O

Here	O
,	O
we	O
test	O
if	O
these	O
two	O
traditionally	O
alternative	O
,	O
but	O
potentially	O
complementary	O
approaches	O
can	O
be	O
combined	O
to	O
design	O
a	O
variant	O
of	O
the	O
ubiquitin	B-PRGE
-	O
ligase	O
E6AP	B-PRGE
that	O
will	O
bind	O
to	O
a	O
nonnatural	O
partner	O
,	O
the	O
NEDD8	B-PRGE
-	O
conjugating	O
enzyme	O
Ubc12	B-PRGE
.	O

Three	O
E6AP	B-PRGE
libraries	O
were	O
constructed	O
:	O
(	O
i	O
)	O
a	O
naive	O
library	O
in	O
which	O
all	O
20	O
amino	O
acids	O
were	O
allowed	O
at	O
every	O
position	O
on	O
the	O
target	O
-	O
binding	O
surface	O
of	O
E6AP	B-PRGE
(	O
13	O
positions	O
)	O
,	O
(	O
ii	O
)	O
a	O
semidirected	O
library	O
that	O
varied	O
the	O
same	O
residue	O
positions	O
as	O
in	O
the	O
naive	O
library	O
but	O
disallowed	O
mutations	O
computationally	O
predicted	O
to	O
destabilize	O
E6AP	B-PRGE
,	O
and	O
(	O
iii	O
)	O
a	O
directed	O
library	O
that	O
used	O
docking	O
and	O
sequence	O
optimization	O
simulations	O
to	O
identify	O
mutations	O
predicted	O
to	O
be	O
favorable	O
for	O
binding	O
Ubc12	B-PRGE
.	O

Both	O
of	O
the	O
directed	O
libraries	O
showed	O
>	O
30	O
-	O
fold	O
enrichment	O
over	O
the	O
naive	O
library	O
after	O
the	O
first	O
round	O
of	O
screening	O
with	O
a	O
split	O
-	O
dihydrofolate	B-PRGE
reductase	I-PRGE
complementation	O
assay	O
and	O
produced	O
multiple	O
tight	O
binders	O
(	O
K	O
(	O
d	O
)	O
<	O
100	O
nM	O
)	O
after	O
four	O
rounds	O
of	O
selection	O
.	O

Four	O
rounds	O
of	O
selection	O
with	O
the	O
naive	O
library	O
failed	O
to	O
produce	O
any	O
binders	O
with	O
K	O
(	O
d	O
)	O
'	O
s	O
lower	O
than	O
50	O
mu	O
M	O
.	O

These	O
results	O
indicate	O
that	O
protein	O
design	O
simulations	O
can	O
be	O
used	O
to	O
create	O
directed	O
libraries	O
that	O
are	O
enriched	O
in	O
tight	O
binders	O
and	O
that	O
in	O
some	O
cases	O
it	O
is	O
sufficient	O
to	O
computationally	O
screen	O
for	O
well	O
-	O
folded	O
sequences	O
without	O
explicit	O
binding	O
calculations	O
.	O

Involvement	O
of	O
a	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
protein	O
in	O
the	O
regulation	O
of	O
angiotensinogen	O
production	O
by	O
an	O
angiotensin	B-PRGE
II	I-PRGE
analog	O
in	O
HepG2	O
cells	O
.	O

The	O
cellular	O
mechanism	O
by	O
which	O
the	O
angiotensin	B-PRGE
II	I-PRGE
(	O
AII	B-PRGE
)	O
agonist	O
,	O
Sar1	O
-	O
AII	O
,	O
inhibits	O
production	O
and	O
release	O
of	O
angiotensinogen	B-PRGE
in	O
human	O
hepatoma	O
HepG2	O
cells	O
was	O
examined	O
.	O

Pretreatment	O
of	O
HepG2	O
cells	O
with	O
pertussis	O
toxin	O
attenuated	O
the	O
ability	O
of	O
Sar1	O
-	O
AII	O
to	O
block	O
angiotensinogen	B-PRGE
production	O
.	O

This	O
effect	O
could	O
be	O
correlated	O
with	O
the	O
in	O
situ	O
ADP	O
-	O
ribosylation	O
of	O
a	O
protein	O
(	O
s	O
)	O
of	O
apparent	O
molecular	O
weight	O
39	O
,	O
000	O
-	O
41	O
,	O
000	O
on	O
SDS	O
-	O
PAGE	O
,	O
and	O
attenuation	O
of	O
the	O
ability	O
of	O
Sar1	O
-	O
AII	O
to	O
inhibit	O
cAMP	O
accumulation	O
.	O

The	O
role	O
of	O
cAMP	O
in	O
angiotensinogen	B-PRGE
production	O
was	O
examined	O
.	O

A	O
transient	O
increase	O
in	O
cAMP	O
accumulation	O
above	O
basal	O
could	O
be	O
evoked	O
by	O
forskolin	O
(	O
8	O
-	O
fold	O
)	O
or	O
by	O
glucagon	B-PRGE
(	O
5	O
-	O
fold	O
)	O
using	O
insulin	B-PRGE
-	O
deficient	O
media	O
.	O

Although	O
neither	O
forskolin	O
nor	O
glucagon	B-PRGE
had	O
a	O
significant	O
effect	O
on	O
angiotensinogen	B-PRGE
production	O
agents	O
producing	O
a	O
sustained	O
increase	O
in	O
intracellular	O
cAMP	O
(	O
8	O
-	O
bromo	O
-	O
cAMP	O
,	O
dibutyryl	O
-	O
cAMP	O
,	O
cholera	O
toxin	O
)	O
were	O
able	O
to	O
increase	O
angiotensinogen	B-PRGE
production	O
.	O

Although	O
these	O
data	O
indicate	O
that	O
intracellular	O
cAMP	O
is	O
a	O
regulatory	O
factor	O
in	O
angiotensinogen	B-PRGE
production	O
other	O
evidence	O
suggests	O
that	O
modulation	O
of	O
intracellular	O
cAMP	O
is	O
not	O
entirely	O
responsible	O
for	O
the	O
effects	O
of	O
Sar1	O
-	O
AII	O
.	O

Evidence	O
for	O
a	O
non	O
-	O
myristoylated	O
pool	O
of	O
the	O
80	O
kDa	O
protein	O
kinase	O
C	O
substrate	O
of	O
rat	O
brain	O
.	O

A	O
protein	O
of	O
80	O
kDa	O
apparent	O
molecular	O
mass	O
was	O
found	O
to	O
be	O
specifically	O
myristolylated	O
in	O
rat	O
brain	O
cytosols	O
derived	O
from	O
either	O
whole	O
brain	O
or	O
synaptosomes	O
.	O

The	O
attachment	O
of	O
the	O
fatty	O
acid	O
took	O
place	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
,	O
since	O
the	O
cytosols	O
did	O
not	O
incorporate	O
[	O
14C	O
]	O
lysine	O
into	O
protein	O
,	O
nor	O
did	O
cycloheximide	O
affect	O
the	O
incorporation	O
of	O
the	O
myristic	O
acid	O
into	O
the	O
protein	O
.	O

The	O
fatty	O
acid	O
was	O
incorporated	O
into	O
the	O
protein	O
via	O
an	O
acid	O
-	O
labile	O
/	O
alkali	O
-	O
resistant	O
band	O
,	O
and	O
Pronase	O
digestion	O
of	O
the	O
labelled	O
protein	O
showed	O
that	O
the	O
lipid	O
was	O
covalently	O
linked	O
to	O
a	O
glycine	O
residue	O
.	O

Together	O
,	O
these	O
data	O
suggested	O
that	O
the	O
myristic	O
acid	O
was	O
amide	O
-	O
linked	O
to	O
the	O
N	O
-	O
terminal	O
residue	O
of	O
the	O
protein	O
.	O

The	O
protein	O
was	O
identified	O
as	O
one	O
of	O
the	O
major	O
protein	O
kinase	O
C	O
substrates	O
,	O
the	O
MARCKS	B-PRGE
(	O
myristoylated	B-PRGE
alanine	I-PRGE
-	I-PRGE
rich	I-PRGE
C	I-PRGE
kinase	I-PRGE
substrate	I-PRGE
)	O
protein	O
,	O
by	O
showing	O
that	O
Ca2	O
+	O
stimulated	O
its	O
phosphorylation	O
,	O
by	O
its	O
heat	O
stability	O
and	O
by	O
immune	O
precipitation	O
(	O
using	O
an	O
antiserum	O
to	O
the	O
MARCKS	B-PRGE
protein	O
)	O
.	O

Incorporation	O
of	O
myristic	O
acid	O
into	O
intact	O
protein	O
continued	O
for	O
up	O
to	O
12	O
h	O
,	O
despite	O
the	O
fact	O
that	O
over	O
this	O
period	O
some	O
degradation	O
of	O
the	O
protein	O
could	O
be	O
demonstrated	O
.	O

In	O
pulse	O
-	O
chase	O
experiments	O
,	O
the	O
pattern	O
of	O
loss	O
of	O
the	O
incorporated	O
fatty	O
acid	O
was	O
similar	O
to	O
that	O
of	O
the	O
protein	O
itself	O
,	O
and	O
therefore	O
the	O
loss	O
of	O
radioactivity	O
probably	O
reflects	O
protein	O
degradation	O
rather	O
than	O
specific	O
de	O
-	O
acylation	O
of	O
the	O
protein	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
there	O
is	O
a	O
pool	O
of	O
unacylated	O
MARCKS	B-PRGE
protein	O
in	O
the	O
rat	O
brain	O
.	O

Identification	O
of	O
amino	O
acids	O
in	O
the	O
gamma	O
-	O
carboxylation	O
recognition	O
site	O
on	O
the	O
propeptide	O
of	O
prothrombin	B-PRGE
.	O

A	O
gamma	O
-	O
carboxylation	O
recognition	O
site	O
on	O
the	O
propeptide	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
blood	O
coagulation	O
proteins	O
directs	O
the	O
carboxylation	O
of	O
glutamic	O
acid	O
residues	O
by	O
binding	O
to	O
the	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
carboxylase	I-PRGE
.	O

To	O
determine	O
residues	O
that	O
define	O
this	O
site	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
mutation	O
of	O
certain	O
residues	O
in	O
the	O
prothrombin	B-PRGE
propeptide	O
on	O
the	O
extent	O
of	O
carboxylation	O
.	O

The	O
prothrombin	B-PRGE
cDNA	O
modified	O
by	O
site	O
-	O
specific	O
mutagenesis	O
was	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
using	O
a	O
system	O
that	O
yields	O
functional	O
fully	O
carboxylated	O
prothrombin	B-PRGE
.	O

The	O
cell	O
supernatants	O
containing	O
recombinant	O
prothrombin	B-PRGE
were	O
evaluated	O
for	O
the	O
extent	O
of	O
gamma	O
-	O
carboxylation	O
by	O
immunoassay	O
.	O

Conformation	O
-	O
specific	O
anti	O
-	O
prothrombin	B-PRGE
:	O
Ca	O
(	O
II	O
)	O
-	O
specific	O
antibodies	O
measure	O
native	O
completely	O
carboxylated	O
prothrombin	B-PRGE
;	O
anti	O
-	O
prothrombin	B-PRGE
:	O
total	O
antibodies	O
measure	O
all	O
forms	O
of	O
prothrombin	B-PRGE
,	O
regardless	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
content	O
.	O

Mutation	O
of	O
His	O
-	O
18	O
to	O
Gly	O
,	O
Val	O
-	O
17	O
to	O
Ser	O
,	O
Leu	O
-	O
15	O
to	O
Gly	O
or	O
Asp	O
,	O
or	O
Ala	O
-	O
10	O
to	O
Asp	O
was	O
associated	O
with	O
a	O
partial	O
(	O
30	O
-	O
65	O
%	O
)	O
inhibition	O
of	O
gamma	O
-	O
carboxylation	O
.	O

Mutation	O
of	O
Ala	O
-	O
14	O
to	O
Ser	O
or	O
Ser	O
-	O
8	O
to	O
Val	O
did	O
not	O
inhibit	O
gamma	O
-	O
carboxylation	O
.	O

From	O
this	O
and	O
earlier	O
work	O
,	O
residues	O
whose	O
mutation	O
leads	O
to	O
a	O
significant	O
impairment	O
of	O
carboxylation	O
include	O
His	O
-	O
18	O
,	O
Val	O
-	O
17	O
,	O
Phe	O
-	O
16	O
,	O
Leu	O
-	O
15	O
,	O
and	O
Ala	O
-	O
10	O
.	O

Residues	O
whose	O
mutation	O
does	O
not	O
alter	O
the	O
carboxylation	O
recognition	O
site	O
include	O
Ala	O
-	O
14	O
,	O
Ser	O
-	O
8	O
,	O
Arg	O
-	O
4	O
,	O
and	O
Arg	O
-	O
1	O
.	O

To	O
determine	O
the	O
size	O
of	O
the	O
recognition	O
site	O
,	O
the	O
in	O
vitro	O
carboxylation	O
of	O
propeptide	O
-	O
containing	O
synthetic	O
peptides	O
was	O
compared	O
.	O

A	O
28	O
-	O
residue	O
peptide	O
,	O
based	O
upon	O
residues	O
-	O
18	O
to	O
+	O
10	O
of	O
prothrombin	B-PRGE
,	O
and	O
a	O
54	O
-	O
residue	O
peptide	O
,	O
based	O
upon	O
residues	O
-	O
18	O
to	O
+	O
36	O
of	O
prothrombin	B-PRGE
,	O
were	O
carboxylated	O
by	O
partially	O
purified	O
bovine	O
carboxylase	O
with	O
similar	O
Km	O
values	O
of	O
2	O
-	O
5	O
microM	O
.	O

These	O
results	O
indicate	O
that	O
the	O
gamma	O
-	O
carboxyglutamic	O
acid	O
-	O
rich	O
region	O
of	O
prothrombin	B-PRGE
makes	O
a	O
minimal	O
contribution	O
to	O
carboxylase	O
binding	O
.	O

A	O
molecular	O
surface	O
of	O
about	O
five	O
amino	O
acids	O
located	O
within	O
the	O
propeptide	O
appears	O
to	O
define	O
the	O
carboxylation	O
recognition	O
site	O
on	O
the	O
precursor	O
forms	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
proteins	O
.	O

[	O
Experimental	O
animal	O
research	O
on	O
the	O
thrombolytic	O
effect	O
of	O
acyl	O
-	O
plasmin	B-PRGE
]	O
.	O

Plasmin	B-PRGE
was	O
acylated	O
by	O
reaction	O
with	O
benzoic	O
acid	O
or	O
p	O
-	O
chlorobenzoic	O
acid	O
p	O
'	O
-	O
amidinophenyl	O
ester	O
.	O

Enzymatically	O
inactive	O
acyl	O
-	O
plasmin	B-PRGE
is	O
reactivated	O
in	O
buffer	O
(	O
pH	O
7	O
.	O
5	O
)	O
with	O
a	O
half	O
-	O
life	O
of	O
22	O
min	O
(	O
benzoyl	O
-	O
plasmin	B-PRGE
)	O
and	O
9	O
min	O
(	O
p	O
-	O
chlorobenzoyl	O
-	O
plasmin	B-PRGE
)	O
,	O
respectively	O
.	O

Plasmin	B-PRGE
is	O
rapidly	O
inactivated	O
in	O
plasma	O
by	O
naturally	O
occurring	O
plasma	O
inhibitors	O
so	O
that	O
also	O
upon	O
incubation	O
of	O
acyl	O
-	O
plasmin	B-PRGE
in	O
plasma	O
only	O
low	O
enzymatic	O
activity	O
is	O
detectable	O
.	O

Following	O
high	O
doses	O
of	O
plasmin	O
fibrinogenolysis	O
typical	O
of	O
nonspecific	O
proteolysis	O
occurs	O
in	O
vivo	O
but	O
no	O
fibrinolytic	O
effects	O
is	O
demonstrable	O
.	O

On	O
the	O
other	O
hand	O
,	O
acyl	O
-	O
plasmins	B-PRGE
are	O
able	O
either	O
to	O
prevent	O
microthrombosis	O
in	O
the	O
lungs	O
induced	O
by	O
infusion	O
of	O
thrombin	B-PRGE
or	O
to	O
achieve	O
repatency	O
of	O
the	O
microvasculature	O
after	O
the	O
onset	O
of	O
microthrombosis	O
.	O

Spectroscopic	O
analysis	O
of	O
acylated	O
and	O
deacylated	O
myelin	B-PRGE
proteolipid	I-PRGE
protein	I-PRGE
.	O

The	O
effect	O
of	O
covalently	O
bound	O
fatty	O
acid	O
on	O
the	O
conformation	O
of	O
the	O
myelin	B-PRGE
proteolipid	I-PRGE
protein	I-PRGE
has	O
been	O
studied	O
by	O
ultraviolet	O
and	O
intrinsic	O
fluorescence	O
spectroscopy	O
.	O

With	O
dimethyl	O
sulfoxide	O
used	O
as	O
a	O
perturbant	O
,	O
the	O
exposure	O
of	O
Trp	O
and	O
Tyr	O
residues	O
in	O
various	O
mixtures	O
of	O
chloroform	O
-	O
methanol	O
was	O
evaluated	O
by	O
difference	O
spectroscopy	O
of	O
the	O
proteolipid	B-PRGE
protein	I-PRGE
(	O
APL	B-PRGE
)	O
and	O
its	O
chemically	O
deacylated	O
form	O
(	O
d	O
-	O
APL	B-PRGE
)	O
.	O

The	O
fraction	O
of	O
chromophoric	O
groups	O
exposed	O
increased	O
with	O
the	O
proportion	O
of	O
chloroform	O
with	O
25	O
%	O
of	O
the	O
groups	O
exposed	O
in	O
1	O
:	O
2	O
chloroform	O
-	O
methanol	O
and	O
98	O
%	O
in	O
3	O
:	O
1	O
chloroform	O
-	O
methanol	O
.	O

These	O
conformational	O
changes	O
correlate	O
well	O
with	O
changes	O
in	O
intrinsic	O
viscosity	O
.	O

Values	O
for	O
the	O
deacylated	O
form	O
were	O
indistinguishable	O
from	O
those	O
of	O
the	O
acylated	O
protein	O
,	O
suggesting	O
that	O
fatty	O
acids	O
do	O
not	O
affect	O
protein	O
conformation	O
in	O
organic	O
solvents	O
.	O

In	O
water	O
,	O
UV	O
difference	O
spectroscopy	O
indicated	O
that	O
the	O
number	O
of	O
Tyr	O
and	O
Trp	O
groups	O
exposed	O
in	O
both	O
APL	B-PRGE
and	O
d	O
-	O
APL	B-PRGE
was	O
relatively	O
small	O
and	O
was	O
independent	O
of	O
the	O
molecular	O
size	O
of	O
the	O
perturbant	O
.	O

However	O
,	O
differences	O
in	O
the	O
environment	O
of	O
the	O
Trp	O
groups	O
in	O
the	O
two	O
forms	O
of	O
the	O
protein	O
could	O
be	O
demonstrated	O
by	O
intrinsic	O
fluorescence	O
.	O

When	O
the	O
protein	O
was	O
excited	O
at	O
295	O
nm	O
,	O
the	O
maximum	O
emission	O
wavelength	O
for	O
the	O
acylated	O
protein	O
was	O
330	O
nm	O
,	O
whereas	O
it	O
was	O
335	O
nm	O
for	O
the	O
deacylated	O
form	O
.	O

Furthermore	O
,	O
the	O
Trp	O
groups	O
in	O
d	O
-	O
APL	B-PRGE
were	O
more	O
easily	O
quenched	O
by	O
acrylamide	O
than	O
in	O
APL	B-PRGE
,	O
indicating	O
that	O
they	O
were	O
more	O
exposed	O
,	O
or	O
in	O
a	O
more	O
hydrophilic	O
environment	O
,	O
following	O
deacylation	O
.	O

Protein	O
aggregation	O
appears	O
to	O
be	O
independent	O
of	O
the	O
presence	O
of	O
fatty	O
acids	O
,	O
suggesting	O
that	O
the	O
fluorescence	O
differences	O
between	O
APL	B-PRGE
and	O
d	O
-	O
APL	B-PRGE
are	O
related	O
to	O
factors	O
other	O
than	O
aggregation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cell	O
-	O
type	O
-	O
specific	O
and	O
site	O
-	O
specific	O
N	O
-	O
glycosylation	O
of	O
type	O
I	O
and	O
type	O
II	O
human	O
tissue	B-PRGE
plasminogen	I-PRGE
activator	I-PRGE
.	O

Tissue	B-PRGE
plasminogen	I-PRGE
activator	I-PRGE
(	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
)	O
is	O
an	O
important	O
initiator	O
of	O
fibrinolysis	O
.	O

The	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
polypeptide	O
has	O
four	O
potential	O
N	O
-	O
glycosylation	O
sites	O
of	O
which	O
three	O
are	O
occupied	O
in	O
type	O
I	O
(	O
Asn	O
-	O
117	O
,	O
-	O
184	O
,	O
and	O
-	O
448	O
)	O
and	O
two	O
in	O
type	O
II	O
(	O
Asn	O
-	O
117	O
and	O
-	O
448	O
)	O
.	O

In	O
an	O
effort	O
to	O
elucidate	O
the	O
factors	O
controlling	O
the	O
expression	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
on	O
this	O
polypeptide	O
,	O
we	O
have	O
used	O
a	O
combination	O
of	O
sequential	O
exoglycosidase	O
digestion	O
,	O
methylation	O
analysis	O
,	O
and	O
controlled	O
acetolysis	O
to	O
determine	O
the	O
oligosaccharide	O
structures	O
at	O
each	O
of	O
the	O
N	O
-	O
glycosylation	O
sites	O
of	O
type	O
I	O
and	O
type	O
II	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
when	O
isolated	O
from	O
a	O
human	O
colon	O
fibroblast	O
cell	O
strain	O
and	O
from	O
a	O
Bowes	O
melanoma	O
cell	O
line	O
.	O

Our	O
results	O
suggest	O
the	O
following	O
:	O
(	O
i	O
)	O
type	O
I	O
and	O
type	O
II	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
are	O
N	O
-	O
glycosylated	O
in	O
an	O
identical	O
way	O
at	O
Asn	O
-	O
117	O
and	O
Asn	O
-	O
448	O
,	O
when	O
isolated	O
from	O
the	O
same	O
cell	O
line	O
;	O
(	O
ii	O
)	O
Asn	O
-	O
117	O
is	O
predominantly	O
associated	O
with	O
oligomannose	O
-	O
type	O
structures	O
in	O
all	O
cases	O
;	O
(	O
iii	O
)	O
Asn	O
-	O
184	O
and	O
Asn	O
-	O
448	O
are	O
predominantly	O
associated	O
with	O
complex	O
-	O
type	O
structures	O
when	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
is	O
isolated	O
from	O
fibroblast	O
cells	O
,	O
but	O
with	O
both	O
complex	O
-	O
and	O
oligomannose	O
-	O
type	O
structures	O
when	O
isolated	O
from	O
melanoma	O
cells	O
;	O
(	O
iv	O
)	O
fibroblast	O
cell	O
derived	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
is	O
associated	O
with	O
both	O
neutral	O
and	O
sialylated	O
oligosaccharides	O
,	O
while	O
melanoma	O
cell	O
derived	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
is	O
also	O
associated	O
with	O
sulfated	O
oligosaccharides	O
,	O
which	O
are	O
located	O
exclusively	O
at	O
Asn	O
-	O
448	O
of	O
type	O
II	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
;	O
(	O
v	O
)	O
no	O
complex	O
-	O
type	O
structures	O
occur	O
in	O
common	O
between	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
from	O
the	O
two	O
cell	O
lines	O
.	O

These	O
results	O
indicate	O
that	O
the	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
glycoprotein	O
is	O
secreted	O
by	O
each	O
cell	O
line	O
as	O
a	O
set	O
of	O
glycoforms	O
,	O
each	O
glycoform	O
being	O
unique	O
with	O
respect	O
to	O
the	O
nature	O
and	O
disposition	O
of	O
oligosaccharides	O
on	O
a	O
common	O
polypeptide	O
.	O

Further	O
,	O
the	O
two	O
cell	O
lines	O
express	O
no	O
glycoform	O
in	O
common	O
,	O
despite	O
expressing	O
the	O
same	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
polypeptide	O
.	O

The	O
implications	O
of	O
these	O
results	O
for	O
both	O
the	O
control	O
of	O
oligosaccharide	O
processing	O
in	O
different	O
cell	O
lines	O
and	O
the	O
genetic	O
engineering	O
of	O
mammalian	O
glycoproteins	O
are	O
discussed	O
.	O

Role	O
of	O
variant	O
prealbumin	B-PRGE
in	O
the	O
pathogenesis	O
of	O
familial	O
amyloidotic	O
polyneuropathy	O
:	O
fate	O
of	O
normal	O
and	O
variant	O
prealbumin	B-PRGE
in	O
the	O
circulation	O
.	O

According	O
to	O
recent	O
studies	O
on	O
protein	O
chemistry	O
and	O
genetic	O
engineering	O
,	O
replacement	O
of	O
the	O
Val30	O
residue	O
of	O
prealbumin	B-PRGE
by	O
methionine	O
is	O
believed	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
formation	O
of	O
amyloid	B-PRGE
deposit	O
and	O
the	O
pathogenesis	O
of	O
familial	O
amyloidotic	O
polyneuropathy	O
(	O
FAP	O
)	O
.	O

However	O
,	O
only	O
limited	O
information	O
is	O
available	O
concerning	O
the	O
behavior	O
of	O
prealbumin	B-PRGE
in	O
the	O
circulation	O
.	O

To	O
obtain	O
the	O
molecular	O
insight	O
into	O
the	O
mechanism	O
of	O
amyloid	B-PRGE
deposition	O
,	O
it	O
is	O
indispensable	O
to	O
know	O
the	O
fates	O
of	O
normal	O
and	O
variant	O
prealbumin	B-PRGE
in	O
vivo	O
.	O

Thus	O
,	O
the	O
fates	O
of	O
prealbumin	B-PRGE
samples	O
from	O
normal	O
and	O
FAP	O
patients	O
were	O
studied	O
in	O
normal	O
rats	O
as	O
well	O
as	O
in	O
animals	O
that	O
were	O
challenged	O
with	O
acute	O
inflammation	O
induced	O
by	O
turpentine	O
.	O

The	O
effect	O
of	O
in	O
vitro	O
photooxidation	O
of	O
prealbumin	B-PRGE
samples	O
on	O
their	O
behavior	O
was	O
also	O
examined	O
in	O
vivo	O
.	O

Kinetic	O
analysis	O
revealed	O
no	O
appreciable	O
difference	O
between	O
prealbumin	B-PRGE
samples	O
from	O
normal	O
and	O
FAP	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
factors	O
other	O
than	O
the	O
rate	O
of	O
transfer	O
of	O
the	O
variant	O
form	O
prealbumin	B-PRGE
from	O
plasma	O
to	O
an	O
extravascular	O
compartment	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
amyloid	B-PRGE
deposition	O
in	O
FAP	O
patients	O
.	O

Characterization	O
of	O
tyrosylprotein	O
sulfotransferase	O
from	O
rat	O
liver	O
and	O
other	O
tissues	O
.	O

The	O
sulfoconjugation	O
of	O
tyrosyl	O
residues	O
is	O
a	O
widespread	O
post	O
-	O
translational	O
modification	O
of	O
biologically	O
active	O
peptides	O
and	O
proteins	O
.	O

In	O
this	O
paper	O
we	O
describe	O
the	O
characterization	O
of	O
a	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
that	O
is	O
capable	O
of	O
catalyzing	O
the	O
transfer	O
of	O
a	O
sulfate	O
moiety	O
from	O
3	O
'	O
-	O
phosphoadenosine	O
5	O
'	O
-	O
phosphosulfate	O
(	O
PAPS	O
)	O
to	O
the	O
synthetic	O
polymer	O
,	O
poly	O
-	O
(	O
Glu6	O
,	O
Ala3	O
,	O
Tyr1	O
)	O
(	O
EAY	O
;	O
Mr	O
47	O
,	O
000	O
)	O
using	O
a	O
simple	O
filter	O
paper	O
assay	O
.	O

Following	O
sucrose	O
density	O
gradient	O
centrifugation	O
and	O
comparison	O
with	O
known	O
subcellular	O
marker	O
enzyme	O
activities	O
,	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
shown	O
to	O
have	O
a	O
distribution	O
similar	O
to	O
the	O
Golgi	O
enzyme	O
,	O
galactosyltransferase	O
.	O

Using	O
the	O
enriched	O
Golgi	O
preparation	O
,	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
displayed	O
a	O
pH	O
optimum	O
of	O
6	O
.	O
7	O
and	O
required	O
the	O
presence	O
of	O
20	O
mM	O
Mn2	O
+	O
for	O
maximal	O
activity	O
.	O

Co2	O
+	O
(	O
20	O
mM	O
)	O
was	O
able	O
to	O
produce	O
26	O
%	O
of	O
the	O
maximal	O
stimulation	O
observed	O
with	O
Mn2	O
+	O
,	O
whereas	O
other	O
metal	O
ions	O
,	O
such	O
as	O
Mg2	O
+	O
,	O
Ca2	O
+	O
,	O
and	O
Co2	O
+	O
,	O
were	O
not	O
effective	O
in	O
stimulating	O
tyrosylprotein	O
sulfotransferase	O
activity	O
.	O

Whereas	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
observed	O
in	O
the	O
native	O
membrane	O
-	O
bound	O
state	O
,	O
EAY	O
sulfation	O
was	O
maximally	O
enhanced	O
3	O
-	O
fold	O
when	O
assayed	O
in	O
the	O
presence	O
of	O
Lubrol	O
Px	O
.	O

Under	O
the	O
optimal	O
conditions	O
for	O
assaying	O
the	O
sulfation	O
of	O
EAY	O
by	O
a	O
rat	O
liver	O
enriched	O
Golgi	O
fraction	O
,	O
significant	O
degradation	O
of	O
the	O
sulfate	O
donor	O
,	O
PAPS	O
,	O
was	O
observed	O
.	O

The	O
addition	O
of	O
both	O
NaF	O
and	O
5	O
'	O
-	O
AMP	O
to	O
the	O
incubation	O
mixture	O
was	O
found	O
to	O
effectively	O
prevent	O
PAPS	O
degradation	O
and	O
increase	O
the	O
amount	O
of	O
product	O
formed	O
in	O
the	O
assay	O
by	O
10	O
-	O
fold	O
.	O

Using	O
the	O
optimized	O
conditions	O
for	O
the	O
sulfation	O
of	O
EAY	O
by	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
,	O
membrane	O
-	O
bound	O
sulfotransferase	O
activity	O
was	O
also	O
observed	O
in	O
the	O
crude	O
microsomal	O
pellets	O
of	O
a	O
variety	O
of	O
rat	O
tissues	O
,	O
including	O
lung	O
,	O
pituitary	O
,	O
and	O
cerebellum	O
,	O
as	O
well	O
as	O
in	O
livers	O
from	O
different	O
species	O
.	O

Role	O
of	O
counter	O
ions	O
in	O
trypsin	O
acylation	O
.	O

NaCl	O
effect	O
.	O

The	O
Asp102	O
-	O
carboxylate	O
negative	O
charge	O
of	O
the	O
trypsin	O
catalytic	O
-	O
triad	O
has	O
been	O
substituted	O
in	O
part	O
by	O
Cl	O
-	O
counter	O
-	O
ions	O
.	O

A	O
His57	O
-	O
imidazolium	O
cation	O
and	O
Ser195	O
-	O
tetrahedral	O
oxyanion	O
ionpair	O
generated	O
in	O
the	O
acylation	O
step	O
of	O
catalysis	O
is	O
stabilized	O
by	O
the	O
negative	O
charge	O
of	O
Asp102	O
.	O

The	O
importance	O
of	O
correct	O
location	O
of	O
this	O
negative	O
charge	O
has	O
been	O
investigated	O
by	O
experimental	O
analysis	O
of	O
the	O
NaCl	O
influence	O
on	O
the	O
acylation	O
-	O
rate	O
of	O
trypsin	O
,	O
as	O
well	O
as	O
by	O
electrostatic	O
,	O
potential	O
calculations	O
.	O

The	O
acylation	O
-	O
rate	O
was	O
determined	O
with	O
stopped	O
-	O
flow	O
technique	O
under	O
pseudo	O
-	O
first	O
order	O
conditions	O
,	O
by	O
using	O
4	O
-	O
nitrophenyl	O
-	O
4	O
'	O
-	O
guanidinium	O
benzoate	O
active	O
site	O
titrant	O
at	O
pH	O
4	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
in	O
an	O
unbuffered	O
solution	O
of	O
I	O
=	O
O	O
or	O
0	O
.	O
5	O
M	O
NaCl	O
.	O

The	O
acylation	O
-	O
rate	O
constants	O
,	O
kappa	O
2	O
,	O
are	O
:	O
kappa	O
H2O	O
=	O
0	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
02	O
s	O
-	O
1	O
and	O
kappa	O
NaCl	O
=	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
s	O
-	O
1	O
,	O
and	O
they	O
correlate	O
to	O
beta	B-PRGE
-	I-PRGE
trypsin	I-PRGE
(	O
the	O
most	O
rapid	O
single	O
-	O
chained	O
form	O
of	O
the	O
enzyme	O
)	O
.	O

The	O
rate	O
increasing	O
effect	O
of	O
NaCl	O
,	O
together	O
with	O
the	O
calculated	O
electrostatic	O
energies	O
,	O
indicate	O
that	O
the	O
negative	O
charge	O
contribution	O
of	O
the	O
Asp102	O
-	O
carboxylate	O
to	O
the	O
stabilization	O
of	O
the	O
imidazolium	O
cation	O
and	O
tetrahedral	O
oxyanion	O
intermediate	O
is	O
larger	O
of	O
more	O
orders	O
,	O
than	O
that	O
of	O
the	O
Cl	O
-	O
counter	O
-	O
ion	O
,	O
located	O
in	O
a	O
less	O
favourable	O
position	O
.	O

Effect	O
of	O
oxidation	O
on	O
the	O
stability	O
of	O
tuberculin	O
purified	O
protein	O
derivative	O
(	O
PPD	O
)	O
.	O

The	O
purpose	O
of	O
the	O
present	O
work	O
was	O
two	O
-	O
fold	O
:	O
firstly	O
,	O
to	O
collect	O
data	O
on	O
the	O
effect	O
that	O
air	O
may	O
have	O
on	O
the	O
biological	O
potency	O
of	O
a	O
dilute	O
solution	O
of	O
tuberculin	O
PPD	O
(	O
5	O
TU	O
/	O
dose	O
)	O
,	O
and	O
secondly	O
,	O
to	O
find	O
out	O
whether	O
or	O
not	O
the	O
solubility	O
of	O
a	O
tuberculin	O
PPD	O
preparation	O
stored	O
in	O
powder	O
form	O
would	O
be	O
affected	O
by	O
air	O
over	O
a	O
long	O
period	O
of	O
time	O
.	O

It	O
was	O
shown	O
that	O
the	O
presence	O
of	O
air	O
in	O
the	O
headspace	O
of	O
multidose	O
vials	O
containing	O
a	O
dilute	O
tuberculin	O
PPD	O
solution	O
contributed	O
to	O
the	O
lowering	O
of	O
its	O
potency	O
by	O
approximately	O
50	O
%	O
over	O
a	O
period	O
of	O
4	O
months	O
at	O
5	O
degrees	O
C	O
,	O
and	O
that	O
thereafter	O
the	O
potency	O
remained	O
constant	O
for	O
up	O
to	O
12	O
months	O
.	O

It	O
was	O
also	O
shown	O
that	O
approximately	O
55	O
%	O
of	O
a	O
PPD	O
preparation	O
,	O
stored	O
in	O
powder	O
form	O
over	O
a	O
period	O
of	O
7	O
years	O
at	O
24	O
degrees	O
C	O
in	O
containers	O
closed	O
with	O
non	O
-	O
absorbent	O
cotton	O
plugs	O
,	O
allowing	O
free	O
access	O
of	O
air	O
,	O
became	O
insoluble	O
,	O
whereas	O
when	O
an	O
identical	O
preparation	O
was	O
stored	O
for	O
the	O
same	O
length	O
of	O
time	O
,	O
at	O
24	O
degrees	O
C	O
or	O
for	O
at	O
least	O
14	O
years	O
at	O
5	O
degrees	O
C	O
,	O
in	O
tightly	O
closed	O
containers	O
,	O
it	O
retained	O
its	O
solubility	O
.	O

The	O
partial	O
loss	O
of	O
potency	O
and	O
the	O
loss	O
of	O
some	O
solubility	O
were	O
attributed	O
to	O
the	O
denaturation	O
of	O
PPD	O
through	O
the	O
process	O
of	O
air	O
oxidation	O
.	O

To	O
reduce	O
the	O
loss	O
of	O
potency	O
of	O
tuberculin	O
PPD	O
products	O
through	O
the	O
process	O
of	O
oxidation	O
,	O
it	O
was	O
suggested	O
that	O
:	O
firstly	O
,	O
the	O
vials	O
be	O
filled	O
as	O
fully	O
as	O
possible	O
to	O
minimize	O
the	O
amount	O
of	O
air	O
trapped	O
in	O
the	O
headspace	O
,	O
or	O
the	O
filling	O
of	O
vials	O
be	O
carried	O
out	O
under	O
nitrogen	O
so	O
as	O
to	O
expel	O
any	O
air	O
in	O
the	O
headspace	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Interference	O
of	O
active	O
site	O
specific	O
reagents	O
in	O
plasminogen	B-PRGE
-	O
streptokinase	B-PRGE
active	O
site	O
formation	O
.	O

We	O
have	O
recently	O
observed	O
slow	O
,	O
non	O
-	O
Michaelis	O
-	O
Menten	O
kinetics	O
of	O
activation	O
of	O
native	O
cat	O
plasminogen	B-PRGE
by	O
catalytic	O
concentrations	O
of	O
streptokinase	B-PRGE
.	O

In	O
order	O
to	O
understand	O
the	O
reasons	O
for	O
this	O
phenomenon	O
,	O
we	O
undertook	O
to	O
study	O
the	O
formation	O
of	O
the	O
plasminogen	B-PRGE
-	O
streptokinase	B-PRGE
activator	O
complex	O
under	O
the	O
same	O
plasminogen	B-PRGE
activation	O
conditions	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
show	O
that	O
the	O
potential	O
active	O
site	O
in	O
both	O
cat	O
and	O
human	O
plasminogen	B-PRGE
is	O
capable	O
of	O
binding	O
strongly	O
the	O
specific	O
substrates	O
(	O
S	O
)	O
p	O
-	O
nitrophenyl	O
p	O
-	O
guanidinobenzoate	O
(	O
NPGB	O
)	O
and	O
H	O
-	O
D	O
-	O
valyl	O
-	O
L	O
-	O
leucyl	O
-	O
L	O
-	O
lysyl	O
-	O
p	O
-	O
nitroanilide	O
,	O
through	O
the	O
active	O
site	O
is	O
incapable	O
of	O
hydrolyzing	O
these	O
substrates	O
.	O

Binding	O
studies	O
support	O
these	O
and	O
the	O
following	O
conclusions	O
.	O

Streptokinase	B-PRGE
binds	O
to	O
this	O
zymogen	O
-	O
substrate	O
complex	O
to	O
create	O
the	O
ternary	O
plasminogen	B-PRGE
-	O
S	O
-	O
streptokinase	B-PRGE
complex	O
,	O
which	O
then	O
slowly	O
converts	O
to	O
an	O
acylated	O
plasminogen	B-PRGE
-	O
streptokinase	B-PRGE
form	O
.	O

This	O
acylation	O
reaction	O
is	O
550	O
times	O
slower	O
than	O
acylation	O
of	O
the	O
preformed	O
plasminogen	B-PRGE
-	O
streptokinase	B-PRGE
complex	O
by	O
NPGB	O
.	O

The	O
same	O
reaction	O
also	O
occurs	O
with	O
human	O
plasminogen	B-PRGE
,	O
though	O
the	O
acylation	O
reaction	O
is	O
10	O
times	O
faster	O
than	O
when	O
the	O
cat	O
zymogen	O
is	O
used	O
.	O

NPGB	O
binds	O
specifically	O
to	O
plasminogen	B-PRGE
but	O
not	O
to	O
streptokinase	B-PRGE
.	O

These	O
studies	O
proved	O
that	O
inhibition	O
of	O
cat	O
plasminogen	B-PRGE
activation	O
by	O
streptokinase	B-PRGE
occurs	O
at	O
the	O
level	O
of	O
activator	O
complex	O
formation	O
.	O

We	O
conclude	O
from	O
our	O
studies	O
that	O
streptokinase	B-PRGE
binding	O
to	O
both	O
cat	O
and	O
human	O
plasminogen	B-PRGE
occurs	O
at	O
the	O
potential	O
active	O
site	O
of	O
the	O
zymogen	O
.	O

Consequently	O
,	O
it	O
is	O
probable	O
that	O
plasminogen	B-PRGE
activation	O
in	O
vivo	O
is	O
inhibited	O
by	O
binding	O
of	O
active	O
site	O
specific	O
inhibitors	O
to	O
plasminogen	B-PRGE
.	O

Biosynthesis	O
of	O
GlyCAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
mucin	O
-	O
like	O
ligand	O
for	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

L	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
a	O
member	O
of	O
the	O
selectin	O
family	O
of	O
leukocyte	O
-	O
endothelial	O
adhesion	O
proteins	O
,	O
mediates	O
the	O
initial	O
attachment	O
of	O
lymphocytes	O
to	O
lymph	O
node	O
high	O
endothelial	O
venules	O
during	O
lymphocyte	O
recirculation	O
.	O

One	O
of	O
the	O
endothelial	O
-	O
associated	O
ligands	O
for	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
is	O
GlyCAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
mucin	O
-	O
like	O
glycoprotein	O
,	O
which	O
presents	O
novel	O
sulfated	O
,	O
sialylated	O
and	O
fucosylated	O
O	O
-	O
glycans	O
.	O

In	O
order	O
to	O
understand	O
the	O
generation	O
of	O
these	O
glycans	O
,	O
we	O
have	O
examined	O
the	O
biosynthesis	O
of	O
GlyCAM	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
lymph	O
node	O
organ	O
culture	O
.	O

Using	O
peptide	O
-	O
specific	O
antibodies	O
,	O
lectins	O
,	O
and	O
recombinant	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
we	O
detected	O
the	O
following	O
species	O
of	O
GlyCAM	B-PRGE
-	I-PRGE
1	I-PRGE
:	O
unglycosylated	O
(	O
<	O
28	O
kDa	O
)	O
;	O
modified	O
with	O
GalNAc	O
only	O
(	O
28	O
-	O
33	O
kDa	O
)	O
;	O
modified	O
with	O
sialic	O
acid	O
,	O
fucose	O
,	O
and	O
sulfate	O
but	O
lacking	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
reactivity	O
(	O
40	O
-	O
50	O
kDa	O
)	O
;	O
and	O
mature	O
(	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
-	O
reactive	O
)	O
ligand	O
(	O
50	O
-	O
60	O
kDa	O
)	O
.	O

Pulse	O
-	O
chase	O
labeling	O
at	O
15	O
degrees	O
C	O
suggested	O
that	O
GalNAc	O
is	O
added	O
in	O
a	O
pre	O
-	O
Golgi	O
compartment	O
.	O

Treatment	O
with	O
brefeldin	O
A	O
almost	O
completely	O
blocked	O
sulfation	O
,	O
indicating	O
that	O
this	O
modification	O
occurs	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
.	O

Two	O
distinct	O
sialylation	O
events	O
occurred	O
in	O
the	O
presence	O
of	O
brefeldin	O
A	O
,	O
while	O
fucosylation	O
was	O
partially	O
blocked	O
.	O

We	O
conclude	O
that	O
sialylation	O
precedes	O
both	O
fucosylation	O
and	O
sulfation	O
during	O
biosynthesis	O
.	O

This	O
ordering	O
will	O
help	O
to	O
identify	O
the	O
critical	O
acceptor	O
structures	O
recognized	O
by	O
lymph	O
node	O
glycosyltransferases	O
and	O
sulfotransferases	O
.	O

Properties	O
of	O
type	B-PRGE
II	I-PRGE
inositol	I-PRGE
polyphosphate	I-PRGE
5	I-PRGE
-	I-PRGE
phosphatase	I-PRGE
.	O

We	O
have	O
isolated	O
additional	O
cDNA	O
clones	O
encoding	O
type	B-PRGE
II	I-PRGE
inositol	I-PRGE
polyphosphate	I-PRGE
5	I-PRGE
-	I-PRGE
phosphatase	I-PRGE
(	O
5	B-PRGE
-	I-PRGE
phosphatase	I-PRGE
II	I-PRGE
)	O
resulting	O
in	O
a	O
combined	O
cDNA	O
of	O
3076	O
nucleotides	O
encoding	O
a	O
protein	O
of	O
942	O
amino	O
acids	O
.	O

The	O
5	B-PRGE
-	I-PRGE
phosphatase	I-PRGE
II	I-PRGE
hydrolyzed	O
both	O
Ins	O
(	O
1	O
,	O
4	O
,	O
5	O
)	O
P3	O
to	O
Ins	O
(	O
1	O
,	O
4	O
)	O
P2	O
and	O
the	O
phospholipid	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
to	O
PtdIns	O
(	O
4	O
)	O
P	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

There	O
are	O
two	O
motifs	O
highly	O
conserved	O
between	O
types	B-PRGE
I	I-PRGE
and	O
II	B-PRGE
5	I-PRGE
-	I-PRGE
phosphatase	I-PRGE
and	O
several	O
other	O
proteins	O
presumed	O
to	O
be	O
inositol	O
phosphatases	O
suggesting	O
a	O
possible	O
role	O
in	O
catalysis	O
.	O

The	O
type	B-PRGE
II	I-PRGE
5	I-PRGE
-	I-PRGE
phosphatase	I-PRGE
also	O
contains	O
homology	O
to	O
several	O
GTPase	O
activating	O
proteins	O
although	O
no	O
such	O
activity	O
for	O
5	B-PRGE
-	I-PRGE
phosphatase	I-PRGE
II	I-PRGE
was	O
found	O
.	O

The	O
predicted	O
protein	O
ends	O
with	O
the	O
sequence	O
CNPL	O
,	O
suggesting	O
that	O
it	O
is	O
isoprenylated	O
as	O
a	O
mechanism	O
for	O
membrane	O
attachment	O
.	O

We	O
found	O
evidence	O
for	O
isoprenylation	O
by	O
demonstrating	O
incorporation	O
of	O
[	O
3H	O
]	O
mevalonate	O
into	O
native	O
but	O
not	O
C939S	O
mutant	O
5	B-PRGE
-	I-PRGE
phosphatase	I-PRGE
II	I-PRGE
expressed	O
in	O
Sf9	O
insect	O
cells	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
membrane	O
localization	O
and	O
the	O
activity	O
of	O
5	B-PRGE
-	I-PRGE
phosphatase	I-PRGE
II	I-PRGE
toward	O
its	O
lipid	O
substrate	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
is	O
reduced	O
by	O
eliminating	O
5	B-PRGE
-	I-PRGE
phosphatase	I-PRGE
II	I-PRGE
isoprenylation	O
in	O
the	O
mutant	O
C939S	O
relative	O
to	O
the	O
native	O
enzyme	O
.	O

Farnesol	O
is	O
utilized	O
for	O
protein	O
isoprenylation	O
and	O
the	O
biosynthesis	O
of	O
cholesterol	O
in	O
mammalian	O
cells	O
.	O

Evidence	O
has	O
been	O
obtained	O
indicating	O
that	O
free	O
farnesol	O
(	O
F	O
-	O
OH	O
)	O
can	O
be	O
utilized	O
for	O
isoprenoid	O
biosynthesis	O
in	O
mammalian	O
cells	O
.	O

When	O
rat	O
C6	O
glial	O
cells	O
and	O
an	O
African	O
green	O
monkey	O
kidney	O
cell	O
line	O
(	O
CV	O
-	O
1	O
)	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
F	O
-	O
OH	O
,	O
radioactivity	O
was	O
incorporated	O
into	O
cholesterol	O
,	O
ubiquinone	O
(	O
CoQ	O
)	O
and	O
isoprenylated	O
proteins	O
.	O

The	O
incorporation	O
of	O
label	O
from	O
[	O
3H	O
]	O
F	O
-	O
OH	O
into	O
cholesterol	O
in	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
was	O
blocked	O
by	O
squalestatin	O
1	O
(	O
SQ	O
)	O
which	O
specifically	O
inhibits	O
the	O
conversion	O
of	O
farnesyl	O
pyrophosphate	O
(	O
F	O
-	O
P	O
-	O
P	O
)	O
to	O
squalene	O
.	O

This	O
result	O
strongly	O
suggests	O
that	O
cholesterol	O
,	O
and	O
probably	O
CoQ	O
and	O
protein	O
,	O
is	O
metabolically	O
labeled	O
via	O
F	O
-	O
P	O
-	O
P	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
of	O
the	O
delipidated	O
protein	O
fractions	O
from	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
revealed	O
several	O
labeled	O
polypeptides	O
.	O

Consistent	O
with	O
these	O
proteins	O
being	O
modified	O
by	O
isoprenylation	O
of	O
cysteine	O
residues	O
.	O

Pronase	O
E	O
digestion	O
released	O
a	O
major	O
labeled	O
product	O
with	O
the	O
chromatographic	O
mobility	O
of	O
[	O
3H	O
]	O
farnesyl	O
-	O
cysteine	O
(	O
F	O
-	O
Cys	O
)	O
.	O

A	O
different	O
set	O
of	O
polypeptides	O
was	O
labeled	O
when	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
geranylgeraniol	O
(	O
GG	O
-	O
OH	O
)	O
.	O

Both	O
sets	O
of	O
proteins	O
appear	O
to	O
be	O
metabolically	O
labeled	O
by	O
[	O
3H	O
]	O
mevalonolactone	O
,	O
and	O
[	O
3H	O
]	O
-	O
labeled	O
F	O
-	O
Cys	O
and	O
geranylgeranyl	O
-	O
cysteine	O
(	O
GG	O
-	O
Cys	O
)	O
were	O
liberated	O
from	O
these	O
proteins	O
by	O
Pronase	O
E	O
treatment	O
.	O

These	O
cellular	O
and	O
biochemical	O
studies	O
indicate	O
that	O
F	O
-	O
OH	O
can	O
be	O
used	O
for	O
isoprenoid	O
biosynthesis	O
and	O
protein	O
isoprenylation	O
in	O
mammalian	O
cells	O
after	O
being	O
converted	O
to	O
F	O
-	O
P	O
-	O
P	O
by	O
phosphorylation	O
reactions	O
that	O
remain	O
to	O
be	O
elucidated	O
.	O

ADP	O
-	O
ribosylation	O
of	O
Rhizobium	O
meliloti	O
glutamine	B-PRGE
synthetase	I-PRGE
III	I-PRGE
in	O
vivo	O
.	O

The	O
control	O
of	O
glutamine	O
synthetase	O
(	O
GS	O
)	O
,	O
the	O
first	O
enzyme	O
in	O
the	O
main	O
pathway	O
used	O
by	O
Rhizobium	O
meliloti	O
to	O
assimilate	O
ammonia	O
,	O
is	O
central	O
to	O
cellular	O
nitrogen	O
metabolism	O
.	O

R	O
.	O
meliloti	O
is	O
unusual	O
in	O
having	O
three	O
distinct	O
types	O
of	O
GS	O
,	O
including	O
a	O
unique	O
GS	O
,	O
GSIII	B-PRGE
,	O
that	O
differs	O
considerably	O
from	O
both	O
GSI	B-PRGE
,	O
which	O
resembles	O
other	O
bacterial	O
GS	O
proteins	O
and	O
GSII	B-PRGE
,	O
which	O
resembles	O
the	O
GS	O
found	O
in	O
eukaryotes	O
.	O

We	O
show	O
here	O
that	O
GSIII	B-PRGE
can	O
be	O
post	O
-	O
translationally	O
modified	O
in	O
vivo	O
by	O
ADP	O
-	O
ribosylation	O
at	O
an	O
arginine	O
residue	O
.	O

32PO4	O
attached	O
to	O
GSIII	B-PRGE
during	O
bacterial	O
growth	O
as	O
part	O
of	O
the	O
modifying	O
group	O
could	O
be	O
removed	O
by	O
treatment	O
with	O
snake	O
venom	O
phosphodiesterase	O
or	O
by	O
turkey	O
erythrocyte	O
ADP	B-PRGE
-	I-PRGE
ribosylarginine	I-PRGE
hydrolase	I-PRGE
.	O

Treatment	O
of	O
modified	O
GSIII	B-PRGE
with	O
hydroxylamine	O
at	O
neutral	O
pH	O
releases	O
a	O
chromophore	O
that	O
has	O
the	O
retention	O
time	O
of	O
ADP	O
-	O
ribose	O
when	O
analyzed	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

ADP	O
-	O
ribosylation	O
inhibits	O
GSIII	B-PRGE
activity	O
.	O

Recombinant	O
expression	O
and	O
evaluation	O
of	O
the	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	B-PRGE
acetyltransferase	I-PRGE
component	I-PRGE
of	I-PRGE
the	I-PRGE
human	I-PRGE
pyruvate	I-PRGE
dehydrogenase	I-PRGE
complex	I-PRGE
.	O

The	O
subunits	O
of	O
the	O
dihydrolipoyl	B-PRGE
acetyltransferase	I-PRGE
(	I-PRGE
E2	I-PRGE
)	I-PRGE
component	I-PRGE
of	I-PRGE
mammalian	I-PRGE
pyruvate	I-PRGE
dehydrogenase	I-PRGE
complex	I-PRGE
(	O
PDC	O
)	O
associate	O
to	O
form	O
a	O
large	O
inner	O
core	O
with	O
a	O
protruding	O
structure	O
composed	O
of	O
three	O
globular	O
domains	O
connected	O
by	O
mobile	O
linker	O
regions	O
.	O

This	O
exterior	O
region	O
of	O
E2	B-PRGE
includes	O
two	O
lipoyl	O
domains	O
which	O
engage	O
not	O
only	O
in	O
the	O
intermediate	O
reactions	O
of	O
the	O
complex	O
but	O
also	O
have	O
integral	O
roles	O
in	O
the	O
kinase	O
-	O
phosphatase	O
regulatory	O
interconversion	O
of	O
the	O
pyruvate	O
dehydrogenase	O
(	O
E1	O
)	O
component	O
.	O

To	O
facilitate	O
understanding	O
of	O
these	O
roles	O
,	O
lipoyl	O
domain	O
constructs	O
of	O
the	O
E2	B-PRGE
component	I-PRGE
of	O
human	O
PDC	O
were	O
expressed	O
as	O
glutathione	B-PRGE
S	I-PRGE
-	I-PRGE
transferase	I-PRGE
(	O
GST	B-PRGE
)	O
-	O
linked	O
fusion	O
proteins	O
from	O
plasmid	O
inserts	O
prepared	O
by	O
polymerase	O
chain	O
reaction	O
procedures	O
.	O

The	O
NH2	O
-	O
terminal	O
lipoyl	O
domain	O
,	O
E2L1	O
,	O
and	O
the	O
interior	O
lipoyl	O
domain	O
,	O
E2L2	O
,	O
are	O
connected	O
by	O
a	O
30	O
-	O
amino	O
-	O
acid	O
hinge	O
region	O
,	O
H1	O
.	O

Constructs	O
designed	O
and	O
expressed	O
were	O
E2L1	O
(	O
1	O
-	O
98	O
)	O
,	O
E2L1	O
.	O
H1	O
(	O
1	O
-	O
128	O
)	O
,	O
E2L2	O
(	O
120	O
-	O
233	O
)	O
,	O
E2H1	O
.	O
L2	O
(	O
98	O
-	O
233	O
)	O
,	O
and	O
E2L1	O
.	O
H1	O
.	O
L2	O
(	O
1	O
-	O
233	O
)	O
,	O
where	O
numbers	O
in	O
parentheses	O
give	O
the	O
amino	O
acid	O
sequence	O
for	O
the	O
portions	O
of	O
the	O
E2	B-PRGE
component	I-PRGE
incorporated	O
into	O
a	O
construct	O
.	O

The	O
domains	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
with	O
and	O
without	O
lipoate	O
supplementation	O
.	O

GST	B-PRGE
constructs	O
were	O
purified	O
to	O
homogeneity	O
by	O
affinity	O
chromatography	O
and	O
selectively	O
released	O
by	O
thrombin	B-PRGE
treatment	O
.	O

Sequencing	O
of	O
insert	O
DNAs	O
and	O
NH2	O
-	O
terminal	O
sequencing	O
confirmed	O
that	O
domains	O
were	O
produced	O
as	O
designed	O
.	O

Measurement	O
of	O
masses	O
by	O
electrospray	O
mass	O
spectrometry	O
indicated	O
that	O
constructs	O
with	O
lipoylated	O
,	O
nonlipoylated	O
,	O
and	O
octanoylated	O
forms	O
were	O
produced	O
when	O
expression	O
was	O
with	O
E	O
.	O
coli	O
grown	O
without	O
lipoate	O
supplementation	O
and	O
that	O
fully	O
lipoylated	O
forms	O
were	O
produced	O
upon	O
lipoate	O
supplementation	O
.	O

The	O
lipoylation	O
status	O
was	O
confirmed	O
,	O
following	O
delipoylation	O
with	O
Enterococcus	O
faecalis	O
lipoamidase	O
,	O
by	O
the	O
expected	O
decrease	O
in	O
mass	O
and	O
by	O
the	O
observation	O
in	O
native	O
gel	O
electrophoresis	O
of	O
a	O
shift	O
to	O
a	O
slower	O
mobility	O
(	O
possibly	O
less	O
compact	O
)	O
form	O
.	O

Constructs	O
were	O
used	O
in	O
E1	O
-	O
catalyzed	O
reductive	O
-	O
acetylation	O
reaction	O
in	O
proportion	O
to	O
their	O
degree	O
of	O
lipoylation	O
and	O
were	O
effective	O
substrates	O
in	O
a	O
NADH	O
-	O
dependent	O
dihydrolipoyl	B-PRGE
dehydrogenase	I-PRGE
reduction	O
reaction	O
.	O

Thus	O
,	O
we	O
have	O
produced	O
lipoyl	O
domain	O
constructs	O
that	O
can	O
be	O
employed	O
in	O
sorting	O
the	O
specific	O
roles	O
of	O
E2L1	O
and	O
E2L2	O
in	O
facilitating	O
catalytic	O
and	O
regulatory	O
processes	O
.	O

Lipoic	O
acid	O
metabolism	O
in	O
Escherichia	O
coli	O
:	O
the	O
lplA	B-PRGE
and	O
lipB	B-PRGE
genes	O
define	O
redundant	O
pathways	O
for	O
ligation	O
of	O
lipoyl	O
groups	O
to	O
apoprotein	O
.	O

Lipoic	O
acid	O
is	O
a	O
covalently	O
bound	O
disulfide	O
-	O
containing	O
cofactor	O
required	O
for	O
function	O
of	O
the	O
pyruvate	O
dehydrogenase	O
,	O
alpha	O
-	O
ketoglutarate	O
dehydrogenase	O
,	O
and	O
glycine	O
cleavage	O
enzyme	O
complexes	O
of	O
Escherichia	O
coli	O
.	O

Recently	O
we	O
described	O
the	O
isolation	O
of	O
the	O
lplA	B-PRGE
locus	O
,	O
the	O
first	O
gene	O
known	O
to	O
encode	O
a	O
lipoyl	O
-	O
protein	O
ligase	O
for	O
the	O
attachment	O
of	O
lipoyl	O
groups	O
to	O
lipoate	O
-	O
dependent	O
apoenzymes	O
(	O
T	O
.	O
W	O
.	O
Morris	O
,	O
K	O
.	O
E	O
.	O
Reed	O
,	O
and	O
J	O
.	O
E	O
.	O
Cronan	O
,	O
Jr	O
.	O
,	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
269	O
:	O
16091	O
-	O
16100	O
,	O
1994	O
)	O
.	O

Here	O
,	O
we	O
report	O
an	O
unexpected	O
redundancy	O
between	O
the	O
functions	O
of	O
lplA	B-PRGE
and	O
lipB	B-PRGE
,	O
a	O
gene	O
previously	O
identified	O
as	O
a	O
putative	O
lipoate	O
biosynthetic	O
locus	O
.	O

First	O
,	O
analysis	O
of	O
lplA	B-PRGE
null	O
mutants	O
revealed	O
the	O
existence	O
of	O
a	O
second	O
lipoyl	O
ligase	O
enzyme	O
.	O

We	O
found	O
that	O
lplA	B-PRGE
null	O
mutants	O
displayed	O
no	O
growth	O
defects	O
unless	O
combined	O
with	O
lipA	B-PRGE
(	O
lipoate	O
synthesis	O
)	O
or	O
lipB	B-PRGE
mutations	O
and	O
that	O
overexpression	O
of	O
wild	O
-	O
type	O
LplA	B-PRGE
suppressed	O
lipB	B-PRGE
null	O
mutations	O
.	O

Assays	O
of	O
growth	O
,	O
transport	O
,	O
lipoyl	O
-	O
protein	O
content	O
,	O
and	O
apoprotein	O
modification	O
demonstrated	O
that	O
lplA	B-PRGE
encoded	O
a	O
ligase	O
for	O
the	O
incorporation	O
of	O
exogenously	O
supplied	O
lipoate	O
,	O
whereas	O
lipB	B-PRGE
was	O
required	O
for	O
function	O
of	O
the	O
second	O
lipoyl	O
ligase	O
,	O
which	O
utilizes	O
lipoyl	O
groups	O
generated	O
via	O
endogenous	O
(	O
lipA	B-PRGE
-	O
mediated	O
)	O
biosynthesis	O
.	O

The	O
lipB	B-PRGE
-	O
dependent	O
ligase	O
was	O
further	O
shown	O
to	O
cause	O
the	O
accumulation	O
of	O
aberrantly	O
modified	O
octanoyl	O
-	O
proteins	O
in	O
lipoate	O
-	O
deficient	O
cells	O
.	O

Lipoate	O
uptake	O
assays	O
of	O
strains	O
that	O
overproduced	O
lipoate	O
-	O
accepting	O
apoproteins	O
also	O
demonstrated	O
coupling	O
between	O
transport	O
and	O
the	O
subsequent	O
ligation	O
of	O
lipoate	O
to	O
apoprotein	O
by	O
the	O
LplA	B-PRGE
enzyme	O
.	O

Although	O
mutations	O
in	O
two	O
genes	O
(	O
fadD	B-PRGE
and	O
fadL	B-PRGE
)	O
involved	O
in	O
fatty	O
acid	O
failed	O
to	O
affect	O
lipoate	O
utilization	O
,	O
disruption	O
of	O
the	O
smp	B-PRGE
gene	O
severely	O
decreased	O
lipoate	O
utilization	O
.	O

DNA	O
sequencing	O
of	O
the	O
previously	O
identified	O
slr1	B-PRGE
selenolipoate	O
resistance	O
mutation	O
(	O
K	O
.	O
E	O
.	O
Reed	O
,	O
T	O
.	O
W	O
.	O
Morris	O
,	O
and	O
J	O
.	O
E	O
.	O
Cronan	O
,	O
Jr	O
.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
91	O
:	O
3720	O
-	O
3724	O
,	O
1994	O
)	O
showed	O
this	O
mutation	O
(	O
now	O
called	O
lplA1	B-PRGE
)	O
to	O
be	O
a	O
G76S	O
substitution	O
in	O
the	O
LplA	B-PRGE
ligase	O
.	O

When	O
compared	O
with	O
the	O
wild	O
-	O
type	O
allele	O
,	O
the	O
cloned	O
lplA1	B-PRGE
allele	O
conferred	O
a	O
threefold	O
increase	O
in	O
the	O
ability	O
to	O
discriminate	O
against	O
the	O
selenium	O
-	O
containing	O
analog	O
.	O

These	O
results	O
support	O
a	O
two	O
-	O
pathway	O
/	O
two	O
-	O
ligase	O
model	O
of	O
lipoate	O
metabolism	O
in	O
E	O
.	O
coli	O
.	O

Regulation	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
by	O
glucose	O
in	O
culture	O
medium	O
:	O
involvement	O
of	O
Gi	O
protein	O
.	O

The	O
reduction	O
of	O
the	O
glucose	O
concentrations	O
in	O
the	O
culture	O
medium	O
results	O
in	O
an	O
increase	O
in	O
Na	O
+	O
/	O
glucose	O
cotransport	O
activity	O
in	O
the	O
epithelial	O
cells	O
.	O

To	O
study	O
this	O
regulation	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
,	O
we	O
have	O
attempted	O
to	O
examine	O
the	O
involvement	O
of	O
Gi	O
protein	O
.	O

The	O
immunoblotting	O
with	O
an	O
antibody	O
for	O
the	O
carboxy	O
-	O
terminal	O
of	O
alpha	O
subunit	O
of	O
Gi	O
protein	O
(	O
Gi	O
alpha	O
)	O
revealed	O
no	O
significant	O
change	O
in	O
the	O
level	O
of	O
Gi	O
alpha	O
in	O
cells	O
cultured	O
with	O
low	O
(	O
5	O
mM	O
)	O
or	O
high	O
(	O
25	O
mM	O
)	O
glucose	O
concentrations	O
.	O

In	O
contrast	O
,	O
the	O
cultured	O
with	O
low	O
glucose	O
concentrations	O
induced	O
the	O
increases	O
of	O
both	O
islet	O
activating	O
protein	O
(	O
IAP	O
)	O
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
Gi	O
alpha	O
and	O
Na	O
+	O
/	O
glucose	O
cotransport	O
activity	O
.	O

Furthermore	O
,	O
this	O
increase	O
in	O
the	O
transport	O
activity	O
was	O
blocked	O
by	O
the	O
presence	O
of	O
IAP	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

These	O
results	O
suggest	O
that	O
there	O
is	O
a	O
close	O
relationship	O
between	O
the	O
concentration	O
of	O
the	O
heterotrimeric	O
form	O
of	O
Gi	O
protein	O
(	O
Gi	O
alpha	O
beta	O
gamma	O
)	O
and	O
the	O
activity	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
.	O

Posttranslational	O
modification	O
of	O
nitrogenase	O
.	O

Differences	O
between	O
the	O
purple	O
bacterium	O
Rhodospirillum	O
rubrum	O
and	O
the	O
cyanobacterium	O
Anabaena	O
variabilis	O
.	O

In	O
the	O
photosynthetic	O
bacteria	O
Rhodospirillum	O
rubrum	O
and	O
Rhodopseudomonas	O
capsulatus	O
post	O
-	O
translational	O
regulation	O
of	O
nitrogenase	O
is	O
due	O
to	O
ADP	O
-	O
ribosylation	O
of	O
the	O
Fe	O
-	O
protein	O
,	O
the	O
dinitrogenase	B-PRGE
reductase	I-PRGE
[	O
Burris	O
,	O
R	O
.	O
H	O
.	O
(	O
1991	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
266	O
,	O
9339	O
-	O
9342	O
]	O
.	O

This	O
mechanism	O
has	O
been	O
assumed	O
to	O
be	O
responsible	O
for	O
nitrogenase	O
modification	O
in	O
a	O
variety	O
of	O
organisms	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
ADP	O
-	O
ribosylation	O
holds	O
true	O
for	O
the	O
filamentous	O
cyanobacterium	O
Anabaena	O
variabilis	O
.	O

Genes	O
coding	O
for	O
the	O
nitrogenase	O
-	O
modifying	O
enzymes	O
dinitrogenase	B-PRGE
reductase	I-PRGE
-	I-PRGE
activating	I-PRGE
glycohydrolase	I-PRGE
(	O
DRAG	B-PRGE
)	O
and	O
dinitrogenase	B-PRGE
reductase	I-PRGE
ADP	I-PRGE
-	I-PRGE
ribosyl	I-PRGE
transferase	I-PRGE
(	O
DRAT	B-PRGE
)	O
from	O
R	O
.	O
rubrum	O
have	O
been	O
subcloned	O
and	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O

After	O
isolation	O
under	O
anaerobic	O
conditions	O
,	O
both	O
proteins	O
were	O
functional	O
as	O
determined	O
by	O
in	O
-	O
vitro	O
assays	O
using	O
nitrogenase	O
from	O
R	O
.	O
rubrum	O
as	O
substrate	O
.	O

In	O
contrast	O
to	O
the	O
R	O
.	O
rubrum	O
enzyme	O
,	O
nitrogenase	O
from	O
A	O
.	O
variabilis	O
was	O
not	O
affected	O
by	O
DRAG	B-PRGE
or	O
DRAT	B-PRGE
.	O

Neither	O
could	O
inactive	O
nitrogenase	O
be	O
restored	O
by	O
DRAG	B-PRGE
,	O
nor	O
nitrogenase	O
activity	O
suppressed	O
by	O
DRAT	B-PRGE
.	O

Using	O
specific	O
antibodies	O
against	O
arginine	O
-	O
bound	O
ADP	O
-	O
ribose	O
[	O
Meyer	O
,	O
T	O
.	O
&	O
Hilz	O
,	O
H	O
.	O
(	O
1986	O
)	O
Eur	O
.	O
J	O
.	O
Biochem	O
.	O
155	O
,	O
157	O
-	O
165	O
]	O
,	O
immunoblotting	O
of	O
the	O
inactive	O
,	O
modified	O
form	O
of	O
the	O
Fe	O
-	O
protein	O
from	O
R	O
.	O
rubrum	O
but	O
not	O
that	O
from	O
A	O
.	O
variabilis	O
showed	O
a	O
strong	O
cross	O
reaction	O
.	O

Furthermore	O
,	O
differently	O
to	O
R	O
.	O
rubrum	O
no	O
ADP	O
-	O
ribosylated	O
proteins	O
could	O
be	O
detected	O
at	O
all	O
,	O
indicating	O
the	O
absence	O
of	O
this	O
posttranslational	O
modification	O
in	O
A	O
.	O
variabilis	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
an	O
isoprenylated	O
67	O
kDa	O
protein	O
.	O

The	O
cDNA	O
coding	O
for	O
a	O
67	O
kDa	O
protein	O
(	O
p67	B-PRGE
)	O
was	O
isolated	O
from	O
a	O
rat	O
Schwann	O
cell	O
library	O
.	O

A	O
recombinant	O
form	O
of	O
p67	B-PRGE
expressed	O
in	O
bacteria	O
was	O
used	O
to	O
produce	O
polyclonal	O
anti	O
-	O
p67	B-PRGE
antibodies	O
.	O

By	O
immunoblot	O
analysis	O
p67	B-PRGE
was	O
found	O
to	O
be	O
expressed	O
in	O
most	O
tissues	O
and	O
cell	O
lines	O
examined	O
.	O

Inspection	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
revealed	O
a	O
COOH	O
-	O
terminal	O
consensus	O
sequence	O
for	O
isoprenylation	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
p67	B-PRGE
was	O
a	O
substrate	O
for	O
isoprenylation	O
in	O
vitro	O
by	O
geranylgeranylpyrophosphate	O
.	O

p67	B-PRGE
was	O
associated	O
predominantly	O
with	O
the	O
particulate	O
fraction	O
of	O
rat	O
smooth	O
muscle	O
cells	O
.	O

The	O
rat	O
p67	B-PRGE
sequence	O
was	O
highly	O
homologous	O
to	O
a	O
family	O
of	O
recently	O
described	O
human	O
and	O
mouse	O
gamma	B-PRGE
-	I-PRGE
interferon	I-PRGE
inducible	O
,	O
guanine	O
nucleotide	O
binding	O
proteins	O
.	O

The	O
use	O
of	O
active	O
centre	O
acylation	O
to	O
control	O
the	O
pharmacokinetic	O
profile	O
of	O
a	O
recombinant	O
chimaeric	O
plasminogen	B-PRGE
activator	O
.	O

Recombinant	O
hybrid	O
plasminogen	B-PRGE
activators	O
consisting	O
of	O
the	O
"	O
A	O
"	O
chain	O
of	O
plasminogen	B-PRGE
linked	O
to	O
the	O
"	O
B	O
"	O
chain	O
of	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
that	O
are	O
inhibited	O
rapidly	O
by	O
plasma	O
protease	O
inhibitors	O
have	O
recently	O
been	O
described	O
(	O
Robinson	O
et	O
al	O
.	O
Circulation	O
1992	O
;	O
86	O
:	O
548	O
-	O
552	O
)	O
.	O

We	O
have	O
now	O
shown	O
that	O
following	O
bolus	O
administration	O
of	O
native	O
hybrid	O
to	O
guinea	O
pigs	O
,	O
fibrinolytic	O
activity	O
was	O
cleared	O
rapidly	O
from	O
the	O
circulation	O
.	O

Active	O
centre	O
acylation	O
appeared	O
to	O
protect	O
the	O
hybrid	O
from	O
inhibition	O
and	O
allowed	O
material	O
to	O
circulate	O
as	O
potentially	O
active	O
species	O
for	O
prolonged	O
periods	O
.	O

Clearance	O
rates	O
of	O
a	O
range	O
of	O
acyl	O
derivatives	O
of	O
the	O
hybrid	O
were	O
7	O
-	O
35	O
-	O
fold	O
slower	O
than	O
for	O
native	O
hybrid	O
and	O
20	O
-	O
100	O
-	O
fold	O
slower	O
than	O
for	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
.	O

Clearance	O
rates	O
were	O
influenced	O
markedly	O
by	O
deacylation	O
rate	O
,	O
such	O
that	O
clearance	O
half	O
-	O
life	O
correlated	O
well	O
with	O
deacylation	O
half	O
-	O
life	O
.	O

We	O
have	O
thus	O
shown	O
that	O
it	O
is	O
feasible	O
to	O
control	O
the	O
pharmacokinetic	O
profile	O
of	O
a	O
recombinant	O
hybrid	O
plasminogen	B-PRGE
activator	O
over	O
a	O
wide	O
range	O
by	O
selection	O
of	O
an	O
appropriate	O
acyl	O
group	O
for	O
attachment	O
to	O
the	O
active	O
site	O
.	O

Such	O
control	O
is	O
not	O
possible	O
with	O
plasminogen	B-PRGE
activators	O
that	O
are	O
cleared	O
predominantly	O
by	O
mechanisms	O
other	O
than	O
inhibition	O
.	O

The	O
31	O
-	O
kDa	O
precursor	O
of	O
interleukin	B-PRGE
1	I-PRGE
alpha	I-PRGE
is	O
myristoylated	O
on	O
specific	O
lysines	O
within	O
the	O
16	O
-	O
kDa	O
N	O
-	O
terminal	O
propiece	O
.	O

The	O
cytokine	O
interleukin	B-PRGE
1	I-PRGE
alpha	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
)	O
is	O
a	O
critical	O
mediator	O
of	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

A	O
unique	O
determinant	O
of	O
its	O
activity	O
as	O
compared	O
with	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
may	O
be	O
its	O
association	O
with	O
the	O
plasma	O
membrane	O
.	O

While	O
the	O
biologic	O
activity	O
of	O
"	O
membrane	O
IL	O
-	O
1	O
"	O
has	O
been	O
extensively	O
reported	O
,	O
the	O
mechanism	O
of	O
membrane	O
binding	O
remains	O
unclear	O
.	O

We	O
report	O
that	O
the	O
N	O
terminus	O
of	O
the	O
31	O
-	O
kDa	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
precursor	O
is	O
myristoylated	O
on	O
specific	O
internal	O
lysine	O
residues	O
.	O

Immunoprecipitation	O
of	O
[	O
3H	O
]	O
myristic	O
acid	O
-	O
radiolabeled	O
human	O
monocyte	O
lysates	O
with	O
IgG	O
antibodies	O
to	O
the	O
31	O
-	O
kDa	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
precursor	O
recovered	O
a	O
protein	O
with	O
the	O
physicochemical	O
properties	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
N	O
-	O
terminal	O
propiece	O
(	O
16	O
kDa	O
,	O
pI	O
4	O
.	O
45	O
)	O
.	O

Glycyl	O
N	O
-	O
myristoylation	O
of	O
this	O
protein	O
is	O
precluded	O
by	O
the	O
absence	O
of	O
a	O
glycine	O
residue	O
at	O
position	O
2	O
,	O
suggesting	O
that	O
the	O
propiece	O
is	O
myristoylated	O
on	O
epsilon	O
-	O
amino	O
groups	O
of	O
lysine	O
.	O

To	O
determine	O
which	O
lysine	O
(	O
s	O
)	O
are	O
acylated	O
,	O
a	O
series	O
of	O
synthetic	O
peptides	O
containing	O
all	O
lysines	O
found	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
N	O
-	O
terminal	O
propiece	O
were	O
used	O
in	O
an	O
in	O
vitro	O
myristoylation	O
assay	O
containing	O
peptide	O
,	O
myristoyl	O
-	O
CoA	O
,	O
and	O
monocyte	O
lysate	O
as	O
enzyme	O
source	O
.	O

Analysis	O
of	O
the	O
reaction	O
products	O
by	O
reverse	O
-	O
phase	O
HPLC	O
and	O
gas	O
-	O
phase	O
sequencing	O
demonstrated	O
the	O
specific	O
myristoylation	O
of	O
Lys	O
-	O
82	O
and	O
Lys	O
-	O
83	O
,	O
yielding	O
predominantly	O
monoacylated	O
product	O
.	O

A	O
conserved	O
sequence	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
propiece	O
was	O
myristoylated	O
with	O
at	O
least	O
8	O
-	O
fold	O
less	O
efficiency	O
.	O

Acylation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
precursor	O
by	O
a	O
previously	O
unrecognized	O
lysyl	O
epsilon	O
-	O
amino	O
N	O
-	O
myristoyl	O
-	O
transferase	O
activity	O
may	O
facilitate	O
its	O
specific	O
membrane	O
targeting	O
.	O

Nerve	B-PRGE
growth	I-PRGE
factor	I-PRGE
induces	O
a	O
succession	O
of	O
increases	O
in	O
isoprenylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
PC	O
-	O
12	O
pheochromocytoma	O
cells	O
.	O

Pheochromocytoma	O
(	O
PC	O
-	O
12	O
)	O
cells	O
exposed	O
to	O
nerve	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
NGF	B-PRGE
)	O
acquire	O
a	O
sympathetic	O
neuron	O
-	O
like	O
phenotype	O
.	O

This	O
NGF	B-PRGE
-	O
response	O
is	O
blocked	O
by	O
methylation	O
inhibitors	O
and	O
can	O
be	O
mimicked	O
by	O
the	O
farnesylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
protein	O
p21ras	B-PRGE
.	O

The	O
implicated	O
involvement	O
of	O
prenylation	O
,	O
methylation	O
and	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
in	O
the	O
NGF	B-PRGE
-	O
response	O
has	O
been	O
studied	O
by	O
directly	O
measuring	O
3H	O
-	O
mevalonic	O
acid	O
(	O
MVA	O
)	O
-	O
metabolites	O
incorporated	O
into	O
proteins	O
,	O
protein	O
carboxy	O
[	O
methyl	O
-	O
3H	O
]	O
ester	O
formation	O
and	O
levels	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
proteins	O
in	O
NGF	B-PRGE
-	O
induced	O
PC	O
-	O
12	O
cells	O
.	O

We	O
demonstrate	O
that	O
NGF	B-PRGE
induces	O
a	O
2	O
-	O
3	O
-	O
fold	O
increase	O
in	O
21	O
-	O
24	O
kDa	O
methylated	O
membrane	O
proteins	O
that	O
incorporate	O
3H	O
-	O
MVA	O
-	O
metabolites	O
,	O
and	O
bind	O
GTP	O
.	O

Levels	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
in	O
these	O
proteins	O
were	O
increased	O
by	O
2	O
-	O
3	O
-	O
fold	O
.	O

Methylation	O
and	O
membrane	O
association	O
of	O
the	O
small	O
GTP	O
-	O
binding	O
proteins	O
were	O
blocked	O
by	O
lovastatin	O
,	O
an	O
inhibitor	O
of	O
3	B-PRGE
-	I-PRGE
hydroxy	I-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
methylglutaryl	I-PRGE
-	I-PRGE
CoA	I-PRGE
(	I-PRGE
HMG	I-PRGE
-	I-PRGE
CoA	I-PRGE
)	I-PRGE
reductase	I-PRGE
,	O
which	O
also	O
enhanced	O
their	O
labeling	O
by	O
3H	O
-	O
MVA	O
-	O
metabolites	O
.	O

Cycloheximide	O
reduced	O
the	O
levels	O
of	O
[	O
methyl	O
-	O
3H	O
]	O
labeled	O
21	O
-	O
24	O
kDa	O
proteins	O
and	O
of	O
the	O
overlapping	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
binding	O
-	O
proteins	O
.	O

About	O
70	O
%	O
of	O
the	O
[	O
methyl	O
-	O
3H	O
]	O
-	O
groups	O
found	O
in	O
these	O
proteins	O
were	O
recovered	O
from	O
two	O
dimensional	O
gel	O
blots	O
in	O
nine	O
distinct	O
spots	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
proteins	O
.	O

Taken	O
together	O
these	O
results	O
strongly	O
suggest	O
that	O
in	O
PC	O
-	O
12	O
cells	O
,	O
NGF	B-PRGE
induces	O
an	O
increase	O
in	O
the	O
synthesis	O
of	O
prenylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
.	O

The	O
efficacy	O
of	O
lovastatin	O
blockage	O
of	O
protein	O
methylation	O
and	O
enhancement	O
of	O
3H	O
-	O
MVA	O
-	O
metabolites	O
incorporation	O
into	O
GTP	O
-	O
binding	O
proteins	O
was	O
lower	O
in	O
NGF	B-PRGE
-	O
induced	O
cells	O
than	O
in	O
controls	O
.	O

This	O
suggests	O
that	O
NGF	B-PRGE
also	O
induces	O
an	O
increase	O
in	O
HMG	B-PRGE
-	I-PRGE
CoA	I-PRGE
reductase	I-PRGE
activity	O
.	O

At	O
the	O
early	O
phase	O
of	O
the	O
NGF	B-PRGE
response	O
in	O
PC	O
-	O
12	O
cells	O
(	O
15	O
min	O
-	O
1	O
h	O
)	O
,	O
the	O
levels	O
of	O
two	O
small	O
GTP	O
-	O
binding	O
proteins	O
(	O
molecular	O
mass	O
of	O
21	O
-	O
22	O
kDa	O
and	O
23	O
-	O
24	O
kDa	O
)	O
were	O
increased	O
.	O

Thus	O
,	O
at	O
least	O
two	O
proteins	O
,	O
of	O
which	O
one	O
but	O
not	O
the	O
other	O
may	O
be	O
p21ras	B-PRGE
,	O
appear	O
to	O
be	O
involved	O
in	O
the	O
early	O
response	O
.	O

After	O
a	O
lag	O
period	O
of	O
24	O
h	O
with	O
NGF	B-PRGE
,	O
a	O
second	O
more	O
robust	O
phase	O
of	O
increase	O
in	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
was	O
apparent	O
.	O

This	O
relatively	O
late	O
response	O
,	O
which	O
was	O
almost	O
completed	O
within	O
24	O
h	O
,	O
may	O
reflect	O
involvement	O
of	O
small	O
GTP	O
-	O
binding	O
proteins	O
in	O
neurite	O
-	O
outgrowth	O
and	O
in	O
the	O
functional	O
activity	O
of	O
the	O
differentiated	O
cells	O
.	O

Many	O
small	O
GTP	O
-	O
binding	O
proteins	O
were	O
increased	O
during	O
the	O
second	O
phase	O
,	O
precluding	O
electrophoretic	O
separation	O
of	O
all	O
of	O
them	O
.	O

3	O
proteins	O
,	O
however	O
,	O
were	O
well	O
separated	O
(	O
one	O
23	O
-	O
24	O
kDa	O
protein	O
and	O
two	O
21	O
-	O
22	O
kDa	O
proteins	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Posttranslational	O
regulation	O
of	O
nitrogenase	O
in	O
Rhodobacter	O
capsulatus	O
:	O
existence	O
of	O
two	O
independent	O
regulatory	O
effects	O
of	O
ammonium	O
.	O

In	O
the	O
photosynthetic	O
bacterium	O
Rhodobacter	O
capsulatus	O
,	O
nitrogenase	O
activity	O
is	O
regulated	O
by	O
ADP	O
-	O
ribosylation	O
of	O
component	B-PRGE
II	I-PRGE
in	O
response	O
to	O
the	O
addition	O
of	O
ammonium	O
to	O
cultures	O
or	O
to	O
the	O
removal	O
of	O
light	O
.	O

The	O
ammonium	O
stimulus	O
results	O
in	O
a	O
fast	O
and	O
almost	O
complete	O
inhibition	O
of	O
the	O
in	O
vivo	O
acetylene	O
reduction	O
activity	O
,	O
termed	O
switch	O
-	O
off	O
,	O
which	O
is	O
reversed	O
after	O
the	O
ammonium	O
is	O
exhausted	O
.	O

In	O
the	O
present	O
study	O
of	O
the	O
response	O
of	O
cells	O
to	O
ammonium	O
,	O
ADP	O
-	O
ribosylation	O
of	O
component	B-PRGE
II	I-PRGE
occurred	O
but	O
could	O
not	O
account	O
for	O
the	O
extent	O
and	O
timing	O
of	O
the	O
inhibition	O
of	O
activity	O
.	O

The	O
presence	O
of	O
an	O
additional	O
response	O
was	O
confirmed	O
with	O
strains	O
expressing	O
mutant	O
component	B-PRGE
II	I-PRGE
proteins	O
;	O
although	O
these	O
proteins	O
are	O
not	O
a	O
substrate	O
for	O
ADP	O
-	O
ribosylation	O
,	O
the	O
strains	O
continued	O
to	O
exhibit	O
a	O
switch	O
-	O
off	O
response	O
to	O
ammonium	O
.	O

This	O
second	O
regulatory	O
response	O
of	O
nitrogenase	O
to	O
ammonium	O
was	O
found	O
to	O
be	O
synchronous	O
with	O
ADP	O
-	O
ribosylation	O
and	O
was	O
responsible	O
for	O
the	O
bulk	O
of	O
the	O
observed	O
effects	O
on	O
nitrogenase	O
activity	O
.	O

In	O
comparison	O
,	O
ADP	O
-	O
ribosylation	O
in	O
R	O
.	O
capsulatus	O
was	O
found	O
to	O
be	O
relatively	O
slow	O
and	O
incomplete	O
but	O
responded	O
independently	O
to	O
both	O
known	O
stimuli	O
,	O
darkness	O
and	O
ammonium	O
.	O

Based	O
on	O
the	O
in	O
vitro	O
nitrogenase	O
activity	O
of	O
both	O
the	O
wild	O
type	O
and	O
strains	O
whose	O
component	B-PRGE
II	I-PRGE
proteins	O
cannot	O
be	O
ADP	O
-	O
ribosylated	O
,	O
it	O
seems	O
likely	O
that	O
the	O
second	O
response	O
blocks	O
either	O
the	O
ATP	O
or	O
the	O
electron	O
supply	O
to	O
nitrogenase	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
functional	O
characterization	O
of	O
bovine	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
gamma	I-PRGE
-	I-PRGE
carboxylase	I-PRGE
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Coagulation	B-PRGE
factor	I-PRGE
IX	I-PRGE
is	O
a	O
serine	O
protease	O
for	O
which	O
high	O
-	O
level	O
expression	O
of	O
biologically	O
active	O
protein	O
in	O
heterologous	O
cells	O
is	O
limited	O
due	O
to	O
inefficient	O
proteolytic	O
removal	O
of	O
the	O
propeptide	O
as	O
well	O
as	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
multiple	O
amino	O
-	O
terminal	O
glutamic	O
acid	O
residues	O
.	O

We	O
have	O
overexpressed	O
the	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
gamma	I-PRGE
-	I-PRGE
carboxylase	I-PRGE
cDNA	O
and	O
monitored	O
its	O
ability	O
to	O
improve	O
factor	B-PRGE
IX	I-PRGE
processing	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
.	O

From	O
amino	O
acid	O
sequence	O
analysis	O
of	O
bovine	O
liver	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
gamma	I-PRGE
-	I-PRGE
carboxylase	I-PRGE
,	O
degenerate	O
oligonucleotides	O
were	O
used	O
to	O
isolate	O
a	O
3	O
.	O
5	O
-	O
kbp	O
bovine	O
cDNA	O
that	O
encoded	O
a	O
758	O
-	O
residue	O
open	O
reading	O
frame	O
.	O

Expression	O
of	O
the	O
cDNA	O
in	O
COS	O
-	O
1	O
and	O
CHO	O
cells	O
yielded	O
17	O
-	O
and	O
16	O
-	O
fold	O
increases	O
in	O
the	O
in	O
vitro	O
gamma	O
-	O
carboxylase	O
activity	O
of	O
microsomal	O
preparations	O
,	O
respectively	O
.	O

Anti	O
-	O
serum	O
raised	O
against	O
a	O
predicted	O
peptide	O
sequence	O
reacted	O
with	O
a	O
94	O
-	O
kDa	O
polypeptide	O
in	O
the	O
partially	O
purified	O
bovine	O
liver	O
preparation	O
as	O
well	O
as	O
in	O
stably	O
transfected	O
CHO	O
cells	O
.	O

The	O
amount	O
of	O
antibody	O
reactivity	O
correlated	O
with	O
the	O
increased	O
ability	O
to	O
carboxylate	O
a	O
peptide	O
substrate	O
in	O
vitro	O
.	O

These	O
results	O
strongly	O
support	O
the	O
conclusion	O
that	O
the	O
cDNA	O
encodes	O
the	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
gamma	I-PRGE
-	I-PRGE
carboxylase	I-PRGE
.	O

Transient	O
transfection	O
of	O
the	O
gamma	B-PRGE
-	I-PRGE
carboxylase	I-PRGE
expression	O
vector	O
into	O
factor	B-PRGE
IX	I-PRGE
-	O
expressing	O
CHO	O
cells	O
did	O
not	O
improve	O
the	O
specific	O
procoagulant	O
activity	O
of	O
secreted	O
factor	B-PRGE
IX	I-PRGE
.	O

In	O
contrast	O
,	O
transfection	O
of	O
an	O
expression	O
vector	O
encoding	O
the	O
propeptide	O
processing	O
enzyme	O
PACE	B-PRGE
(	O
paired	B-PRGE
basic	I-PRGE
amino	I-PRGE
acid	I-PRGE
cleaving	I-PRGE
enzyme	I-PRGE
)	O
did	O
improve	O
the	O
specific	O
activity	O
of	O
secreted	O
factor	B-PRGE
IX	I-PRGE
by	O
3	O
-	O
fold	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
ability	O
of	O
CHO	O
cells	O
to	O
modify	O
glutamic	O
acid	O
residues	O
to	O
gamma	O
-	O
carboxyglutamic	O
acid	O
in	O
secreted	O
factor	B-PRGE
IX	I-PRGE
is	O
not	O
limited	O
by	O
the	O
expression	O
of	O
the	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
gamma	I-PRGE
-	I-PRGE
carboxylase	I-PRGE
alone	O
.	O

Processive	O
post	O
-	O
translational	O
modification	O
.	O

Vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
a	O
peptide	O
substrate	O
.	O

Mass	O
spectrometry	O
has	O
been	O
used	O
to	O
demonstrate	O
that	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
is	O
a	O
processive	O
post	O
-	O
translational	O
modification	O
(	O
i	O
.	O
e	O
.	O
multiple	O
carboxylations	O
occur	O
during	O
a	O
single	O
association	O
between	O
enzyme	O
and	O
substrate	O
)	O
.	O

Purified	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
carboxylase	I-PRGE
can	O
carboxylate	O
as	O
many	O
as	O
12	O
glutamate	O
residues	O
in	O
FIXQ	O
/	O
S	O
,	O
a	O
peptide	O
substrate	O
based	O
on	O
amino	O
acids	O
-	O
18	O
to	O
41	O
of	O
the	O
human	O
blood	O
clotting	O
enzyme	O
factor	B-PRGE
IX	I-PRGE
.	O

Mass	O
spectrometry	O
was	O
used	O
to	O
determine	O
the	O
number	O
of	O
gamma	O
-	O
carboxyl	O
groups	O
added	O
to	O
FIXQ	O
/	O
S	O
by	O
the	O
carboxylase	O
during	O
an	O
in	O
vitro	O
reaction	O
.	O

Despite	O
the	O
fact	O
that	O
most	O
substrate	O
molecules	O
in	O
a	O
reaction	O
were	O
uncarboxylated	O
,	O
almost	O
all	O
carboxylated	O
FIXQ	O
/	O
S	O
molecules	O
were	O
carboxylated	O
many	O
times	O
.	O

This	O
observation	O
can	O
only	O
be	O
explained	O
by	O
two	O
types	O
of	O
mechanisms	O
.	O

In	O
a	O
processive	O
mechanism	O
,	O
multiple	O
carboxylations	O
could	O
occur	O
during	O
a	O
single	O
substrate	O
binding	O
event	O
.	O

Alternatively	O
,	O
a	O
distributive	O
mechanism	O
could	O
result	O
in	O
the	O
observed	O
behavior	O
if	O
the	O
initial	O
carboxylation	O
event	O
results	O
in	O
a	O
substrate	O
that	O
is	O
additionally	O
carboxylated	O
far	O
more	O
efficiently	O
than	O
the	O
uncarboxylated	O
FIXQ	O
/	O
S	O
.	O

Kinetic	O
experiments	O
and	O
arguments	O
were	O
used	O
to	O
show	O
that	O
the	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
carboxylase	I-PRGE
is	O
not	O
distributive	O
but	O
rather	O
is	O
one	O
of	O
the	O
first	O
well	O
documented	O
examples	O
of	O
an	O
enzyme	O
that	O
catalyzes	O
a	O
processive	O
post	O
-	O
translation	O
modification	O
.	O

Size	O
variations	O
in	O
the	O
mucin	O
-	O
type	O
domain	O
of	O
hamster	O
oviductin	B-PRGE
:	O
identification	O
of	O
the	O
polypeptide	O
precursors	O
and	O
characterization	O
of	O
their	O
biosynthetic	O
maturation	O
.	O

The	O
recent	O
sequencing	O
of	O
a	O
cDNA	O
clone	O
for	O
hamster	O
oviductin	B-PRGE
revealed	O
that	O
this	O
zona	O
pellucida	O
-	O
associated	O
glycoprotein	O
is	O
a	O
particularly	O
intriguing	O
chimeric	O
molecule	O
because	O
it	O
encloses	O
regions	O
of	O
significant	O
similarity	O
with	O
chitinase	O
-	O
related	O
proteins	O
as	O
well	O
as	O
a	O
carboxyterminal	O
mucin	O
-	O
type	O
domain	O
.	O

This	O
domain	O
contains	O
contiguous	O
Ser	O
/	O
Thr	O
-	O
rich	O
repeated	O
stretches	O
of	O
15	O
amino	O
acids	O
;	O
similar	O
units	O
are	O
also	O
found	O
in	O
the	O
deduced	O
sequence	O
of	O
human	O
oviductin	O
.	O

Such	O
structural	O
domains	O
constitute	O
a	O
central	O
feature	O
of	O
mucins	O
.	O

We	O
amplified	O
this	O
region	O
from	O
16	O
hamster	O
oviductin	B-PRGE
cDNA	O
clones	O
and	O
identified	O
three	O
length	O
variants	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
biosynthetic	O
maturation	O
of	O
the	O
glycoprotein	O
,	O
a	O
high	O
-	O
titer	O
antiserum	O
against	O
synthetic	O
peptides	O
derived	O
from	O
internal	O
sequences	O
of	O
hamster	O
oviductin	B-PRGE
was	O
produced	O
and	O
used	O
in	O
pulse	O
-	O
chase	O
experiments	O
.	O

Two	O
major	O
and	O
one	O
minor	O
polypeptide	O
precursors	O
were	O
identified	O
from	O
tunicamycin	O
-	O
treated	O
cell	O
lysates	O
and	O
in	O
vitro	O
translated	O
products	O
from	O
oviductal	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
.	O

Their	O
apparent	O
molecular	O
masses	O
correlate	O
with	O
the	O
predicted	O
lengths	O
of	O
the	O
three	O
size	O
variants	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
.	O

Using	O
glycosylation	O
and	O
transport	O
inhibitors	O
,	O
we	O
sought	O
to	O
dissect	O
the	O
posttranslational	O
sequential	O
steps	O
leading	O
to	O
the	O
final	O
maturation	O
of	O
hamster	O
oviductin	B-PRGE
and	O
proposed	O
a	O
compartmental	O
model	O
for	O
its	O
biosynthesis	O
.	O

The	O
polypeptide	O
precursors	O
are	O
rapidly	O
converted	O
in	O
the	O
endoplasmic	O
reticulum	O
into	O
an	O
N	O
-	O
and	O
O	O
-	O
glycosylated	O
premature	O
form	O
of	O
80	O
-	O
90	O
kDa	O
(	O
time	O
<	O
20	O
min	O
)	O
,	O
which	O
is	O
further	O
O	O
-	O
glycosylated	O
and	O
sulfated	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
,	O
giving	O
rise	O
to	O
the	O
secreted	O
species	O
of	O
160	O
-	O
350	O
kDa	O
.	O

The	O
polymorphism	O
in	O
the	O
heavily	O
O	O
-	O
glycosylated	O
region	O
of	O
hamster	O
oviductin	B-PRGE
is	O
predicted	O
to	O
increase	O
the	O
heterogeneity	O
of	O
the	O
glycoprotein	O
.	O

Such	O
changes	O
may	O
alter	O
the	O
putative	O
biological	O
function	O
of	O
the	O
different	O
variants	O
mediated	O
by	O
their	O
mucin	O
-	O
type	O
domain	O
,	O
such	O
as	O
protection	O
of	O
the	O
embryo	O
and	O
/	O
or	O
adhesion	O
-	O
related	O
phenomena	O
.	O

Design	O
and	O
synthesis	O
of	O
non	O
-	O
peptide	O
Ras	O
CAAX	O
mimetics	O
as	O
potent	O
farnesyltransferase	O
inhibitors	O
.	O

Cysteine	O
farnesylation	O
of	O
the	O
ras	O
oncogene	O
product	O
Ras	O
is	O
required	O
for	O
its	O
transforming	O
activity	O
and	O
is	O
catalyzed	O
by	O
farnesyltransferase	O
(	O
FTase	O
)	O
.	O

The	O
Ras	O
carboxyl	O
terminal	O
tetrapeptide	O
CAAX	O
(	O
C	O
is	O
cysteine	O
,	O
A	O
is	O
any	O
aliphatic	O
amino	O
acid	O
,	O
X	O
is	O
methionine	O
or	O
serine	O
)	O
is	O
the	O
minimum	O
sequence	O
for	O
FTase	O
recognition	O
.	O

We	O
report	O
here	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
characterization	O
of	O
Ras	O
CAAX	O
non	O
-	O
peptide	O
mimetics	O
in	O
which	O
the	O
cysteine	O
is	O
linked	O
through	O
a	O
reduced	O
pseudopeptide	O
bond	O
to	O
4	O
-	O
amino	O
-	O
3	O
'	O
-	O
carboxybiphenyl	O
.	O

These	O
non	O
-	O
peptide	O
mimetics	O
are	O
potent	O
inhibitors	O
of	O
FTase	O
(	O
IC50	O
=	O
40	O
nM	O
for	O
the	O
most	O
potent	O
inhibitor	O
)	O
and	O
are	O
highly	O
selective	O
for	O
FTase	O
over	O
GGTase	O
I	O
(	O
geranylgeranyltransferase	O
I	O
)	O
.	O

They	O
are	O
not	O
substrates	O
for	O
farnesylation	O
,	O
do	O
not	O
have	O
peptidic	O
features	O
,	O
and	O
have	O
no	O
hydrolyzable	O
bonds	O
.	O

Structure	O
-	O
activity	O
studies	O
reveal	O
the	O
importance	O
of	O
the	O
position	O
of	O
the	O
carboxylic	O
acid	O
on	O
the	O
aryl	O
ring	O
as	O
well	O
as	O
the	O
reduction	O
of	O
the	O
cysteine	O
amide	O
bond	O
.	O

Substitution	O
at	O
the	O
2	O
-	O
position	O
of	O
4	O
-	O
amino	O
-	O
3	O
'	O
-	O
carboxybiphenyl	O
increases	O
inhibitory	O
potency	O
,	O
while	O
the	O
removal	O
of	O
the	O
carboxylic	O
acid	O
results	O
in	O
a	O
10	O
-	O
fold	O
loss	O
of	O
inhibitory	O
activity	O
.	O

Multiple	O
palmitoylation	O
of	O
synaptotagmin	O
and	O
the	O
t	O
-	O
SNARE	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
.	O

Synaptotagmin	O
,	O
a	O
likely	O
calcium	O
sensor	O
for	O
synaptic	O
transmission	O
,	O
and	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
,	O
a	O
t	O
-	O
SNARE	O
of	O
the	O
presynaptic	O
plasma	O
membrane	O
,	O
are	O
key	O
proteins	O
for	O
the	O
docking	O
and	O
fusion	O
of	O
synaptic	O
and	O
other	O
vesicles	O
.	O

We	O
report	O
that	O
both	O
synaptotagmin	O
and	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
are	O
palmitoylated	O
with	O
their	O
fatty	O
acids	O
attached	O
in	O
a	O
labile	O
thioester	O
-	O
type	O
bond	O
.	O

A	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
mutant	O
with	O
deleted	O
palmitoylation	O
sites	O
is	O
found	O
exclusively	O
in	O
the	O
cytosol	O
after	O
cell	O
fractionation	O
,	O
whereas	O
the	O
palmitoylated	O
form	O
of	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
is	O
membrane	O
-	O
bound	O
,	O
establishing	O
that	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
is	O
membrane	O
-	O
anchored	O
via	O
covalently	O
linked	O
palmitate	O
.	O

Rate	O
limitations	O
in	O
posttranslational	O
processing	O
by	O
the	O
mammary	O
gland	O
of	O
transgenic	O
animals	O
.	O

Our	O
studies	O
in	O
transgenic	O
animal	O
bioreactors	O
sought	O
to	O
determine	O
the	O
rate	O
limitations	O
in	O
posttranslational	O
processing	O
of	O
recombinant	O
human	O
protein	B-PRGE
C	I-PRGE
(	O
rhPC	B-PRGE
)	O
made	O
in	O
mammary	O
gland	O
of	O
mice	O
and	O
pigs	O
.	O

Human	O
protein	B-PRGE
C	I-PRGE
(	O
hPC	B-PRGE
)	O
is	O
a	O
complex	O
plasma	O
protein	O
containing	O
nine	O
gamma	O
-	O
carboxylated	O
glutamic	O
acid	O
(	O
gla	O
)	O
residues	O
that	O
bind	O
calcium	O
at	O
about	O
1	O
to	O
3	O
mM	O
.	O

Gamma	O
carboxylation	O
is	O
a	O
vitamin	O
K	O
-	O
dependent	O
posttranslational	O
modification	O
.	O

The	O
effect	O
of	O
rhPC	B-PRGE
synthesis	O
rate	O
on	O
the	O
extent	O
of	O
gamma	O
-	O
carboxylation	O
of	O
glutamic	O
acid	O
was	O
studied	O
.	O

We	O
have	O
perturbed	O
the	O
biosynthesis	O
of	O
rhPC	B-PRGE
by	O
using	O
two	O
different	O
transgenes	O
to	O
direct	O
mammary	O
gland	O
-	O
specific	O
expression	O
.	O

Promoter	O
elements	O
of	O
the	O
murine	O
whey	B-PRGE
acid	I-PRGE
protein	I-PRGE
(	O
mWAP	B-PRGE
)	O
gene	O
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
hPC	B-PRGE
-	O
cDNA	O
and	O
hPC	B-PRGE
-	O
genomic	O
transgenes	O
.	O

Transgenic	O
mice	O
with	O
hPC	B-PRGE
-	O
cDNA	O
and	O
hPC	B-PRGE
-	O
genomic	O
sequences	O
gave	O
expression	O
levels	O
of	O
11	O
+	O
/	O
-	O
4	O
micrograms	O
rhPC	B-PRGE
/	O
ml	O
of	O
milk	O
and	O
895	O
+	O
/	O
-	O
21	O
micrograms	O
rhPC	B-PRGE
/	O
ml	O
of	O
milk	O
,	O
respectively	O
.	O

Transgenic	O
pigs	O
with	O
hPC	B-PRGE
-	O
cDNA	O
and	O
hPC	B-PRGE
-	O
genomic	O
sequences	O
gave	O
expression	O
levels	O
of	O
100	O
to	O
500	O
micrograms	O
rhPC	B-PRGE
/	O
ml	O
of	O
milk	O
and	O
800	O
to	O
2000	O
micrograms	O
rhPC	B-PRGE
/	O
ml	O
of	O
milk	O
,	O
respectively	O
.	O

A	O
monoclonal	O
antibody	O
(	O
7D7B10	O
-	O
mAb	O
)	O
that	O
binds	O
an	O
epitope	O
in	O
the	O
gla	O
domain	O
of	O
hPC	B-PRGE
in	O
the	O
absence	O
of	O
calcium	O
was	O
used	O
to	O
study	O
the	O
conformational	O
behavior	O
of	O
immunopurified	O
rhPC	B-PRGE
.	O

Immunopurified	O
rhPC	B-PRGE
from	O
lower	O
expressing	O
mice	O
and	O
pigs	O
gave	O
a	O
calcium	O
-	O
dependent	O
binding	O
inhibition	O
by	O
7D7B10	O
-	O
mAb	O
similar	O
to	O
that	O
of	O
hPC	B-PRGE
.	O

Immunopurified	O
rhPC	B-PRGE
from	O
higher	O
expressing	O
mice	O
and	O
pigs	O
gave	O
a	O
less	O
calcium	O
-	O
dependent	O
response	O
.	O

This	O
study	O
suggests	O
that	O
a	O
rate	O
limitation	O
in	O
gamma	O
-	O
carboxylation	O
by	O
the	O
mammary	O
gland	O
occurs	O
at	O
expression	O
levels	O
about	O
>	O
20	O
micrograms	O
/	O
ml	O
in	O
mice	O
and	O
>	O
500	O
micrograms	O
/	O
ml	O
in	O
pigs	O
.	O

Identification	O
and	O
isoprenylation	O
of	O
plant	O
GTP	O
-	O
binding	O
proteins	O
.	O

To	O
identify	O
isoprenylated	O
plant	O
GTP	O
-	O
binding	O
proteins	O
,	O
Arabidopsis	O
thaliana	O
and	O
Nicotiana	O
tabacum	O
cDNA	O
expression	O
libraries	O
were	O
screened	O
for	O
cDNA	O
-	O
encoded	O
proteins	O
capable	O
of	O
binding	O
[	O
32P	O
]	O
GTP	O
in	O
vitro	O
.	O

ATGB2	B-PRGE
,	O
an	O
Arabidopsis	O
homologue	O
of	O
the	O
GTP	O
-	O
binding	O
protein	O
Rab2	B-PRGE
,	O
was	O
found	O
to	O
bind	O
GTP	O
in	O
vitro	O
and	O
to	O
be	O
a	O
substrate	O
for	O
a	O
geranylgeranyl	O
:	O
protein	O
transferase	O
(	O
GGTase	O
)	O
present	O
in	O
plant	O
extracts	O
.	O

The	O
carboxyl	O
terminus	O
of	O
this	O
protein	O
contains	O
a	O
-	O
GCCG	O
sequence	O
,	O
which	O
has	O
not	O
previously	O
been	O
shown	O
to	O
be	O
recognized	O
by	O
any	O
prenyl	O
:	O
protein	O
transferase	O
(	O
PTase	O
)	O
,	O
but	O
which	O
most	O
closely	O
resembles	O
that	O
isoprenylated	O
by	O
the	O
type	O
II	O
GGTase	O
(	O
-	O
XXCC	O
,	O
-	O
XCXC	O
,	O
or	O
-	O
CCXX	O
)	O
.	O

In	O
vitro	O
geranylgeranylation	O
of	O
an	O
Arabidopsis	O
Rab1	B-PRGE
protein	O
containing	O
a	O
carboxyl	O
-	O
terminal	O
-	O
CCGQ	O
sequence	O
confirmed	O
the	O
presence	O
of	O
a	O
type	O
II	O
GGTase	O
-	O
like	O
activity	O
in	O
plant	O
extracts	O
.	O

Several	O
other	O
proteins	O
were	O
also	O
identified	O
by	O
in	O
vitro	O
GTP	O
binding	O
,	O
including	O
Arabidopsis	O
and	O
tobacco	O
homologues	O
of	O
Rab11	B-PRGE
,	O
ARF	O
(	O
ADP	O
-	O
ribosylation	O
factor	O
)	O
and	O
Sar	O
proteins	O
,	O
as	O
well	O
as	O
a	O
novel	O
22	O
kDa	O
Arabidopsis	O
protein	O
(	O
ATG81	B-PRGE
)	O
.	O

This	O
22	O
kDa	O
protein	O
had	O
consensus	O
GTP	O
-	O
binding	O
motifs	O
and	O
bound	O
GTP	O
with	O
high	O
specificity	O
,	O
but	O
its	O
structure	O
was	O
not	O
closely	O
related	O
to	O
that	O
of	O
any	O
known	O
GTP	O
-	O
binding	O
protein	O
(	O
it	O
most	O
resembled	O
proteins	O
within	O
the	O
ARF	O
/	O
Sar	O
and	O
G	O
protein	O
alpha	O
-	O
subunit	O
superfamilies	O
)	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
nlpH	B-PRGE
,	O
encoding	O
a	O
novel	O
,	O
surface	O
-	O
exposed	O
,	O
polymorphic	O
,	O
plasmid	O
-	O
encoded	O
33	O
-	O
kilodalton	O
lipoprotein	O
of	O
Borrelia	O
afzelii	O
.	O

Borrelia	O
burgdorferi	O
sensu	O
lato	O
organisms	O
,	O
comprising	O
B	O
.	O
burgdorferi	O
sensu	O
stricto	O
,	O
Borrelia	O
afzelii	O
,	O
and	O
Borrelia	O
garinii	O
,	O
are	O
tick	O
-	O
borne	O
pathogens	O
causing	O
Lyme	O
borreliosis	O
in	O
humans	O
.	O

To	O
identify	O
putative	O
virulence	O
determinants	O
,	O
a	O
B	O
.	O
afzelii	O
DNA	O
library	O
was	O
screened	O
for	O
Congo	O
red	O
dye	O
binding	O
,	O
a	O
property	O
associated	O
with	O
virulence	O
in	O
pathogenic	O
bacteria	O
.	O

One	O
clone	O
was	O
found	O
to	O
carry	O
a	O
663	O
-	O
nucleotide	O
-	O
long	O
open	O
reading	O
frame	O
encoding	O
a	O
Congo	O
red	O
dye	O
-	O
binding	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
25	O
,	O
660	O
Da	O
.	O

The	O
amino	O
acid	O
sequence	O
deduced	O
from	O
its	O
nucleotide	O
sequence	O
was	O
found	O
to	O
include	O
a	O
consensus	O
bacterial	O
lipidation	O
site	O
present	O
at	O
residues	O
15	O
to	O
18	O
(	O
Leu	O
-	O
Ser	O
-	O
Gly	O
-	O
Cys	O
)	O
.	O

The	O
lipoprotein	O
nature	O
was	O
demonstrated	O
by	O
incorporation	O
of	O
radioactive	O
palmitate	O
;	O
hence	O
,	O
this	O
protein	O
has	O
been	O
termed	O
NlpH	B-PRGE
,	O
for	O
new	O
lipoprotein	O
H	O
.	O

NlpH	B-PRGE
is	O
located	O
on	O
the	O
surface	O
of	O
B	O
.	O
afzelii	O
,	O
and	O
the	O
nlpH	B-PRGE
gene	O
is	O
found	O
on	O
a	O
circular	O
plasmid	O
.	O

The	O
nlpH	B-PRGE
gene	O
is	O
also	O
found	O
in	O
B	O
.	O
burgdorferi	O
sensu	O
stricto	O
and	O
B	O
.	O
garinii	O
.	O

Immediately	O
upstream	O
of	O
nlpH	B-PRGE
is	O
located	O
a	O
smaller	O
reading	O
frame	O
encoding	O
a	O
polypeptide	O
containing	O
the	O
casein	O
kinase	O
II	O
phosphorylation	O
recognition	O
sequence	O
,	O
(	O
Ser	O
/	O
Thr	O
)	O
-	O
X	O
-	O
Y	O
-	O
(	O
Glu	O
/	O
Asp	O
)	O
,	O
repeated	O
10	O
times	O
.	O

Fatty	O
acylation	O
of	O
the	O
rat	O
and	O
human	O
asialoglycoprotein	O
receptors	O
.	O

A	O
conserved	O
cytoplasmic	O
cysteine	O
residue	O
is	O
acylated	O
in	O
all	O
receptor	O
subunits	O
.	O

Functional	O
rat	O
or	O
human	O
asialoglycoprotein	O
receptors	O
(	O
ASGP	O
-	O
Rs	O
)	O
are	O
hetero	O
-	O
oligomeric	O
integral	O
membrane	O
glycoproteins	O
.	O

Rat	O
ASGP	O
-	O
R	O
contains	O
three	O
subunits	O
,	O
designated	O
rat	O
hepatic	B-PRGE
lectins	I-PRGE
(	I-PRGE
RHL	I-PRGE
)	I-PRGE
1	I-PRGE
,	O
2	B-PRGE
,	O
and	O
3	B-PRGE
;	O
human	O
ASGP	O
-	O
R	O
contains	O
two	O
subunits	O
,	O
HHL1	B-PRGE
and	O
HHL2	B-PRGE
.	O

Both	O
receptors	O
are	O
covalently	O
modified	O
by	O
fatty	O
acylation	O
(	O
Zeng	O
,	O
F	O
.	O
-	O
Y	O
.	O
,	O
Kaphalia	O
,	O
B	O
.	O
S	O
.	O
,	O
Ansari	O
,	O
G	O
.	O
A	O
.	O
S	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1995	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
21382	O
-	O
21387	O
;	O
Zeng	O
,	O
F	O
.	O
-	O
Y	O
.	O
,	O
Oka	O
,	O
J	O
.	O
A	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1996	O
)	O
Biochem	O
.	O
Biophys	O
.	O
Res	O
.	O
Commun	O
.	O
218	O
,	O
325	O
-	O
330	O
)	O
.	O

We	O
report	O
here	O
that	O
the	O
single	O
Cys	O
residue	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
each	O
RHL	O
or	O
HHL	O
subunit	O
is	O
fatty	O
acylated	O
.	O

The	O
degree	O
of	O
acylation	O
is	O
>	O
/	O
=	O
90	O
%	O
per	O
subunit	O
.	O

Deacylation	O
of	O
affinity	O
-	O
purified	O
ASGP	O
-	O
Rs	O
with	O
hydroxylamine	O
results	O
in	O
the	O
spontaneous	O
formation	O
of	O
dimers	O
through	O
reversible	O
disulfide	O
bonds	O
,	O
indicating	O
that	O
deacylation	O
concomitantly	O
generates	O
free	O
thiol	O
groups	O
.	O

Reaction	O
of	O
hydroxylamine	O
-	O
treated	O
ASGP	O
-	O
R	O
with	O
[	O
14C	O
]	O
iodoacetamide	O
resulted	O
in	O
the	O
specific	O
incorporation	O
of	O
radioactivity	O
into	O
all	O
RHL	O
and	O
HHL	O
subunits	O
,	O
verifying	O
that	O
fatty	O
acids	O
are	O
attached	O
via	O
thioester	O
linkages	O
.	O

To	O
identify	O
the	O
Cys	O
residue	O
involved	O
in	O
the	O
thioester	O
linkages	O
,	O
14C	O
-	O
carboxyamidomethylated	O
RHL	O
subunits	O
were	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
digested	O
in	O
-	O
gel	O
with	O
trypsin	O
,	O
and	O
the	O
resulting	O
peptides	O
were	O
separated	O
by	O
reverse	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

Amino	O
acid	O
sequence	O
of	O
radioactive	O
peptides	O
revealed	O
that	O
Cys35	O
in	O
RHL1	B-PRGE
and	O
Cys54	O
in	O
RHL2	B-PRGE
and	O
RHL3	B-PRGE
were	O
radiolabeled	O
and	O
,	O
therefore	O
,	O
are	O
fatty	O
acylation	O
sites	O
.	O

Fatty	O
acylation	O
of	O
HHL	O
subunits	O
was	O
analyzed	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Metabolic	O
labeling	O
of	O
Cos7	O
cells	O
transfected	O
with	O
wild	O
type	O
HHL1	B-PRGE
cDNA	O
resulted	O
in	O
substantial	O
incorporation	O
of	O
[	O
3H	O
]	O
palmitate	O
into	O
purified	O
HHL1	B-PRGE
.	O

Incorporation	O
of	O
[	O
3H	O
]	O
palmitate	O
into	O
a	O
C36S	O
mutant	O
of	O
HHL1	B-PRGE
was	O
negligible	O
(	O
approximately	O
1	O
%	O
)	O
compared	O
with	O
wild	O
type	O
.	O

This	O
result	O
also	O
shows	O
that	O
Cys57	O
within	O
the	O
transmembrane	O
domain	O
of	O
HHL1	B-PRGE
is	O
not	O
normally	O
palmitoylated	O
.	O

We	O
conclude	O
that	O
Cys35	O
in	O
RHL1	B-PRGE
,	O
Cys54	O
in	O
RHL2	B-PRGE
and	O
RHL3	B-PRGE
,	O
and	O
Cys36	O
in	O
HHL1	B-PRGE
are	O
fatty	O
acylated	O
.	O

Cys57	O
in	O
HHL1	B-PRGE
and	O
probably	O
Cys56	O
in	O
RHL1	B-PRGE
are	O
not	O
palmitoylated	O
.	O

HSDJ	B-PRGE
,	O
a	O
human	O
homolog	O
of	O
DnaJ	B-PRGE
,	O
is	O
farnesylated	O
and	O
is	O
involved	O
in	O
protein	O
import	O
into	O
mitochondria	O
.	O

The	O
role	O
of	O
HSDJ	B-PRGE
,	O
a	O
human	O
homolog	O
of	O
bacterial	O
DnaJ	B-PRGE
and	O
yeast	O
YDJ1p	B-PRGE
/	O
MAS5	B-PRGE
,	O
in	O
mitochondrial	O
protein	O
import	O
was	O
examined	O
.	O

Recombinant	O
HSDJ	B-PRGE
was	O
purified	O
and	O
an	O
antibody	O
was	O
prepared	O
.	O

HSDJ	B-PRGE
mRNA	O
was	O
heat	O
-	O
induced	O
in	O
cultured	O
cells	O
.	O

In	O
pulse	O
-	O
labeling	O
and	O
chase	O
experiments	O
using	O
COS	O
-	O
7	O
cells	O
,	O
the	O
endogenous	O
HSDJ	B-PRGE
homolog	O
was	O
prenylated	O
.	O

Transiently	O
expressed	O
HSDJ	B-PRGE
was	O
also	O
prenylated	O
,	O
whereas	O
its	O
mutant	O
C394S	O
in	O
which	O
cysteine	O
of	O
the	O
"	O
CaaX	O
box	O
"	O
was	O
mutated	O
to	O
serine	O
,	O
was	O
not	O
.	O

HSDJ	B-PRGE
,	O
but	O
not	O
C394S	O
,	O
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysate	O
was	O
farnesylated	O
.	O

The	O
HSDJ	B-PRGE
antibody	O
inhibited	O
import	O
of	O
ornithine	B-PRGE
transcarbamylase	I-PRGE
precursor	O
(	O
pOTC	B-PRGE
)	O
into	O
isolated	O
mitochondria	O
when	O
added	O
prior	O
to	O
pOTC	B-PRGE
synthesis	O
,	O
but	O
not	O
when	O
added	O
prior	O
to	O
import	O
assay	O
.	O

In	O
transient	O
expression	O
of	O
pOTC	B-PRGE
in	O
COS	O
-	O
7	O
cells	O
,	O
pOTC	B-PRGE
was	O
synthesized	O
and	O
processed	O
to	O
the	O
mature	O
form	O
with	O
an	O
apparent	O
half	O
-	O
life	O
of	O
2	O
-	O
3	O
min	O
.	O

Coexpression	O
of	O
HSDJ	B-PRGE
or	O
C394S	O
resulted	O
in	O
slight	O
retardation	O
of	O
the	O
pOTC	B-PRGE
processing	O
.	O

These	O
results	O
indicate	O
that	O
HSDJ	B-PRGE
is	O
involved	O
in	O
an	O
early	O
step	O
(	O
s	O
)	O
of	O
protein	O
import	O
into	O
mitochondria	O
.	O

Farnesyl	O
:	O
proteintransferase	O
inhibitors	O
as	O
agents	O
to	O
inhibit	O
tumor	O
growth	O
.	O

Ras	O
,	O
a	O
signal	O
-	O
transducing	O
protein	O
involved	O
in	O
mediating	O
growth	O
factor	O
-	O
stimulated	O
proliferation	O
,	O
is	O
mutationally	O
activated	O
in	O
over	O
30	O
%	O
of	O
human	O
tumors	O
.	O

To	O
be	O
functional	O
Ras	O
must	O
bind	O
to	O
the	O
inner	O
surface	O
of	O
the	O
plasma	O
membrane	O
,	O
with	O
post	O
-	O
translational	O
lipid	O
modifications	O
being	O
necessary	O
for	O
this	O
localization	O
.	O

The	O
essential	O
,	O
first	O
modification	O
of	O
Ras	O
is	O
farnesylation	O
catalyzed	O
by	O
the	O
enzyme	O
farnesyl	O
:	O
proteintransferase	O
(	O
FPTase	O
)	O
.	O

Inhibitors	O
of	O
FPTase	O
(	O
FTIs	O
)	O
are	O
currently	O
being	O
tested	O
to	O
determine	O
if	O
they	O
are	O
capable	O
of	O
tumor	O
growth	O
inhibition	O
.	O

Here	O
we	O
describe	O
our	O
efforts	O
,	O
along	O
with	O
those	O
of	O
other	O
groups	O
,	O
in	O
testing	O
the	O
biological	O
and	O
biochemical	O
effects	O
of	O
FTIs	O
.	O

Long	O
-	O
term	O
alcohol	O
effects	O
on	O
hepatic	O
phosphoglucomutase	B-PRGE
activities	O
in	O
relation	O
to	O
posttranslational	O
modification	O
of	O
the	O
protein	O
.	O

ADP	O
-	O
ribosylation	O
is	O
a	O
posttranslational	O
protein	O
modification	O
catalyzed	O
by	O
two	O
classes	O
of	O
enzymes	O
:	O
mono	O
-	O
ADP	O
-	O
ribosyltransferase	O
and	O
poly	O
-	O
ADP	O
-	O
ribose	O
polymerases	O
.	O

We	O
previously	O
demonstrated	O
that	O
long	O
-	O
term	O
alcohol	O
intake	O
remarkably	O
enhanced	O
an	O
endogenous	O
ADP	O
-	O
ribosylation	O
of	O
a	O
58	O
kDa	O
protein	O
in	O
rat	O
liver	O
and	O
also	O
identified	O
the	O
58	O
kDa	O
protein	O
as	O
phosphoglucomutase	B-PRGE
(	O
PGM	B-PRGE
)	O
.	O

To	O
assess	O
biological	O
significance	O
of	O
this	O
phenomenon	O
,	O
we	O
tested	O
the	O
effects	O
of	O
long	O
-	O
term	O
alcohol	O
intake	O
on	O
PGM	B-PRGE
activities	O
in	O
connection	O
with	O
posttranslational	O
modification	O
of	O
the	O
protein	O
.	O

ADP	O
-	O
ribosylation	O
of	O
PGM	B-PRGE
was	O
mono	O
-	O
rather	O
than	O
poly	O
-	O
ADP	O
-	O
ribosylation	O
.	O

Also	O
,	O
nonenzymatic	O
binding	O
of	O
ADP	O
-	O
ribose	O
was	O
excluded	O
.	O

It	O
was	O
of	O
note	O
that	O
ADP	O
-	O
ribosylation	O
of	O
exogenous	O
PGM	B-PRGE
was	O
remarkably	O
increased	O
by	O
adding	O
rat	O
liver	O
plasma	O
membranes	O
,	O
and	O
that	O
the	O
extent	O
of	O
the	O
increase	O
was	O
greater	O
in	O
alcohol	O
-	O
fed	O
rats	O
than	O
in	O
pair	O
-	O
fed	O
controls	O
.	O

Furthermore	O
,	O
PGM	B-PRGE
activities	O
were	O
significantly	O
increased	O
after	O
long	O
-	O
term	O
alcohol	O
intake	O
concomitant	O
with	O
increased	O
ADP	O
-	O
ribosyltransferase	O
activities	O
toward	O
PGM	B-PRGE
.	O

In	O
view	O
of	O
the	O
variety	O
of	O
roles	O
of	O
PGM	B-PRGE
in	O
the	O
liver	O
,	O
such	O
as	O
carbohydrate	O
metabolism	O
and	O
Ca2	O
+	O
homeostasis	O
,	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
increased	O
ADP	O
-	O
ribosylation	O
of	O
PGM	B-PRGE
may	O
play	O
a	O
role	O
in	O
long	O
-	O
term	O
alcohol	O
effects	O
on	O
hepatocytes	O
.	O

Specific	O
isoprenyl	O
group	O
linked	O
to	O
transducin	B-PRGE
gamma	I-PRGE
-	O
subunit	O
is	O
a	O
determinant	O
of	O
its	O
unique	O
signaling	O
properties	O
among	O
G	O
-	O
proteins	O
.	O

Among	O
11	O
subtypes	O
of	O
heterotrimeric	O
G	O
-	O
protein	O
gamma	O
-	O
subunit	O
,	O
gamma1	B-PRGE
(	O
rod	O
)	O
,	O
gamma8	B-PRGE
(	O
cone	O
)	O
and	O
gamma11	B-PRGE
are	O
modified	O
with	O
farnesyl	O
while	O
the	O
others	O
are	O
modified	O
with	O
geranylgeranyl	O
at	O
the	O
C	O
-	O
terminus	O
.	O

To	O
understand	O
the	O
role	O
of	O
specific	O
isoprenylation	O
(	O
farnesylation	O
)	O
of	O
retinal	O
transducin	O
,	O
we	O
examined	O
how	O
and	O
to	O
what	O
extent	O
the	O
type	O
of	O
isoprenyl	O
group	O
affects	O
transducin	O
-	O
beta	O
gamma	B-PRGE
(	O
beta1	B-PRGE
gamma1	B-PRGE
)	O
functions	O
such	O
as	O
interactions	O
with	O
membranes	O
,	O
Galpha	O
/	O
receptor	O
,	O
and	O
effectors	O
.	O

To	O
this	O
end	O
,	O
the	O
C	O
-	O
terminal	O
farnesylation	O
signal	O
sequence	O
(	O
CVIS	O
)	O
of	O
gamma1	B-PRGE
was	O
replaced	O
by	O
a	O
geranylgeranylation	O
signal	O
(	O
CVIL	O
)	O
,	O
and	O
the	O
resultant	O
mutant	O
(	O
S74L	O
)	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
gamma1	B-PRGE
was	O
coexpressed	O
with	O
beta1	B-PRGE
in	O
the	O
baculovirus	O
-	O
Tn5	O
insect	O
cell	O
system	O
.	O

Both	O
gamma1WT	B-PRGE
and	O
gamma1S74L	B-PRGE
expressed	O
as	O
a	O
beta	O
gamma	O
complex	O
were	O
mixtures	O
modified	O
with	O
farnesyl	O
and	O
geranylgeranyl	O
groups	O
.	O

The	O
ratio	O
of	O
farnesyl	O
to	O
geranylgeranyl	O
in	O
preparations	O
of	O
beta1	B-PRGE
gamma1WT	B-PRGE
and	O
beta1	B-PRGE
gamma1S74L	B-PRGE
purified	O
from	O
the	O
Tn5	O
cell	O
membrane	O
fraction	O
was	O
about	O
1	O
:	O
2	O
and	O
1	O
:	O
6	O
,	O
respectively	O
.	O

These	O
two	O
forms	O
of	O
recombinant	O
beta1	B-PRGE
gamma1	B-PRGE
and	O
retinal	O
beta1	B-PRGE
gamma1	B-PRGE
were	O
different	O
in	O
their	O
abilities	O
to	O
associate	O
with	O
rod	O
outer	O
segment	O
membranes	O
with	O
the	O
following	O
rank	O
order	O
:	O
beta1	B-PRGE
gamma1S74L	B-PRGE
>	O
beta1	B-PRGE
gamma1WT	B-PRGE
>	O
retinal	O
beta1	B-PRGE
gamma1	B-PRGE
.	O

Functionally	O
,	O
beta1	B-PRGE
gamma1S74L	B-PRGE
was	O
the	O
most	O
potent	O
to	O
promote	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
ribosylation	O
of	O
transducin	O
-	O
alpha	O
(	O
Talpha	O
)	O
,	O
to	O
stimulate	O
metarhodopsin	B-PRGE
II	I-PRGE
-	O
catalyzed	O
GTPgammaS	O
-	O
binding	O
reaction	O
to	O
Talpha	O
and	O
to	O
modulate	O
adenylyl	O
cyclase	O
and	O
phospholipase	O
C	O
activities	O
.	O

All	O
of	O
the	O
beta1	B-PRGE
gamma1	B-PRGE
functions	O
absolutely	O
required	O
the	O
isoprenylation	O
of	O
the	O
gamma	O
-	O
subunit	O
.	O

As	O
for	O
the	O
interaction	O
with	O
Goalpha	B-PRGE
and	O
adenylyl	O
cyclase	O
,	O
predominantly	O
geranylgeranylated	O
beta1	B-PRGE
gamma1S74L	B-PRGE
was	O
less	O
effective	O
than	O
geranylgeranylated	O
beta1	B-PRGE
gamma2	B-PRGE
purified	O
from	O
bovine	O
brain	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
properties	O
of	O
Gbeta	O
gamma	O
are	O
strongly	O
affected	O
by	O
the	O
type	O
of	O
functionally	O
indispensable	O
isoprenylation	O
in	O
addition	O
to	O
the	O
amino	O
acid	O
sequence	O
of	O
Ggamma	O
.	O

The	O
relative	O
contribution	O
of	O
the	O
two	O
factors	O
depends	O
on	O
proteins	O
with	O
which	O
Gbeta	O
gamma	O
interacts	O
.	O

What	O
does	O
insulin	B-PRGE
do	O
to	O
Ras	O
?	O

The	O
Ras	O
pathway	O
lies	O
in	O
the	O
center	O
of	O
signalling	O
cascades	O
of	O
numerous	O
growth	O
-	O
promoting	O
factors	O
.	O

The	O
Ras	O
pathway	O
appears	O
to	O
connect	O
signalling	O
events	O
that	O
begin	O
at	O
the	O
plasma	O
membrane	O
with	O
nuclear	O
events	O
.	O

Insulin	B-PRGE
is	O
one	O
of	O
the	O
major	O
stimulants	O
of	O
the	O
Ras	O
signalling	O
pathway	O
.	O

The	O
influence	O
of	O
insulin	B-PRGE
on	O
this	O
pathway	O
consists	O
of	O
five	O
important	O
events	O
:	O
(	O
1	O
)	O
p21Ras	B-PRGE
activation	O
is	O
promoted	O
by	O
insulin	B-PRGE
stimulation	O
of	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
,	O
Sos	O
,	O
resulting	O
in	O
increased	O
GTP	O
-	O
loading	O
of	O
p21Ras	B-PRGE
;	O
(	O
2	O
)	O
p21Ras	B-PRGE
deactivation	O
involves	O
the	O
hyperphosphorylation	O
of	O
Sos	O
;	O
(	O
3	O
)	O
insulin	B-PRGE
increases	O
farnesyltransferase	O
(	O
FTase	O
)	O
activity	O
that	O
farnesylates	O
p21Ras	B-PRGE
;	O
(	O
4	O
)	O
increased	O
amounts	O
of	O
farnesylated	O
p21Ras	B-PRGE
translocate	O
to	O
the	O
plasma	O
membrane	O
where	O
they	O
can	O
be	O
activated	O
by	O
other	O
growth	O
-	O
promoting	O
agents	O
;	O
and	O
(	O
5	O
)	O
cellular	O
responses	O
to	O
other	O
growth	O
factors	O
are	O
potentiated	O
by	O
insulin	B-PRGE
-	O
stimulated	O
pre	O
-	O
loading	O
of	O
the	O
plasma	O
membrane	O
with	O
farnesylated	O
p21Ras	B-PRGE
.	O

3	O
-	O
Hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitors	O
increase	O
fibrinolytic	O
activity	O
in	O
rat	O
aortic	O
endothelial	O
cells	O
.	O

Role	O
of	O
geranylgeranylation	O
and	O
Rho	O
proteins	O
.	O

3	O
-	O
Hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
(	O
HMG	O
CoA	O
)	O
reductase	O
inhibitors	O
(	O
HRIs	O
)	O
have	O
been	O
recently	O
shown	O
to	O
prevent	O
atherosclerosis	O
progression	O
.	O

Clinical	O
benefit	O
results	O
from	O
combined	O
actions	O
on	O
various	O
components	O
of	O
the	O
atherosclerotic	O
lesion	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
the	O
effects	O
of	O
HRI	O
on	O
one	O
of	O
these	O
components	O
,	O
the	O
endothelial	O
fibrinolytic	O
system	O
.	O

Aortas	O
isolated	O
from	O
rats	O
treated	O
for	O
2	O
days	O
with	O
lovastatin	O
(	O
4	O
mg	O
/	O
kg	O
body	O
wt	O
per	O
day	O
)	O
showed	O
a	O
3	O
-	O
fold	O
increase	O
in	O
tissue	B-PRGE
plasminogen	I-PRGE
activator	I-PRGE
(	O
tPA	B-PRGE
)	O
activity	O
.	O

In	O
a	O
rat	O
aortic	O
endothelial	O
cell	O
line	O
(	O
SVARECs	O
)	O
and	O
in	O
human	O
nontransformed	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
HRI	O
induced	O
an	O
increase	O
in	O
tPA	B-PRGE
activity	O
and	O
antigen	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

In	O
SVARECs	O
,	O
the	O
maximal	O
response	O
was	O
observed	O
when	O
cells	O
were	O
incubated	O
for	O
48	O
hours	O
with	O
50	O
micromol	O
/	O
L	O
HRI	O
.	O

An	O
increase	O
of	O
tPA	B-PRGE
mRNA	O
was	O
also	O
in	O
evidence	O
.	O

In	O
contrast	O
,	O
HRI	O
inhibited	O
plasminogen	B-PRGE
activator	I-PRGE
inhibitor	I-PRGE
-	I-PRGE
1	I-PRGE
activity	O
and	O
mRNA	O
.	O

The	O
effects	O
of	O
HRI	O
were	O
reversed	O
by	O
mevalonate	O
and	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
by	O
LDL	O
cholesterol	O
and	O
farnesyl	O
pyrophosphate	O
,	O
and	O
were	O
not	O
induced	O
by	O
alpha	O
-	O
hydroxyfarnesyl	O
phosphonic	O
acid	O
,	O
an	O
inhibitor	O
of	O
protein	O
farnesyl	O
transferase	O
.	O

C3	B-PRGE
exoenzyme	I-PRGE
,	O
an	O
inhibitor	O
of	O
the	O
geranylgeranylated	O
-	O
activated	O
Rho	O
protein	O
,	O
reproduced	O
the	O
effect	O
of	O
lovastatin	O
on	O
tPA	B-PRGE
and	O
plasminogen	B-PRGE
activator	I-PRGE
inhibitor	I-PRGE
-	I-PRGE
1	I-PRGE
activity	O
and	O
blocked	O
its	O
reversal	O
by	O
geranylgeranyl	O
pyrophosphate	O
.	O

The	O
effect	O
of	O
HRI	O
was	O
associated	O
with	O
a	O
disruption	O
of	O
cellular	O
actin	O
filaments	O
without	O
modification	O
of	O
microtubules	O
.	O

A	O
disrupter	O
of	O
actin	O
filaments	O
,	O
cytochalasin	O
D	O
,	O
induced	O
the	O
same	O
effect	O
as	O
lovastatin	O
on	O
tPA	B-PRGE
,	O
whereas	O
a	O
disrupter	O
of	O
microtubules	O
,	O
nocodazole	O
,	O
did	O
not	O
.	O

In	O
conclusion	O
,	O
HRI	O
can	O
modify	O
the	O
fibrinolytic	O
potential	O
of	O
endothelial	O
cells	O
,	O
likely	O
via	O
inhibition	O
of	O
geranylgeranylated	O
Rho	O
protein	O
and	O
disruption	O
of	O
the	O
actin	O
filaments	O
.	O

The	O
resulting	O
increase	O
of	O
fibrinolytic	O
activity	O
of	O
endothelial	O
cells	O
may	O
contribute	O
to	O
the	O
beneficial	O
effects	O
of	O
HRI	O
in	O
the	O
progression	O
of	O
atherosclerosis	O
.	O

Cleavage	O
of	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-PRGE
by	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
.	O

NEDD8	B-PRGE
is	O
a	O
novel	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
that	O
has	O
been	O
shown	O
to	O
conjugate	O
to	O
nuclear	O
proteins	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitination	O
and	O
sentrinization	O
.	O

To	O
identify	O
proteins	O
that	O
are	O
involved	O
in	O
the	O
NEDD8	B-PRGE
-	O
conjugation	O
and	O
de	O
-	O
conjugation	O
pathway	O
,	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
was	O
used	O
to	O
screen	O
a	O
human	O
heart	O
cDNA	O
library	O
using	O
NEDD8	B-PRGE
as	O
a	O
bait	O
.	O

Seven	O
strongly	O
positive	O
clones	O
were	O
found	O
to	O
contain	O
a	O
cDNA	O
insert	O
encoding	O
the	O
ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
,	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
.	O

In	O
vitro	O
GST	O
pull	O
-	O
down	O
assay	O
demonstrated	O
that	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
bound	O
to	O
both	O
NEDD8	B-PRGE
and	O
ubiquitin	B-PRGE
.	O

In	O
contrast	O
,	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
did	O
not	O
bind	O
to	O
sentrin	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
sentrin	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
or	O
sentrin	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

Recombinant	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
,	O
but	O
not	O
UCH	B-PRGE
-	I-PRGE
L1	I-PRGE
,	O
was	O
able	O
to	O
cleave	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-PRGE
.	O

Thus	O
,	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
can	O
function	O
as	O
a	O
C	O
-	O
terminal	O
hydrolase	O
for	O
both	O
NEDD8	B-PRGE
and	O
ubiquitin	B-PRGE
.	O

UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
may	O
play	O
a	O
physiologically	O
significant	O
role	O
in	O
the	O
cleavage	O
of	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-PRGE
,	O
which	O
is	O
required	O
for	O
NEDD8	B-PRGE
to	O
conjugate	O
to	O
target	O
proteins	O
.	O

Crm1p	B-PRGE
mediates	O
regulated	O
nuclear	O
export	O
of	O
a	O
yeast	O
AP	O
-	O
1	O
-	O
like	O
transcription	O
factor	O
.	O

The	O
yeast	O
AP	O
-	O
1	O
-	O
like	O
transcription	O
factor	O
,	O
Yap1p	B-PRGE
,	O
activates	O
genes	O
required	O
for	O
the	O
response	O
to	O
oxidative	O
stress	O
.	O

Yap1p	B-PRGE
is	O
normally	O
cytoplasmic	O
and	O
inactive	O
,	O
but	O
will	O
activate	O
by	O
nuclear	O
translocation	O
if	O
cells	O
are	O
placed	O
in	O
an	O
oxidative	O
environment	O
.	O

Here	O
we	O
show	O
that	O
Yap1p	B-PRGE
is	O
a	O
target	O
of	O
the	O
beta	O
-	O
karyopherin	O
-	O
like	O
nuclear	O
exporter	O
,	O
Crm1p	B-PRGE
.	O

Yap1p	B-PRGE
is	O
constitutively	O
nuclear	O
in	O
a	O
crm1	B-PRGE
mutant	O
,	O
and	O
Crm1p	B-PRGE
binds	O
to	O
a	O
nuclear	O
export	O
sequence	O
(	O
NES	O
)	O
-	O
like	O
sequence	O
in	O
Yap1p	B-PRGE
in	O
the	O
presence	O
of	O
RanGTP	B-PRGE
.	O

Recognition	O
of	O
Yap1p	B-PRGE
by	O
Crm1p	B-PRGE
is	O
inhibited	O
by	O
oxidation	O
,	O
and	O
this	O
inhibition	O
requires	O
at	O
least	O
one	O
of	O
the	O
three	O
cysteine	O
residues	O
flanking	O
the	O
NES	O
.	O

These	O
results	O
suggest	O
that	O
Yap1p	B-PRGE
localization	O
is	O
largely	O
regulated	O
at	O
the	O
level	O
of	O
nuclear	O
export	O
,	O
and	O
that	O
the	O
oxidation	O
state	O
affects	O
the	O
accessibility	O
of	O
the	O
Yap1p	B-PRGE
NES	O
to	O
Crm1p	B-PRGE
directly	O
.	O

We	O
also	O
show	O
that	O
a	O
mutation	O
in	O
RanGAP	B-PRGE
(	O
rna1	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
synthetically	O
lethal	O
with	O
crm1	B-PRGE
mutants	O
.	O

Yap1p	B-PRGE
export	O
is	O
inhibited	O
in	O
both	O
rna1	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
prp20	B-PRGE
(	O
RanGNRF	B-PRGE
)	O
mutant	O
strains	O
,	O
but	O
Yap1p	B-PRGE
rapidly	O
accumulates	O
at	O
the	O
nuclear	O
periphery	O
after	O
shifting	O
rna1	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
but	O
not	O
other	O
mutant	O
cells	O
to	O
the	O
non	O
-	O
permissive	O
temperature	O
.	O

Thus	O
,	O
disassembly	O
of	O
export	O
complexes	O
in	O
response	O
to	O
RanGTP	B-PRGE
hydrolysis	O
may	O
be	O
required	O
for	O
release	O
of	O
substrate	O
from	O
a	O
terminal	O
binding	O
site	O
at	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
.	O

The	O
dynamic	O
role	O
of	O
GRP78	B-PRGE
/	O
BiP	B-PRGE
in	O
the	O
coordination	O
of	O
mRNA	O
translation	O
with	O
protein	O
processing	O
.	O

The	O
role	O
of	O
GRP78	B-PRGE
/	O
BiP	B-PRGE
in	O
coordinating	O
endoplasmic	O
reticular	O
(	O
ER	O
)	O
protein	O
processing	O
with	O
mRNA	O
translation	O
was	O
examined	O
in	O
GH3	O
pituitary	O
cells	O
.	O

ADP	O
-	O
ribosylation	O
of	O
GRP78	B-PRGE
and	O
eukaryotic	B-PRGE
initiation	I-PRGE
factor	I-PRGE
(	I-PRGE
eIF	I-PRGE
)	I-PRGE
-	I-PRGE
2alpha	I-PRGE
phosphorylation	O
were	O
assessed	O
,	O
respectively	O
,	O
as	O
indices	O
of	O
chaperone	O
inactivation	O
and	O
the	O
inhibition	O
of	O
translational	O
initiation	O
.	O

Inhibition	O
of	O
protein	O
processing	O
by	O
ER	O
stress	O
(	O
ionomycin	O
and	O
dithiothreitol	O
)	O
resulted	O
in	O
GRP78	B-PRGE
deribosylation	O
and	O
eIF	O
-	O
2	O
phosphorylation	O
.	O

Suppression	O
of	O
translation	O
relative	O
to	O
ER	O
protein	O
processing	O
(	O
cycloheximide	O
)	O
produced	O
approximately	O
50	O
%	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-PRGE
within	O
90	O
min	O
without	O
eIF	O
-	O
2	O
phosphorylation	O
.	O

ADP	O
-	O
ribosylation	O
was	O
reversed	O
in	O
90	O
min	O
by	O
cycloheximide	O
removal	O
in	O
a	O
manner	O
accelerated	O
by	O
ER	O
stressors	O
.	O

Cycloheximide	O
sharply	O
reduced	O
eIF	O
-	O
2	O
phosphorylation	O
in	O
response	O
to	O
ER	O
stressors	O
for	O
about	O
30	O
min	O
;	O
sensitivity	O
returned	O
as	O
GRP78	B-PRGE
became	O
increasingly	O
ADP	O
-	O
ribosylated	O
.	O

Reduced	O
sensitivity	O
of	O
eIF	O
-	O
2	O
to	O
phosphorylation	O
appeared	O
to	O
derive	O
from	O
the	O
accumulation	O
of	O
free	O
,	O
unmodified	O
chaperone	O
as	O
proteins	O
completed	O
processing	O
without	O
replacements	O
.	O

Prolonged	O
(	O
24	O
h	O
)	O
incubations	O
with	O
cycloheximide	O
resulted	O
in	O
the	O
selective	O
loss	O
of	O
the	O
ADP	O
-	O
ribosylated	O
form	O
of	O
GRP78	B-PRGE
and	O
increased	O
sensitivity	O
of	O
eIF	O
-	O
2	O
phosphorylation	O
in	O
response	O
to	O
ER	O
stressors	O
.	O

Brefeldin	O
A	O
decreased	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-PRGE
in	O
parallel	O
with	O
increased	O
eIF	O
-	O
2	O
phosphorylation	O
.	O

The	O
cytoplasmic	O
stressor	O
,	O
arsenite	O
,	O
which	O
inhibits	O
translational	O
initiation	O
through	O
eIF	O
-	O
2	O
phosphorylation	O
without	O
affecting	O
the	O
ER	O
,	O
also	O
produced	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-PRGE
.	O

Identification	O
of	O
the	O
activating	O
and	O
conjugating	O
enzymes	O
of	O
the	O
NEDD8	B-PRGE
conjugation	O
pathway	O
.	O

NEDD8	B-PRGE
is	O
a	O
ubiquitin	B-PRGE
-	O
like	O
molecule	O
that	O
can	O
be	O
covalently	O
conjugated	O
to	O
a	O
limited	O
number	O
of	O
cellular	O
proteins	O
,	O
such	O
as	O
Cdc53	B-PRGE
/	O
cullin	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
C	O
terminus	O
of	O
NEDD8	B-PRGE
is	O
efficiently	O
processed	O
to	O
expose	O
Gly	O
-	O
76	O
,	O
which	O
is	O
required	O
for	O
conjugation	O
to	O
target	O
proteins	O
.	O

A	O
combination	O
of	O
data	O
base	O
searches	O
and	O
polymerase	O
chain	O
reaction	O
cloning	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
human	O
UBA3	B-PRGE
,	O
which	O
is	O
38	O
%	O
identical	O
to	O
the	O
yeast	O
homologue	O
,	O
22	O
%	O
identical	O
to	O
human	O
UBA2	B-PRGE
,	O
and	O
19	O
%	O
identical	O
to	O
the	O
C	O
-	O
terminal	O
region	O
of	O
human	O
UBE1	B-PRGE
.	O

The	O
human	O
UBA3	B-PRGE
gene	O
is	O
located	O
on	O
chromosome	O
3p13	O
and	O
gave	O
rise	O
to	O
a	O
2	O
.	O
2	O
-	O
kilobase	O
pair	O
transcript	O
that	O
was	O
detected	O
in	O
all	O
tissues	O
.	O

Human	O
UBA3	B-PRGE
could	O
be	O
precipitated	O
with	O
glutathione	B-PRGE
S	I-PRGE
-	I-PRGE
transferase	I-PRGE
(	O
GST	B-PRGE
)	O
-	O
NEDD8	B-PRGE
,	O
but	O
not	O
with	O
GST	B-PRGE
-	O
ubiquitin	B-PRGE
or	O
GST	B-PRGE
-	O
sentrin	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Moreover	O
,	O
human	O
UBA3	B-PRGE
could	O
form	O
a	O
beta	O
-	O
mercaptoethanol	O
-	O
sensitive	O
conjugate	O
with	O
NEDD8	B-PRGE
in	O
the	O
presence	O
of	O
APP	B-PRGE
-	I-PRGE
BP1	I-PRGE
,	O
a	O
protein	O
with	O
sequence	O
homology	O
to	O
the	O
N	O
-	O
terminal	O
half	O
of	O
ubiquitin	O
-	O
activating	O
enzyme	O
.	O

We	O
have	O
also	O
cloned	O
human	O
UBC12	B-PRGE
and	O
demonstrated	O
that	O
it	O
could	O
form	O
a	O
thiol	O
ester	O
linkage	O
with	O
NEDD8	B-PRGE
in	O
the	O
presence	O
of	O
the	O
activating	O
enzyme	O
complex	O
.	O

Identification	O
of	O
the	O
activating	O
and	O
conjugating	O
enzymes	O
of	O
the	O
NEDD8	B-PRGE
conjugation	O
pathway	O
should	O
allow	O
for	O
a	O
more	O
detailed	O
study	O
of	O
the	O
role	O
of	O
NEDD8	B-PRGE
modification	O
in	O
health	O
and	O
disease	O
.	O

Correlation	O
between	O
MRI	O
and	O
clinico	O
-	O
pathological	O
manifestations	O
in	O
Lewis	O
rats	O
protected	O
from	O
experimental	O
allergic	O
encephalomyelitis	O
by	O
acylated	O
synthetic	O
peptide	O
of	O
myelin	B-PRGE
basic	I-PRGE
protein	I-PRGE
.	O

Experimental	O
allergic	O
encephalomyelitis	O
(	O
EAE	O
)	O
is	O
an	O
autoimmune	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
which	O
constitutes	O
an	O
accepted	O
animal	O
model	O
for	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

The	O
disease	O
can	O
take	O
an	O
acute	O
or	O
chronic	O
form	O
depending	O
on	O
the	O
injection	O
route	O
,	O
animal	O
strain	O
and	O
nature	O
of	O
the	O
disease	O
-	O
inducing	O
antigen	O
administered	O
.	O

The	O
neuroinflammation	O
associated	O
with	O
the	O
acute	O
form	O
can	O
be	O
detected	O
with	O
T2	O
-	O
weighted	O
,	O
T1	O
-	O
weighted	O
and	O
diffusion	O
MRI	O
,	O
and	O
blood	O
-	O
brain	O
barrier	O
changes	O
can	O
be	O
investigated	O
with	O
Gd	O
-	O
DTPA	O
-	O
enhanced	O
T1	O
-	O
weighted	O
imaging	O
,	O
similar	O
to	O
that	O
of	O
MS	O
patients	O
.	O

A	O
synthetic	O
peptide	O
of	O
myelin	B-PRGE
basic	I-PRGE
protein	I-PRGE
(	O
MBP	B-PRGE
)	O
encephalitogenic	O
for	O
the	O
Lewis	O
rat	O
(	O
MBP	O
68	O
-	O
86	O
)	O
was	O
acylated	O
by	O
the	O
attachment	O
of	O
a	O
palmitoyl	O
residue	O
(	O
PAL68	O
-	O
86	O
)	O
,	O
and	O
was	O
shown	O
to	O
confer	O
almost	O
complete	O
protection	O
against	O
EAE	O
,	O
when	O
administered	O
to	O
rats	O
before	O
and	O
after	O
an	O
encephalitogenic	O
challenge	O
.	O

In	O
this	O
study	O
,	O
treatment	O
of	O
Lewis	O
rats	O
with	O
PAL68	O
-	O
86	O
prevented	O
the	O
appearance	O
of	O
clinical	O
signs	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
after	O
challenge	O
with	O
the	O
native	O
peptide	O
(	O
p68	O
-	O
86	O
)	O
in	O
complete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
CFA	O
)	O
,	O
and	O
reduced	O
considerably	O
the	O
MRI	O
and	O
histopathological	O
signs	O
of	O
the	O
disease	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Measurement	O
of	O
the	O
gadolinium	O
leakage	O
due	O
to	O
neuroinflammation	O
revealed	O
a	O
significant	O
decrease	O
in	O
permeability	O
from	O
4	O
.	O
09	O
+	O
/	O
-	O
2	O
.	O
1	O
to	O
2	O
.	O
95	O
+	O
/	O
-	O
1	O
.	O
79	O
%	O
pixels	O
>	O
mean	O
+	O
2	O
SD	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

Therefore	O
,	O
quantitative	O
MRI	O
measurements	O
correlate	O
very	O
well	O
with	O
the	O
reduced	O
cellular	O
infiltration	O
in	O
the	O
CNS	O
and	O
the	O
absence	O
of	O
clinical	O
signs	O
in	O
the	O
EAE	O
-	O
protected	O
animal	O
.	O

Synthesis	O
of	O
the	O
palmitoylated	O
and	O
prenylated	O
C	O
-	O
terminal	O
lipopeptides	O
of	O
the	O
human	O
R	B-PRGE
-	I-PRGE
and	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
proteins	O
.	O

For	O
the	O
study	O
of	O
biological	O
phenomena	O
influenced	O
by	O
the	O
R	B-PRGE
-	I-PRGE
and	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
proteins	O
,	O
characteristic	O
peptides	O
which	O
embody	O
the	O
correct	O
lipid	O
modifications	O
of	O
their	O
parent	O
proteins	O
(	O
palmitoyl	O
thioesters	O
,	O
geranylgeranyl	O
thioethers	O
,	O
and	O
farnesyl	O
thioethers	O
)	O
,	O
as	O
well	O
as	O
analogues	O
thereof	O
,	O
may	O
serve	O
as	O
efficient	O
tools	O
.	O

For	O
the	O
construction	O
of	O
such	O
acid	O
-	O
and	O
base	O
labile	O
peptide	O
conjugates	O
the	O
allyl	O
ester	O
was	O
developed	O
as	O
C	O
-	O
terminal	O
protecting	O
group	O
.	O

Allyl	O
esters	O
are	O
cleaved	O
selectively	O
and	O
in	O
high	O
yields	O
from	O
lipidated	O
peptides	O
by	O
Pd	O
(	O
0	O
)	O
-	O
mediated	O
allyl	O
transfer	O
to	O
accepting	O
N	O
-	O
or	O
C	O
-	O
nucleophiles	O
like	O
morpholine	O
and	O
N	O
,	O
N	O
'	O
-	O
dimethylbarbituric	O
acid	O
.	O

This	O
protecting	O
group	O
technique	O
formed	O
the	O
key	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
characteristic	O
S	O
-	O
palmitoylated	O
and	O
S	O
-	O
isoprenylated	O
C	O
-	O
terminus	O
of	O
human	O
R	B-PRGE
-	I-PRGE
Ras	I-PRGE
and	O
human	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
proteins	O
,	O
as	O
well	O
as	O
several	O
analogues	O
thereof	O
.	O

Deprotections	O
are	O
so	O
mild	O
that	O
no	O
undesired	O
side	O
reactions	O
of	O
the	O
lipid	O
conjugates	O
are	O
observed	O
.	O

HIV	O
-	O
1	O
Nef	B-PRGE
alters	O
the	O
expression	O
of	O
betaII	O
and	O
epsilon	O
isoforms	O
of	O
protein	O
kinase	O
C	O
and	O
the	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
promoter	O
in	O
human	O
astrocytoma	O
cells	O
.	O

In	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
-	O
infected	O
brain	O
,	O
the	O
virus	O
does	O
not	O
replicate	O
in	O
astrocytes	O
,	O
but	O
a	O
synthesis	O
of	O
viral	O
regulatory	O
proteins	O
occurs	O
in	O
these	O
cells	O
,	O
leading	O
to	O
accumulation	O
of	O
Nef	B-PRGE
.	O

As	O
an	O
approach	O
to	O
understand	O
the	O
effects	O
of	O
Nef	B-PRGE
on	O
astrocyte	O
functional	O
activity	O
,	O
we	O
analyzed	O
whether	O
intracellular	O
Nef	B-PRGE
interferes	O
with	O
the	O
expression	O
and	O
activation	O
of	O
the	O
enzyme	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
which	O
is	O
an	O
important	O
regulator	O
of	O
astroglial	O
functions	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

Astrocytoma	O
clones	O
(	O
U251	O
MG	O
)	O
not	O
expressing	O
Nef	B-PRGE
(	O
Neo	O
)	O
,	O
or	O
expressing	O
wild	O
-	O
type	O
Nef	B-PRGE
(	O
Bru	O
)	O
or	O
nonmyristoylated	O
Nef	B-PRGE
(	O
TH	O
)	O
were	O
used	O
to	O
monitor	O
the	O
expression	O
and	O
activation	O
of	O
10	O
PKC	O
isoforms	O
.	O

The	O
same	O
clones	O
were	O
used	O
to	O
evaluate	O
the	O
effect	O
of	O
Nef	B-PRGE
on	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
after	O
activation	O
of	O
PKC	O
with	O
the	O
phorbol	O
ester	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

PKC	O
intracellular	O
distribution	O
and	O
activation	O
were	O
evaluated	O
by	O
Western	O
blot	O
analysis	O
of	O
cytosolic	O
and	O
membrane	O
fractions	O
of	O
control	O
and	O
Nef	B-PRGE
-	O
expressing	O
clones	O
.	O

PMA	O
-	O
induced	O
LTR	O
activation	O
was	O
analyzed	O
in	O
clones	O
transfected	O
with	O
a	O
plasmid	O
encoding	O
for	O
the	O
CAT	B-PRGE
reporter	O
gene	O
controlled	O
by	O
the	O
LTR	O
promoter	O
,	O
by	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
to	O
measure	O
CAT	B-PRGE
expression	O
.	O

Nef	B-PRGE
selectively	O
downregulated	O
the	O
expression	O
and	O
activation	O
of	O
betaII	B-PRGE
and	O
epsilon	B-PRGE
PKC	I-PRGE
isoforms	O
in	O
astrocytoma	O
cells	O
.	O

Such	O
downregulation	O
correlated	O
with	O
an	O
inhibition	O
of	O
LTR	O
activation	O
after	O
PMA	O
stimulation	O
.	O

The	O
myristoylation	O
of	O
Nef	B-PRGE
and	O
its	O
membrane	O
localization	O
were	O
essential	O
for	O
these	O
effects	O
.	O

These	O
results	O
suggest	O
that	O
Nef	B-PRGE
may	O
alter	O
astrocytic	O
functions	O
by	O
interfering	O
with	O
PKC	O
expression	O
and	O
activation	O
and	O
contribute	O
to	O
the	O
restriction	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
astrocytes	O
.	O

Farnesyl	O
protein	O
transferase	O
:	O
identification	O
of	O
K164	O
alpha	O
and	O
Y300	O
beta	O
as	O
catalytic	O
residues	O
by	O
mutagenesis	O
and	O
kinetic	O
studies	O
.	O

Farnesyl	O
protein	O
transferase	O
(	O
FPT	O
)	O
is	O
an	O
alpha	O
/	O
beta	O
heterodimeric	O
zinc	O
enzyme	O
that	O
catalyzes	O
posttranslational	O
farnesylation	O
of	O
many	O
key	O
cellular	O
regulatory	O
proteins	O
,	O
including	O
oncogenic	O
Ras	O
.	O

On	O
the	O
basis	O
of	O
the	O
recently	O
reported	O
crystal	O
structure	O
of	O
FPT	O
complexed	O
with	O
a	O
CVIM	O
peptide	O
and	O
alpha	O
-	O
hydroxyfarnesylphosphonic	O
acid	O
,	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
FPT	O
active	O
site	O
was	O
performed	O
so	O
key	O
residues	O
that	O
are	O
responsible	O
for	O
substrate	O
binding	O
and	O
catalysis	O
could	O
be	O
identified	O
.	O

Eight	O
single	O
mutants	O
,	O
including	O
K164N	O
alpha	O
,	O
Y166F	O
alpha	O
,	O
Y166A	O
alpha	O
,	O
Y200F	O
alpha	O
,	O
H201A	O
alpha	O
,	O
H248A	O
beta	O
,	O
Y300F	O
beta	O
,	O
and	O
Y361F	O
beta	O
,	O
and	O
a	O
double	O
mutant	O
,	O
H248A	O
beta	O
/	O
Y300F	O
beta	O
,	O
were	O
prepared	O
.	O

Steady	O
-	O
state	O
kinetic	O
analysis	O
along	O
with	O
structural	O
evidence	O
indicated	O
that	O
residues	O
Y200	O
alpha	O
,	O
H201	O
alpha	O
,	O
H248	O
beta	O
,	O
and	O
Y361	O
beta	O
are	O
mainly	O
involved	O
in	O
substrate	O
binding	O
.	O

In	O
addition	O
,	O
biochemical	O
results	O
confirm	O
structural	O
observations	O
which	O
show	O
that	O
residue	O
Y166	O
alpha	O
plays	O
a	O
key	O
role	O
in	O
stabilizing	O
the	O
active	O
site	O
conformation	O
of	O
several	O
FPT	O
residues	O
through	O
cation	O
-	O
pi	O
interactions	O
.	O

Two	O
mutants	O
,	O
K164N	O
alpha	O
and	O
Y300F	O
beta	O
,	O
have	O
moderately	O
decreased	O
catalytic	O
constants	O
(	O
kcat	O
)	O
.	O

Pre	O
-	O
steady	O
-	O
state	O
kinetic	O
analysis	O
of	O
these	O
mutants	O
from	O
rapid	O
quench	O
experiments	O
showed	O
that	O
the	O
chemical	O
step	O
rate	O
constant	O
was	O
reduced	O
by	O
41	O
-	O
and	O
30	O
-	O
fold	O
,	O
respectively	O
.	O

The	O
product	O
-	O
releasing	O
rate	O
for	O
each	O
dropped	O
approximately	O
10	O
-	O
fold	O
.	O

In	O
pH	O
-	O
dependent	O
kinetic	O
studies	O
,	O
Y300F	O
beta	O
was	O
observed	O
to	O
have	O
both	O
acidic	O
and	O
basic	O
pKa	O
values	O
shifted	O
1	O
log	O
unit	O
from	O
those	O
of	O
the	O
wild	O
-	O
type	O
enzyme	O
,	O
consistent	O
with	O
a	O
possible	O
role	O
for	O
Y300	O
beta	O
as	O
an	O
acid	O
-	O
base	O
catalyst	O
.	O

K164N	O
alpha	O
had	O
a	O
pKa	O
shift	O
from	O
6	O
.	O
0	O
to	O
5	O
.	O
3	O
,	O
which	O
suggests	O
it	O
may	O
function	O
as	O
a	O
general	O
acid	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
along	O
with	O
structural	O
evidence	O
,	O
a	O
possible	O
FPT	O
reaction	O
mechanism	O
is	O
proposed	O
with	O
both	O
Y300	O
beta	O
and	O
K164	O
alpha	O
playing	O
key	O
catalytic	O
roles	O
in	O
enhancing	O
the	O
reactivity	O
of	O
the	O
farnesyl	O
diphosphate	O
leaving	O
group	O
.	O

Cloning	O
and	O
characterization	O
of	O
a	O
mammalian	O
N	O
-	O
acetylglucosamine	O
-	O
6	O
-	O
sulfotransferase	O
that	O
is	O
highly	O
restricted	O
to	O
intestinal	O
tissue	O
.	O

Using	O
the	O
sequences	O
of	O
a	O
galactose	O
6	O
-	O
O	O
-	O
sulfotransferase	O
and	O
an	O
N	O
-	O
acetylglucosamine	O
6	O
-	O
O	O
-	O
sulfotransferase	O
as	O
probes	O
in	O
an	O
EST	O
approach	O
,	O
we	O
have	O
identified	O
a	O
highly	O
related	O
cDNA	O
in	O
human	O
and	O
an	O
apparent	O
orthologue	O
in	O
mouse	O
.	O

The	O
cDNAs	O
predict	O
type	O
II	O
transmembrane	O
proteins	O
that	O
constitute	O
new	O
members	O
of	O
the	O
Gal	O
/	O
GalNAc	O
/	O
GlcNAc	O
6	O
-	O
O	O
-	O
sulfotransferase	O
(	O
GST	O
)	O
family	O
.	O

Members	O
of	O
this	O
family	O
have	O
previously	O
been	O
implicated	O
in	O
the	O
sulfation	O
of	O
GAG	O
chains	O
within	O
proteoglycans	O
and	O
the	O
sulfation	O
of	O
O	O
-	O
linked	O
chains	O
within	O
sialomucin	O
ligands	O
for	O
l	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

Expression	O
of	O
the	O
newly	O
identified	O
cDNA	O
in	O
COS	O
cells	O
led	O
to	O
the	O
addition	O
of	O
sulfate	O
to	O
C	O
-	O
6	O
of	O
GlcNAc	O
in	O
an	O
acceptor	O
glycoprotein	O
.	O

The	O
tissue	O
expression	O
of	O
transcripts	O
corresponding	O
to	O
the	O
cDNA	O
was	O
highly	O
restricted	O
to	O
the	O
small	O
intestine	O
and	O
colon	O
in	O
humans	O
.	O

Based	O
on	O
these	O
characteristics	O
,	O
the	O
novel	O
sulfotransferase	O
is	O
designated	O
I	B-PRGE
-	I-PRGE
GlcNAc6ST	I-PRGE
for	O
intestinal	B-PRGE
GlcNAc	I-PRGE
6	I-PRGE
-	I-PRGE
O	I-PRGE
-	I-PRGE
sulfotransferase	I-PRGE
.	O

Inhibition	O
of	O
protein	O
palmitoylation	O
,	O
raft	O
localization	O
,	O
and	O
T	O
cell	O
signaling	O
by	O
2	O
-	O
bromopalmitate	O
and	O
polyunsaturated	O
fatty	O
acids	O
.	O

The	O
ability	O
of	O
the	O
Src	O
family	O
kinases	O
Fyn	B-PRGE
and	O
Lck	B-PRGE
to	O
participate	O
in	O
signaling	O
through	O
the	O
T	O
cell	O
receptor	O
is	O
critically	O
dependent	O
on	O
their	O
dual	O
fatty	O
acylation	O
with	O
myristate	O
and	O
palmitate	O
.	O

Here	O
we	O
identify	O
a	O
palmitate	O
analog	O
,	O
2	O
-	O
bromopalmitate	O
,	O
that	O
effectively	O
blocks	O
Fyn	B-PRGE
fatty	O
acylation	O
in	O
general	O
and	O
palmitoylation	O
in	O
particular	O
.	O

Treatment	O
of	O
COS	O
-	O
1	O
cells	O
with	O
2	O
-	O
bromopalmitate	O
blocked	O
myristoylation	O
and	O
palmitoylation	O
of	O
Fyn	B-PRGE
and	O
inhibited	O
membrane	O
binding	O
and	O
localization	O
of	O
Fyn	B-PRGE
to	O
detergent	O
-	O
resistant	O
membranes	O
(	O
DRMs	O
)	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
2	O
-	O
bromopalmitate	O
blocked	O
localization	O
of	O
the	O
endogenous	O
palmitoylated	O
proteins	O
Fyn	B-PRGE
,	O
Lck	B-PRGE
,	O
and	O
LAT	B-PRGE
to	O
DRMs	O
.	O

This	O
resulted	O
in	O
impaired	O
signaling	O
through	O
the	O
T	O
cell	O
receptor	O
as	O
evidenced	O
by	O
reductions	O
in	O
tyrosine	O
phosphorylation	O
,	O
calcium	O
release	O
,	O
and	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

We	O
also	O
examined	O
the	O
ability	O
of	O
long	O
chain	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
to	O
inhibit	O
protein	O
fatty	O
acylation	O
.	O

PUFAs	O
have	O
been	O
reported	O
to	O
inhibit	O
T	O
cell	O
signaling	O
by	O
excluding	O
Src	O
family	O
kinases	O
from	O
DRMs	O
.	O

Here	O
we	O
show	O
that	O
the	O
PUFAs	O
arachidonic	O
acid	O
and	O
eicosapentaenoic	O
acid	O
inhibit	O
Fyn	B-PRGE
palmitoylation	O
and	O
consequently	O
block	O
Fyn	B-PRGE
localization	O
to	O
DRMs	O
.	O

We	O
propose	O
that	O
inhibition	O
of	O
protein	O
palmitoylation	O
represents	O
a	O
novel	O
mechanism	O
by	O
which	O
PUFAs	O
exert	O
their	O
immunosuppressive	O
effects	O
.	O

Iontophoresis	O
of	O
lysophosphatidic	O
acid	O
into	O
rabbit	O
cornea	O
induces	O
HSV	O
-	O
1	O
reactivation	O
:	O
evidence	O
that	O
neuronal	O
signaling	O
changes	O
after	O
infection	O
.	O

PURPOSE	O
:	O
Lysophosphatidic	O
acid	O
induces	O
neurite	O
retraction	O
;	O
it	O
is	O
also	O
present	O
in	O
tears	O
and	O
aqueous	O
humor	O
.	O

We	O
determined	O
whether	O
lysophosphatidic	O
acid	O
induces	O
HSV	O
-	O
1	O
reactivation	O
in	O
latently	O
infected	O
rabbits	O
and	O
whether	O
the	O
nerve	O
growth	O
associated	O
protein	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
undergoes	O
posttranslational	O
modification	O
during	O
the	O
course	O
of	O
HSV	O
-	O
1	O
infection	O
.	O

METHODS	O
:	O
Rabbits	O
were	O
infected	O
with	O
HSV	O
-	O
1	O
and	O
acute	O
infection	O
was	O
documented	O
by	O
slit	O
lamp	O
examination	O
.	O

Corneas	O
of	O
latently	O
infected	O
rabbits	O
were	O
treated	O
with	O
lysophosphatidic	O
acid	O
or	O
lysophosphatidylserine	O
(	O
structurally	O
similar	O
but	O
lacking	O
biological	O
potency	O
)	O
.	O

For	O
application	O
to	O
the	O
cornea	O
,	O
these	O
compounds	O
were	O
impregnated	O
into	O
collagen	O
shields	O
,	O
applied	O
as	O
topical	O
drops	O
,	O
or	O
iontophoresed	O
.	O

In	O
another	O
experiment	O
,	O
corneas	O
of	O
latently	O
infected	O
rabbits	O
were	O
either	O
untreated	O
or	O
treated	O
iontophoretically	O
with	O
lysophosphatidic	O
acid	O
,	O
lysophosphatidylserine	O
,	O
or	O
saline	O
.	O

Ocular	O
swabs	O
detected	O
shedding	O
of	O
infectious	O
virus	O
.	O

Western	O
blot	O
and	O
immunoprecipitation	O
identified	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
in	O
corneal	O
extracts	O
and	O
densitometry	O
of	O
silver	O
-	O
stained	O
isoelectric	O
focusing	O
gels	O
measured	O
changes	O
in	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
isoform	O
abundance	O
.	O

RESULTS	O
:	O
Iontophoresis	O
of	O
lysophosphatidic	O
acid	O
induced	O
HSV	O
-	O
1	O
shedding	O
more	O
frequently	O
than	O
lysophosphatidylserine	O
or	O
saline	O
.	O

Viral	O
shedding	O
induced	O
by	O
collagen	O
shield	O
and	O
topical	O
drop	O
administration	O
was	O
low	O
and	O
not	O
significantly	O
different	O
for	O
lysophosphatidic	O
acid	O
and	O
lysophosphatidylserine	O
.	O

Five	O
discrete	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
isoforms	O
predominated	O
in	O
the	O
IEF	O
gels	O
.	O

Most	O
abundant	O
were	O
the	O
pI	O
4	O
.	O
7	O
band	O
in	O
uninfected	O
cornea	O
and	O
the	O
pI	O
5	O
.	O
05	O
band	O
in	O
latently	O
-	O
infected	O
cornea	O
.	O

Compared	O
to	O
latently	O
-	O
infected	O
cornea	O
,	O
there	O
was	O
no	O
significant	O
change	O
in	O
isoform	O
abundance	O
1	O
h	O
after	O
lysophosphatidic	O
acid	O
iontophoresis	O
,	O
but	O
24	O
and	O
72	O
h	O
later	O
,	O
the	O
pI	O
5	O
.	O

05	O
band	O
was	O
diminished	O
.	O

CONCLUSIONS	O
:	O
Lysophosphatidic	O
acid	O
can	O
induce	O
HSV	O
-	O
1	O
reactivation	O
and	O
changes	O
in	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
pI	O
suggest	O
that	O
posttranslational	O
modifications	O
,	O
possibly	O
related	O
to	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
,	O
are	O
occurring	O
during	O
HSV	O
-	O
1	O
latency	O
and	O
after	O
LPA	O
is	O
iontophoretically	O
applied	O
to	O
the	O
cornea	O
.	O

How	O
lysophosphatidic	O
acid	O
-	O
induced	O
signaling	O
,	O
HSV	O
-	O
1	O
reactivation	O
,	O
and	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
pI	O
are	O
related	O
remains	O
to	O
be	O
determined	O
.	O

Nedd8	B-PRGE
modification	O
of	O
cul	B-PRGE
-	I-PRGE
1	I-PRGE
activates	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
-	O
dependent	O
ubiquitination	O
of	O
IkappaBalpha	B-PRGE
.	O

Regulation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
through	O
phosphorylation	O
-	O
dependent	O
ubiquitination	O
of	O
IkappaBalpha	B-PRGE
,	O
which	O
is	O
degraded	O
by	O
the	O
26S	O
proteasome	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
ubiquitination	O
of	O
IkappaBalpha	B-PRGE
is	O
carried	O
out	O
by	O
a	O
ubiquitin	B-PRGE
-	O
ligase	O
enzyme	O
complex	O
called	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
.	O

Here	O
we	O
show	O
that	O
Nedd8	B-PRGE
modification	O
of	O
the	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
component	O
of	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
is	O
important	O
for	O
function	O
of	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
in	O
ubiquitination	O
of	O
IkappaBalpha	B-PRGE
.	O

In	O
cells	O
,	O
Nedd8	B-PRGE
-	O
conjugated	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
complexed	O
with	O
two	O
substrates	O
of	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
,	O
phosphorylated	O
IkappaBalpha	B-PRGE
and	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
,	O
indicating	O
that	O
Nedd8	B-PRGE
-	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
conjugates	O
are	O
part	O
of	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
in	O
vivo	O
.	O

Although	O
only	O
a	O
minute	O
fraction	O
of	O
total	O
cellular	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
modified	O
by	O
Nedd8	B-PRGE
,	O
the	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
associated	O
with	O
ectopically	O
expressed	O
betaTrCP	B-PRGE
was	O
highly	O
enriched	O
for	O
the	O
Nedd8	B-PRGE
-	O
conjugated	O
form	O
.	O

Moreover	O
,	O
optimal	O
ubiquitination	O
of	O
IkappaBalpha	B-PRGE
required	O
Nedd8	B-PRGE
and	O
the	O
Nedd8	B-PRGE
-	O
conjugating	O
enzyme	O
,	O
Ubc12	B-PRGE
.	O

The	O
site	O
of	O
Nedd8	B-PRGE
ligation	O
to	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
essential	O
,	O
as	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
containing	O
a	O
K720R	O
mutant	O
of	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
only	O
weakly	O
supported	O
IkappaBalpha	B-PRGE
ubiquitination	O
compared	O
to	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
containing	O
WT	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
suggesting	O
that	O
the	O
Nedd8	B-PRGE
ligation	O
of	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
affects	O
the	O
ubiquitination	O
activity	O
of	O
SCF	O
(	O
beta	B-PRGE
(	I-PRGE
TrCP	I-PRGE
)	I-PRGE
)	O
.	O

These	O
observations	O
provide	O
a	O
functional	O
link	O
between	O
the	O
highly	O
related	O
ubiquitin	B-PRGE
and	O
Nedd8	B-PRGE
pathways	O
of	O
protein	O
modification	O
and	O
show	O
how	O
they	O
operate	O
together	O
to	O
selectively	O
target	O
the	O
signal	O
-	O
dependent	O
degradation	O
of	O
IkappaBalpha	B-PRGE
.	O

v	B-PRGE
-	I-PRGE
Src	I-PRGE
suppresses	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
via	O
the	O
Ras	O
-	O
MAP	O
kinase	O
pathway	O
to	O
promote	O
the	O
oncogenic	O
growth	O
of	O
cells	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
cell	O
transformation	O
by	O
v	B-PRGE
-	I-PRGE
src	I-PRGE
on	O
the	O
expression	O
and	O
tyrosine	O
phosphorylation	O
of	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
putative	O
docking	O
protein	O
for	O
SHP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
SHP	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

We	O
found	O
that	O
transformation	O
by	O
v	B-PRGE
-	I-PRGE
src	I-PRGE
virtually	O
inhibited	O
the	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
at	O
mRNA	O
level	O
.	O

While	O
nontransforming	O
Src	O
kinases	O
including	O
c	B-PRGE
-	I-PRGE
Src	I-PRGE
,	O
nonmyristoylated	O
forms	O
of	O
v	B-PRGE
-	I-PRGE
Src	I-PRGE
had	O
no	O
inhibitory	O
effect	O
on	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
,	O
transforming	O
Src	O
kinases	O
including	O
wild	O
-	O
type	O
v	B-PRGE
-	I-PRGE
Src	I-PRGE
and	O
chimeric	O
mutant	O
of	O
c	B-PRGE
-	I-PRGE
Src	I-PRGE
bearing	O
v	B-PRGE
-	I-PRGE
Src	I-PRGE
SH3	O
substantially	O
suppressed	O
the	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

In	O
cells	O
expressing	O
temperature	O
sensitive	O
mutant	O
of	O
v	B-PRGE
-	I-PRGE
Src	I-PRGE
,	O
suppression	O
of	O
the	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
was	O
temperature	O
-	O
dependent	O
.	O

In	O
contrast	O
,	O
tyrosine	O
phosphorylation	O
of	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
rather	O
activated	O
in	O
cells	O
expressing	O
c	B-PRGE
-	I-PRGE
Src	I-PRGE
or	O
nonmyristoylated	O
forms	O
of	O
v	B-PRGE
-	I-PRGE
Src	I-PRGE
.	O

SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
SR3Y1	O
was	O
restored	O
by	O
treatment	O
with	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	O
kinase	O
,	O
or	O
by	O
the	O
expression	O
of	O
dominant	O
negative	O
form	O
of	O
Ras	O
.	O

Contrary	O
,	O
active	O
form	O
of	O
Mekl	B-PRGE
markedly	O
suppressed	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

Finally	O
,	O
overexpression	O
of	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
SR3Y1	O
led	O
to	O
the	O
drastic	O
reduction	O
of	O
anchorage	O
independent	O
growth	O
of	O
the	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
SHPS	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
is	O
a	O
pivotal	O
event	O
for	O
cell	O
transformation	O
by	O
v	B-PRGE
-	I-PRGE
src	I-PRGE
,	O
and	O
the	O
Ras	O
-	O
MAP	O
kinase	O
cascade	O
plays	O
a	O
critical	O
role	O
in	O
the	O
suppression	O
.	O

A	O
Nedd8	B-PRGE
conjugation	O
pathway	O
is	O
essential	O
for	O
proteolytic	O
targeting	O
of	O
p27Kip1	B-PRGE
by	O
ubiquitination	O
.	O

Temporal	O
control	O
of	O
p27	B-PRGE
(	I-PRGE
Kip1	I-PRGE
)	I-PRGE
(	O
p27	B-PRGE
)	O
degradation	O
imposes	O
periodicity	O
in	O
its	O
activity	O
during	O
cell	O
cycle	O
progression	O
and	O
its	O
accumulation	O
during	O
cell	O
cycle	O
exit	O
.	O

Degradation	O
of	O
p27	B-PRGE
is	O
initiated	O
by	O
phosphorylation	O
of	O
p27	B-PRGE
at	O
Thr	O
-	O
187	O
,	O
which	O
marks	O
the	O
protein	O
for	O
ubiquitination	O
by	O
SCF	O
(	O
Skp2	B-PRGE
)	O
and	O
subsequent	O
proteolysis	O
by	O
the	O
26S	O
proteasome	O
.	O

Here	O
we	O
show	O
that	O
the	O
p27	B-PRGE
ubiquitination	O
activity	O
in	O
cell	O
extracts	O
depends	O
on	O
the	O
presence	O
of	O
the	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
Nedd8	B-PRGE
and	O
enzymes	O
that	O
catalyze	O
Nedd8	B-PRGE
conjugation	O
to	O
proteins	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
reconstitution	O
of	O
the	O
p27	B-PRGE
ubiquitination	O
activity	O
of	O
recombinant	O
SCF	O
(	O
Skp2	B-PRGE
)	O
also	O
requires	O
Nedd8	B-PRGE
conjugation	O
pathway	O
components	O
.	O

Inactivation	O
of	O
the	O
Nedd8	B-PRGE
conjugation	O
pathway	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
the	O
Nedd8	B-PRGE
-	O
conjugating	O
enzyme	O
Nce1	B-PRGE
/	O
Ubc12	B-PRGE
blocks	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
p27	B-PRGE
in	O
cell	O
extracts	O
.	O

Consistent	O
with	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
Nedd8	B-PRGE
is	O
expressed	O
in	O
proliferating	O
cells	O
and	O
is	O
itself	O
down	O
-	O
regulated	O
upon	O
cellular	O
differentiation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Nedd8	B-PRGE
conjugation	O
pathway	O
may	O
regulate	O
the	O
turnover	O
of	O
p27	B-PRGE
(	I-PRGE
Kip1	I-PRGE
)	I-PRGE
,	O
independently	O
of	O
p27	B-PRGE
phosphorylation	O
,	O
and	O
further	O
establishes	O
the	O
identity	O
of	O
protein	O
components	O
involved	O
in	O
p27	B-PRGE
ubiquitination	O
.	O

Finally	O
,	O
these	O
findings	O
provide	O
a	O
direct	O
demonstration	O
of	O
a	O
function	O
for	O
Nedd8	B-PRGE
in	O
a	O
biological	O
process	O
.	O

Isoprenylation	O
/	O
methylation	O
and	O
transducin	O
function	O
.	O

Freshly	O
prepared	O
proteolyzed	O
(	O
deprenylated	O
)	O
T	O
beta	O
gamma	O
and	O
material	O
isolated	O
from	O
retina	O
are	O
inert	O
with	O
respect	O
to	O
activating	O
T	O
alpha	O
in	O
the	O
presence	O
of	O
R	O
*	O
in	O
detergent	O
and	O
in	O
disk	O
membranes	O
.	O

In	O
addition	O
,	O
proteolyzed	O
T	O
beta	O
gamma	O
is	O
also	O
incapable	O
of	O
supporting	O
the	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
ribosylation	O
of	O
T	O
alpha	O
-	O
GDP	O
.	O

These	O
experiments	O
show	O
that	O
isoprenylation	O
/	O
methylation	O
is	O
essential	O
for	O
the	O
fruitful	O
interactions	O
between	O
T	O
alpha	O
and	O
T	O
beta	O
gamma	O
at	O
the	O
membrane	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
support	O
GTP	O
-	O
for	O
-	O
GDP	O
exchange	O
catalyzed	O
by	O
R	O
*	O
,	O
demethylated	O
T	O
beta	O
gamma	O
proved	O
to	O
be	O
approximately	O
50	O
%	O
as	O
active	O
as	O
methylated	O
T	O
beta	O
gamma	O
in	O
photoreceptor	O
disk	O
membranes	O
(	O
Fig	O
.	O
3	O
)	O
and	O
in	O
reconstituted	O
liposomes	O
containing	O
rhodopsin	B-PRGE
.	O

In	O
detergent	O
,	O
no	O
difference	O
was	O
observed	O
between	O
methylated	O
and	O
demethylated	O
T	O
beta	O
gamma	O
,	O
suggesting	O
no	O
role	O
at	O
all	O
for	O
the	O
methyl	O
group	O
in	O
functional	O
interactions	O
between	O
T	O
alpha	O
,	O
T	O
beta	O
gamma	O
,	O
and	O
R	O
*	O
.	O

The	O
twofold	O
activity	O
difference	O
observed	O
in	O
membranes	O
can	O
be	O
accounted	O
for	O
by	O
the	O
twofold	O
lessened	O
affinity	O
of	O
the	O
demethylated	O
T	O
beta	O
gamma	O
,	O
compared	O
with	O
its	O
methylated	O
counterpart	O
,	O
for	O
membranes	O
in	O
the	O
presence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
a	O
substantially	O
larger	O
difference	O
(	O
>	O
10	O
-	O
fold	O
)	O
in	O
the	O
relative	O
binding	O
of	O
methylated	O
versus	O
demethylated	O
T	O
beta	O
gamma	O
to	O
membranes	O
is	O
observed	O
in	O
the	O
absence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
.	O

However	O
,	O
R	O
*	O
has	O
a	O
substantial	O
affinity	O
for	O
T	O
alpha	O
beta	O
gamma	O
,	O
and	O
the	O
influence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
greatly	O
reduces	O
any	O
differences	O
resulting	O
from	O
the	O
presence	O
or	O
absence	O
of	O
a	O
methyl	O
group	O
on	O
T	O
beta	O
gamma	O
.	O

The	O
results	O
from	O
studies	O
of	O
demethylated	O
T	O
beta	O
gamma	O
demonstrate	O
that	O
specific	O
lipid	O
-	O
receptor	O
interactions	O
are	O
unlikely	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
rhodopsin	B-PRGE
-	O
transducin	O
system	O
,	O
and	O
further	O
show	O
that	O
the	O
effect	O
of	O
methylation	O
is	O
probably	O
due	O
to	O
the	O
increased	O
hydrophobicity	O
of	O
methylated	O
T	O
beta	O
gamma	O
versus	O
its	O
unmethylated	O
counterpart	O
.	O

These	O
studies	O
are	O
,	O
of	O
course	O
,	O
relevant	O
to	O
heterotrimeric	O
G	O
proteins	O
,	O
and	O
specifically	O
to	O
the	O
interactions	O
of	O
receptor	O
(	O
R	O
*	O
)	O
with	O
T	O
alpha	O
and	O
T	O
beta	O
gamma	O
.	O

If	O
a	O
hydrophobic	O
lipid	O
-	O
lipid	O
mechanism	O
is	O
operative	O
,	O
the	O
state	O
of	O
methylation	O
would	O
be	O
expected	O
to	O
have	O
a	O
more	O
profound	O
effect	O
on	O
the	O
membrane	O
-	O
associative	O
properties	O
of	O
farnesylated	O
proteins	O
,	O
but	O
not	O
on	O
those	O
of	O
geranylgeranylated	O
proteins	O
.	O

The	O
increased	O
hydrophobicity	O
of	O
the	O
C20	O
geranylgeranyl	O
group	O
relative	O
to	O
the	O
C15	O
farnesyl	O
group	O
will	O
compensate	O
for	O
the	O
loss	O
of	O
the	O
methyl	O
substituent	O
.	O

The	O
results	O
obtained	O
in	O
the	O
transducin	O
-	O
rhodopsin	B-PRGE
system	O
can	O
be	O
contrasted	O
with	O
the	O
effect	O
of	O
gamma	O
-	O
subunit	O
methylation	O
on	O
effector	O
enzyme	O
activation	O
.	O

In	O
the	O
case	O
of	O
the	O
geranylgeranylated	O
beta	B-PRGE
1	I-PRGE
gamma	B-PRGE
2	I-PRGE
,	O
methylation	O
proved	O
to	O
have	O
only	O
a	O
small	O
effect	O
on	O
PIPLC	O
beta	O
activation	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

An	O
approximately	O
25	O
%	O
diminution	O
in	O
efficacy	O
,	O
but	O
not	O
potency	O
,	O
was	O
observed	O
for	O
the	O
demethylated	O
geranylgeranylated	O
beta	B-PRGE
1	I-PRGE
gamma	B-PRGE
2	I-PRGE
versus	O
its	O
methylated	O
counterpart	O
.	O

This	O
again	O
shows	O
that	O
specific	O
lipid	O
-	O
protein	O
interactions	O
are	O
unimportant	O
.	O

The	O
effect	O
of	O
methylation	O
on	O
membrane	O
binding	O
would	O
be	O
expected	O
to	O
be	O
small	O
,	O
given	O
that	O
beta	B-PRGE
1	I-PRGE
gamma	B-PRGE
2	I-PRGE
is	O
geranylgeranylated	O
.	O

It	O
is	O
of	O
interest	O
to	O
compare	O
these	O
results	O
with	O
those	O
found	O
with	O
methylated	O
and	O
unmethylated	O
T	O
beta	O
gamma	O
as	O
activators	O
of	O
PIPLC	O
beta	O
.	O

In	O
this	O
instance	O
there	O
was	O
a	O
large	O
effect	O
noted	O
,	O
with	O
methylated	O
T	O
beta	O
gamma	O
being	O
at	O
least	O
10	O
-	O
fold	O
more	O
potent	O
than	O
its	O
unmethylated	O
counterpart	O
with	O
respect	O
to	O
activating	O
either	O
enzyme	O
(	O
Fig	O
.	O
4A	O
)	O
.	O

This	O
result	O
is	O
readily	O
understandable	O
in	O
light	O
of	O
the	O
role	O
of	O
methylation	O
in	O
selectively	O
enhancing	O
hydrophobicity	O
of	O
farnesylated	O
proteins	O
as	O
opposed	O
to	O
geranyl	O
-	O
geranylated	O
proteins	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
the	O
activation	O
of	O
PI3K	O
,	O
further	O
strengthening	O
the	O
conclusion	O
that	O
it	O
is	O
lipid	O
-	O
lipid	O
interactions	O
that	O
direct	O
beta	O
gamma	O
subunit	O
membrane	O
association	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
)	O

A	O
dominant	O
-	O
negative	O
UBC12	B-PRGE
mutant	O
sequesters	O
NEDD8	B-PRGE
and	O
inhibits	O
NEDD8	B-PRGE
conjugation	O
in	O
vivo	O
.	O

NEDD8	B-PRGE
,	O
a	O
novel	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
,	O
has	O
been	O
shown	O
to	O
conjugate	O
to	O
proteins	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitination	O
and	O
sentrinization	O
.	O

Recently	O
,	O
human	O
UBC12	B-PRGE
was	O
identified	O
as	O
a	O
putative	O
NEDD8	B-PRGE
conjugation	O
enzyme	O
(	O
E2	O
)	O
.	O

While	O
investigating	O
the	O
in	O
vivo	O
function	O
of	O
UBC12	B-PRGE
,	O
we	O
found	O
that	O
the	O
point	O
mutant	O
,	O
UBC12	B-PRGE
(	O
C111S	O
)	O
,	O
showed	O
a	O
dominant	O
-	O
negative	O
effect	O
on	O
NEDD8	B-PRGE
conjugation	O
.	O

This	O
mutant	O
,	O
with	O
a	O
single	O
Cys	O
-	O
to	O
-	O
Ser	O
substitution	O
at	O
the	O
conserved	O
Cys	O
residue	O
in	O
the	O
E2	O
family	O
,	O
could	O
specifically	O
inhibit	O
NEDD8	B-PRGE
conjugation	O
.	O

We	O
observed	O
the	O
dominant	O
-	O
negative	O
effect	O
on	O
NEDD8	B-PRGE
conjugation	O
to	O
substrates	O
,	O
including	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
cullin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
Cul	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
DeltaN	O
)	O
,	O
full	O
-	O
length	O
cullin	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
also	O
other	O
uncharacterized	O
target	O
proteins	O
.	O

Interestingly	O
,	O
UBC12	B-PRGE
(	O
C111S	O
)	O
formed	O
a	O
heterodimeric	O
conjugate	O
with	O
NEDD8	B-PRGE
.	O

This	O
conjugate	O
was	O
stable	O
under	O
stringent	O
conditions	O
,	O
including	O
6	O
m	O
guanidine	O
HCl	O
,	O
8	O
m	O
urea	O
,	O
2	O
%	O
SDS	O
,	O
or	O
5	O
%	O
beta	O
-	O
mercaptoethanol	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
UBC12	B-PRGE
(	O
C111S	O
)	O
sequesters	O
the	O
NEDD8	B-PRGE
monomer	O
by	O
forming	O
a	O
UBC12	B-PRGE
(	O
C111S	O
)	O
-	O
NEDD8	B-PRGE
conjugate	O
and	O
,	O
in	O
turn	O
,	O
inhibits	O
the	O
subsequent	O
transfer	O
of	O
NEDD8	B-PRGE
to	O
its	O
targets	O
.	O

To	O
examine	O
the	O
biological	O
role	O
of	O
NEDD8	B-PRGE
conjugation	O
,	O
this	O
dominant	O
-	O
negative	O
form	O
of	O
UBC12	B-PRGE
was	O
applied	O
to	O
a	O
cell	O
growth	O
assay	O
.	O

Overexpression	O
of	O
UBC12	B-PRGE
(	O
C111S	O
)	O
led	O
to	O
inhibition	O
of	O
growth	O
in	O
U2OS	O
and	O
HEK293	O
cells	O
.	O

Thus	O
,	O
this	O
dominant	O
-	O
negative	O
form	O
of	O
UBC12	B-PRGE
could	O
be	O
useful	O
in	O
defining	O
the	O
role	O
of	O
NEDD8	B-PRGE
modification	O
in	O
other	O
biological	O
systems	O
.	O

Heterogeneity	O
of	O
cardiac	O
rat	O
and	O
human	O
elongation	B-PRGE
factor	I-PRGE
2	I-PRGE
.	O

Elongation	B-PRGE
factor	I-PRGE
2	I-PRGE
(	O
EF	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
catalyses	O
the	O
last	O
step	O
of	O
the	O
elongation	O
cycle	O
,	O
translocation	O
,	O
in	O
the	O
course	O
of	O
protein	O
biosynthesis	O
.	O

A	O
system	O
for	O
analyzing	O
post	O
-	O
translational	O
modifications	O
of	O
EF	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
which	O
is	O
a	O
single	O
polypeptide	O
of	O
857	O
amino	O
acids	O
,	O
is	O
reported	O
and	O
its	O
application	O
to	O
cytosolic	O
extracts	O
of	O
cultured	O
neonatal	O
rat	O
heart	O
myocytes	O
,	O
neonatal	O
and	O
adult	O
rat	O
cardiac	O
tissue	O
,	O
and	O
extracts	O
of	O
human	O
left	O
ventricular	O
myocardium	O
is	O
described	O
.	O

Comparing	O
different	O
pH	O
ranges	O
in	O
immobilized	O
pH	O
gradient	O
-	O
isoelectric	O
focusing	O
(	O
IPG	O
-	O
IEF	O
)	O
,	O
a	O
range	O
of	O
pH	O
3	O
-	O
10	O
and	O
4	O
-	O
9	O
resulted	O
in	O
a	O
highly	O
defined	O
and	O
reproducible	O
resolution	O
of	O
six	O
different	O
EF	B-PRGE
-	I-PRGE
2	I-PRGE
variants	O
of	O
all	O
extracts	O
in	O
the	O
first	O
dimension	O
.	O

These	O
six	O
variants	O
were	O
detected	O
by	O
the	O
"	O
imaging	O
plate	O
"	O
(	O
phosphor	O
radiation	O
image	O
sensor	O
)	O
after	O
specific	O
labeling	O
with	O
Pseudomonas	O
exotoxin	B-PRGE
A	I-PRGE
catalyzed	O
[	O
32P	O
]	O
ADP	O
-	O
ribosylation	O
.	O

This	O
finding	O
could	O
be	O
confirmed	O
in	O
Western	O
blot	O
analysis	O
with	O
a	O
specific	O
polyclonal	O
rabbit	O
antibody	O
.	O

Using	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
2	O
-	O
D	O
-	O
PAGE	O
)	O
,	O
five	O
to	O
six	O
EF	B-PRGE
-	I-PRGE
2	I-PRGE
variants	O
could	O
be	O
demonstrated	O
in	O
all	O
extracts	O
.	O

By	O
application	O
of	O
a	O
second	O
IPG	O
indicator	O
strip	O
to	O
the	O
2	O
-	O
D	O
gel	O
,	O
they	O
could	O
be	O
aligned	O
with	O
corresponding	O
spots	O
in	O
a	O
silver	O
-	O
stained	O
2	O
-	O
D	O
separation	O
of	O
human	O
myocardial	O
tissue	O
,	O
revealing	O
that	O
the	O
EF	B-PRGE
-	I-PRGE
2	I-PRGE
variants	O
belong	O
to	O
the	O
group	O
of	O
low	O
-	O
abundance	O
proteins	O
.	O

Heteronuclear	O
NMR	O
studies	O
of	O
the	O
specificity	O
of	O
the	O
post	O
-	O
translational	O
modification	O
of	O
biotinyl	O
domains	O
by	O
biotinyl	B-PRGE
protein	I-PRGE
ligase	I-PRGE
.	O

The	O
lipoyl	O
domains	O
of	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
multienzyme	O
complexes	O
and	O
the	O
biotinyl	O
domains	O
of	O
biotin	O
-	O
dependent	O
enzymes	O
have	O
homologous	O
structures	O
,	O
but	O
the	O
target	O
lysine	O
residue	O
in	O
each	O
domain	O
is	O
correctly	O
selected	O
for	O
posttranslational	O
modification	O
by	O
lipoyl	B-PRGE
protein	I-PRGE
ligase	I-PRGE
and	O
biotinyl	B-PRGE
protein	I-PRGE
ligase	I-PRGE
,	O
respectively	O
.	O

We	O
have	O
applied	O
two	O
-	O
dimensional	O
heteronuclear	O
NMR	O
spectroscopy	O
to	O
investigate	O
the	O
interaction	O
between	O
the	O
apo	O
form	O
of	O
the	O
biotinyl	O
domain	O
of	O
the	O
biotin	B-PRGE
carboxyl	I-PRGE
carrier	I-PRGE
protein	I-PRGE
of	I-PRGE
acetyl	I-PRGE
-	I-PRGE
CoA	I-PRGE
carboxylase	I-PRGE
and	O
the	O
biotinyl	B-PRGE
protein	I-PRGE
ligase	I-PRGE
(	O
BPL	B-PRGE
)	O
from	O
Escherichia	O
coli	O
.	O

Heteronuclear	O
multiple	O
quantum	O
coherence	O
NMR	O
spectra	O
of	O
the	O
15N	O
-	O
labelled	O
biotinyl	O
domain	O
were	O
recorded	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
ligase	O
and	O
backbone	O
amide	O
1H	O
and	O
15N	O
chemical	O
shifts	O
were	O
evaluated	O
.	O

Small	O
,	O
but	O
significant	O
,	O
changes	O
in	O
chemical	O
shift	O
were	O
found	O
in	O
two	O
regions	O
,	O
including	O
the	O
tight	O
beta	O
-	O
turn	O
that	O
houses	O
the	O
lysine	O
residue	O
targetted	O
for	O
biotinylation	O
,	O
and	O
the	O
beta	O
-	O
strand	O
2	O
and	O
the	O
loop	O
that	O
precedes	O
it	O
in	O
the	O
domain	O
.	O

When	O
compared	O
with	O
the	O
three	O
-	O
dimensional	O
structure	O
,	O
sequence	O
alignments	O
of	O
other	O
biotinyl	O
and	O
lipoyl	O
domains	O
,	O
and	O
mutagenesis	O
data	O
,	O
these	O
results	O
give	O
a	O
clear	O
indication	O
of	O
how	O
the	O
biotinyl	O
domain	O
is	O
both	O
recognised	O
by	O
BPL	B-PRGE
and	O
distinguished	O
from	O
the	O
structurally	O
related	O
lipoyl	O
domain	O
to	O
ensure	O
correct	O
posttranslational	O
modification	O
.	O

Alternative	O
O	O
-	O
glycosylation	O
/	O
O	O
-	O
phosphorylation	O
of	O
the	O
murine	O
estrogen	B-PRGE
receptor	I-PRGE
beta	I-PRGE
.	O

Estrogen	B-PRGE
receptor	I-PRGE
beta	I-PRGE
,	O
a	O
homologue	O
to	O
estrogen	B-PRGE
receptor	I-PRGE
alpha	I-PRGE
,	O
is	O
a	O
new	O
member	O
of	O
the	O
steroid	O
hormone	O
receptor	O
family	O
.	O

Recently	O
,	O
we	O
documented	O
that	O
estrogen	B-PRGE
receptor	I-PRGE
alpha	I-PRGE
,	O
like	O
other	O
transcription	O
factors	O
,	O
is	O
modified	O
by	O
O	O
-	O
linked	O
N	O
-	O
acetylglucosamine	O
(	O
O	O
-	O
GlcNAc	O
)	O
,	O
a	O
ubiquitous	O
transitory	O
posttranslational	O
modification	O
on	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
.	O

Here	O
,	O
we	O
report	O
that	O
estrogen	B-PRGE
receptor	I-PRGE
beta	I-PRGE
is	O
alternatively	O
modified	O
by	O
either	O
O	O
-	O
GlcNAc	O
or	O
O	O
-	O
phosphate	O
.	O

Lectin	O
chromatography	O
of	O
in	O
vitro	O
translated	O
protein	O
first	O
suggested	O
that	O
murine	O
estrogen	B-PRGE
receptor	I-PRGE
beta	I-PRGE
(	O
mER	B-PRGE
-	I-PRGE
beta	I-PRGE
)	O
is	O
O	O
-	O
GlcNAcylated	O
.	O

Structural	O
characterization	O
of	O
the	O
carbohydrate	O
moieties	O
on	O
mER	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
overexpressed	O
in	O
insect	O
Sf9	O
cells	O
,	O
confirmed	O
the	O
presence	O
of	O
O	O
-	O
GlcNAc	O
.	O

mER	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
overexpressed	O
in	O
mammalian	O
cells	O
,	O
is	O
also	O
O	O
-	O
GlcNAcylated	O
.	O

The	O
major	O
site	O
of	O
O	O
-	O
GlcNAc	O
on	O
mER	B-PRGE
-	I-PRGE
beta	I-PRGE
from	O
Sf9	O
cells	O
is	O
Ser	O
(	O
16	O
)	O
near	O
the	O
N	O
-	O
terminus	O
.	O

Concomitant	O
analyses	O
also	O
documented	O
the	O
O	O
-	O
phosphorylation	O
of	O
mER	B-PRGE
-	I-PRGE
beta	I-PRGE
at	O
Ser	O
(	O
16	O
)	O
.	O

MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
showed	O
alternative	O
occupancy	O
of	O
this	O
locus	O
by	O
these	O
two	O
abundant	O
and	O
dynamic	O
posttranslational	O
modifications	O
.	O

The	O
localization	O
of	O
a	O
major	O
O	O
-	O
GlcNAc	O
/	O
O	O
-	O
phosphate	O
site	O
in	O
proximity	O
of	O
the	O
transactivation	O
domain	O
and	O
as	O
part	O
of	O
a	O
PEST	O
region	O
(	O
target	O
sequences	O
for	O
rapid	O
protein	O
degradation	O
)	O
on	O
mER	B-PRGE
-	I-PRGE
beta	I-PRGE
suggests	O
that	O
these	O
modifications	O
may	O
play	O
a	O
role	O
in	O
regulating	O
estrogen	B-PRGE
receptor	I-PRGE
beta	I-PRGE
transactivation	O
and	O
turnover	O
.	O

Inhibitors	O
of	O
prenylation	O
of	O
Ras	O
and	O
other	O
G	O
-	O
proteins	O
and	O
their	O
application	O
as	O
therapeutics	O
.	O

Anchoring	O
of	O
small	O
G	O
-	O
proteins	O
to	O
cellular	O
membranes	O
via	O
a	O
covalently	O
bound	O
lipophylic	O
prenyl	O
group	O
is	O
essential	O
for	O
the	O
functioning	O
of	O
these	O
proteins	O
.	O

For	O
example	O
,	O
the	O
farnesylation	O
of	O
Ras	O
by	O
the	O
action	O
of	O
the	O
enzyme	O
protein	O
:	O
farnesyl	O
transferase	O
(	O
PFT	O
)	O
is	O
pivotal	O
for	O
its	O
signalling	O
function	O
in	O
cell	O
growth	O
and	O
differentiation	O
.	O

The	O
development	O
of	O
inhibitors	O
of	O
PFT	O
was	O
triggered	O
by	O
the	O
role	O
of	O
mutated	O
Ras	O
in	O
certain	O
types	O
of	O
cancer	O
and	O
by	O
the	O
observation	O
that	O
non	O
-	O
farnesylated	O
Ras	O
is	O
inactive	O
.	O

Besides	O
the	O
screening	O
of	O
existing	O
compounds	O
for	O
PFT	O
inhibition	O
,	O
rational	O
drug	O
design	O
has	O
also	O
led	O
to	O
new	O
inhibitors	O
.	O

Our	O
research	O
is	O
in	O
the	O
field	O
of	O
atherosclerosis	O
and	O
concerns	O
the	O
development	O
of	O
inhibitors	O
of	O
the	O
growth	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

The	O
latter	O
process	O
gives	O
rise	O
to	O
reocclusion	O
of	O
the	O
coronary	O
artery	O
(	O
restenosis	O
)	O
after	O
balloon	O
angioplasty	O
.	O

We	O
and	O
others	O
have	O
developed	O
several	O
analogues	O
of	O
the	O
two	O
substrates	O
of	O
PFT	O
,	O
i	O
.	O
e	O
.	O
farnesyl	O
pyrophosphate	O
(	O
FPP	O
)	O
and	O
the	O
so	O
-	O
called	O
CAAX	O
peptide	O
consensus	O
sequence	O
,	O
which	O
were	O
tested	O
in	O
vitro	O
for	O
the	O
inhibition	O
of	O
PFT	O
and	O
of	O
other	O
enzymes	O
involved	O
in	O
protein	O
prenylation	O
,	O
such	O
as	O
protein	O
:	O
geranylgeranyl	O
transferase	O
-	O
1	O
(	O
PGGT	O
-	O
1	O
)	O
.	O

The	O
FPP	O
analogue	O
TR006	O
,	O
a	O
strong	O
inhibitor	O
of	O
PFT	O
(	O
IC	O
(	O
50	O
)	O
of	O
67	O
nM	O
)	O
,	O
blocked	O
the	O
proliferation	O
of	O
cultured	O
human	O
smooth	O
muscle	O
cells	O
and	O
inhibited	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
-	O
induced	O
DNA	O
synthesis	O
.	O

Similar	O
but	O
more	O
highly	O
charged	O
compounds	O
failed	O
in	O
this	O
respect	O
,	O
probably	O
because	O
of	O
an	O
impaired	O
uptake	O
in	O
the	O
cells	O
.	O

Less	O
charged	O
derivatives	O
were	O
designed	O
to	O
circumvent	O
this	O
problem	O
.	O

The	O
effect	O
on	O
the	O
GF	O
-	O
induced	O
activation	O
of	O
intermediates	O
in	O
signal	O
transduction	O
pathways	O
was	O
investigated	O
in	O
order	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
action	O
within	O
the	O
cells	O
.	O

TR006	O
decreased	O
the	O
bFGF	B-PRGE
activation	O
of	O
extracellular	B-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
kinase	I-PRGE
1	I-PRGE
(	O
ERK1	B-PRGE
)	O
,	O
suggesting	O
its	O
involvement	O
in	O
inhibiting	O
Ras	O
activity	O
.	O

Although	O
other	O
analogues	O
inhibited	O
DNA	O
synthesis	O
,	O
they	O
affected	O
neither	O
ERK1	B-PRGE
activation	O
nor	O
p38	B-PRGE
/	O
stress	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
2	I-PRGE
or	O
Jun	B-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
1	I-PRGE
activation	O
.	O

Since	O
some	O
of	O
these	O
compounds	O
were	O
also	O
shown	O
to	O
be	O
inhibitors	O
of	O
in	O
vitro	O
PGGT	O
-	O
1	O
activity	O
,	O
the	O
geranylgeranylation	O
of	O
other	O
G	O
-	O
proteins	O
may	O
be	O
decreased	O
by	O
these	O
compounds	O
.	O

Rho	O
seems	O
to	O
be	O
a	O
good	O
candidate	O
as	O
a	O
target	O
for	O
inhibitors	O
of	O
PGGT	O
-	O
1	O
.	O

This	O
uncertainty	O
as	O
to	O
the	O
mechanism	O
of	O
action	O
within	O
non	O
-	O
transformed	O
as	O
well	O
as	O
transformed	O
cells	O
applies	O
to	O
all	O
prenylation	O
inhibitors	O
,	O
but	O
is	O
not	O
holding	O
back	O
their	O
further	O
development	O
as	O
drugs	O
.	O

Their	O
current	O
and	O
possible	O
future	O
application	O
as	O
therapeutics	O
in	O
cancer	O
,	O
restenosis	O
,	O
angiogenesis	O
,	O
and	O
osteoporosis	O
is	O
briefly	O
discussed	O
.	O

Role	O
of	O
metals	O
in	O
the	O
reaction	O
catalyzed	O
by	O
protein	O
farnesyltransferase	O
.	O

Protein	O
farnesyltransferase	O
catalyzes	O
the	O
posttranslational	O
farnesylation	O
of	O
several	O
proteins	O
involved	O
in	O
signal	O
transduction	O
,	O
including	O
Ras	O
,	O
and	O
is	O
a	O
target	O
enzyme	O
for	O
antitumor	O
therapies	O
.	O

Efficient	O
product	O
formation	O
catalyzed	O
by	O
protein	O
farnesyltransferase	O
requires	O
an	O
enzyme	O
-	O
bound	O
zinc	O
cation	O
and	O
high	O
concentrations	O
of	O
magnesium	O
ions	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
measured	O
the	O
pH	O
dependence	O
of	O
the	O
chemical	O
step	O
of	O
product	O
formation	O
,	O
determined	O
under	O
single	O
-	O
turnover	O
conditions	O
,	O
and	O
have	O
demonstrated	O
that	O
the	O
prenylation	O
rate	O
constant	O
is	O
enhanced	O
by	O
two	O
deprotonations	O
.	O

Substitution	O
of	O
the	O
active	O
site	O
zinc	O
by	O
cadmium	O
demonstrated	O
that	O
one	O
of	O
the	O
ionizations	O
reflects	O
deprotonation	O
of	O
the	O
metal	O
-	O
coordinated	O
thiol	O
of	O
the	O
peptide	O
"	O
CaaX	O
"	O
motif	O
,	O
pK	O
(	O
a1	O
)	O
=	O
6	O
.	O
0	O
.	O

These	O
data	O
provide	O
additional	O
evidence	O
for	O
the	O
direct	O
involvement	O
of	O
a	O
metal	O
-	O
coordinated	O
sulfur	O
nucleophile	O
in	O
catalysis	O
.	O

The	O
second	O
ionization	O
was	O
assigned	O
to	O
a	O
hydroxyl	O
on	O
the	O
pyrophosphate	O
moiety	O
of	O
farnesyl	O
pyrophosphate	O
,	O
pK	O
(	O
a2	O
)	O
=	O
7	O
.	O
4	O
.	O

Deprotonation	O
of	O
this	O
group	O
is	O
important	O
for	O
binding	O
of	O
magnesium	O
.	O

This	O
second	O
ionization	O
is	O
not	O
observed	O
for	O
catalysis	O
in	O
the	O
absence	O
of	O
magnesium	O
or	O
when	O
the	O
substrate	O
is	O
farnesyl	O
monophosphate	O
.	O

These	O
data	O
indicate	O
that	O
the	O
maximal	O
rate	O
constant	O
for	O
prenylation	O
requires	O
formation	O
of	O
a	O
zinc	O
-	O
coordinated	O
thiolate	O
nucleophile	O
and	O
enhancement	O
of	O
the	O
electrophilic	O
character	O
at	O
C1	O
of	O
the	O
farnesyl	O
chain	O
by	O
magnesium	O
ion	O
coordination	O
of	O
the	O
pyrophosphate	O
leaving	O
group	O
.	O

Prenylated	B-PRGE
Rab	I-PRGE
acceptor	I-PRGE
protein	I-PRGE
is	O
a	O
receptor	O
for	O
prenylated	O
small	O
GTPases	O
.	O

Localization	O
of	O
Ras	O
and	O
Ras	O
-	O
like	O
proteins	O
to	O
the	O
correct	O
subcellular	O
compartment	O
is	O
essential	O
for	O
these	O
proteins	O
to	O
mediate	O
their	O
biological	O
effects	O
.	O

Many	O
members	O
of	O
the	O
Ras	O
superfamily	O
(	O
Ha	B-PRGE
-	I-PRGE
Ras	I-PRGE
,	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
,	O
TC21	B-PRGE
,	O
and	O
RhoA	B-PRGE
)	O
are	O
prenylated	O
in	O
the	O
cytoplasm	O
and	O
then	O
transit	O
through	O
the	O
endomembrane	O
system	O
on	O
their	O
way	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
proteins	O
that	O
aid	O
in	O
the	O
trafficking	O
of	O
the	O
small	O
GTPases	O
have	O
not	O
been	O
well	O
characterized	O
.	O

We	O
report	O
here	O
that	O
prenylated	B-PRGE
Rab	I-PRGE
acceptor	I-PRGE
protein	I-PRGE
(	O
PRA1	B-PRGE
)	O
,	O
which	O
others	O
previously	O
identified	O
as	O
a	O
prenylation	O
-	O
dependent	O
receptor	O
for	O
Rab	O
proteins	O
,	O
also	O
interacts	O
with	O
Ha	B-PRGE
-	I-PRGE
Ras	I-PRGE
,	O
RhoA	B-PRGE
,	O
TC21	B-PRGE
,	O
and	O
Rap1a	B-PRGE
.	O

The	O
interaction	O
of	O
these	O
small	O
GTPases	O
with	O
PRA1	B-PRGE
requires	O
their	O
post	O
-	O
translational	O
modification	O
by	O
prenylation	O
.	O

The	O
prenylation	O
-	O
dependent	O
association	O
of	O
PRA1	B-PRGE
with	O
multiple	O
GTPases	O
is	O
conserved	O
in	O
evolution	O
;	O
the	O
yeast	O
PRA1	B-PRGE
protein	O
associates	O
with	O
both	O
Ha	B-PRGE
-	I-PRGE
Ras	I-PRGE
and	O
RhoA	B-PRGE
.	O

Earlier	O
studies	O
reported	O
the	O
presence	O
of	O
PRA1	B-PRGE
in	O
the	O
Golgi	O
,	O
and	O
we	O
show	O
here	O
that	O
PRA1	B-PRGE
co	O
-	O
localizes	O
with	O
Ha	B-PRGE
-	I-PRGE
Ras	I-PRGE
and	O
RhoA	B-PRGE
in	O
the	O
Golgi	O
compartment	O
.	O

We	O
suggest	O
that	O
PRA1	B-PRGE
acts	O
as	O
an	O
escort	O
protein	O
for	O
small	O
GTPases	O
by	O
binding	O
to	O
the	O
hydrophobic	O
isoprenoid	O
moieties	O
of	O
the	O
small	O
GTPases	O
and	O
facilitates	O
their	O
trafficking	O
through	O
the	O
endomembrane	O
system	O
.	O

Cloning	O
and	O
identification	O
of	O
MYPT3	B-PRGE
:	O
a	O
prenylatable	O
myosin	O
targetting	O
subunit	O
of	O
protein	O
phosphatase	O
1	O
.	O

To	O
identify	O
novel	O
protein	O
phosphatase	O
1	O
(	O
PP1	O
)	O
-	O
interacting	O
proteins	O
,	O
a	O
yeast	O
two	O
-	O
hybrid	O
3T3	O
-	O
L1	O
adipocyte	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
catalytic	O
subunit	O
of	O
PP1	O
as	O
bait	O
.	O

In	O
the	O
present	O
work	O
,	O
the	O
isolation	O
,	O
identification	O
and	O
initial	O
biochemical	O
characterization	O
of	O
a	O
novel	O
PP1	O
-	O
interacting	O
protein	O
,	O
MYPT3	B-PRGE
,	O
which	O
is	O
homologous	O
with	O
the	O
myosin	O
phosphatase	O
targetting	O
subunit	O
(	O
MYPT	O
)	O
family	O
,	O
is	O
described	O
.	O

MYPT3	B-PRGE
aligns	O
>	O
99	O
%	O
with	O
a	O
region	O
of	O
mouse	O
genomic	O
DNA	O
clone	O
RP23	O
-	O
156P23	O
and	O
localizes	O
to	O
chromosome	O
15	O
,	O
between	O
markers	O
at	O
44	O
.	O
1	O
-	O
46	O
.	O
5	O
cM	O
,	O
as	O
demonstrated	O
by	O
radiation	O
hybrid	O
mapping	O
.	O

The	O
gene	O
consists	O
of	O
ten	O
exons	O
that	O
encode	O
for	O
a	O
524	O
-	O
amino	O
acid	O
sequence	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
57529	O
Da	O
.	O

The	O
N	O
-	O
terminal	O
region	O
of	O
MYPT3	B-PRGE
consists	O
of	O
a	O
consensus	O
PP1	O
-	O
binding	O
site	O
and	O
multiple	O
ankyrin	O
repeats	O
.	O

MYPT3	B-PRGE
is	O
distinguished	O
from	O
related	O
approximately	O
110	O
-	O
130	O
kDa	O
MYPT	O
subunits	O
by	O
its	O
molecular	O
mass	O
of	O
58	O
kDa	O
,	O
and	O
a	O
unique	O
C	O
-	O
terminal	O
region	O
that	O
contains	O
several	O
potential	O
signalling	O
motifs	O
and	O
a	O
CaaX	O
prenylation	O
site	O
.	O

We	O
have	O
shown	O
that	O
affinity	O
-	O
purified	O
glutathione	B-PRGE
S	I-PRGE
-	I-PRGE
transferase	I-PRGE
(	O
GST	B-PRGE
)	O
-	O
MYPT3	B-PRGE
is	O
prenylated	O
by	O
purified	O
recombinant	O
farnesyltransferase	O
in	O
vitro	O
.	O

Endogenous	O
PP1	O
from	O
3T3	O
-	O
L1	O
lysates	O
specifically	O
interacts	O
with	O
MYPT3	B-PRGE
.	O

Additionally	O
,	O
purified	O
PP1	O
activity	O
was	O
inhibited	O
by	O
GST	B-PRGE
-	O
MYPT3	B-PRGE
toward	O
phosphorylase	O
a	O
,	O
myosin	O
light	O
chain	O
and	O
myosin	O
substrate	O
in	O
vitro	O
.	O

Overall	O
,	O
our	O
findings	O
identify	O
a	O
novel	O
prenylatable	O
subunit	O
of	O
PP1	O
that	O
defines	O
a	O
new	O
subfamily	O
of	O
MYPT	O
.	O

Physiological	O
substrates	O
for	O
human	O
lysosomal	O
beta	O
-	O
hexosaminidase	O
S	O
.	O

Human	O
lysosomal	O
beta	O
-	O
hexosaminidases	O
remove	O
terminal	O
beta	O
-	O
glycosidically	O
bound	O
N	O
-	O
acetylhexosamine	O
residues	O
from	O
a	O
number	O
of	O
glycoconjugates	O
.	O

Three	O
different	O
isozymes	O
composed	O
of	O
two	O
noncovalently	O
linked	O
subunits	O
alpha	O
and	O
beta	O
exist	O
:	O
Hex	O
A	O
(	O
alphabeta	O
)	O
,	O
Hex	O
B	O
(	O
betabeta	O
)	O
,	O
and	O
Hex	O
S	O
(	O
alphaalpha	O
)	O
.	O

While	O
the	O
role	O
of	O
Hex	O
A	O
and	O
B	O
for	O
the	O
degradation	O
of	O
several	O
anionic	O
and	O
neutral	O
glycoconjugates	O
has	O
been	O
well	O
established	O
,	O
the	O
physiological	O
significance	O
of	O
labile	O
Hex	O
S	O
has	O
remained	O
unclear	O
.	O

However	O
,	O
the	O
striking	O
accumulation	O
of	O
anionic	O
oligosaccharides	O
in	O
double	O
knockout	O
mice	O
totally	O
deficient	O
in	O
hexosaminidase	O
activity	O
but	O
not	O
in	O
mice	O
expressing	O
Hex	O
S	O
(	O
Sango	O
,	O
K	O
.	O
,	O
McDonald	O
,	O
M	O
.	O
P	O
.	O
,	O
Crawley	O
,	O
J	O
.	O
N	O
.	O
,	O
Mack	O
,	O
M	O
.	O
L	O
.	O
,	O
Tifft	O
,	O
C	O
.	O
J	O
.	O
,	O
Skop	O
,	O
E	O
.	O
,	O
Starr	O
,	O
C	O
.	O
M	O
.	O
,	O
Hoffmann	O
,	O
A	O
.	O
,	O
Sandhoff	O
,	O
K	O
.	O
,	O
Suzuki	O
,	O
K	O
.	O
,	O
and	O
Proia	O
,	O
R	O
.	O
L	O
.	O
,	O
(	O
1996	O
)	O
Nat	O
.	O
Genet	O
.	O
14	O
,	O
348	O
-	O
352	O
)	O
prompted	O
us	O
to	O
reinvestigate	O
the	O
substrate	O
specificity	O
of	O
Hex	O
S	O
.	O

To	O
identify	O
physiological	O
substrates	O
of	O
Hex	O
S	O
,	O
anionic	O
and	O
neutral	O
oligosaccharides	O
excreted	O
in	O
the	O
urine	O
of	O
the	O
double	O
knockout	O
mice	O
were	O
isolated	O
and	O
analyzed	O
.	O

Using	O
ESI	O
-	O
MS	O
/	O
MS	O
and	O
glycosidase	O
digestion	O
the	O
anionic	O
glycans	O
were	O
identified	O
as	O
products	O
of	O
incomplete	O
dermatan	O
sulfate	O
degradation	O
whereas	O
the	O
neutral	O
storage	O
oligosaccharides	O
were	O
found	O
to	O
be	O
fragments	O
of	O
N	O
-	O
glycan	O
degradation	O
.	O

In	O
vitro	O
,	O
recombinant	O
Hex	O
S	O
was	O
highly	O
active	O
on	O
water	O
-	O
soluble	O
and	O
amphiphilic	O
glycoconjugates	O
including	O
artificial	O
substrates	O
,	O
sulfated	O
GAG	O
fragments	O
,	O
and	O
the	O
sulfated	O
glycosphingolipid	O
SM2	O
.	O

Hydrolysis	O
of	O
membrane	O
-	O
bound	O
SM2	O
by	O
the	O
recombinant	O
Hex	O
S	O
was	O
synergistically	O
stimulated	O
by	O
the	O
GM2	B-PRGE
activator	I-PRGE
protein	I-PRGE
and	O
the	O
lysosomal	O
anionic	O
phospholipid	O
bis	O
(	O
monoacylglycero	O
)	O
phosphate	O
.	O

An	O
intact	O
NEDD8	B-PRGE
pathway	O
is	O
required	O
for	O
Cullin	O
-	O
dependent	O
ubiquitylation	O
in	O
mammalian	O
cells	O
.	O

Skp1	B-PRGE
-	O
Cdc53	B-PRGE
/	O
Cul1	B-PRGE
-	O
F	O
-	O
box	O
(	O
SCF	O
)	O
complexes	O
constitute	O
a	O
class	O
of	O
E3	O
ubiquitin	B-PRGE
ligases	O
.	O

Recently	O
,	O
a	O
multiprotein	O
complex	O
containing	O
pVHL	B-PRGE
,	O
elongin	B-PRGE
C	I-PRGE
and	O
Cul2	B-PRGE
(	O
VEC	O
)	O
was	O
shown	O
to	O
structurally	O
and	O
functionally	O
resemble	O
SCF	O
complexes	O
.	O

Cdc53	B-PRGE
and	O
the	O
Cullins	O
can	O
become	O
covalently	O
linked	O
to	O
the	O
ubiquitin	B-PRGE
-	O
like	O
molecule	O
Rub1	B-PRGE
/	O
NEDD8	B-PRGE
.	O

Inhibition	O
of	O
neddylation	O
inhibits	O
SCF	O
function	O
in	O
vitro	O
and	O
in	O
yeast	O
and	O
plants	O
.	O

Here	O
we	O
show	O
that	O
ongoing	O
neddylation	O
is	O
likewise	O
required	O
for	O
VEC	O
function	O
in	O
vitro	O
and	O
for	O
the	O
degradation	O
of	O
SCF	O
and	O
VEC	O
targets	O
in	O
mammalian	O
cells	O
.	O

Thus	O
,	O
neddylation	O
regulates	O
the	O
activity	O
of	O
two	O
specific	O
subclasses	O
of	O
mammalian	O
ubiquitin	B-PRGE
ligases	O
.	O

Effect	O
of	O
modification	O
on	O
physicochemical	O
and	O
biological	O
properties	O
of	O
haptoglobin	B-PRGE
.	O

VI	O
.	O

Reaction	O
with	O
azlactone	O
of	O
p	O
-	O
nitrobenzoyl	O
-	O
valine	O
.	O

The	O
azlactone	O
of	O
p	O
-	O
nitrobenzoyl	O
-	O
valine	O
(	O
Nbz	O
-	O
Val	O
)	O
has	O
been	O
used	O
for	O
modification	O
of	O
xi	O
-	O
amino	O
groups	O
of	O
lysine	O
in	O
haptoglobin	B-PRGE
type	I-PRGE
1	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
in	O
hemoglobin	O
,	O
and	O
in	O
the	O
haptoglobin	B-PRGE
-	O
hemoglobin	O
complex	O
.	O

By	O
the	O
use	O
of	O
this	O
reagent	O
95	O
%	O
of	O
amino	O
groups	O
in	O
haptoglobin	B-PRGE
and	O
90	O
%	O
in	O
hemoglobin	O
have	O
been	O
blocked	O
without	O
any	O
changes	O
in	O
peroxidase	O
activity	O
of	O
the	O
formed	O
complexes	O
:	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-PRGE
with	O
hemoglobin	O
,	O
Nbz	O
-	O
Val	O
.	O
hemoglobin	O
with	O
haptoglobin	B-PRGE
,	O
and	O
Nbz	O
-	O
Val	O
.	O
(	O
haptoglonin	B-PRGE
-	O
hemoglobin	O
)	O
.	O

After	O
reduction	O
and	O
reoxidation	O
,	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-PRGE
was	O
found	O
to	O
retain	O
90	O
%	O
of	O
peroxidase	O
activity	O
when	O
complexed	O
with	O
hemoglobin	O
.	O

Beta	O
chains	O
separated	O
either	O
from	O
haptoglobin	B-PRGE
or	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-PRGE
showed	O
15	O
%	O
of	O
peroxidase	O
activity	O
in	O
the	O
complex	O
with	O
hemoglobin	O
,	O
alpha	O
chains	O
of	O
the	O
same	O
origin	O
were	O
completely	O
inactive	O
.	O

Whereas	O
recombination	O
of	O
haptoglobin	B-PRGE
from	O
alpha	O
and	O
beta	O
chains	O
resulted	O
in	O
42	O
%	O
hemoglobin	O
-	O
binding	O
capacity	O
,	O
renaturation	O
of	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-PRGE
from	O
separated	O
subunits	O
was	O
found	O
to	O
proceed	O
with	O
almost	O
100	O
%	O
yield	O
.	O

In	O
immunodiffusion	O
with	O
rabbit	O
anti	O
-	O
haptoglobin	B-PRGE
or	O
anti	O
-	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-PRGE
sera	O
,	O
preparations	O
of	O
haptoglobin	B-PRGE
and	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-PRGE
after	O
reduction	O
and	O
reoxidation	O
or	O
after	O
recombination	O
from	O
separated	O
subunits	O
gave	O
similar	O
precipitation	O
arcs	O
showing	O
the	O
reaction	O
of	O
immunological	O
identity	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
platelet	B-PRGE
glycoprotein	I-PRGE
Ib	I-PRGE
alpha	I-PRGE
demonstrating	O
residues	O
involved	O
in	O
the	O
sulfation	O
of	O
tyrosines	O
276	O
,	O
278	O
,	O
and	O
279	O
.	O

The	O
interaction	O
between	O
platelet	B-PRGE
glycoprotein	I-PRGE
(	I-PRGE
GP	I-PRGE
)	I-PRGE
Ib	I-PRGE
alpha	I-PRGE
and	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
(	O
VWF	B-PRGE
)	O
is	O
essential	O
for	O
initiation	O
of	O
hemostasis	O
.	O

The	O
sulfation	O
of	O
the	O
3	O
tyrosine	O
residues	O
276	O
,	O
278	O
,	O
and	O
279	O
in	O
GPIb	B-PRGE
alpha	I-PRGE
is	O
an	O
important	O
posttranslational	O
modification	O
that	O
seems	O
to	O
promote	O
the	O
interaction	O
with	O
VWF	B-PRGE
.	O

The	O
environment	O
where	O
sulfation	O
of	O
tyrosines	O
occurs	O
has	O
been	O
proposed	O
to	O
contain	O
highly	O
acidic	O
residues	O
.	O

This	O
investigation	O
has	O
examined	O
the	O
highly	O
acidic	O
region	O
from	O
Asp249	O
to	O
Asp287	O
in	O
the	O
mature	O
GPIb	B-PRGE
alpha	I-PRGE
protein	O
.	O

Changes	O
to	O
most	O
of	O
the	O
carboxylic	O
acids	O
in	O
this	O
region	O
resulted	O
in	O
decreased	O
reactivity	O
to	O
VWF	B-PRGE
.	O

Only	O
3	O
mutants	O
(	O
Glu270Gln	O
,	O
Asp283Asn	O
,	O
Asp283Asn	O
/	O
Glu285Gln	O
/	O
Asp287Asn	O
)	O
resulted	O
in	O
the	O
abolition	O
of	O
sulfation	O
.	O

Two	O
novel	O
mutations	O
were	O
also	O
created	O
.	O

First	O
,	O
a	O
deletion	O
of	O
the	O
7	O
amino	O
acids	O
from	O
Tyr276	O
to	O
Glu282	O
led	O
to	O
a	O
loss	O
of	O
sulfation	O
and	O
totally	O
abolished	O
VWF	B-PRGE
binding	O
in	O
the	O
presence	O
of	O
botrocetin	O
.	O

This	O
confirms	O
that	O
it	O
is	O
these	O
3	O
tyrosines	O
that	O
undergo	O
sulfation	O
and	O
that	O
this	O
region	O
is	O
crucial	O
for	O
botrocetin	O
-	O
mediated	O
VWF	B-PRGE
binding	O
.	O

The	O
second	O
mutation	O
involves	O
changing	O
the	O
lysine	O
residues	O
at	O
253	O
,	O
258	O
,	O
and	O
262	O
to	O
alanine	O
.	O

This	O
also	O
led	O
to	O
distinct	O
changes	O
in	O
VWF	B-PRGE
binding	O
and	O
abolition	O
of	O
sulfation	O
.	O

Farnesylation	O
of	O
Cenp	B-PRGE
-	I-PRGE
F	I-PRGE
is	O
required	O
for	O
G2	O
/	O
M	O
progression	O
and	O
degradation	O
after	O
mitosis	O
.	O

Farnesyl	O
transferase	O
inhibitors	O
induce	O
G2	O
/	O
M	O
cell	O
cycle	O
delays	O
that	O
cannot	O
be	O
explained	O
by	O
inhibition	O
of	O
the	O
Ras	O
GTPase	O
.	O

Recently	O
,	O
the	O
kinetochore	O
protein	O
Cenp	B-PRGE
-	I-PRGE
F	I-PRGE
has	O
been	O
shown	O
to	O
be	O
farnesylated	O
.	O

Here	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
the	O
kinetochore	O
targeting	O
domain	O
of	O
Cenp	B-PRGE
-	I-PRGE
F	I-PRGE
delays	O
progression	O
through	O
G2	O
/	O
M	O
.	O

Significantly	O
,	O
this	O
is	O
dependent	O
on	O
the	O
CAAX	O
farnesylation	O
motif	O
.	O

We	O
also	O
show	O
that	O
localisation	O
of	O
Cenp	B-PRGE
-	I-PRGE
F	I-PRGE
to	O
the	O
nuclear	O
envelope	O
at	O
G2	O
/	O
M	O
and	O
kinetochores	O
in	O
prometaphase	O
is	O
dependent	O
both	O
on	O
its	O
CAAX	O
motif	O
and	O
farnesyl	O
transferase	O
activity	O
.	O

Strikingly	O
,	O
farnesyl	O
transferase	O
activity	O
is	O
also	O
required	O
for	O
Cenp	B-PRGE
-	I-PRGE
F	I-PRGE
degradation	O
after	O
mitosis	O
.	O

Thus	O
,	O
these	O
observations	O
suggest	O
that	O
farnesylation	O
of	O
Cenp	B-PRGE
-	I-PRGE
F	I-PRGE
is	O
required	O
not	O
only	O
for	O
its	O
localisation	O
to	O
the	O
nuclear	O
envelope	O
and	O
kinetochores	O
but	O
also	O
for	O
timely	O
progression	O
through	O
G2	O
/	O
M	O
and	O
its	O
degradation	O
after	O
mitosis	O
.	O

In	O
addition	O
,	O
these	O
observations	O
raise	O
the	O
possibility	O
that	O
the	O
anti	O
-	O
proliferative	O
effects	O
induced	O
by	O
farnesyl	O
transferase	O
inhibitors	O
may	O
be	O
due	O
to	O
inhibition	O
of	O
Cenp	B-PRGE
-	I-PRGE
F	I-PRGE
function	O
and	O
/	O
or	O
turnover	O
.	O

Structural	O
basis	O
for	O
the	O
beta	O
lactam	O
resistance	O
of	O
PBP2a	B-PRGE
from	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O

The	O
multiple	O
antibiotic	O
resistance	O
of	O
methicillin	O
-	O
resistant	O
strains	O
of	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
has	O
become	O
a	O
major	O
clinical	O
problem	O
worldwide	O
.	O

The	O
key	O
determinant	O
of	O
the	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactam	O
resistance	O
in	O
MRSA	O
strains	O
is	O
the	O
penicillin	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
2a	I-PRGE
(	O
PBP2a	B-PRGE
)	O
.	O

Because	O
of	O
its	O
low	O
affinity	O
for	O
beta	O
-	O
lactams	O
,	O
PBP2a	B-PRGE
provides	O
transpeptidase	O
activity	O
to	O
allow	O
cell	O
wall	O
synthesis	O
at	O
beta	O
-	O
lactam	O
concentrations	O
that	O
inhibit	O
the	O
beta	O
-	O
lactam	O
-	O
sensitive	O
PBPs	O
normally	O
produced	O
by	O
S	O
.	O
aureus	O
.	O

The	O
crystal	O
structure	O
of	O
a	O
soluble	O
derivative	O
of	O
PBP2a	B-PRGE
has	O
been	O
determined	O
to	O
1	O
.	O
8	O
A	O
resolution	O
and	O
provides	O
the	O
highest	O
resolution	O
structure	O
for	O
a	O
high	O
molecular	O
mass	O
PBP	O
.	O

Additionally	O
,	O
structures	O
of	O
the	O
acyl	O
-	O
PBP	O
complexes	O
of	O
PBP2a	B-PRGE
with	O
nitrocefin	O
,	O
penicillin	O
G	O
and	O
methicillin	O
allow	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
comparison	O
of	O
an	O
apo	O
and	O
acylated	O
resistant	O
PBP	O
.	O

An	O
analysis	O
of	O
the	O
PBP2a	B-PRGE
active	O
site	O
in	O
these	O
forms	O
reveals	O
the	O
structural	O
basis	O
of	O
its	O
resistance	O
and	O
identifies	O
features	O
in	O
newly	O
developed	O
beta	O
-	O
lactams	O
that	O
are	O
likely	O
important	O
for	O
high	O
affinity	O
binding	O
.	O

Shift	O
of	O
serum	O
osteocalcin	B-PRGE
components	O
between	O
cord	O
blood	O
and	O
blood	O
at	O
day	O
5	O
of	O
life	O
.	O

Vitamin	O
K	O
deficiency	O
is	O
a	O
relatively	O
common	O
condition	O
in	O
neonates	O
.	O

However	O
,	O
the	O
role	O
of	O
vitamin	O
K	O
in	O
neonatal	O
bone	O
metabolism	O
remains	O
to	O
be	O
determined	O
.	O

Osteocalcin	B-PRGE
(	O
OC	B-PRGE
)	O
is	O
the	O
most	O
abundant	O
noncollagenous	O
protein	O
in	O
bone	O
,	O
and	O
is	O
regulated	O
to	O
be	O
gamma	O
-	O
carboxylated	O
by	O
vitamin	O
K	O
.	O

In	O
this	O
study	O
,	O
we	O
measured	O
gamma	O
-	O
carboxylated	O
osteocalcin	B-PRGE
(	O
Gla	O
-	O
OC	B-PRGE
)	O
and	O
non	O
-	O
or	O
undercarboxylated	O
osteocalcin	B-PRGE
(	O
Glu	O
-	O
OC	B-PRGE
)	O
separately	O
,	O
and	O
examined	O
the	O
effects	O
of	O
vitamin	O
K	O
on	O
osteocalcin	B-PRGE
metabolism	O
.	O

Eighteen	O
full	O
-	O
term	O
healthy	O
neonates	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

In	O
the	O
cord	O
and	O
d	O
-	O
5	O
blood	O
samples	O
,	O
the	O
OC	B-PRGE
levels	O
were	O
determined	O
by	O
three	O
different	O
methods	O
to	O
examine	O
the	O
intact	O
OC	B-PRGE
by	O
immunoradiometric	O
assay	O
(	O
IRMA	O
)	O
,	O
Gla	O
-	O
OC	B-PRGE
,	O
and	O
Glu	O
-	O
OC	B-PRGE
.	O

Serum	O
vitamin	O
K	O
fractions	O
,	O
hepaplastin	O
test	O
,	O
and	O
type	O
1	O
procollagen	O
carboxyl	O
extension	O
peptide	O
were	O
also	O
determined	O
.	O

Urine	O
samples	O
were	O
also	O
collected	O
from	O
the	O
first	O
voiding	O
and	O
on	O
d	O
5	O
to	O
determine	O
urinary	O
pyridinoline	O
,	O
deoxypyridinoline	O
,	O
and	O
gamma	O
-	O
carboxylated	O
glutamic	O
acid	O
.	O

Serum	O
levels	O
of	O
phylloquinone	O
(	O
PK	O
)	O
and	O
menaquinone	O
(	O
MK	O
)	O
-	O
4	O
increased	O
on	O
d	O
5	O
following	O
vitamin	O
K	O
administration	O
and	O
increased	O
intake	O
in	O
breast	O
milk	O
and	O
/	O
or	O
formula	O
.	O

The	O
OC	B-PRGE
levels	O
determined	O
by	O
IRMA	O
did	O
not	O
change	O
between	O
cord	O
and	O
d	O
-	O
5	O
blood	O
samples	O
,	O
but	O
the	O
Gla	O
-	O
OC	B-PRGE
level	O
increased	O
remarkably	O
and	O
Glu	O
-	O
OC	B-PRGE
reduced	O
to	O
a	O
negligible	O
level	O
.	O

OC	B-PRGE
in	O
cord	O
blood	O
is	O
mainly	O
Glu	O
-	O
OC	B-PRGE
,	O
and	O
Glu	O
-	O
OC	B-PRGE
is	O
replaced	O
with	O
Gla	O
-	O
OC	B-PRGE
within	O
5	O
d	O
of	O
life	O
after	O
vitamin	O
K	O
supplement	O
.	O

The	O
IRMA	O
assay	O
fails	O
to	O
distinguish	O
Gla	O
-	O
OC	B-PRGE
from	O
Glu	O
-	O
OC	B-PRGE
and	O
caution	O
is	O
needed	O
to	O
estimate	O
bone	O
turnover	O
with	O
this	O
method	O
in	O
the	O
perinatal	O
period	O
.	O

Ubc9	B-PRGE
is	O
essential	O
for	O
viability	O
of	O
higher	O
eukaryotic	O
cells	O
.	O

Ubc9	B-PRGE
is	O
an	O
enzyme	O
involved	O
in	O
the	O
conjugation	O
of	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
small	B-PRGE
ubiquitin	I-PRGE
related	I-PRGE
modifier	I-PRGE
1	I-PRGE
)	O
to	O
target	O
proteins	O
.	O

The	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
conjugation	O
system	O
is	O
well	O
conserved	O
from	O
yeasts	O
to	O
higher	O
eukaryotes	O
,	O
but	O
many	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
target	O
proteins	O
reported	O
recently	O
in	O
higher	O
eukaryotic	O
cells	O
,	O
including	O
IkappaBalpha	B-PRGE
,	O
MDM2	B-PRGE
,	O
p53	B-PRGE
,	O
and	O
PML	B-PRGE
,	O
are	O
not	O
present	O
in	O
yeasts	O
.	O

To	O
determine	O
the	O
physiological	O
roles	O
of	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
conjugation	O
in	O
higher	O
eukaryotic	O
cells	O
,	O
we	O
constructed	O
a	O
conditional	O
UBC9	B-PRGE
mutant	O
of	O
chicken	O
DT40	O
cells	O
containing	O
the	O
UBC9	B-PRGE
transgene	O
under	O
control	O
of	O
a	O
tetracycline	O
-	O
repressible	O
promoter	O
and	O
characterized	O
their	O
loss	O
of	O
function	O
phenotypes	O
.	O

Ubc9	B-PRGE
disappeared	O
3	O
days	O
after	O
the	O
addition	O
of	O
tetracycline	O
and	O
the	O
increase	O
in	O
viable	O
cell	O
number	O
stopped	O
4	O
days	O
after	O
the	O
addition	O
of	O
drug	O
.	O

In	O
contrast	O
to	O
the	O
cases	O
of	O
ubc9	B-PRGE
mutants	O
of	O
budding	O
and	O
fission	O
yeasts	O
,	O
which	O
show	O
defects	O
in	O
progression	O
of	O
G2	O
or	O
early	O
M	O
phase	O
and	O
in	O
chromosome	O
segregation	O
,	O
respectively	O
,	O
we	O
did	O
not	O
observe	O
accumulation	O
of	O
cells	O
in	O
G2	O
/	O
M	O
phase	O
or	O
a	O
considerable	O
increase	O
in	O
the	O
frequency	O
of	O
chromosome	O
missegregation	O
upon	O
depletion	O
of	O
Ubc9	B-PRGE
but	O
we	O
did	O
observe	O
an	O
increase	O
in	O
the	O
number	O
of	O
cells	O
containing	O
multiple	O
nuclei	O
,	O
indicating	O
defects	O
in	O
cytokinesis	O
.	O

A	O
considerable	O
portion	O
of	O
the	O
Ubc9	B-PRGE
-	O
depleted	O
cell	O
population	O
was	O
committed	O
to	O
apoptosis	O
without	O
accumulating	O
in	O
a	O
specific	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
chromosome	O
damages	O
are	O
accumulated	O
in	O
Ubc9	B-PRGE
-	O
depleted	O
cells	O
,	O
and	O
apoptosis	O
is	O
triggered	O
without	O
activating	O
checkpoint	O
mechanisms	O
under	O
conditions	O
of	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
conjugation	O
system	O
impairment	O
.	O

Involvement	O
of	O
Src	O
family	O
protein	O
tyrosine	O
kinases	O
in	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
coronary	O
artery	O
contraction	O
mediated	O
by	O
a	O
sphingosylphosphorylcholine	O
-	O
Rho	O
-	O
kinase	O
pathway	O
.	O

We	O
recently	O
reported	O
that	O
sphingosylphosphorylcholine	O
(	O
SPC	O
)	O
is	O
a	O
novel	O
messenger	O
for	O
Rho	O
-	O
kinase	O
-	O
mediated	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
vascular	O
smooth	O
muscle	O
(	O
VSM	O
)	O
contraction	O
.	O

Subcellular	O
localization	O
and	O
kinase	O
activity	O
of	O
Src	O
family	O
protein	O
kinases	O
(	O
SrcPTKs	O
)	O
,	O
except	O
for	O
c	B-PRGE
-	I-PRGE
Src	I-PRGE
,	O
is	O
controlled	O
by	O
a	O
reversible	O
S	O
-	O
palmitoylation	O
,	O
an	O
event	O
inhibited	O
by	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
.	O

We	O
examined	O
the	O
possible	O
involvement	O
of	O
SrcPTKs	O
in	O
SPC	O
-	O
induced	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
and	O
effects	O
of	O
EPA	O
.	O

We	O
used	O
porcine	O
coronary	O
VSM	O
and	O
rat	O
aortic	O
VSM	O
cells	O
(	O
VSMCs	O
)	O
in	O
primary	O
culture	O
.	O

An	O
SrcPTKs	O
inhibitor	O
,	O
PP1	O
,	O
and	O
EPA	O
inhibited	O
SPC	O
-	O
induced	O
contraction	O
,	O
concentration	O
-	O
dependently	O
,	O
without	O
affecting	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
levels	O
and	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
contraction	O
induced	O
by	O
high	O
K	O
(	O
+	O
)	O
depolarization	O
.	O

A	O
digitized	O
immunocytochemical	O
analysis	O
in	O
VSMCs	O
revealed	O
that	O
SPC	O
induced	O
translocation	O
of	O
Fyn	B-PRGE
,	O
but	O
not	O
of	O
c	B-PRGE
-	I-PRGE
Src	I-PRGE
,	O
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
,	O
an	O
event	O
abolished	O
by	O
EPA	O
.	O

Translocation	O
of	O
Rho	O
-	O
kinase	O
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
by	O
SPC	O
was	O
also	O
inhibited	O
by	O
EPA	O
and	O
PP1	O
.	O

The	O
SPC	O
-	O
induced	O
activation	O
of	O
SrcPTKs	O
was	O
blocked	O
by	O
EPA	O
and	O
PP1	O
,	O
but	O
not	O
by	O
Y27632	O
,	O
an	O
Rho	O
-	O
kinase	O
inhibitor	O
.	O

Rho	O
-	O
kinase	O
-	O
dependent	O
phosphorylation	O
of	O
myosin	O
phosphatase	O
induced	O
by	O
SPC	O
was	O
inhibited	O
by	O
EPA	O
,	O
PP1	O
,	O
and	O
Y27632	O
.	O

Translocation	O
and	O
activation	O
of	O
SrcPTKs	O
,	O
including	O
Fyn	B-PRGE
,	O
play	O
an	O
important	O
role	O
in	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
VSM	O
contractions	O
mediated	O
by	O
a	O
SPC	O
-	O
Rho	O
-	O
kinase	O
pathway	O
.	O

The	O
central	O
role	O
of	O
the	O
trans	O
-	O
Golgi	O
network	O
as	O
a	O
gateway	O
of	O
the	O
early	O
secretory	O
pathway	O
:	O
physiologic	O
vs	O
nonphysiologic	O
protein	O
transit	O
.	O

The	O
current	O
review	O
focuses	O
upon	O
recent	O
advances	O
concerning	O
the	O
interrelationship	O
between	O
the	O
ER	O
and	O
the	O
trans	O
-	O
Golgi	O
network	O
(	O
ER	O
-	O
TGN	O
)	O
,	O
the	O
ER	O
and	O
the	O
nucleus	O
(	O
ER	O
-	O
nucleus	O
)	O
,	O
and	O
the	O
ER	O
-	O
ubiquitin	B-PRGE
-	O
proteasomal	O
pathways	O
at	O
the	O
level	O
of	O
basic	O
cell	O
biology	O
.	O

The	O
overall	O
emphasis	O
of	O
this	O
paper	O
centers	O
upon	O
the	O
high	O
likelihood	O
that	O
measurements	O
of	O
ER	O
-	O
associated	O
protein	O
or	O
gene	O
expression	O
levels	O
are	O
not	O
representative	O
of	O
a	O
strict	O
ER	O
alone	O
phenotype	O
.	O

Rather	O
,	O
that	O
ER	O
phenotype	O
reflects	O
a	O
synthesis	O
of	O
phenotypes	O
derived	O
from	O
intracellular	O
compartments	O
and	O
phosphorylated	O
messengers	O
in	O
rapport	O
with	O
the	O
ER	O
.	O

The	O
ER	O
-	O
TGN	O
,	O
ER	O
-	O
nuclear	O
,	O
and	O
ER	O
-	O
ubiquitin	B-PRGE
-	O
proteasomal	O
transit	O
paths	O
share	O
the	O
ability	O
to	O
feed	O
into	O
the	O
decision	O
of	O
whether	O
TGN	O
vesicles	O
can	O
interact	O
with	O
specific	O
phosphorylated	O
residues	O
in	O
order	O
to	O
drive	O
physiologic	O
,	O
constitutive	O
,	O
anterograde	O
traffic	O
,	O
retrograde	O
traffic	O
,	O
and	O
degradation	O
.	O

TGN	O
vesicles	O
can	O
:	O
(	O
a	O
)	O
traffic	O
to	O
endosomes	O
versus	O
plasma	O
membrane	O
phosphodomains	O
depending	O
upon	O
the	O
presence	O
or	O
the	O
absence	O
of	O
select	O
Golgi	O
-	O
localized	O
gamma	O
-	O
ear	O
containing	O
ADP	O
ribosylation	O
factor	O
-	O
binding	O
proteins	O
and	O
/	O
or	O
protein	O
kinase	O
D	O
;	O
(	O
b	O
)	O
be	O
maintained	O
within	O
the	O
TGN	O
in	O
the	O
presence	O
of	O
a	O
phosphosorting	O
acidic	O
cluster	O
motif	O
adaptor	O
;	O
(	O
c	O
)	O
transit	O
back	O
to	O
the	O
ER	O
via	O
specialized	O
TGN	O
/	O
ER	O
glycosyltransferases	O
(	O
which	O
modulate	O
phosphorylated	O
proteins	O
)	O
;	O
(	O
d	O
)	O
transit	O
to	O
the	O
nucleus	O
via	O
phosphatidylinositol	O
-	O
4	O
-	O
kinase	O
-	O
associated	O
phosphodomains	O
;	O
and	O
/	O
or	O
(	O
e	O
)	O
retrotranslocate	O
to	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
equipped	O
with	O
E3	O
ligase	O
potential	O
,	O
in	O
order	O
to	O
further	O
regulate	O
endosomal	O
versus	O
plasma	O
membrane	O
traffic	O
.	O

The	O
TGN	O
is	O
also	O
a	O
critical	O
gateway	O
for	O
protein	O
transit	O
in	O
the	O
sense	O
that	O
,	O
as	O
a	O
function	O
of	O
sorting	O
within	O
this	O
compartment	O
,	O
proteins	O
are	O
sent	O
to	O
the	O
axon	O
,	O
cell	O
body	O
,	O
or	O
dendrites	O
.	O

As	O
the	O
decision	O
to	O
sort	O
to	O
the	O
axon	O
versus	O
the	O
somatodendritic	O
compartment	O
is	O
intimately	O
tied	O
to	O
TGN	O
function	O
,	O
future	O
understanding	O
of	O
TGN	O
biology	O
at	O
the	O
levels	O
of	O
neurogenesis	O
and	O
protein	O
sorting	O
is	O
predicted	O
to	O
also	O
effectively	O
increase	O
our	O
understanding	O
of	O
synaptic	O
sorting	O
/	O
regulation	O
.	O

CAND1	B-PRGE
binds	O
to	O
unneddylated	O
CUL1	B-PRGE
and	O
regulates	O
the	O
formation	O
of	O
SCF	O
ubiquitin	B-PRGE
E3	O
ligase	O
complex	O
.	O

The	O
SCF	O
ubiquitin	B-PRGE
E3	O
ligase	O
regulates	O
ubiquitin	B-PRGE
-	O
dependent	O
proteolysis	O
of	O
many	O
regulatory	O
proteins	O
such	O
as	O
p27	B-PRGE
(	O
Kip1	B-PRGE
)	O
,	O
IkappaB	O
,	O
and	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
.	O

We	O
report	O
the	O
isolation	O
of	O
a	O
CUL1	B-PRGE
binding	O
protein	O
,	O
p120	B-PRGE
(	O
CAND1	B-PRGE
)	O
.	O

We	O
found	O
the	O
majority	O
of	O
CUL1	B-PRGE
is	O
in	O
a	O
complex	O
with	O
CAND1	B-PRGE
and	O
ROC1	B-PRGE
independent	O
of	O
SKP1	B-PRGE
and	O
F	O
box	O
protein	O
SKP2	B-PRGE
.	O

Both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
CAND1	B-PRGE
prevents	O
the	O
binding	O
of	O
SKP1	B-PRGE
and	O
SKP2	B-PRGE
to	O
CUL1	B-PRGE
while	O
dissociation	O
of	O
CAND1	B-PRGE
from	O
CUL1	B-PRGE
promotes	O
the	O
reverse	O
reaction	O
.	O

Neddylation	O
of	O
CUL1	B-PRGE
or	O
the	O
presence	O
of	O
SKP1	B-PRGE
and	O
ATP	O
causes	O
CAND1	B-PRGE
dissociation	O
.	O

Our	O
data	O
suggest	O
that	O
CAND1	B-PRGE
regulates	O
the	O
formation	O
of	O
the	O
SCF	O
complex	O
,	O
and	O
its	O
dissociation	O
from	O
CUL1	B-PRGE
is	O
coupled	O
with	O
the	O
incorporation	O
of	O
F	O
box	O
proteins	O
into	O
the	O
SCF	O
complex	O
,	O
causing	O
their	O
destabilization	O
.	O

Rheb	B-PRGE
binds	O
tuberous	B-PRGE
sclerosis	I-PRGE
complex	I-PRGE
2	I-PRGE
(	O
TSC2	B-PRGE
)	O
and	O
promotes	O
S6	B-PRGE
kinase	O
activation	O
in	O
a	O
rapamycin	O
-	O
and	O
farnesylation	O
-	O
dependent	O
manner	O
.	O

Recently	O
the	O
tuberous	B-PRGE
sclerosis	I-PRGE
complex	I-PRGE
2	I-PRGE
(	O
TSC2	B-PRGE
)	O
tumor	O
suppressor	O
gene	O
product	O
has	O
been	O
identified	O
as	O
a	O
negative	O
regulator	O
of	O
protein	O
synthesis	O
upstream	O
of	O
the	O
mTOR	B-PRGE
and	O
ribosomal	O
S6	B-PRGE
kinases	O
.	O

Because	O
of	O
the	O
homology	O
of	O
TSC2	B-PRGE
with	O
GTPase	O
-	O
activating	O
proteins	O
for	O
Rap1	B-PRGE
,	O
we	O
examined	O
whether	O
a	O
Ras	O
/	O
Rap	O
-	O
related	O
GTPase	O
might	O
be	O
involved	O
in	O
this	O
process	O
.	O

TSC2	B-PRGE
was	O
found	O
to	O
bind	O
to	O
Rheb	B-PRGE
-	O
GTP	O
in	O
vitro	O
and	O
to	O
reduce	O
Rheb	B-PRGE
GTP	O
levels	O
in	O
vivo	O
.	O

Over	O
-	O
expression	O
of	O
Rheb	B-PRGE
but	O
not	O
Rap1	B-PRGE
promoted	O
the	O
activation	O
of	O
S6	B-PRGE
kinase	O
in	O
a	O
rapamycin	O
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
Rheb	B-PRGE
acts	O
upstream	O
of	O
mTOR	B-PRGE
.	O

The	O
ability	O
of	O
Rheb	B-PRGE
to	O
induce	O
S6	B-PRGE
phosphorylation	O
was	O
also	O
inhibited	O
by	O
a	O
farnesyl	O
transferase	O
inhibitor	O
,	O
suggesting	O
that	O
Rheb	B-PRGE
may	O
be	O
responsible	O
for	O
the	O
Ras	O
-	O
independent	O
anti	O
-	O
neoplastic	O
properties	O
of	O
this	O
drug	O
.	O

Rab	O
and	O
ARF	O
GTPase	O
regulation	O
of	O
exocytosis	O
.	O

Our	O
understanding	O
of	O
the	O
mechanisms	O
governing	O
of	O
Rab	O
and	O
Arf	O
protein	O
function	O
has	O
exploded	O
in	O
recent	O
years	O
with	O
a	O
convergence	O
of	O
information	O
from	O
model	O
genetic	O
organisms	O
,	O
biochemical	O
studies	O
,	O
cell	O
biological	O
observations	O
and	O
protein	O
structural	O
information	O
.	O

However	O
,	O
the	O
list	O
of	O
known	O
Rab	O
and	O
Arf	O
interacting	O
factors	O
still	O
remains	O
small	O
relative	O
to	O
the	O
number	O
of	O
these	O
small	O
GTPases	O
that	O
have	O
been	O
identified	O
through	O
complete	O
genomic	O
sequencing	O
.	O

It	O
can	O
be	O
anticipated	O
that	O
the	O
factors	O
listed	O
and	O
discussed	O
in	O
this	O
review	O
probably	O
represent	O
a	O
small	O
fraction	O
of	O
the	O
Rab	O
and	O
Arf	O
accessory	O
molecules	O
that	O
remain	O
to	O
be	O
discovered	O
.	O

The	O
identification	O
of	O
regulators	O
and	O
accessory	O
molecules	O
for	O
the	O
Rab	O
and	O
Arf	O
families	O
has	O
allowed	O
investigators	O
to	O
elaborate	O
themes	O
and	O
develop	O
a	O
framework	O
for	O
a	O
mechanistic	O
understanding	O
of	O
these	O
proteins	O
.	O

The	O
themes	O
are	O
highlighted	O
in	O
this	O
review	O
,	O
which	O
aims	O
to	O
concentrate	O
on	O
Rab	O
and	O
Arf	O
function	O
in	O
exocytosis	O
.	O

Studies	O
on	O
G	O
-	O
protein	O
alpha	O
.	O
betagamma	O
heterotrimer	O
formation	O
reveal	O
a	O
putative	O
S	O
-	O
prenyl	O
-	O
binding	O
site	O
in	O
the	O
alpha	O
subunit	O
.	O

The	O
alpha	O
and	O
betagamma	O
subunits	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
contain	O
specific	O
lipid	O
modifications	O
,	O
which	O
are	O
required	O
for	O
their	O
biological	O
function	O
.	O

However	O
,	O
the	O
relevance	O
of	O
these	O
modifications	O
to	O
the	O
interactions	O
within	O
the	O
heterotrimeric	O
G	O
-	O
protein	O
is	O
not	O
fully	O
understood	O
.	O

In	O
order	O
to	O
explore	O
the	O
role	O
of	O
the	O
S	O
-	O
prenyl	O
moiety	O
of	O
the	O
isoprenylated	O
betagamma	O
dimer	O
of	O
retinal	O
transducin	O
,	O
betagamma	B-PRGE
(	I-PRGE
t	I-PRGE
)	I-PRGE
,	O
in	O
the	O
formation	O
of	O
the	O
heterotrimeric	O
complex	O
with	O
the	O
corresponding	O
N	O
-	O
acylated	O
alpha	O
subunit	O
,	O
alpha	O
(	O
t	O
)	O
,	O
we	O
employed	O
purified	O
fully	O
processed	O
subunits	O
,	O
which	O
are	O
soluble	O
in	O
aqueous	O
solutions	O
without	O
detergents	O
.	O

Pertussis	O
-	O
toxin	O
-	O
mediated	O
[	O
(	O
32	O
)	O
P	O
]	O
ADP	O
-	O
ribosylation	O
of	O
alpha	O
(	O
t	O
)	O
is	O
strongly	O
stimulated	O
(	O
approximately	O
10	O
-	O
fold	O
)	O
in	O
the	O
presence	O
of	O
betagamma	B-PRGE
(	I-PRGE
t	I-PRGE
)	I-PRGE
and	O
can	O
thus	O
serve	O
as	O
a	O
measure	O
for	O
heterotrimer	O
formation	O
.	O

Using	O
this	O
assay	O
,	O
preincubation	O
of	O
alpha	O
(	O
t	O
)	O
with	O
S	O
-	O
prenyl	O
analogues	O
containing	O
farnesyl	O
or	O
geranylgeranyl	O
moieties	O
was	O
found	O
to	O
inhibit	O
heterotrimer	O
formation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
inhibition	O
was	O
competitive	O
and	O
reversible	O
,	O
as	O
indicated	O
by	O
its	O
reversal	O
upon	O
increase	O
of	O
the	O
betagamma	B-PRGE
(	I-PRGE
t	I-PRGE
)	I-PRGE
dimer	O
concentration	O
or	O
by	O
removal	O
of	O
the	O
S	O
-	O
prenyl	O
analogue	O
using	O
gel	O
filtration	O
.	O

The	O
competitive	O
nature	O
of	O
the	O
inhibition	O
is	O
supported	O
by	O
the	O
marked	O
attenuation	O
of	O
the	O
inhibition	O
when	O
the	O
S	O
-	O
prenyl	O
analogue	O
was	O
added	O
to	O
alpha	O
(	O
t	O
)	O
together	O
with	O
or	O
after	O
betagamma	B-PRGE
(	I-PRGE
t	I-PRGE
)	I-PRGE
.	O

The	O
inhibition	O
does	O
not	O
involve	O
interaction	O
with	O
the	O
alpha	O
(	O
t	O
)	O
acyl	O
group	O
,	O
since	O
an	O
S	O
-	O
prenyl	O
analogue	O
inhibited	O
the	O
[	O
(	O
32	O
)	O
P	O
]	O
ADP	O
-	O
ribosylation	O
of	O
an	O
unlipidated	O
alpha	O
(	O
t	O
)	O
mutant	O
.	O

These	O
data	O
suggest	O
the	O
existence	O
of	O
a	O
hitherto	O
unrecognized	O
S	O
-	O
prenyl	O
-	O
binding	O
site	O
in	O
alpha	O
(	O
t	O
)	O
,	O
which	O
is	O
critical	O
for	O
its	O
interaction	O
with	O
prenylated	O
betagamma	B-PRGE
(	I-PRGE
t	I-PRGE
)	I-PRGE
.	O

Retroviral	O
insertional	O
mutagenesis	O
identifies	O
a	O
small	O
protein	O
required	O
for	O
synthesis	O
of	O
diphthamide	O
,	O
the	O
target	O
of	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
.	O

Retroviral	O
insertional	O
mutagenesis	O
was	O
used	O
to	O
produce	O
a	O
mutant	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
that	O
is	O
completely	O
resistant	O
to	O
several	O
different	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
.	O

The	O
gene	O
responsible	O
for	O
toxin	O
resistance	O
,	O
termed	O
diphtheria	B-PRGE
toxin	I-PRGE
(	I-PRGE
DT	I-PRGE
)	I-PRGE
and	I-PRGE
Pseudomonas	I-PRGE
exotoxin	I-PRGE
A	I-PRGE
(	I-PRGE
ETA	I-PRGE
)	I-PRGE
sensitivity	I-PRGE
required	I-PRGE
gene	I-PRGE
1	I-PRGE
(	O
DESR1	B-PRGE
)	O
,	O
encodes	O
two	O
small	O
protein	O
isoforms	O
of	O
82	O
and	O
57	O
residues	O
.	O

DESR1	B-PRGE
is	O
evolutionally	O
conserved	O
and	O
ubiquitously	O
expressed	O
.	O

Only	O
the	O
longer	O
isoform	O
is	O
functional	O
because	O
the	O
mutant	O
cell	O
line	O
can	O
be	O
complemented	O
by	O
transfection	O
with	O
the	O
long	O
but	O
not	O
the	O
short	O
isoform	O
.	O

We	O
demonstrate	O
that	O
DESR1	B-PRGE
is	O
required	O
for	O
the	O
first	O
step	O
in	O
the	O
posttranslational	O
modification	O
of	O
elongation	B-PRGE
factor	I-PRGE
-	I-PRGE
2	I-PRGE
at	O
His	O
(	O
715	O
)	O
that	O
yields	O
diphthamide	O
,	O
the	O
target	O
site	O
for	O
ADP	O
ribosylation	O
by	O
DT	B-PRGE
and	O
ETA	B-PRGE
.	O

KTI11	B-PRGE
,	O
the	O
analog	O
of	O
DESR1	B-PRGE
in	O
yeast	O
,	O
which	O
was	O
originally	O
identified	O
as	O
a	O
gene	O
regulating	O
the	O
sensitivity	O
of	O
yeast	O
to	O
zymocin	O
,	O
is	O
also	O
required	O
for	O
diphthamide	O
biosynthesis	O
,	O
implicating	O
DESR1	B-PRGE
/	O
KTI11	B-PRGE
in	O
multiple	O
biological	O
processes	O
.	O

The	O
redox	O
domain	O
of	O
the	O
Yap1p	B-PRGE
transcription	O
factor	O
contains	O
two	O
disulfide	O
bonds	O
.	O

The	O
subcellular	O
localization	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
transcription	O
factor	O
Yap1p	B-PRGE
is	O
regulated	O
by	O
oxidation	O
and	O
reduction	O
.	O

We	O
purified	O
Yap1p	B-PRGE
from	O
yeast	O
and	O
characterized	O
its	O
properties	O
in	O
vitro	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
the	O
purified	O
protein	O
can	O
specifically	O
bind	O
the	O
TRX2	B-PRGE
target	O
promoter	O
.	O

Yap1p	B-PRGE
was	O
purified	O
under	O
reducing	O
conditions	O
,	O
but	O
removal	O
of	O
reducing	O
agents	O
resulted	O
in	O
the	O
formation	O
of	O
an	O
oxidized	O
Yap1p	B-PRGE
species	O
with	O
properties	O
similar	O
to	O
in	O
vivo	O
oxidized	O
Yap1p	B-PRGE
.	O

MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
analysis	O
revealed	O
that	O
the	O
oxidized	O
form	O
of	O
Yap1p	B-PRGE
contains	O
two	O
disulfide	O
bonds	O
between	O
C303	O
-	O
C598	O
and	O
C310	O
-	O
C629	O
.	O

A	O
stable	O
domain	O
of	O
approximately	O
15	O
kDa	O
was	O
detected	O
upon	O
limited	O
proteolysis	O
of	O
oxidized	O
but	O
not	O
reduced	O
Yap1p	B-PRGE
.	O

This	O
Yap1p	B-PRGE
protease	O
resistant	O
domain	O
was	O
purified	O
,	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
analysis	O
showed	O
that	O
it	O
was	O
comprised	O
of	O
two	O
separate	O
cysteine	O
-	O
containing	O
peptides	O
of	O
Yap1p	B-PRGE
.	O

These	O
peptides	O
are	O
separated	O
by	O
250	O
amino	O
acids	O
and	O
are	O
joined	O
by	O
the	O
C303	O
-	O
C598	O
and	O
C310	O
-	O
C629	O
disulfide	O
bonds	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
domain	O
that	O
controls	O
Yap1p	B-PRGE
subcellular	O
localization	O
is	O
modular	O
and	O
contains	O
a	O
redox	O
center	O
comprised	O
of	O
four	O
cysteine	O
residues	O
.	O

Rho	B-PRGE
A	I-PRGE
negatively	O
regulates	O
cytokine	O
-	O
mediated	O
inducible	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
expression	O
in	O
brain	O
-	O
derived	O
transformed	O
cell	O
lines	O
:	O
negative	O
regulation	O
of	O
IKKalpha	B-PRGE
.	O

The	O
present	O
study	O
describes	O
the	O
role	O
of	O
RhoA	B-PRGE
as	O
a	O
negative	O
regulator	O
of	O
iNOS	B-PRGE
expression	O
via	O
the	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
in	O
transformed	O
brain	O
cell	O
lines	O
[	O
C	O
(	O
6	O
)	O
glioma	O
,	O
human	O
astrocytoma	O
(	O
T98G	O
,	O
A172	O
)	O
,	O
neuroblastoma	O
(	O
NEB	O
)	O
,	O
and	O
immortal	O
rat	O
astrocytes	O
]	O
.	O

Treatment	O
with	O
lovastatin	O
resulted	O
in	O
the	O
induction	O
of	O
LPS	O
/	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
mediated	O
iNOS	B-PRGE
mRNA	O
and	O
increased	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
.	O

The	O
addition	O
of	O
mevalonate	O
and	O
geranylgeranylpyrophosphate	O
(	O
GGPP	O
)	O
reversed	O
the	O
lovastatin	O
-	O
mediated	O
effect	O
,	O
whereas	O
FPP	O
had	O
no	O
effect	O
.	O

An	O
inhibitor	O
of	O
geranylgeranyltransferase	O
inhibitor	O
(	O
GGTI	O
298	O
)	O
further	O
induced	O
the	O
cytokine	O
and	O
lovastatin	O
-	O
mediated	O
iNOS	B-PRGE
expression	O
,	O
suggesting	O
the	O
involvement	O
of	O
geranylgeranylated	O
proteins	O
in	O
the	O
regulation	O
of	O
iNOS	B-PRGE
.	O

Bacterial	O
toxin	B-PRGE
B	I-PRGE
(	O
inactivates	O
RhoA	B-PRGE
,	O
B	B-PRGE
,	O
and	O
C	B-PRGE
;	O
CDC42	B-PRGE
;	O
Rac	O
proteins	O
)	O
,	O
C3	B-PRGE
ADP	I-PRGE
-	I-PRGE
ribosyltransferase	I-PRGE
(	O
C3	B-PRGE
)	O
toxin	O
from	O
C	O
.	O
botulinum	O
(	O
inactivates	O
RhoA	B-PRGE
,	O
B	B-PRGE
,	O
and	O
C	B-PRGE
proteins	O
)	O
,	O
and	O
Y	O
-	O
27632	O
(	O
selective	O
inhibitor	O
of	O
Rho	O
-	O
associated	O
kinases	O
)	O
increased	O
the	O
LPS	O
/	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
mediated	O
iNOS	B-PRGE
expression	O
.	O

Lovastatin	O
treatment	O
induced	O
NO	O
by	O
increasing	O
NF	O
-	O
kappaB	O
translocation	O
and	O
its	O
association	O
with	O
the	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	B-PRGE
/	O
p300	B-PRGE
)	O
via	O
the	O
downregulation	O
of	O
RhoA	B-PRGE
.	O

Inhibition	O
of	O
RhoA	B-PRGE
resulted	O
in	O
increased	O
activation	O
of	O
IKKalpha	B-PRGE
.	O

Cotransfection	O
studies	O
with	O
dominant	O
-	O
negative	O
form	O
of	O
RhoA	B-PRGE
and	O
iNOS	B-PRGE
-	O
luciferase	B-PRGE
or	O
NF	O
-	O
kappaB	O
-	O
luciferase	B-PRGE
reporter	O
constructs	O
further	O
support	O
these	O
observations	O
.	O

Taken	O
together	O
,	O
these	O
studies	O
show	O
that	O
downregulation	O
of	O
RhoA	B-PRGE
by	O
lovastatin	O
resulted	O
in	O
increased	O
iNOS	B-PRGE
expression	O
via	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
CBP	B-PRGE
/	O
p300	B-PRGE
pathway	O
in	O
transformed	O
brain	O
cells	O
.	O

Caspase	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
NEDD	B-PRGE
-	I-PRGE
2	I-PRGE
protease	O
mediates	O
execution	O
of	O
apoptosis	O
in	O
AK	O
-	O
5	O
tumor	O
cells	O
.	O

AK	O
-	O
5	O
tumour	O
cells	O
have	O
been	O
shown	O
to	O
undergo	O
apoptosis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
efficient	O
killing	O
of	O
tumour	O
cells	O
by	O
necrosis	O
and	O
apoptosis	O
leads	O
to	O
spontaneous	O
regression	O
of	O
the	O
tumour	O
.	O

To	O
investigate	O
a	O
possible	O
involvement	O
of	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
Nedd	B-PRGE
-	I-PRGE
2	I-PRGE
protease	O
in	O
AK	O
-	O
5	O
apoptosis	O
,	O
we	O
introduced	O
Nedd	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
in	O
antisense	O
orientation	O
and	O
showed	O
inhibition	O
of	O
tumour	O
cell	O
apoptosis	O
.	O

Similarly	O
introduction	O
of	O
the	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
in	O
tumour	O
cells	O
also	O
inhibited	O
the	O
apoptotic	O
programme	O
.	O

NK	O
cells	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
the	O
effector	O
cells	O
also	O
fail	O
to	O
induce	O
apoptosis	O
in	O
Nedd	B-PRGE
-	I-PRGE
2	I-PRGE
antisense	O
and	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
transfected	O
clones	O
whereas	O
NK	O
mediated	O
cytotoxic	O
activity	O
is	O
not	O
altered	O
in	O
the	O
transfectants	O
.	O

These	O
results	O
suggest	O
participation	O
of	O
Nedd	B-PRGE
-	I-PRGE
2	I-PRGE
protease	O
in	O
the	O
induction	O
of	O
apoptosis	O
in	O
AK	O
-	O
5	O
cells	O
leading	O
to	O
tumour	O
regression	O
.	O

Antifungal	O
activity	O
of	O
fluconazole	O
in	O
combination	O
with	O
lovastatin	O
and	O
their	O
effects	O
on	O
gene	O
expression	O
in	O
the	O
ergosterol	O
and	O
prenylation	O
pathways	O
in	O
Candida	O
albicans	O
.	O

The	O
sterol	O
pathway	O
in	O
Candida	O
albicans	O
is	O
the	O
target	O
for	O
several	O
classes	O
of	O
antifungal	O
drugs	O
.	O

Intermediates	O
in	O
the	O
sterol	O
pathway	O
are	O
involved	O
in	O
ergosterol	O
synthesis	O
,	O
prenylation	O
and	O
dolichol	O
synthesis	O
.	O

This	O
study	O
examines	O
gene	O
expression	O
of	O
the	O
sterol	O
pathway	O
in	O
response	O
to	O
lovastatin	O
,	O
an	O
inhibitor	O
of	O
HMG	B-PRGE
-	I-PRGE
CoA	I-PRGE
reductase	I-PRGE
(	O
Hmg1p	B-PRGE
)	O
,	O
and	O
fluconazole	O
,	O
an	O
inhibitor	O
of	O
14	B-PRGE
alpha	I-PRGE
-	I-PRGE
lanosterol	I-PRGE
demethylase	I-PRGE
(	O
Erg11p	B-PRGE
)	O
.	O

Minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
studies	O
indicated	O
that	O
lovastatin	O
acts	O
synergistically	O
with	O
fluconazole	O
in	O
vitro	O
.	O

Semi	O
-	O
quantitative	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
results	O
indicated	O
that	O
genes	O
in	O
the	O
early	O
part	O
of	O
the	O
sterol	O
pathway	O
,	O
such	O
as	O
HMG1	B-PRGE
and	O
ERG20	B-PRGE
,	O
did	O
not	O
alter	O
expression	O
in	O
the	O
presence	O
of	O
both	O
lovastatin	O
and	O
fluconazole	O
,	O
whereas	O
genes	O
in	O
the	O
later	O
part	O
of	O
the	O
sterol	O
pathway	O
,	O
such	O
as	O
ERG9	B-PRGE
and	O
ERG11	B-PRGE
,	O
had	O
increased	O
expression	O
in	O
response	O
to	O
these	O
drugs	O
in	O
mid	O
-	O
logarithmic	O
growth	O
.	O

Genes	O
involved	O
in	O
prenylation	O
,	O
such	O
as	O
RAM1	B-PRGE
and	O
RAM2	B-PRGE
,	O
also	O
respond	O
to	O
these	O
drugs	O
in	O
mid	O
-	O
logarithmic	O
growth	O
,	O
although	O
another	O
prenylation	O
gene	O
,	O
CDC43	B-PRGE
,	O
was	O
not	O
affected	O
.	O

After	O
24	O
h	O
of	O
growth	O
,	O
the	O
relative	O
expression	O
of	O
ERG20	B-PRGE
,	O
ERG9	B-PRGE
,	O
and	O
ERG11	B-PRGE
remained	O
unchanged	O
or	O
increased	O
in	O
the	O
presence	O
of	O
both	O
drugs	O
,	O
while	O
all	O
other	O
genes	O
decreased	O
in	O
expression	O
under	O
all	O
drug	O
treatments	O
.	O

Neisseria	O
gonorrhoeae	O
penicillin	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
3	I-PRGE
exhibits	O
exceptionally	O
high	O
carboxypeptidase	O
and	O
beta	O
-	O
lactam	O
binding	O
activities	O
.	O

A	O
soluble	O
form	O
of	O
penicillin	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
3	I-PRGE
(	O
PBP	B-PRGE
3	I-PRGE
)	O
from	O
Neisseria	O
gonorrhoeae	O
was	O
expressed	O
and	O
purified	O
from	O
Escherichia	O
coli	O
and	O
characterized	O
for	O
its	O
interaction	O
with	O
beta	O
-	O
lactam	O
antibiotics	O
,	O
its	O
catalytic	O
properties	O
with	O
peptide	O
and	O
peptidoglycan	O
substrates	O
,	O
and	O
its	O
role	O
in	O
cell	O
viability	O
and	O
morphology	O
.	O

PBP	B-PRGE
3	I-PRGE
had	O
an	O
unusually	O
high	O
k	O
(	O
2	O
)	O
/	O
K	O
'	O
value	O
relative	O
to	O
other	O
PBPs	O
for	O
acylation	O
with	O
penicillin	O
(	O
7	O
.	O
7	O
x	O
10	O
(	O
5	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
)	O
at	O
pH	O
8	O
.	O
5	O
at	O
25	O
degrees	O
C	O
and	O
hydrolyzed	O
bound	O
antibiotic	O
very	O
slowly	O
(	O
k	O
(	O
3	O
)	O
<	O
4	O
.	O
6	O
x	O
10	O
(	O
-	O
5	O
)	O
s	O
(	O
-	O
1	O
)	O
,	O
t	O
(	O
1	O
/	O
2	O
)	O
>	O
230	O
min	O
)	O
.	O

PBP	B-PRGE
3	I-PRGE
also	O
demonstrated	O
exceptionally	O
high	O
carboxypeptidase	O
activity	O
with	O
a	O
k	O
(	O
cat	O
)	O
of	O
580	O
s	O
(	O
-	O
1	O
)	O
and	O
a	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
of	O
1	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
with	O
the	O
substrate	O
N	O
(	O
alpha	O
)	O
-	O
Boc	O
-	O
N	O
(	O
epsilon	O
)	O
-	O
Cbz	O
-	O
L	O
-	O
Lys	O
-	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Ala	O
.	O

This	O
is	O
the	O
highest	O
k	O
(	O
cat	O
)	O
value	O
yet	O
reported	O
for	O
a	O
PBP	O
or	O
other	O
serine	O
peptidases	O
.	O

Activity	O
against	O
a	O
approximately	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Lac	O
peptide	O
substrate	O
was	O
approximately	O
2	O
-	O
fold	O
lower	O
than	O
against	O
the	O
analogous	O
approximately	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Ala	O
peptide	O
substrate	O
,	O
indicating	O
that	O
deacylation	O
is	O
rate	O
determining	O
for	O
both	O
amide	O
and	O
ester	O
hydrolysis	O
.	O

The	O
pH	O
dependence	O
profiles	O
of	O
both	O
carboxypeptidase	O
activity	O
and	O
beta	O
-	O
lactam	O
acylation	O
were	O
bell	O
-	O
shaped	O
with	O
maximal	O
activity	O
at	O
pH	O
8	O
.	O
0	O
-	O
8	O
.	O
5	O
.	O

PBP	B-PRGE
3	I-PRGE
displayed	O
weak	O
transpeptidase	O
activity	O
in	O
a	O
model	O
transpeptidase	O
reaction	O
but	O
was	O
active	O
as	O
an	O
endopeptidase	O
,	O
cleaving	O
dimeric	O
peptide	O
cross	O
-	O
links	O
.	O

Deletion	O
of	O
PBP	B-PRGE
3	I-PRGE
alone	O
had	O
little	O
effect	O
on	O
viability	O
,	O
growth	O
rate	O
,	O
and	O
morphology	O
of	O
N	O
.	O
gonorrhoeae	O
,	O
although	O
deletion	O
of	O
both	O
PBP	B-PRGE
3	I-PRGE
and	O
PBP	B-PRGE
4	I-PRGE
,	O
the	O
other	O
low	O
-	O
molecular	O
-	O
mass	O
PBP	O
in	O
N	O
.	O
gonorrhoeae	O
,	O
resulted	O
in	O
a	O
decreased	O
growth	O
rate	O
and	O
marked	O
morphological	O
abnormalities	O
.	O

A	O
recombinant	O
form	O
of	O
Pseudomonas	O
exotoxin	O
directed	O
at	O
the	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
that	O
is	O
cytotoxic	O
without	O
requiring	O
proteolytic	O
processing	O
.	O

Pseudomonas	O
exotoxin	B-PRGE
A	I-PRGE
is	O
composed	O
of	O
three	O
structural	O
domains	O
that	O
mediate	O
cell	O
recognition	O
(	O
I	O
)	O
,	O
membrane	O
translocation	O
(	O
II	O
)	O
,	O
and	O
ADP	O
-	O
ribosylation	O
(	O
III	O
)	O
.	O

Within	O
the	O
cell	O
,	O
the	O
toxin	O
is	O
cleaved	O
within	O
domain	O
II	O
to	O
produce	O
a	O
37	O
-	O
kDa	O
carboxyl	O
-	O
terminal	O
fragment	O
,	O
containing	O
amino	O
acids	O
280	O
-	O
613	O
,	O
which	O
is	O
translocated	O
to	O
the	O
cytosol	O
and	O
causes	O
cell	O
death	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
a	O
mutant	O
protein	O
(	O
PE37	O
)	O
,	O
composed	O
of	O
amino	O
acids	O
280	O
-	O
613	O
of	O
Pseudomonas	O
exotoxin	B-PRGE
A	I-PRGE
,	O
which	O
does	O
not	O
require	O
proteolysis	O
to	O
translocate	O
.	O

PE37	O
was	O
targeted	O
specifically	O
to	O
cells	O
with	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptors	I-PRGE
by	O
inserting	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TGF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
after	O
amino	O
acid	O
607	O
near	O
the	O
carboxyl	O
terminus	O
of	O
Pseudomonas	O
exotoxin	B-PRGE
A	I-PRGE
.	O

PE37	O
/	O
TGF	B-PRGE
-	I-PRGE
alpha	I-PRGE
was	O
very	O
cytotoxic	O
to	O
cells	O
with	O
epidermal	O
growth	O
factor	O
receptors	O
.	O

It	O
was	O
severalfold	O
more	O
cytotoxic	O
than	O
a	O
derivative	O
of	O
full	O
-	O
length	O
Pseudomonas	O
exotoxin	B-PRGE
A	I-PRGE
containing	O
TGF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
the	O
same	O
position	O
,	O
probably	O
because	O
the	O
latter	O
requires	O
intracellular	O
proteolytic	O
processing	O
to	O
exhibit	O
its	O
cytotoxicity	O
,	O
and	O
proteolytic	O
processing	O
is	O
not	O
100	O
%	O
efficient	O
.	O

Deletion	O
of	O
2	O
,	O
4	O
,	O
or	O
7	O
amino	O
acids	O
from	O
the	O
amino	O
terminus	O
of	O
PE37	O
/	O
TGF	B-PRGE
-	I-PRGE
alpha	I-PRGE
greatly	O
diminished	O
cytotoxic	O
activity	O
,	O
indicating	O
the	O
need	O
for	O
a	O
proper	O
amino	O
-	O
terminal	O
sequence	O
.	O

In	O
addition	O
,	O
a	O
mutant	O
containing	O
an	O
internal	O
deletion	O
of	O
amino	O
acids	O
314	O
-	O
380	O
was	O
minimally	O
active	O
,	O
indicating	O
that	O
other	O
regions	O
of	O
domain	O
II	O
are	O
also	O
required	O
for	O
the	O
cytotoxic	O
activity	O
of	O
Pseudomonas	O
exotoxin	B-PRGE
A	I-PRGE
.	O

The	O
RAM1	B-PRGE
gene	O
encoding	O
a	O
protein	B-PRGE
-	I-PRGE
farnesyltransferase	I-PRGE
beta	I-PRGE
-	I-PRGE
subunit	I-PRGE
homologue	I-PRGE
is	O
essential	O
in	O
Cryptococcus	O
neoformans	O
.	O

Many	O
small	O
G	O
proteins	O
require	O
post	O
-	O
translational	O
modification	O
to	O
allow	O
functional	O
association	O
to	O
the	O
cell	O
membrane	O
.	O

This	O
process	O
often	O
involves	O
the	O
enzymic	O
addition	O
of	O
hydrophobic	O
prenyl	O
groups	O
to	O
a	O
conserved	O
cysteine	O
residue	O
near	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

The	O
enzymes	O
that	O
catalyse	O
these	O
reactions	O
include	O
protein	O
farnesyltransferase	O
and	O
protein	O
geranylgeranyltransferases	O
.	O

The	O
human	O
fungal	O
pathogen	O
Cryptococcus	O
neoformans	O
requires	O
functional	O
Ras	B-PRGE
and	O
Rho	B-PRGE
proteins	O
in	O
order	O
to	O
undergo	O
normal	O
growth	O
and	O
differentiation	O
.	O

Since	O
farnesylation	O
and	O
geranylgeranylation	O
are	O
likely	O
required	O
for	O
the	O
proper	O
function	O
of	O
these	O
small	O
G	O
proteins	O
,	O
we	O
hypothesized	O
that	O
inhibition	O
of	O
these	O
prenylation	O
events	O
would	O
alter	O
the	O
growth	O
and	O
cellular	O
morphogenesis	O
of	O
this	O
fungus	O
.	O

We	O
cloned	O
the	O
RAM1	B-PRGE
gene	O
encoding	O
the	O
single	O
protein	B-PRGE
-	I-PRGE
farnesyltransferase	I-PRGE
beta	I-PRGE
-	I-PRGE
chain	I-PRGE
homologue	I-PRGE
in	O
C	O
.	O
neoformans	O
.	O

Using	O
a	O
gene	O
-	O
disruption	O
strategy	O
in	O
a	O
diploid	O
C	O
.	O
neoformans	O
strain	O
,	O
we	O
demonstrated	O
that	O
this	O
gene	O
encodes	O
an	O
essential	O
function	O
,	O
in	O
contrast	O
to	O
the	O
case	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
in	O
which	O
the	O
homologous	O
RAM1	B-PRGE
gene	O
is	O
not	O
essential	O
for	O
growth	O
.	O

Pharmacological	O
inhibition	O
of	O
farnesyltransferase	O
activity	O
resulted	O
in	O
dose	O
-	O
dependent	O
cytostasis	O
of	O
C	O
.	O
neoformans	O
,	O
as	O
well	O
as	O
prevention	O
of	O
hyphal	O
differentiation	O
.	O

Simultaneous	O
inhibition	O
of	O
farnesylation	O
and	O
calcineurin	O
signalling	O
results	O
in	O
a	O
synthetic	O
effect	O
on	O
growth	O
.	O

Protein	O
farnesylation	O
is	O
required	O
for	O
the	O
growth	O
and	O
cellular	O
differentiation	O
of	O
C	O
.	O
neoformans	O
and	O
may	O
provide	O
novel	O
targets	O
for	O
antifungal	O
therapy	O
.	O

Lipoprotein	O
processing	O
is	O
required	O
for	O
virulence	O
of	O
Mycobacterium	O
tuberculosis	O
.	O

Lipoproteins	O
are	O
a	O
subgroup	O
of	O
secreted	O
bacterial	O
proteins	O
characterized	O
by	O
a	O
lipidated	O
N	O
-	O
terminus	O
,	O
processing	O
of	O
which	O
is	O
mediated	O
by	O
the	O
consecutive	O
activity	O
of	O
prolipoprotein	B-PRGE
diacylglyceryl	I-PRGE
transferase	I-PRGE
(	O
Lgt	B-PRGE
)	O
and	O
lipoprotein	B-PRGE
signal	I-PRGE
peptidase	I-PRGE
(	O
LspA	B-PRGE
)	O
.	O

The	O
study	O
of	O
LspA	B-PRGE
function	O
has	O
been	O
limited	O
mainly	O
to	O
non	O
-	O
pathogenic	O
microorganisms	O
.	O

To	O
study	O
a	O
potential	O
role	O
for	O
LspA	B-PRGE
in	O
the	O
pathogenesis	O
of	O
bacterial	O
infections	O
,	O
we	O
have	O
disrupted	O
lspA	B-PRGE
by	O
allelic	O
replacement	O
in	O
Mycobacterium	O
tuberculosis	O
,	O
one	O
of	O
the	O
world	O
'	O
s	O
most	O
devastating	O
pathogens	O
.	O

Despite	O
the	O
presence	O
of	O
an	O
impermeable	O
lipid	O
outer	O
layer	O
,	O
it	O
was	O
found	O
that	O
LspA	B-PRGE
was	O
dispensable	O
for	O
growth	O
under	O
in	O
vitro	O
culture	O
conditions	O
.	O

In	O
contrast	O
,	O
the	O
mutant	O
was	O
markedly	O
attenuated	O
in	O
virulence	O
models	O
of	O
tuberculosis	O
.	O

Our	O
findings	O
establish	O
lipoprotein	O
metabolism	O
as	O
a	O
major	O
virulence	O
determinant	O
of	O
tuberculosis	O
and	O
define	O
a	O
role	O
for	O
lipoprotein	O
processing	O
in	O
bacterial	O
pathogenesis	O
.	O

In	O
addition	O
,	O
these	O
results	O
hint	O
at	O
a	O
promising	O
new	O
target	O
for	O
therapeutic	O
intervention	O
,	O
as	O
a	O
highly	O
specific	O
inhibitor	O
of	O
bacterial	O
lipoprotein	O
signal	O
peptidases	O
is	O
available	O
.	O

Two	O
closely	O
related	O
ubiquitin	B-PRGE
C	O
-	O
terminal	O
hydrolase	O
isozymes	O
function	O
as	O
reciprocal	O
modulators	O
of	O
germ	O
cell	O
apoptosis	O
in	O
cryptorchid	O
testis	O
.	O

The	O
experimentally	O
induced	O
cryptorchid	O
mouse	O
model	O
is	O
useful	O
for	O
elucidating	O
the	O
in	O
vivo	O
molecular	O
mechanism	O
of	O
germ	O
cell	O
apoptosis	O
.	O

Apoptosis	O
,	O
in	O
general	O
,	O
is	O
thought	O
to	O
be	O
partly	O
regulated	O
by	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
system	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
function	O
of	O
two	O
closely	O
related	O
members	O
of	O
the	O
ubiquitin	B-PRGE
C	O
-	O
terminal	O
hydrolase	O
(	O
UCH	O
)	O
family	O
in	O
testicular	O
germ	O
cell	O
apoptosis	O
experimentally	O
induced	O
by	O
cryptorchidism	O
.	O

The	O
two	O
enzymes	O
,	O
UCH	B-PRGE
-	I-PRGE
L1	I-PRGE
and	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
,	O
deubiquitinate	O
ubiquitin	B-PRGE
-	O
protein	O
conjugates	O
and	O
control	O
the	O
cellular	O
balance	O
of	O
ubiquitin	B-PRGE
.	O

The	O
testes	O
of	O
gracile	O
axonal	O
dystrophy	O
(	O
gad	O
)	O
mice	O
,	O
which	O
lack	O
UCH	B-PRGE
-	I-PRGE
L1	I-PRGE
,	O
were	O
resistant	O
to	O
cryptorchid	O
stress	O
-	O
related	O
injury	O
and	O
had	O
reduced	O
ubiquitin	B-PRGE
levels	O
.	O

The	O
level	O
of	O
both	O
anti	O
-	O
apoptotic	O
(	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
family	O
and	O
XIAP	B-PRGE
)	O
and	O
prosurvival	O
(	O
pCREB	O
and	O
BDNF	B-PRGE
)	O
proteins	O
was	O
significantly	O
higher	O
in	O
gad	O
mice	O
after	O
cryptorchid	O
stress	O
.	O

In	O
contrast	O
,	O
Uchl3	B-PRGE
knockout	O
mice	O
showed	O
profound	O
testicular	O
atrophy	O
and	O
apoptotic	O
germ	O
cell	O
loss	O
after	O
cryptorchid	O
injury	O
.	O

Ubiquitin	B-PRGE
level	O
was	O
not	O
significantly	O
different	O
between	O
wild	O
-	O
type	O
and	O
Uchl3	B-PRGE
knockout	O
mice	O
,	O
whereas	O
the	O
levels	O
of	O
Nedd8	B-PRGE
and	O
the	O
apoptotic	O
proteins	O
p53	B-PRGE
,	O
Bax	B-PRGE
,	O
and	O
caspase3	B-PRGE
were	O
elevated	O
in	O
Uchl3	B-PRGE
knockout	O
mice	O
.	O

These	O
results	O
demonstrate	O
that	O
UCH	B-PRGE
-	I-PRGE
L1	I-PRGE
and	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
function	O
differentially	O
to	O
regulate	O
the	O
cellular	O
levels	O
of	O
anti	O
-	O
apoptotic	O
,	O
prosurvival	O
,	O
and	O
apoptotic	O
proteins	O
during	O
testicular	O
germ	O
cell	O
apoptosis	O
.	O

Structure	O
of	O
a	O
complex	O
between	O
Nedd8	B-PRGE
and	O
the	O
Ulp	O
/	O
Senp	O
protease	O
family	O
member	O
Den1	B-PRGE
.	O

The	O
Nedd8	B-PRGE
conjugation	O
pathway	O
is	O
conserved	O
from	O
yeast	O
to	O
humans	O
and	O
is	O
essential	O
in	O
many	O
organisms	O
.	O

Nedd8	B-PRGE
is	O
conjugated	O
to	O
cullin	O
proteins	O
in	O
a	O
process	O
that	O
alters	O
SCF	O
E3	O
ubiquitin	B-PRGE
ligase	O
activity	O
,	O
and	O
it	O
is	O
presumed	O
that	O
Nedd8	B-PRGE
deconjugation	O
would	O
reverse	O
these	O
effects	O
.	O

We	O
now	O
report	O
the	O
X	O
-	O
ray	O
structures	O
of	O
the	O
human	O
Nedd8	B-PRGE
-	O
specific	O
protease	O
,	O
Den1	B-PRGE
,	O
in	O
a	O
complex	O
with	O
the	O
inhibitor	O
Nedd8	B-PRGE
aldehyde	O
,	O
thus	O
revealing	O
a	O
model	O
for	O
the	O
tetrahedral	O
transition	O
state	O
intermediate	O
generated	O
during	O
proteolysis	O
.	O

Although	O
Den1	B-PRGE
is	O
closely	O
related	O
to	O
the	O
SUMO	O
-	O
specific	O
protease	O
family	O
(	O
Ulp	O
/	O
Senp	O
family	O
)	O
,	O
structural	O
analysis	O
of	O
the	O
interface	O
suggests	O
determinants	O
involved	O
in	O
Nedd8	B-PRGE
selectivity	O
by	O
Den1	B-PRGE
over	O
other	O
ubiquitin	B-PRGE
-	O
like	O
family	O
members	O
and	O
suggests	O
how	O
the	O
Ulp	O
/	O
Senp	O
architecture	O
has	O
been	O
modified	O
to	O
interact	O
with	O
different	O
ubiquitin	B-PRGE
-	O
like	O
modifiers	O
.	O

Functional	O
analysis	O
of	O
TbARL1	B-PRGE
,	O
an	O
N	O
-	O
myristoylated	O
Golgi	O
protein	O
essential	O
for	O
viability	O
in	O
bloodstream	O
trypanosomes	O
.	O

Myristoyl	B-PRGE
-	I-PRGE
CoA	I-PRGE
:	I-PRGE
protein	I-PRGE
N	I-PRGE
-	I-PRGE
myristoyltransferase	I-PRGE
(	O
NMT	B-PRGE
)	O
,	O
an	O
essential	O
protein	O
in	O
Trypanosoma	O
brucei	O
and	O
Leishmania	O
major	O
,	O
catalyses	O
the	O
covalent	O
attachment	O
of	O
the	O
fatty	O
acid	O
myristate	O
to	O
the	O
N	O
-	O
terminus	O
of	O
a	O
range	O
of	O
target	O
proteins	O
.	O

In	O
order	O
to	O
define	O
the	O
essential	O
targets	O
contributing	O
to	O
lethality	O
in	O
the	O
absence	O
of	O
NMT	B-PRGE
activity	O
,	O
we	O
have	O
focused	O
on	O
the	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
Arf	O
)	O
family	O
of	O
GTP	O
-	O
binding	O
proteins	O
,	O
as	O
growth	O
arrest	O
in	O
Saccharomyces	O
cerevisiae	O
mutants	O
with	O
reduced	O
NMT	B-PRGE
activity	O
correlates	O
with	O
a	O
decrease	O
in	O
N	O
-	O
myristoylated	O
Arf	O
proteins	O
.	O

We	O
have	O
identified	O
nine	O
Arf	O
/	O
Arls	O
in	O
the	O
T	O
.	O
brucei	O
and	O
T	O
.	O
cruzi	O
genomes	O
and	O
ten	O
in	O
L	O
.	O
major	O
.	O

Characterization	O
of	O
the	O
T	O
.	O
brucei	O
ARL1	B-PRGE
homologue	O
has	O
revealed	O
that	O
the	O
protein	O
is	O
localized	O
in	O
the	O
Golgi	O
apparatus	O
and	O
is	O
expressed	O
only	O
in	O
the	O
mammalian	O
bloodstream	O
form	O
of	O
the	O
parasite	O
and	O
not	O
in	O
the	O
insect	O
procyclic	O
stage	O
.	O

This	O
is	O
the	O
only	O
reported	O
example	O
to	O
date	O
of	O
a	O
differentially	O
expressed	O
ARL1	B-PRGE
homologue	O
in	O
any	O
species	O
.	O

We	O
have	O
used	O
RNA	O
interference	O
to	O
demonstrate	O
that	O
ARL1	B-PRGE
is	O
essential	O
for	O
viability	O
in	O
T	O
.	O
brucei	O
bloodstream	O
parasites	O
.	O

Prior	O
to	O
cell	O
death	O
,	O
depletion	O
of	O
ARL1	B-PRGE
protein	O
in	O
bloodstream	O
parasites	O
results	O
in	O
abnormal	O
morphology	O
,	O
including	O
disintegration	O
of	O
the	O
Golgi	O
structure	O
,	O
multiple	O
flagella	O
and	O
nuclei	O
,	O
and	O
the	O
presence	O
of	O
large	O
numbers	O
of	O
vesicles	O
.	O

The	O
cells	O
have	O
only	O
a	O
minor	O
apparent	O
defect	O
in	O
endocytosis	O
but	O
exocytosis	O
of	O
variant	O
surface	O
glycoprotein	O
to	O
the	O
parasite	O
surface	O
is	O
significantly	O
delayed	O
.	O

RNA	O
interference	O
of	O
ARL1	B-PRGE
in	O
procyclic	O
cells	O
has	O
no	O
effect	O
on	O
parasite	O
growth	O
or	O
morphology	O
.	O

Our	O
results	O
suggest	O
that	O
there	O
may	O
be	O
different	O
pathways	O
regulating	O
Golgi	O
structure	O
and	O
function	O
in	O
the	O
two	O
major	O
life	O
cycle	O
stages	O
of	O
T	O
.	O
brucei	O
.	O

Effects	O
of	O
over	O
-	O
expression	O
of	O
the	O
regulatory	O
enzymes	O
DraT	B-PRGE
and	O
DraG	B-PRGE
on	O
the	O
ammonium	O
-	O
dependent	O
post	O
-	O
translational	O
regulation	O
of	O
nitrogenase	O
reductase	O
in	O
Azospirillum	O
brasilense	O
.	O

Nitrogen	O
fixation	O
in	O
Azospirillum	O
brasilense	O
is	O
regulated	O
at	O
transcriptional	O
and	O
post	O
-	O
translational	O
levels	O
.	O

Post	O
-	O
translational	O
control	O
occurs	O
through	O
the	O
reversible	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-PRGE
reductase	I-PRGE
(	O
Fe	B-PRGE
Protein	I-PRGE
)	O
,	O
mediated	O
by	O
the	O
dinitrogenase	B-PRGE
reductase	I-PRGE
ADP	I-PRGE
-	I-PRGE
ribosyltransferase	I-PRGE
(	O
DraT	B-PRGE
)	O
and	O
dinitrogenase	B-PRGE
reductase	I-PRGE
glycohydrolase	I-PRGE
(	O
DraG	B-PRGE
)	O
.	O

Although	O
the	O
DraT	B-PRGE
and	O
DraG	B-PRGE
activities	O
are	O
regulated	O
in	O
vivo	O
,	O
the	O
molecules	O
responsible	O
for	O
such	O
regulation	O
remain	O
unknown	O
.	O

We	O
have	O
constructed	O
broad	O
-	O
host	O
-	O
range	O
plasmids	O
capable	O
of	O
over	O
-	O
expressing	O
,	O
upon	O
IPTG	O
induction	O
,	O
the	O
regulatory	O
enzymes	O
DraT	B-PRGE
and	O
DraG	B-PRGE
as	O
six	O
-	O
histidine	O
-	O
N	O
-	O
terminal	O
fused	O
proteins	O
(	O
His	O
)	O
.	O

Both	O
DraT	B-PRGE
-	O
His	O
and	O
DraG	B-PRGE
-	O
His	O
are	O
functional	O
in	O
vivo	O
.	O

We	O
have	O
analyzed	O
the	O
effects	O
of	O
DraT	B-PRGE
-	O
His	O
and	O
DraG	B-PRGE
-	O
His	O
over	O
-	O
expression	O
on	O
the	O
post	O
-	O
translational	O
modification	O
of	O
Fe	B-PRGE
Protein	I-PRGE
.	O

The	O
DraT	B-PRGE
-	O
His	O
over	O
-	O
expression	O
led	O
to	O
Fe	B-PRGE
Protein	I-PRGE
modification	O
in	O
the	O
absence	O
of	O
ammonium	O
addition	O
,	O
while	O
cells	O
over	O
-	O
expressing	O
DraG	B-PRGE
-	O
His	O
showed	O
only	O
partial	O
ADP	O
-	O
ribosylation	O
of	O
Fe	B-PRGE
Protein	I-PRGE
by	O
adding	O
ammonium	O
.	O

These	O
results	O
suggest	O
that	O
both	O
DraT	B-PRGE
-	O
His	O
and	O
DraG	B-PRGE
-	O
His	O
lose	O
their	O
regulation	O
upon	O
over	O
-	O
expression	O
,	O
possible	O
by	O
titrating	O
out	O
negative	O
regulators	O
.	O

Nep1	B-PRGE
,	O
a	O
Schizosaccharomyces	O
pombe	O
deneddylating	O
enzyme	O
.	O

Nedd8	B-PRGE
is	O
a	O
ubiquitin	B-PRGE
-	O
like	O
modifier	O
that	O
is	O
attached	O
to	O
the	O
cullin	O
components	O
of	O
E3	O
ubiquitin	B-PRGE
ligases	O
.	O

More	O
recently	O
,	O
p53	B-PRGE
has	O
also	O
been	O
shown	O
to	O
be	O
Nedd8	B-PRGE
-	O
modified	O
.	O

Nedd8	B-PRGE
attachment	O
occurs	O
in	O
a	O
manner	O
similar	O
to	O
that	O
observed	O
for	O
other	O
ubiquitin	B-PRGE
-	O
like	O
modifiers	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
on	O
the	O
characterization	O
of	O
Nep1	B-PRGE
,	O
a	O
deneddylating	O
enzyme	O
in	O
fission	O
yeast	O
(	O
Schizosaccharomyces	O
pombe	O
)	O
.	O

Unlike	O
loss	O
of	O
ned8	B-PRGE
,	O
deletion	O
of	O
the	O
nep1	B-PRGE
gene	O
is	O
not	O
lethal	O
,	O
although	O
nep1	B-PRGE
.	O
d	O
cells	O
are	O
heterogeneous	O
in	O
length	O
,	O
suggesting	O
a	O
defect	O
in	O
cell	O
-	O
cycle	O
progression	O
.	O

Viability	O
of	O
nep1	B-PRGE
.	O
d	O
cells	O
is	O
dependent	O
on	O
a	O
functional	O
spindle	O
checkpoint	O
but	O
not	O
on	O
the	O
DNA	O
integrity	O
checkpoint	O
.	O

Deletion	O
of	O
a	O
related	O
gene	O
(	O
nep2	B-PRGE
)	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
nep1	B-PRGE
.	O
d	O
,	O
also	O
has	O
little	O
effect	O
on	O
cell	O
viability	O
.	O

We	O
show	O
that	O
Nep1	B-PRGE
can	O
deneddylate	O
the	O
Pcu1	B-PRGE
,	O
Pcu3	B-PRGE
and	O
Pcu4	B-PRGE
cullins	O
in	O
vitro	O
and	O
that	O
its	O
activity	O
is	O
sensitive	O
to	O
N	O
-	O
ethylmaleimide	O
,	O
consistent	O
with	O
the	O
idea	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
cysteine	O
protease	O
family	O
.	O

nep1	B-PRGE
.	O
d	O
cells	O
accumulate	O
Nedd8	B-PRGE
-	O
modified	O
proteins	O
,	O
although	O
these	O
do	O
not	O
correspond	O
to	O
modified	O
forms	O
of	O
the	O
cullins	O
,	O
suggesting	O
that	O
,	O
although	O
Nep1	B-PRGE
can	O
deneddylate	O
cullins	O
in	O
vitro	O
,	O
this	O
is	O
not	O
its	O
main	O
function	O
in	O
vivo	O
.	O

Nep1	B-PRGE
can	O
be	O
co	O
-	O
precipitated	O
with	O
the	O
signalosome	O
subunit	O
Csn5	B-PRGE
.	O

Nep1	B-PRGE
itself	O
is	O
present	O
in	O
a	O
high	O
-	O
molecular	O
-	O
mass	O
complex	O
,	O
but	O
the	O
presence	O
of	O
this	O
complex	O
is	O
not	O
dependent	O
on	O
the	O
production	O
of	O
intact	O
signalosomes	O
.	O

Our	O
results	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
Nep1	B-PRGE
may	O
be	O
responsible	O
for	O
deneddylating	O
proteins	O
other	O
than	O
cullins	O
.	O

Requirement	O
of	O
Cul3	B-PRGE
for	O
axonal	O
arborization	O
and	O
dendritic	O
elaboration	O
in	O
Drosophila	O
mushroom	O
body	O
neurons	O
.	O

Cul3	B-PRGE
belongs	O
to	O
the	O
family	O
of	O
cullin	O
proteins	O
,	O
which	O
function	O
as	O
scaffold	O
proteins	O
of	O
E3	O
ubiquitin	B-PRGE
ligase	O
complexes	O
.	O

Here	O
we	O
show	O
cell	O
-	O
autonomous	O
involvement	O
of	O
Cul3	B-PRGE
in	O
axonal	O
arborization	O
and	O
dendritic	O
elaboration	O
of	O
Drosophila	O
mushroom	O
body	O
neurons	O
.	O

Cul3	B-PRGE
mutant	O
neurons	O
are	O
defective	O
in	O
terminal	O
morphogenesis	O
of	O
neurites	O
.	O

Interestingly	O
,	O
mutant	O
axons	O
often	O
terminate	O
around	O
branching	O
points	O
.	O

In	O
addition	O
,	O
dendritic	O
elaboration	O
is	O
severely	O
affected	O
in	O
Cul3	B-PRGE
mutant	O
neurons	O
.	O

However	O
,	O
loss	O
of	O
Cul3	B-PRGE
function	O
does	O
not	O
affect	O
extension	O
of	O
the	O
axons	O
that	O
rarely	O
arborize	O
.	O

Function	O
of	O
cullin	O
-	O
type	O
proteins	O
has	O
been	O
shown	O
to	O
require	O
covalent	O
attachment	O
of	O
Nedd8	B-PRGE
(	O
neural	O
precursor	O
cell	O
-	O
expressed	O
developmentally	O
downregulated	O
)	O
,	O
a	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
Cul3	B-PRGE
is	O
inactivated	O
by	O
a	O
mutation	O
in	O
its	O
conserved	O
neddylation	O
site	O
,	O
and	O
Nedd8	B-PRGE
mutant	O
neurons	O
exhibit	O
similar	O
neuronal	O
morphogenetic	O
defects	O
.	O

Together	O
,	O
Cul3	B-PRGE
plays	O
an	O
essential	O
role	O
in	O
both	O
axonal	O
arborization	O
and	O
proper	O
elaboration	O
of	O
dendrites	O
and	O
may	O
require	O
neddylation	O
for	O
its	O
proper	O
function	O
.	O

Phosphonocarboxylate	O
inhibitors	O
of	O
Rab	O
geranylgeranyl	O
transferase	O
disrupt	O
the	O
prenylation	O
and	O
membrane	O
localization	O
of	O
Rab	O
proteins	O
in	O
osteoclasts	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Nitrogen	O
-	O
containing	O
bisphosphonate	O
drugs	O
such	O
as	O
risedronate	O
act	O
by	O
inhibiting	O
farnesyl	B-PRGE
diphosphate	I-PRGE
synthase	I-PRGE
,	O
thereby	O
disrupting	O
protein	O
prenylation	O
in	O
osteoclasts	O
.	O

We	O
recently	O
found	O
that	O
an	O
anti	O
-	O
resorptive	O
phosphonocarboxylate	O
analogue	O
of	O
risedronate	O
,	O
3	O
-	O
PEHPC	O
(	O
previously	O
referred	O
to	O
as	O
NE10790	O
)	O
,	O
selectively	O
prevents	O
prenylation	O
of	O
Rab	O
GTPases	O
in	O
vitro	O
by	O
specifically	O
inhibiting	O
Rab	O
geranylgeranyl	O
transferase	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
unprenylated	O
Rab6	B-PRGE
could	O
be	O
detected	O
in	O
J774	O
cells	O
after	O
treatment	O
with	O
3	O
-	O
PEHPC	O
or	O
risedronate	O
for	O
as	O
little	O
as	O
4	O
h	O
,	O
and	O
reached	O
50	O
%	O
after	O
24	O
h	O
.	O

Furthermore	O
,	O
treatment	O
of	O
J774	O
cells	O
or	O
osteoclasts	O
with	O
either	O
3	O
-	O
PEHPC	O
or	O
risedronate	O
disrupted	O
membrane	O
association	O
of	O
several	O
Rab	O
family	O
proteins	O
.	O

Like	O
risedronate	O
,	O
the	O
effects	O
of	O
3	O
-	O
PEHPC	O
are	O
likely	O
to	O
be	O
restricted	O
to	O
osteoclasts	O
in	O
vivo	O
,	O
since	O
both	O
risedronate	O
and	O
3	O
-	O
PEHPC	O
inhibited	O
Rab	O
prenylation	O
in	O
osteoclasts	O
,	O
but	O
not	O
in	O
general	O
bone	O
marrow	O
cells	O
,	O
when	O
administered	O
to	O
rabbits	O
in	O
vivo	O
.	O

Analysis	O
of	O
two	O
new	O
phosphonocarboxylate	O
analogues	O
of	O
3	O
-	O
PEHPC	O
(	O
3	O
-	O
PEPC	O
and	O
2	O
-	O
PEPC	O
)	O
revealed	O
that	O
,	O
first	O
,	O
the	O
geminal	O
hydroxyl	O
group	O
is	O
not	O
essential	O
for	O
inhibition	O
of	O
Rab	O
prenylation	O
by	O
phosphonocarboxylates	O
,	O
but	O
does	O
contribute	O
to	O
their	O
anti	O
-	O
resorptive	O
potency	O
,	O
most	O
likely	O
by	O
enhancing	O
their	O
affinity	O
for	O
bone	O
mineral	O
.	O

Second	O
,	O
the	O
position	O
of	O
the	O
nitrogen	O
in	O
the	O
side	O
chain	O
of	O
phosphonocarboxylates	O
is	O
crucial	O
for	O
their	O
ability	O
to	O
inhibit	O
Rab	O
prenylation	O
and	O
hence	O
to	O
inhibit	O
bone	O
resorption	O
.	O

In	O
addition	O
,	O
there	O
is	O
a	O
good	O
correlation	O
between	O
the	O
ability	O
of	O
the	O
phosphonocarboxylates	O
to	O
inhibit	O
Rab	O
prenylation	O
and	O
to	O
inhibit	O
bone	O
resorption	O
in	O
vitro	O
,	O
indicating	O
that	O
these	O
compounds	O
are	O
a	O
new	O
class	O
of	O
pharmacological	O
agents	O
that	O
inhibit	O
bone	O
resorption	O
by	O
specifically	O
preventing	O
prenylation	O
of	O
Rab	O
proteins	O
.	O

Furthermore	O
,	O
although	O
phosphonocarboxylates	O
are	O
analogues	O
of	O
bisphosphonates	O
,	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
phosphonocarboxylates	O
for	O
inhibiting	O
Rab	O
geranylgeranyltransferase	O
appear	O
to	O
differ	O
from	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
bisphosphonates	O
for	O
inhibiting	O
farnesyl	B-PRGE
diphosphate	I-PRGE
synthase	I-PRGE
.	O

CAND1	B-PRGE
enhances	O
deneddylation	O
of	O
CUL1	B-PRGE
by	O
COP9	O
signalosome	O
.	O

Cullin	O
-	O
RING	O
ligases	O
(	O
CRLs	O
)	O
regulate	O
diverse	O
cellular	O
functions	O
such	O
as	O
cell	O
cycle	O
progression	O
and	O
cytokine	O
signaling	O
by	O
ubiquitinating	O
key	O
regulatory	O
proteins	O
.	O

The	O
activity	O
of	O
CRLs	O
is	O
controlled	O
by	O
Nedd8	B-PRGE
modification	O
of	O
the	O
cullin	O
subunits	O
.	O

Recent	O
reports	O
have	O
suggested	O
that	O
CAND1	B-PRGE
,	O
which	O
specifically	O
binds	O
to	O
unmodified	O
CUL1	B-PRGE
but	O
not	O
to	O
neddylated	O
one	O
,	O
is	O
required	O
for	O
the	O
in	O
vivo	O
function	O
of	O
SCFs	O
,	O
the	O
CUL1	B-PRGE
-	O
containing	O
CRLs	O
.	O

We	O
show	O
here	O
that	O
CAND1	B-PRGE
and	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
the	O
major	O
deneddylase	O
of	O
cullins	O
,	O
bind	O
to	O
unneddylated	O
CUL1	B-PRGE
in	O
a	O
mutually	O
exclusive	O
way	O
.	O

The	O
suppression	O
of	O
CAND1	B-PRGE
expression	O
by	O
small	O
inhibitory	O
RNA	O
enhanced	O
the	O
interaction	O
between	O
CUL1	B-PRGE
and	O
CSN	O
,	O
suggesting	O
that	O
CAND1	B-PRGE
inhibited	O
the	O
binding	O
of	O
CSN	O
to	O
CUL1	B-PRGE
.	O

We	O
found	O
that	O
the	O
binding	O
of	O
CSN	O
to	O
CUL1	B-PRGE
required	O
the	O
four	O
helix	O
bundle	O
in	O
CUL1	B-PRGE
C	O
-	O
terminal	O
domain	O
,	O
which	O
was	O
wrapped	O
around	O
by	O
CAND1	B-PRGE
in	O
the	O
CAND1	B-PRGE
-	O
CUL1	B-PRGE
-	O
Rbx1	B-PRGE
complex	O
.	O

CAND1	B-PRGE
greatly	O
facilitated	O
CSN	O
-	O
mediated	O
deneddylation	O
of	O
CUL1	B-PRGE
in	O
vitro	O
,	O
which	O
was	O
dependent	O
on	O
its	O
binding	O
to	O
CUL1	B-PRGE
.	O

Our	O
data	O
suggest	O
that	O
enhancement	O
of	O
CSN	O
-	O
mediated	O
deneddylation	O
by	O
CAND1	B-PRGE
may	O
contribute	O
to	O
its	O
function	O
as	O
a	O
positive	O
regulator	O
of	O
SCFs	O
in	O
vivo	O
.	O

Interaction	O
of	O
NUB1	B-PRGE
with	O
the	O
proteasome	O
subunit	O
S5a	B-PRGE
.	O

NUB1	B-PRGE
interacts	O
with	O
a	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
NEDD8	B-PRGE
to	O
target	O
the	O
NEDD8	B-PRGE
monomer	O
and	O
neddylated	O
proteins	O
to	O
the	O
proteasome	O
for	O
degradation	O
.	O

Therefore	O
,	O
NUB1	B-PRGE
is	O
thought	O
to	O
be	O
a	O
potent	O
downregulator	O
of	O
NEDD8	B-PRGE
conjugation	O
system	O
.	O

Since	O
NUB1	B-PRGE
possesses	O
a	O
UBL	O
domain	O
,	O
which	O
was	O
previously	O
shown	O
to	O
be	O
an	O
S5a	B-PRGE
-	O
interacting	O
motif	O
in	O
RAD23	B-PRGE
/	O
HHR23	B-PRGE
,	O
we	O
initially	O
hypothesized	O
that	O
NUB1	B-PRGE
interacts	O
with	O
the	O
S5a	B-PRGE
subunit	O
of	O
the	O
proteasome	O
through	O
its	O
UBL	O
domain	O
.	O

To	O
examine	O
this	O
,	O
we	O
performed	O
an	O
in	O
vitro	O
GST	O
pull	O
-	O
down	O
assay	O
and	O
a	O
yeast	O
two	O
-	O
hybrid	O
assay	O
.	O

Unexpectedly	O
,	O
our	O
studies	O
revealed	O
that	O
NUB1	B-PRGE
directly	O
interacts	O
with	O
the	O
S5a	B-PRGE
subunit	O
through	O
its	O
C	O
-	O
terminal	O
region	O
between	O
amino	O
acid	O
residues	O
536	O
and	O
584	O
,	O
not	O
through	O
its	O
UBL	O
domain	O
.	O

Although	O
the	O
UBL	O
domain	O
was	O
not	O
an	O
S5a	B-PRGE
-	O
interacting	O
motif	O
in	O
NUB1	B-PRGE
,	O
our	O
further	O
studies	O
revealed	O
that	O
the	O
UBL	O
domain	O
is	O
required	O
for	O
the	O
function	O
of	O
NUB1	B-PRGE
.	O

S	O
-	O
palmitoylation	O
modulates	O
estrogen	B-PRGE
receptor	I-PRGE
alpha	I-PRGE
localization	O
and	O
functions	O
.	O

17beta	O
-	O
Estradiol	O
(	O
E2	O
)	O
acts	O
as	O
a	O
chemical	O
messenger	O
in	O
target	O
tissues	O
inducing	O
both	O
slow	O
nuclear	O
and	O
rapid	O
extra	O
-	O
nuclear	O
responses	O
.	O

E2	O
binds	O
to	O
its	O
cognate	O
nuclear	O
receptors	O
(	O
ER	O
)	O
resulting	O
in	O
the	O
activation	O
of	O
target	O
gene	O
transcription	O
in	O
the	O
nucleus	O
.	O

In	O
addition	O
to	O
these	O
genomic	O
effects	O
,	O
E2	O
modulates	O
cell	O
functions	O
through	O
rapid	O
non	O
-	O
genomic	O
actions	O
.	O

Stimulation	O
of	O
G	O
-	O
proteins	O
,	O
Ca	O
(	O
2	O
+	O
)	O
influx	O
,	O
inositol	O
phosphate	O
generation	O
as	O
well	O
as	O
phospholipase	O
C	O
,	O
ERK	O
/	O
MAPK	O
,	O
and	O
PI3K	O
/	O
AKT	O
activation	O
all	O
occur	O
within	O
seconds	O
to	O
minutes	O
after	O
E2	O
binding	O
to	O
a	O
small	O
population	O
of	O
ERalpha	B-PRGE
located	O
at	O
the	O
plasma	O
membrane	O
.	O

The	O
great	O
impact	O
of	O
these	O
rapid	O
signals	O
on	O
cell	O
physiology	O
renders	O
central	O
the	O
knowledge	O
of	O
the	O
structural	O
bases	O
and	O
mechanisms	O
that	O
mediate	O
extra	O
-	O
nuclear	O
signaling	O
by	O
E2	O
.	O

Several	O
laboratories	O
,	O
including	O
our	O
own	O
,	O
have	O
recently	O
elucidated	O
the	O
structural	O
requirements	O
for	O
localization	O
and	O
function	O
of	O
plasma	O
membrane	O
ERalpha	B-PRGE
.	O

This	O
review	O
summarizes	O
the	O
molecular	O
mechanisms	O
of	O
E2	O
-	O
induced	O
rapid	O
non	O
-	O
genomic	O
actions	O
relevant	O
for	O
cell	O
functions	O
,	O
highlighting	O
the	O
role	O
of	O
lipid	O
modification	O
(	O
i	O
.	O
e	O
.	O
,	O
palmitoylation	O
)	O
in	O
the	O
ERalpha	B-PRGE
localization	O
to	O
and	O
residence	O
at	O
the	O
plasma	O
membrane	O
.	O

Functional	O
interactions	O
of	O
stimulatory	O
and	O
inhibitory	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
and	O
their	O
common	O
substrate	O
small	O
GTP	O
-	O
binding	O
protein	O
.	O

smg	B-PRGE
GDS	I-PRGE
and	O
rho	O
GDI	O
are	O
stimulatory	O
and	O
inhibitory	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
,	O
respectively	O
,	O
for	O
a	O
group	O
of	O
ras	B-PRGE
p21	I-PRGE
-	O
related	O
small	O
GTP	O
-	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
.	O
rho	B-PRGE
p21	I-PRGE
is	O
a	O
common	O
substrate	O
small	O
G	O
protein	O
for	O
both	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
.	O

We	O
examined	O
here	O
the	O
functional	O
interactions	O
of	O
these	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
with	O
rho	B-PRGE
p21	I-PRGE
as	O
a	O
substrate	O
.	O
smg	B-PRGE
GDS	I-PRGE
and	O
rho	O
GDI	O
interacted	O
with	O
the	O
GDP	O
-	O
bound	O
form	O
of	O
rho	B-PRGE
p21	I-PRGE
and	O
thereby	O
stimulated	O
and	O
inhibited	O
,	O
respectively	O
,	O
the	O
dissociation	O
of	O
GDP	O
.	O

The	O
inhibitory	O
effect	O
of	O
rho	O
GDI	O
was	O
much	O
stronger	O
than	O
the	O
stimulatory	O
effect	O
of	O
smg	B-PRGE
GDS	I-PRGE
.	O

The	O
GDP	O
-	O
bound	O
form	O
of	O
rho	B-PRGE
p21	I-PRGE
formed	O
a	O
complex	O
with	O
rho	O
GDI	O
but	O
not	O
with	O
smg	B-PRGE
GDS	I-PRGE
in	O
their	O
simultaneous	O
presence	O
.	O

Since	O
the	O
content	O
of	O
smg	B-PRGE
GDS	I-PRGE
was	O
generally	O
less	O
than	O
that	O
of	O
rho	O
GDI	O
in	O
cells	O
,	O
these	O
results	O
suggest	O
that	O
there	O
is	O
some	O
mechanism	O
to	O
release	O
the	O
inhibitory	O
action	O
of	O
rho	O
GDI	O
and	O
to	O
make	O
rho	B-PRGE
p21	I-PRGE
sensitive	O
to	O
the	O
smg	B-PRGE
GDS	I-PRGE
action	O
during	O
the	O
conversion	O
of	O
rhoA	B-PRGE
p21	B-PRGE
from	O
the	O
GDP	O
-	O
bound	O
inactive	O
form	O
to	O
the	O
GTP	O
-	O
bound	O
active	O
form	O
in	O
intact	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
rho	B-PRGE
p21	I-PRGE
was	O
previously	O
shown	O
to	O
be	O
ADP	O
-	O
ribosylated	O
by	O
bacterial	O
ADP	O
-	O
ribosyltransferases	O
,	O
named	O
C3	B-PRGE
and	O
EDIN	B-PRGE
,	O
at	O
Asn41	O
in	O
the	O
putative	O
effector	O
region	O
of	O
rho	B-PRGE
p21	I-PRGE
.	O

This	O
ADP	O
-	O
ribosylation	O
was	O
inhibited	O
by	O
rho	O
GDI	O
much	O
more	O
efficiently	O
than	O
by	O
smg	B-PRGE
GDS	I-PRGE
.	O

These	O
results	O
suggest	O
that	O
rho	O
GDI	O
may	O
mask	O
the	O
putative	O
effector	O
region	O
of	O
rho	B-PRGE
p21	I-PRGE
and	O
thereby	O
inhibit	O
its	O
interaction	O
with	O
the	O
target	O
protein	O
even	O
in	O
the	O
presence	O
of	O
smg	B-PRGE
GDS	I-PRGE
.	O

Thus	O
,	O
both	O
smg	B-PRGE
GDS	I-PRGE
and	O
rho	O
GDI	O
are	O
important	O
to	O
regulate	O
the	O
rho	B-PRGE
p21	I-PRGE
activity	O
and	O
action	O
in	O
cooperation	O
with	O
each	O
other	O
.	O

Structure	O
of	O
a	O
putative	O
lipoate	B-PRGE
protein	I-PRGE
ligase	I-PRGE
from	O
Thermoplasma	O
acidophilum	O
and	O
the	O
mechanism	O
of	O
target	O
selection	O
for	O
post	O
-	O
translational	O
modification	O
.	O

Lipoyl	O
-	O
lysine	O
swinging	O
arms	O
are	O
crucial	O
to	O
the	O
reactions	O
catalysed	O
by	O
the	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
multienzyme	O
complexes	O
.	O

A	O
gene	O
encoding	O
a	O
putative	O
lipoate	B-PRGE
protein	I-PRGE
ligase	I-PRGE
(	O
LplA	B-PRGE
)	O
of	O
Thermoplasma	O
acidophilum	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
recombinant	O
protein	O
,	O
a	O
monomer	O
of	O
molecular	O
mass	O
29	O
kDa	O
,	O
was	O
catalytically	O
inactive	O
.	O

Crystal	O
structures	O
in	O
the	O
absence	O
and	O
presence	O
of	O
bound	O
lipoic	O
acid	O
were	O
solved	O
at	O
2	O
.	O
1	O
A	O
resolution	O
.	O

The	O
protein	O
was	O
found	O
to	O
fall	O
into	O
the	O
alpha	O
/	O
beta	O
class	O
and	O
to	O
be	O
structurally	O
homologous	O
to	O
the	O
catalytic	O
domains	O
of	O
class	O
II	O
aminoacyl	O
-	O
tRNA	O
synthases	O
and	O
biotin	B-PRGE
protein	I-PRGE
ligase	I-PRGE
,	O
BirA	B-PRGE
.	O

Lipoic	O
acid	O
in	O
LplA	B-PRGE
was	O
bound	O
in	O
the	O
same	O
position	O
as	O
biotin	O
in	O
BirA	B-PRGE
.	O

The	O
structure	O
of	O
the	O
T	O
.	O
acidophilum	O
LplA	B-PRGE
and	O
limited	O
proteolysis	O
of	O
E	O
.	O
coli	O
LplA	B-PRGE
together	O
highlighted	O
some	O
key	O
features	O
of	O
the	O
post	O
-	O
translational	O
modification	O
.	O

A	O
loop	O
comprising	O
residues	O
71	O
-	O
79	O
in	O
the	O
T	O
.	O
acidophilum	O
ligase	O
is	O
proposed	O
as	O
interacting	O
with	O
the	O
dithiolane	O
ring	O
of	O
lipoic	O
acid	O
and	O
discriminating	O
against	O
the	O
entry	O
of	O
biotin	O
.	O

A	O
second	O
loop	O
comprising	O
residues	O
179	O
-	O
193	O
was	O
disordered	O
in	O
the	O
T	O
.	O
acidophilum	O
structure	O
;	O
tryptic	O
cleavage	O
of	O
the	O
corresponding	O
loop	O
in	O
the	O
E	O
.	O
coli	O
LplA	B-PRGE
under	O
non	O
-	O
denaturing	O
conditions	O
rendered	O
the	O
enzyme	O
catalytically	O
inactive	O
,	O
emphasizing	O
its	O
importance	O
.	O

The	O
putative	O
LplA	B-PRGE
of	O
T	O
.	O
acidophilum	O
lacks	O
a	O
C	O
-	O
terminal	O
domain	O
found	O
in	O
its	O
counterparts	O
in	O
E	O
.	O
coli	O
(	O
Gram	O
-	O
negative	O
)	O
or	O
Streptococcus	O
pneumoniae	O
(	O
Gram	O
-	O
positive	O
)	O
.	O

A	O
gene	O
encoding	O
a	O
protein	O
that	O
appears	O
to	O
have	O
structural	O
homology	O
to	O
the	O
additional	O
domain	O
in	O
the	O
E	O
.	O
coli	O
and	O
S	O
.	O
pneumoniae	O
enzymes	O
was	O
detected	O
alongside	O
the	O
structural	O
gene	O
encoding	O
the	O
putative	O
LplA	B-PRGE
in	O
the	O
T	O
.	O
acidophilum	O
genome	O
.	O

It	O
is	O
likely	O
that	O
this	O
protein	O
is	O
required	O
to	O
confer	O
activity	O
on	O
the	O
LplA	B-PRGE
as	O
currently	O
purified	O
,	O
one	O
protein	O
perhaps	O
catalysing	O
the	O
formation	O
of	O
the	O
obligatory	O
lipoyl	O
-	O
AMP	O
intermediate	O
,	O
and	O
the	O
other	O
transferring	O
the	O
lipoyl	O
group	O
from	O
it	O
to	O
the	O
specific	O
lysine	O
residue	O
in	O
the	O
target	O
protein	O
.	O

Tax	B-PRGE
ubiquitylation	O
and	O
sumoylation	O
control	O
critical	O
cytoplasmic	O
and	O
nuclear	O
steps	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

The	O
Tax	B-PRGE
oncoprotein	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-	O
infected	O
T	O
lymphocytes	O
through	O
various	O
mechanisms	O
,	O
including	O
activation	O
of	O
the	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
pathway	O
.	O

We	O
found	O
that	O
cytoplasmic	O
ubiquitylation	O
of	O
Tax	B-PRGE
C	O
-	O
terminal	O
lysines	O
is	O
critical	O
for	O
Tax	B-PRGE
binding	O
to	O
the	O
IkappaB	O
kinase	O
complex	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
RelA	B-PRGE
.	O

Conversely	O
,	O
we	O
demonstrate	O
that	O
the	O
same	O
lysines	O
are	O
sumoylated	O
in	O
the	O
nucleus	O
,	O
an	O
event	O
required	O
for	O
the	O
formation	O
of	O
RelA	B-PRGE
/	O
p300	B-PRGE
-	O
enriched	O
Tax	B-PRGE
nuclear	O
bodies	O
and	O
full	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
Tax	B-PRGE
ubiquitylation	O
and	O
sumoylation	O
are	O
dispensable	O
for	O
its	O
activation	O
of	O
cyclic	B-PRGE
adenosine	I-PRGE
monophosphate	I-PRGE
response	I-PRGE
element	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
CREB	B-PRGE
)	O
-	O
dependent	O
genes	O
.	O

Thus	O
,	O
ubiquitylation	O
and	O
sumoylation	O
of	O
the	O
same	O
residues	O
of	O
Tax	B-PRGE
regulate	O
2	O
essential	O
steps	O
controlling	O
NF	O
-	O
kappaB	O
activation	O
,	O
demonstrating	O
how	O
these	O
posttranslational	O
modifications	O
can	O
cooperate	O
to	O
promote	O
Tax	B-PRGE
-	O
induced	O
transformation	O
.	O

Understanding	O
GFP	B-PRGE
posttranslational	O
chemistry	O
:	O
structures	O
of	O
designed	O
variants	O
that	O
achieve	O
backbone	O
fragmentation	O
,	O
hydrolysis	O
,	O
and	O
decarboxylation	O
.	O

The	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	B-PRGE
)	O
creates	O
a	O
fluorophore	O
out	O
of	O
three	O
sequential	O
amino	O
acids	O
by	O
promoting	O
spontaneous	O
posttranslational	O
modifications	O
.	O

Here	O
,	O
we	O
use	O
high	O
-	O
resolution	O
crystallography	O
to	O
characterize	O
GFP	B-PRGE
variants	O
that	O
not	O
only	O
undergo	O
peptide	O
backbone	O
cyclization	O
but	O
additional	O
denaturation	O
-	O
induced	O
peptide	O
backbone	O
fragmentation	O
,	O
native	O
peptide	O
hydrolysis	O
,	O
and	O
decarboxylation	O
reactions	O
.	O

Our	O
analyses	O
indicate	O
that	O
architectural	O
features	O
that	O
favor	O
GFP	B-PRGE
peptide	O
cyclization	O
also	O
drive	O
peptide	O
hydrolysis	O
.	O

These	O
results	O
are	O
relevant	O
for	O
the	O
maturation	O
pathways	O
of	O
GFP	B-PRGE
homologues	O
,	O
such	O
as	O
the	O
kindling	O
fluorescent	O
protein	O
and	O
the	O
Kaede	O
protein	O
,	O
which	O
use	O
backbone	O
cleavage	O
to	O
red	O
-	O
shift	O
the	O
spectral	O
properties	O
of	O
their	O
chromophores	O
.	O

We	O
further	O
propose	O
a	O
photochemical	O
mechanism	O
for	O
the	O
decarboxylation	O
reaction	O
,	O
supporting	O
a	O
role	O
for	O
the	O
GFP	B-PRGE
protein	O
environment	O
in	O
facilitating	O
radical	O
formation	O
and	O
one	O
-	O
electron	O
chemistry	O
,	O
which	O
may	O
be	O
important	O
in	O
activating	O
oxygen	O
for	O
the	O
oxidation	O
step	O
of	O
chromophore	O
biosynthesis	O
.	O

Together	O
,	O
our	O
results	O
characterize	O
GFP	B-PRGE
posttranslational	O
modification	O
chemistry	O
with	O
implications	O
for	O
the	O
energetic	O
landscape	O
of	O
backbone	O
cyclization	O
and	O
subsequent	O
reactions	O
,	O
and	O
for	O
the	O
rational	O
design	O
of	O
predetermined	O
spontaneous	O
backbone	O
cyclization	O
and	O
cleavage	O
reactions	O
.	O

Gs	B-PRGE
alpha	I-PRGE
availability	O
to	O
cholera	O
toxin	O
-	O
catalysed	O
ADP	O
-	O
ribosylation	O
is	O
decreased	O
in	O
membranes	O
of	O
retinoic	O
acid	O
-	O
treated	O
leukemic	O
cell	O
lines	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
.	O

A	O
posttranslational	O
effect	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
leukemic	O
cell	O
lines	O
to	O
differentiate	O
into	O
granulocyte	O
-	O
like	O
and	O
monocyte	O
-	O
like	O
cells	O
.	O

Limited	O
data	O
are	O
available	O
concerning	O
the	O
effects	O
of	O
RA	O
on	O
components	O
of	O
the	O
cyclic	O
AMP	O
pathway	O
in	O
human	O
myeloid	O
leukemic	O
cells	O
.	O

We	O
showed	O
previously	O
a	O
decrease	O
in	O
adenylate	O
cyclase	O
activity	O
in	O
the	O
presence	O
of	O
histamine	O
,	O
prostaglandin	O
E1	O
and	O
forskolin	O
in	O
RA	O
-	O
treated	O
HL	O
-	O
60	O
cells	O
as	O
compared	O
to	O
untreated	O
cells	O
.	O

We	O
examined	O
the	O
elements	O
of	O
the	O
signal	O
transduction	O
pathway	O
utilized	O
by	O
RA	O
in	O
the	O
human	O
myeloid	O
cell	O
line	O
HL	O
-	O
60	O
and	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

We	O
therefore	O
studied	O
the	O
effect	O
of	O
RA	O
on	O
the	O
activity	O
of	O
the	O
stimulatory	O
G	O
-	O
protein	O
(	O
Gs	O
)	O
.	O

We	O
demonstrate	O
that	O
addition	O
of	O
RA	O
to	O
two	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
,	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
,	O
does	O
not	O
induce	O
a	O
reduction	O
of	O
the	O
2	O
subunit	O
of	O
Gs	O
(	O
Gs	B-PRGE
alpha	I-PRGE
)	O
RNA	O
or	O
Gs	B-PRGE
alpha	I-PRGE
protein	O
in	O
the	O
plasma	O
membrane	O
but	O
leads	O
to	O
a	O
rapid	O
decrease	O
in	O
the	O
cholera	O
toxin	O
(	O
CTX	O
)	O
-	O
catalysed	O
ADP	O
-	O
ribosylation	O
of	O
Gs	B-PRGE
alpha	I-PRGE
.	O

In	O
addition	O
,	O
this	O
effect	O
seems	O
to	O
be	O
specific	O
to	O
RA	O
,	O
since	O
there	O
was	O
no	O
modification	O
in	O
Gs	B-PRGE
alpha	I-PRGE
ADP	O
-	O
ribosylation	O
in	O
the	O
membranes	O
of	O
cells	O
treated	O
with	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
another	O
inducer	O
of	O
differentiation	O
in	O
HL	O
-	O
60	O
cells	O
.	O

ADP	O
-	O
ribosylation	O
of	O
membrane	O
proteins	O
:	O
unveiling	O
the	O
secrets	O
of	O
a	O
crucial	O
regulatory	O
mechanism	O
in	O
mammalian	O
cells	O
.	O

Many	O
bacterial	O
toxins	O
kill	O
animal	O
cells	O
by	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
-	O
ribosylating	O
intracellular	O
target	O
proteins	O
.	O

Mammalian	O
cells	O
express	O
toxin	O
-	O
related	O
cell	O
surface	O
ADP	O
-	O
ribosyltransferases	O
(	O
ARTs	O
)	O
that	O
transfer	O
ADP	O
-	O
ribose	O
from	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
)	O
onto	O
arginine	O
residues	O
of	O
other	O
membrane	O
proteins	O
.	O

The	O
association	O
of	O
these	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-	O
anchored	O
ectoenzymes	O
with	O
glycolipid	O
rafts	O
focuses	O
them	O
onto	O
components	O
of	O
the	O
signal	O
transduction	O
machinery	O
.	O

Exposing	O
murine	O
T	O
cells	O
to	O
NAD	O
,	O
the	O
ART	O
substrate	O
,	O
induces	O
a	O
cascade	O
of	O
reactions	O
that	O
culminates	O
in	O
cell	O
death	O
by	O
apoptosis	O
.	O

This	O
mechanism	O
,	O
dubbed	O
'	O
NAD	O
-	O
induced	O
cell	O
death	O
'	O
or	O
NICD	O
,	O
is	O
initiated	O
when	O
ART2	B-PRGE
ADP	O
-	O
ribosylates	O
the	O
cytolytic	O
P2X7	B-PRGE
purinergic	O
receptor	O
,	O
inducing	O
formation	O
of	O
a	O
cation	O
channel	O
,	O
opening	O
of	O
a	O
nonselective	O
pore	O
,	O
shedding	O
of	O
CD62L	B-PRGE
from	O
the	O
cell	O
surface	O
,	O
exposure	O
of	O
phosphatidylserine	O
on	O
the	O
outer	O
leaflet	O
of	O
the	O
plasma	O
membrane	O
,	O
breakdown	O
of	O
the	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
DNA	O
-	O
fragmentation	O
.	O

The	O
ART	O
substrate	O
NAD	O
is	O
produced	O
in	O
large	O
amounts	O
inside	O
the	O
cell	O
and	O
can	O
be	O
released	O
from	O
damaged	O
cells	O
during	O
inflammation	O
and	O
tissue	O
injury	O
.	O

In	O
the	O
extracellular	O
environment	O
,	O
the	O
signaling	O
function	O
of	O
NAD	O
is	O
terminated	O
by	O
NAD	O
-	O
degrading	O
ectoenzymes	O
such	O
as	O
CD38	B-PRGE
.	O

We	O
propose	O
that	O
ART2	B-PRGE
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
P2X7	B-PRGE
represents	O
the	O
paradigm	O
of	O
a	O
regulatory	O
mechanism	O
by	O
which	O
ART	O
-	O
expressing	O
cells	O
can	O
sense	O
and	O
respond	O
to	O
the	O
release	O
of	O
NAD	O
from	O
damaged	O
cells	O
.	O

SUMO	O
modification	O
enhances	O
p66	O
-	O
mediated	O
transcriptional	O
repression	O
of	O
the	O
Mi	O
-	O
2	O
/	O
NuRD	O
complex	O
.	O

Human	B-PRGE
p66alpha	I-PRGE
and	O
p66beta	B-PRGE
are	O
two	O
potent	O
transcriptional	O
repressors	O
that	O
interact	O
with	O
the	O
methyl	O
-	O
CpG	O
-	O
binding	O
domain	O
proteins	O
MBD2	B-PRGE
and	O
MBD3	B-PRGE
.	O

An	O
analysis	O
of	O
the	O
molecular	O
mechanisms	O
mediating	O
repression	O
resulted	O
in	O
the	O
identification	O
of	O
two	O
major	O
repression	O
domains	O
in	O
p66alpha	B-PRGE
and	O
one	O
in	O
p66beta	B-PRGE
.	O

Both	O
p66alpha	B-PRGE
and	O
p66beta	B-PRGE
are	O
SUMO	O
-	O
modified	O
in	O
vivo	O
:	O
p66alpha	B-PRGE
at	O
two	O
sites	O
(	O
Lys	O
-	O
30	O
and	O
Lys	O
-	O
487	O
)	O
and	O
p66beta	B-PRGE
at	O
one	O
site	O
(	O
Lys	O
-	O
33	O
)	O
.	O

Expression	O
of	O
SUMO1	B-PRGE
enhanced	O
the	O
transcriptional	O
repression	O
activity	O
of	O
Gal	B-PRGE
-	O
p66alpha	B-PRGE
and	O
Gal	B-PRGE
-	O
p66beta	B-PRGE
.	O

Mutation	O
of	O
the	O
SUMO	O
modification	O
sites	O
or	O
using	O
a	O
SUMO1	B-PRGE
mutant	O
or	O
a	O
dominant	O
negative	O
Ubc9	B-PRGE
ligase	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
transcriptional	O
repression	O
of	O
p66alpha	B-PRGE
and	O
p66beta	B-PRGE
.	O

The	O
Mi	O
-	O
2	O
/	O
NuRD	O
components	O
MBD3	B-PRGE
,	O
RbAp46	B-PRGE
,	O
RbAp48	B-PRGE
,	O
and	O
HDAC1	B-PRGE
were	O
found	O
to	O
bind	O
to	O
both	O
p66alpha	B-PRGE
and	O
p66beta	B-PRGE
in	O
vivo	O
.	O

Most	O
of	O
the	O
interactions	O
were	O
not	O
affected	O
by	O
the	O
SUMO	O
site	O
mutations	O
in	O
p66alpha	B-PRGE
or	O
p66beta	B-PRGE
,	O
with	O
two	O
exceptions	O
.	O

HDAC1	B-PRGE
binding	O
to	O
p66alpha	B-PRGE
was	O
lost	O
in	O
the	O
case	O
of	O
a	O
p66alphaK30R	B-PRGE
mutant	O
,	O
and	O
RbAp46	B-PRGE
binding	O
was	O
reduced	O
in	O
the	O
case	O
of	O
a	O
p66betaK33R	B-PRGE
mutant	O
.	O

These	O
results	O
suggest	O
that	O
interactions	O
within	O
the	O
Mi	O
-	O
2	O
/	O
NuRD	O
complex	O
as	O
well	O
as	O
optimal	O
repression	O
are	O
mediated	O
by	O
SUMOylation	O
.	O

[	O
Ubiquitins	B-PRGE
,	O
proteasomes	O
,	O
sumoylation	O
and	O
therapeutic	O
application	O
today	O
and	O
in	O
future	O
for	O
cancer	O
and	O
other	O
diseases	O
.	O
I	O
.	O
Ubiquitin	B-PRGE
-	O
proteasome	O
system	O
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
]	O
.	O

Proteasome	O
is	O
protein	O
complex	O
with	O
proteolytic	O
activity	O
.	O

Proteasomes	O
are	O
in	O
addition	O
to	O
lysosomes	O
the	O
main	O
proteolytic	O
machinery	O
of	O
the	O
eukaryotic	O
cell	O
.	O

Proteins	O
destined	O
for	O
degradation	O
in	O
proteasomes	O
are	O
marked	O
by	O
ubiquitinylation	O
,	O
which	O
consists	O
in	O
attachment	O
of	O
polyubiquitin	B-PRGE
to	O
relevant	O
protein	O
.	O

The	O
transport	O
of	O
polyubiquitinylated	O
protein	O
follows	O
to	O
proteasome	O
,	O
where	O
protein	O
is	O
cleaved	O
into	O
small	O
peptides	O
.	O

Besides	O
polyubiquitin	B-PRGE
attachment	O
to	O
protein	O
,	O
monoubiquitinylation	O
of	O
proteins	O
exists	O
and	O
has	O
an	O
important	O
role	O
in	O
DNA	O
repair	O
,	O
transcription	O
of	O
genes	O
,	O
endocytosis	O
and	O
signal	O
transduction	O
.	O

The	O
function	O
of	O
an	O
important	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
connected	O
with	O
proteasome	O
.	O

NF	O
-	O
kappaB	O
is	O
activated	O
after	O
the	O
proteolysis	O
of	O
its	O
inhibitor	O
IkappaB	O
in	O
proteasome	O
.	O

Ubiqutinylation	O
and	O
degradation	O
of	O
protein	O
in	O
proteasome	O
and	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
play	O
significant	O
roles	O
in	O
taking	O
proteins	O
away	O
and	O
in	O
expression	O
of	O
great	O
numbers	O
of	O
genes	O
important	O
for	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
and	O
apoptosis	O
of	O
cells	O
.	O

The	O
inhibition	O
of	O
proteasomes	O
has	O
antiproliferative	O
and	O
antiinflammatory	O
effects	O
and	O
opens	O
new	O
therapeutic	O
approaches	O
to	O
a	O
treatment	O
of	O
cancer	O
and	O
some	O
inflammatory	O
diseases	O
.	O

We	O
divided	O
the	O
review	O
into	O
three	O
parts	O
:	O
I	O
.	O

Ubiquitin	B-PRGE
-	O
proteasome	O
system	O
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
II	O
.	O

Sumoylation	O
and	O
neddylation	O
as	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
similar	O
to	O
ubiquitinylation	O
and	O
their	O
significance	O
and	O
lastly	O
III	O
.	O

Using	O
of	O
the	O
knowledge	O
of	O
ubiquitin	B-PRGE
-	O
proteasome	O
system	O
in	O
cancer	O
and	O
other	O
diseases	O
therapy	O
.	O

A	O
theoretical	O
study	O
on	O
the	O
substrate	O
deacylation	O
mechanism	O
of	O
class	O
C	O
beta	O
-	O
lactamase	O
.	O

The	O
whole	O
reaction	O
of	O
the	O
deacylation	O
of	O
class	O
C	O
beta	O
-	O
lactamase	O
was	O
investigated	O
by	O
performing	O
quantum	O
chemical	O
calculations	O
under	O
physiological	O
conditions	O
.	O

In	O
this	O
study	O
,	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
of	O
the	O
inhibitor	O
moxalactam	O
-	O
bound	O
class	O
C	O
beta	O
-	O
lactamase	O
(	O
Patera	O
et	O
al	O
.	O
J	O
.	O
Am	O
.	O
Chem	O
.	O
Soc	O
.	O
2000	O
,	O
122	O
,	O
10504	O
-	O
10512	O
.	O
)	O
was	O
utilized	O
and	O
moxalactam	O
was	O
changed	O
into	O
the	O
substrate	O
cefaclor	O
.	O

A	O
model	O
for	O
quantum	O
chemical	O
calculations	O
was	O
constructed	O
using	O
an	O
energy	O
-	O
minimized	O
structure	O
of	O
the	O
substrate	O
-	O
bound	O
enzyme	O
obtained	O
by	O
molecular	O
mechanics	O
calculation	O
,	O
in	O
which	O
the	O
enzyme	O
was	O
soaked	O
in	O
thousands	O
of	O
TIP3P	O
water	O
molecules	O
.	O

It	O
was	O
found	O
that	O
the	O
deacylation	O
reaction	O
consisted	O
of	O
two	O
elementary	O
processes	O
.	O

The	O
first	O
process	O
was	O
formation	O
of	O
a	O
tetrahedral	O
intermediate	O
,	O
which	O
was	O
initiated	O
by	O
the	O
activation	O
of	O
catalytic	O
water	O
by	O
Tyr150	O
,	O
and	O
the	O
second	O
process	O
was	O
detachment	O
of	O
the	O
hydroxylated	O
substrate	O
from	O
the	O
enzyme	O
,	O
which	O
associated	O
with	O
proton	O
transfer	O
from	O
the	O
side	O
chain	O
of	O
Lys67	O
to	O
Ser64O	O
(	O
gamma	O
)	O
.	O

The	O
first	O
process	O
is	O
a	O
rate	O
-	O
determining	O
process	O
,	O
and	O
the	O
activation	O
energy	O
was	O
estimated	O
to	O
be	O
30	O
.	O
47	O
kcal	O
/	O
mol	O
from	O
density	O
functional	O
theory	O
calculations	O
considering	O
electron	O
correlation	O
(	O
B3LYP	O
/	O
6	O
-	O
31G	O
*	O
*	O
)	O
.	O

The	O
side	O
chain	O
of	O
Tyr150	O
was	O
initially	O
in	O
a	O
deprotonated	O
state	O
and	O
was	O
stably	O
present	O
in	O
the	O
active	O
site	O
of	O
the	O
acyl	O
-	O
enzyme	O
complex	O
,	O
being	O
held	O
by	O
Lys67	O
and	O
Lys315	O
cooperatively	O
.	O

Chemical	O
characterization	O
of	O
the	O
parasitophorous	O
vacuole	O
membrane	O
antigen	O
QF	B-PRGE
116	I-PRGE
from	O
Plasmodium	O
falciparum	O
.	O

On	O
the	O
basis	O
of	O
amino	O
acid	O
sequencing	O
and	O
immunological	O
cross	O
-	O
reactivity	O
,	O
the	O
Plasmodium	O
falciparum	O
parasitophorous	O
vacuole	O
antigens	O
QF116	B-PRGE
and	O
exp	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
CRA	B-PRGE
are	O
apparently	O
identical	O
.	O

The	O
epitope	O
recognized	O
by	O
an	O
inhibitory	O
monoclonal	O
antibody	O
directed	O
against	O
QF116	B-PRGE
is	O
located	O
proximal	O
to	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

The	O
QF116	B-PRGE
protein	O
is	O
processed	O
during	O
maturation	O
by	O
the	O
cleavage	O
of	O
a	O
22	O
-	O
amino	O
-	O
acid	O
signal	O
peptide	O
and	O
acylated	O
as	O
measured	O
by	O
labeling	O
with	O
myristic	O
acid	O
.	O

Insulin	B-PRGE
secretion	O
:	O
SIRT4	B-PRGE
gets	O
in	O
on	O
the	O
act	O
.	O

Despite	O
their	O
initial	O
characterization	O
as	O
histone	B-PRGE
deacetylases	O
controlling	O
transcription	O
,	O
sirtuins	O
also	O
turn	O
out	O
to	O
be	O
critical	O
regulators	O
of	O
metabolism	O
.	O

In	O
this	O
issue	O
of	O
Cell	O
,	O
Haigis	O
et	O
al	O
.	O

(	O
2006	O
)	O
demonstrate	O
that	O
the	O
mammalian	O
Sir2	B-PRGE
homolog	O
SIRT4	B-PRGE
acts	O
in	O
the	O
mitochondria	O
of	O
pancreatic	O
beta	O
cells	O
to	O
repress	O
the	O
activity	O
of	O
glutamate	B-PRGE
dehydrogenase	I-PRGE
through	O
ADP	O
-	O
ribosylation	O
.	O

In	O
this	O
way	O
,	O
SIRT4	B-PRGE
downregulates	O
insulin	B-PRGE
secretion	O
by	O
beta	O
cells	O
in	O
response	O
to	O
amino	O
acids	O
.	O

Triterpenoid	O
CDDO	O
-	O
Me	O
blocks	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
direct	O
inhibition	O
of	O
IKKbeta	B-PRGE
on	O
Cys	O
-	O
179	O
.	O

The	O
novel	O
oleanane	O
triterpenoid	O
2	O
-	O
cyano	O
-	O
3	O
,	O
12	O
-	O
dioxooleana	O
-	O
1	O
,	O
9	O
,	O
-	O
dien	O
-	O
28	O
-	O
oic	O
acid	O
(	O
CDDO	O
)	O
and	O
the	O
C	O
-	O
28	O
methyl	O
ester	O
(	O
CDDO	O
-	O
Me	O
)	O
induce	O
apoptosis	O
of	O
human	O
tumor	O
cells	O
by	O
disruption	O
of	O
redox	O
balance	O
and	O
are	O
currently	O
in	O
clinical	O
trials	O
.	O

The	O
present	O
studies	O
show	O
that	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
block	O
tumor	O
necrosis	O
factoralpha	O
-	O
induced	O
targeting	O
of	O
NF	O
-	O
kappaB	O
p65	B-PRGE
to	O
the	O
nucleus	O
.	O

CDDO	O
-	O
Me	O
also	O
blocked	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
-	O
induced	O
phosphorylation	O
of	O
IkappaBalpha	B-PRGE
.	O

In	O
concert	O
with	O
these	O
results	O
,	O
we	O
found	O
that	O
CDDO	O
-	O
Me	O
inhibits	O
IkappaBalpha	B-PRGE
kinasebeta	I-PRGE
(	O
IKKbeta	B-PRGE
)	O
activity	O
in	O
cells	O
.	O

In	O
support	O
of	O
a	O
direct	O
mechanism	O
,	O
CDDO	O
-	O
Me	O
inhibited	O
recombinant	O
IKKbeta	B-PRGE
activity	O
in	O
vitro	O
.	O

The	O
results	O
also	O
demonstrate	O
that	O
(	O
i	O
)	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
form	O
adducts	O
with	O
IKKbeta	B-PRGE
,	O
but	O
not	O
IKKbeta	B-PRGE
with	O
mutation	O
of	O
Cys	O
-	O
179	O
to	O
Ala	O
,	O
and	O
(	O
ii	O
)	O
CDDO	O
-	O
Me	O
inhibits	O
IKKbeta	B-PRGE
by	O
a	O
mechanism	O
dependent	O
on	O
oxidation	O
of	O
Cys	O
-	O
179	O
.	O

These	O
findings	O
indicate	O
that	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
directly	O
block	O
IKKbeta	B-PRGE
activity	O
and	O
thereby	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
interacting	O
with	O
Cys	O
-	O
179	O
in	O
the	O
IKKbeta	B-PRGE
activation	O
loop	O
.	O

Processing	O
of	O
the	O
gastrin	B-PRGE
precursor	O
.	O

Modulation	O
of	O
phosphorylated	O
,	O
sulfated	O
,	O
and	O
amidated	O
products	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
the	O
precursor	O
for	O
rat	O
gastrin	B-PRGE
yields	O
products	O
that	O
include	O
peptides	O
phosphorylated	O
at	O
Ser96	O
,	O
amidated	O
at	O
Phe92	O
,	O
and	O
sulfated	O
at	O
Tyr87	O
or	O
Tyr103	O
.	O

The	O
phosphorylation	O
site	O
is	O
immediately	O
adjacent	O
to	O
the	O
processing	O
point	O
that	O
gives	O
rise	O
to	O
the	O
biologically	O
active	O
amidated	O
gastrins	B-PRGE
.	O

We	O
have	O
examined	O
changes	O
in	O
post	O
-	O
translational	O
processing	O
which	O
occur	O
in	O
gastrin	B-PRGE
cells	O
from	O
rats	O
that	O
are	O
physiologically	O
stimulated	O
(	O
by	O
feeding	O
)	O
or	O
unstimulated	O
(	O
by	O
fasting	O
)	O
.	O

Peptides	O
were	O
identified	O
using	O
site	O
-	O
directed	O
radioimmunoassays	O
and	O
chromatographic	O
systems	O
that	O
resolve	O
phosphorylated	O
,	O
amidated	O
,	O
and	O
sulfated	O
progastrin	B-PRGE
products	O
,	O
including	O
intermediates	O
generated	O
prior	O
to	O
amidation	O
(	O
i	O
.	O
e	O
.	O
C	O
-	O
terminal	O
glycine	O
-	O
extended	O
variants	O
)	O
.	O

Assays	O
for	O
Phe92	O
-	O
amidated	O
peptides	O
and	O
for	O
the	O
C	O
-	O
terminal	O
tryptic	O
fragment	O
of	O
progastrin	B-PRGE
indicated	O
decreases	O
in	O
the	O
total	O
tissue	O
concentrations	O
of	O
immunoreactive	O
peptide	O
with	O
fasting	O
;	O
in	O
contrast	O
,	O
the	O
tissue	O
concentrations	O
of	O
glycine	O
-	O
extended	O
biosynthetic	O
intermediates	O
were	O
similar	O
in	O
fasted	O
and	O
fed	O
rats	O
.	O

Taken	O
together	O
the	O
data	O
suggest	O
a	O
relative	O
failure	O
in	O
amidation	O
mechanisms	O
in	O
unstimulated	O
cells	O
.	O

The	O
endopeptidase	O
cleavage	O
of	O
progastrin	B-PRGE
was	O
not	O
influenced	O
significantly	O
by	O
fasting	O
.	O

However	O
,	O
the	O
phosphorylation	O
of	O
peptide	O
products	O
containing	O
Ser96	O
was	O
depressed	O
significantly	O
in	O
fasted	O
rats	O
.	O

The	O
proportions	O
of	O
amidated	O
peptides	O
sulfated	O
at	O
Tyr87	O
were	O
generally	O
lower	O
than	O
their	O
corresponding	O
glycine	O
-	O
extended	O
biosynthetic	O
precursors	O
,	O
but	O
in	O
both	O
cases	O
the	O
proportion	O
of	O
peptide	O
in	O
the	O
sulfated	O
form	O
was	O
lower	O
than	O
for	O
peptides	O
sulfated	O
at	O
Tyr103	O
.	O

Feeding	O
did	O
not	O
change	O
the	O
sulfation	O
of	O
amidated	O
heptadecapeptide	O
gastrin	B-PRGE
or	O
its	O
glycine	O
-	O
extended	O
variant	O
.	O

The	O
results	O
suggest	O
that	O
the	O
mechanisms	O
determining	O
phosphorylation	O
and	O
amidation	O
of	O
progastrin	B-PRGE
-	O
related	O
peptides	O
depend	O
on	O
the	O
patterns	O
of	O
stimulation	O
of	O
gastrin	B-PRGE
cells	O
.	O

The	O
observation	O
that	O
decreased	O
phosphorylation	O
is	O
associated	O
with	O
a	O
failure	O
to	O
produce	O
active	O
amidated	O
products	O
is	O
consistent	O
with	O
a	O
regulatory	O
function	O
for	O
phosphorylation	O
in	O
gastrin	B-PRGE
production	O
.	O

Involvement	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
-	O
related	O
kinases	O
tank	B-PRGE
-	I-PRGE
binding	I-PRGE
kinase	I-PRGE
1	I-PRGE
/	O
IKKi	B-PRGE
and	O
cullin	O
-	O
based	O
ubiquitin	B-PRGE
ligases	O
in	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
3	I-PRGE
degradation	O
.	O

Activation	O
of	O
the	O
innate	O
arm	O
of	O
the	O
immune	O
system	O
following	O
pathogen	O
infection	O
relies	O
on	O
the	O
recruitment	O
of	O
latent	O
transcription	O
factors	O
involved	O
in	O
the	O
induction	O
of	O
a	O
subset	O
of	O
genes	O
responsible	O
for	O
viral	O
clearance	O
.	O

One	O
of	O
these	O
transcription	O
factors	O
,	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
,	O
is	O
targeted	O
for	O
proteosomal	O
degradation	O
following	O
virus	O
infection	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
process	O
are	O
still	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
polyubiquitination	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
increases	O
in	O
response	O
to	O
Sendai	O
virus	O
infection	O
.	O

Using	O
an	O
E1	O
temperature	O
-	O
sensitive	O
cell	O
line	O
,	O
we	O
demonstrate	O
that	O
polyubiquitination	O
is	O
required	O
for	O
the	O
observed	O
degradation	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

Inactivation	O
of	O
NEDD8	B-PRGE
-	O
activating	O
E1	O
enzyme	O
also	O
results	O
in	O
stabilization	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
suggesting	O
the	O
NEDDylation	O
also	O
plays	O
a	O
role	O
in	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
degradation	O
following	O
Sendai	O
virus	O
infection	O
.	O

In	O
agreement	O
with	O
this	O
observation	O
,	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
recruited	O
to	O
Cullin1	B-PRGE
following	O
virus	O
infection	O
and	O
overexpression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
Cullin1	B-PRGE
significantly	O
inhibits	O
the	O
degradation	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
observed	O
in	O
infected	O
cells	O
.	O

We	O
also	O
asked	O
whether	O
the	O
C	O
-	O
terminal	O
cluster	O
of	O
phosphoacceptor	O
sites	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
could	O
serve	O
as	O
a	O
destabilization	O
signal	O
and	O
we	O
therefore	O
measured	O
the	O
half	O
-	O
life	O
of	O
C	O
-	O
terminal	O
phosphomimetic	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
mutants	O
.	O

Interestingly	O
,	O
we	O
found	O
them	O
to	O
be	O
short	O
-	O
lived	O
in	O
contrast	O
to	O
wild	O
-	O
type	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

In	O
addition	O
,	O
no	O
degradation	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
was	O
observed	O
in	O
TBK1	B-PRGE
(	O
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
.	O

All	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
virus	O
infection	O
stimulates	O
a	O
host	O
cell	O
signaling	O
pathway	O
that	O
modulates	O
the	O
expression	O
level	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
through	O
its	O
C	O
-	O
terminal	O
phosphorylation	O
by	O
the	O
IkappaB	O
kinase	O
-	O
related	O
kinases	O
followed	O
by	O
its	O
polyubiquitination	O
,	O
which	O
is	O
mediated	O
in	O
part	O
by	O
a	O
Cullin	O
-	O
based	O
ubiquitin	B-PRGE
ligase	O
.	O

Structural	O
basis	O
for	O
SENP2	B-PRGE
protease	O
interactions	O
with	O
SUMO	O
precursors	O
and	O
conjugated	O
substrates	O
.	O

SUMO	O
processing	O
and	O
deconjugation	O
are	O
essential	O
proteolytic	O
activities	O
for	O
nuclear	O
metabolism	O
and	O
cell	O
-	O
cycle	O
progression	O
in	O
yeast	O
and	O
higher	O
eukaryotes	O
.	O

To	O
elucidate	O
the	O
mechanisms	O
used	O
during	O
substrate	O
lysine	O
deconjugation	O
,	O
SUMO	O
isoform	O
processing	O
and	O
SUMO	O
isoform	O
interactions	O
,	O
X	O
-	O
ray	O
structures	O
were	O
determined	O
for	O
a	O
catalytically	O
inert	O
SENP2	B-PRGE
protease	O
domain	O
in	O
complex	O
with	O
conjugated	O
RanGAP1	B-PRGE
-	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
RanGAP1	B-PRGE
-	O
SUMO	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
or	O
in	O
complex	O
with	O
SUMO	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
SUMO	B-PRGE
-	I-PRGE
3	I-PRGE
precursors	O
.	O

Common	O
features	O
within	O
the	O
active	O
site	O
include	O
a	O
90	O
degrees	O
kink	O
proximal	O
to	O
the	O
scissile	O
bond	O
that	O
forces	O
C	O
-	O
terminal	O
amino	O
acid	O
residues	O
or	O
the	O
lysine	O
side	O
chain	O
toward	O
a	O
protease	O
surface	O
that	O
appears	O
optimized	O
for	O
lysine	O
deconjugation	O
.	O

Analysis	O
of	O
this	O
surface	O
reveals	O
SENP2	B-PRGE
residues	O
,	O
particularly	O
Met497	O
,	O
that	O
mediate	O
,	O
and	O
in	O
some	O
instances	O
reverse	O
,	O
in	O
vitro	O
substrate	O
specificity	O
.	O

Mutational	O
analysis	O
and	O
biochemistry	O
provide	O
a	O
mechanism	O
for	O
SENP2	B-PRGE
substrate	O
preferences	O
that	O
explains	O
why	O
SENP2	B-PRGE
catalyzes	O
SUMO	O
deconjugation	O
more	O
efficiently	O
than	O
processing	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
-	O
encoded	O
protein	O
kinase	O
and	O
its	O
interaction	O
with	O
K	B-PRGE
-	I-PRGE
bZIP	I-PRGE
.	O

The	O
oncogenic	O
herpesvirus	O
,	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
,	O
also	O
identified	O
as	O
human	O
herpesvirus	O
8	O
,	O
contains	O
genes	O
producing	O
proteins	O
that	O
control	O
transcription	O
and	O
influence	O
cell	O
signaling	O
.	O

Open	B-PRGE
reading	I-PRGE
frame	I-PRGE
36	I-PRGE
(	O
ORF36	B-PRGE
)	O
of	O
this	O
virus	O
encodes	O
a	O
serine	O
/	O
threonine	O
protein	O
kinase	O
,	O
which	O
is	O
designated	O
the	O
viral	O
protein	B-PRGE
kinase	I-PRGE
(	O
vPK	B-PRGE
)	O
.	O

Our	O
recent	O
efforts	O
to	O
elucidate	O
the	O
role	O
of	O
vPK	B-PRGE
in	O
the	O
viral	O
life	O
cycle	O
have	O
focused	O
on	O
identifying	O
viral	O
protein	O
substrates	O
and	O
determining	O
the	O
effects	O
of	O
vPK	B-PRGE
-	O
mediated	O
phosphorylation	O
on	O
specific	O
steps	O
in	O
viral	O
replication	O
.	O

The	O
vPK	B-PRGE
gene	O
was	O
transcribed	O
into	O
4	O
.	O
2	O
-	O
kb	O
and	O
3	O
.	O
6	O
-	O
kb	O
mRNAs	O
during	O
the	O
early	O
and	O
late	O
phases	O
of	O
viral	O
reactivation	O
.	O

vPK	B-PRGE
is	O
colocalized	O
with	O
viral	O
DNA	O
replication	O
/	O
transcription	O
compartments	O
as	O
marked	O
by	O
a	O
polymerase	O
processivity	O
factor	O
,	O
and	O
K	B-PRGE
-	I-PRGE
bZIP	I-PRGE
,	O
a	O
protein	O
known	O
to	O
bind	O
the	O
viral	O
DNA	O
replication	O
origin	O
(	O
Ori	O
-	O
Lyt	O
)	O
and	O
to	O
regulate	O
viral	O
transcription	O
.	O

The	O
vPK	B-PRGE
physically	O
associated	O
with	O
and	O
strongly	O
phosphorylated	O
K	B-PRGE
-	I-PRGE
bZIP	I-PRGE
at	O
threonine	O
111	O
,	O
a	O
site	O
also	O
recognized	O
by	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
Cdk2	B-PRGE
.	O

Both	O
K	B-PRGE
-	I-PRGE
bZIP	I-PRGE
and	O
vPK	B-PRGE
were	O
corecruited	O
to	O
viral	O
promoters	O
targeted	O
by	O
K	B-PRGE
-	I-PRGE
bZIP	I-PRGE
as	O
well	O
as	O
to	O
the	O
Ori	O
-	O
Lyt	O
region	O
.	O

Phosphorylation	O
of	O
K	B-PRGE
-	I-PRGE
bZIP	I-PRGE
by	O
vPK	B-PRGE
had	O
a	O
negative	O
impact	O
on	O
K	B-PRGE
-	I-PRGE
bZIP	I-PRGE
transcription	O
repression	O
activity	O
.	O

The	O
extent	O
of	O
posttranslational	O
modification	O
of	O
K	B-PRGE
-	I-PRGE
bZIP	I-PRGE
by	O
sumoylation	O
,	O
a	O
process	O
that	O
influences	O
its	O
repression	O
function	O
,	O
was	O
decreased	O
by	O
vPK	B-PRGE
phosphorylation	O
at	O
threonine	O
111	O
.	O

Our	O
data	O
thus	O
identify	O
a	O
new	O
role	O
of	O
vPK	B-PRGE
as	O
a	O
modulator	O
of	O
viral	O
transcription	O
.	O

Preventing	O
apoptotic	O
cell	O
death	O
by	O
a	O
novel	O
small	O
heat	O
shock	O
protein	O
.	O

NCBI	O
database	O
analysis	O
indicated	O
that	O
the	O
human	O
C1orf41	B-PRGE
protein	O
(	O
small	O
heat	O
shock	O
-	O
like	O
protein	O
-	O
Hsp16	B-PRGE
.	I-PRGE
2	I-PRGE
)	O
has	O
sequence	O
similarity	O
with	O
small	O
heat	O
shock	O
proteins	O
(	O
sHsps	O
)	O
.	O

Since	O
sHsps	O
have	O
chaperone	O
function	O
,	O
and	O
so	O
prevent	O
aggregation	O
of	O
denatured	O
proteins	O
,	O
we	O
determined	O
whether	O
Hsp16	B-PRGE
.	I-PRGE
2	I-PRGE
could	O
prevent	O
the	O
heat	O
-	O
induced	O
aggregation	O
of	O
denatured	O
proteins	O
.	O

Under	O
our	O
experimental	O
conditions	O
,	O
recombinant	O
Hsp16	B-PRGE
.	I-PRGE
2	I-PRGE
prevented	O
aggregation	O
of	O
aldolase	O
and	O
glyceraldehyde	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
phosphate	I-PRGE
dehydrogenase	I-PRGE
,	O
and	O
protected	O
Escherichia	O
coli	O
cells	O
from	O
heat	O
stress	O
indicating	O
its	O
chaperone	O
function	O
.	O

Hsp16	B-PRGE
.	I-PRGE
2	I-PRGE
also	O
formed	O
oligomeric	O
complexes	O
in	O
aqueous	O
solution	O
.	O

Hsp16	B-PRGE
.	I-PRGE
2	I-PRGE
was	O
found	O
to	O
be	O
expressed	O
at	O
different	O
levels	O
in	O
cell	O
lines	O
and	O
tissues	O
,	O
and	O
was	O
mainly	O
localized	O
to	O
the	O
nucleus	O
and	O
the	O
cytosol	O
,	O
but	O
to	O
a	O
smaller	O
extent	O
,	O
it	O
could	O
be	O
also	O
found	O
in	O
mitochondria	O
.	O

Hsp16	B-PRGE
.	I-PRGE
2	I-PRGE
could	O
be	O
modified	O
covalently	O
by	O
poly	O
(	O
ADP	O
ribosylation	O
)	O
and	O
acetylation	O
.	O

Hsp16	B-PRGE
.	I-PRGE
2	I-PRGE
over	O
-	O
expression	O
prevented	O
etoposide	O
-	O
induced	O
cell	O
death	O
as	O
well	O
as	O
the	O
release	O
of	O
mitochondrial	O
cytochrome	B-PRGE
c	I-PRGE
and	O
caspase	O
activation	O
.	O

These	O
data	O
suggest	O
that	O
Hsp16	B-PRGE
.	I-PRGE
2	I-PRGE
can	O
prevent	O
the	O
destabilization	O
of	O
mitochondrial	O
membrane	O
systems	O
and	O
could	O
represent	O
a	O
suitable	O
target	O
for	O
modulating	O
cell	O
death	O
pathways	O
.	O

Coupling	O
of	O
the	O
de	O
novo	O
fatty	O
acid	O
biosynthesis	O
and	O
lipoylation	O
pathways	O
in	O
mammalian	O
mitochondria	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
products	O
and	O
possible	O
role	O
of	O
a	O
putative	O
pathway	O
for	O
de	O
novo	O
fatty	O
acid	O
synthesis	O
in	O
mammalian	O
mitochondria	O
.	O

Bovine	O
heart	O
mitochondrial	O
matrix	O
preparations	O
were	O
prepared	O
free	O
from	O
contamination	O
by	O
proteins	O
from	O
other	O
subcellular	O
components	O
and	O
,	O
using	O
a	O
combination	O
of	O
radioisotopic	O
labeling	O
and	O
mass	O
spectrometry	O
,	O
were	O
shown	O
to	O
contain	O
all	O
of	O
the	O
enzymes	O
required	O
for	O
the	O
extension	O
of	O
a	O
2	O
-	O
carbon	O
precursor	O
by	O
malonyl	O
moieties	O
to	O
saturated	O
acyl	O
-	O
ACP	B-PRGE
thioesters	O
containing	O
up	O
to	O
14	O
carbon	O
atoms	O
.	O

A	O
major	O
product	O
was	O
octanoyl	O
-	O
ACP	B-PRGE
and	O
,	O
in	O
the	O
presence	O
of	O
the	O
apo	O
-	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
of	O
the	O
glycine	O
cleavage	O
complex	O
,	O
the	O
newly	O
synthesized	O
octanoyl	O
moieties	O
were	O
translocated	O
to	O
the	O
lipoylation	O
site	O
on	O
the	O
acceptor	O
protein	O
.	O

These	O
studies	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	O
of	O
the	O
de	O
novo	O
fatty	O
acid	O
biosynthetic	O
pathway	O
in	O
mammalian	O
mitochondria	O
is	O
to	O
provide	O
the	O
octanoyl	O
precursor	O
required	O
for	O
the	O
essential	O
protein	O
lipoylation	O
pathway	O
.	O

Depletion	O
of	O
GGA3	B-PRGE
stabilizes	O
BACE	B-PRGE
and	O
enhances	O
beta	O
-	O
secretase	O
activity	O
.	O

Beta	B-PRGE
-	I-PRGE
site	I-PRGE
APP	I-PRGE
-	I-PRGE
cleaving	I-PRGE
enzyme	I-PRGE
(	O
BACE	B-PRGE
)	O
is	O
required	O
for	O
production	O
of	O
the	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
-	O
associated	O
Abeta	B-PRGE
protein	O
.	O

BACE	B-PRGE
levels	O
are	O
elevated	O
in	O
AD	O
brain	O
,	O
and	O
increasing	O
evidence	O
reveals	O
BACE	B-PRGE
as	O
a	O
stress	O
-	O
related	O
protease	O
that	O
is	O
upregulated	O
following	O
cerebral	O
ischemia	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
responsible	O
is	O
unknown	O
.	O

We	O
show	O
that	O
increases	O
in	O
BACE	B-PRGE
and	O
beta	O
-	O
secretase	O
activity	O
are	O
due	O
to	O
posttranslational	O
stabilization	O
following	O
caspase	O
activation	O
.	O

We	O
also	O
found	O
that	O
during	O
cerebral	O
ischemia	O
,	O
levels	O
of	O
GGA3	B-PRGE
,	O
an	O
adaptor	O
protein	O
involved	O
in	O
BACE	B-PRGE
trafficking	O
,	O
are	O
reduced	O
,	O
while	O
BACE	B-PRGE
levels	O
are	O
increased	O
.	O

RNAi	O
silencing	O
of	O
GGA3	B-PRGE
also	O
elevated	O
levels	O
of	O
BACE	B-PRGE
and	O
Abeta	B-PRGE
.	O

Finally	O
,	O
in	O
AD	O
brain	O
samples	O
,	O
GGA3	B-PRGE
protein	O
levels	O
were	O
significantly	O
decreased	O
and	O
inversely	O
correlated	O
with	O
increased	O
levels	O
of	O
BACE	B-PRGE
.	O

In	O
summary	O
,	O
we	O
have	O
elucidated	O
a	O
GGA3	B-PRGE
-	O
dependent	O
mechanism	O
regulating	O
BACE	B-PRGE
levels	O
and	O
beta	O
-	O
secretase	O
activity	O
.	O

This	O
mechanism	O
may	O
explain	O
increased	O
cerebral	O
levels	O
of	O
BACE	B-PRGE
and	O
Abeta	B-PRGE
following	O
cerebral	O
ischemia	O
and	O
existing	O
in	O
AD	O
.	O

Increased	O
acylated	O
plasma	O
ghrelin	B-PRGE
,	O
but	O
improved	O
lipid	O
profiles	O
24	O
-	O
h	O
after	O
consumption	O
of	O
carob	O
pulp	O
preparation	O
rich	O
in	O
dietary	O
fibre	O
and	O
polyphenols	O
.	O

We	O
have	O
recently	O
shown	O
that	O
a	O
polyphenol	O
-	O
rich	O
insoluble	O
dietary	O
fibre	O
preparation	O
from	O
carob	O
pulp	O
(	O
Ceratonia	O
siliqua	O
L	O
;	O
carob	O
fibre	O
)	O
decreased	O
postprandial	O
acylated	O
ghrelin	B-PRGE
,	O
TAG	O
and	O
NEFA	O
during	O
an	O
acute	O
liquid	O
meal	O
challenge	O
test	O
.	O

However	O
,	O
delayed	O
effects	O
of	O
carob	O
fibre	O
consumption	O
are	O
unknown	O
.	O

Therefore	O
,	O
a	O
randomized	O
controlled	O
crossover	O
study	O
in	O
nineteen	O
healthy	O
volunteers	O
consuming	O
foods	O
with	O
or	O
without	O
50	O
g	O
carob	O
fibre	O
was	O
conducted	O
.	O

On	O
the	O
subsequent	O
day	O
(	O
day	O
2	O
)	O
,	O
glucose	O
,	O
TAG	O
,	O
total	O
and	O
acylated	O
ghrelin	B-PRGE
as	O
well	O
as	O
insulin	B-PRGE
,	O
NEFA	O
and	O
leptin	B-PRGE
were	O
assessed	O
at	O
baseline	O
and	O
at	O
timed	O
intervals	O
for	O
300	O
min	O
after	O
ingestion	O
of	O
standardized	O
bread	O
.	O

Consumption	O
of	O
carob	O
fibre	O
-	O
enriched	O
foods	O
did	O
not	O
affect	O
fasting	O
concentrations	O
of	O
glucose	O
,	O
TAG	O
,	O
total	O
ghrelin	B-PRGE
,	O
NEFA	O
,	O
insulin	B-PRGE
and	O
leptin	B-PRGE
.	O

Fasting	O
acylated	O
ghrelin	B-PRGE
was	O
increased	O
on	O
the	O
day	O
subsequent	O
to	O
carob	O
fibre	O
consumption	O
compared	O
with	O
control	O
(	O
P	O
=	O
0	O
.	O
046	O
)	O
.	O

After	O
consumption	O
of	O
the	O
standard	O
bread	O
on	O
day	O
2	O
,	O
glucose	O
response	O
(	O
P	O
=	O
0	O
.	O
029	O
)	O
was	O
increased	O
,	O
and	O
TAG	O
(	O
P	O
=	O
0	O
.	O
033	O
)	O
and	O
NEFA	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
responses	O
were	O
decreased	O
compared	O
with	O
control	O
.	O

Postprandial	O
responses	O
of	O
total	O
and	O
acylated	O
ghrelin	B-PRGE
,	O
insulin	B-PRGE
and	O
leptin	B-PRGE
on	O
day	O
2	O
were	O
unaffected	O
by	O
carob	O
fibre	O
consumption	O
the	O
previous	O
day	O
.	O

In	O
conclusion	O
,	O
an	O
increase	O
in	O
total	O
and	O
acylated	O
plasma	O
ghrelin	B-PRGE
accompanied	O
by	O
enhanced	O
lipid	O
metabolism	O
after	O
carob	O
fibre	O
consumption	O
suggests	O
higher	O
lipid	O
utilization	O
and	O
suppressed	O
lipolysis	O
on	O
the	O
day	O
subsequent	O
to	O
carob	O
fibre	O
consumption	O
.	O

However	O
,	O
elevated	O
glucose	O
levels	O
after	O
carob	O
fibre	O
consumption	O
need	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

Evidence	O
for	O
two	O
protein	O
-	O
lipoylation	O
activities	O
in	O
Escherichia	O
coli	O
.	O

The	O
lipoate	O
acyltransferase	O
subunits	O
of	O
the	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
complexes	O
are	O
post	O
-	O
translationally	O
modified	O
with	O
one	O
or	O
more	O
covalently	O
-	O
bound	O
lipoyl	O
cofactors	O
.	O

Two	O
distinct	O
lipoate	O
-	O
protein	O
ligase	O
activities	O
,	O
LPL	B-PRGE
-	I-PRGE
A	I-PRGE
and	O
LPL	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
have	O
been	O
detected	O
in	O
E	O
.	O
coli	O
by	O
their	O
ability	O
to	O
modify	O
purified	O
lipoyl	O
apo	O
-	O
domains	O
of	O
the	O
bacterial	O
pyruvate	O
dehydrogenase	O
complex	O
.	O

Both	O
enzymes	O
require	O
ATP	O
and	O
Mg2	O
+	O
,	O
use	O
L	O
-	O
lipoate	O
,	O
8	O
-	O
methyllipoate	O
,	O
lipoyl	O
adenylate	O
and	O
octanoyl	O
adenylate	O
as	O
substrates	O
,	O
and	O
both	O
activate	O
lipoyl	O
-	O
deficient	O
pyruvate	O
dehydrogenase	O
complexes	O
.	O

In	O
contrast	O
,	O
only	O
LPL	B-PRGE
-	I-PRGE
B	I-PRGE
uses	O
D	O
-	O
lipoate	O
and	O
octanoate	O
and	O
there	O
are	O
differences	O
in	O
the	O
metal	O
-	O
ion	O
and	O
phosphate	O
requirements	O
.	O

It	O
is	O
suggested	O
that	O
LPL	B-PRGE
-	I-PRGE
B	I-PRGE
may	O
be	O
responsible	O
for	O
the	O
octanoylation	O
of	O
lipoyl	O
domains	O
observed	O
previously	O
under	O
lipoate	O
-	O
deficient	O
conditions	O
.	O

Selectivity	O
in	O
ISG15	B-PRGE
and	O
ubiquitin	B-PRGE
recognition	O
by	O
the	O
SARS	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
.	O

The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
SARS	O
-	O
CoV	O
PLpro	B-PRGE
)	O
carries	O
out	O
N	O
-	O
terminal	O
processing	O
of	O
the	O
viral	O
replicase	B-PRGE
polyprotein	I-PRGE
,	O
and	O
also	O
exhibits	O
Lys48	O
-	O
linked	O
polyubiquitin	B-PRGE
chain	O
debranching	O
and	O
ISG15	B-PRGE
precursor	O
processing	O
activities	O
in	O
vitro	O
.	O

Here	O
,	O
we	O
used	O
SDS	O
-	O
PAGE	O
and	O
fluorescence	O
-	O
based	O
assays	O
to	O
demonstrate	O
that	O
ISG15	B-PRGE
derivatives	O
are	O
the	O
preferred	O
substrates	O
for	O
the	O
deubiquitinating	O
activity	O
of	O
the	O
PLpro	B-PRGE
.	O

With	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
M	O
)	O
of	O
602	O
,	O
000	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
,	O
PLpro	B-PRGE
hydrolyzes	O
ISG15	B-PRGE
-	O
AMC	O
30	O
-	O
and	O
60	O
-	O
fold	O
more	O
efficiently	O
than	O
Ub	B-PRGE
-	O
AMC	O
and	O
Nedd8	B-PRGE
-	O
AMC	O
,	O
respectively	O
.	O

Data	O
obtained	O
with	O
truncated	O
ISG15	B-PRGE
and	O
hybrid	O
Ub	B-PRGE
/	O
ISG15	B-PRGE
substrates	O
indicate	O
that	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
Ub	B-PRGE
-	O
like	O
domains	O
of	O
ISG15	B-PRGE
contribute	O
to	O
this	O
preference	O
.	O

The	O
enzyme	O
also	O
displays	O
a	O
preference	O
for	O
debranching	O
Lys48	O
-	O
over	O
Lys63	O
-	O
linked	O
polyubiquitin	B-PRGE
chains	O
.	O

Our	O
results	O
demonstrate	O
that	O
SARS	O
-	O
CoV	O
PLpro	B-PRGE
can	O
differentiate	O
between	O
ubiquitin	B-PRGE
-	O
like	O
modifiers	O
sharing	O
a	O
common	O
C	O
-	O
terminal	O
sequence	O
,	O
and	O
that	O
the	O
debranching	O
activity	O
of	O
the	O
PLpro	B-PRGE
is	O
linkage	O
type	O
selective	O
.	O

The	O
potential	O
structural	O
basis	O
for	O
the	O
demonstrated	O
specificity	O
of	O
SARS	O
-	O
CoV	O
PLpro	B-PRGE
is	O
discussed	O
.	O

Modification	O
of	O
cellular	O
autophagy	O
protein	O
LC3	O
by	O
poliovirus	O
.	O

Poliovirus	O
infection	O
remodels	O
intracellular	O
membranes	O
,	O
creating	O
a	O
large	O
number	O
of	O
membranous	O
vesicles	O
on	O
which	O
viral	O
RNA	O
replication	O
occurs	O
.	O

Poliovirus	O
-	O
induced	O
vesicles	O
display	O
hallmarks	O
of	O
cellular	O
autophagosomes	O
,	O
including	O
delimiting	O
double	O
membranes	O
surrounding	O
the	O
cytosolic	O
lumen	O
,	O
acquisition	O
of	O
the	O
endosomal	O
marker	O
LAMP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
recruitment	O
of	O
the	O
18	O
-	O
kDa	O
host	O
protein	O
LC3	O
.	O

Autophagy	O
results	O
in	O
the	O
covalent	O
lipidation	O
of	O
LC3	O
,	O
conferring	O
the	O
property	O
of	O
membrane	O
association	O
to	O
this	O
previously	O
microtubule	O
-	O
associated	O
protein	O
and	O
providing	O
a	O
biochemical	O
marker	O
for	O
the	O
induction	O
of	O
autophagy	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
similar	O
modification	O
of	O
LC3	O
occurs	O
both	O
during	O
poliovirus	O
infection	O
and	O
following	O
expression	O
of	O
a	O
single	O
viral	O
protein	O
,	O
a	O
stable	O
precursor	O
termed	O
2BC	B-PRGE
.	O

Therefore	O
,	O
one	O
of	O
the	O
early	O
steps	O
in	O
cellular	O
autophagy	O
,	O
LC3	O
modification	O
,	O
can	O
be	O
genetically	O
separated	O
from	O
the	O
induction	O
of	O
double	O
-	O
membraned	O
vesicles	O
that	O
contain	O
the	O
modified	O
LC3	O
,	O
which	O
requires	O
both	O
viral	O
proteins	O
2BC	B-PRGE
and	O
3A	B-PRGE
.	O

The	O
existence	O
of	O
viral	O
inducers	O
that	O
promote	O
a	O
distinct	O
aspect	O
of	O
the	O
formation	O
of	O
autophagosome	O
-	O
like	O
membranes	O
both	O
facilitates	O
the	O
dissection	O
of	O
this	O
cellular	O
process	O
and	O
supports	O
the	O
hypothesis	O
that	O
this	O
branch	O
of	O
the	O
innate	O
immune	O
response	O
is	O
directly	O
subverted	O
by	O
poliovirus	O
.	O

Refined	O
crystal	O
structures	O
of	O
red	B-PRGE
and	O
green	B-PRGE
fluorescent	I-PRGE
proteins	I-PRGE
from	O
the	O
button	O
polyp	O
Zoanthus	O
.	O

The	O
three	O
-	O
dimensional	O
structures	O
of	O
the	O
wild	O
-	O
type	O
red	O
(	O
zRFP574	B-PRGE
)	O
and	O
green	O
(	O
zGFP506	B-PRGE
)	O
fluorescent	O
proteins	O
(	O
FP	O
)	O
from	O
the	O
button	O
polyp	O
Zoanthus	O
have	O
been	O
determined	O
at	O
1	O
.	O
51	O
and	O
2	O
.	O
2	O
A	O
resolution	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
crystal	O
structures	O
of	O
a	O
zGFP506	B-PRGE
variant	O
(	O
zGFP506	B-PRGE
_	O
N66D	O
)	O
with	O
replacement	O
of	O
the	O
first	O
chromophore	O
-	O
forming	O
residue	O
(	O
Asn66	O
to	O
Asp	O
)	O
have	O
been	O
determined	O
in	O
the	O
transitional	O
'	O
green	O
'	O
and	O
mature	O
'	O
red	O
'	O
states	O
at	O
2	O
.	O
4	O
and	O
2	O
.	O
2	O
A	O
,	O
respectively	O
.	O

The	O
monomers	O
of	O
these	O
proteins	O
adopt	O
the	O
typical	O
fold	O
of	O
the	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
)	O
family	O
,	O
consisting	O
of	O
an	O
11	O
-	O
stranded	O
beta	O
-	O
barrel	O
with	O
a	O
chromophore	O
embedded	O
in	O
the	O
middle	O
of	O
an	O
internal	O
alpha	O
-	O
helix	O
directed	O
along	O
the	O
beta	O
-	O
barrel	O
axis	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
the	O
chromophore	O
-	O
forming	O
sequence	O
Asn66	O
-	O
Tyr67	O
-	O
Gly68	O
within	O
zGFP506	B-PRGE
results	O
in	O
a	O
typical	O
GFP	O
-	O
like	O
coplanar	O
two	O
-	O
ring	O
structure	O
consisting	O
of	O
a	O
five	O
-	O
membered	O
imidazolinone	O
heterocycle	O
with	O
the	O
phenolic	O
ring	O
of	O
Tyr67	O
in	O
a	O
cis	O
orientation	O
to	O
the	O
C	O
(	O
alpha	O
)	O
-	O
N	O
(	O
67	O
)	O
bond	O
.	O

A	O
novel	O
post	O
-	O
translational	O
modification	O
of	O
the	O
chromophore	O
-	O
forming	O
sequence	O
Asp66	O
-	O
Tyr67	O
-	O
Gly68	O
in	O
zRFP574	B-PRGE
expands	O
the	O
protein	O
maturation	O
beyond	O
the	O
green	O
-	O
emitting	O
form	O
and	O
results	O
in	O
decarboxylation	O
of	O
the	O
Asp66	O
side	O
chain	O
.	O

It	O
is	O
suggested	O
that	O
electrostatic	O
conflict	O
between	O
the	O
closely	O
spaced	O
negatively	O
charged	O
side	O
chains	O
of	O
the	O
chromophore	O
Asp66	O
and	O
the	O
proximal	O
catalytic	O
Glu221	O
is	O
most	O
likely	O
to	O
be	O
the	O
trigger	O
for	O
the	O
chain	O
of	O
reactions	O
resulting	O
in	O
the	O
observed	O
decarboxylation	O
.	O

The	O
chromophore	O
structures	O
of	O
wild	O
-	O
type	O
zGFP506	B-PRGE
and	O
of	O
its	O
mutant	O
zGFP506	B-PRGE
_	O
N66D	O
in	O
the	O
'	O
green	O
'	O
and	O
'	O
red	O
'	O
states	O
support	O
this	O
suggestion	O
.	O

The	O
beta	O
-	O
barrel	O
frames	O
of	O
zRFP574	B-PRGE
and	O
zGFP506	B-PRGE
reveal	O
the	O
presence	O
of	O
a	O
water	O
-	O
filled	O
pore	O
leading	O
to	O
the	O
chromophore	O
Tyr67	O
,	O
similar	O
to	O
that	O
observed	O
previously	O
in	O
TurboGFP	B-PRGE
.	O

An	O
analysis	O
of	O
the	O
residue	O
composition	O
at	O
two	O
inter	O
-	O
monomer	O
interfaces	O
in	O
the	O
tetrameric	O
biological	O
unit	O
of	O
zRFP574	B-PRGE
and	O
zGFP506	B-PRGE
,	O
as	O
well	O
as	O
of	O
zYFP538	B-PRGE
from	O
the	O
same	O
species	O
,	O
has	O
revealed	O
a	O
group	O
of	O
highly	O
conserved	O
residues	O
that	O
are	O
apparently	O
responsible	O
for	O
oligomerization	O
.	O

These	O
residues	O
present	O
initial	O
useful	O
targets	O
for	O
rational	O
mutagenesis	O
aimed	O
at	O
designing	O
monomeric	O
forms	O
of	O
the	O
fluorescent	O
proteins	O
,	O
which	O
are	O
more	O
suitable	O
for	O
practical	O
applications	O
.	O

Genetic	O
characterization	O
of	O
mutants	O
resistant	O
to	O
the	O
antiauxin	O
p	O
-	O
chlorophenoxyisobutyric	O
acid	O
reveals	O
that	O
AAR3	B-PRGE
,	O
a	O
gene	O
encoding	O
a	O
DCN1	B-PRGE
-	O
like	O
protein	O
,	O
regulates	O
responses	O
to	O
the	O
synthetic	O
auxin	O
2	O
,	O
4	O
-	O
dichlorophenoxyacetic	O
acid	O
in	O
Arabidopsis	O
roots	O
.	O

To	O
isolate	O
novel	O
auxin	O
-	O
responsive	O
mutants	O
in	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
,	O
we	O
screened	O
mutants	O
for	O
root	O
growth	O
resistance	O
to	O
a	O
putative	O
antiauxin	O
,	O
p	O
-	O
chlorophenoxyisobutyric	O
acid	O
(	O
PCIB	O
)	O
,	O
which	O
inhibits	O
auxin	O
action	O
by	O
interfering	O
the	O
upstream	O
auxin	O
-	O
signaling	O
events	O
.	O

Eleven	O
PCIB	O
-	O
resistant	O
mutants	O
were	O
obtained	O
.	O

Genetic	O
mapping	O
indicates	O
that	O
the	O
mutations	O
are	O
located	O
in	O
at	O
least	O
five	O
independent	O
loci	O
,	O
including	O
two	O
known	O
auxin	O
-	O
related	O
loci	O
,	O
TRANSPORT	B-PRGE
INHIBITOR	I-PRGE
RESPONSE1	I-PRGE
and	O
Arabidopsis	O
CULLIN1	B-PRGE
.	O
antiauxin	O
-	O
resistant	O
mutants	O
(	O
aars	O
)	O
aar3	O
-	O
1	O
,	O
aar4	O
,	O
and	O
aar5	O
were	O
also	O
resistant	O
to	O
2	O
,	O
4	O
-	O
dichlorophenoxyacetic	O
acid	O
as	O
shown	O
by	O
a	O
root	O
growth	O
assay	O
.	O

Positional	O
cloning	O
of	O
aar3	O
-	O
1	O
revealed	O
that	O
the	O
AAR3	B-PRGE
gene	O
encodes	O
a	O
protein	O
with	O
a	O
domain	O
of	O
unknown	O
function	O
(	O
DUF298	O
)	O
,	O
which	O
has	O
not	O
previously	O
been	O
implicated	O
in	O
auxin	O
signaling	O
.	O

The	O
protein	O
has	O
a	O
putative	O
nuclear	O
localization	O
signal	O
and	O
shares	O
homology	O
with	O
the	O
DEFECTIVE	B-PRGE
IN	I-PRGE
CULLIN	I-PRGE
NEDDYLATION	I-PRGE
-	I-PRGE
1	I-PRGE
protein	O
through	O
the	O
DUF298	O
domain	O
.	O

The	O
results	O
also	O
indicate	O
that	O
PCIB	O
can	O
facilitate	O
the	O
identification	O
of	O
factors	O
involved	O
in	O
auxin	O
or	O
auxin	O
-	O
related	O
signaling	O
.	O

Not	O
insulin	B-PRGE
but	O
insulin	B-PRGE
sensitivity	O
,	O
leptin	B-PRGE
,	O
and	O
cortisol	O
are	O
major	O
factors	O
regulating	O
serum	O
acylated	O
ghrelin	B-PRGE
level	O
in	O
healthy	O
women	O
.	O

It	O
has	O
been	O
suggested	O
that	O
insulin	B-PRGE
and	O
glucose	O
are	O
the	O
most	O
important	O
factors	O
for	O
ghrelin	B-PRGE
secretion	O
.	O

Most	O
of	O
these	O
studies	O
were	O
performed	O
using	O
total	O
ghrelin	B-PRGE
assays	O
,	O
detecting	O
two	O
forms	O
of	O
ghrelin	B-PRGE
(	O
acylated	O
and	O
desacyl	O
)	O
,	O
derived	O
from	O
the	O
same	O
peptide	O
precursor	O
but	O
having	O
different	O
biological	O
effects	O
.	O

This	O
study	O
was	O
therefore	O
designed	O
to	O
characterize	O
associations	O
between	O
serum	O
acylated	O
ghrelin	B-PRGE
levels	O
(	O
Ghr	B-PRGE
)	O
,	O
selected	O
adipocytokines	O
,	O
hormones	O
,	O
and	O
carbohydrate	O
metabolism	O
parameters	O
in	O
healthy	O
women	O
in	O
stable	O
energy	O
metabolism	O
.	O

The	O
study	O
was	O
performed	O
on	O
32	O
healthy	O
,	O
normal	O
-	O
weight	O
,	O
non	O
-	O
pregnant	O
women	O
with	O
normal	O
[	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
18	O
.	O
9	O
-	O
24	O
.	O
2	O
kg	O
/	O
m2	O
]	O
and	O
stable	O
(	O
the	O
difference	O
between	O
two	O
measurements	O
performed	O
within	O
1	O
month	O
being	O
less	O
than	O
0	O
.	O
5	O
kg	O
)	O
body	O
weight	O
,	O
aged	O
22	O
-	O
47	O
yr	O
.	O

Leptin	B-PRGE
,	O
Ghr	B-PRGE
,	O
GH	B-PRGE
,	O
IGF	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
cortisol	O
,	O
insulin	B-PRGE
,	O
and	O
glucose	O
were	O
measured	O
in	O
the	O
early	O
follicular	O
phase	O
of	O
the	O
menstruation	O
cycle	O
.	O

Insulin	B-PRGE
sensitivity	O
was	O
measured	O
using	O
quantitative	O
insulin	B-PRGE
sensitivity	O
check	O
index	O
(	O
QUICKI	O
)	O
.	O

Body	O
composition	O
was	O
assessed	O
by	O
bioimpedance	O
.	O

We	O
found	O
a	O
positive	O
linear	O
correlation	O
between	O
leptin	B-PRGE
and	O
Ghr	B-PRGE
(	O
r	O
=	O
0	O
.	O
375	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
and	O
negative	O
correlation	O
between	O
insulin	B-PRGE
and	O
Ghr	B-PRGE
(	O
r	O
=	O
-	O
0	O
.	O
374	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
.	O

GH	B-PRGE
,	O
IGF	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
adiponectin	B-PRGE
,	O
and	O
body	O
composition	O
parameters	O
did	O
not	O
correlate	O
with	O
Ghr	B-PRGE
.	O

In	O
multiple	O
regression	O
analysis	O
only	O
QUICKI	O
,	O
leptin	B-PRGE
,	O
glucose	O
,	O
and	O
cortisol	O
(	O
positively	O
)	O
and	O
age	O
(	O
negatively	O
)	O
accounted	O
for	O
50	O
%	O
variation	O
of	O
Ghr	B-PRGE
.	O

Insulin	B-PRGE
and	O
BMI	O
did	O
not	O
contribute	O
significantly	O
to	O
the	O
model	O
.	O

Our	O
results	O
suggest	O
that	O
in	O
healthy	O
women	O
basal	O
Ghr	B-PRGE
level	O
is	O
regulated	O
by	O
multiple	O
factors	O
,	O
mainly	O
by	O
insulin	B-PRGE
sensitivity	O
,	O
leptin	B-PRGE
,	O
and	O
adrenal	O
glands	O
activity	O
.	O

However	O
,	O
further	O
studies	O
are	O
needed	O
to	O
elucidate	O
the	O
physiological	O
mechanisms	O
involved	O
in	O
acylated	O
Ghr	B-PRGE
secretion	O
.	O

The	O
role	O
of	O
loop	O
and	O
beta	O
-	O
turn	O
residues	O
as	O
structural	O
and	O
functional	O
determinants	O
for	O
the	O
lipoyl	O
domain	O
from	O
the	O
Escherichia	O
coli	O
2	O
-	O
oxoglutarate	O
dehydrogenase	O
complex	O
.	O

The	O
lipoyl	O
domain	O
of	O
the	O
dihydrolipoyl	B-PRGE
succinyltransferase	I-PRGE
(	I-PRGE
E2o	I-PRGE
)	I-PRGE
component	I-PRGE
of	I-PRGE
the	I-PRGE
2OGDH	I-PRGE
(	I-PRGE
2	I-PRGE
-	I-PRGE
oxoglutarate	I-PRGE
dehydrogenase	I-PRGE
)	I-PRGE
multienzyme	I-PRGE
complex	I-PRGE
houses	O
the	O
lipoic	O
acid	O
cofactor	O
through	O
covalent	O
attachment	O
to	O
a	O
specific	O
lysine	O
side	O
chain	O
residing	O
at	O
the	O
tip	O
of	O
a	O
beta	O
-	O
turn	O
.	O

Residues	O
within	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
and	O
a	O
nearby	O
prominent	O
loop	O
have	O
been	O
implicated	O
as	O
determinants	O
of	O
lipoyl	O
domain	O
structure	O
and	O
function	O
.	O

Protein	O
engineering	O
of	O
the	O
Escherichia	O
coli	O
E2o	B-PRGE
lipoyl	O
domain	O
(	O
E2olip	B-PRGE
)	O
revealed	O
that	O
removal	O
of	O
residues	O
from	O
the	O
loop	O
caused	O
a	O
major	O
structural	O
change	O
in	O
the	O
protein	O
,	O
which	O
rendered	O
the	O
domain	O
incapable	O
of	O
reductive	O
succinylation	O
by	O
2	B-PRGE
-	I-PRGE
oxoglutarate	I-PRGE
decarboxylase	I-PRGE
(	O
E1o	B-PRGE
)	O
and	O
reduced	O
the	O
lipoylation	O
efficiency	O
.	O

Insertion	O
of	O
a	O
new	O
loop	O
corresponding	O
to	O
that	O
of	O
the	O
E	O
.	O
coli	O
pyruvate	O
dehydrogenase	O
lipoyl	O
domain	O
(	O
E2plip	B-PRGE
)	O
restored	O
lipoylation	O
efficiency	O
and	O
the	O
capacity	O
to	O
undergo	O
reductive	O
succinylation	O
returned	O
,	O
albeit	O
at	O
a	O
lower	O
rate	O
.	O

Exchange	O
of	O
the	O
E2olip	B-PRGE
loop	O
sequence	O
significantly	O
improved	O
the	O
ability	O
of	O
the	O
domain	O
to	O
be	O
reductively	O
acetylated	O
by	O
pyruvate	B-PRGE
decarboxylase	I-PRGE
(	O
E1p	B-PRGE
)	O
,	O
retaining	O
approx	O
.	O
10	O
-	O
fold	O
more	O
acetyl	O
groups	O
after	O
25	O
min	O
than	O
wild	O
-	O
type	O
E2olip	B-PRGE
.	O

Exchange	O
of	O
the	O
beta	O
-	O
turn	O
residue	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
E2o	B-PRGE
lipoyl	O
-	O
lysine	O
DK	O
(	O
A	O
)	O
/	O
(	O
V	O
)	O
motif	O
to	O
the	O
equivalent	O
residue	O
in	O
E2plip	B-PRGE
(	O
T42G	O
)	O
,	O
both	O
singly	O
and	O
in	O
conjunction	O
with	O
the	O
loop	O
exchange	O
,	O
reduced	O
the	O
ability	O
of	O
the	O
domain	O
to	O
be	O
reductively	O
succinylated	O
,	O
but	O
led	O
to	O
an	O
increased	O
capacity	O
to	O
be	O
reductively	O
acetylated	O
by	O
the	O
non	O
-	O
cognate	O
E1p	B-PRGE
.	O

The	O
T42G	O
mutation	O
also	O
slightly	O
enhanced	O
the	O
lipoylation	O
rate	O
of	O
the	O
domain	O
.	O

The	O
surface	O
loop	O
is	O
important	O
to	O
the	O
structural	O
integrity	O
of	O
the	O
protein	O
and	O
together	O
with	O
Thr42	O
plays	O
an	O
important	O
role	O
in	O
specifying	O
the	O
interaction	O
of	O
the	O
lipoyl	O
domain	O
with	O
its	O
partner	O
E1o	O
in	O
the	O
E	O
.	O
coli	O
2OGDH	O
complex	O
.	O

Daxx	B-PRGE
mediates	O
SUMO	O
-	O
dependent	O
transcriptional	O
control	O
and	O
subnuclear	O
compartmentalization	O
.	O

SUMO	O
(	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
)	O
modification	O
is	O
emerging	O
as	O
an	O
important	O
post	O
-	O
translational	O
control	O
in	O
transcription	O
.	O

In	O
general	O
,	O
SUMO	O
modification	O
is	O
associated	O
with	O
transcriptional	O
repression	O
.	O

Although	O
many	O
SUMO	O
-	O
modified	O
transcription	O
factors	O
and	O
co	O
-	O
activators	O
have	O
been	O
identified	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
underlying	O
SUMOylation	O
-	O
elicited	O
transcriptional	O
repression	O
.	O

Here	O
,	O
we	O
summarize	O
that	O
SUMO	O
modification	O
of	O
transcription	O
factors	O
such	O
as	O
androgen	B-PRGE
receptor	I-PRGE
,	O
glucocorticoid	B-PRGE
receptor	I-PRGE
,	O
Smad4	B-PRGE
and	O
CBP	B-PRGE
[	O
CREB	B-PRGE
(	I-PRGE
cAMP	I-PRGE
-	I-PRGE
response	I-PRGE
-	I-PRGE
element	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
)	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
]	O
co	O
-	O
activator	O
results	O
in	O
the	O
recruitment	O
of	O
a	O
transcriptional	O
co	O
-	O
repressor	O
Daxx	B-PRGE
,	O
thereby	O
causing	O
transcriptional	O
repression	O
.	O

Such	O
a	O
SUMO	O
-	O
dependent	O
recruitment	O
of	O
Daxx	B-PRGE
is	O
mediated	O
by	O
the	O
interaction	O
between	O
the	O
SUMO	O
moiety	O
of	O
SUMOylated	O
factors	O
and	O
Daxx	B-PRGE
SUMO	O
-	O
interacting	O
motif	O
.	O

Interestingly	O
,	O
the	O
transrepression	O
effect	O
of	O
Daxx	B-PRGE
on	O
these	O
SUMOylated	O
transcription	O
factors	O
can	O
be	O
relieved	O
by	O
SUMOylated	O
PML	B-PRGE
(	O
promyelocytic	B-PRGE
leukaemia	I-PRGE
)	O
via	O
altering	O
Daxx	B-PRGE
partition	O
from	O
the	O
targeted	O
gene	O
promoter	O
to	O
PML	B-PRGE
nuclear	O
bodies	O
.	O

Because	O
Daxx	B-PRGE
SUMO	O
-	O
interacting	O
motif	O
is	O
a	O
common	O
binding	O
site	O
for	O
SUMOylated	O
factors	O
,	O
a	O
model	O
of	O
competition	O
for	O
Daxx	B-PRGE
recruitment	O
between	O
SUMOylated	O
PML	B-PRGE
and	O
SUMOylated	O
transcription	O
factors	O
was	O
proposed	O
.	O

Together	O
,	O
our	O
findings	O
strongly	O
suggest	O
that	O
Daxx	B-PRGE
functions	O
as	O
a	O
SUMO	O
reader	O
in	O
the	O
SUMO	O
-	O
dependent	O
regulation	O
of	O
transcription	O
and	O
subnuclear	O
compartmentalization	O
.	O

Drugs	O
affecting	O
prelamin	B-PRGE
A	I-PRGE
processing	O
:	O
effects	O
on	O
heterochromatin	O
organization	O
.	O

Increasing	O
interest	O
in	O
drugs	O
acting	O
on	O
prelamin	B-PRGE
A	I-PRGE
has	O
derived	O
from	O
the	O
finding	O
of	O
prelamin	B-PRGE
A	I-PRGE
involvement	O
in	O
severe	O
laminopathies	O
.	O

Amelioration	O
of	O
the	O
nuclear	O
morphology	O
by	O
inhibitors	O
of	O
prelamin	B-PRGE
A	I-PRGE
farnesylation	O
has	O
been	O
widely	O
reported	O
in	O
progeroid	O
laminopathies	O
.	O

We	O
investigated	O
the	O
effects	O
on	O
chromatin	O
organization	O
of	O
two	O
drugs	O
inhibiting	O
prelamin	B-PRGE
A	I-PRGE
processing	O
by	O
an	O
ultrastructural	O
and	O
biochemical	O
approach	O
.	O

The	O
farnesyltransferase	O
inhibitor	O
FTI	O
-	O
277	O
and	O
the	O
non	O
-	O
peptidomimetic	O
drug	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
farnesyl	O
-	O
l	O
-	O
cysteine	O
methylester	O
(	O
AFCMe	O
)	O
were	O
administered	O
to	O
cultured	O
control	O
human	O
fibroblasts	O
for	O
6	O
or	O
18	O
h	O
.	O

FTI	O
-	O
277	O
interferes	O
with	O
protein	O
farnesylation	O
causing	O
accumulation	O
of	O
non	O
-	O
farnesylated	O
prelamin	B-PRGE
A	I-PRGE
,	O
while	O
AFCMe	O
impairs	O
the	O
last	O
cleavage	O
of	O
the	O
lamin	B-PRGE
A	I-PRGE
precursor	O
and	O
is	O
expected	O
to	O
accumulate	O
farnesylated	O
prelamin	B-PRGE
A	I-PRGE
.	O

FTI	O
-	O
277	O
caused	O
redistribution	O
of	O
heterochromatin	O
domains	O
at	O
the	O
nuclear	O
interior	O
,	O
while	O
AFCMe	O
caused	O
loss	O
of	O
heterochromatin	O
domains	O
,	O
increase	O
of	O
nuclear	O
size	O
and	O
nuclear	O
lamina	O
thickening	O
.	O

At	O
the	O
biochemical	O
level	O
,	O
heterochromatin	O
-	O
associated	O
proteins	O
and	O
LAP2	B-PRGE
alpha	I-PRGE
were	O
clustered	O
at	O
the	O
nuclear	O
interior	O
following	O
FTI	O
-	O
277	O
treatment	O
,	O
while	O
they	O
were	O
unevenly	O
distributed	O
or	O
absent	O
in	O
AFCMe	O
-	O
treated	O
nuclei	O
.	O

The	O
reported	O
effects	O
show	O
that	O
chromatin	O
is	O
an	O
immediate	O
target	O
of	O
FTI	O
-	O
277	O
and	O
AFCMe	O
and	O
that	O
dramatic	O
remodeling	O
of	O
chromatin	O
domains	O
occurs	O
following	O
treatment	O
with	O
the	O
drugs	O
.	O

These	O
effects	O
appear	O
to	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
the	O
accumulation	O
of	O
prelamin	B-PRGE
A	I-PRGE
forms	O
,	O
since	O
impairment	O
of	O
prelamin	B-PRGE
A	I-PRGE
accumulation	O
,	O
here	O
obtained	O
by	O
5	O
-	O
azadeoxycytidine	O
treatment	O
,	O
abolishes	O
the	O
chromatin	O
effects	O
.	O

These	O
results	O
may	O
be	O
used	O
to	O
evaluate	O
downstream	O
effects	O
of	O
FTIs	O
or	O
other	O
prelamin	B-PRGE
A	I-PRGE
inhibitors	O
potentially	O
useful	O
for	O
the	O
therapy	O
of	O
laminopathies	O
.	O

H2O2	O
/	O
nitrite	O
-	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
hemoglobin	O
determined	O
by	O
mass	O
spectrometry	O
:	O
redox	O
regulation	O
of	O
tyrosine	O
nitration	O
and	O
3	O
-	O
nitrotyrosine	O
reduction	O
by	O
antioxidants	O
.	O

Covalent	O
modifications	O
of	O
proteins	O
by	O
endogenous	O
reactive	O
nitrogen	O
oxide	O
species	O
lead	O
to	O
cytotoxic	O
effects	O
that	O
are	O
implicated	O
in	O
diseases	O
associated	O
with	O
chronic	O
infections	O
and	O
inflammation	O
.	O

Tyrosine	O
nitration	O
is	O
a	O
major	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
by	O
reactive	O
nitrogen	O
oxide	O
species	O
.	O

Recent	O
studies	O
suggest	O
that	O
nitrotyrosine	O
is	O
not	O
a	O
permanent	O
protein	O
modification	O
.	O

We	O
previously	O
demonstrated	O
that	O
lipoyl	O
dehydrogenase	O
is	O
capable	O
of	O
converting	O
3	O
-	O
nitrotyrosine	O
into	O
3	O
-	O
aminotyrosine	O
in	O
the	O
presence	O
of	O
certain	O
reducing	O
agents	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
various	O
hemoproteins	O
,	O
hemin	O
,	O
and	O
the	O
cobalt	O
-	O
containing	O
cofactor	O
cyanocobalamin	O
to	O
mediate	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
-	O
dependent	O
tyrosine	O
nitration	O
and	O
found	O
that	O
these	O
hemoproteins	O
and	O
metal	O
-	O
containing	O
cofactors	O
also	O
catalyzed	O
the	O
reduction	O
of	O
3	O
-	O
nitrotyrosine	O
to	O
various	O
extents	O
in	O
the	O
presence	O
of	O
thiol	O
reducing	O
agents	O
or	O
ascorbate	O
.	O

The	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
-	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
hemoglobin	O
identified	O
by	O
nanoLC	O
/	O
nanospray	O
ionization	O
tandem	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
tryptic	O
digest	O
include	O
nitration	O
of	O
tyrosine	O
and	O
tryptophan	O
,	O
as	O
well	O
as	O
oxidation	O
of	O
methionine	O
and	O
cysteine	O
residues	O
.	O

Nitration	O
of	O
human	O
hemoglobin	O
by	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
was	O
detected	O
on	O
Tyr24	O
and	O
Tyr42	O
(	O
alpha	B-PRGE
-	I-PRGE
chain	I-PRGE
)	O
and	O
on	O
Tyr130	O
and	O
Trp15	O
(	O
beta	B-PRGE
-	I-PRGE
chain	I-PRGE
)	O
in	O
the	O
alphabeta	O
-	O
dimer	O
.	O

Oxidation	O
of	O
methionine	O
and	O
cysteine	O
residues	O
was	O
also	O
observed	O
.	O

Furthermore	O
,	O
hemoglobin	O
also	O
catalyzed	O
nitro	O
reduction	O
of	O
3	O
-	O
nitrotyrosine	O
to	O
form	O
3	O
-	O
aminotyrosine	O
,	O
at	O
Tyr24	O
in	O
the	O
alpha	B-PRGE
-	I-PRGE
chain	I-PRGE
peptide	O
of	O
human	O
Hb	O
in	O
the	O
presence	O
of	O
ascorbate	O
.	O

The	O
enhanced	O
peroxidase	O
activity	O
of	O
nitrated	O
hemoglobin	O
can	O
be	O
reversed	O
by	O
the	O
antioxidant	O
ascorbate	O
.	O

These	O
results	O
suggest	O
a	O
possible	O
in	O
vivo	O
pathway	O
for	O
hemoglobin	O
contributing	O
to	O
denitration	O
of	O
nitrated	O
proteins	O
through	O
redox	O
regulation	O
.	O

Specific	O
ion	O
influences	O
on	O
self	O
-	O
association	O
of	O
pyruvate	B-PRGE
dehydrogenase	I-PRGE
kinase	I-PRGE
isoform	I-PRGE
2	I-PRGE
(	O
PDHK2	B-PRGE
)	O
,	O
binding	O
of	O
PDHK2	B-PRGE
to	O
the	O
L2	O
lipoyl	O
domain	O
,	O
and	O
effects	O
of	O
the	O
lipoyl	O
group	O
-	O
binding	O
site	O
inhibitor	O
,	O
Nov3r	O
.	O

Association	O
of	O
the	O
PDHK2	B-PRGE
and	O
GST	B-PRGE
-	O
L2	O
(	O
glutathione	B-PRGE
-	I-PRGE
S	I-PRGE
-	I-PRGE
transferase	I-PRGE
fused	O
to	O
the	O
inner	O
lipoyl	O
domain	O
(	O
L2	O
)	O
of	O
dihydrolipoyl	B-PRGE
acetyltransferase	I-PRGE
(	O
E2	B-PRGE
)	O
)	O
dimers	O
was	O
enhanced	O
by	O
K	O
+	O
with	O
higher	O
affinity	O
K	O
+	O
binding	O
than	O
occurs	O
at	O
the	O
PDHK2	B-PRGE
active	O
site	O
.	O

Supporting	O
a	O
distinct	O
K	O
+	O
binding	O
site	O
,	O
the	O
NH4	O
+	O
ion	O
did	O
not	O
effectively	O
replace	O
K	O
+	O
in	O
aiding	O
GST	B-PRGE
-	O
L2	O
binding	O
.	O

With	O
50	O
mM	O
K	O
+	O
,	O
Pi	O
enhanced	O
interference	O
by	O
ADP	O
,	O
ATP	O
,	O
or	O
pyruvate	O
of	O
PDHK2	B-PRGE
binding	O
to	O
GST	B-PRGE
-	O
L2	O
.	O

The	O
inclusion	O
of	O
Pi	O
with	O
ADP	O
or	O
ATP	O
plus	O
pyruvate	O
greatly	O
hindered	O
PDHK2	B-PRGE
binding	O
to	O
GST	B-PRGE
-	O
L2	O
and	O
promoted	O
PDHK2	O
forming	O
a	O
tetramer	O
.	O

Reciprocally	O
,	O
GST	B-PRGE
-	O
L2	O
interference	O
with	O
ATP	O
/	O
ADP	O
binding	O
also	O
required	O
elevated	O
K	O
+	O
and	O
was	O
increased	O
by	O
Pi	O
.	O

Potent	O
inhibition	O
by	O
Nov3r	O
of	O
E2	B-PRGE
-	O
activated	O
PDHK2	B-PRGE
activity	O
(	O
IC50	O
of	O
approximately	O
7	O
.	O
8	O
nM	O
)	O
required	O
elevated	O
K	O
+	O
and	O
Pi	O
.	O

Nov3r	O
only	O
modestly	O
inhibited	O
the	O
low	O
activity	O
of	O
PDHK2	B-PRGE
without	O
E2	B-PRGE
.	O

By	O
binding	O
at	O
the	O
lipoyl	O
group	O
binding	O
site	O
,	O
Nov3r	O
prevented	O
PDHK2	O
binding	O
to	O
E2	B-PRGE
and	O
GST	B-PRGE
-	O
L2	O
.	O

Nov3r	O
interfered	O
with	O
high	O
-	O
affinity	O
binding	O
of	O
ADP	O
and	O
pyruvate	O
via	O
a	O
Pi	O
-	O
dependent	O
mechanism	O
.	O

Thus	O
,	O
GST	B-PRGE
-	O
L2	O
binding	O
to	O
PDHK2	B-PRGE
is	O
supported	O
by	O
K	O
+	O
binding	O
at	O
a	O
site	O
distinct	O
from	O
the	O
active	O
site	O
.	O

Pi	O
makes	O
major	O
contributions	O
to	O
ligands	O
interfering	O
with	O
PDHK2	B-PRGE
binding	O
to	O
GST	B-PRGE
-	O
L2	O
,	O
the	O
conversion	O
of	O
PDHK2	B-PRGE
dimer	O
to	O
a	O
tetramer	O
,	O
and	O
Nov3r	O
(	O
an	O
acetyl	O
-	O
lipoate	O
analog	O
)	O
interfering	O
with	O
binding	O
of	O
ADP	O
and	O
pyruvate	O
.	O

Pi	O
is	O
suggested	O
to	O
facilitate	O
transmission	O
within	O
PDHK2	B-PRGE
of	O
the	O
stimulatory	O
signal	O
of	O
acetylation	O
from	O
the	O
distal	O
lipoyl	O
-	O
group	O
binding	O
site	O
to	O
the	O
active	O
site	O
.	O

Studies	O
of	O
the	O
ubiquitin	B-PRGE
proteasome	O
system	O
.	O

A	O
concept	O
that	O
has	O
arisen	O
over	O
the	O
last	O
decade	O
is	O
that	O
proteins	O
can	O
,	O
in	O
general	O
,	O
be	O
covalently	O
modified	O
by	O
polypeptides	O
,	O
resulting	O
in	O
alterations	O
in	O
their	O
fate	O
and	O
function	O
.	O

The	O
first	O
-	O
identified	O
and	O
most	O
well	O
studied	O
of	O
these	O
modifying	O
polypeptides	O
is	O
ubiquitin	B-PRGE
.	O

Although	O
targeting	O
for	O
proteasomal	O
degradation	O
is	O
the	O
best	O
studied	O
outcome	O
of	O
ubiquitylation	O
,	O
we	O
now	O
understand	O
that	O
modification	O
of	O
proteins	O
with	O
ubiquitin	B-PRGE
has	O
numerous	O
other	O
cellular	O
roles	O
that	O
alter	O
protein	O
function	O
and	O
that	O
are	O
unrelated	O
to	O
proteasomal	O
degradation	O
.	O

Ubiquitylation	O
is	O
a	O
complex	O
process	O
that	O
is	O
regulated	O
at	O
the	O
level	O
of	O
both	O
addition	O
and	O
removal	O
of	O
ubiquitin	B-PRGE
from	O
target	O
proteins	O
.	O

This	O
unit	O
includes	O
a	O
number	O
of	O
different	O
basic	O
protocols	O
that	O
will	O
facilitate	O
the	O
study	O
of	O
components	O
of	O
the	O
ubiquitin	B-PRGE
system	O
and	O
substrate	O
ubiquitylation	O
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Because	O
another	O
protein	O
modifier	O
,	O
NEDD8	B-PRGE
,	O
itself	O
regulates	O
aspects	O
of	O
the	O
ubiquitin	B-PRGE
system	O
,	O
basic	O
protocols	O
on	O
neddylation	O
are	O
also	O
included	O
in	O
this	O
unit	O
.	O

Fine	O
mapping	O
of	O
posttranslational	O
modifications	O
of	O
the	O
linker	O
histone	B-PRGE
H1	I-PRGE
from	O
Drosophila	O
melanogaster	O
.	O

The	O
linker	O
histone	B-PRGE
H1	I-PRGE
binds	O
to	O
the	O
DNA	O
in	O
between	O
adjacent	O
nucleosomes	O
and	O
contributes	O
to	O
chromatin	O
organization	O
and	O
transcriptional	O
control	O
.	O

It	O
is	O
known	O
that	O
H1	B-PRGE
carries	O
diverse	O
posttranslational	O
modifications	O
(	O
PTMs	O
)	O
,	O
including	O
phosphorylation	O
,	O
lysine	O
methylation	O
and	O
ADP	O
-	O
ribosylation	O
.	O

Their	O
biological	O
functions	O
,	O
however	O
,	O
remain	O
largely	O
unclear	O
.	O

This	O
is	O
in	O
part	O
due	O
to	O
the	O
fact	O
that	O
most	O
of	O
the	O
studies	O
have	O
been	O
performed	O
in	O
organisms	O
that	O
have	O
several	O
H1	B-PRGE
variants	O
,	O
which	O
complicates	O
the	O
analyses	O
.	O

We	O
have	O
chosen	O
Drosophila	O
melanogaster	O
,	O
a	O
model	O
organism	O
,	O
which	O
has	O
a	O
single	O
H1	B-PRGE
variant	O
,	O
to	O
approach	O
the	O
study	O
of	O
the	O
role	O
of	O
H1	B-PRGE
PTMs	O
during	O
embryonic	O
development	O
.	O

Mass	O
spectrometry	O
mapping	O
of	O
the	O
entire	O
sequence	O
of	O
the	O
protein	O
showed	O
phosphorylation	O
only	O
in	O
the	O
ten	O
N	O
-	O
terminal	O
amino	O
acids	O
,	O
mostly	O
at	O
S10	O
.	O

For	O
the	O
first	O
time	O
,	O
changes	O
in	O
the	O
PTMs	O
of	O
a	O
linker	O
H1	B-PRGE
during	O
the	O
development	O
of	O
a	O
multicellular	O
organism	O
are	O
reported	O
.	O

The	O
abundance	O
of	O
H1	B-PRGE
monophosphorylated	O
at	O
S10	O
decreases	O
as	O
the	O
embryos	O
age	O
,	O
which	O
suggests	O
that	O
this	O
PTM	O
is	O
related	O
to	O
cell	O
cycle	O
progression	O
and	O
/	O
or	O
cell	O
differentiation	O
.	O

Additionally	O
,	O
we	O
have	O
found	O
a	O
polymorphism	O
in	O
the	O
protein	O
sequence	O
that	O
can	O
be	O
mistaken	O
with	O
lysine	O
methylation	O
if	O
the	O
analysis	O
is	O
not	O
rigorous	O
.	O

NEDD8	B-PRGE
acts	O
as	O
a	O
'	O
molecular	O
switch	O
'	O
defining	O
the	O
functional	O
selectivity	O
of	O
VHL	B-PRGE
.	O

The	O
von	B-PRGE
Hippel	I-PRGE
-	I-PRGE
Lindau	I-PRGE
(	I-PRGE
VHL	I-PRGE
)	I-PRGE
tumour	I-PRGE
suppressor	I-PRGE
protein	O
is	O
important	O
in	O
the	O
E3	O
ubiquitin	B-PRGE
ligase	O
ECV	O
(	O
Elongin	B-PRGE
B	I-PRGE
/	O
C	B-PRGE
-	O
CUL2	B-PRGE
-	O
VHL	B-PRGE
)	O
-	O
mediated	O
destruction	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
and	O
the	O
promotion	O
of	O
fibronectin	B-PRGE
(	O
FN	B-PRGE
)	O
extracellular	O
matrix	O
assembly	O
.	O

Although	O
the	O
precise	O
molecular	O
mechanism	O
controlling	O
the	O
selectivity	O
of	O
VHL	B-PRGE
function	O
remains	O
unknown	O
,	O
a	O
failure	O
in	O
either	O
process	O
is	O
associated	O
with	O
oncogenic	O
progression	O
.	O

Here	O
,	O
we	O
show	O
that	O
VHL	B-PRGE
performs	O
its	O
FN	B-PRGE
-	O
associated	O
function	O
independently	O
of	O
the	O
ECV	O
complex	O
,	O
highlighting	O
the	O
autonomy	O
of	O
these	O
pathways	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
NEDD8	B-PRGE
,	O
a	O
ubiquitin	B-PRGE
-	O
like	O
molecule	O
,	O
acts	O
as	O
a	O
'	O
molecular	O
switch	O
'	O
in	O
which	O
its	O
covalent	O
conjugation	O
to	O
VHL	B-PRGE
prohibits	O
the	O
engagement	O
of	O
the	O
scaffold	O
component	O
CUL2	B-PRGE
and	O
,	O
concomitantly	O
,	O
activates	O
the	O
association	O
with	O
FN	B-PRGE
.	O

These	O
findings	O
provide	O
the	O
first	O
mechanistic	O
step	O
in	O
defining	O
the	O
functional	O
selectivity	O
of	O
VHL	B-PRGE
and	O
explain	O
a	O
previously	O
unrecognized	O
function	O
of	O
NEDD8	B-PRGE
.	O

Redox	O
-	O
mediated	O
modification	O
of	O
PLZF	B-PRGE
by	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
ubiquitin	B-PRGE
.	O

Earlier	O
,	O
we	O
reported	O
that	O
the	O
transcriptional	O
repressor	O
promyelocytic	B-PRGE
leukemia	I-PRGE
zinc	I-PRGE
-	I-PRGE
finger	I-PRGE
protein	I-PRGE
(	O
PLZF	B-PRGE
)	O
is	O
sumoylated	O
at	O
position	O
K242	O
,	O
and	O
the	O
sumoylation	O
regulated	O
its	O
biological	O
function	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
sumoylation	O
site	O
can	O
be	O
modified	O
by	O
ubiquitin	B-PRGE
.	O

The	O
stability	O
and	O
nuclear	O
localization	O
of	O
PLZF	B-PRGE
were	O
regulated	O
by	O
the	O
antagonistic	O
relationship	O
between	O
sumoylation	O
and	O
ubiquitination	O
.	O

We	O
observed	O
the	O
antagonistic	O
effects	O
of	O
ubiquitin	B-PRGE
and	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
on	O
PLZF	B-PRGE
under	O
oxidative	O
stress	O
induced	O
by	O
serum	O
deprivation	O
.	O

Thus	O
,	O
the	O
choice	O
between	O
modification	O
of	O
PLZF	B-PRGE
by	O
SUMO	O
or	O
ubiquitin	B-PRGE
was	O
determined	O
by	O
the	O
intracellular	O
level	O
of	O
ROS	O
,	O
which	O
was	O
generated	O
by	O
serum	O
deprivation	O
that	O
inactivated	O
the	O
SUMO	O
-	O
conjugating	O
enzymes	O
Uba2	B-PRGE
and	O
Ubc9	B-PRGE
,	O
and	O
resulted	O
in	O
decrease	O
of	O
sumoylation	O
.	O

The	O
ubiquitination	O
was	O
increased	O
under	O
these	O
conditions	O
.	O

The	O
expression	O
of	O
BID	B-PRGE
,	O
a	O
known	O
transcriptional	O
target	O
protein	O
of	O
PLZF	B-PRGE
,	O
was	O
decreased	O
,	O
and	O
the	O
consequent	O
apoptosis	O
was	O
induced	O
by	O
the	O
ROS	O
generated	O
during	O
serum	O
starvation	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
PLZF	B-PRGE
post	O
-	O
translational	O
modification	O
is	O
controlled	O
by	O
intracellular	O
ROS	O
,	O
and	O
the	O
biological	O
function	O
of	O
PLZF	B-PRGE
is	O
regulated	O
by	O
sumoylation	O
and	O
ubiquitination	O
.	O

Sumoylation	O
and	O
the	O
function	O
of	O
CCAAT	B-PRGE
enhancer	I-PRGE
binding	I-PRGE
protein	I-PRGE
alpha	I-PRGE
(	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
)	O
.	O

CCAAT	B-PRGE
enhancer	I-PRGE
binding	I-PRGE
protein	I-PRGE
alpha	I-PRGE
(	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
)	O
is	O
the	O
founding	O
member	O
of	O
a	O
family	O
of	O
basic	O
region	O
/	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
transcription	O
factors	O
and	O
is	O
a	O
master	O
regulator	O
of	O
granulopoiesis	O
.	O

It	O
is	O
expressed	O
at	O
high	O
levels	O
throughout	O
myeloid	O
differentiation	O
and	O
binds	O
to	O
the	O
promoters	O
of	O
multiple	O
myeloid	O
-	O
specific	O
genes	O
at	O
different	O
stages	O
of	O
myeloid	O
maturation	O
.	O

Profound	O
hematopoietic	O
abnormalities	O
occur	O
in	O
mice	O
nullizygous	O
for	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
including	O
a	O
selective	O
early	O
block	O
in	O
the	O
differentiation	O
of	O
granulocytes	O
.	O

Mutations	O
in	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
are	O
present	O
in	O
a	O
subset	O
of	O
patients	O
with	O
AML	O
presenting	O
with	O
a	O
normal	O
karyotype	O
.	O

These	O
mutations	O
can	O
result	O
in	O
the	O
expression	O
of	O
a	O
30	O
kDa	O
dominant	O
negative	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
isoform	O
,	O
which	O
contributes	O
to	O
loss	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
function	O
.	O

The	O
molecular	O
basis	O
for	O
this	O
observation	O
remains	O
unknown	O
.	O

In	O
addition	O
to	O
phosphorylation	O
,	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
is	O
modified	O
,	O
post	O
-	O
translationally	O
by	O
a	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
at	O
a	O
lysine	O
residue	O
(	O
K159	O
)	O
,	O
which	O
lies	O
within	O
the	O
growth	O
inhibitory	O
region	O
of	O
the	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
protein	O
.	O

Sumoylation	O
at	O
K159	O
in	O
the	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
protein	O
prevents	O
association	O
of	O
the	O
SWI	O
/	O
SNF	O
chromatin	O
remodeling	O
complex	O
with	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
,	O
thereby	O
hampering	O
transactivation	O
.	O

In	O
this	O
review	O
,	O
the	O
functional	O
implications	O
of	O
post	O
-	O
translational	O
modification	O
,	O
particularly	O
sumoylation	O
,	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
in	O
normal	O
granulopoiesis	O
and	O
leukemia	O
are	O
considered	O
.	O

Interaction	O
of	O
a	O
peptide	O
derived	O
from	O
glycoprotein	O
gp36	B-PRGE
of	O
feline	O
immunodeficiency	O
virus	O
and	O
its	O
lipoylated	O
analogue	O
with	O
phospholipid	O
membranes	O
.	O

P59	O
,	O
a	O
20	O
-	O
mer	O
peptide	O
modeled	O
on	O
the	O
membrane	O
-	O
proximal	O
external	O
region	O
(	O
MPER	O
)	O
of	O
the	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
)	O
gp36	B-PRGE
ectodomain	O
,	O
has	O
potent	O
antiviral	O
activity	O
.	O

The	O
lipoylated	O
analogue	O
,	O
lipo	O
-	O
P59	O
,	O
displays	O
a	O
similar	O
activity	O
,	O
which	O
is	O
preferentially	O
retained	O
by	O
cellular	O
substrates	O
.	O

A	O
mechanism	O
has	O
been	O
proposed	O
recently	O
in	O
which	O
the	O
peptide	O
,	O
being	O
positioned	O
on	O
the	O
surface	O
of	O
the	O
cell	O
membrane	O
,	O
inhibits	O
its	O
fusion	O
with	O
the	O
virus	O
;	O
the	O
lipophilic	O
chain	O
of	O
lipo	O
-	O
P59	O
is	O
thought	O
to	O
insert	O
into	O
the	O
membrane	O
interior	O
,	O
thus	O
anchoring	O
the	O
peptide	O
at	O
the	O
surface	O
.	O

In	O
the	O
present	O
work	O
,	O
lipid	O
-	O
peptide	O
interactions	O
of	O
P59	O
and	O
lipo	O
-	O
P59	O
with	O
phospholipid	O
liposomes	O
are	O
investigated	O
using	O
spin	O
-	O
label	O
electron	O
spin	O
resonance	O
spectroscopy	O
.	O

Two	O
phospholipids	O
have	O
been	O
examined	O
,	O
the	O
zwitterionic	O
dimyristoyl	O
phosphatidylcholine	O
and	O
the	O
anionic	O
dimyristoyl	O
phosphatidylglycerol	O
,	O
and	O
a	O
wide	O
range	O
of	O
lipid	O
spin	O
labels	O
,	O
including	O
positional	O
isomers	O
.	O

Independent	O
of	O
the	O
membrane	O
charge	O
,	O
both	O
peptides	O
bind	O
to	O
lipid	O
bilayers	O
;	O
however	O
,	O
whereas	O
P59	O
insertion	O
between	O
the	O
lipid	O
headgroups	O
leads	O
to	O
significant	O
liposome	O
destabilization	O
,	O
eventually	O
resulting	O
in	O
vesicle	O
fragmentation	O
with	O
the	O
formation	O
of	O
smaller	O
aggregates	O
,	O
lipo	O
-	O
P59	O
inserts	O
with	O
the	O
lipophilic	O
tail	O
among	O
the	O
lipid	O
chains	O
,	O
while	O
the	O
peptidic	O
portion	O
remains	O
adsorbed	O
onto	O
the	O
membrane	O
,	O
where	O
it	O
can	O
effectively	O
exert	O
its	O
antiviral	O
activity	O
.	O

MEC	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
MEC	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
the	O
Caenorhabditis	O
elegans	O
sensory	O
mechanotransduction	O
complex	O
:	O
auxiliary	O
subunits	O
that	O
enable	O
channel	O
activity	O
.	O

The	O
ion	O
channel	O
formed	O
by	O
the	O
homologous	O
proteins	O
MEC	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
MEC	B-PRGE
-	I-PRGE
10	I-PRGE
forms	O
the	O
core	O
of	O
a	O
sensory	O
mechanotransduction	O
channel	O
in	O
Caenorhabditis	O
elegans	O
.	O

Although	O
the	O
products	O
of	O
other	O
mec	O
genes	O
are	O
key	O
players	O
in	O
the	O
biophysics	O
of	O
transduction	O
,	O
the	O
mechanism	O
by	O
which	O
they	O
contribute	O
to	O
the	O
properties	O
of	O
the	O
channel	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
two	O
auxiliary	O
channel	O
subunits	O
,	O
MEC	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
stomatin	O
-	O
like	O
)	O
and	O
MEC	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
paraoxonase	O
-	O
like	O
)	O
,	O
by	O
coexpressing	O
them	O
with	O
constitutively	O
active	O
MEC	B-PRGE
-	I-PRGE
4	I-PRGE
/	O
MEC	B-PRGE
-	I-PRGE
10	I-PRGE
heteromeric	O
channels	O
in	O
Xenopus	O
oocytes	O
.	O

This	O
work	O
extends	O
prior	O
work	O
demonstrating	O
that	O
MEC	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
MEC	B-PRGE
-	I-PRGE
6	I-PRGE
synergistically	O
increase	O
macroscopic	O
current	O
.	O

We	O
use	O
single	O
-	O
channel	O
recordings	O
and	O
biochemistry	O
to	O
show	O
that	O
these	O
auxiliary	O
subunits	O
alter	O
function	O
by	O
increasing	O
the	O
number	O
of	O
channels	O
in	O
an	O
active	O
state	O
rather	O
than	O
by	O
dramatically	O
affecting	O
either	O
single	O
-	O
channel	O
properties	O
or	O
surface	O
expression	O
.	O

We	O
also	O
use	O
two	O
-	O
electrode	O
voltage	O
clamp	O
and	O
outside	O
-	O
out	O
macropatch	O
recording	O
to	O
examine	O
the	O
effects	O
of	O
divalent	O
cations	O
and	O
proteases	O
,	O
known	O
regulators	O
of	O
channel	O
family	O
members	O
.	O

Finally	O
,	O
we	O
examine	O
the	O
role	O
of	O
cholesterol	O
binding	O
in	O
the	O
mechanism	O
of	O
MEC	B-PRGE
-	I-PRGE
2	I-PRGE
action	O
by	O
measuring	O
whole	O
-	O
cell	O
and	O
single	O
-	O
channel	O
currents	O
in	O
MEC	B-PRGE
-	I-PRGE
2	I-PRGE
mutants	O
deficient	O
in	O
cholesterol	O
binding	O
.	O

We	O
suggest	O
that	O
MEC	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
MEC	B-PRGE
-	I-PRGE
6	I-PRGE
play	O
essential	O
roles	O
in	O
modulating	O
both	O
the	O
local	O
membrane	O
environment	O
of	O
MEC	B-PRGE
-	I-PRGE
4	I-PRGE
/	O
MEC	B-PRGE
-	I-PRGE
10	I-PRGE
channels	O
and	O
the	O
availability	O
of	O
such	O
channels	O
to	O
be	O
gated	O
by	O
force	O
in	O
vivo	O
.	O

Constitutively	O
active	O
Rheb	B-PRGE
induces	O
oncogenic	O
transformation	O
.	O

Rheb	B-PRGE
(	O
Ras	B-PRGE
-	I-PRGE
homolog	I-PRGE
enriched	I-PRGE
in	I-PRGE
brain	I-PRGE
)	O
is	O
a	O
component	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
target	B-PRGE
of	I-PRGE
rapamycin	I-PRGE
(	O
TOR	B-PRGE
)	O
signaling	O
pathway	O
,	O
functioning	O
as	O
a	O
positive	O
regulator	O
of	O
TOR	B-PRGE
.	O

Constitutively	O
active	O
mutants	O
of	O
Rheb	B-PRGE
induce	O
oncogenic	O
transformation	O
in	O
cell	O
culture	O
.	O

The	O
transformed	O
cells	O
are	O
larger	O
and	O
contain	O
more	O
protein	O
than	O
their	O
normal	O
counterparts	O
.	O

They	O
show	O
constitutive	O
phosphorylation	O
of	O
the	O
ribosomal	O
protein	O
S6	O
kinase	O
and	O
the	O
eukaryotic	B-PRGE
initiation	I-PRGE
factor	I-PRGE
4E	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
1	I-PRGE
,	O
two	O
downstream	O
targets	O
of	O
TOR	B-PRGE
.	O

The	O
TOR	B-PRGE
-	O
specific	O
inhibitor	O
rapamycin	O
strongly	O
interferes	O
with	O
transformation	O
induced	O
by	O
constitutively	O
active	O
Rheb	B-PRGE
,	O
suggesting	O
that	O
TOR	B-PRGE
activity	O
is	O
essential	O
for	O
the	O
oncogenic	O
effects	O
of	O
mutant	O
Rheb	B-PRGE
.	O

Rheb	B-PRGE
-	O
induced	O
transformation	O
is	O
also	O
dependent	O
on	O
a	O
C	O
-	O
terminal	O
farnesylation	O
signal	O
that	O
mediates	O
localization	O
to	O
a	O
cellular	O
membrane	O
.	O

An	O
engineered	O
N	O
-	O
terminal	O
myristylation	O
signal	O
can	O
substitute	O
for	O
the	O
farnesylation	O
.	O

Immunofluorescence	O
localizes	O
wild	O
-	O
type	O
and	O
mutant	O
Rheb	B-PRGE
to	O
vesicular	O
structures	O
in	O
the	O
cytoplasm	O
,	O
overlapping	O
with	O
the	O
endoplasmic	O
reticulum	O
.	O

Hhat	B-PRGE
is	O
a	O
palmitoylacyltransferase	O
with	O
specificity	O
for	O
N	O
-	O
palmitoylation	O
of	O
Sonic	B-PRGE
Hedgehog	I-PRGE
.	O

Palmitoylation	O
of	O
Sonic	B-PRGE
Hedgehog	I-PRGE
(	O
Shh	B-PRGE
)	O
is	O
critical	O
for	O
effective	O
long	O
-	O
and	O
short	O
-	O
range	O
signaling	O
.	O

Genetic	O
screens	O
uncovered	O
a	O
potential	O
palmitoylacyltransferase	O
(	O
PAT	O
)	O
for	O
Shh	B-PRGE
,	O
Hhat	B-PRGE
,	O
but	O
the	O
molecular	O
mechanism	O
of	O
Shh	B-PRGE
palmitoylation	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
have	O
developed	O
and	O
exploited	O
an	O
in	O
vitro	O
Shh	B-PRGE
palmitoylation	O
assay	O
to	O
purify	O
Hhat	B-PRGE
to	O
homogeneity	O
.	O

We	O
provide	O
direct	O
biochemical	O
evidence	O
that	O
Hhat	B-PRGE
is	O
a	O
PAT	O
with	O
specificity	O
for	O
attaching	O
palmitate	O
via	O
amide	O
linkage	O
to	O
the	O
N	O
-	O
terminal	O
cysteine	O
of	O
Shh	B-PRGE
.	O

Other	O
palmitoylated	O
proteins	O
(	O
e	O
.	O
g	O
.	O
PSD95	B-PRGE
and	O
Wnt	O
)	O
are	O
not	O
substrates	O
for	O
Hhat	B-PRGE
,	O
and	O
Porcupine	O
,	O
a	O
putative	O
Wnt	O
PAT	O
,	O
does	O
not	O
palmitoylate	O
Shh	B-PRGE
.	O

Neither	O
autocleavage	O
nor	O
cholesterol	O
modification	O
is	O
required	O
for	O
Shh	B-PRGE
palmitoylation	O
.	O

Both	O
the	O
Shh	B-PRGE
precursor	O
and	O
mature	O
protein	O
are	O
N	O
-	O
palmitoylated	O
by	O
Hhat	B-PRGE
,	O
and	O
the	O
reaction	O
occurs	O
during	O
passage	O
through	O
the	O
secretory	O
pathway	O
.	O

This	O
study	O
establishes	O
Hhat	B-PRGE
as	O
a	O
bona	O
fide	O
Shh	B-PRGE
PAT	O
and	O
serves	O
as	O
a	O
model	O
for	O
understanding	O
how	O
secreted	O
morphogens	O
are	O
modified	O
by	O
distinct	O
PATs	O
.	O

Effect	O
of	O
metal	O
binding	O
and	O
posttranslational	O
lysine	O
carboxylation	O
on	O
the	O
activity	O
of	O
recombinant	O
hydantoinase	B-PRGE
.	O

Bacterial	O
hydantoinase	B-PRGE
possesses	O
a	O
binuclear	O
metal	O
center	O
in	O
which	O
two	O
metal	O
ions	O
are	O
bridged	O
by	O
a	O
posttranslationally	O
carboxylated	O
lysine	O
.	O

How	O
the	O
carboxylated	O
lysine	O
and	O
metal	O
binding	O
affect	O
the	O
activity	O
of	O
hydantoinase	B-PRGE
was	O
investigated	O
.	O

A	O
significant	O
amount	O
of	O
iron	O
was	O
always	O
found	O
in	O
Agrobacterium	O
radiobacter	O
hydantoinase	B-PRGE
purified	O
from	O
unsupplemented	O
cobalt	O
-	O
,	O
manganese	O
-	O
,	O
or	O
zinc	O
-	O
amended	O
Escherichia	O
coli	O
cell	O
cultures	O
.	O

A	O
titration	O
curve	O
for	O
the	O
reactivation	O
of	O
apohydantoinase	B-PRGE
with	O
cobalt	O
indicates	O
that	O
the	O
first	O
metal	O
was	O
preferentially	O
bound	O
but	O
did	O
not	O
give	O
any	O
enzyme	O
activity	O
until	O
the	O
second	O
metal	O
was	O
also	O
attached	O
to	O
the	O
hydantoinase	B-PRGE
.	O

The	O
pH	O
profiles	O
of	O
the	O
metal	O
-	O
reconstituted	O
hydantoinase	O
were	O
dependent	O
on	O
the	O
specific	O
metal	O
ion	O
bound	O
to	O
the	O
active	O
site	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
metal	O
in	O
catalysis	O
.	O

Mutation	O
of	O
the	O
metal	O
binding	O
site	O
residues	O
,	O
H57A	O
,	O
H59A	O
,	O
K148A	O
,	O
H181A	O
,	O
H237A	O
,	O
and	O
D313A	O
,	O
completely	O
abolished	O
hydantoinase	B-PRGE
activity	O
but	O
preserved	O
about	O
half	O
of	O
the	O
metal	O
content	O
,	O
except	O
for	O
K148A	O
,	O
which	O
lost	O
both	O
metals	O
in	O
its	O
active	O
site	O
.	O

However	O
,	O
the	O
activity	O
of	O
K148A	O
could	O
be	O
chemically	O
rescued	O
by	O
short	O
-	O
chain	O
carboxylic	O
acids	O
in	O
the	O
presence	O
of	O
cobalt	O
,	O
indicating	O
that	O
the	O
carboxylated	O
lysine	O
was	O
needed	O
to	O
coordinate	O
the	O
binuclear	O
ion	O
within	O
the	O
active	O
site	O
of	O
hydantoinase	B-PRGE
.	O

The	O
mutant	O
D313E	O
enzyme	O
was	O
also	O
active	O
but	O
resulted	O
in	O
a	O
pH	O
profile	O
different	O
from	O
that	O
of	O
wild	O
-	O
type	O
hydantoinase	B-PRGE
.	O

A	O
mechanism	O
for	O
hydantoinase	B-PRGE
involving	O
metal	O
,	O
carboxylated	O
K148	O
,	O
and	O
D313	O
was	O
proposed	O
.	O

Versatile	O
role	O
of	O
the	O
yeast	O
ubiquitin	B-PRGE
ligase	O
Rsp5p	B-PRGE
in	O
intracellular	O
trafficking	O
.	O

The	O
ubiquitin	B-PRGE
ligase	O
(	O
E3	O
)	O
Rsp5p	B-PRGE
is	O
the	O
only	O
member	O
of	O
the	O
Nedd	B-PRGE
(	I-PRGE
neural	I-PRGE
-	I-PRGE
precursor	I-PRGE
-	I-PRGE
cell	I-PRGE
-	I-PRGE
expressed	I-PRGE
,	I-PRGE
developmentally	I-PRGE
down	I-PRGE
-	I-PRGE
regulated	I-PRGE
)	I-PRGE
4	I-PRGE
family	O
of	O
E3s	O
present	O
in	O
yeast	O
.	O

Rsp5p	B-PRGE
has	O
several	O
proteasome	O
-	O
independent	O
functions	O
in	O
membrane	O
protein	O
trafficking	O
,	O
including	O
a	O
role	O
in	O
the	O
ubiquitination	O
of	O
most	O
plasma	O
membrane	O
proteins	O
,	O
leading	O
to	O
their	O
endocytosis	O
.	O

Rsp5p	B-PRGE
is	O
also	O
required	O
for	O
the	O
ubiquitination	O
of	O
endosomal	O
proteins	O
,	O
leading	O
to	O
their	O
sorting	O
to	O
the	O
internal	O
vesicles	O
of	O
MVBs	O
(	O
multivesicular	O
bodies	O
)	O
.	O

Rsp5p	B-PRGE
catalyses	O
the	O
attachment	O
of	O
non	O
-	O
conventional	O
ubiquitin	B-PRGE
chains	O
,	O
linked	O
through	O
ubiquitin	B-PRGE
Lys	O
-	O
63	O
,	O
to	O
some	O
endocytic	O
and	O
MVB	O
cargoes	O
.	O

This	O
modification	O
appears	O
to	O
be	O
required	O
for	O
efficient	O
sorting	O
,	O
possibly	O
because	O
these	O
chains	O
have	O
a	O
greater	O
affinity	O
for	O
the	O
ubiquitin	B-PRGE
-	O
binding	O
domains	O
present	O
within	O
endocytic	O
or	O
MVB	O
sorting	O
complexes	O
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
recognition	O
of	O
plasma	O
membrane	O
and	O
MVB	O
substrates	O
by	O
Rsp5p	B-PRGE
remain	O
unclear	O
.	O

A	O
subset	O
of	O
Rsp5	B-PRGE
/	O
Nedd4	B-PRGE
substrates	O
have	O
a	O
'	O
PY	O
motif	O
'	O
and	O
are	O
recognized	O
directly	O
by	O
the	O
WW	O
(	O
Trp	O
-	O
Trp	O
)	O
domains	O
of	O
Rsp5p	B-PRGE
.	O

Most	O
Rsp5p	B-PRGE
substrates	O
do	O
not	O
carry	O
PY	O
motifs	O
,	O
but	O
some	O
may	O
depend	O
on	O
PY	O
-	O
containing	O
proteins	O
for	O
their	O
ubiquitination	O
by	O
Rsp5p	B-PRGE
,	O
consistent	O
with	O
the	O
latter	O
'	O
s	O
acting	O
as	O
specificity	O
factors	O
or	O
adaptors	O
.	O

As	O
in	O
other	O
ubiquitin	B-PRGE
-	O
conjugating	O
systems	O
,	O
these	O
adaptors	O
are	O
also	O
Rsp5p	B-PRGE
substrates	O
and	O
undergo	O
ubiquitin	B-PRGE
-	O
dependent	O
trafficking	O
.	O

In	O
the	O
present	O
review	O
,	O
we	O
discuss	O
recent	O
examples	O
illustrating	O
the	O
role	O
of	O
Rsp5p	B-PRGE
in	O
membrane	O
protein	O
trafficking	O
and	O
providing	O
new	O
insights	O
into	O
the	O
regulation	O
of	O
this	O
E3	O
by	O
adaptor	O
proteins	O
.	O

Characterization	O
of	O
the	O
35	O
-	O
kilodalton	O
Treponema	O
pallidum	O
subsp	O
.	O
pallidum	O
recombinant	O
lipoprotein	O
TmpC	B-PRGE
and	O
antibody	O
response	O
to	O
lipidated	O
and	O
nonlipidated	O
T	O
.	O
pallidum	O
antigens	O
.	O

The	O
gene	O
encoding	O
the	O
35	O
-	O
kDa	O
immunogenic	O
Treponema	O
pallidium	O
subsp	O
.	O
pallidum	O
(	O
T	O
.	O
pallidum	O
)	O
membrane	O
protein	O
C	O
,	O
TmpC	B-PRGE
,	O
was	O
cloned	O
,	O
sequenced	O
,	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
carries	O
on	O
N	O
-	O
terminal	O
signal	O
sequence	O
with	O
a	O
four	O
-	O
amino	O
-	O
acid	O
motif	O
,	O
which	O
is	O
characteristic	O
for	O
bacterial	O
lipoproteins	O
.	O

Metabolic	O
labeling	O
with	O
radioactive	O
palmitic	O
acid	O
of	O
E	O
.	O
coli	O
expressing	O
TmpC	B-PRGE
revealed	O
incorporation	O
of	O
the	O
fatty	O
acid	O
into	O
the	O
antigen	O
.	O

The	O
antigen	O
was	O
overproduced	O
,	O
purified	O
to	O
near	O
homogeneity	O
and	O
used	O
in	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
to	O
evaluate	O
its	O
potential	O
for	O
the	O
serodiagnosis	O
of	O
syphilis	O
.	O

Although	O
all	O
sera	O
from	O
untreated	O
secondary	O
syphilis	O
patients	O
were	O
reactive	O
in	O
this	O
TmpC	B-PRGE
ELISA	O
,	O
only	O
a	O
minority	O
of	O
the	O
serum	O
samples	O
from	O
untreated	O
patients	O
in	O
the	O
primary	O
or	O
early	O
latent	O
stage	O
of	O
the	O
disease	O
contained	O
significant	O
anti	O
-	O
TmpC	B-PRGE
antibodies	O
.	O

To	O
study	O
the	O
influence	O
of	O
the	O
lipid	O
moiety	O
on	O
the	O
antigenic	O
properties	O
of	O
the	O
TmpC	B-PRGE
,	O
TmpA	B-PRGE
,	O
and	O
TpD	B-PRGE
lipoproteins	O
,	O
plasmids	O
encoding	O
nonlipidated	O
forms	O
of	O
these	O
antigens	O
were	O
constructed	O
.	O

In	O
addition	O
,	O
a	O
plasmid	O
expressing	O
a	O
lipidated	O
form	O
of	O
the	O
otherwise	O
non	O
-	O
lipid	O
-	O
modified	O
antigen	O
TmpB	B-PRGE
was	O
constructed	O
.	O

Immunization	O
and	O
absorption	O
experiments	O
with	O
these	O
lipidated	O
and	O
nonlipidated	O
antigens	O
showed	O
that	O
antibodies	O
against	O
the	O
lipid	O
moiety	O
of	O
lipoproteins	O
could	O
not	O
be	O
detected	O
on	O
immunoblots	O
,	O
neither	O
in	O
sera	O
from	O
infected	O
rabbits	O
nor	O
in	O
sera	O
from	O
animals	O
immunized	O
with	O
the	O
lipoproteins	O
.	O

In	O
addition	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
cross	O
-	O
reactivity	O
between	O
antibodies	O
against	O
the	O
T	O
.	O
pallidum	O
lipoproteins	O
and	O
those	O
reactive	O
to	O
the	O
Venereal	O
Diseases	O
Research	O
Laboratories	O
test	O
,	O
suggesting	O
that	O
antibodies	O
reactive	O
to	O
the	O
Venereal	O
Diseases	O
Research	O
Laboratories	O
test	O
are	O
unrelated	O
to	O
antilipoprotein	O
antibodies	O
.	O

Xenobiotic	O
incorporation	O
into	O
pyruvate	O
dehydrogenase	O
complex	O
can	O
occur	O
via	O
the	O
exogenous	O
lipoylation	O
pathway	O
.	O

Lipoylated	O
enzymes	O
such	O
as	O
the	O
E2	O
component	O
of	O
pyruvate	O
dehydrogenase	O
complex	O
(	O
PDC	B-PRGE
-	I-PRGE
E2	I-PRGE
)	O
are	O
targets	O
for	O
autoreactive	O
immune	O
responses	O
in	O
primary	O
biliary	O
cirrhosis	O
,	O
with	O
lipoic	O
acid	O
itself	O
forming	O
a	O
component	O
of	O
the	O
dominant	O
auto	O
-	O
epitopes	O
.	O

A	O
candidate	O
mechanism	O
for	O
the	O
initiation	O
of	O
tolerance	O
breakdown	O
in	O
this	O
disease	O
is	O
immune	O
recognition	O
of	O
neo	O
-	O
antigens	O
formed	O
by	O
xenobiotic	O
substitution	O
of	O
normal	O
proteins	O
.	O

Importantly	O
,	O
sensitization	O
with	O
proteins	O
artificially	O
substituted	O
with	O
the	O
lipoic	O
acid	O
analogue	O
xenobiotic	O
6	O
-	O
bromohexanoic	O
acid	O
(	O
6BH	O
)	O
can	O
induce	O
an	O
immune	O
response	O
that	O
cross	O
-	O
reacts	O
with	O
PDC	B-PRGE
-	I-PRGE
E2	I-PRGE
.	O

This	O
study	O
investigated	O
the	O
potential	O
of	O
recombinant	O
lipoylation	O
enzymes	O
lipoate	O
activating	O
enzyme	O
and	O
lipoyl	O
-	O
AMP	O
(	O
GMP	O
)	O
:	O
N	O
-	O
lysine	O
lipoyl	O
transferase	O
to	O
aberrantly	O
incorporate	O
xenobiotics	O
into	O
PDC	B-PRGE
-	I-PRGE
E2	I-PRGE
.	O

It	O
was	O
found	O
that	O
these	O
enzymes	O
could	O
incorporate	O
lipoic	O
acid	O
analogues	O
including	O
octanoic	O
and	O
hexanoic	O
acids	O
and	O
the	O
xenobiotic	O
6BH	O
into	O
PDC	B-PRGE
-	I-PRGE
E2	I-PRGE
.	O

The	O
efficiency	O
of	O
incorporation	O
of	O
these	O
analogues	O
showed	O
a	O
variable	O
dependence	O
on	O
activation	O
by	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
or	O
guanosine	O
triphosphate	O
(	O
GTP	O
)	O
,	O
with	O
ATP	O
favoring	O
the	O
incorporation	O
of	O
hexanoic	O
acid	O
and	O
6BH	O
whereas	O
GTP	O
enhanced	O
substitution	O
by	O
octanoic	O
acid	O
.	O

Importantly	O
,	O
competition	O
studies	O
showed	O
that	O
the	O
relative	O
incorporation	O
of	O
both	O
6BH	O
and	O
lipoic	O
acid	O
could	O
be	O
regulated	O
by	O
the	O
balance	O
between	O
ATP	O
and	O
GTP	O
,	O
with	O
the	O
formation	O
of	O
6BH	O
-	O
substituted	O
PDC	B-PRGE
-	I-PRGE
E2	I-PRGE
predominating	O
in	O
an	O
ATP	O
-	O
rich	O
environment	O
.	O

Conclusion	O
:	O
Using	O
a	O
well	O
-	O
defined	O
system	O
in	O
vitro	O
we	O
have	O
shown	O
that	O
an	O
important	O
xenobiotic	O
can	O
be	O
incorporated	O
into	O
PDC	O
in	O
place	O
of	O
lipoic	O
acid	O
by	O
the	O
exogenous	O
lipoylation	O
system	O
;	O
the	O
relative	O
levels	O
of	O
lipoic	O
acid	O
and	O
xenobiotic	O
incorporation	O
may	O
be	O
determined	O
by	O
the	O
balance	O
between	O
ATP	O
and	O
GTP	O
.	O

These	O
observations	O
suggest	O
a	O
clear	O
mechanism	O
for	O
the	O
generation	O
of	O
an	O
auto	O
-	O
immunogenic	O
neo	O
-	O
antigen	O
of	O
relevance	O
for	O
the	O
pathogenesis	O
of	O
primary	O
biliary	O
cirrhosis	O
.	O

SUMOylation	O
inhibits	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
by	O
reducing	O
CDK7	B-PRGE
-	O
mediated	O
serine	O
203	O
phosphorylation	O
.	O

Steroidogenic	B-PRGE
factor	I-PRGE
1	I-PRGE
(	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
an	O
orphan	O
nuclear	O
receptor	O
selectively	O
expressed	O
in	O
the	O
adrenal	O
cortex	O
and	O
gonads	O
,	O
where	O
it	O
mediates	O
the	O
hormonal	O
stimulation	O
of	O
multiple	O
genes	O
involved	O
in	O
steroid	O
hormone	O
biosynthesis	O
.	O

SF	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
the	O
target	O
of	O
both	O
phosphorylation	O
and	O
SUMOylation	O
,	O
but	O
how	O
these	O
modifications	O
interact	O
or	O
contribute	O
to	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
regulation	O
of	O
endogenous	O
genes	O
remains	O
poorly	O
defined	O
.	O

We	O
found	O
that	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
selectively	O
SUMOylated	O
at	O
K194	O
in	O
Y1	O
adrenocarcinoma	O
cells	O
and	O
that	O
although	O
SUMOylation	O
does	O
not	O
alter	O
the	O
subcellular	O
localization	O
of	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
the	O
modification	O
inhibits	O
the	O
ability	O
of	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
activate	O
target	O
genes	O
.	O

Notably	O
,	O
whereas	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
SUMOylation	O
is	O
independent	O
of	O
S203	O
phosphorylation	O
and	O
is	O
unaffected	O
by	O
adrenocorticotropin	B-PRGE
(	O
ACTH	B-PRGE
)	O
treatment	O
,	O
loss	O
of	O
SUMOylation	O
leads	O
to	O
enhanced	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
phosphorylation	O
at	O
serine	O
203	O
.	O

Furthermore	O
,	O
preventing	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
SUMOylation	O
increases	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
multiple	O
steroidogenic	O
enzyme	O
genes	O
.	O

Analysis	O
of	O
the	O
StAR	B-PRGE
promoter	O
indicates	O
that	O
blockade	O
of	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
SUMOylation	O
leads	O
to	O
an	O
increase	O
in	O
overall	O
promoter	O
occupancy	O
but	O
does	O
not	O
alter	O
the	O
oscillatory	O
recruitment	O
dynamics	O
in	O
response	O
to	O
ACTH	B-PRGE
.	O

Notably	O
,	O
we	O
find	O
that	O
CDK7	B-PRGE
binds	O
preferentially	O
to	O
the	O
SUMOylation	O
-	O
deficient	O
form	O
of	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
that	O
CDK7	B-PRGE
inhibition	O
reduces	O
phosphorylation	O
of	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
propose	O
a	O
coordinated	O
modification	O
model	O
in	O
which	O
inhibition	O
of	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
transcription	O
by	O
SUMOylation	O
in	O
adrenocortical	O
cancer	O
cells	O
is	O
mediated	O
through	O
reduced	O
CDK7	B-PRGE
-	O
induced	O
phosphorylation	O
of	O
SF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Dynamic	O
compartmentalization	O
of	O
base	O
excision	O
repair	O
proteins	O
in	O
response	O
to	O
nuclear	O
and	O
mitochondrial	O
oxidative	O
stress	O
.	O

DNAs	O
harbored	O
in	O
both	O
nuclei	O
and	O
mitochondria	O
of	O
eukaryotic	O
cells	O
are	O
subject	O
to	O
continuous	O
oxidative	O
damage	O
resulting	O
from	O
normal	O
metabolic	O
activities	O
or	O
environmental	O
insults	O
.	O

Oxidative	O
DNA	O
damage	O
is	O
primarily	O
reversed	O
by	O
the	O
base	O
excision	O
repair	O
(	O
BER	O
)	O
pathway	O
,	O
initiated	O
by	O
N	O
-	O
glycosylase	O
apurinic	O
/	O
apyrimidinic	O
(	O
AP	O
)	O
lyase	O
proteins	O
.	O

To	O
execute	O
an	O
appropriate	O
repair	O
response	O
,	O
BER	O
components	O
must	O
be	O
distributed	O
to	O
accommodate	O
levels	O
of	O
genotoxic	O
stress	O
that	O
may	O
vary	O
considerably	O
between	O
nuclei	O
and	O
mitochondria	O
,	O
depending	O
on	O
the	O
growth	O
state	O
and	O
stress	O
environment	O
of	O
the	O
cell	O
.	O

Numerous	O
examples	O
exist	O
where	O
cells	O
respond	O
to	O
signals	O
,	O
resulting	O
in	O
relocalization	O
of	O
proteins	O
involved	O
in	O
key	O
biological	O
transactions	O
.	O

To	O
address	O
whether	O
such	O
dynamic	O
localization	O
contributes	O
to	O
efficient	O
organelle	O
-	O
specific	O
DNA	O
repair	O
,	O
we	O
determined	O
the	O
intracellular	O
localization	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
N	O
-	O
glycosylase	O
/	O
AP	O
lyases	O
,	O
Ntg1	B-PRGE
and	O
Ntg2	B-PRGE
,	O
in	O
response	O
to	O
nuclear	O
and	O
mitochondrial	O
oxidative	O
stress	O
.	O

Fluorescence	O
microscopy	O
revealed	O
that	O
Ntg1	B-PRGE
is	O
differentially	O
localized	O
to	O
nuclei	O
and	O
mitochondria	O
,	O
likely	O
in	O
response	O
to	O
the	O
oxidative	O
DNA	O
damage	O
status	O
of	O
the	O
organelle	O
.	O

Sumoylation	O
is	O
associated	O
with	O
targeting	O
of	O
Ntg1	B-PRGE
to	O
nuclei	O
containing	O
oxidative	O
DNA	O
damage	O
.	O

These	O
studies	O
demonstrate	O
that	O
trafficking	O
of	O
DNA	O
repair	O
proteins	O
to	O
organelles	O
containing	O
high	O
levels	O
of	O
oxidative	O
DNA	O
damage	O
may	O
be	O
a	O
central	O
point	O
for	O
regulating	O
BER	O
in	O
response	O
to	O
oxidative	O
stress	O
.	O

Lipid	O
-	O
mediated	O
presentation	O
of	O
MHC	O
class	O
II	O
molecules	O
guides	O
thymocytes	O
to	O
the	O
CD4	B-PRGE
lineage	O
.	O

Previous	O
studies	O
on	O
the	O
MHC	O
class	O
-	O
specific	O
differentiation	O
of	O
CD4	B-PRGE
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocytes	O
into	O
CD4	B-PRGE
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
have	O
focused	O
on	O
the	O
role	O
of	O
coreceptor	O
molecules	O
.	O

However	O
,	O
CD4	B-PRGE
and	O
CD8	O
T	O
cells	O
develop	O
according	O
to	O
their	O
MHC	O
class	O
specificities	O
even	O
in	O
these	O
mice	O
lacking	O
coreceptors	O
.	O

This	O
study	O
investigated	O
the	O
possibility	O
that	O
lineage	O
is	O
determined	O
not	O
only	O
by	O
coreceptors	O
,	O
but	O
is	O
also	O
guided	O
by	O
the	O
way	O
how	O
MHC	O
molecules	O
are	O
presented	O
.	O

MHC	O
class	O
II	O
molecules	O
possess	O
a	O
highly	O
conserved	O
Cys	O
in	O
their	O
transmembrane	O
domain	O
,	O
which	O
is	O
palmitoylated	O
and	O
thereby	O
associates	O
with	O
lipid	O
rafts	O
,	O
whereas	O
neither	O
palmitoylation	O
nor	O
raft	O
association	O
was	O
observed	O
with	O
MHC	O
class	O
I	O
molecules	O
.	O

The	O
generation	O
of	O
CD4	B-PRGE
T	O
cells	O
was	O
impaired	O
and	O
that	O
of	O
CD8	O
T	O
cells	O
was	O
augmented	O
when	O
the	O
rafts	O
on	O
the	O
thymic	O
epithelial	O
cells	O
were	O
disrupted	O
.	O

This	O
was	O
due	O
to	O
the	O
conversion	O
of	O
MHC	O
class	O
II	O
-	O
specific	O
thymocytes	O
from	O
the	O
CD4	B-PRGE
lineage	O
to	O
CD8	O
.	O

The	O
ability	O
of	O
I	B-PRGE
-	I-PRGE
A	I-PRGE
(	O
d	O
)	O
molecule	O
to	O
associate	O
with	O
rafts	O
was	O
lost	O
when	O
its	O
transmembrane	O
Cys	O
was	O
replaced	O
.	O

The	O
development	O
of	O
DO11	O
.	O
10	O
thymocytes	O
recognizing	O
this	O
mutant	O
I	B-PRGE
-	I-PRGE
A	I-PRGE
(	O
dm	O
)	O
was	O
converted	O
from	O
CD4	B-PRGE
to	O
CD8	O
.	O

These	O
results	O
suggest	O
that	O
the	O
CD4	B-PRGE
lineage	O
commitment	O
is	O
directed	O
by	O
the	O
raft	O
-	O
associated	O
presentation	O
of	O
MHC	O
class	O
II	O
molecules	O
.	O

Protein	O
acylation	O
and	O
localization	O
in	O
T	O
cell	O
signaling	O
(	O
Review	O
)	O
.	O

Many	O
proteins	O
with	O
pivotal	O
roles	O
in	O
T	O
cell	O
activation	O
are	O
modified	O
by	O
fatty	O
acylation	O
.	O

Examples	O
of	O
these	O
include	O
transmembrane	O
proteins	O
such	O
as	O
the	O
co	O
-	O
receptors	O
CD4	B-PRGE
and	O
CD8	O
,	O
the	O
adaptors	O
LAT	B-PRGE
and	O
Cbp	B-PRGE
/	O
PAG	B-PRGE
,	O
the	O
pre	O
-	O
TCR	O
as	O
well	O
as	O
proteins	O
synthesized	O
on	O
free	O
cytosolic	O
ribosomes	O
,	O
such	O
as	O
the	O
Src	O
-	O
related	O
tyrosine	O
kinases	O
Lck	B-PRGE
and	O
Fyn	B-PRGE
.	O

The	O
two	O
main	O
types	O
of	O
fatty	O
acylations	O
in	O
eukaryotic	O
cells	O
are	O
N	O
-	O
myristoylation	O
and	O
S	O
-	O
acylation	O
,	O
the	O
latter	O
being	O
more	O
commonly	O
referred	O
to	O
as	O
palmitoylation	O
.	O

N	O
-	O
Myristoylation	O
occurs	O
exclusively	O
on	O
proteins	O
synthesized	O
on	O
soluble	O
ribosomes	O
and	O
provides	O
substrates	O
with	O
an	O
affinity	O
for	O
membranes	O
.	O

Palmitoylation	O
modifies	O
a	O
wide	O
range	O
of	O
substrates	O
that	O
includes	O
both	O
cytosolic	O
and	O
transmembrane	O
proteins	O
,	O
its	O
functions	O
are	O
diverse	O
and	O
in	O
many	O
cases	O
not	O
yet	O
understood	O
.	O

Like	O
myristoylation	O
,	O
palmitoylation	O
promotes	O
membrane	O
-	O
binding	O
of	O
cytosolic	O
proteins	O
,	O
but	O
it	O
has	O
also	O
been	O
implicated	O
in	O
protein	O
targeting	O
,	O
trafficking	O
,	O
stability	O
and	O
activity	O
.	O

In	O
addition	O
,	O
many	O
palmitoylated	O
proteins	O
are	O
insoluble	O
in	O
cold	O
non	O
-	O
ionic	O
detergent	O
,	O
and	O
have	O
therefore	O
been	O
proposed	O
to	O
localize	O
to	O
lipid	O
rafts	O
.	O

The	O
organization	O
of	O
receptors	O
and	O
signaling	O
proteins	O
into	O
microdomains	O
such	O
as	O
lipid	O
rafts	O
provides	O
an	O
attractive	O
model	O
for	O
the	O
initiation	O
and	O
propagation	O
of	O
T	O
cell	O
signaling	O
,	O
although	O
many	O
aspects	O
of	O
this	O
are	O
still	O
poorly	O
understood	O
.	O

This	O
review	O
will	O
discuss	O
the	O
current	O
evidence	O
for	O
the	O
involvement	O
of	O
acylations	O
in	O
the	O
localizations	O
and	O
functions	O
of	O
T	O
cell	O
signaling	O
proteins	O
.	O

Palmitoylation	O
modification	O
of	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
depresses	O
its	O
susceptibility	O
to	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
activation	O
.	O

Interaction	O
between	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
(	O
growth	B-PRGE
associated	I-PRGE
protein	I-PRGE
-	I-PRGE
43	I-PRGE
)	O
and	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
(	O
alpha	O
subunit	O
of	O
Go	O
protein	O
)	O
influences	O
the	O
signal	O
transduction	O
pathways	O
leading	O
to	O
differentiation	O
of	O
neural	O
cells	O
.	O

GAP	B-PRGE
-	I-PRGE
43	I-PRGE
is	O
known	O
to	O
increase	O
guanine	O
nucleotide	O
exchange	O
by	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
,	O
which	O
is	O
a	O
major	O
component	O
of	O
neuronal	O
growth	O
cone	O
membranes	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
stimulation	O
is	O
related	O
to	O
the	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
palmitoylation	O
or	O
the	O
conversion	O
of	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
from	O
oligmers	O
to	O
monomers	O
,	O
which	O
was	O
shown	O
to	O
be	O
a	O
necessary	O
regulatory	O
factor	O
in	O
GDP	O
/	O
GTP	O
exchange	O
of	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
.	O

Here	O
we	O
expressed	O
and	O
purified	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
,	O
GST	B-PRGE
-	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
and	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
proteins	O
,	O
detected	O
their	O
stimulatory	O
effect	O
on	O
[	O
(	O
35	O
)	O
S	O
]	O
-	O
GTPgammaS	O
binding	O
of	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
.	O

It	O
was	O
found	O
that	O
the	O
EC	O
(	O
50	O
)	O
of	O
both	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
and	O
GST	B-PRGE
-	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
activation	O
were	O
tenfold	O
lower	O
in	O
case	O
of	O
depalmitoylated	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
than	O
palmitoylated	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
.	O

Non	O
-	O
denaturing	O
gel	O
electrophoresis	O
and	O
p	O
-	O
PDM	O
cross	O
-	O
linking	O
analysis	O
revealed	O
that	O
addition	O
of	O
GST	B-PRGE
-	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
induced	O
disassociation	O
of	O
depalmitoylated	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
from	O
oligomers	O
to	O
monomers	O
,	O
but	O
did	O
not	O
influence	O
the	O
oligomeric	O
state	O
of	O
palmitoylated	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
,	O
which	O
suggests	O
that	O
palmitoylation	O
is	O
a	O
key	O
regulatory	O
factor	O
in	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
stimulation	O
on	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
.	O

These	O
results	O
indicated	O
the	O
interaction	O
of	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
and	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
could	O
accelerate	O
conversion	O
of	O
depalmitoylated	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
but	O
not	O
palmitoylated	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
from	O
oligomers	O
to	O
monomers	O
,	O
so	O
as	O
to	O
increase	O
the	O
GTPgammaS	O
binding	O
activity	O
of	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
.	O

Results	O
here	O
provide	O
new	O
evidence	O
about	O
how	O
signaling	O
protein	O
palmitoylation	O
is	O
involved	O
in	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
signal	O
transduction	O
cascade	O
,	O
and	O
give	O
a	O
useful	O
clue	O
on	O
the	O
participation	O
of	O
GAP	B-PRGE
-	I-PRGE
43	I-PRGE
in	O
G	O
-	O
protein	O
cycle	O
by	O
its	O
preferential	O
activation	O
of	O
depalmitoylated	O
Galpha	B-PRGE
(	I-PRGE
o	I-PRGE
)	I-PRGE
.	O

Identification	O
of	O
a	O
palmitoyl	O
acyltransferase	O
required	O
for	O
protein	O
sorting	O
to	O
the	O
flagellar	O
membrane	O
.	O

Protein	O
palmitoylation	O
has	O
diverse	O
effects	O
in	O
regulating	O
protein	O
membrane	O
affinity	O
,	O
localization	O
,	O
binding	O
partner	O
interactions	O
,	O
turnover	O
and	O
function	O
.	O

Here	O
,	O
we	O
show	O
that	O
palmitoylation	O
also	O
contributes	O
to	O
the	O
sorting	O
of	O
proteins	O
to	O
the	O
eukaryotic	O
flagellum	O
.	O

African	O
trypanosomes	O
are	O
protozoan	O
pathogens	O
that	O
express	O
a	O
family	O
of	O
unique	O
Ca	O
(	O
2	O
+	O
)	O
-	O
binding	O
proteins	O
,	O
the	O
calflagins	O
,	O
which	O
undergo	O
N	O
-	O
terminal	O
myristoylation	O
and	O
palmitoylation	O
.	O

The	O
localization	O
of	O
calflagins	O
depends	O
on	O
their	O
acylation	O
status	O
.	O

Myristoylation	O
alone	O
is	O
sufficient	O
for	O
membrane	O
association	O
,	O
but	O
,	O
in	O
the	O
absence	O
of	O
palmitoylation	O
,	O
the	O
calflagins	O
localize	O
to	O
the	O
pellicular	O
(	O
cell	O
body	O
)	O
membrane	O
.	O

Palmitoylation	O
,	O
which	O
is	O
mediated	O
by	O
a	O
specific	O
palmitoyl	O
acyltransferase	O
,	O
is	O
then	O
required	O
for	O
subsequent	O
trafficking	O
of	O
calflagin	O
to	O
the	O
flagellar	O
membrane	O
.	O

Coincident	O
with	O
the	O
redistribution	O
of	O
calflagin	O
from	O
the	O
pellicular	O
to	O
the	O
flagellar	O
membrane	O
is	O
their	O
association	O
with	O
lipid	O
rafts	O
,	O
which	O
are	O
highly	O
enriched	O
in	O
the	O
flagellar	O
membrane	O
.	O

Screening	O
of	O
candidate	O
palmitoyl	O
acyltranferases	O
identified	O
a	O
single	O
enzyme	O
,	O
TbPAT7	B-PRGE
,	O
that	O
is	O
necessary	O
for	O
calflagin	O
palmitoylation	O
and	O
flagellar	O
membrane	O
targeting	O
.	O

Our	O
results	O
implicate	O
protein	O
palmitoylation	O
in	O
flagellar	O
trafficking	O
,	O
and	O
demonstrate	O
the	O
conservation	O
and	O
specificity	O
of	O
palmitoyl	O
acyltransferase	O
activity	O
by	O
DHHC	O
-	O
CRD	O
proteins	O
across	O
kingdoms	O
.	O

Mutation	O
of	O
juxtamembrane	O
cysteines	O
in	O
the	O
tetraspanin	O
CD81	B-PRGE
affects	O
palmitoylation	O
and	O
alters	O
interaction	O
with	O
other	O
proteins	O
at	O
the	O
cell	O
surface	O
.	O

Palmitoylation	O
of	O
tetraspanins	O
affects	O
protein	O
-	O
protein	O
interactions	O
,	O
suggesting	O
a	O
key	O
role	O
in	O
the	O
assembly	O
of	O
the	O
tetraspanin	O
web	O
.	O

Since	O
palmitoylation	O
occurs	O
on	O
intracellular	O
cysteine	O
residues	O
,	O
we	O
examined	O
whether	O
mutating	O
these	O
residues	O
in	O
the	O
human	O
tetraspanin	O
CD81	B-PRGE
would	O
affect	O
the	O
association	O
of	O
CD81	B-PRGE
with	O
other	O
surface	O
membrane	O
proteins	O
.	O

Mutation	O
of	O
at	O
least	O
six	O
of	O
the	O
eight	O
juxtamembrane	O
cysteines	O
was	O
required	O
to	O
completely	O
eliminate	O
detectable	O
CD81	B-PRGE
palmitoylation	O
,	O
indicating	O
that	O
several	O
sites	O
can	O
be	O
palmitoylated	O
.	O

Interestingly	O
,	O
these	O
mutated	O
proteins	O
exhibited	O
reduced	O
cell	O
surface	O
detection	O
by	O
antibody	O
compared	O
to	O
wild	O
-	O
type	O
CD81	B-PRGE
,	O
but	O
this	O
was	O
not	O
due	O
to	O
differences	O
in	O
the	O
level	O
of	O
protein	O
expression	O
,	O
trafficking	O
to	O
the	O
cell	O
surface	O
,	O
protein	O
stability	O
,	O
or	O
anti	O
-	O
CD81	B-PRGE
antibody	O
binding	O
affinity	O
.	O

Instead	O
,	O
the	O
mutant	O
CD81	B-PRGE
proteins	O
appeared	O
to	O
be	O
partially	O
hidden	O
from	O
detection	O
by	O
anti	O
-	O
CD81	B-PRGE
antibody	O
,	O
presumably	O
due	O
to	O
altered	O
interactions	O
with	O
other	O
proteins	O
at	O
the	O
cell	O
surface	O
.	O

Associations	O
with	O
the	O
known	O
CD81	B-PRGE
-	O
interacting	O
proteins	O
CD9	B-PRGE
and	O
EWI	B-PRGE
-	I-PRGE
2	I-PRGE
were	O
also	O
impaired	O
with	O
the	O
mutant	O
CD81	B-PRGE
proteins	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
mutation	O
of	O
juxtamembrane	O
cysteines	O
alters	O
the	O
interaction	O
of	O
CD81	B-PRGE
with	O
other	O
proteins	O
,	O
either	O
because	O
of	O
reduced	O
palmitoylation	O
,	O
structural	O
alterations	O
in	O
the	O
mutant	O
proteins	O
,	O
or	O
a	O
combination	O
of	O
both	O
factors	O
,	O
and	O
this	O
affects	O
the	O
CD81	B-PRGE
microenvironment	O
on	O
the	O
cell	O
surface	O
.	O

INF2	B-PRGE
is	O
an	O
endoplasmic	O
reticulum	O
-	O
associated	O
formin	O
protein	O
.	O

In	O
addition	O
to	O
its	O
ability	O
to	O
accelerate	O
filament	O
assembly	O
,	O
which	O
is	O
common	O
to	O
formins	O
,	O
INF2	B-PRGE
is	O
a	O
formin	O
protein	O
with	O
the	O
unique	O
biochemical	O
ability	O
to	O
accelerate	O
actin	O
filament	O
depolymerization	O
.	O

The	O
depolymerization	O
activity	O
of	O
INF2	B-PRGE
requires	O
its	O
actin	O
monomer	O
-	O
binding	O
WASP	O
homology	O
2	O
(	O
WH2	O
)	O
motif	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
INF2	B-PRGE
is	O
peripherally	O
bound	O
to	O
the	O
cytoplasmic	O
face	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
in	O
Swiss	O
3T3	O
cells	O
.	O

Both	O
endogenous	O
INF2	B-PRGE
and	O
GFP	B-PRGE
-	O
fusion	O
constructs	O
display	O
ER	O
localization	O
.	O

INF2	B-PRGE
is	O
post	O
-	O
translationally	O
modified	O
by	O
a	O
C	O
-	O
terminal	O
farnesyl	O
group	O
,	O
and	O
this	O
modification	O
is	O
required	O
for	O
ER	O
interaction	O
.	O

However	O
,	O
farnesylation	O
is	O
not	O
sufficient	O
for	O
ER	O
association	O
,	O
and	O
membrane	O
extraction	O
experiments	O
suggest	O
that	O
ionic	O
interactions	O
are	O
also	O
important	O
.	O

The	O
WH2	O
motif	O
also	O
serves	O
as	O
a	O
diaphanous	O
autoregulatory	O
domain	O
(	O
DAD	O
)	O
,	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
diaphanous	O
inhibitory	O
domain	O
(	O
DID	O
)	O
,	O
with	O
an	O
apparent	O
dissociation	O
constant	O
of	O
1	O
.	O
1	O
muM	O
.	O

Surprisingly	O
,	O
the	O
DID	O
-	O
DAD	O
interaction	O
does	O
not	O
inhibit	O
the	O
actin	O
nucleation	O
activity	O
of	O
INF2	B-PRGE
;	O
however	O
,	O
it	O
does	O
inhibit	O
the	O
depolymerization	O
activity	O
.	O

Point	O
mutations	O
to	O
the	O
DAD	O
/	O
WH2	O
inhibit	O
both	O
the	O
DID	O
-	O
DAD	O
interaction	O
and	O
depolymerization	O
activity	O
.	O

Expression	O
of	O
GFP	B-PRGE
-	O
INF2	B-PRGE
containing	O
these	O
DAD	O
/	O
WH2	O
mutations	O
causes	O
the	O
ER	O
to	O
collapse	O
around	O
the	O
nucleus	O
,	O
with	O
accumulation	O
of	O
actin	O
filaments	O
around	O
the	O
collapsed	O
ER	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
association	O
of	O
an	O
actin	O
-	O
assembly	O
factor	O
with	O
the	O
ER	O
.	O

Mouse	O
recombinant	O
phenylalanine	B-PRGE
monooxygenase	I-PRGE
and	O
the	O
S	O
-	O
oxygenation	O
of	O
thioether	O
substrates	O
.	O

The	O
substrate	O
specificity	O
of	O
mouse	O
recombinant	O
phenylalanine	B-PRGE
monooxygenase	I-PRGE
(	O
mPAH	B-PRGE
)	O
has	O
been	O
investigated	O
with	O
respect	O
to	O
the	O
mucoactive	O
drug	O
,	O
S	O
-	O
carboxymethyl	O
-	O
L	O
-	O
cysteine	O
(	O
SCMC	O
)	O
and	O
its	O
thioether	O
metabolites	O
.	O

Phenylalanine	B-PRGE
monooxygenase	I-PRGE
was	O
shown	O
to	O
be	O
able	O
to	O
catalyze	O
the	O
S	O
-	O
oxygenation	O
of	O
SCMC	O
,	O
its	O
decarboxylated	O
metabolite	O
,	O
S	O
-	O
methyl	O
-	O
L	O
-	O
cysteine	O
and	O
both	O
their	O
corresponding	O
N	O
-	O
acetylated	O
forms	O
.	O

However	O
,	O
thiodiglycolic	O
acid	O
was	O
found	O
not	O
to	O
be	O
a	O
substrate	O
.	O

The	O
enzyme	O
profiles	O
for	O
both	O
phenylalanine	O
and	O
SCMC	O
showed	O
Michaelis	O
-	O
Menten	O
with	O
noncompetitive	O
substrate	O
inhibition	O
for	O
both	O
the	O
substrate	O
-	O
activated	O
and	O
the	O
lysophosphatidylcholine	O
-	O
activated	O
mPAH	B-PRGE
assays	O
.	O

The	O
tetrameric	O
enzyme	O
was	O
shown	O
to	O
undergo	O
posttranslational	O
activation	O
by	O
preincubation	O
with	O
substrate	O
,	O
lysophosphatidylcholine	O
,	O
N	O
-	O
ethylmaleimide	O
(	O
a	O
thiol	O
alkylating	O
agent	O
)	O
,	O
and	O
the	O
proteolytic	O
enzymes	O
alpha	B-PRGE
-	I-PRGE
chymotrypsin	I-PRGE
and	O
trypsin	O
.	O

Similar	O
posttranslational	O
activation	O
of	O
PAH	B-PRGE
activity	O
in	O
the	O
rat	O
and	O
human	O
has	O
also	O
been	O
reported	O
.	O

These	O
results	O
suggest	O
that	O
in	O
the	O
mouse	O
,	O
PAH	B-PRGE
was	O
responsible	O
for	O
the	O
S	O
-	O
oxidation	O
of	O
SCMC	O
and	O
that	O
the	O
mouse	O
models	O
of	O
the	O
hyperphenylalaninemias	O
may	O
be	O
a	O
potential	O
tool	O
in	O
the	O
investigation	O
of	O
the	O
S	O
-	O
oxidation	O
polymorphism	O
in	O
man	O
.	O

The	O
cataract	O
-	O
associated	O
R14C	O
mutant	O
of	O
human	O
gamma	B-PRGE
D	I-PRGE
-	I-PRGE
crystallin	I-PRGE
shows	O
a	O
variety	O
of	O
intermolecular	O
disulfide	O
cross	O
-	O
links	O
:	O
a	O
Raman	O
spectroscopic	O
study	O
.	O

The	O
Arg14	O
to	O
Cys	O
(	O
R14C	O
)	O
mutation	O
in	O
the	O
human	O
gammaD	B-PRGE
-	I-PRGE
crystallin	I-PRGE
(	O
HGD	B-PRGE
)	O
gene	O
has	O
been	O
associated	O
with	O
a	O
juvenile	O
-	O
onset	O
hereditary	O
cataract	O
.	O

We	O
showed	O
previously	O
[	O
Pande	O
,	O
A	O
.	O
,	O
et	O
al	O
.	O
(	O
2000	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
97	O
,	O
1993	O
-	O
1998	O
]	O
that	O
rapid	O
oxidation	O
of	O
Cys14	O
in	O
the	O
mutant	O
leads	O
to	O
the	O
formation	O
of	O
intermolecular	O
,	O
disulfide	O
-	O
cross	O
-	O
linked	O
aggregates	O
at	O
physiological	O
pH	O
.	O

Here	O
we	O
present	O
a	O
Raman	O
spectroscopic	O
analysis	O
of	O
R14C	O
and	O
HGD	B-PRGE
and	O
show	O
that	O
R14C	O
forms	O
such	O
aggregates	O
even	O
at	O
pH	O
4	O
.	O
5	O
.	O

The	O
lower	O
pH	O
enabled	O
us	O
to	O
monitor	O
the	O
evolution	O
of	O
a	O
variety	O
of	O
disulfide	O
cross	O
-	O
links	O
with	O
distinct	O
conformations	O
around	O
the	O
CC	O
-	O
SS	O
-	O
CC	O
dihedral	O
angles	O
.	O

At	O
least	O
three	O
cysteine	O
residues	O
are	O
involved	O
,	O
forming	O
protein	O
-	O
protein	O
cross	O
-	O
links	O
through	O
disulfide	O
-	O
exchange	O
reactions	O
.	O

From	O
the	O
pattern	O
of	O
the	O
S	O
-	O
S	O
and	O
Trp	O
Raman	O
bands	O
,	O
we	O
infer	O
that	O
Cys32	O
is	O
likely	O
to	O
be	O
involved	O
in	O
the	O
cross	O
-	O
linking	O
.	O

The	O
data	O
suggest	O
that	O
protein	O
precipitation	O
in	O
the	O
mutant	O
may	O
not	O
be	O
the	O
direct	O
result	O
of	O
disulfide	O
cross	O
-	O
linking	O
,	O
although	O
such	O
cross	O
-	O
linking	O
is	O
the	O
initiating	O
event	O
.	O

Thus	O
,	O
our	O
Raman	O
data	O
not	O
only	O
enhance	O
the	O
understanding	O
of	O
the	O
reactivity	O
of	O
Cys14	O
in	O
the	O
R14C	O
mutant	O
and	O
the	O
mechanism	O
of	O
opacity	O
,	O
but	O
also	O
shed	O
light	O
on	O
the	O
mechanism	O
of	O
oxidative	O
degradation	O
during	O
long	O
-	O
term	O
storage	O
of	O
thiol	O
-	O
containing	O
pharmaceuticals	O
.	O

Bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
:	O
molecular	O
structures	O
and	O
signal	O
transducing	O
functions	O
.	O

Mono	O
-	O
ADP	O
-	O
ribosylation	O
is	O
a	O
posttranslational	O
modification	O
of	O
proteins	O
employed	O
by	O
a	O
variety	O
of	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
to	O
modify	O
the	O
metabolism	O
of	O
target	O
cells	O
.	O

The	O
ADP	O
-	O
ribosyltransferases	O
of	O
bacterial	O
toxins	O
,	O
in	O
general	O
,	O
use	O
NAD	O
as	O
a	O
substrate	O
for	O
covalent	O
modification	O
by	O
ADP	O
-	O
ribose	O
to	O
certain	O
GTP	O
-	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
as	O
signal	O
transducers	O
resulting	O
in	O
altered	O
enzymatic	O
activity	O
of	O
the	O
membrane	O
enzymes	O
as	O
effectors	O
.	O

Such	O
a	O
mechanism	O
has	O
the	O
potential	O
of	O
being	O
of	O
importance	O
in	O
the	O
physiological	O
regulation	O
of	O
cellular	O
metabolism	O
,	O
particularly	O
if	O
the	O
process	O
is	O
reversible	O
.	O

These	O
ADP	O
-	O
ribosylating	O
toxins	O
are	O
characterized	O
in	O
Table	O
1	O
.	O

Concerted	O
action	O
of	O
the	O
cytosolic	O
sulfotransferase	O
,	O
SULT1A3	B-PRGE
,	O
and	O
catechol	B-PRGE
-	I-PRGE
O	I-PRGE
-	I-PRGE
methyltransferase	I-PRGE
in	O
the	O
metabolism	O
of	O
dopamine	O
in	O
SK	O
-	O
N	O
-	O
MC	O
human	O
neuroblastoma	O
cells	O
.	O

Conjugation	O
reactions	O
catalyzed	O
by	O
the	O
cytosolic	O
sulfotransferase	O
,	O
SULT1A3	B-PRGE
,	O
or	O
catechol	B-PRGE
-	I-PRGE
O	I-PRGE
-	I-PRGE
methyltransferase	I-PRGE
(	O
COMT	B-PRGE
)	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
and	O
homeostasis	O
of	O
dopamine	O
and	O
other	O
monoamine	O
neurotransmitters	O
.	O

Whether	O
different	O
conjugation	O
reactions	O
may	O
act	O
in	O
a	O
concerted	O
manner	O
,	O
however	O
,	O
remains	O
unclear	O
.	O

The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
concerted	O
action	O
of	O
SULT1A3	B-PRGE
and	O
COMT	B-PRGE
in	O
dopamine	O
metabolism	O
.	O

Analysis	O
of	O
the	O
medium	O
of	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
,	O
metabolically	O
labeled	O
with	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfate	O
in	O
the	O
presence	O
of	O
dopamine	O
,	O
revealed	O
the	O
generation	O
and	O
release	O
of	O
predominantly	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
3	O
-	O
methyldopamine	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
dopamine	O
.	O

Addition	O
to	O
the	O
labeling	O
medium	O
of	O
tropolone	O
,	O
a	O
COMT	B-PRGE
inhibitor	O
,	O
enhanced	O
the	O
production	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
dopamine	O
,	O
with	O
a	O
concomitant	O
decrease	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
3	O
-	O
methyldopamine	O
.	O

Enzymatic	O
assays	O
using	O
the	O
eleven	O
known	O
human	O
cytosolic	O
SULTs	O
revealed	O
SULT1A3	B-PRGE
as	O
the	O
major	O
enzyme	O
responsible	O
for	O
the	O
sulfation	O
of	O
both	O
dopamine	O
and	O
3	O
-	O
methyldopamine	O
.	O

Kinetic	O
analysis	O
showed	O
that	O
the	O
catalytic	O
efficiency	O
of	O
SULT1A3	B-PRGE
with	O
3	O
-	O
methyldopamine	O
was	O
1	O
.	O
6	O
times	O
than	O
that	O
with	O
dopamine	O
.	O

Using	O
subcellular	O
fractions	O
prepared	O
from	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
,	O
the	O
majority	O
of	O
COMT	B-PRGE
dopamine	O
-	O
methylating	O
activity	O
was	O
found	O
to	O
be	O
present	O
in	O
the	O
cytosol	O
.	O

Collectively	O
,	O
these	O
results	O
imply	O
a	O
concerted	O
action	O
of	O
sulfation	O
and	O
methylation	O
in	O
the	O
irreversible	O
inactivation	O
and	O
disposal	O
of	O
excess	O
dopamine	O
in	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
.	O

Palmitoylation	O
of	O
the	O
synaptic	O
vesicle	O
fusion	O
machinery	O
.	O

The	O
fusion	O
of	O
synaptic	O
vesicles	O
with	O
the	O
pre	O
-	O
synaptic	O
plasma	O
membrane	O
mediates	O
the	O
secretion	O
of	O
neurotransmitters	O
at	O
nerve	O
terminals	O
.	O

This	O
pathway	O
is	O
regulated	O
by	O
an	O
array	O
of	O
protein	O
-	O
protein	O
interactions	O
.	O

Of	O
central	O
importance	O
are	O
the	O
soluble	O
NSF	B-PRGE
(	O
N	B-PRGE
-	I-PRGE
ethylmaleimide	I-PRGE
-	I-PRGE
sensitive	I-PRGE
factor	I-PRGE
)	O
attachment	O
protein	O
receptor	O
(	O
SNARE	O
)	O
proteins	O
syntaxin	O
1	O
and	O
SNAP25	B-PRGE
,	O
which	O
are	O
associated	O
with	O
the	O
pre	O
-	O
synaptic	O
plasma	O
membrane	O
and	O
vesicle	O
-	O
associated	O
membrane	O
protein	O
(	O
VAMP2	B-PRGE
)	O
,	O
a	O
synaptic	O
vesicle	O
SNARE	O
.	O

Syntaxin	O
1	O
,	O
SNAP25	B-PRGE
and	O
VAMP2	B-PRGE
interact	O
to	O
form	O
a	O
tight	O
complex	O
bridging	O
the	O
vesicle	O
and	O
plasma	O
membranes	O
,	O
which	O
has	O
been	O
suggested	O
to	O
represent	O
the	O
minimal	O
membrane	O
fusion	O
machinery	O
.	O

Synaptic	O
vesicle	O
fusion	O
is	O
stimulated	O
by	O
a	O
rise	O
in	O
intraterminal	O
Ca2	O
+	O
levels	O
,	O
and	O
a	O
major	O
Ca2	O
+	O
sensor	O
for	O
vesicle	O
fusion	O
is	O
synaptotagmin	B-PRGE
I	I-PRGE
.	O

Synaptotagmin	O
is	O
likely	O
to	O
couple	O
Ca2	O
+	O
entry	O
to	O
vesicle	O
fusion	O
via	O
Ca2	O
+	O
-	O
dependent	O
and	O
independent	O
interactions	O
with	O
membrane	O
phospholipids	O
and	O
the	O
SNARE	O
proteins	O
.	O

Intriguingly	O
,	O
syntaxin	O
1	O
,	O
SNAP25	B-PRGE
,	O
VAMP2	B-PRGE
and	O
synaptotagmin	B-PRGE
I	I-PRGE
have	O
all	O
been	O
reported	O
to	O
be	O
modified	O
by	O
palmitoylation	O
in	O
neurons	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
mechanisms	O
and	O
dynamics	O
of	O
palmitoylation	O
of	O
these	O
proteins	O
and	O
speculate	O
on	O
how	O
palmitoylation	O
might	O
contribute	O
to	O
the	O
regulation	O
of	O
synaptic	O
vesicle	O
fusion	O
.	O

Palmitoylation	O
-	O
dependent	O
plasma	O
membrane	O
transport	O
but	O
lipid	O
raft	O
-	O
independent	O
signaling	O
by	O
linker	B-PRGE
for	I-PRGE
activation	I-PRGE
of	I-PRGE
T	I-PRGE
cells	I-PRGE
.	O

Linker	B-PRGE
for	I-PRGE
activation	I-PRGE
of	I-PRGE
T	I-PRGE
cells	I-PRGE
(	O
LAT	B-PRGE
)	O
is	O
a	O
dually	O
palmitoylated	O
transmembrane	O
adaptor	O
protein	O
essential	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

However	O
,	O
whether	O
LAT	B-PRGE
palmitoylation	O
and	O
/	O
or	O
lipid	O
raft	O
localization	O
are	O
required	O
for	O
its	O
function	O
is	O
controversial	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
used	O
a	O
combination	O
of	O
biochemical	O
,	O
imaging	O
,	O
and	O
genetic	O
approaches	O
,	O
including	O
LAT	B-PRGE
retrovirus	O
-	O
transduced	O
mouse	O
T	O
cells	O
and	O
bone	O
marrow	O
chimeric	O
mice	O
.	O

A	O
nonpalmitoylated	O
,	O
non	O
-	O
lipid	O
raft	O
-	O
residing	O
mutant	O
of	O
transmembrane	O
LAT	B-PRGE
could	O
not	O
reconstitute	O
T	O
cell	O
development	O
in	O
bone	O
marrow	O
chimeric	O
mice	O
.	O

This	O
mutant	O
was	O
absent	O
from	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
and	O
was	O
restricted	O
mainly	O
to	O
the	O
Golgi	O
apparatus	O
.	O

A	O
chimeric	O
,	O
nonpalmitoylated	O
LAT	B-PRGE
protein	O
consisting	O
of	O
the	O
PM	O
-	O
targeting	O
N	O
-	O
terminal	O
sequence	O
of	O
Src	O
kinase	O
and	O
the	O
LAT	B-PRGE
cytoplasmic	O
domain	O
(	O
Src	O
-	O
LAT	O
)	O
localized	O
as	O
a	O
peripheral	O
membrane	O
protein	O
in	O
the	O
PM	O
,	O
but	O
outside	O
lipid	O
rafts	O
.	O

Nevertheless	O
,	O
Src	O
-	O
LAT	O
restored	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Lastly	O
,	O
monopalmitoylation	O
of	O
LAT	B-PRGE
on	O
Cys	O
(	O
26	O
)	O
(	O
but	O
not	O
Cys	O
(	O
29	O
)	O
)	O
was	O
required	O
and	O
sufficient	O
for	O
its	O
PM	O
transport	O
and	O
function	O
.	O

Thus	O
,	O
the	O
function	O
of	O
LAT	B-PRGE
in	O
T	O
cells	O
requires	O
its	O
PM	O
,	O
but	O
not	O
raft	O
,	O
localization	O
,	O
even	O
when	O
expressed	O
as	O
a	O
peripheral	O
membrane	O
protein	O
.	O

Furthermore	O
,	O
LAT	B-PRGE
palmitoylation	O
functions	O
primarily	O
as	O
a	O
sorting	O
signal	O
required	O
for	O
its	O
PM	O
transport	O
.	O

Mobile	O
DHHC	O
palmitoylating	O
enzyme	O
mediates	O
activity	O
-	O
sensitive	O
synaptic	O
targeting	O
of	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
.	O

Protein	O
palmitoylation	O
is	O
the	O
most	O
common	O
posttranslational	O
lipid	O
modification	O
;	O
its	O
reversibility	O
mediates	O
protein	O
shuttling	O
between	O
intracellular	O
compartments	O
.	O

A	O
large	O
family	O
of	O
DHHC	O
(	O
Asp	O
-	O
His	O
-	O
His	O
-	O
Cys	O
)	O
proteins	O
has	O
emerged	O
as	O
protein	O
palmitoyl	O
acyltransferases	O
(	O
PATs	O
)	O
.	O

However	O
,	O
mechanisms	O
that	O
regulate	O
these	O
PATs	O
in	O
a	O
physiological	O
context	O
remain	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
efficiently	O
monitored	O
the	O
dynamic	O
palmitate	O
cycling	O
on	O
synaptic	O
scaffold	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
.	O

We	O
found	O
that	O
blocking	O
synaptic	O
activity	O
rapidly	O
induces	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
palmitoylation	O
and	O
mediates	O
synaptic	O
clustering	O
of	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
and	O
associated	O
AMPA	O
(	O
alpha	O
-	O
amino	O
-	O
3	O
-	O
hydroxy	O
-	O
5	O
-	O
methyl	O
-	O
4	O
-	O
isoxazole	O
propionic	O
acid	O
)	O
-	O
type	O
glutamate	O
receptors	O
.	O

A	O
dendritically	O
localized	O
DHHC2	B-PRGE
but	O
not	O
the	O
Golgi	O
-	O
resident	O
DHHC3	B-PRGE
mediates	O
this	O
activity	O
-	O
sensitive	O
palmitoylation	O
.	O

Upon	O
activity	O
blockade	O
,	O
DHHC2	B-PRGE
translocates	O
to	O
the	O
postsynaptic	O
density	O
to	O
transduce	O
this	O
effect	O
.	O

These	O
data	O
demonstrate	O
that	O
individual	O
DHHC	O
members	O
are	O
differentially	O
regulated	O
and	O
that	O
dynamic	O
recruitment	O
of	O
protein	O
palmitoylation	O
machinery	O
enables	O
compartmentalized	O
regulation	O
of	O
protein	O
trafficking	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O

The	O
trafficking	O
/	O
interaction	O
of	O
eNOS	B-PRGE
and	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
induced	O
by	O
insulin	B-PRGE
modulates	O
endothelial	O
nitric	O
oxide	O
production	O
.	O

Endothelial	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
(	O
eNOS	B-PRGE
)	O
activity	O
is	O
tightly	O
regulated	O
by	O
posttranscriptional	O
modification	O
and	O
its	O
subcellular	O
localization	O
.	O

Here	O
we	O
examined	O
whether	O
insulin	B-PRGE
modulates	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
by	O
regulating	O
eNOS	B-PRGE
subcellular	O
localization	O
.	O

We	O
used	O
confocal	O
microscopy	O
and	O
immunoblots	O
to	O
examine	O
the	O
time	O
course	O
for	O
1	O
)	O
subcellular	O
targeting	O
/	O
association	O
of	O
eNOS	B-PRGE
and	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
;	O
2	O
)	O
eNOS	B-PRGE
Ser	O
(	O
1179	O
)	O
phosphorylation	O
;	O
and	O
3	O
)	O
NO	O
production	O
in	O
cultured	O
bovine	O
aorta	O
endothelial	O
cells	O
.	O

Serum	O
starvation	O
increased	O
eNOS	B-PRGE
/	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
localization	O
to	O
the	O
perinuclear	O
region	O
.	O

Adding	O
insulin	B-PRGE
provoked	O
their	O
prompt	O
translocation	O
to	O
and	O
association	O
at	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
.	O

Specific	O
monoclonal	O
antibodies	O
against	O
either	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
eNOS	B-PRGE
coimmunoprecipitated	O
the	O
other	O
from	O
bovine	O
aorta	O
endothelial	O
cell	O
membrane	O
extracts	O
,	O
and	O
insulin	B-PRGE
increased	O
this	O
interaction	O
.	O

Insulin	B-PRGE
stimulated	O
NO	O
production	O
transiently	O
despite	O
a	O
persistent	O
eNOS	B-PRGE
Ser	O
(	O
1179	O
)	O
phosphorylation	O
.	O

The	O
decline	O
of	O
NO	O
production	O
correlated	O
temporally	O
to	O
insulin	B-PRGE
-	O
induced	O
translocation	O
of	O
eNOS	B-PRGE
and	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
PM	O
.	O

Knockdown	O
of	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
with	O
a	O
specific	O
small	O
interfering	O
RNA	O
duplex	O
resulted	O
in	O
eNOS	B-PRGE
redistributing	O
to	O
the	O
perinuclear	O
region	O
and	O
nearly	O
doubled	O
insulin	B-PRGE
-	O
induced	O
NO	O
production	O
.	O

Inhibition	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
activity	O
with	O
wortmannin	O
not	O
only	O
significantly	O
inhibited	O
insulin	B-PRGE
-	O
induced	O
translocation	O
of	O
eNOS	B-PRGE
and	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
PM	O
but	O
also	O
blocked	O
insulin	B-PRGE
-	O
induced	O
interaction	O
of	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
with	O
eNOS	B-PRGE
at	O
PM	O
.	O

Insulin	B-PRGE
increased	O
incorporation	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
palmitic	O
acid	O
into	O
eNOS	B-PRGE
immunoprecipitates	O
by	O
approximately	O
140	O
%	O
.	O

Insulin	B-PRGE
-	O
induced	O
translocation	O
of	O
eNOS	B-PRGE
and	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
PM	O
was	O
palmitoylation	O
dependent	O
.	O

Inhibiting	O
eNOS	B-PRGE
and	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
palmitoylation	O
enhanced	O
the	O
NO	O
production	O
while	O
blocking	O
the	O
translocation	O
of	O
eNOS	B-PRGE
and	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
PM	O
induced	O
by	O
insulin	B-PRGE
.	O

These	O
data	O
show	O
that	O
insulin	B-PRGE
acutely	O
regulates	O
eNOS	B-PRGE
and	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
trafficking	O
to	O
PM	O
of	O
vascular	O
endothelial	O
cells	O
where	O
their	O
interaction	O
can	O
regulate	O
eNOS	B-PRGE
activity	O
.	O

Crosstalk	O
between	O
the	O
NF	O
-	O
kappaB	O
activating	O
IKK	O
-	O
complex	O
and	O
the	O
CSN	O
signalosome	O
.	O

A	O
great	O
variety	O
of	O
signalling	O
pathways	O
regulating	O
inflammation	O
,	O
cell	O
development	O
and	O
cell	O
survival	O
require	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
,	O
which	O
are	O
normally	O
inactive	O
due	O
to	O
binding	O
to	O
inhibitors	O
,	O
such	O
as	O
IkappaBalpha	B-PRGE
.	O

The	O
canonical	O
activation	O
pathway	O
of	O
NF	O
-	O
kappaB	O
is	O
initiated	O
by	O
phosphorylation	O
of	O
the	O
inhibitor	O
by	O
an	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
triggering	O
ubiquitination	O
of	O
IkappaB	O
molecules	O
by	O
SCF	O
-	O
type	O
E3	O
-	O
ligase	O
complexes	O
and	O
rapid	O
degradation	O
by	O
26S	O
-	O
proteasomes	O
.	O

The	O
ubiquitination	O
machinery	O
is	O
regulated	O
by	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
.	O

We	O
show	O
that	O
IkappaB	O
kinases	O
interact	O
with	O
the	O
CSN	O
-	O
complex	O
,	O
as	O
well	O
as	O
the	O
SCF	O
-	O
ubiquitination	O
machinery	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
rapid	O
signalling	O
-	O
induced	O
ubiquitination	O
and	O
degradation	O
of	O
IkappaBalpha	B-PRGE
.	O

Furthermore	O
,	O
we	O
reveal	O
that	O
IKK	O
'	O
s	O
phosphorylate	O
not	O
only	O
IkappaBalpha	B-PRGE
,	O
but	O
also	O
the	O
CSN	O
-	O
subunit	O
Csn5	B-PRGE
/	O
JAB1	B-PRGE
(	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
activation	I-PRGE
domain	I-PRGE
binding	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
that	O
IKK2	B-PRGE
influences	O
ubiquitination	O
of	O
Csn5	B-PRGE
/	O
JAB1	B-PRGE
.	O

Our	O
observations	O
imply	O
that	O
the	O
CSN	O
complex	O
acts	O
as	O
an	O
inhibitor	O
of	O
constitutive	O
NF	O
-	O
kappaB	O
activity	O
in	O
non	O
-	O
activated	O
cells	O
.	O

Knock	O
-	O
down	O
of	O
Csn5	B-PRGE
/	O
JAB1	B-PRGE
clearly	O
enhanced	O
basal	O
NF	O
-	O
kappaB	O
activity	O
and	O
improved	O
cell	O
survival	O
under	O
stress	O
.	O

The	O
inhibitory	O
effect	O
of	O
Csn5	B-PRGE
/	O
JAB1	B-PRGE
requires	O
a	O
functional	O
MPN	O
(	O
+	O
)	O
metalloprotease	O
domain	O
,	O
which	O
is	O
responsible	O
for	O
cleaving	O
ubiquitin	B-PRGE
-	O
like	O
Nedd8	B-PRGE
-	O
modifications	O
.	O

Upon	O
activation	O
of	O
cells	O
with	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
the	O
CSN	O
complex	O
dissociates	O
from	O
IKK	O
'	O
s	O
allowing	O
full	O
and	O
rapid	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
the	O
concerted	O
action	O
of	O
interacting	O
protein	O
complexes	O
.	O

Prenylation	O
-	O
deficient	O
G	O
protein	O
gamma	O
subunits	O
disrupt	O
GPCR	O
signaling	O
in	O
the	O
zebrafish	O
.	O

Prenylation	O
of	O
G	O
protein	O
gamma	O
(	O
gamma	O
)	O
subunits	O
is	O
necessary	O
for	O
the	O
membrane	O
localization	O
of	O
heterotrimeric	O
G	O
proteins	O
and	O
for	O
functional	O
heterotrimeric	O
G	O
protein	O
coupled	O
receptor	O
(	O
GPCR	O
)	O
signaling	O
.	O

To	O
evaluate	O
GPCR	O
signaling	O
pathways	O
during	O
development	O
,	O
we	O
injected	O
zebrafish	O
embryos	O
with	O
mRNAs	O
encoding	O
Ggamma	O
subunits	O
mutated	O
so	O
that	O
they	O
can	O
no	O
longer	O
be	O
prenylated	O
.	O

Low	O
-	O
level	O
expression	O
of	O
these	O
prenylation	O
-	O
deficient	O
Ggamma	O
subunits	O
driven	O
either	O
ubiquitously	O
or	O
specifically	O
in	O
the	O
primordial	O
germ	O
cells	O
(	O
PGCs	O
)	O
disrupts	O
GPCR	O
signaling	O
and	O
manifests	O
as	O
a	O
PGC	O
migration	O
defect	O
.	O

This	O
disruption	O
results	O
in	O
a	O
reduction	O
of	O
calcium	O
accumulation	O
in	O
the	O
protrusions	O
of	O
migrating	O
PGCs	O
and	O
a	O
failure	O
of	O
PGCs	O
to	O
directionally	O
migrate	O
.	O

When	O
co	O
-	O
expressed	O
with	O
a	O
prenylation	O
-	O
deficient	O
Ggamma	O
,	O
8	O
of	O
the	O
17	O
wildtype	O
Ggamma	O
isoforms	O
individually	O
confer	O
the	O
ability	O
to	O
restore	O
calcium	O
accumulation	O
and	O
directional	O
migration	O
.	O

These	O
results	O
suggest	O
that	O
while	O
the	O
Ggamma	O
subunits	O
possess	O
the	O
ability	O
to	O
interact	O
with	O
G	O
Beta	O
(	O
beta	O
)	O
proteins	O
,	O
only	O
a	O
subset	O
of	O
wildtype	O
Ggamma	O
proteins	O
are	O
stable	O
within	O
PGCs	O
and	O
can	O
interact	O
with	O
key	O
signaling	O
components	O
necessary	O
for	O
PGC	O
migration	O
.	O

This	O
in	O
vivo	O
study	O
highlights	O
the	O
functional	O
redundancy	O
of	O
these	O
signaling	O
components	O
and	O
demonstrates	O
that	O
prenylation	O
-	O
deficient	O
Ggamma	O
subunits	O
are	O
an	O
effective	O
tool	O
to	O
investigate	O
the	O
roles	O
of	O
GPCR	O
signaling	O
events	O
during	O
vertebrate	O
development	O
.	O

Statins	O
inhibit	O
protein	O
lipidation	O
and	O
induce	O
the	O
unfolded	O
protein	O
response	O
in	O
the	O
non	O
-	O
sterol	O
producing	O
nematode	O
Caenorhabditis	O
elegans	O
.	O

Statins	O
are	O
compounds	O
prescribed	O
to	O
lower	O
blood	O
cholesterol	O
in	O
millions	O
of	O
patients	O
worldwide	O
.	O

They	O
act	O
by	O
inhibiting	O
HMG	B-PRGE
-	I-PRGE
CoA	I-PRGE
reductase	I-PRGE
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
mevalonate	O
pathway	O
that	O
leads	O
to	O
the	O
synthesis	O
of	O
farnesyl	O
pyrophosphate	O
,	O
a	O
precursor	O
for	O
cholesterol	O
synthesis	O
and	O
the	O
source	O
of	O
lipid	O
moieties	O
for	O
protein	O
prenylation	O
.	O

The	O
nematode	O
Caenorhabditis	O
elegans	O
possesses	O
a	O
mevalonate	O
pathway	O
that	O
lacks	O
the	O
branch	O
leading	O
to	O
cholesterol	O
synthesis	O
,	O
and	O
thus	O
represents	O
an	O
ideal	O
organism	O
to	O
specifically	O
study	O
the	O
noncholesterol	O
roles	O
of	O
the	O
pathway	O
.	O

Inhibiting	O
HMG	B-PRGE
-	I-PRGE
CoA	I-PRGE
reductase	I-PRGE
in	O
C	O
.	O
elegans	O
using	O
statins	O
or	O
RNAi	O
leads	O
to	O
developmental	O
arrest	O
and	O
loss	O
of	O
membrane	O
association	O
of	O
a	O
GFP	B-PRGE
-	O
based	O
prenylation	O
reporter	O
.	O

The	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
is	O
also	O
strongly	O
activated	O
,	O
suggesting	O
that	O
impaired	O
prenylation	O
of	O
small	O
GTPases	O
leads	O
to	O
the	O
accumulation	O
of	O
unfolded	O
proteins	O
and	O
ER	O
stress	O
.	O

UPR	O
induction	O
was	O
also	O
observed	O
upon	O
pharmacological	O
inhibition	O
of	O
farnesyl	O
transferases	O
or	O
RNAi	O
inhibition	O
of	O
a	O
specific	O
isoprenoid	O
transferase	O
(	O
M57	B-PRGE
.	I-PRGE
2	I-PRGE
)	O
and	O
found	O
to	O
be	O
dependent	O
on	O
both	O
ire	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
xbp	B-PRGE
-	I-PRGE
1	I-PRGE
but	O
not	O
on	O
pek	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
atf	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
which	O
are	O
all	O
known	O
regulators	O
of	O
the	O
UPR	O
.	O

The	O
lipid	O
stores	O
and	O
fatty	O
acid	O
composition	O
were	O
unaffected	O
in	O
statin	O
-	O
treated	O
worms	O
,	O
even	O
though	O
they	O
showed	O
reduced	O
staining	O
with	O
Nile	O
red	O
.	O

We	O
conclude	O
that	O
inhibitors	O
of	O
HMG	B-PRGE
-	I-PRGE
CoA	I-PRGE
reductase	I-PRGE
or	O
of	O
farnesyl	O
transferases	O
induce	O
the	O
UPR	O
by	O
inhibiting	O
the	O
prenylation	O
of	O
M57	B-PRGE
.	I-PRGE
2	I-PRGE
substrates	O
,	O
resulting	O
in	O
developmental	O
arrest	O
in	O
C	O
.	O
elegans	O
.	O

These	O
results	O
provide	O
a	O
mechanism	O
for	O
the	O
pleiotropic	O
effects	O
of	O
statins	O
and	O
suggest	O
that	O
statins	O
could	O
be	O
used	O
clinically	O
where	O
UPR	O
activation	O
may	O
be	O
of	O
therapeutic	O
benefit	O
.	O

SUMOylation	O
attenuates	O
the	O
aggregation	O
propensity	O
and	O
cellular	O
toxicity	O
of	O
the	O
polyglutamine	O
expanded	O
ataxin	B-PRGE
-	I-PRGE
7	I-PRGE
.	O

Post	O
-	O
translational	O
modification	O
by	O
SUMO	O
(	O
small	O
ubiquitin	B-PRGE
-	O
like	O
modifier	O
)	O
was	O
proposed	O
to	O
modulate	O
the	O
pathogenesis	O
of	O
several	O
neurodegenerative	O
diseases	O
.	O

Spinocerebellar	O
ataxia	O
type	O
7	O
(	O
SCA7	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
,	O
whose	O
pathology	O
is	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
polyglutamine	O
stretch	O
in	O
the	O
protein	O
ataxin	B-PRGE
-	I-PRGE
7	I-PRGE
(	O
ATXN7	B-PRGE
)	O
.	O

Here	O
,	O
we	O
identified	O
ATXN7	B-PRGE
as	O
new	O
target	O
for	O
SUMOylation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
major	O
SUMO	O
acceptor	O
site	O
was	O
mapped	O
to	O
lysine	O
257	O
,	O
which	O
is	O
part	O
of	O
an	O
evolutionarily	O
conserved	O
consensus	O
SUMOylation	O
motif	O
.	O

SUMOylation	O
did	O
not	O
influence	O
the	O
subcellular	O
localization	O
of	O
ATXN7	B-PRGE
nor	O
its	O
interaction	O
with	O
components	O
of	O
the	O
TFTC	O
/	O
STAGA	O
complex	O
.	O

Expansion	O
of	O
the	O
polyglutamine	O
stretch	O
did	O
not	O
impair	O
the	O
SUMOylation	O
of	O
ATXN7	B-PRGE
.	O

Furthermore	O
,	O
SUMO1	B-PRGE
and	O
SUMO2	B-PRGE
colocalized	O
with	O
ATXN7	B-PRGE
in	O
a	O
subset	O
of	O
neuronal	O
intranuclear	O
inclusions	O
in	O
the	O
brain	O
of	O
SCA7	O
patients	O
and	O
SCA7	O
knock	O
-	O
in	O
mice	O
.	O

In	O
a	O
COS	O
-	O
7	O
cellular	O
model	O
of	O
SCA7	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
staining	O
we	O
identified	O
two	O
populations	O
of	O
nuclear	O
inclusions	O
:	O
homogenous	O
or	O
non	O
-	O
homogenous	O
.	O

Non	O
-	O
homogenous	O
inclusions	O
showed	O
significantly	O
reduced	O
colocalization	O
with	O
SUMO1	B-PRGE
and	O
SUMO2	B-PRGE
,	O
but	O
were	O
highly	O
enriched	O
in	O
Hsp70	B-PRGE
,	O
19S	O
proteasome	O
and	O
ubiquitin	B-PRGE
.	O

Interestingly	O
,	O
they	O
were	O
characterized	O
by	O
increased	O
staining	O
with	O
the	O
apoptotic	O
marker	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
by	O
disruption	O
of	O
PML	B-PRGE
nuclear	O
bodies	O
.	O

Importantly	O
,	O
preventing	O
the	O
SUMOylation	O
of	O
expanded	O
ATXN7	B-PRGE
by	O
mutating	O
the	O
SUMO	O
site	O
increased	O
both	O
the	O
amount	O
of	O
SDS	O
-	O
insoluble	O
aggregates	O
and	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
positive	O
non	O
-	O
homogenous	O
inclusions	O
,	O
which	O
act	O
toxic	O
to	O
the	O
cells	O
.	O

Our	O
results	O
demonstrate	O
an	O
influence	O
of	O
SUMOylation	O
on	O
the	O
multistep	O
aggregation	O
process	O
of	O
ATXN7	B-PRGE
and	O
implicate	O
a	O
role	O
for	O
ATXN7	B-PRGE
SUMOylation	O
in	O
SCA7	O
pathogenesis	O
.	O

Orientation	O
of	O
palmitoylated	O
CaVbeta2a	B-PRGE
relative	O
to	O
CaV2	O
.	O
2	O
is	O
critical	O
for	O
slow	O
pathway	O
modulation	O
of	O
N	O
-	O
type	O
Ca2	O
+	O
current	O
by	O
tachykinin	O
receptor	O
activation	O
.	O

The	O
G	O
(	O
q	O
)	O
-	O
coupled	O
tachykinin	O
receptor	O
(	O
neurokinin	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
[	O
NK	B-PRGE
-	I-PRGE
1R	I-PRGE
]	O
)	O
modulates	O
N	O
-	O
type	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
(	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
or	O
N	O
channel	O
)	O
activity	O
at	O
two	O
distinct	O
sites	O
by	O
a	O
pathway	O
involving	O
a	O
lipid	O
metabolite	O
,	O
most	O
likely	O
arachidonic	O
acid	O
(	O
AA	O
)	O
.	O

In	O
another	O
study	O
published	O
in	O
this	O
issue	O
(	O
Heneghan	O
et	O
al	O
.	O
2009	O
.	O
J	O
.	O
Gen	O
Physiol	O
.	O
doi	O
:	O
10	O
.	O
1085	O
/	O
jgp	O
.	O
200910203	O
)	O
,	O
we	O
found	O
that	O
the	O
form	O
of	O
modulation	O
observed	O
depends	O
on	O
which	O
Ca	O
(	O
V	O
)	O
beta	O
is	O
coexpressed	O
with	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
.	O

When	O
palmitoylated	O
Ca	B-PRGE
(	I-PRGE
V	I-PRGE
)	I-PRGE
beta2a	I-PRGE
is	O
coexpressed	O
,	O
activation	O
of	O
NK	B-PRGE
-	I-PRGE
1Rs	I-PRGE
by	O
substance	B-PRGE
P	I-PRGE
(	O
SP	B-PRGE
)	O
enhances	O
N	O
current	O
.	O

In	O
contrast	O
,	O
when	O
Ca	B-PRGE
(	I-PRGE
V	I-PRGE
)	I-PRGE
beta3	I-PRGE
is	O
coexpressed	O
,	O
SP	B-PRGE
inhibits	O
N	O
current	O
.	O

However	O
,	O
exogenously	O
applied	O
palmitic	O
acid	O
minimizes	O
this	O
inhibition	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
palmitoyl	O
groups	O
of	O
Ca	B-PRGE
(	I-PRGE
V	I-PRGE
)	I-PRGE
beta2a	I-PRGE
may	O
occupy	O
an	O
inhibitory	O
site	O
on	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
or	O
prevent	O
AA	O
from	O
interacting	O
with	O
that	O
site	O
,	O
thereby	O
minimizing	O
inhibition	O
.	O

If	O
so	O
,	O
changing	O
the	O
orientation	O
of	O
Ca	B-PRGE
(	I-PRGE
V	I-PRGE
)	I-PRGE
beta2a	I-PRGE
relative	O
to	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
may	O
displace	O
the	O
palmitoyl	O
groups	O
and	O
prevent	O
them	O
from	O
antagonizing	O
AA	O
'	O
s	O
actions	O
,	O
thereby	O
allowing	O
inhibition	O
even	O
in	O
the	O
presence	O
of	O
Ca	B-PRGE
(	I-PRGE
V	I-PRGE
)	I-PRGE
beta2a	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
this	O
hypothesis	O
by	O
deleting	O
one	O
(	O
Bdel1	O
)	O
or	O
two	O
(	O
Bdel2	O
)	O
amino	O
acids	O
proximal	O
to	O
the	O
alpha	O
interacting	O
domain	O
(	O
AID	O
)	O
of	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
'	O
s	O
I	O
-	O
II	O
linker	O
.	O

Ca	O
(	O
V	O
)	O
betas	O
bind	O
tightly	O
to	O
the	O
AID	O
,	O
whereas	O
the	O
rigid	O
region	O
proximal	O
to	O
the	O
AID	O
is	O
thought	O
to	O
couple	O
Ca	O
(	O
V	O
)	O
beta	O
'	O
s	O
movements	O
to	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
gating	O
.	O

Although	O
Bdel1	O
/	O
beta2a	O
currents	O
exhibited	O
more	O
variable	O
enhancement	O
by	O
SP	B-PRGE
,	O
Bdel2	O
/	O
beta2a	O
current	O
enhancement	O
was	O
lost	O
at	O
all	O
voltages	O
.	O

Instead	O
,	O
inhibition	O
was	O
observed	O
that	O
matched	O
the	O
profile	O
of	O
N	O
-	O
current	O
inhibition	O
from	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
coexpressed	O
with	O
Ca	B-PRGE
(	I-PRGE
V	I-PRGE
)	I-PRGE
beta3	I-PRGE
.	O

Moreover	O
,	O
adding	O
back	O
exogenous	O
palmitic	O
acid	O
minimized	O
inhibition	O
of	O
Bdel2	O
/	O
beta2a	O
currents	O
,	O
suggesting	O
that	O
when	O
palmitoylated	O
Ca	B-PRGE
(	I-PRGE
V	I-PRGE
)	I-PRGE
beta2a	I-PRGE
is	O
sufficiently	O
displaced	O
,	O
endogenously	O
released	O
AA	O
can	O
bind	O
to	O
the	O
inhibitory	O
site	O
.	O

These	O
findings	O
support	O
our	O
previous	O
hypothesis	O
that	O
Ca	B-PRGE
(	I-PRGE
V	I-PRGE
)	I-PRGE
beta2a	I-PRGE
'	O
s	O
palmitoyl	O
groups	O
directly	O
interact	O
with	O
an	O
inhibitory	O
site	O
on	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
to	O
block	O
N	O
-	O
current	O
inhibition	O
by	O
SP	B-PRGE
.	O

Validation	O
of	O
a	O
method	O
for	O
the	O
quantitation	O
of	O
ghrelin	B-PRGE
and	O
unacylated	O
ghrelin	B-PRGE
by	O
HPLC	O
.	O

An	O
HPLC	O
/	O
UV	O
method	O
was	O
first	O
optimized	O
for	O
the	O
separation	O
and	O
quantitation	O
of	O
human	O
acylated	O
and	O
unacylated	O
(	O
or	O
des	O
-	O
acyl	O
)	O
ghrelin	B-PRGE
from	O
aqueous	O
solutions	O
.	O

This	O
method	O
was	O
validated	O
by	O
an	O
original	O
approach	O
using	O
accuracy	O
profiles	O
based	O
on	O
tolerance	O
intervals	O
for	O
the	O
total	O
error	O
measurement	O
.	O

The	O
concentration	O
range	O
that	O
achieved	O
adequate	O
accuracy	O
extended	O
from	O
1	O
.	O
85	O
to	O
59	O
.	O
30microM	O
and	O
1	O
.	O
93	O
to	O
61	O
.	O
60microM	O
for	O
acylated	O
and	O
unacylated	O
ghrelin	B-PRGE
,	O
respectively	O
.	O

Then	O
,	O
optimal	O
temperature	O
,	O
pH	O
and	O
buffer	O
for	O
sample	O
storage	O
were	O
determined	O
.	O

Unacylated	O
ghrelin	B-PRGE
was	O
found	O
to	O
be	O
stable	O
in	O
all	O
conditions	O
tested	O
.	O

At	O
37	O
degrees	O
C	O
acylated	O
ghrelin	B-PRGE
was	O
stable	O
at	O
pH	O
4	O
but	O
unstable	O
at	O
pH	O
7	O
.	O
4	O
,	O
the	O
main	O
degradation	O
product	O
was	O
unacylated	O
ghrelin	B-PRGE
.	O

Finally	O
,	O
this	O
validated	O
HPLC	O
/	O
UV	O
method	O
was	O
used	O
to	O
evaluate	O
the	O
binding	O
of	O
acylated	O
and	O
unacylated	O
ghrelin	B-PRGE
to	O
liposomes	O
.	O

Phosphorylation	O
of	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
Cul5	B-PRGE
by	O
protein	O
kinase	O
A	O
regulates	O
its	O
neddylation	O
and	O
antiproliferative	O
effect	O
.	O

Expression	O
of	O
the	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
cul5	B-PRGE
gene	O
in	O
endothelial	O
and	O
in	O
cancer	O
cell	O
lines	O
in	O
vitro	O
inhibits	O
cellular	O
proliferation	O
and	O
decreases	O
phosphorylation	O
of	O
MAPK	O
.	O

Structure	O
-	O
function	O
analysis	O
of	O
the	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
sequence	O
identified	O
consensus	O
sites	O
specific	O
for	O
phosphorylation	O
by	O
protein	O
kinases	O
A	O
and	O
C	O
(	O
PKA	O
and	O
PKC	O
)	O
and	O
a	O
Nedd8	B-PRGE
protein	O
modification	O
site	O
.	O

Mutations	O
at	O
the	O
PKA	O
-	O
specific	O
site	O
in	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
Cul5	B-PRGE
(	O
(	O
S730A	O
)	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
sequence	O
resulted	O
in	O
increased	O
cellular	O
growth	O
and	O
the	O
appearance	O
of	O
a	O
Nedd8	B-PRGE
-	O
modified	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
Cul5	B-PRGE
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
if	O
PKA	O
-	O
dependent	O
phosphorylation	O
of	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
Cul5	B-PRGE
controls	O
its	O
neddylation	O
status	O
,	O
phosphorylation	O
by	O
PKC	O
,	O
and	O
ultimately	O
growth	O
.	O

Our	O
results	O
indicate	O
that	O
in	O
vitro	O
transfection	O
of	O
rat	O
adrenal	O
medullary	O
endothelial	O
cells	O
with	O
anti	O
-	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
specific	O
small	O
interfering	O
RNA	O
oligonucleotides	O
decreases	O
endogenous	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
concentration	O
and	O
increases	O
cell	O
growth	O
.	O

Western	O
blot	O
analysis	O
of	O
cell	O
lysates	O
immunoprecipitated	O
with	O
an	O
antibody	O
directed	O
against	O
a	O
PKA	O
-	O
specific	O
phosphorylation	O
site	O
and	O
probed	O
with	O
anti	O
-	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
specific	O
antibody	O
showed	O
that	O
PKA	O
-	O
dependent	O
phosphorylation	O
of	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
was	O
decreased	O
in	O
cells	O
transfected	O
with	O
(	O
S730A	O
)	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
cDNA	O
when	O
compared	O
with	O
the	O
cytomegalovirus	O
-	O
transfected	O
cells	O
.	O

This	O
change	O
was	O
associated	O
with	O
increased	O
modification	O
of	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
by	O
Nedd8	B-PRGE
.	O

Induction	O
of	O
PKA	O
activity	O
with	O
forskolin	O
reduced	O
modification	O
of	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
by	O
Nedd8	B-PRGE
.	O

Finally	O
,	O
rat	O
adrenal	O
medullary	O
endothelial	O
cells	O
transfected	O
with	O
(	O
S730A	O
)	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
cul5	B-PRGE
cDNA	O
and	O
treated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
10	O
and	O
100	O
nm	O
)	O
to	O
induce	O
PKC	O
activity	O
grew	O
significantly	O
faster	O
than	O
the	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
antiproliferative	O
effect	O
of	O
VACM	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
Cul5	B-PRGE
is	O
dependent	O
on	O
its	O
posttranslational	O
modifications	O
and	O
will	O
help	O
in	O
the	O
design	O
of	O
new	O
anticancer	O
therapeutics	O
that	O
target	O
the	O
Nedd8	B-PRGE
pathway	O
.	O

Recognition	O
of	O
lipopeptide	O
patterns	O
by	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
2	I-PRGE
-	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
6	I-PRGE
heterodimer	O
.	O

Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
2	I-PRGE
(	O
TLR2	B-PRGE
)	O
initiates	O
potent	O
immune	O
responses	O
by	O
recognizing	O
diacylated	O
and	O
triacylated	O
lipopeptides	O
.	O

Its	O
ligand	O
specificity	O
is	O
controlled	O
by	O
whether	O
it	O
heterodimerizes	O
with	O
TLR1	B-PRGE
or	O
TLR6	B-PRGE
.	O

We	O
have	O
determined	O
the	O
crystal	O
structures	O
of	O
TLR2	B-PRGE
-	O
TLR6	B-PRGE
-	O
diacylated	O
lipopeptide	O
,	O
TLR2	B-PRGE
-	O
lipoteichoic	O
acid	O
,	O
and	O
TLR2	B-PRGE
-	O
PE	O
-	O
DTPA	O
complexes	O
.	O

PE	O
-	O
DTPA	O
,	O
1	O
,	O
2	O
-	O
dimyristoyl	O
-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphoethanolamine	O
-	O
N	O
-	O
diethylenetriaminepentaacetic	O
acid	O
,	O
is	O
a	O
synthetic	O
phospholipid	O
derivative	O
.	O

Two	O
major	O
factors	O
contribute	O
to	O
the	O
ligand	O
specificity	O
of	O
TLR2	B-PRGE
-	O
TLR1	B-PRGE
or	O
TLR2	B-PRGE
-	O
TLR6	B-PRGE
heterodimers	O
.	O

First	O
,	O
the	O
lipid	O
channel	O
of	O
TLR6	B-PRGE
is	O
blocked	O
by	O
two	O
phenylalanines	O
.	O

Simultaneous	O
mutation	O
of	O
these	O
phenylalanines	O
made	O
TLR2	B-PRGE
-	O
TLR6	B-PRGE
fully	O
responsive	O
not	O
only	O
to	O
diacylated	O
but	O
also	O
to	O
triacylated	O
lipopeptides	O
.	O

Second	O
,	O
the	O
hydrophobic	O
dimerization	O
interface	O
of	O
TLR2	B-PRGE
-	O
TLR6	B-PRGE
is	O
increased	O
by	O
80	O
%	O
,	O
which	O
compensates	O
for	O
the	O
lack	O
of	O
amide	O
lipid	O
interaction	O
between	O
the	O
lipopeptide	O
and	O
TLR2	B-PRGE
-	O
TLR6	B-PRGE
.	O

The	O
structures	O
of	O
the	O
TLR2	B-PRGE
-	O
lipoteichoic	O
acid	O
and	O
the	O
TLR2	B-PRGE
-	O
PE	O
-	O
DTPA	O
complexes	O
demonstrate	O
that	O
a	O
precise	O
interaction	O
pattern	O
of	O
the	O
head	O
group	O
is	O
essential	O
for	O
a	O
robust	O
immune	O
response	O
by	O
TLR2	B-PRGE
heterodimers	O
.	O

Palmitoylation	O
regulates	O
epidermal	O
homeostasis	O
and	O
hair	O
follicle	O
differentiation	O
.	O

Palmitoylation	O
is	O
a	O
key	O
post	O
-	O
translational	O
modification	O
mediated	O
by	O
a	O
family	O
of	O
DHHC	O
-	O
containing	O
palmitoyl	O
acyl	O
-	O
transferases	O
(	O
PATs	O
)	O
.	O

Unlike	O
other	O
lipid	O
modifications	O
,	O
palmitoylation	O
is	O
reversible	O
and	O
thus	O
often	O
regulates	O
dynamic	O
protein	O
interactions	O
.	O

We	O
find	O
that	O
the	O
mouse	O
hair	O
loss	O
mutant	O
,	O
depilated	O
,	O
(	O
dep	O
)	O
is	O
due	O
to	O
a	O
single	O
amino	O
acid	O
deletion	O
in	O
the	O
PAT	O
,	O
Zdhhc21	B-PRGE
,	O
resulting	O
in	O
protein	O
mislocalization	O
and	O
loss	O
of	O
palmitoylation	O
activity	O
.	O

We	O
examined	O
expression	O
of	O
Zdhhc21	B-PRGE
protein	O
in	O
skin	O
and	O
find	O
it	O
restricted	O
to	O
specific	O
hair	O
lineages	O
.	O

Loss	O
of	O
Zdhhc21	B-PRGE
function	O
results	O
in	O
delayed	O
hair	O
shaft	O
differentiation	O
,	O
at	O
the	O
site	O
of	O
expression	O
of	O
the	O
gene	O
,	O
but	O
also	O
leads	O
to	O
hyperplasia	O
of	O
the	O
interfollicular	O
epidermis	O
(	O
IFE	O
)	O
and	O
sebaceous	O
glands	O
,	O
distant	O
from	O
the	O
expression	O
site	O
.	O

The	O
specific	O
delay	O
in	O
follicle	O
differentiation	O
is	O
associated	O
with	O
attenuated	O
anagen	O
propagation	O
and	O
is	O
reflected	O
by	O
decreased	O
levels	O
of	O
Lef1	B-PRGE
,	O
nuclear	B-PRGE
beta	I-PRGE
-	I-PRGE
catenin	I-PRGE
,	O
and	O
Foxn1	B-PRGE
in	O
hair	O
shaft	O
progenitors	O
.	O

In	O
the	O
thickened	O
basal	O
compartment	O
of	O
mutant	O
IFE	O
,	O
phospho	O
-	O
ERK	O
and	O
cell	O
proliferation	O
are	O
increased	O
,	O
suggesting	O
increased	O
signaling	O
through	O
EGFR	B-PRGE
or	O
integrin	O
-	O
related	O
receptors	O
,	O
with	O
a	O
parallel	O
reduction	O
in	O
expression	O
of	O
the	O
key	O
differentiation	O
factor	O
Gata3	B-PRGE
.	O

We	O
show	O
that	O
the	O
Src	O
-	O
family	O
kinase	O
,	O
Fyn	B-PRGE
,	O
involved	O
in	O
keratinocyte	O
differentiation	O
,	O
is	O
a	O
direct	O
palmitoylation	O
target	O
of	O
Zdhhc21	B-PRGE
and	O
is	O
mislocalized	O
in	O
mutant	O
follicles	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
a	O
key	O
role	O
for	O
palmitoylation	O
in	O
regulating	O
developmental	O
signals	O
in	O
mammalian	O
tissue	O
homeostasis	O
.	O

Rapid	O
and	O
selective	O
detection	O
of	O
fatty	O
acylated	O
proteins	O
using	O
omega	O
-	O
alkynyl	O
-	O
fatty	O
acids	O
and	O
click	O
chemistry	O
.	O

Progress	O
in	O
understanding	O
the	O
biology	O
of	O
protein	O
fatty	O
acylation	O
has	O
been	O
impeded	O
by	O
the	O
lack	O
of	O
rapid	O
direct	O
detection	O
and	O
identification	O
methods	O
.	O

We	O
first	O
report	O
that	O
a	O
synthetic	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
analog	O
can	O
be	O
readily	O
and	O
specifically	O
incorporated	O
into	O
GAPDH	B-PRGE
or	O
mitochondrial	O
3	B-PRGE
-	I-PRGE
hydroxyl	I-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
methylglutaryl	I-PRGE
-	I-PRGE
CoA	I-PRGE
synthase	I-PRGE
in	O
vitro	O
and	O
reacted	O
with	O
an	O
azido	O
-	O
biotin	O
probe	O
or	O
the	O
fluorogenic	O
probe	O
3	O
-	O
azido	O
-	O
7	O
-	O
hydroxycoumarin	O
using	O
click	O
chemistry	O
for	O
rapid	O
detection	O
by	O
Western	O
blotting	O
or	O
flat	O
bed	O
fluorescence	O
scanning	O
.	O

The	O
acylated	O
cysteine	O
residues	O
were	O
confirmed	O
by	O
MS	O
.	O

Second	O
,	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
is	O
preferentially	O
incorporated	O
into	O
transiently	O
expressed	O
H	B-PRGE
-	I-PRGE
or	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
proteins	O
(	O
but	O
not	O
nonpalmitoylated	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
)	O
,	O
compared	O
with	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
or	O
omega	O
-	O
alkynyl	O
-	O
stearate	O
,	O
via	O
an	O
alkali	O
sensitive	O
thioester	O
bond	O
.	O

Third	O
,	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
is	O
specifically	O
incorporated	O
into	O
endogenous	O
co	O
-	O
and	O
posttranslationally	O
myristoylated	O
proteins	O
.	O

The	O
competitive	O
inhibitors	O
2	O
-	O
bromopalmitate	O
and	O
2	O
-	O
hydroxymyristate	O
prevented	O
incorporation	O
of	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
and	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
into	O
palmitoylated	O
and	O
myristoylated	O
proteins	O
,	O
respectively	O
.	O

Labeling	O
cells	O
with	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
does	O
not	O
affect	O
membrane	O
association	O
of	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
.	O

Furthermore	O
,	O
the	O
palmitoylation	O
of	O
endogenous	O
proteins	O
including	O
H	B-PRGE
-	I-PRGE
and	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
could	O
be	O
easily	O
detected	O
using	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
as	O
label	O
in	O
cultured	O
HeLa	O
,	O
Jurkat	O
,	O
and	O
COS	O
-	O
7	O
cells	O
,	O
and	O
,	O
promisingly	O
,	O
in	O
mice	O
.	O

The	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
and	O
-	O
palmitate	O
analogs	O
used	O
with	O
click	O
chemistry	O
and	O
azido	O
-	O
probes	O
will	O
be	O
invaluable	O
to	O
study	O
protein	O
acylation	O
in	O
vitro	O
,	O
in	O
cells	O
,	O
and	O
in	O
vivo	O
.	O

Regulation	O
of	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
trafficking	O
and	O
function	O
by	O
palmitoylation	O
.	O

The	O
SNARE	O
(	O
soluble	O
N	O
-	O
ethylmaleimide	O
-	O
sensitive	O
fusion	O
protein	O
-	O
attachment	O
protein	O
receptor	O
)	O
protein	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
(	O
25	B-PRGE
kDa	I-PRGE
synaptosome	I-PRGE
-	I-PRGE
associated	I-PRGE
protein	I-PRGE
)	O
is	O
essential	O
for	O
regulated	O
exocytosis	O
in	O
neuronal	O
and	O
neuroendocrine	O
cells	O
.	O

Whereas	O
the	O
majority	O
of	O
SNARE	O
proteins	O
contain	O
transmembrane	O
domains	O
,	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
is	O
instead	O
anchored	O
to	O
membranes	O
by	O
the	O
palmitoylation	O
of	O
a	O
central	O
cysteine	O
-	O
rich	O
region	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
mechanisms	O
of	O
SNAP	B-PRGE
-	I-PRGE
25	I-PRGE
palmitoylation	O
and	O
how	O
this	O
modification	O
regulates	O
the	O
intracellular	O
trafficking	O
and	O
exocytotic	O
function	O
of	O
this	O
essential	O
protein	O
.	O

Regulation	O
of	O
synaptic	O
structure	O
and	O
function	O
by	O
palmitoylated	O
AMPA	O
receptor	O
binding	O
protein	O
.	O

AMPA	O
receptor	O
binding	O
protein	O
(	O
ABP	O
)	O
is	O
a	O
multi	O
-	O
PDZ	O
domain	O
scaffold	O
that	O
binds	O
and	O
stabilizes	O
AMPA	O
receptor	O
(	O
AMPAR	O
)	O
GluR2	B-PRGE
/	O
3	B-PRGE
subunits	O
at	O
synapses	O
.	O

A	O
palmitoylated	O
N	O
-	O
terminal	O
splice	O
variant	O
(	O
pABP	O
-	O
L	O
)	O
concentrates	O
in	O
spine	O
heads	O
,	O
whereas	O
a	O
non	O
-	O
palmitoylated	O
form	O
(	O
ABP	O
-	O
L	O
)	O
is	O
intracellular	O
.	O

We	O
show	O
that	O
postsynaptic	O
Sindbis	O
viral	O
expression	O
of	O
pABP	O
-	O
L	O
increased	O
AMPAR	O
mediated	O
mEPSC	O
amplitude	O
and	O
frequency	O
and	O
elevated	O
surface	O
levels	O
of	O
GluR1	B-PRGE
and	O
GluR2	B-PRGE
,	O
suggesting	O
an	O
increase	O
in	O
AMPA	O
receptors	O
at	O
individual	O
synapses	O
.	O

Spines	O
were	O
enlarged	O
and	O
more	O
numerous	O
and	O
nerve	O
terminals	O
contacting	O
these	O
cells	O
displayed	O
enlarged	O
synaptophysin	B-PRGE
puncta	O
.	O

A	O
non	O
-	O
palmitoylated	O
pABP	O
-	O
L	O
mutant	O
(	O
C11A	O
)	O
did	O
not	O
change	O
spine	O
density	O
or	O
size	O
.	O

Exogenous	O
pABP	O
-	O
L	O
and	O
endogenous	O
GRIP	O
,	O
a	O
related	O
scaffold	O
,	O
colocalized	O
with	O
NPRAP	B-PRGE
(	O
delta	O
-	O
catenin	O
)	O
,	O
to	O
which	O
ABP	O
and	O
GRIP	O
bind	O
,	O
and	O
with	O
cadherins	O
,	O
which	O
bind	O
NPRAP	B-PRGE
.	O

Thus	O
postsynaptic	O
pABP	O
-	O
L	O
induces	O
pre	O
and	O
postsynaptic	O
changes	O
that	O
are	O
dependent	O
on	O
palmitoylation	O
and	O
likely	O
achieved	O
through	O
ABP	O
association	O
with	O
a	O
multi	O
-	O
molecular	O
cell	O
surface	O
signaling	O
complex	O
.	O

DELLA	O
proteins	O
restrain	O
germination	O
and	O
elongation	O
growth	O
in	O
Arabidopsis	O
thaliana	O
COP9	O
signalosome	O
mutants	O
.	O

The	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
is	O
an	O
evolutionarily	O
conserved	O
multiprotein	O
complex	O
with	O
an	O
essential	O
role	O
in	O
the	O
development	O
of	O
higher	O
eukaryotes	O
.	O

CSN	O
deconjugates	O
the	O
ubiquitin	B-PRGE
-	O
related	O
modifier	O
NEDD8	B-PRGE
from	O
the	O
cullin	O
subunit	O
of	O
cullin	O
-	O
RING	O
type	O
E3	O
ubiquitin	B-PRGE
ligases	O
(	O
CRLs	O
)	O
,	O
and	O
CSN	O
-	O
mediated	O
cullin	O
deneddylation	O
is	O
required	O
for	O
full	O
CRL	O
activity	O
.	O

Although	O
several	O
plant	O
E3	O
CRL	O
functions	O
have	O
been	O
shown	O
to	O
be	O
compromised	O
in	O
Arabidopsis	O
csn	O
mutants	O
,	O
none	O
of	O
these	O
functions	O
have	O
so	O
far	O
been	O
shown	O
to	O
limit	O
growth	O
in	O
these	O
mutants	O
.	O

Here	O
,	O
we	O
examine	O
the	O
role	O
of	O
CSN	O
in	O
the	O
context	O
of	O
the	O
E3	O
ubiquitin	B-PRGE
ligase	O
SCF	O
(	O
SLEEPY1	B-PRGE
(	O
SLY1	B-PRGE
)	O
)	O
,	O
which	O
promotes	O
gibberellic	O
acid	O
(	O
GA	O
)	O
-	O
dependent	O
responses	O
in	O
Arabidopsis	O
thaliana	O
.	O

We	O
show	O
that	O
csn	O
mutants	O
are	O
impaired	O
in	O
GA	O
-	O
and	O
SCF	O
(	O
SLY1	B-PRGE
)	O
-	O
dependent	O
germination	O
and	O
elongation	O
growth	O
,	O
and	O
we	O
show	O
that	O
these	O
defects	O
correlate	O
with	O
an	O
accumulation	O
and	O
reduced	O
turnover	O
of	O
an	O
SCF	O
(	O
SLY1	B-PRGE
)	O
-	O
degradation	O
target	O
,	O
the	O
DELLA	O
protein	O
REPRESSOR	B-PRGE
-	I-PRGE
OF	I-PRGE
-	I-PRGE
ga1	I-PRGE
-	I-PRGE
3	I-PRGE
(	O
RGA	B-PRGE
)	O
.	O

Genetic	O
interaction	O
studies	O
between	O
csn	O
mutants	O
and	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
of	O
RGA	B-PRGE
and	O
its	O
functional	O
homologue	O
GIBBERELLIC	B-PRGE
ACID	I-PRGE
INSENSITIVE	I-PRGE
(	O
GAI	B-PRGE
)	O
further	O
reveal	O
that	O
RGA	B-PRGE
and	O
GAI	B-PRGE
repress	O
defects	O
of	O
germination	O
in	O
strong	O
csn	O
mutants	O
.	O

In	O
addition	O
,	O
we	O
find	O
that	O
these	O
two	O
DELLA	O
proteins	O
are	O
largely	O
responsible	O
for	O
the	O
elongation	O
defects	O
of	O
a	O
weak	O
csn5	B-PRGE
mutant	O
allele	O
.	O

We	O
thus	O
conclude	O
that	O
an	O
impairment	O
of	O
SCF	O
(	O
SLY1	B-PRGE
)	O
is	O
at	O
least	O
in	O
part	O
causative	O
for	O
the	O
germination	O
and	O
elongation	O
defects	O
of	O
csn	O
mutants	O
,	O
and	O
suggest	O
that	O
DELLA	O
proteins	O
are	O
major	O
growth	O
repressors	O
in	O
these	O
mutants	O
.	O

Designed	O
semisynthetic	O
protein	O
inhibitors	O
of	O
Ub	O
/	O
Ubl	O
E1	O
activating	O
enzymes	O
.	O

Semisynthetic	O
,	O
mechanism	O
-	O
based	O
protein	O
inhibitors	O
of	O
ubiquitin	B-PRGE
(	O
Ub	B-PRGE
)	O
and	O
ubiquitin	O
-	O
like	O
modifier	O
(	O
Ubl	O
)	O
activating	O
enzymes	O
(	O
E1s	O
)	O
have	O
been	O
developed	O
to	O
target	O
E1	O
-	O
catalyzed	O
adenylation	O
and	O
thioesterification	O
of	O
the	O
Ub	B-PRGE
/	O
Ubl	O
C	O
-	O
terminus	O
during	O
the	O
processes	O
of	O
protein	O
SUMOylation	O
and	O
ubiquitination	O
.	O

The	O
inhibitors	O
were	O
generated	O
by	O
intein	O
-	O
mediated	O
expressed	O
protein	O
ligation	O
using	O
a	O
truncated	O
Ub	B-PRGE
/	O
Ubl	O
protein	O
(	O
SUMO	O
residues	O
1	O
-	O
94	O
;	O
Ub	B-PRGE
residues	O
1	O
-	O
71	O
)	O
with	O
a	O
C	O
-	O
terminal	O
thioester	O
and	O
synthetic	O
tripeptides	O
having	O
a	O
C	O
-	O
terminal	O
adenosine	O
analogue	O
and	O
an	O
N	O
-	O
terminal	O
cysteine	O
residue	O
.	O

SUMO	O
-	O
AMSN	O
(	O
4a	O
)	O
and	O
Ub	B-PRGE
-	O
AMSN	O
(	O
4b	O
)	O
contain	O
a	O
sulfamide	O
group	O
as	O
a	O
nonhydrolyzable	O
mimic	O
of	O
the	O
phosphate	O
group	O
in	O
the	O
cognate	O
Ub	B-PRGE
/	O
Ubl	O
-	O
AMP	O
adenylate	O
intermediate	O
in	O
the	O
first	O
half	O
-	O
reaction	O
,	O
and	O
these	O
constructs	O
selectively	O
inhibit	O
SUMO	O
E1	O
and	O
Ub	O
E1	O
,	O
respectively	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

SUMO	O
-	O
AVSN	O
(	O
5a	O
)	O
and	O
Ub	B-PRGE
-	O
AVSN	O
(	O
5b	O
)	O
contain	O
an	O
electrophilic	O
vinyl	O
sulfonamide	O
designed	O
to	O
trap	O
the	O
incoming	O
E1	O
cysteine	O
nucleophile	O
(	O
Uba2	B-PRGE
Cys173	O
in	O
SUMO	O
E1	O
;	O
Uba1	B-PRGE
Cys593	O
in	O
Ub	O
E1	O
)	O
in	O
the	O
second	O
half	O
-	O
reaction	O
,	O
and	O
these	O
constructs	O
selectively	O
,	O
covalently	O
,	O
and	O
stably	O
cross	O
-	O
link	O
to	O
SUMO	O
E1	O
and	O
Ub	B-PRGE
E1	O
,	O
respectively	O
,	O
in	O
a	O
cysteine	O
nucleophile	O
-	O
dependent	O
manner	O
.	O

These	O
inhibitors	O
are	O
powerful	O
tools	O
to	O
probe	O
outstanding	O
mechanistic	O
questions	O
in	O
E1	O
function	O
and	O
can	O
also	O
be	O
used	O
to	O
study	O
the	O
biological	O
functions	O
of	O
E1	O
enzymes	O
.	O

Characterization	O
of	O
the	O
self	O
-	O
palmitoylation	O
activity	O
of	O
the	O
transport	O
protein	O
particle	O
component	O
Bet3	B-PRGE
.	O

Bet3	B-PRGE
,	O
a	O
transport	O
protein	O
particle	O
component	O
involved	O
in	O
vesicular	O
trafficking	O
,	O
contains	O
a	O
hydrophobic	O
tunnel	O
occupied	O
by	O
a	O
fatty	O
acid	O
linked	O
to	O
cysteine	O
68	O
.	O

We	O
reported	O
that	O
Bet3	B-PRGE
has	O
a	O
unique	O
self	O
-	O
palmitoylating	O
activity	O
.	O

Here	O
we	O
show	O
that	O
mutation	O
of	O
arginine	O
67	O
reduced	O
self	O
-	O
palmitoylation	O
of	O
Bet3	B-PRGE
,	O
but	O
the	O
effect	O
was	O
compensated	O
by	O
increasing	O
the	O
pH	O
.	O

Thus	O
,	O
arginine	O
helps	O
to	O
deprotonate	O
cysteine	O
such	O
that	O
it	O
could	O
function	O
as	O
a	O
nucleophile	O
in	O
the	O
acylation	O
reaction	O
which	O
is	O
supported	O
by	O
the	O
structural	O
analysis	O
of	O
non	O
-	O
acylated	O
Bet3	B-PRGE
.	O

Using	O
fluorescence	O
spectroscopy	O
we	O
show	O
that	O
long	O
-	O
chain	O
acyl	O
-	O
CoAs	O
bind	O
with	O
micromolar	O
affinity	O
to	O
Bet3	B-PRGE
,	O
whereas	O
shorter	O
-	O
chain	O
acyl	O
-	O
CoAs	O
do	O
not	O
interact	O
.	O

Mutants	O
with	O
a	O
deleted	O
acylation	O
site	O
or	O
a	O
blocked	O
tunnel	O
bind	O
to	O
Pal	O
-	O
CoA	O
,	O
only	O
the	O
latter	O
with	O
slightly	O
reduced	O
affinity	O
.	O

Bet3	B-PRGE
contains	O
three	O
binding	O
sites	O
for	O
Pal	O
-	O
CoA	O
,	O
but	O
their	O
number	O
was	O
reduced	O
to	O
two	O
in	O
the	O
mutant	O
with	O
an	O
obstructed	O
tunnel	O
,	O
indicating	O
that	O
Bet3	B-PRGE
contains	O
binding	O
sites	O
on	O
its	O
surface	O
.	O

Farnesyltransferase	O
inhibitors	O
in	O
myelodysplastic	O
syndrome	O
.	O

The	O
farnesyltransferase	O
inhibitors	O
(	O
FTIs	O
)	O
are	O
in	O
active	O
clinical	O
development	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
.	O

The	O
most	O
promising	O
activity	O
to	O
date	O
has	O
been	O
demonstrated	O
in	O
patients	O
with	O
hematologic	O
malignancies	O
,	O
in	O
particular	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
and	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O

In	O
patients	O
with	O
MDS	O
,	O
two	O
nonpeptidomimetic	O
agents	O
,	O
tipifarnib	O
(	O
Zarnestra	O
,	O
Johnson	O
&	O
Johnson	O
,	O
New	O
Brunswick	O
,	O
NJ	O
)	O
and	O
lonafarnib	O
(	O
Sarasar	O
,	O
Schering	O
-	O
Plough	O
,	O
Kenilworth	O
,	O
NJ	O
)	O
have	O
been	O
the	O
most	O
extensively	O
studied	O
.	O

In	O
both	O
phase	O
I	O
and	O
phase	O
II	O
trials	O
,	O
tipifarnib	O
has	O
demonstrated	O
significant	O
efficacy	O
,	O
with	O
overall	O
response	O
rates	O
of	O
30	O
%	O
and	O
complete	O
remissions	O
in	O
about	O
15	O
%	O
.	O

Dose	O
-	O
limiting	O
adverse	O
effects	O
have	O
been	O
primarily	O
myelosuppression	O
,	O
although	O
fatigue	O
,	O
neurotoxicity	O
,	O
and	O
occasional	O
renal	O
dysfunction	O
have	O
required	O
dose	O
reductions	O
.	O

Lonafarnib	O
in	O
patients	O
with	O
MDS	O
has	O
also	O
resulted	O
in	O
clinical	O
responses	O
in	O
approximately	O
30	O
%	O
,	O
including	O
significant	O
improvements	O
in	O
platelet	O
counts	O
.	O

Lonafarnib	O
has	O
been	O
associated	O
primarily	O
with	O
diarrhea	O
and	O
other	O
gastrointestinal	O
toxicity	O
,	O
anorexia	O
,	O
and	O
nausea	O
,	O
which	O
has	O
limited	O
its	O
efficacy	O
.	O

Clinical	O
response	O
correlation	O
with	O
documentation	O
of	O
inhibition	O
of	O
farnesyltransferase	O
and	O
/	O
or	O
evidence	O
of	O
decreased	O
farnesylation	O
of	O
downstream	O
protein	O
targets	O
has	O
not	O
been	O
demonstrated	O
with	O
either	O
agent	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
activating	O
Ras	O
mutation	O
has	O
not	O
predicted	O
response	O
to	O
therapy	O
with	O
FTIs	O
in	O
MDS	O
and	O
AML	O
.	O

Despite	O
this	O
lack	O
of	O
evidence	O
,	O
significant	O
clinical	O
efficacy	O
of	O
the	O
FTIs	O
has	O
been	O
observed	O
in	O
MDS	O
,	O
on	O
a	O
par	O
with	O
the	O
efficacy	O
of	O
currently	O
available	O
chemotherapeutic	O
agents	O
,	O
leading	O
to	O
further	O
development	O
of	O
this	O
new	O
class	O
of	O
drugs	O
in	O
MDS	O
and	O
AML	O
.	O

An	O
S	O
-	O
acylation	O
switch	O
of	O
conserved	O
G	O
domain	O
cysteines	O
is	O
required	O
for	O
polarity	O
signaling	O
by	O
ROP	O
GTPases	O
.	O

Rho	O
GTPases	O
are	O
master	O
regulators	O
of	O
cell	O
polarity	O
.	O

For	O
their	O
function	O
,	O
Rhos	O
must	O
associate	O
with	O
discrete	O
plasma	O
membrane	O
domains	O
.	O

Rho	O
of	O
Plants	O
(	O
ROPs	O
)	O
or	O
RACs	O
comprise	O
a	O
single	O
family	O
.	O

Prenylation	O
and	O
S	O
-	O
acylation	O
of	O
hypervariable	O
domain	O
cysteines	O
of	O
Ras	O
and	O
Rho	O
GTPases	O
are	O
required	O
for	O
their	O
function	O
;	O
however	O
,	O
lipid	O
modifications	O
in	O
the	O
G	O
domain	O
have	O
never	O
been	O
reported	O
.	O

Reversible	O
S	O
-	O
acylation	O
involves	O
the	O
attachment	O
of	O
palmitate	O
(	O
C16	O
:	O
0	O
)	O
or	O
other	O
saturated	O
lipids	O
to	O
cysteines	O
through	O
a	O
thioester	O
linkage	O
and	O
was	O
implicated	O
in	O
the	O
regulation	O
of	O
signaling	O
.	O

Here	O
we	O
show	O
that	O
transient	O
S	O
-	O
acylation	O
of	O
Arabidopsis	O
AtROP6	B-PRGE
takes	O
place	O
on	O
two	O
conserved	O
G	O
domain	O
cysteine	O
residues	O
,	O
C21	O
and	O
C156	O
.	O

C21	O
is	O
relatively	O
exposed	O
and	O
is	O
accessible	O
for	O
modification	O
,	O
but	O
C156	O
is	O
not	O
,	O
implying	O
that	O
its	O
S	O
-	O
acylation	O
involves	O
a	O
conformational	O
change	O
.	O

Fluorescence	O
recovery	O
after	O
photobleaching	O
beam	O
-	O
size	O
analysis	O
shows	O
that	O
S	O
-	O
acylation	O
of	O
AtROP6	B-PRGE
regulates	O
its	O
membrane	O
-	O
association	O
dynamics	O
,	O
and	O
detergent	O
-	O
solubilization	O
studies	O
indicate	O
that	O
it	O
regulates	O
AtROP6	B-PRGE
association	O
with	O
lipid	O
rafts	O
.	O

Site	O
-	O
specific	O
acylation	O
-	O
deficient	O
AtROP6	B-PRGE
mutants	O
can	O
bind	O
and	O
hydrolyze	O
GTP	O
but	O
display	O
compromised	O
effects	O
on	O
polar	O
cell	O
growth	O
,	O
endocytic	O
uptake	O
of	O
the	O
tracer	O
dye	O
FM4	O
-	O
64	O
,	O
and	O
distribution	O
of	O
reactive	O
oxygen	O
species	O
.	O

These	O
data	O
reveal	O
an	O
S	O
-	O
acylation	O
switch	O
that	O
regulates	O
Rho	O
signaling	O
.	O

Simultaneous	O
C7	O
-	O
and	O
N1	O
-	O
prenylation	O
of	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
catalyzed	O
by	O
a	O
prenyltransferase	O
from	O
Aspergillus	O
oryzae	O
.	O

A	O
putative	O
prenyltransferase	O
gene	O
cTrpPT	B-PRGE
was	O
amplified	O
from	O
Aspergillus	O
oryzae	O
DSM1147	O
,	O
cloned	O
into	O
pQE70	O
and	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
overproduced	O
His	O
(	O
6	O
)	O
-	O
CTrpPT	B-PRGE
was	O
purified	O
to	O
near	O
homogeneity	O
and	O
incubated	O
with	O
L	O
-	O
tryptophan	O
or	O
tryptophan	O
-	O
containing	O
cyclic	O
dipeptides	O
in	O
the	O
presence	O
of	O
dimethylallyl	O
diphosphate	O
.	O

The	O
formation	O
of	O
the	O
enzyme	O
products	O
was	O
monitored	O
with	O
HPLC	O
.	O

It	O
was	O
shown	O
that	O
CTrpPT	B-PRGE
differed	O
clearly	O
from	O
other	O
known	O
indole	O
prenyltransferases	O
in	O
several	O
aspects	O
.	O

This	O
enzyme	O
showed	O
higher	O
substrate	O
specificity	O
towards	O
aromatic	O
substrates	O
,	O
but	O
lower	O
regioselectivity	O
regarding	O
the	O
prenylation	O
position	O
than	O
other	O
indole	O
prenyltransferases	O
.	O

Cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
was	O
much	O
better	O
accepted	O
than	O
other	O
cyclic	O
dipeptides	O
tested	O
in	O
this	O
study	O
.	O

In	O
comparison	O
to	O
other	O
indole	O
prenyltransferases	O
with	O
one	O
dominant	O
enzyme	O
product	O
,	O
at	O
least	O
two	O
product	O
peaks	O
were	O
detected	O
in	O
the	O
reaction	O
mixtures	O
of	O
CTrpPT	B-PRGE
.	O

(	O
1	O
)	O
H	O
-	O
and	O
(	O
13	O
)	O
C	O
-	O
NMR	O
analyses	O
,	O
including	O
long	O
-	O
range	O
(	O
1	O
)	O
H	O
-	O
(	O
13	O
)	O
C	O
connectivities	O
in	O
Heteronuclear	O
Multiple	O
-	O
Bond	O
Correlation	O
(	O
HMBC	O
)	O
and	O
Nuclear	O
Overhauser	O
Effect	O
Spectroscopy	O
(	O
NOESY	O
)	O
,	O
proved	O
the	O
structures	O
of	O
the	O
enzyme	O
products	O
as	O
C7	O
-	O
and	O
N1	O
-	O
prenylated	O
derivatives	O
with	O
a	O
ratio	O
of	O
1	O
:	O
1	O
.	O
2	O
using	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
as	O
substrate	O
.	O

The	O
K	O
(	O
M	O
)	O
values	O
were	O
determined	O
at	O
about	O
2	O
.	O
5	O
mM	O
for	O
dimethylallyl	O
diphosphate	O
and	O
0	O
.	O
3	O
mM	O
for	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
with	O
a	O
turnover	O
number	O
of	O
0	O
.	O
33	O
s	O
(	O
-	O
1	O
)	O
.	O

The	O
lipoatrophic	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
deficient	O
mouse	O
model	O
reveals	O
autophagy	O
in	O
mature	O
adipocytes	O
.	O

Adipose	O
tissue	O
lipoatrophy	O
caused	O
by	O
caveolin	O
gene	O
deletion	O
in	O
mice	O
is	O
not	O
linked	O
to	O
defective	O
adipocyte	O
differentiation	O
.	O

We	O
show	O
that	O
adipose	O
tissue	O
development	O
cannot	O
be	O
rescued	O
by	O
endothelial	O
specific	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
re	O
-	O
expression	O
,	O
indicating	O
primordial	O
role	O
of	O
caveolin	O
in	O
mature	O
adipocytes	O
.	O

Partial	O
or	O
total	O
caveolin	O
deficiency	O
in	O
adipocytes	O
induced	O
broad	O
protein	O
expression	O
defects	O
,	O
including	O
but	O
not	O
limited	O
to	O
previously	O
described	O
downregulation	O
of	O
insulin	B-PRGE
receptor	I-PRGE
.	O

Global	O
alterations	O
in	O
protein	O
turnover	O
,	O
and	O
accelerated	O
degradation	O
of	O
long	O
-	O
lived	O
proteins	O
were	O
found	O
in	O
caveolin	O
-	O
deficient	O
adipocytes	O
.	O

Lipidation	O
of	O
endogenous	O
LC3	O
autophagy	O
marker	O
and	O
distribution	O
of	O
GFP	B-PRGE
-	O
LC3	O
into	O
aggregates	O
demonstrated	O
activated	O
autophagy	O
in	O
the	O
absence	O
of	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
adipocytes	O
.	O

Furthermore	O
,	O
electron	O
microscopy	O
revealed	O
autophagic	O
vacuoles	O
in	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
deficient	O
but	O
not	O
control	O
adipocytes	O
.	O

Surprisingly	O
,	O
significant	O
levels	O
of	O
lipidated	O
LC3	B-PRGE
-	I-PRGE
II	I-PRGE
were	O
found	O
around	O
lipid	O
droplets	O
of	O
normal	O
adipocytes	O
,	O
maintained	O
in	O
nutrient	O
-	O
rich	O
conditions	O
or	O
isolated	O
from	O
fed	O
mice	O
,	O
which	O
do	O
not	O
display	O
autophagy	O
.	O

Altogether	O
,	O
these	O
data	O
indicate	O
that	O
caveolin	O
deficiency	O
induce	O
autophagy	O
in	O
adipocytes	O
,	O
a	O
feature	O
that	O
is	O
not	O
a	O
physiological	O
response	O
to	O
fasting	O
in	O
normal	O
fat	O
cells	O
.	O

This	O
likely	O
resulted	O
from	O
defective	O
insulin	B-PRGE
and	O
lipolytic	O
responses	O
that	O
converge	O
in	O
chronic	O
nutrient	O
shortage	O
in	O
adipocytes	O
lacking	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
pathological	O
situation	O
with	O
autophagy	O
as	O
an	O
adaptative	O
response	O
to	O
adipocyte	O
failure	O
.	O

Regulation	O
of	O
the	O
p53	B-PRGE
pathway	O
by	O
ubiquitin	B-PRGE
and	O
related	O
proteins	O
.	O

The	O
p53	B-PRGE
tumour	O
suppressor	O
protein	O
is	O
subject	O
to	O
many	O
levels	O
of	O
control	O
,	O
including	O
modification	O
with	O
ubiquitin	B-PRGE
and	O
related	O
proteins	O
such	O
as	O
SUMO	O
and	O
NEDD8	B-PRGE
.	O

These	O
modifications	O
regulate	O
p53	B-PRGE
at	O
a	O
number	O
of	O
levels	O
,	O
including	O
control	O
of	O
protein	O
turnover	O
,	O
alterations	O
in	O
sub	O
-	O
cellular	O
localization	O
and	O
changes	O
in	O
the	O
ability	O
to	O
regulate	O
gene	O
expression	O
.	O

Numerous	O
E3	O
ligases	O
that	O
can	O
mediate	O
these	O
modifications	O
of	O
p53	B-PRGE
have	O
been	O
described	O
,	O
some	O
of	O
which	O
promote	O
conjugation	O
with	O
more	O
than	O
one	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
.	O

Understanding	O
the	O
complexity	O
of	O
this	O
mechanism	O
of	O
p53	B-PRGE
regulation	O
will	O
help	O
in	O
the	O
development	O
of	O
therapeutic	O
drugs	O
that	O
function	O
to	O
modulate	O
these	O
events	O
.	O

Interplay	O
of	O
palmitoylation	O
and	O
phosphorylation	O
in	O
the	O
trafficking	O
and	O
localization	O
of	O
phosphodiesterase	B-PRGE
10A	I-PRGE
:	O
implications	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O

Phosphodiesterase	B-PRGE
10A	I-PRGE
(	O
PDE10A	B-PRGE
)	O
is	O
a	O
striatum	O
-	O
enriched	O
,	O
dual	O
-	O
specific	O
cyclic	O
nucleotide	O
phosphodiesterase	O
that	O
has	O
gained	O
considerable	O
attention	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
psychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

As	O
such	O
,	O
a	O
PDE10A	B-PRGE
-	O
selective	O
inhibitor	O
compound	O
,	O
MP	O
-	O
10	O
,	O
has	O
recently	O
entered	O
clinical	O
testing	O
.	O

Since	O
little	O
is	O
known	O
about	O
the	O
cellular	O
regulation	O
of	O
PDE10A	B-PRGE
,	O
we	O
sought	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
govern	O
its	O
subcellular	O
localization	O
in	O
striatal	O
medium	O
spiny	O
neurons	O
.	O

Previous	O
reports	O
suggest	O
that	O
PDE10A	B-PRGE
is	O
primarily	O
membrane	O
bound	O
and	O
is	O
transported	O
throughout	O
medium	O
spiny	O
neuron	O
axons	O
and	O
dendrites	O
.	O

Moreover	O
,	O
it	O
has	O
been	O
shown	O
in	O
PC12	O
cells	O
that	O
the	O
localization	O
of	O
the	O
major	O
splice	O
form	O
,	O
PDE10A2	B-PRGE
,	O
may	O
be	O
regulated	O
by	O
protein	O
kinase	O
A	O
phosphorylation	O
at	O
threonine	O
16	O
(	O
Thr	O
-	O
16	O
)	O
.	O

Using	O
an	O
antibody	O
that	O
specifically	O
recognizes	O
phosphorylated	O
Thr	O
-	O
16	O
(	O
pThr	O
-	O
16	O
)	O
of	O
PDE10A2	B-PRGE
,	O
we	O
provide	O
evidence	O
that	O
phosphorylation	O
at	O
Thr	O
-	O
16	O
is	O
critical	O
for	O
the	O
regulation	O
of	O
PDE10A	B-PRGE
subcellular	O
localization	O
in	O
vivo	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
in	O
primary	O
mouse	O
striatal	O
neuron	O
cultures	O
that	O
PDE10A	B-PRGE
membrane	O
association	O
and	O
transport	O
throughout	O
dendritic	O
processes	O
requires	O
palmitoylation	O
of	O
cysteine	O
11	O
(	O
Cys	O
-	O
11	O
)	O
of	O
PDE10A2	B-PRGE
,	O
likely	O
by	O
the	O
palmitoyl	O
acyltransferases	O
DHHC	B-PRGE
-	I-PRGE
7	I-PRGE
and	O
-	B-PRGE
19	I-PRGE
.	O

Finally	O
,	O
we	O
show	O
that	O
Thr	O
-	O
16	O
phosphorylation	O
regulates	O
PDE10A	B-PRGE
trafficking	O
and	O
localization	O
by	O
preventing	O
palmitoylation	O
of	O
Cys	O
-	O
11	O
rather	O
than	O
by	O
interfering	O
with	O
palmitate	O
-	O
lipid	O
interactions	O
.	O

These	O
data	O
support	O
a	O
model	O
whereby	O
PDE10A	B-PRGE
trafficking	O
and	O
localization	O
can	O
be	O
regulated	O
in	O
response	O
to	O
local	O
fluctuations	O
in	O
cAMP	O
levels	O
.	O

Given	O
this	O
,	O
we	O
propose	O
that	O
excessive	O
striatal	O
dopamine	O
release	O
,	O
as	O
occurs	O
in	O
schizophrenia	O
,	O
might	O
exert	O
differential	O
effects	O
on	O
the	O
regulation	O
of	O
PDE10A	B-PRGE
localization	O
in	O
the	O
two	O
striatal	O
output	O
pathways	O
.	O

Characterization	O
of	O
an	O
acyltransferase	O
acting	O
on	O
p21N	B-PRGE
-	I-PRGE
ras	I-PRGE
protein	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

We	O
have	O
identified	O
a	O
protein	O
-	O
acyltransferase	O
activity	O
in	O
membranes	O
from	O
mouse	O
fibroblasts	O
which	O
transfers	O
palmitate	O
from	O
palmitoyl	O
-	O
CoA	O
to	O
p21N	B-PRGE
-	I-PRGE
ras	I-PRGE
.	O

Specificity	O
of	O
acylation	O
has	O
been	O
confirmed	O
by	O
linkage	O
analysis	O
using	O
hydroxylamine	O
and	O
by	O
peptide	O
mapping	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
acylated	O
p21N	B-PRGE
-	I-PRGE
ras	I-PRGE
.	O

The	O
acylation	O
was	O
temperature	O
-	O
and	O
time	O
-	O
dependent	O
,	O
and	O
prevented	O
by	O
prior	O
boiling	O
of	O
membranes	O
,	O
consistent	O
with	O
an	O
enzymatic	O
process	O
.	O

The	O
activity	O
was	O
detected	O
in	O
membranes	O
,	O
but	O
not	O
cytosol	O
,	O
and	O
co	O
-	O
fractionated	O
on	O
Percoll	O
gradients	O
with	O
Golgi	O
markers	O
.	O

Cytosolic	O
p21N	B-PRGE
-	I-PRGE
ras	I-PRGE
from	O
mouse	O
fibroblasts	O
,	O
which	O
is	O
C	O
-	O
terminally	O
modified	O
at	O
its	O
CAAX	O
sequence	O
,	O
was	O
a	O
better	O
substrate	O
for	O
the	O
enzyme	O
that	O
recombinant	O
bacterially	O
expressed	O
,	O
unmodified	O
p21N	B-PRGE
-	I-PRGE
ras	I-PRGE
.	O

The	O
activity	O
could	O
be	O
solubilised	O
in	O
non	O
-	O
ionic	O
detergents	O
,	O
making	O
it	O
amenable	O
to	O
purification	O
.	O

Survival	O
defects	O
of	O
Cryptococcus	O
neoformans	O
mutants	O
exposed	O
to	O
human	O
cerebrospinal	O
fluid	O
result	O
in	O
attenuated	O
virulence	O
in	O
an	O
experimental	O
model	O
of	O
meningitis	O
.	O

Cryptococcus	O
neoformans	O
is	O
a	O
fungal	O
pathogen	O
that	O
encounters	O
various	O
microenvironments	O
during	O
growth	O
in	O
the	O
mammalian	O
host	O
,	O
including	O
intracellular	O
vacuoles	O
,	O
blood	O
,	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

Because	O
the	O
CSF	O
is	O
isolated	O
by	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
we	O
hypothesize	O
that	O
CSF	O
presents	O
unique	O
stresses	O
that	O
C	O
.	O
neoformans	O
must	O
overcome	O
to	O
establish	O
an	O
infection	O
.	O

We	O
assayed	O
1	O
,	O
201	O
mutants	O
for	O
survival	O
defects	O
in	O
growth	O
media	O
,	O
saline	O
,	O
and	O
human	O
CSF	O
.	O

We	O
assessed	O
CSF	O
-	O
specific	O
mutants	O
for	O
(	O
i	O
)	O
mutant	O
survival	O
in	O
both	O
human	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
and	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
(	O
ii	O
)	O
survival	O
in	O
macrophages	O
,	O
and	O
(	O
iii	O
)	O
virulence	O
using	O
both	O
Caenorhabditis	O
elegans	O
and	O
rabbit	O
models	O
of	O
cryptococcosis	O
.	O

Thirteen	O
mutants	O
exhibited	O
significant	O
survival	O
defects	O
unique	O
to	O
CSF	O
.	O

The	O
mutations	O
of	O
three	O
of	O
these	O
mutants	O
were	O
recreated	O
in	O
the	O
clinical	O
serotype	O
A	O
strain	O
H99	O
:	O
deletions	O
of	O
the	O
genes	O
for	O
a	O
cation	O
ATPase	O
transporter	O
(	O
ena1	B-PRGE
Delta	O
)	O
,	O
a	O
putative	O
NEDD8	B-PRGE
ubiquitin	B-PRGE
-	O
like	O
protein	O
(	O
rub1	B-PRGE
Delta	O
)	O
,	O
and	O
a	O
phosphatidylinositol	B-PRGE
4	I-PRGE
-	I-PRGE
kinase	I-PRGE
(	O
pik1	B-PRGE
Delta	O
)	O
.	O

Mutant	O
survival	O
rates	O
in	O
yeast	O
media	O
,	O
saline	O
,	O
and	O
BAL	O
fluid	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	O
type	O
;	O
however	O
,	O
survival	O
in	O
FBS	O
was	O
reduced	O
but	O
not	O
to	O
the	O
levels	O
in	O
CSF	O
.	O

These	O
mutant	O
strains	O
also	O
exhibited	O
decreased	O
intracellular	O
survival	O
in	O
macrophages	O
,	O
various	O
degrees	O
of	O
virulence	O
in	O
nematodes	O
,	O
and	O
severe	O
attenuation	O
of	O
survival	O
in	O
a	O
rabbit	O
meningitis	O
model	O
.	O

We	O
analyzed	O
the	O
CSF	O
by	O
mass	O
spectrometry	O
for	O
candidate	O
compounds	O
responsible	O
for	O
the	O
survival	O
defect	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
genes	O
required	O
for	O
C	O
.	O
neoformans	O
survival	O
in	O
CSF	O
ex	O
vivo	O
are	O
necessary	O
for	O
survival	O
and	O
infection	O
in	O
this	O
unique	O
host	O
environment	O
.	O

miR	B-PRGE
-	I-PRGE
148a	I-PRGE
is	O
an	O
androgen	O
-	O
responsive	O
microRNA	O
that	O
promotes	O
LNCaP	O
prostate	O
cell	O
growth	O
by	O
repressing	O
its	O
target	O
CAND1	B-PRGE
expression	O
.	O

Recent	O
advances	O
in	O
cancer	O
biology	O
reveal	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
cancer	O
-	O
related	O
genes	O
,	O
or	O
they	O
function	O
as	O
tumor	O
suppressors	O
or	O
oncogenes	O
.	O

In	O
prostate	O
cancer	O
,	O
evidence	O
has	O
accumulated	O
for	O
the	O
contribution	O
of	O
the	O
androgen	O
-	O
dependent	O
gene	O
network	O
to	O
tumor	O
growth	O
,	O
although	O
the	O
precise	O
functions	O
of	O
miRNAs	O
in	O
prostate	O
cancer	O
remain	O
to	O
be	O
investigated	O
.	O

Here	O
,	O
we	O
identified	O
androgen	O
-	O
responsive	O
miRNAs	O
by	O
the	O
short	O
RNA	O
sequencing	O
analysis	O
in	O
LNCaP	O
prostate	O
cancer	O
cells	O
.	O

Among	O
10	O
miRNAs	O
with	O
known	O
sequences	O
,	O
we	O
have	O
determined	O
that	O
miR	B-PRGE
-	I-PRGE
148a	I-PRGE
reduces	O
the	O
expression	O
of	O
cullin	B-PRGE
-	I-PRGE
associated	I-PRGE
and	I-PRGE
neddylation	I-PRGE
-	I-PRGE
dissociated	I-PRGE
1	I-PRGE
(	O
CAND1	B-PRGE
)	O
,	O
a	O
negative	O
regulator	O
of	O
SKP1	B-PRGE
-	O
Cullin1	B-PRGE
-	O
F	O
-	O
box	O
(	O
SCF	O
)	O
ubiquitin	B-PRGE
ligases	O
,	O
by	O
binding	O
to	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
CAND1	B-PRGE
mRNA	O
.	O

CAND1	B-PRGE
knockdown	O
by	O
small	O
interfering	O
RNA	O
promoted	O
the	O
proliferation	O
of	O
LNCaP	O
cells	O
.	O

Our	O
study	O
indicates	O
the	O
potential	O
contribution	O
of	O
miR	B-PRGE
-	I-PRGE
148a	I-PRGE
to	O
the	O
growth	O
of	O
human	O
prostate	O
cancer	O
.	O

A	O
mechanistic	O
view	O
of	O
the	O
role	O
of	O
E3	O
in	O
sumoylation	O
.	O

Sumoylation	O
,	O
the	O
covalent	O
attachment	O
of	O
SUMO	O
(	O
Small	O
Ubiquitin	B-PRGE
-	O
Like	O
Modifier	O
)	O
to	O
proteins	O
,	O
differs	O
from	O
other	O
Ubl	O
(	O
Ubiquitin	B-PRGE
-	O
like	O
)	O
pathways	O
.	O

In	O
sumoylation	O
,	O
E2	O
ligase	O
Ubc9	B-PRGE
can	O
function	O
without	O
E3	O
enzymes	O
,	O
albeit	O
with	O
lower	O
reaction	O
efficiency	O
.	O

Here	O
,	O
we	O
study	O
the	O
mechanism	O
through	O
which	O
E3	O
ligase	O
RanBP2	B-PRGE
triggers	O
target	O
recognition	O
and	O
catalysis	O
by	O
E2	O
Ubc9	B-PRGE
.	O

Two	O
mechanisms	O
were	O
proposed	O
for	O
sumoylation	O
.	O

While	O
in	O
both	O
the	O
first	O
step	O
involves	O
Ubc9	B-PRGE
conjugation	O
to	O
SUMO	O
,	O
the	O
subsequent	O
sequence	O
of	O
events	O
differs	O
:	O
in	O
the	O
first	O
E2	O
-	O
SUMO	O
forms	O
a	O
complex	O
with	O
the	O
target	O
and	O
E3	O
,	O
followed	O
by	O
SUMO	O
transfer	O
to	O
the	O
target	O
.	O

In	O
the	O
second	O
,	O
Ubc9	B-PRGE
-	O
SUMO	O
binds	O
to	O
the	O
target	O
and	O
facilitates	O
SUMO	O
transfer	O
without	O
E3	O
.	O

Using	O
dynamic	O
correlations	O
obtained	O
from	O
explicit	O
solvent	O
molecular	O
dynamic	O
simulations	O
we	O
illustrate	O
the	O
key	O
roles	O
played	O
by	O
allostery	O
in	O
both	O
mechanisms	O
.	O

Pre	O
-	O
existence	O
of	O
conformational	O
states	O
explains	O
the	O
experimental	O
observations	O
that	O
sumoylation	O
can	O
occur	O
without	O
E3	O
,	O
even	O
though	O
at	O
a	O
reduced	O
rate	O
.	O

Furthermore	O
,	O
we	O
propose	O
a	O
mechanism	O
for	O
enhancement	O
of	O
sumoylation	O
by	O
E3	O
.	O

Analysis	O
of	O
the	O
conformational	O
ensembles	O
of	O
the	O
complex	O
of	O
E2	O
conjugated	O
to	O
SUMO	O
illustrates	O
that	O
the	O
E2	O
enzyme	O
is	O
already	O
largely	O
pre	O
-	O
organized	O
for	O
target	O
binding	O
and	O
catalysis	O
;	O
E3	O
binding	O
shifts	O
the	O
equilibrium	O
and	O
enhances	O
these	O
pre	O
-	O
existing	O
populations	O
.	O

We	O
further	O
observe	O
that	O
E3	O
binding	O
regulates	O
allosterically	O
the	O
key	O
residues	O
in	O
E2	O
,	O
Ubc9	B-PRGE
Asp100	O
/	O
Lys101	O
E2	O
,	O
for	O
the	O
target	O
recognition	O
.	O

Human	O
stanniocalcin	B-PRGE
-	I-PRGE
1	I-PRGE
interacts	O
with	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
and	O
acts	O
as	O
a	O
SUMO	O
E3	O
ligase	O
.	O

Human	O
stanniocalcin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
STC1	B-PRGE
)	O
is	O
a	O
glycoprotein	O
that	O
has	O
been	O
implicated	O
in	O
different	O
physiological	O
process	O
,	O
including	O
angiogenesis	O
,	O
apoptosis	O
and	O
carcinogenesis	O
.	O

Here	O
we	O
identified	O
STC1	B-PRGE
as	O
a	O
putative	O
molecular	O
marker	O
for	O
the	O
leukemic	O
bone	O
marrow	O
microenvironment	O
and	O
identified	O
new	O
interacting	O
protein	O
partners	O
for	O
STC1	B-PRGE
.	O

Seven	O
selected	O
interactions	O
retrieved	O
from	O
yeast	O
two	O
-	O
hybrid	O
screens	O
were	O
confirmed	O
by	O
GST	B-PRGE
-	O
pull	O
down	O
assays	O
in	O
vitro	O
.	O

The	O
N	O
-	O
terminal	O
region	O
was	O
mapped	O
to	O
be	O
the	O
region	O
that	O
mediates	O
the	O
interaction	O
with	O
cytoplasmic	O
,	O
mitochondrial	O
and	O
nuclear	O
proteins	O
.	O

STC1	B-PRGE
interacts	O
with	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
several	O
proteins	O
that	O
have	O
been	O
shown	O
to	O
be	O
SUMOylated	O
and	O
localized	O
to	O
SUMOylation	O
related	O
nuclear	O
bodies	O
.	O

Although	O
STC1	B-PRGE
interacts	O
with	O
SUMO	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
has	O
a	O
high	O
theoretical	O
prediction	O
score	O
for	O
a	O
SUMOylation	O
site	O
,	O
endogenous	O
co	O
-	O
immunoprecipitation	O
and	O
in	O
vitro	O
SUMOylation	O
assays	O
with	O
the	O
purified	O
recombinant	O
protein	O
could	O
not	O
detect	O
STC1	B-PRGE
SUMOylation	O
.	O

However	O
,	O
when	O
we	O
tested	O
STC1	B-PRGE
for	O
SUMO	O
E3	O
ligase	O
activity	O
,	O
we	O
found	O
in	O
an	O
in	O
vitro	O
assay	O
,	O
that	O
it	O
significantly	O
increases	O
the	O
SUMOylation	O
of	O
two	O
other	O
proteins	O
.	O

Confocal	O
microscopic	O
subcellular	O
localization	O
studies	O
using	O
both	O
transfected	O
cells	O
and	O
specific	O
antibodies	O
for	O
endogenous	O
STC1	B-PRGE
revealed	O
a	O
cytoplasmic	O
and	O
nuclear	O
deposition	O
,	O
the	O
latter	O
in	O
the	O
form	O
of	O
some	O
specific	O
dot	O
-	O
like	O
substructure	O
resembling	O
SUMOylation	O
related	O
nuclear	O
bodies	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
a	O
new	O
role	O
for	O
STC1	B-PRGE
in	O
SUMOylation	O
pathways	O
,	O
in	O
nuclear	O
bodies	O
.	O

Experimental	O
priapism	O
is	O
associated	O
with	O
increased	O
oxidative	O
stress	O
and	O
activation	O
of	O
protein	O
degradation	O
pathways	O
in	O
corporal	O
tissue	O
.	O

Priapism	O
is	O
a	O
debilitating	O
disease	O
for	O
which	O
there	O
is	O
at	O
present	O
no	O
clinically	O
accepted	O
pharmacological	O
intervention	O
.	O

It	O
has	O
been	O
estimated	O
that	O
priapism	O
lasting	O
more	O
than	O
24	O
h	O
in	O
patients	O
is	O
associated	O
with	O
a	O
44	O
-	O
90	O
%	O
rate	O
of	O
ED	O
.	O

In	O
this	O
investigation	O
,	O
we	O
determined	O
in	O
two	O
animal	O
models	O
of	O
priapism	O
(	O
opiorphin	B-PRGE
-	O
induced	O
priapism	O
in	O
the	O
rat	O
and	O
priapism	O
in	O
a	O
mouse	O
model	O
of	O
sickle	O
cell	O
disease	O
)	O
if	O
there	O
is	O
evidence	O
for	O
an	O
increase	O
in	O
markers	O
of	O
oxidative	O
stress	O
in	O
corporal	O
tissue	O
.	O

In	O
both	O
animal	O
models	O
,	O
we	O
demonstrate	O
that	O
priapism	O
results	O
in	O
increased	O
levels	O
of	O
lipid	O
peroxidation	O
,	O
glutathione	B-PRGE
S	I-PRGE
-	I-PRGE
transferase	I-PRGE
activity	O
and	O
oxidatively	O
damaged	O
proteins	O
in	O
corporal	O
tissue	O
.	O

Using	O
western	O
blot	O
analysis	O
,	O
we	O
demonstrated	O
there	O
is	O
upregulation	O
of	O
the	O
ubiquitination	O
ligase	O
proteins	O
,	O
Nedd	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
Mdm	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
the	O
lysosomal	O
autophage	O
protein	O
,	O
LC3	O
.	O

The	O
antiapoptotic	O
protein	O
,	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
was	O
also	O
upregulated	O
.	O

Overall	O
,	O
we	O
demonstrate	O
that	O
priapism	O
is	O
associated	O
with	O
increased	O
oxidative	O
stress	O
in	O
corporal	O
tissue	O
and	O
the	O
activation	O
of	O
protein	O
degradation	O
pathways	O
.	O

As	O
oxidative	O
stress	O
is	O
known	O
to	O
mediate	O
the	O
development	O
of	O
ED	O
resulting	O
from	O
several	O
etiologies	O
(	O
for	O
example	O
,	O
ED	O
resulting	O
from	O
diabetes	O
and	O
aging	O
)	O
,	O
we	O
suggest	O
that	O
damage	O
to	O
erectile	O
tissue	O
resulting	O
from	O
priapism	O
might	O
be	O
prevented	O
by	O
treatments	O
targeting	O
oxidative	O
stress	O
.	O

The	O
steady	O
-	O
state	O
repertoire	O
of	O
human	O
SCF	O
Ubiquitin	B-PRGE
ligase	O
complexes	O
does	O
not	O
require	O
ongoing	O
Nedd8	B-PRGE
conjugation	O
.	O

The	O
human	O
genome	O
encodes	O
69	O
different	O
F	O
-	O
box	O
proteins	O
(	O
FBPs	O
)	O
,	O
each	O
of	O
which	O
can	O
potentially	O
assemble	O
with	O
Skp1	B-PRGE
-	O
Cul1	B-PRGE
-	O
RING	O
to	O
serve	O
as	O
the	O
substrate	O
specificity	O
subunit	O
of	O
an	O
SCF	O
ubiquitin	B-PRGE
ligase	O
complex	O
.	O

SCF	O
activity	O
is	O
switched	O
on	O
by	O
conjugation	O
of	O
the	O
ubiquitin	B-PRGE
-	O
like	O
protein	O
Nedd8	B-PRGE
to	O
Cul1	B-PRGE
.	O

Cycles	O
of	O
Nedd8	B-PRGE
conjugation	O
and	O
deconjugation	O
acting	O
in	O
conjunction	O
with	O
the	O
Cul1	B-PRGE
-	O
sequestering	O
factor	O
Cand1	B-PRGE
are	O
thought	O
to	O
control	O
dynamic	O
cycles	O
of	O
SCF	O
assembly	O
and	O
disassembly	O
,	O
which	O
would	O
enable	O
a	O
dynamic	O
equilibrium	O
between	O
the	O
Cul1	B-PRGE
-	O
RING	O
catalytic	O
core	O
of	O
SCF	O
and	O
the	O
cellular	O
repertoire	O
of	O
FBPs	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
determined	O
the	O
cellular	O
composition	O
of	O
SCF	O
complexes	O
and	O
evaluated	O
the	O
impact	O
of	O
Nedd8	B-PRGE
conjugation	O
on	O
this	O
steady	O
-	O
state	O
.	O

At	O
least	O
42	O
FBPs	O
assembled	O
with	O
Cul1	B-PRGE
in	O
HEK	O
293	O
cells	O
,	O
and	O
the	O
levels	O
of	O
Cul1	B-PRGE
-	O
bound	O
FBPs	O
varied	O
by	O
over	O
two	O
orders	O
of	O
magnitude	O
.	O

Unexpectedly	O
,	O
quantitative	O
mass	O
spectrometry	O
revealed	O
that	O
blockade	O
of	O
Nedd8	B-PRGE
conjugation	O
led	O
to	O
a	O
modest	O
increase	O
,	O
rather	O
than	O
a	O
decrease	O
,	O
in	O
the	O
overall	O
level	O
of	O
most	O
SCF	O
complexes	O
.	O

We	O
suggest	O
that	O
multiple	O
mechanisms	O
including	O
FBP	O
dissociation	O
and	O
turnover	O
cooperate	O
to	O
maintain	O
the	O
cellular	O
pool	O
of	O
SCF	O
ubiquitin	B-PRGE
ligases	O
.	O

Crystal	O
structure	O
of	O
UBA2	B-PRGE
(	O
ufd	O
)	O
-	O
Ubc9	B-PRGE
:	O
insights	O
into	O
E1	O
-	O
E2	O
interactions	O
in	O
Sumo	O
pathways	O
.	O

Canonical	O
ubiquitin	B-PRGE
-	O
like	O
proteins	O
(	O
UBLs	O
)	O
such	O
as	O
ubiquitin	B-PRGE
,	O
Sumo	O
,	O
NEDD8	B-PRGE
,	O
and	O
ISG15	B-PRGE
are	O
ligated	O
to	O
targets	O
by	O
E1	O
-	O
E2	O
-	O
E3	O
multienzyme	O
cascades	O
.	O

The	O
Sumo	O
cascade	O
,	O
conserved	O
among	O
all	O
eukaryotes	O
,	O
regulates	O
numerous	O
biological	O
processes	O
including	O
protein	O
localization	O
,	O
transcription	O
,	O
DNA	O
replication	O
,	O
and	O
mitosis	O
.	O

Sumo	O
conjugation	O
is	O
initiated	O
by	O
the	O
heterodimeric	O
Aos1	B-PRGE
-	O
Uba2	B-PRGE
E1	O
enzyme	O
(	O
in	O
humans	O
called	O
Sae1	B-PRGE
-	O
Uba2	B-PRGE
)	O
,	O
which	O
activates	O
Sumo	O
'	O
s	O
C	O
-	O
terminus	O
,	O
binds	O
the	O
dedicated	O
E2	O
enzyme	O
Ubc9	B-PRGE
,	O
and	O
promotes	O
Sumo	O
C	O
-	O
terminal	O
transfer	O
between	O
the	O
Uba2	B-PRGE
and	O
Ubc9	B-PRGE
catalytic	O
cysteines	O
.	O

To	O
gain	O
insights	O
into	O
details	O
of	O
E1	O
-	O
E2	O
interactions	O
in	O
the	O
Sumo	O
pathway	O
,	O
we	O
determined	O
crystal	O
structures	O
of	O
the	O
C	O
-	O
terminal	O
ubiquitin	B-PRGE
fold	O
domain	O
(	O
ufd	O
)	O
from	O
yeast	O
Uba2	B-PRGE
(	O
Uba2	B-PRGE
(	O
ufd	O
)	O
)	O
,	O
alone	O
and	O
in	O
complex	O
with	O
Ubc9	B-PRGE
.	O

The	O
overall	O
structures	O
of	O
both	O
yeast	O
Uba2	B-PRGE
(	O
ufd	O
)	O
and	O
Ubc9	B-PRGE
superimpose	O
well	O
on	O
their	O
individual	O
human	O
counterparts	O
,	O
suggesting	O
conservation	O
of	O
fundamental	O
features	O
of	O
Sumo	O
conjugation	O
.	O

Docking	O
the	O
Uba2	B-PRGE
(	O
ufd	O
)	O
-	O
Ubc9	B-PRGE
and	O
prior	O
full	O
-	O
length	O
human	O
Uba2	B-PRGE
structures	O
allows	O
generation	O
of	O
models	O
for	O
steps	O
in	O
Sumo	O
transfer	O
from	O
Uba2	B-PRGE
to	O
Ubc9	B-PRGE
,	O
and	O
supports	O
the	O
notion	O
that	O
Uba2	B-PRGE
undergoes	O
remarkable	O
conformational	O
changes	O
during	O
the	O
reaction	O
.	O

Comparisons	O
to	O
previous	O
structures	O
from	O
the	O
NEDD8	B-PRGE
cascade	O
demonstrate	O
that	O
UBL	O
cascades	O
generally	O
utilize	O
some	O
parallel	O
E1	O
-	O
E2	O
interaction	O
surfaces	O
.	O

In	O
addition	O
,	O
the	O
structure	O
of	O
the	O
Uba2	B-PRGE
(	O
ufd	O
)	O
-	O
Ubc9	B-PRGE
complex	O
reveals	O
interactions	O
unique	O
to	O
Sumo	O
E1	O
and	O
E2	O
.	O

Comparison	O
with	O
a	O
previous	O
Ubc9	B-PRGE
-	O
E3	O
complex	O
structure	O
demonstrates	O
overlap	O
between	O
Uba2	B-PRGE
and	O
E3	O
binding	O
sites	O
on	O
Ubc9	B-PRGE
,	O
indicating	O
that	O
loading	O
with	O
Sumo	O
and	O
E3	O
-	O
catalyzed	O
transfer	O
to	O
substrates	O
are	O
strictly	O
separate	O
steps	O
.	O

The	O
results	O
suggest	O
mechanisms	O
establishing	O
specificity	O
and	O
order	O
in	O
Sumo	O
conjugation	O
cascades	O
.	O

Farnesyl	O
cysteine	O
C	O
-	O
terminal	O
methyltransferase	O
activity	O
is	O
dependent	O
upon	O
the	O
STE14	B-PRGE
gene	O
product	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Membrane	O
extracts	O
of	O
sterile	O
Saccharomyces	O
cerevisiae	O
strains	O
containing	O
the	O
a	O
-	O
specific	O
ste14	B-PRGE
mutation	O
lack	O
a	O
farnesyl	O
cysteine	O
C	O
-	O
terminal	O
carboxyl	O
methyltransferase	O
activity	O
that	O
is	O
present	O
in	O
wild	O
-	O
type	O
a	O
and	O
alpha	O
cells	O
.	O

Other	O
a	O
-	O
specific	O
sterile	O
strains	O
with	O
ste6	B-PRGE
and	O
ste16	B-PRGE
mutations	O
also	O
have	O
wild	O
-	O
type	O
levels	O
of	O
the	O
farnesyl	O
cysteine	O
carboxyl	O
methyltransferase	O
activity	O
.	O

This	O
enzyme	O
activity	O
,	O
detected	O
by	O
using	O
a	O
synthetic	O
peptide	O
sequence	O
based	O
on	O
the	O
C	O
-	O
terminus	O
of	O
a	O
ras	O
protein	O
,	O
may	O
be	O
responsible	O
not	O
only	O
for	O
the	O
essential	O
methylation	O
of	O
the	O
farnesyl	O
cysteine	O
residue	O
of	O
a	O
mating	O
factor	O
,	O
but	O
also	O
for	O
the	O
methylation	O
of	O
yeast	O
RAS1	B-PRGE
and	O
RAS2	B-PRGE
proteins	O
and	O
possibly	O
other	O
polypeptides	O
with	O
similar	O
C	O
-	O
terminal	O
structures	O
.	O

We	O
demonstrate	O
that	O
the	O
farnesylation	O
of	O
the	O
cysteine	O
residue	O
in	O
the	O
peptide	O
is	O
required	O
for	O
the	O
methyltransferase	O
activity	O
,	O
suggesting	O
that	O
methyl	O
esterification	O
follows	O
the	O
lipidation	O
reaction	O
in	O
the	O
cell	O
.	O

To	O
show	O
that	O
the	O
loss	O
of	O
methyltransferase	O
activity	O
is	O
a	O
direct	O
result	O
of	O
the	O
ste14	B-PRGE
mutation	O
,	O
we	O
transformed	O
ste14	B-PRGE
mutant	O
cells	O
with	O
a	O
plasmid	O
complementing	O
the	O
mating	O
defect	O
of	O
this	O
strain	O
and	O
found	O
that	O
active	O
enzyme	O
was	O
produced	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
a	O
similar	O
transformation	O
of	O
cells	O
possessing	O
the	O
wild	O
-	O
type	O
STE14	B-PRGE
gene	O
resulted	O
in	O
sixfold	O
overproduction	O
of	O
the	O
enzyme	O
.	O

Although	O
more	O
complicated	O
possibilities	O
cannot	O
be	O
ruled	O
out	O
,	O
these	O
results	O
suggest	O
that	O
STE14	B-PRGE
is	O
a	O
candidate	O
for	O
the	O
structural	O
gene	O
for	O
a	O
methyltransferase	O
involved	O
in	O
the	O
formation	O
of	O
isoprenylated	O
cysteine	O
alpha	O
-	O
methyl	O
ester	O
C	O
-	O
terminal	O
structures	O
.	O

cDNA	O
sequence	O
,	O
in	O
vitro	O
synthesis	O
,	O
and	O
intramitochondrial	O
lipoylation	O
of	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
of	O
the	O
glycine	O
cleavage	O
system	O
.	O

H	B-PRGE
-	I-PRGE
protein	I-PRGE
is	O
a	O
component	O
of	O
the	O
glycine	O
cleavage	O
system	O
loosely	O
associated	O
with	O
the	O
mitochondrial	O
inner	O
membrane	O
and	O
has	O
lipoic	O
acid	O
as	O
a	O
prosthetic	O
group	O
.	O

cDNA	O
clones	O
encoding	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
were	O
isolated	O
from	O
a	O
bovine	O
liver	O
cDNA	O
library	O
with	O
an	O
oligonucleotide	O
probe	O
from	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
NH2	O
-	O
terminal	O
region	O
.	O

DNA	O
sequence	O
analysis	O
and	O
deduced	O
amino	O
acid	O
sequence	O
showed	O
that	O
the	O
cDNAs	O
encoded	O
an	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
precursor	O
of	O
173	O
amino	O
acids	O
including	O
a	O
48	O
-	O
amino	O
acid	O
presequence	O
.	O

Calculated	O
molecular	O
mass	O
of	O
the	O
precursor	O
and	O
mature	O
protein	O
without	O
lipoic	O
acid	O
were	O
18	O
,	O
790	O
and	O
13	O
,	O
846	O
,	O
respectively	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
a	O
major	O
mRNA	O
component	O
of	O
1	O
.	O
1	O
kilobases	O
and	O
a	O
minor	O
component	O
of	O
0	O
.	O
6	O
kilobase	O
.	O

The	O
result	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
two	O
adenylation	O
signals	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
cDNA	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
cDNA	O
produced	O
a	O
19	O
-	O
kDa	O
protein	O
recognized	O
by	O
antibody	O
raised	O
to	O
chicken	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
.	O

Bovine	O
liver	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
precursor	O
has	O
no	O
lipoic	O
acid	O
prosthetic	O
group	O
.	O

When	O
incubated	O
with	O
isolated	O
bovine	O
liver	O
mitochondria	O
,	O
the	O
precursor	O
was	O
imported	O
into	O
mitochondria	O
,	O
processed	O
to	O
its	O
mature	O
form	O
with	O
a	O
molecular	O
mass	O
of	O
14	O
kDa	O
,	O
and	O
lipoylated	O
at	O
lysine	O
59	O
.	O

These	O
results	O
indicate	O
that	O
lipoylation	O
is	O
not	O
required	O
for	O
the	O
import	O
of	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
precursor	O
into	O
mitochondria	O
and	O
H	B-PRGE
-	I-PRGE
protein	I-PRGE
is	O
lipoylated	O
in	O
mitochondria	O
which	O
probably	O
contain	O
the	O
physiologically	O
active	O
form	O
of	O
lipoic	O
acid	O
as	O
well	O
as	O
the	O
enzyme	O
(	O
s	O
)	O
responsible	O
for	O
the	O
attachment	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
bovine	O
pro	B-PRGE
-	I-PRGE
opiomelanocortin	I-PRGE
.	O

Tyrosine	O
sulfation	O
and	O
pyroglutamate	O
formation	O
,	O
a	O
mass	O
spectrometric	O
study	O
.	O

The	O
amino	O
-	O
terminal	O
fragment	O
of	O
beta	B-PRGE
-	I-PRGE
lipotropin	I-PRGE
(	O
i	O
.	O
e	O
.	O
beta	B-PRGE
-	I-PRGE
lipotropin	I-PRGE
(	O
1	O
-	O
40	O
)	O
)	O
and	O
joining	O
peptide	O
portions	O
of	O
pro	B-PRGE
-	I-PRGE
opiomelanocortin	I-PRGE
have	O
been	O
purified	O
from	O
extracts	O
of	O
bovine	O
posterior	O
pituitaries	O
.	O

Peptides	O
were	O
purified	O
using	O
a	O
combination	O
of	O
reversed	O
-	O
phase	O
and	O
ion	O
-	O
exchange	O
batch	O
extraction	O
procedures	O
followed	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

beta	B-PRGE
-	I-PRGE
Lipotropin	I-PRGE
(	O
1	O
-	O
40	O
)	O
was	O
found	O
to	O
consist	O
of	O
four	O
major	O
components	O
while	O
joining	O
peptide	O
was	O
found	O
to	O
consist	O
of	O
two	O
major	O
components	O
.	O

Fast	O
atom	O
bombardment	O
-	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
tryptic	O
fragments	O
of	O
both	O
peptides	O
revealed	O
that	O
the	O
observed	O
heterogeneity	O
could	O
be	O
explained	O
in	O
terms	O
of	O
post	O
-	O
translational	O
modifications	O
.	O

beta	B-PRGE
-	I-PRGE
Lipotropin	I-PRGE
(	O
1	O
-	O
40	O
)	O
was	O
found	O
to	O
be	O
sulfated	O
at	O
tyrosine	O
residue	O
28	O
to	O
an	O
extent	O
of	O
about	O
50	O
%	O
.	O

The	O
tyrosine	O
residue	O
in	O
beta	B-PRGE
-	I-PRGE
lipotropin	I-PRGE
(	O
1	O
-	O
40	O
)	O
is	O
situated	O
within	O
an	O
amino	O
acid	O
sequence	O
with	O
a	O
preponderance	O
of	O
glutamate	O
residues	O
.	O

Sulfation	O
of	O
this	O
amino	O
acid	O
residue	O
is	O
entirely	O
compatible	O
with	O
the	O
known	O
primary	O
structure	O
requirements	O
of	O
the	O
sulfotransferase	O
enzyme	O
located	O
in	O
the	O
trans	O
-	O
Golgi	O
fraction	O
.	O

Both	O
beta	B-PRGE
-	I-PRGE
lipotropin	I-PRGE
(	O
1	O
-	O
40	O
)	O
and	O
joining	O
peptide	O
were	O
found	O
to	O
have	O
pyroglutamate	O
at	O
their	O
amino	O
termini	O
to	O
an	O
extent	O
of	O
about	O
50	O
%	O
.	O

The	O
cDNA	O
sequence	O
for	O
bovine	O
pro	B-PRGE
-	I-PRGE
opiomelanocortin	I-PRGE
predicts	O
the	O
presence	O
of	O
glutamic	O
acid	O
at	O
position	O
1	O
of	O
both	O
peptides	O
.	O

Pyroglutamate	O
is	O
normally	O
formed	O
through	O
the	O
cyclization	O
of	O
glutamine	O
.	O

This	O
reaction	O
is	O
thought	O
to	O
be	O
catalyzed	O
by	O
a	O
pyroglutamate	O
forming	O
enzyme	O
located	O
within	O
the	O
secretory	O
granule	O
fraction	O
.	O

Under	O
certain	O
circumstances	O
peptides	O
with	O
glutamate	O
at	O
their	O
amino	O
termini	O
may	O
act	O
as	O
substrates	O
for	O
this	O
enzyme	O
.	O

ADP	O
-	O
ribosylation	O
of	O
proteins	O
in	O
brain	O
regions	O
of	O
rats	O
during	O
postnatal	O
development	O
.	O

Post	O
-	O
translational	O
modifications	O
of	O
chromatin	O
-	O
bound	O
proteins	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Processes	O
such	O
as	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
may	O
alter	O
the	O
interaction	O
of	O
these	O
proteins	O
with	O
DNA	O
and	O
consequently	O
affect	O
chromatin	O
conformation	O
and	O
the	O
binding	O
of	O
enzymes	O
and	O
other	O
molecules	O
involved	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

In	O
the	O
present	O
study	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
chromosomal	O
proteins	O
(	O
histone	B-PRGE
and	O
non	O
-	O
histone	O
proteins	O
)	O
in	O
some	O
rat	O
brain	O
regions	O
during	O
postnatal	O
development	O
was	O
investigated	O
;	O
also	O
the	O
effect	O
of	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
EGF	B-PRGE
)	O
on	O
this	O
process	O
in	O
fetal	O
brain	O
slices	O
was	O
studied	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
total	O
histones	B-PRGE
extracted	O
from	O
rat	O
cerebral	O
cortex	O
and	O
cerebellum	O
at	O
1	O
,	O
10	O
and	O
30	O
days	O
of	O
age	O
,	O
increases	O
from	O
1	O
to	O
10	O
days	O
of	O
age	O
(	O
i	O
.	O
e	O
.	O
the	O
period	O
of	O
maximal	O
cell	O
proliferation	O
)	O
and	O
decreases	O
thereafter	O
,	O
while	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
non	O
-	O
histone	O
proteins	O
(	O
NHPs	O
)	O
sharply	O
decreases	O
during	O
the	O
same	O
developmental	O
period	O
.	O

The	O
addition	O
of	O
EGF	B-PRGE
to	O
fetal	O
brain	O
slices	O
causes	O
a	O
significant	O
increase	O
of	O
ADP	O
-	O
ribosylation	O
of	O
total	O
histones	B-PRGE
(	O
particularly	O
of	O
the	O
histone	B-PRGE
H1	I-PRGE
fraction	O
)	O
and	O
also	O
of	O
NHPs	O
and	O
microsomal	O
proteins	O
.	O

This	O
result	O
is	O
in	O
agreement	O
with	O
the	O
effect	O
of	O
EGF	B-PRGE
as	O
a	O
mitogen	O
factor	O
,	O
previously	O
shown	O
in	O
astroglial	O
cell	O
cultures	O
.	O

Characterization	O
of	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
forms	O
of	O
the	O
gag	B-PRGE
-	O
onc	O
fusion	O
proteins	O
of	O
three	O
isolates	O
of	O
feline	O
sarcoma	O
virus	O
:	O
phosphorylation	O
,	O
kinase	O
activity	O
,	O
acylation	O
,	O
and	O
kinetics	O
of	O
complex	O
formation	O
.	O

The	O
gag	B-PRGE
-	O
onc	O
fusion	O
proteins	O
of	O
three	O
isolates	O
of	O
feline	O
sarcoma	O
virus	O
(	O
ST	O
-	O
FeSV	O
,	O
GA	O
-	O
FeSV	O
,	O
TP1	O
-	O
FeSV	O
)	O
from	O
a	O
stable	O
noncovalent	O
complex	O
with	O
two	O
cellular	O
phosphoproteins	O
,	O
pp90	B-PRGE
and	O
pp50	B-PRGE
.	O

These	O
two	O
phosphoproteins	O
are	O
the	O
same	O
phosphoproteins	O
which	O
have	O
been	O
shown	O
to	O
complex	O
with	O
the	O
transforming	O
proteins	O
of	O
Rous	O
sarcoma	O
virus	O
,	O
Fujinami	O
sarcoma	O
virus	O
,	O
Yamaguchi	O
73	O
virus	O
(	O
Lipsich	O
et	O
al	O
.	O
,	O
1982	O
)	O
,	O
and	O
PRCII	O
avian	O
sarcoma	O
virus	O
(	O
Adkins	O
et	O
al	O
.	O
,	O
1982	O
)	O
.	O

Both	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
gag	B-PRGE
-	O
onc	O
fusion	O
proteins	O
are	O
phosphorylated	O
on	O
serine	O
,	O
threonine	O
,	O
and	O
tyrosine	O
;	O
however	O
,	O
quantitative	O
and	O
/	O
or	O
qualitative	O
differences	O
in	O
phosphorylation	O
of	O
the	O
two	O
species	O
were	O
apparent	O
.	O

Only	O
the	O
monomeric	O
form	O
of	O
the	O
gag	B-PRGE
-	O
onc	O
proteins	O
was	O
able	O
to	O
undergo	O
tyrosine	O
specific	O
autophosphorylation	O
in	O
an	O
in	O
vitro	O
kinase	O
reaction	O
.	O

Both	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
forms	O
of	O
the	O
proteins	O
were	O
acylated	O
,	O
the	O
complex	O
-	O
associated	O
molecules	O
to	O
a	O
greater	O
degree	O
.	O

Pulse	O
-	O
chase	O
experiments	O
indicated	O
that	O
newly	O
synthesized	O
gag	B-PRGE
-	O
onc	O
molecules	O
become	O
rapidly	O
incorporated	O
into	O
the	O
complex	O
and	O
that	O
a	O
significant	O
amount	O
of	O
these	O
molecules	O
remained	O
associated	O
with	O
the	O
complex	O
for	O
more	O
than	O
20	O
hr	O
.	O

Autoacylation	O
of	O
myelin	B-PRGE
proteolipid	I-PRGE
protein	I-PRGE
with	O
acyl	O
coenzyme	O
A	O
.	O

Rat	O
brain	O
myelin	B-PRGE
proteolipid	I-PRGE
protein	I-PRGE
(	O
PLP	B-PRGE
)	O
is	O
known	O
to	O
contain	O
long	O
chain	O
,	O
covalently	O
bound	O
fatty	O
acids	O
.	O

In	O
the	O
course	O
of	O
characterizing	O
the	O
mechanism	O
of	O
acylation	O
,	O
we	O
found	O
that	O
the	O
isolated	O
PLP	B-PRGE
,	O
in	O
the	O
absence	O
of	O
any	O
membrane	O
fraction	O
,	O
was	O
esterified	O
after	O
incubation	O
with	O
[	O
3H	O
]	O
palmitoyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
.	O

This	O
observation	O
demonstrated	O
that	O
the	O
protein	O
acts	O
as	O
both	O
an	O
acylating	O
enzyme	O
and	O
an	O
acceptor	O
.	O

Thus	O
,	O
acylation	O
occurs	O
by	O
an	O
autocatalytic	O
process	O
.	O

The	O
possibility	O
of	O
a	O
separate	O
acyltransferase	O
that	O
copurifies	O
with	O
PLP	B-PRGE
was	O
essentially	O
excluded	O
by	O
adding	O
brain	O
subcellular	O
fractions	O
to	O
the	O
reaction	O
mixtures	O
and	O
by	O
changing	O
the	O
isolation	O
procedure	O
.	O

After	O
deacylation	O
,	O
the	O
protein	O
was	O
acylated	O
at	O
a	O
4	O
-	O
fold	O
greater	O
rate	O
,	O
suggesting	O
that	O
the	O
original	O
sites	O
were	O
reacylated	O
.	O

The	O
palmitoyl	O
-	O
CoA	O
concentration	O
followed	O
Michaelis	O
kinetics	O
,	O
confirming	O
that	O
spontaneous	O
acylation	O
was	O
not	O
occurring	O
.	O

Pulse	O
-	O
chase	O
experiments	O
indicated	O
that	O
the	O
reaction	O
entails	O
net	O
addition	O
of	O
acyl	O
groups	O
.	O

Although	O
fatty	O
acids	O
are	O
bound	O
via	O
an	O
O	O
-	O
ester	O
linkage	O
,	O
free	O
SH	O
groups	O
are	O
required	O
in	O
the	O
reaction	O
.	O

Denaturation	O
of	O
the	O
protein	O
by	O
sodium	O
dodecyl	O
sulfate	O
or	O
heat	O
inhibits	O
the	O
reaction	O
,	O
whereas	O
cerulenin	O
has	O
little	O
or	O
no	O
effect	O
.	O

PO	B-PRGE
,	O
the	O
major	O
protein	O
in	O
peripheral	O
nerve	O
myelin	O
,	O
is	O
also	O
an	O
acylated	O
protein	O
,	O
but	O
it	O
was	O
not	O
labeled	O
upon	O
incubation	O
of	O
either	O
peripheral	O
myelin	O
or	O
the	O
isolated	O
protein	O
with	O
[	O
3H	O
]	O
palmitoyl	O
-	O
CoA	O
,	O
demonstrating	O
that	O
it	O
is	O
acylated	O
by	O
a	O
different	O
route	O
.	O

Several	O
synthetic	O
peptides	O
derived	O
from	O
PLP	B-PRGE
sequences	O
with	O
sites	O
known	O
to	O
be	O
acylated	O
in	O
vivo	O
as	O
well	O
as	O
a	O
series	O
of	O
deacylated	O
PLP	B-PRGE
tryptic	O
peptides	O
were	O
not	O
labeled	O
,	O
indicating	O
that	O
integrity	O
of	O
the	O
protein	O
is	O
required	O
for	O
acylation	O
.	O

Limited	O
proteolysis	O
and	O
peptide	O
mapping	O
showed	O
that	O
the	O
same	O
sites	O
are	O
acylated	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
suggesting	O
that	O
the	O
autocatalytic	O
acylation	O
reaction	O
is	O
physiological	O
.	O

Posttranslational	O
regulatory	O
system	O
for	O
nitrogenase	O
activity	O
in	O
Azospirillum	O
spp	O
.	O

The	O
mechanism	O
for	O
"	O
NH4	O
+	O
switch	O
-	O
off	O
/	O
on	O
"	O
of	O
nitrogenase	O
activity	O
in	O
Azospirillum	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
was	O
investigated	O
.	O

A	O
correlation	O
was	O
established	O
between	O
the	O
in	O
vivo	O
regulation	O
of	O
nitrogenase	O
activity	O
by	O
NH4Cl	O
or	O
glutamine	O
and	O
the	O
reversible	O
covalent	O
modification	O
of	O
dinitrogenase	O
reductase	O
.	O

Dinitrogenase	B-PRGE
reductase	I-PRGE
ADP	I-PRGE
-	I-PRGE
ribosyltransferase	I-PRGE
(	O
DRAT	B-PRGE
)	O
activity	O
was	O
detected	O
in	O
extracts	O
of	O
A	O
.	O
brasilense	O
with	O
NAD	O
as	O
the	O
donor	O
molecule	O
.	O

Dinitrogenase	B-PRGE
reductase	I-PRGE
-	I-PRGE
activating	I-PRGE
glycohydrolase	I-PRGE
(	O
DRAG	B-PRGE
)	O
activity	O
was	O
present	O
in	O
extracts	O
of	O
both	O
A	O
.	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
.	O

The	O
DRAG	B-PRGE
activity	O
in	O
A	O
.	O
lipoferum	O
was	O
membrane	O
associated	O
,	O
and	O
it	O
catalyzed	O
the	O
activation	O
of	O
inactive	O
nitrogenase	O
(	O
by	O
covalent	O
modification	O
of	O
dinitrogenase	B-PRGE
reductase	I-PRGE
)	O
from	O
both	O
A	O
.	O
lipoferum	O
and	O
Rhodospirillum	O
rubrum	O
.	O

A	O
region	O
homologous	O
to	O
R	O
.	O
rubrum	O
draT	B-PRGE
and	O
draG	B-PRGE
was	O
identified	O
in	O
the	O
genomic	O
DNA	O
of	O
A	O
.	O
brasilense	O
as	O
a	O
12	O
-	O
kilobase	O
EcoRI	B-PRGE
fragment	O
and	O
in	O
A	O
.	O
lipoferum	O
as	O
a	O
7	O
-	O
kilobase	O
EcoRI	B-PRGE
fragment	O
.	O

It	O
is	O
concluded	O
that	O
a	O
posttranslational	O
regulatory	O
system	O
for	O
nitrogenase	O
activity	O
is	O
present	O
in	O
A	O
.	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
and	O
that	O
it	O
operates	O
via	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-PRGE
reductase	I-PRGE
as	O
it	O
does	O
in	O
R	O
.	O
rubrum	O
.	O

The	O
membrane	O
binding	O
domain	O
of	O
rod	O
cGMP	O
phosphodiesterase	O
is	O
posttranslationally	O
modified	O
by	O
methyl	O
esterification	O
at	O
a	O
C	O
-	O
terminal	O
cysteine	O
.	O

Retinal	O
rod	O
cGMP	O
phosphodiesterase	O
(	O
3	O
'	O
,	O
5	O
'	O
-	O
cyclic	O
-	O
GMP	O
phosphodiesterase	O
;	O
EC	O
3	O
.	O
1	O
.	O
4	O
.	O
35	O
;	O
PDE	O
)	O
,	O
a	O
key	O
regulatory	O
enzyme	O
involved	O
in	O
visual	O
excitation	O
,	O
is	O
one	O
of	O
several	O
outer	O
segment	O
membrane	O
proteins	O
that	O
are	O
carboxyl	O
methylated	O
in	O
the	O
presence	O
of	O
the	O
methyl	O
donor	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
[	O
3H	O
-	O
methyl	O
]	O
methionine	O
.	O

By	O
chromatographic	O
analyses	O
of	O
the	O
3H	O
-	O
methyl	O
amino	O
acid	O
generated	O
by	O
exhaustive	O
proteolysis	O
of	O
purified	O
PDE	O
,	O
followed	O
by	O
performic	O
acid	O
oxidation	O
of	O
the	O
digest	O
,	O
we	O
have	O
shown	O
that	O
this	O
modification	O
occurs	O
at	O
a	O
C	O
-	O
terminal	O
cysteine	O
residue	O
of	O
the	O
alpha	O
subunit	O
of	O
this	O
enzyme	O
.	O

When	O
PDE	O
is	O
subjected	O
to	O
limited	O
proteolysis	O
with	O
trypsin	O
,	O
a	O
3H	O
-	O
methylated	O
fragment	O
of	O
1000	O
daltons	O
or	O
less	O
is	O
rapidly	O
removed	O
prior	O
to	O
the	O
degradation	O
of	O
its	O
inhibitory	O
gamma	O
subunit	O
.	O

This	O
small	O
fragment	O
remains	O
membrane	O
bound	O
,	O
whereas	O
the	O
bulk	O
of	O
the	O
enzyme	O
is	O
released	O
,	O
indicating	O
that	O
a	O
domain	O
responsible	O
for	O
anchoring	O
PDE	O
to	O
the	O
membrane	O
is	O
located	O
near	O
the	O
C	O
terminus	O
.	O

Based	O
on	O
the	O
C	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
Cys	O
-	O
Cys	O
-	O
Val	O
-	O
Gln	O
predicted	O
from	O
the	O
alpha	O
cDNA	O
sequence	O
,	O
we	O
conclude	O
that	O
PDE	O
undergoes	O
posttranslational	O
modifications	O
,	O
including	O
the	O
proteolytic	O
removal	O
of	O
two	O
or	O
three	O
terminal	O
amino	O
acids	O
,	O
and	O
methyl	O
esterification	O
of	O
the	O
alpha	O
-	O
carboxyl	O
group	O
of	O
the	O
terminal	O
cysteine	O
residue	O
.	O

We	O
speculate	O
that	O
the	O
sulfhydryl	O
group	O
of	O
the	O
methylated	O
cysteine	O
is	O
also	O
lipidated	O
to	O
mediate	O
membrane	O
binding	O
.	O

These	O
modifications	O
may	O
play	O
an	O
important	O
role	O
in	O
delivering	O
the	O
nascent	O
PDE	O
chains	O
to	O
the	O
membrane	O
and	O
in	O
correctly	O
positioning	O
the	O
PDE	O
molecule	O
in	O
the	O
rod	O
disks	O
for	O
phototransduction	O
.	O

Purification	O
of	O
bacteriorhodopsin	B-PRGE
and	O
characterization	O
of	O
mature	O
and	O
partially	O
processed	O
forms	O
.	O

Bacteriorhodopsin	B-PRGE
(	O
BR	B-PRGE
)	O
essentially	O
free	O
of	O
native	O
lipids	O
has	O
been	O
prepared	O
in	O
a	O
highly	O
stable	O
state	O
.	O

Purple	O
membrane	O
was	O
solubilized	O
in	O
Triton	O
X	O
-	O
100	O
and	O
BR	B-PRGE
was	O
purified	O
by	O
size	O
exclusion	O
chromatography	O
using	O
3	O
-	O
[	O
cholamidopropyl	O
)	O
dimethylammonio	O
]	O
-	O
2	O
-	O
hydroxyl	O
-	O
1	O
-	O
propanesulfonic	O
acid	O
(	O
CHAPSO	O
)	O
detergent	O
at	O
pH	O
5	O
.	O

Molar	O
ratios	O
of	O
phospholipid	O
/	O
BR	B-PRGE
ranged	O
from	O
0	O
.	O
4	O
to	O
0	O
.	O
05	O
corresponding	O
to	O
94	O
-	O
98	O
%	O
phospholipid	O
removal	O
.	O

Purified	O
BR	B-PRGE
has	O
an	O
absorbance	O
ratio	O
(	O
A280nm	O
/	O
A548nm	O
)	O
of	O
1	O
.	O
5	O
-	O
1	O
.	O
6	O
in	O
the	O
dark	O
-	O
adapted	O
state	O
which	O
is	O
the	O
highest	O
purified	O
BR	B-PRGE
/	O
protein	O
ratio	O
reported	O
to	O
date	O
.	O

The	O
purified	O
BR	B-PRGE
in	O
CHAPSO	O
shows	O
maximum	O
stability	O
in	O
the	O
pH	O
range	O
5	O
.	O
0	O
-	O
5	O
.	O
5	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
profiles	O
of	O
native	O
purple	O
membrane	O
and	O
solubilized	O
BR	B-PRGE
from	O
most	O
Halobacterium	O
halobium	O
JW	O
-	O
3	O
cultures	O
show	O
3	O
higher	O
molecular	O
weight	O
bands	O
in	O
addition	O
to	O
BR	B-PRGE
.	O

Immunological	O
staining	O
and	O
amino	O
acid	O
sequencing	O
indicates	O
that	O
these	O
additional	O
proteins	O
are	O
partially	O
processed	O
forms	O
of	O
the	O
BR	B-PRGE
precursor	O
protein	O
.	O

The	O
BR	B-PRGE
preprotein	O
contains	O
13	O
additional	O
amino	O
acids	O
on	O
the	O
NH2	O
terminus	O
which	O
are	O
removed	O
by	O
post	O
-	O
translational	O
processing	O
in	O
at	O
least	O
four	O
steps	O
.	O

Isoelectric	O
focusing	O
separated	O
most	O
delipidated	O
and	O
non	O
-	O
delipidated	O
BR	O
samples	O
into	O
8	O
bands	O
.	O

Incomplete	O
BR	O
post	O
-	O
translational	O
processing	O
BR	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
multiplicity	O
of	O
isoelectric	O
BR	O
species	O
.	O

The	O
principal	O
components	O
have	O
pI	O
values	O
of	O
5	O
.	O
20	O
and	O
5	O
.	O
24	O
and	O
both	O
have	O
absorption	O
maxima	O
at	O
550	O
nm	O
,	O
characteristic	O
of	O
detergent	O
-	O
solubilized	O
BR	O
.	O

BR	B-PRGE
in	O
Triton	O
X	O
-	O
100	O
or	O
nonylglucoside	O
,	O
delipidated	O
BR	O
in	O
CHAPSO	O
,	O
and	O
BR	B-PRGE
in	O
intact	O
purple	O
membrane	O
all	O
have	O
a	O
dark	O
-	O
adapted	O
ratio	O
of	O
13	O
-	O
cis	O
to	O
all	O
-	O
trans	O
-	O
retinal	O
of	O
1	O
.	O
9	O
:	O
1	O
.	O

In	O
vivo	O
characterization	O
of	O
the	O
poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
SV40	O
chromatin	O
and	O
large	B-PRGE
T	I-PRGE
antigen	I-PRGE
by	O
immunofractionation	O
.	O

We	O
have	O
confirmed	O
the	O
poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
large	B-PRGE
T	I-PRGE
antigen	I-PRGE
of	O
SV40	O
by	O
using	O
antibodies	O
to	O
both	O
large	B-PRGE
T	I-PRGE
antigen	I-PRGE
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
and	O
consequently	O
have	O
begun	O
to	O
characterize	O
how	O
this	O
post	O
-	O
translational	O
nuclear	O
modification	O
of	O
the	O
viral	O
protein	O
modulates	O
its	O
biological	O
functions	O
.	O

SV40	O
minichromosomal	O
subpopulation	O
containing	O
replicative	O
intermediate	O
DNA	O
was	O
shown	O
to	O
have	O
a	O
significantly	O
higher	O
affinity	O
for	O
anti	O
-	O
poly	O
(	O
ADP	O
-	O
Rib	O
)	O
-	O
Sepharose	O
than	O
viral	O
chromatin	O
fractions	O
containing	O
mature	O
minichromosomal	O
DNA	O
.	O

An	O
anti	O
-	O
large	O
T	O
-	O
Sepharose	O
column	O
was	O
used	O
to	O
isolate	O
T	B-PRGE
antigen	I-PRGE
from	O
crude	O
extracts	O
by	O
two	O
different	O
approaches	O
:	O
(	O
1	O
)	O
large	B-PRGE
T	I-PRGE
antigen	I-PRGE
was	O
labeled	O
with	O
[	O
35S	O
]	O
methionine	O
in	O
vivo	O
and	O
the	O
infected	O
cell	O
extract	O
was	O
immunofractionated	O
to	O
isolate	O
large	B-PRGE
T	I-PRGE
antigen	I-PRGE
and	O
(	O
2	O
)	O
large	B-PRGE
T	I-PRGE
antigen	I-PRGE
from	O
infected	O
cell	O
extracts	O
was	O
immunofractionated	O
followed	O
by	O
immunostaining	O
.	O

Using	O
these	O
techniques	O
,	O
1	O
-	O
10	O
%	O
of	O
the	O
total	O
T	B-PRGE
antigen	I-PRGE
from	O
infected	O
cells	O
was	O
found	O
to	O
be	O
poly	O
(	O
ADP	O
-	O
ribosylated	O
)	O
.	O

Minichromosome	O
preparations	O
per	O
se	O
were	O
also	O
subjected	O
to	O
immunofractionation	O
on	O
anti	O
-	O
large	O
T	O
-	O
Sepharose	O
.	O

The	O
high	O
level	O
of	O
retention	O
of	O
poly	O
(	O
ADP	O
-	O
ribosylated	O
)	O
species	O
of	O
minichromosomes	O
on	O
this	O
matrix	O
suggested	O
that	O
this	O
post	O
-	O
translational	O
modification	O
of	O
viral	O
chromatin	O
may	O
be	O
related	O
to	O
those	O
steps	O
in	O
viral	O
replication	O
and	O
transcription	O
under	O
regulation	O
by	O
large	B-PRGE
T	I-PRGE
antigen	I-PRGE
.	O

The	O
human	O
receptor	O
for	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
growth	I-PRGE
factor	I-PRGE
.	O

Evidence	O
for	O
variable	O
post	O
-	O
translational	O
processing	O
,	O
phosphorylation	O
,	O
sulfation	O
,	O
and	O
the	O
ability	O
of	O
precursor	O
forms	O
of	O
the	O
receptor	O
to	O
bind	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
growth	I-PRGE
factor	I-PRGE
.	O

The	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	I-PRGE
TCGF	I-PRGE
)	I-PRGE
receptor	I-PRGE
on	O
phytohemagglutinin	O
-	O
activated	O
normal	O
peripheral	O
blood	O
T	O
-	O
cells	O
is	O
characterized	O
as	O
a	O
glycoprotein	O
with	O
an	O
apparent	O
Mr	O
=	O
55	O
,	O
000	O
that	O
contains	O
N	O
-	O
linked	O
and	O
O	O
-	O
linked	O
carbohydrate	O
with	O
only	O
approximately	O
33	O
,	O
000	O
daltons	O
of	O
peptide	O
structure	O
(	O
p33	B-PRGE
)	O
as	O
evaluated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

There	O
are	O
two	O
N	O
-	O
linked	O
glycosylated	O
intermediate	O
precursor	O
forms	O
(	O
apparent	O
Mr	O
=	O
35	O
,	O
000	O
(	O
p35	B-PRGE
)	O
and	O
37	O
,	O
000	O
(	O
p37	B-PRGE
]	O
.	O

This	O
receptor	O
differs	O
from	O
the	O
TCGF	B-PRGE
receptor	I-PRGE
on	O
HUT	O
-	O
102B2	O
cells	O
(	O
apparent	O
Mr	O
=	O
50	O
,	O
000	O
)	O
because	O
of	O
differences	O
in	O
post	O
-	O
translational	O
processing	O
.	O

Experiments	O
with	O
the	O
carboxylic	O
ionophore	O
monensin	O
demonstrate	O
blockade	O
of	O
the	O
transition	O
of	O
the	O
p35	B-PRGE
and	O
p37	B-PRGE
receptor	O
precursor	O
forms	O
to	O
the	O
mature	O
receptor	O
,	O
presumably	O
secondary	O
to	O
inhibition	O
of	O
Golgi	O
-	O
associated	O
receptor	O
processing	O
.	O

We	O
identify	O
the	O
primary	O
translation	O
product	O
of	O
TCGF	B-PRGE
receptor	I-PRGE
mRNA	O
as	O
intermediate	O
in	O
size	O
between	O
the	O
p33	B-PRGE
and	O
the	O
p35	B-PRGE
/	O
p37	B-PRGE
forms	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p33	B-PRGE
,	O
p35	B-PRGE
,	O
and	O
p37	B-PRGE
precursor	O
forms	O
,	O
but	O
not	O
the	O
primary	O
translation	O
product	O
,	O
are	O
all	O
capable	O
of	O
binding	O
TCGF	B-PRGE
.	O

Thus	O
,	O
the	O
removal	O
of	O
the	O
signal	O
peptide	O
and	O
/	O
or	O
conformational	O
changes	O
of	O
the	O
primary	O
translation	O
product	O
are	O
necessary	O
for	O
ligand	O
binding	O
;	O
however	O
,	O
the	O
extensive	O
post	O
-	O
translational	O
modifications	O
are	O
not	O
.	O

Lastly	O
,	O
we	O
demonstrate	O
that	O
at	O
least	O
some	O
TCGF	B-PRGE
receptors	I-PRGE
are	O
phosphorylated	O
and	O
sulfated	O
,	O
and	O
that	O
TCGF	B-PRGE
receptors	I-PRGE
on	O
phytohemagglutinin	O
-	O
activated	O
normal	O
T	O
-	O
cells	O
are	O
more	O
heavily	O
sulfated	O
than	O
those	O
on	O
HUT	O
-	O
102B2	O
cells	O
.	O

The	O
effects	O
of	O
processing	O
inhibitors	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
on	O
the	O
intracellular	O
migration	O
of	O
glycoprotein	B-PRGE
E2	I-PRGE
of	O
mouse	O
hepatitis	O
virus	O
and	O
the	O
maturation	O
of	O
coronavirus	O
particles	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
tunicamycin	O
and	O
inhibitors	O
of	O
the	O
processing	O
of	O
N	O
-	O
linked	O
glycans	O
including	O
N	O
-	O
methyl	O
-	O
1	O
-	O
deoxynojirimycin	O
,	O
castanospermine	O
,	O
mannodeoxynojirimycin	O
,	O
and	O
swainsonine	O
on	O
the	O
transport	O
of	O
glycoprotein	B-PRGE
E2	I-PRGE
and	O
the	O
intracellular	O
maturation	O
of	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
A59	O
.	O

Indirect	O
immunofluorescence	O
staining	O
with	O
monoclonal	O
antibodies	O
revealed	O
that	O
glycoprotein	B-PRGE
E2	I-PRGE
exhibits	O
different	O
antigenic	O
properties	O
depending	O
on	O
the	O
presence	O
and	O
on	O
the	O
structure	O
of	O
the	O
N	O
-	O
linked	O
oligosaccharides	O
and	O
that	O
efficient	O
transport	O
of	O
glycoprotein	B-PRGE
E2	I-PRGE
to	O
the	O
plasma	O
membrane	O
requires	O
the	O
removal	O
of	O
glucose	O
residues	O
.	O

In	O
the	O
presence	O
of	O
tunicamycin	O
in	O
the	O
nonglycosylated	O
E2	B-PRGE
apoprotein	O
was	O
synthesized	O
in	O
normal	O
amounts	O
and	O
readily	O
acylated	O
throughout	O
the	O
infectious	O
cycle	O
.	O

This	O
E2	B-PRGE
-	O
species	O
could	O
not	O
be	O
detected	O
on	O
the	O
surface	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
-	O
infected	O
cells	O
with	O
indirect	O
immunofluorescence	O
staining	O
or	O
lactoperoxidase	B-PRGE
labeling	O
.	O

N	O
-	O
Methyl	O
-	O
1	O
-	O
deoxynojirimycin	O
and	O
castanospermine	O
,	O
both	O
of	O
which	O
selectively	O
inhibited	O
the	O
processing	O
glucosidases	O
,	O
caused	O
a	O
drop	O
in	O
virion	O
formation	O
by	O
two	O
log	O
steps	O
and	O
a	O
drastic	O
delay	O
in	O
the	O
surface	O
expression	O
of	O
glycoprotein	B-PRGE
E2	I-PRGE
.	O

The	O
E2	B-PRGE
species	O
synthesized	O
under	O
such	O
conditions	O
was	O
acylated	O
but	O
accumulated	O
intracellularly	O
in	O
a	O
compartment	O
distinct	O
from	O
the	O
Golgi	O
.	O

Concomitantly	O
,	O
synthesis	O
of	O
the	O
matrix	O
glycoprotein	B-PRGE
E1	I-PRGE
of	O
mouse	O
hepatitis	O
virus	O
A59	O
was	O
drastically	O
impaired	O
.	O

Mannodeoxynojirimycin	O
and	O
swainsonine	O
,	O
which	O
block	O
later	O
stages	O
of	O
the	O
processing	O
pathway	O
,	O
had	O
less	O
or	O
no	O
effect	O
on	O
the	O
transport	O
of	O
glycoprotein	B-PRGE
E2	I-PRGE
and	O
the	O
formation	O
of	O
virus	O
particles	O
.	O

Purification	O
and	O
postsynthetic	O
modifications	O
of	O
Friend	O
erythroleukemic	O
cell	O
high	O
mobility	O
group	O
protein	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

We	O
have	O
previously	O
detected	O
and	O
purified	O
a	O
Friend	O
erythroleukemic	O
mouse	O
cell	O
nonhistone	O
chromatin	O
protein	O
having	O
extraction	O
and	O
acid	O
-	O
solubility	O
properties	O
like	O
the	O
low	O
molecular	O
weight	O
"	O
high	O
mobility	O
group	O
"	O
(	O
HMG	O
)	O
nuclear	O
proteins	O
.	O

We	O
show	O
here	O
that	O
the	O
electrophoretic	O
properties	O
and	O
the	O
amino	O
acid	O
composition	O
of	O
this	O
mouse	O
cell	O
"	O
HMG	O
-	O
like	O
"	O
protein	O
is	O
comparable	O
to	O
those	O
of	O
the	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
proteins	O
isolated	O
from	O
human	O
HeLa	O
S3	O
cells	O
,	O
African	O
green	O
monkey	O
cells	O
,	O
Ehrlich	O
ascites	O
mouse	O
cells	O
,	O
and	O
rat	O
fibroblast	O
cells	O
.	O

Therefore	O
,	O
we	O
have	O
also	O
designated	O
the	O
Friend	O
erythroleukemic	O
mouse	O
cell	O
protein	O
as	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

In	O
common	O
with	O
the	O
other	O
HMG	O
proteins	O
the	O
Friend	O
cell	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
protein	O
can	O
undergo	O
a	O
variety	O
of	O
post	O
-	O
translational	O
biochemical	O
modifications	O
including	O
acetylation	O
,	O
ADP	O
-	O
ribosylation	O
,	O
glycosylation	O
,	O
and	O
phosphorylation	O
.	O

Surprisingly	O
,	O
in	O
the	O
course	O
of	O
these	O
studies	O
we	O
found	O
that	O
in	O
vivo	O
radiolabeling	O
experiments	O
revealed	O
that	O
only	O
two	O
minor	O
HMG	B-PRGE
-	I-PRGE
14	I-PRGE
subspecies	O
(	O
and	O
/	O
or	O
possibly	O
a	O
minor	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
subspecies	O
)	O
are	O
phosphorylated	O
whereas	O
HMG	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
-	B-PRGE
2	I-PRGE
,	I-PRGE
-	B-PRGE
17	I-PRGE
,	O
and	O
the	O
major	O
HMG	B-PRGE
-	I-PRGE
14	I-PRGE
are	O
not	O
heavily	O
phosphorylated	O
.	O

In	O
vitro	O
sulfation	O
of	O
pulmonary	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
.	O

Surfactant	O
-	O
associated	O
protein	O
-	O
35	O
consists	O
of	O
a	O
group	O
of	O
phospholipid	O
-	O
associated	O
proteins	O
of	O
26	O
-	O
36	O
kDa	O
isolated	O
from	O
pulmonary	O
alveolar	O
surfactant	O
.	O

In	O
the	O
rat	O
,	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
is	O
synthesized	O
from	O
26	O
-	O
kDa	O
primary	O
translation	O
products	O
which	O
are	O
cotranslationally	O
acetylated	O
and	O
glycosylated	O
to	O
heterogeneous	O
30	O
and	O
34	O
kDa	O
forms	O
.	O

High	O
-	O
mannose	O
oligosaccharide	O
-	O
containing	O
precursors	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
are	O
processed	O
in	O
the	O
rough	O
endoplasmic	O
reticulum	O
and	O
Golgi	O
to	O
complex	O
-	O
type	O
oligosaccharides	O
,	O
resulting	O
in	O
a	O
mature	O
glycoprotein	O
which	O
exhibits	O
extensive	O
charge	O
heterogeneity	O
in	O
two	O
-	O
dimensional	O
isoelectric	O
focusing	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Much	O
of	O
this	O
charge	O
heterogeneity	O
is	O
related	O
to	O
terminal	O
sialylation	O
of	O
the	O
two	O
asparagine	O
-	O
linked	O
oligosaccharides	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
that	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
is	O
also	O
sulfated	O
.	O

Sulfation	O
of	O
the	O
30	O
and	O
34	O
kDa	O
forms	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
was	O
clearly	O
detected	O
in	O
primary	O
cultures	O
of	O
rat	O
Type	O
II	O
epithelial	O
cells	O
.	O

These	O
sulfated	O
isoforms	O
were	O
sensitive	O
to	O
endoglycosidase	O
F	O
digestion	O
,	O
but	O
resistant	O
to	O
neuraminidase	O
,	O
suggesting	O
that	O
sulfation	O
occurred	O
at	O
oligosaccharide	O
residues	O
other	O
than	O
sialic	O
acid	O
.	O

The	O
lack	O
of	O
sulfation	O
of	O
the	O
26	O
kDa	O
forms	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
and	O
the	O
resistance	O
of	O
the	O
sulfated	O
isoforms	O
to	O
endoglycosidase	B-PRGE
H	I-PRGE
digestion	O
are	O
consistent	O
with	O
Golgi	O
-	O
associated	O
sulfation	O
of	O
the	O
complex	O
type	O
oligosaccharides	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
.	O

Thus	O
,	O
sulfation	O
is	O
another	O
component	O
of	O
the	O
complex	O
post	O
-	O
translational	O
processing	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
,	O
which	O
includes	O
acetylation	O
,	O
hydroxylation	O
,	O
glycosylation	O
,	O
sialylation	O
,	O
sulfhydryl	O
-	O
dependent	O
oligomerization	O
and	O
sulfation	O
.	O

Effect	O
of	O
propeptide	O
mutations	O
on	O
post	O
-	O
translational	O
processing	O
of	O
factor	B-PRGE
IX	I-PRGE
.	O

Evidence	O
that	O
beta	O
-	O
hydroxylation	O
and	O
gamma	O
-	O
carboxylation	O
are	O
independent	O
events	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
Factor	B-PRGE
IX	I-PRGE
includes	O
glycosylation	O
,	O
cleavage	O
of	O
the	O
signal	O
peptide	O
and	O
propeptide	O
,	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
specific	O
glutamic	O
acid	O
residues	O
to	O
form	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
and	O
beta	O
-	O
hydroxylation	O
of	O
aspartic	O
acid	O
at	O
residue	O
64	O
to	O
form	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O

The	O
human	O
Factor	B-PRGE
IX	I-PRGE
cDNA	O
coding	O
sequence	O
was	O
modified	O
in	O
the	O
propeptide	O
region	O
(	O
residue	O
-	O
18	O
to	O
-	O
1	O
)	O
using	O
oligonucleotide	O
-	O
directed	O
site	O
-	O
specific	O
mutagenesis	O
,	O
and	O
the	O
altered	O
Factor	B-PRGE
IX	I-PRGE
cDNA	O
was	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

The	O
effects	O
of	O
the	O
mutations	O
on	O
proteolytic	O
processing	O
,	O
gamma	O
-	O
carboxylation	O
,	O
and	O
beta	O
-	O
hydroxylation	O
were	O
assessed	O
by	O
direct	O
structural	O
analysis	O
.	O

After	O
purification	O
,	O
the	O
molecular	O
weight	O
of	O
each	O
of	O
the	O
recombinant	O
Factor	B-PRGE
IX	I-PRGE
species	O
and	O
its	O
NH2	O
-	O
terminal	O
amino	O
acid	O
sequence	O
were	O
shown	O
to	O
be	O
identical	O
to	O
those	O
of	O
plasma	O
Factor	B-PRGE
IX	I-PRGE
.	O

gamma	O
-	O
Carboxyglutamic	O
acid	O
and	O
beta	O
-	O
hydroxyaspartic	O
acid	O
analyses	O
revealed	O
that	O
recombinant	O
wild	O
-	O
type	O
Factor	B-PRGE
IX	I-PRGE
contained	O
9	O
.	O
2	O
gamma	O
-	O
carboxyglutamic	O
acid	O
and	O
0	O
.	O
3	O
beta	O
-	O
hydroxyaspartic	O
acid	O
residues	O
/	O
molecule	O
compared	O
with	O
11	O
.	O
4	O
gamma	O
-	O
carboxyglutamic	O
acid	O
and	O
0	O
.	O
39	O
beta	O
-	O
hydroxyaspartic	O
acid	O
residues	O
in	O
plasma	O
Factor	B-PRGE
IX	I-PRGE
.	O

When	O
the	O
18	O
-	O
residue	O
propeptide	O
was	O
deleted	O
or	O
when	O
the	O
cells	O
were	O
grown	O
in	O
the	O
presence	O
of	O
sodium	O
warfarin	O
,	O
secreted	O
Factor	B-PRGE
IX	I-PRGE
contained	O
no	O
detectable	O
gamma	O
-	O
carboxyglutamic	O
acid	O
but	O
0	O
.	O
36	O
and	O
0	O
.	O
40	O
residues	O
of	O
beta	O
-	O
hydroxyaspartic	O
acid	O
,	O
respectively	O
.	O

Point	O
mutations	O
leading	O
to	O
substitution	O
of	O
alanine	O
for	O
phenylalanine	O
at	O
residue	O
-	O
16	O
or	O
glutamic	O
acid	O
for	O
alanine	O
at	O
residue	O
-	O
10	O
contained	O
0	O
.	O
2	O
and	O
1	O
.	O
7	O
gamma	O
-	O
carboxyglutamic	O
acid	O
residues	O
,	O
respectively	O
,	O
and	O
0	O
.	O
2	O
residues	O
of	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O

These	O
data	O
confirm	O
that	O
the	O
propeptide	O
mutations	O
made	O
do	O
not	O
interfere	O
with	O
proteolytic	O
processing	O
and	O
that	O
the	O
Factor	B-PRGE
IX	I-PRGE
propeptide	O
contains	O
a	O
recognition	O
site	O
that	O
designates	O
the	O
adjacent	O
glutamic	O
acid	O
-	O
rich	O
domain	O
for	O
gamma	O
-	O
carboxylation	O
.	O

In	O
contrast	O
,	O
beta	O
-	O
hydroxylation	O
of	O
aspartic	O
acid	O
64	O
is	O
an	O
independent	O
process	O
which	O
does	O
not	O
require	O
vitamin	O
K	O
and	O
is	O
mediated	O
through	O
a	O
hydroxylation	O
recognition	O
site	O
in	O
the	O
mature	O
Factor	B-PRGE
IX	I-PRGE
,	O
not	O
in	O
the	O
propeptide	O
.	O

(	O
Glu62	O
,	O
Ala30	O
,	O
Tyr8	O
)	O
n	O
serves	O
as	O
high	O
-	O
affinity	O
substrate	O
for	O
tyrosylprotein	O
sulfotransferase	O
:	O
a	O
Golgi	O
enzyme	O
.	O

Tyrosylprotein	O
sulfotransferase	O
,	O
the	O
enzyme	O
catalyzing	O
the	O
sulfation	O
of	O
proteins	O
on	O
tyrosine	O
residues	O
,	O
was	O
characterized	O
by	O
using	O
the	O
acidic	O
polymer	O
containing	O
tyrosine	O
(	O
Glu62	O
,	O
Ala30	O
,	O
Tyr8	O
)	O
n	O
(	O
referred	O
to	O
as	O
Glu	O
,	O
Ala	O
,	O
Tyr	O
)	O
as	O
exogenous	O
"	O
protein	O
"	O
substrate	O
.	O

After	O
subcellular	O
fractionation	O
of	O
a	O
bovine	O
adrenal	O
medulla	O
homogenate	O
,	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
found	O
to	O
be	O
highest	O
in	O
fractions	O
enriched	O
in	O
Golgi	O
membrane	O
vesicles	O
.	O

Tyrosylprotein	O
sulfotransferase	O
required	O
the	O
presence	O
of	O
a	O
nonionic	O
detergent	O
for	O
sulfation	O
of	O
exogenous	O
Glu	O
,	O
Ala	O
,	O
Tyr	O
,	O
indicating	O
an	O
orientation	O
of	O
the	O
catalytic	O
site	O
of	O
the	O
enzyme	O
toward	O
the	O
Golgi	O
lumen	O
.	O

Tyrosylprotein	O
sulfotransferase	O
was	O
solubilized	O
by	O
Triton	O
X	O
-	O
100	O
,	O
suggesting	O
that	O
the	O
enzyme	O
was	O
tightly	O
associated	O
with	O
the	O
Golgi	O
membrane	O
,	O
possibly	O
as	O
an	O
integral	O
membrane	O
protein	O
.	O

The	O
apparent	O
Golgi	O
localization	O
of	O
tyrosylprotein	O
sulfotransferase	O
was	O
supported	O
by	O
the	O
observation	O
that	O
tyrosine	O
sulfation	O
of	O
proteins	O
in	O
intact	O
cells	O
was	O
blocked	O
by	O
monensin	O
and	O
was	O
in	O
line	O
with	O
previous	O
observations	O
that	O
all	O
tyrosine	O
-	O
sulfated	O
proteins	O
known	O
so	O
far	O
are	O
secretory	O
.	O

Glu	O
,	O
Ala	O
,	O
Tyr	O
was	O
found	O
to	O
have	O
a	O
very	O
high	O
affinity	O
for	O
tyrosylprotein	O
sulfotransferase	O
(	O
apparent	O
Km	O
,	O
300	O
nM	O
)	O
,	O
similar	O
to	O
that	O
reported	O
for	O
certain	O
tyrosylprotein	O
kinases	O
.	O

While	O
this	O
may	O
suggest	O
some	O
similarity	O
between	O
these	O
enzymes	O
,	O
the	O
Golgi	O
localization	O
of	O
tyrosylprotein	O
sulfotransferase	O
segregates	O
tyrosine	O
sulfation	O
from	O
the	O
sites	O
of	O
tyrosine	O
phosphorylation	O
of	O
proteins	O
in	O
the	O
intact	O
cell	O
.	O

If	O
,	O
however	O
,	O
tyrosylprotein	O
sulfotransferase	O
was	O
allowed	O
to	O
react	O
with	O
cytoplasmic	O
proteins	O
by	O
using	O
a	O
nonionic	O
detergent	O
,	O
tyrosine	O
sulfation	O
of	O
tubulin	O
was	O
observed	O
.	O

Developmental	O
changes	O
in	O
the	O
modification	O
of	O
lysosomal	O
enzymes	O
in	O
Dictyostelium	O
discoideum	O
.	O

Evidence	O
has	O
been	O
found	O
for	O
a	O
generalized	O
change	O
in	O
the	O
post	O
-	O
translational	O
modification	O
of	O
lysosomal	O
enzymes	O
during	O
development	O
of	O
Dictyostelium	O
discoideum	O
.	O

The	O
physical	O
and	O
antigenic	O
properties	O
of	O
four	O
developmentally	O
regulated	O
lysosomal	O
enzymes	O
,	O
N	B-PRGE
-	I-PRGE
acetylglucosaminidase	I-PRGE
,	O
beta	B-PRGE
-	I-PRGE
glucosidase	I-PRGE
,	O
alpha	B-PRGE
-	I-PRGE
mannosidase	I-PRGE
,	O
and	O
acid	B-PRGE
phosphatase	I-PRGE
,	O
have	O
been	O
examined	O
throughout	O
the	O
life	O
cycle	O
.	O

In	O
vegetative	O
cells	O
,	O
a	O
single	O
major	O
isoelectric	O
species	O
is	O
detected	O
for	O
each	O
enzymatic	O
activity	O
on	O
native	O
nonequilibrium	O
isoelectric	O
focusing	O
gels	O
.	O

Between	O
6	O
and	O
10	O
hr	O
of	O
development	O
,	O
all	O
activities	O
,	O
including	O
the	O
preformed	O
enzyme	O
,	O
become	O
less	O
negatively	O
charged	O
,	O
resulting	O
in	O
a	O
modest	O
but	O
reproducible	O
shift	O
in	O
the	O
isoelectric	O
focusing	O
pattern	O
.	O

This	O
alteration	O
is	O
not	O
detected	O
by	O
native	O
gel	O
electrophoresis	O
at	O
constant	O
pH	O
.	O

As	O
development	O
continues	O
,	O
the	O
specific	O
activity	O
of	O
beta	B-PRGE
-	I-PRGE
glucosidase	I-PRGE
,	O
alpha	B-PRGE
-	I-PRGE
mannosidase	I-PRGE
,	O
and	O
acid	B-PRGE
phosphatase	I-PRGE
continues	O
to	O
increase	O
and	O
coincidentally	O
,	O
new	O
,	O
less	O
acidic	O
isozymic	O
bands	O
of	O
activity	O
can	O
be	O
observed	O
on	O
both	O
gel	O
systems	O
.	O

Some	O
of	O
these	O
new	O
isozymes	O
accumulate	O
preferentially	O
in	O
anterior	O
cells	O
,	O
while	O
others	O
accumulate	O
preferentially	O
in	O
posterior	O
cells	O
of	O
migrating	O
slugs	O
.	O

N	B-PRGE
-	I-PRGE
Acetylglucosaminidase	I-PRGE
does	O
not	O
increase	O
in	O
specific	O
activity	O
late	O
in	O
development	O
and	O
no	O
new	O
isozymic	O
species	O
appear	O
.	O

Using	O
a	O
monoclonal	O
antibody	O
that	O
reacts	O
with	O
sulfated	O
N	O
-	O
linked	O
oligosaccharides	O
shared	O
by	O
vegetative	O
lysosomal	O
enzymes	O
in	O
D	O
.	O
discoideum	O
,	O
the	O
antigenicity	O
of	O
the	O
developmental	O
isozymes	O
has	O
been	O
characterized	O
.	O

All	O
of	O
the	O
enzymatic	O
activity	O
present	O
during	O
vegetative	O
growth	O
and	O
early	O
development	O
is	O
immunoprecipitable	O
.	O

However	O
,	O
the	O
less	O
negatively	O
charged	O
isozymes	O
that	O
accumulate	O
after	O
aggregation	O
are	O
not	O
recognized	O
by	O
the	O
antibody	O
.	O

Nonantigenic	O
acid	O
phosphatase	O
and	O
alpha	B-PRGE
-	I-PRGE
mannosidase	I-PRGE
are	O
found	O
in	O
both	O
anterior	O
and	O
posterior	O
cells	O
from	O
migrating	O
pseudoplasmodia	O
.	O

Since	O
each	O
enzyme	O
is	O
coded	O
by	O
a	O
single	O
structural	O
gene	O
,	O
these	O
results	O
suggest	O
that	O
the	O
isozymes	O
present	O
late	O
in	O
development	O
arise	O
from	O
the	O
synthesis	O
of	O
the	O
same	O
polypeptides	O
with	O
altered	O
post	O
-	O
translational	O
modifications	O
.	O

The	O
appearance	O
of	O
anterior	O
and	O
posterior	O
specific	O
isozymes	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
cell	O
type	O
specific	O
changes	O
in	O
the	O
glycoprotein	O
modification	O
pathway	O
for	O
newly	O
synthesized	O
proteins	O
.	O

Sulfation	O
of	O
lutropin	O
oligosaccharides	O
with	O
a	O
cell	O
-	O
free	O
system	O
.	O

Sulfate	O
is	O
covalently	O
linked	O
to	O
the	O
oligosaccharides	O
on	O
the	O
alpha	O
and	O
beta	O
subunits	O
of	O
bovine	O
lutropin	O
(	O
luteinizing	O
hormone	O
;	O
LH	O
)	O
but	O
not	O
to	O
those	O
on	O
human	O
chorionic	O
gonadotropin	O
(	O
hCG	O
)	O
.	O

Since	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
pituitary	O
and	O
placental	O
alpha	O
subunits	O
are	O
homologous	O
,	O
comparison	O
of	O
their	O
asparagine	O
-	O
linked	O
sugars	O
can	O
provide	O
information	O
regarding	O
tissue	O
specificity	O
of	O
oligosaccharide	O
maturation	O
.	O

To	O
characterize	O
this	O
post	O
-	O
translational	O
modification	O
,	O
we	O
have	O
developed	O
a	O
reconstituted	O
cell	O
-	O
free	O
sulfation	O
system	O
.	O

Sulfate	O
is	O
incorporated	O
into	O
exogenously	O
added	O
glycoproteins	O
by	O
sulfotransferases	O
from	O
Triton	O
X	O
-	O
100	O
-	O
lysed	O
Golgi	O
membranes	O
in	O
the	O
presence	O
of	O
3	O
'	O
-	O
phosphoadenosine	O
5	O
'	O
-	O
phospho	O
[	O
35S	O
]	O
sulfate	O
,	O
which	O
is	O
generated	O
from	O
[	O
35S	O
]	O
sulfate	O
by	O
a	O
ribosome	O
-	O
free	O
supernate	O
from	O
Krebs	O
ascites	O
tumor	O
cells	O
.	O

LH	O
is	O
sulfated	O
by	O
pituitary	O
and	O
liver	O
membranes	O
but	O
not	O
by	O
those	O
from	O
placenta	O
.	O

Desialylated	O
hCG	O
(	O
AshCG	O
)	O
is	O
sulfated	O
by	O
membranes	O
from	O
placenta	O
and	O
pituitary	O
,	O
but	O
not	O
liver	O
,	O
while	O
hCG	O
is	O
not	O
sulfated	O
by	O
any	O
of	O
these	O
membranes	O
.	O

Endoglycosidase	O
F	O
releases	O
all	O
the	O
incorporated	O
sulfate	O
from	O
LH	O
in	O
the	O
form	O
of	O
a	O
heterogeneous	O
mixture	O
of	O
mono	O
-	O
and	O
disulfated	O
oligosaccharides	O
.	O

In	O
contrast	O
,	O
the	O
sulfate	O
added	O
to	O
AshCG	O
is	O
apparently	O
attached	O
to	O
peptide	O
rather	O
than	O
oligosaccharide	O
.	O

As	O
found	O
with	O
the	O
cell	O
-	O
free	O
system	O
,	O
sulfate	O
metabolically	O
incorporated	O
into	O
LH	O
by	O
pituitary	O
cells	O
is	O
present	O
on	O
a	O
heterogeneous	O
population	O
of	O
mono	O
-	O
and	O
disulfated	O
oligosaccharides	O
.	O

Thus	O
the	O
cell	O
-	O
free	O
sulfation	O
system	O
accurately	O
duplicates	O
the	O
in	O
vivo	O
process	O
.	O

In	O
vivo	O
participation	O
of	O
a	O
high	O
potential	O
iron	O
-	O
sulfur	O
protein	O
as	O
electron	O
donor	O
to	O
the	O
photochemical	O
reaction	O
center	O
of	O
Rubrivivax	O
gelatinosus	O
.	O

We	O
have	O
found	O
that	O
the	O
only	O
high	O
redox	O
potential	O
electron	O
transfer	O
component	O
in	O
the	O
soluble	O
fraction	O
of	O
Rubrivivax	O
gelatinosus	O
TG	O
-	O
9	O
is	O
a	O
high	B-PRGE
-	I-PRGE
potential	I-PRGE
iron	I-PRGE
-	I-PRGE
sulfur	I-PRGE
protein	I-PRGE
(	O
HiPIP	B-PRGE
)	O
.	O

We	O
demonstrated	O
the	O
participation	O
of	O
this	O
HiPIP	B-PRGE
in	O
the	O
photoinduced	O
electron	O
transfer	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

First	O
,	O
the	O
addition	O
of	O
HiPIP	B-PRGE
to	O
purified	O
membranes	O
enhanced	O
the	O
rate	O
of	O
re	O
-	O
reduction	O
of	O
the	O
photooxidized	O
reaction	O
center	O
.	O

Second	O
,	O
the	O
photooxidation	O
of	O
HiPIP	B-PRGE
was	O
observed	O
in	O
intact	O
cells	O
of	O
Ru	O
.	O
gelatinosus	O
TG	O
-	O
9	O
under	O
anaerobic	O
conditions	O
by	O
EPR	O
and	O
absorption	O
spectroscopies	O
.	O

Analysis	O
of	O
flash	O
-	O
induced	O
absorption	O
changes	O
showed	O
that	O
the	O
equilibration	O
of	O
positive	O
equivalents	O
between	O
the	O
reaction	O
center	O
and	O
HiPIP	B-PRGE
occurs	O
in	O
less	O
than	O
1	O
ms	O
after	O
flash	O
excitation	O
.	O

The	O
complete	O
re	O
-	O
reduction	O
of	O
the	O
photooxidized	O
reaction	O
center	O
is	O
achieved	O
in	O
tens	O
of	O
milliseconds	O
.	O

The	O
turnover	O
of	O
a	O
cyt	O
bc1	O
is	O
also	O
involved	O
in	O
this	O
reaction	O
,	O
as	O
shown	O
by	O
a	O
slow	O
electrogenic	O
phase	O
of	O
the	O
membrane	O
potential	O
linked	O
to	O
this	O
process	O
.	O

Quantitation	O
of	O
procholecystokinin	B-PRGE
and	O
its	O
products	O
in	O
plasma	O
by	O
processing	O
-	O
independent	O
analysis	O
.	O

A	O
procedure	O
for	O
processing	O
-	O
independent	O
quantitation	O
of	O
procholecystokinin	B-PRGE
(	O
proCCK	B-PRGE
)	O
and	O
its	O
products	O
has	O
been	O
applied	O
to	O
plasma	O
.	O

The	O
procedure	O
is	O
based	O
on	O
tryptic	O
cleavage	O
after	O
Lys61	O
and	O
Arg71	O
with	O
subsequent	O
monospecific	O
radioimmuno	O
-	O
analysis	O
of	O
fragment	O
62	O
-	O
71	O
of	O
human	O
proCCK	B-PRGE
,	O
which	O
again	O
corresponds	O
to	O
fragment	O
1	O
-	O
10	O
of	O
CCK	B-PRGE
-	O
22	O
.	O

The	O
detection	O
limit	O
of	O
the	O
analysis	O
was	O
0	O
.	O
2	O
pmol	O
/	O
l	O
.	O

Plasma	O
was	O
extracted	O
with	O
ethanol	O
.	O

In	O
plasma	O
from	O
13	O
healthy	O
volunteers	O
the	O
basal	O
concentration	O
with	O
the	O
above	O
-	O
mentioned	O
radioimmunoassay	O
was	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
.	O
)	O
before	O
,	O
and	O
13	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
pmol	O
/	O
l	O
after	O
,	O
incubation	O
with	O
trypsin	O
.	O

Two	O
hours	O
after	O
ingestion	O
of	O
a	O
mixed	O
meal	O
,	O
the	O
plasma	O
concentration	O
was	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
before	O
,	O
and	O
21	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
2	O
pmol	O
/	O
l	O
after	O
tryptic	O
cleavage	O
.	O

With	O
a	O
conventional	O
CCK	B-PRGE
radioimmunoassay	O
specific	O
for	O
the	O
C	O
-	O
terminally	O
amidated	O
and	O
O	O
-	O
sulfated	O
bioactive	O
epitope	O
,	O
the	O
concentration	O
was	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
in	O
the	O
basal	O
state	O
and	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
pmol	O
/	O
l	O
2	O
h	O
after	O
a	O
meal	O
.	O

Tryptic	O
cleavage	O
did	O
not	O
increase	O
the	O
concentrations	O
of	O
amidated	O
,	O
bioactive	O
CCK	B-PRGE
peptides	O
.	O

In	O
plasma	O
from	O
37	O
patients	O
with	O
the	O
carcinoid	O
syndrome	O
,	O
the	O
basal	O
concentration	O
of	O
proCCK	B-PRGE
and	O
its	O
products	O
was	O
14	O
.	O
1	O
(	O
2	O
.	O
8	O
-	O
150	O
.	O
4	O
)	O
pmol	O
/	O
l	O
(	O
median	O
(	O
range	O
)	O
)	O
,	O
compared	O
with	O
0	O
.	O
3	O
(	O
0	O
-	O
18	O
.	O
8	O
)	O
pmol	O
/	O
l	O
for	O
carboxyamidated	O
CCK	B-PRGE
.	O

Only	O
two	O
patients	O
had	O
significantly	O
elevated	O
CCK	B-PRGE
concentrations	O
.	O

We	O
conclude	O
that	O
processing	O
-	O
independent	O
analysis	O
is	O
useful	O
for	O
quantitation	O
of	O
proCCK	B-PRGE
and	O
its	O
products	O
in	O
plasma	O
,	O
since	O
it	O
quantitates	O
CCK	B-PRGE
cell	O
secretion	O
more	O
accurately	O
than	O
conventional	O
CCK	B-PRGE
assays	O
.	O

Synergistic	O
activation	O
of	O
rat	O
brain	O
phospholipase	B-PRGE
D	I-PRGE
by	O
ADP	O
-	O
ribosylation	O
factor	O
and	O
rhoA	B-PRGE
p21	I-PRGE
,	O
and	O
its	O
inhibition	O
by	O
Clostridium	O
botulinum	O
C3	B-PRGE
exoenzyme	I-PRGE
.	O

An	O
activator	O
of	O
rat	O
brain	O
phospholipase	B-PRGE
D	I-PRGE
(	O
PLD	B-PRGE
)	O
that	O
is	O
distinct	O
from	O
the	O
already	O
identified	O
PLD	B-PRGE
activator	O
,	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
ARF	O
)	O
,	O
was	O
partially	O
purified	O
from	O
bovine	O
brain	O
cytosol	O
by	O
a	O
series	O
of	O
chromatographic	O
steps	O
.	O

The	O
partially	O
purified	O
preparation	O
contained	O
a	O
22	O
-	O
kDa	O
substrate	O
for	O
Clostridium	O
botulinum	O
C3	B-PRGE
exoenzyme	I-PRGE
ADP	O
-	O
ribosyltransferase	O
,	O
which	O
strongly	O
reacted	O
with	O
anti	O
-	O
rhoA	B-PRGE
p21	I-PRGE
antibody	O
,	O
but	O
not	O
with	O
anti	O
-	O
rac1	B-PRGE
p21	I-PRGE
or	O
anti	O
-	O
cdc42Hs	B-PRGE
p21	I-PRGE
antibody	O
.	O

Treatment	O
of	O
the	O
partially	O
purified	O
PLD	B-PRGE
-	O
activating	O
factor	O
with	O
both	O
C3	B-PRGE
exoenzyme	I-PRGE
and	O
NAD	O
significantly	O
inhibited	O
the	O
PLD	B-PRGE
-	O
stimulating	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
rhoA	B-PRGE
p21	I-PRGE
is	O
,	O
at	O
least	O
in	O
part	O
,	O
responsible	O
for	O
the	O
PLD	B-PRGE
-	O
stimulating	O
activity	O
in	O
the	O
preparation	O
.	O

Recombinant	O
isoprenylated	O
rhoA	B-PRGE
p21	I-PRGE
expressed	O
in	O
and	O
purified	O
from	O
Sf9	O
cells	O
activated	O
rat	O
brain	O
PLD	B-PRGE
in	O
a	O
concentration	O
-	O
and	O
GTP	O
gamma	O
S	O
(	O
guanosine	O
5	O
'	O
-	O
O	O
-	O
(	O
3	O
-	O
thiotriphosphate	O
)	O
)	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
recombinant	O
non	O
-	O
isoprenylated	O
rhoA	B-PRGE
p21	I-PRGE
(	O
fused	O
to	O
glutathione	B-PRGE
S	I-PRGE
-	I-PRGE
transferase	I-PRGE
)	O
expressed	O
in	O
Escherichia	O
coli	O
failed	O
to	O
activate	O
the	O
PLD	B-PRGE
.	O

This	O
difference	O
cannot	O
be	O
explained	O
by	O
a	O
lower	O
affinity	O
of	O
non	O
-	O
isoprenylated	O
rhoA	B-PRGE
p21	I-PRGE
for	O
GTP	O
gamma	O
S	O
,	O
as	O
the	O
rates	O
of	O
[	O
35S	O
]	O
GTP	O
gamma	O
S	O
binding	O
were	O
very	O
similar	O
for	O
both	O
recombinant	O
preparations	O
and	O
the	O
GTP	O
gamma	O
S	O
-	O
bound	O
form	O
of	O
non	O
-	O
isoprenylated	O
rhoA	B-PRGE
p21	I-PRGE
did	O
not	O
induce	O
PLD	B-PRGE
activation	O
.	O

Interestingly	O
,	O
recombinant	O
isoprenylated	O
rhoA	B-PRGE
p21	I-PRGE
and	O
ARF	O
synergistically	O
activated	O
rat	O
brain	O
PLD	B-PRGE
;	O
a	O
similar	O
pattern	O
was	O
seen	O
with	O
the	O
partially	O
purified	O
PLD	B-PRGE
-	O
activating	O
factor	O
.	O

The	O
synergistic	O
activation	O
was	O
inhibited	O
by	O
C3	B-PRGE
exoenzyme	I-PRGE
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
recombinant	O
isoprenylated	O
rhoA	B-PRGE
p21	I-PRGE
in	O
a	O
NAD	O
-	O
dependent	O
manner	O
.	O

Inhibition	O
correlated	O
with	O
the	O
extent	O
of	O
ADP	O
-	O
ribosylation	O
.	O

These	O
findings	O
suggest	O
that	O
rhoA	B-PRGE
p21	I-PRGE
regulates	O
rat	O
brain	O
PLD	B-PRGE
in	O
concert	O
with	O
ARF	O
,	O
and	O
that	O
isoprenylation	O
of	O
rhoA	B-PRGE
p21	I-PRGE
is	O
essential	O
for	O
PLD	B-PRGE
regulation	O
in	O
vitro	O
.	O

Farnesyltransferase	O
inhibitors	O
block	O
the	O
neurofibromatosis	O
type	O
I	O
(	O
NF1	O
)	O
malignant	O
phenotype	O
.	O

Neurofibromatosis	O
type	O
I	O
(	O
NF1	O
)	O
is	O
a	O
hereditary	O
tumor	O
and	O
developmental	O
disorder	O
whose	O
defective	O
gene	O
was	O
cloned	O
previously	O
.	O

The	O
protein	O
product	O
of	O
the	O
NF1	B-PRGE
gene	O
,	O
neurofibromin	B-PRGE
,	O
contains	O
a	O
domain	O
that	O
shows	O
significant	O
sequence	O
homology	O
to	O
the	O
known	O
catalytic	O
domains	O
of	O
mammalian	O
Ras	O
GTPase	O
-	O
activating	O
proteins	O
(	O
GAP	O
)	O
and	O
the	O
yeast	O
IRA1	B-PRGE
and	O
IRA2	B-PRGE
proteins	O
.	O

This	O
homologous	O
region	O
of	O
neurofibromin	B-PRGE
has	O
been	O
shown	O
to	O
exhibit	O
GAP	O
activity	O
toward	O
Ras	O
proteins	O
.	O

Malignant	O
schwannoma	O
cell	O
lines	O
from	O
NF1	O
patients	O
contain	O
normal	O
levels	O
of	O
GAP	O
and	O
nonmutated	O
Ras	O
proteins	O
but	O
barely	O
detectable	O
levels	O
of	O
neurofibromin	B-PRGE
,	O
based	O
on	O
genetic	O
mutations	O
in	O
the	O
NF1	B-PRGE
gene	O
.	O

Because	O
these	O
cells	O
contain	O
constitutively	O
activated	O
Ras	O
.	O
GTP	O
,	O
it	O
has	O
been	O
proposed	O
that	O
neurofibromin	B-PRGE
may	O
be	O
the	O
sole	O
negative	O
regulator	O
of	O
Ras	O
in	O
these	O
cells	O
.	O

Overall	O
,	O
these	O
results	O
have	O
implied	O
an	O
important	O
role	O
of	O
the	O
Ras	O
signaling	O
pathway	O
in	O
NF1	O
malignant	O
schwannomas	O
.	O

Recently	O
,	O
several	O
laboratories	O
have	O
developed	O
small	O
molecule	O
inhibitors	O
of	O
Ras	O
function	O
that	O
inhibit	O
the	O
enzyme	O
farnesyltransferase	O
(	O
FT	O
)	O
.	O

FT	O
-	O
mediated	O
post	O
-	O
translational	O
farnesylation	O
of	O
Ras	O
proteins	O
is	O
absolutely	O
necessary	O
for	O
Ras	O
function	O
since	O
this	O
modification	O
is	O
required	O
for	O
the	O
anchoring	O
of	O
Ras	O
proteins	O
to	O
the	O
plasma	O
cell	O
membrane	O
.	O

Although	O
previous	O
studies	O
have	O
shown	O
that	O
FT	O
inhibitors	O
can	O
block	O
the	O
growth	O
of	O
tumor	O
cells	O
carrying	O
mutant	O
Ras	O
proteins	O
,	O
it	O
remained	O
unclear	O
how	O
this	O
class	O
of	O
inhibitors	O
would	O
affect	O
tumor	O
cells	O
such	O
as	O
in	O
NF1	O
,	O
whose	O
malignant	O
growth	O
appears	O
to	O
be	O
mediated	O
by	O
up	O
-	O
regulation	O
of	O
wild	O
-	O
type	O
Ras	O
activity	O
.	O

Thus	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
BMS	O
-	O
186511	O
,	O
a	O
bisubstrate	O
analogue	O
inhibitor	O
of	O
FT	O
,	O
would	O
inhibit	O
the	O
malignant	O
growth	O
properties	O
of	O
a	O
cell	O
line	O
established	O
from	O
malignant	O
schwannoma	O
of	O
an	O
NF1	O
patient	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
malignant	O
growth	O
properties	O
of	O
ST88	O
-	O
14	O
cells	O
,	O
the	O
most	O
malignant	O
cell	O
line	O
among	O
several	O
well	O
-	O
characterized	O
NF1	O
cells	O
,	O
are	O
inhibited	O
by	O
BMS	O
-	O
186511	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Following	O
treatment	O
with	O
BMS	O
-	O
186511	O
,	O
ST88	O
-	O
14	O
cells	O
became	O
flat	O
,	O
nonrefractile	O
,	O
were	O
contact	O
-	O
inhibited	O
,	O
and	O
lost	O
their	O
ability	O
to	O
grow	O
in	O
soft	O
agar	O
.	O

In	O
the	O
drug	O
-	O
exposed	O
cells	O
,	O
Ras	O
proteins	O
were	O
prevented	O
from	O
FT	O
-	O
mediated	O
membrane	O
association	O
.	O

BMS	O
-	O
186511	O
was	O
found	O
to	O
specifically	O
inhibit	O
FT	O
,	O
but	O
not	O
geranylgeranyltransferase	O
I	O
,	O
a	O
closely	O
related	O
enzyme	O
.	O

Thus	O
,	O
it	O
is	O
conceivable	O
that	O
FT	O
inhibitors	O
may	O
ultimately	O
become	O
the	O
first	O
generation	O
of	O
drugs	O
against	O
the	O
malignant	O
phenotype	O
in	O
NF1	O
based	O
on	O
rational	O
insights	O
into	O
the	O
mechanism	O
of	O
action	O
of	O
neurofibromin	B-PRGE
.	O

A	O
novel	O
G	O
protein	O
alpha	O
subunit	O
containing	O
atypical	O
guanine	O
nucleotide	O
-	O
binding	O
domains	O
is	O
differentially	O
expressed	O
in	O
a	O
molluscan	O
nervous	O
system	O
.	O

We	O
described	O
the	O
characterization	O
of	O
a	O
novel	O
G	O
protein	O
alpha	O
subunit	O
,	O
G	B-PRGE
alpha	I-PRGE
a	I-PRGE
.	O

cDNA	O
encoding	O
this	O
subunit	O
was	O
cloned	O
from	O
the	O
central	O
nervous	O
system	O
of	O
the	O
mollusc	O
Lymnaea	O
stagnalis	O
.	O

The	O
deduced	O
protein	O
contains	O
all	O
characteristic	O
guanine	O
nucleotide	O
-	O
binding	O
domains	O
of	O
G	O
alpha	O
subunits	O
but	O
shares	O
only	O
a	O
limited	O
degree	O
of	O
overall	O
sequence	O
identity	O
with	O
known	O
subtypes	O
(	O
approximately	O
30	O
%	O
)	O
.	O

Moreover	O
,	O
two	O
of	O
the	O
nucleotide	O
-	O
binding	O
domains	O
exhibit	O
salient	O
deviations	O
from	O
corresponding	O
sequences	O
in	O
other	O
G	O
protein	O
alpha	O
subunits	O
.	O

The	O
A	O
domain	O
,	O
determining	O
kinetic	O
features	O
of	O
the	O
GTPase	O
cycle	O
,	O
contains	O
a	O
markedly	O
unique	O
amino	O
acid	O
sequence	O
(	O
ILIIGGPGAGK	O
)	O
.	O

In	O
addition	O
,	O
the	O
C	O
domain	O
is	O
also	O
clearly	O
distinct	O
(	O
DVAGQRSL	O
)	O
.	O

The	O
presence	O
of	O
a	O
leucine	O
in	O
this	O
motif	O
,	O
instead	O
of	O
glutamic	O
acid	O
,	O
has	O
important	O
implications	O
for	O
hypotheses	O
concerning	O
the	O
GTPase	O
mechanism	O
.	O

In	O
contrast	O
to	O
other	O
G	O
alpha	O
subtypes	O
,	O
G	B-PRGE
alpha	I-PRGE
a	I-PRGE
has	O
no	O
appropriate	O
N	O
-	O
terminal	O
residues	O
that	O
could	O
be	O
acylated	O
.	O

It	O
does	O
contain	O
the	O
strictly	O
conserved	O
arginine	O
residue	O
that	O
serves	O
as	O
a	O
cholera	O
toxin	O
substrate	O
in	O
G	B-PRGE
alpha	I-PRGE
s	I-PRGE
and	O
G	O
alpha	O
t	O
but	O
lacks	O
a	O
site	O
for	O
ADP	O
-	O
ribosylation	O
by	O
pertussis	O
toxin	O
.	O

In	O
situ	O
hybridization	O
experiments	O
indicate	O
that	O
G	B-PRGE
alpha	I-PRGE
a	I-PRGE
-	O
encoding	O
mRNA	O
is	O
expressed	O
in	O
a	O
limited	O
subpopulation	O
of	O
neurons	O
within	O
the	O
Lymnaea	O
brain	O
.	O

These	O
data	O
suggest	O
that	O
G	B-PRGE
alpha	I-PRGE
a	I-PRGE
defines	O
a	O
separate	O
class	O
of	O
G	O
proteins	O
with	O
cell	O
type	O
-	O
specific	O
functions	O
.	O

Semisynthetic	O
chemical	O
modification	O
of	O
the	O
antifungal	O
lipopeptide	O
echinocandin	O
B	O
(	O
ECB	O
)	O
:	O
structure	O
-	O
activity	O
studies	O
of	O
the	O
lipophilic	O
and	O
geometric	O
parameters	O
of	O
polyarylated	O
acyl	O
analogs	O
of	O
ECB	O
.	O

Echinocandin	O
B	O
(	O
ECB	O
)	O
is	O
a	O
lipopeptide	O
composed	O
of	O
a	O
complex	O
cyclic	O
peptide	O
acylated	O
at	O
the	O
N	O
-	O
terminus	O
by	O
linoleic	O
acid	O
.	O

Enzymatic	O
deacylation	O
of	O
ECB	O
provided	O
the	O
peptide	O
"	O
nucleus	O
"	O
as	O
a	O
biologically	O
inactive	O
substrate	O
from	O
which	O
novel	O
ECB	O
analogs	O
were	O
generated	O
by	O
chemical	O
reacylation	O
at	O
the	O
N	O
-	O
terminus	O
.	O

Varying	O
the	O
acyl	O
group	O
revealed	O
that	O
the	O
structure	O
and	O
physical	O
properties	O
of	O
the	O
side	O
chain	O
,	O
particularly	O
its	O
geometry	O
and	O
lipophilicity	O
,	O
played	O
a	O
pivotal	O
role	O
in	O
determining	O
the	O
antifungal	O
potency	O
properties	O
of	O
the	O
analog	O
.	O

Using	O
CLOGP	O
values	O
to	O
describe	O
and	O
compare	O
the	O
lipophilicities	O
of	O
the	O
side	O
chain	O
fragments	O
,	O
it	O
was	O
shown	O
that	O
values	O
of	O
>	O
3	O
.	O
5	O
were	O
required	O
for	O
expression	O
of	O
antifungal	O
activity	O
.	O

Secondly	O
,	O
a	O
linearly	O
rigid	O
geometry	O
of	O
the	O
side	O
chain	O
was	O
the	O
most	O
effective	O
shape	O
in	O
enhancing	O
the	O
antifungal	O
potency	O
.	O

Using	O
these	O
parameters	O
as	O
a	O
guide	O
,	O
a	O
variety	O
of	O
novel	O
ECB	O
analogs	O
were	O
synthesized	O
which	O
included	O
arylacyl	O
groups	O
that	O
incorporated	O
biphenyl	O
,	O
terphenyl	O
,	O
tetraphenyl	O
,	O
and	O
arylethynyl	O
groups	O
.	O

Generally	O
the	O
glucan	O
synthase	O
inhibition	O
by	O
these	O
analogs	O
correlated	O
well	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
activities	O
and	O
was	O
likewise	O
influenced	O
by	O
the	O
structure	O
of	O
the	O
side	O
chain	O
.	O

These	O
structural	O
variations	O
resulted	O
in	O
enhancement	O
of	O
antifungal	O
activity	O
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	O
.	O

Some	O
of	O
these	O
analogs	O
,	O
including	O
LY303366	O
(	O
14a	O
)	O
,	O
were	O
effective	O
by	O
the	O
oral	O
route	O
of	O
administration	O
.	O

Fatty	O
acylation	O
of	O
the	O
rat	O
asialoglycoprotein	O
receptor	O
.	O

The	O
three	O
subunits	O
from	O
active	O
receptors	O
contain	O
covalently	O
bound	O
palmitate	O
and	O
stearate	O
.	O

Rat	O
hepatic	O
asialoglycoprotein	O
receptors	O
(	O
ASGP	O
-	O
Rs	O
)	O
are	O
hetero	O
-	O
oligomers	O
composed	O
of	O
three	O
homologous	O
glycoprotein	O
subunits	O
,	O
designated	O
rat	O
hepatic	B-PRGE
lectins	I-PRGE
(	I-PRGE
RHL	I-PRGE
)	I-PRGE
1	I-PRGE
,	O
2	B-PRGE
,	O
and	O
3	B-PRGE
.	O

ASGP	O
-	O
Rs	O
mediate	O
the	O
endocytosis	O
and	O
degradation	O
of	O
circulating	O
glycoconjugates	O
containing	O
terminal	O
N	O
-	O
acetylgalactosamine	O
or	O
galactose	O
,	O
including	O
desialylated	O
plasma	O
glycoproteins	O
.	O

We	O
have	O
shown	O
in	O
permeable	O
rat	O
hepatocytes	O
that	O
the	O
ligand	O
binding	O
activity	O
of	O
one	O
subpopulation	O
of	O
receptors	O
(	O
designated	O
State	O
2	O
ASGP	O
-	O
Rs	O
)	O
can	O
be	O
decreased	O
or	O
increased	O
,	O
respectively	O
,	O
by	O
ATP	O
and	O
palmitoyl	O
-	O
CoA	O
(	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
,	O
and	O
Oka	O
,	O
J	O
.	O
A	O
.	O
(	O
1993	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
268	O
,	O
27186	O
-	O
27190	O
)	O
.	O

We	O
proposed	O
that	O
a	O
reversible	O
and	O
cyclic	O
acylation	O
/	O
deacylation	O
process	O
may	O
regulate	O
ASGP	O
-	O
R	O
activity	O
during	O
endocytosis	O
,	O
receptor	O
-	O
ligand	O
dissociation	O
,	O
and	O
receptor	O
recycling	O
.	O

In	O
the	O
accompanying	O
paper	O
(	O
Zeng	O
,	O
F	O
-	O
Y	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1995	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
21388	O
-	O
21395	O
)	O
,	O
we	O
show	O
that	O
the	O
ligand	O
binding	O
activity	O
of	O
affinity	O
-	O
purified	O
State	O
2	O
ASGP	O
-	O
Rs	O
is	O
decreased	O
by	O
treatment	O
with	O
hydroxylamine	O
under	O
mild	O
conditions	O
consistent	O
with	O
these	O
ASGP	O
-	O
Rs	O
being	O
fatty	O
acylated	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
chemical	O
method	O
to	O
determine	O
the	O
presence	O
of	O
covalently	O
-	O
bound	O
fatty	O
acids	O
in	O
individual	O
ASGP	O
-	O
R	O
subunits	O
.	O

The	O
affinity	O
-	O
purified	O
ASGP	O
-	O
R	O
preparations	O
were	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
under	O
nonreducing	O
conditions	O
,	O
and	O
the	O
gel	O
slices	O
containing	O
individual	O
RHL	O
subunits	O
were	O
treated	O
with	O
alkali	O
to	O
release	O
covalently	O
bound	O
fatty	O
acids	O
,	O
which	O
were	O
subsequently	O
analyzed	O
by	O
gas	O
chromatography	O
and	O
confirmed	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Both	O
stearic	O
and	O
palmitic	O
acids	O
were	O
detected	O
in	O
all	O
three	O
receptor	O
subunits	O
.	O

Pretreatment	O
of	O
ASGP	O
-	O
Rs	O
with	O
hydroxylamine	O
before	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
reduced	O
the	O
content	O
of	O
both	O
fatty	O
acids	O
by	O
66	O
-	O
80	O
%	O
,	O
indicating	O
that	O
most	O
of	O
these	O
fatty	O
acids	O
are	O
attached	O
to	O
cysteine	O
residues	O
via	O
thioester	O
linkages	O
.	O

Furthermore	O
,	O
when	O
freshly	O
isolated	O
hepatocytes	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
[	O
3H	O
]	O
palmitate	O
,	O
all	O
three	O
RHL	O
subunits	O
in	O
affinity	O
-	O
purified	O
ASGP	O
-	O
Rs	O
were	O
metabolically	O
labeled	O
.	O

We	O
conclude	O
that	O
RHL1	B-PRGE
,	O
RHL2	B-PRGE
,	O
and	O
RHL3	B-PRGE
are	O
modified	O
by	O
fatty	O
acylation	O
in	O
intact	O
cells	O
.	O

Terminal	O
marking	O
of	O
avian	O
triosephosphate	O
isomerases	O
by	O
deamidation	O
and	O
oxidation	O
.	O

Triosephosphate	B-PRGE
isomerase	I-PRGE
(	O
TPI	B-PRGE
)	O
provides	O
an	O
excellent	O
model	O
for	O
terminal	O
marking	O
and	O
protein	O
degradation	O
.	O

Mammalian	O
TPI	B-PRGE
is	O
terminally	O
modified	O
by	O
deamidation	O
at	O
Asn71	O
-	O
Gly	O
,	O
resulting	O
in	O
unfolding	O
,	O
dissociation	O
,	O
and	O
proteolysis	O
.	O

In	O
contrast	O
,	O
chicken	O
TPI	B-PRGE
,	O
which	O
contains	O
a	O
lysine	O
at	O
position	O
71	O
,	O
is	O
terminally	O
modified	O
by	O
the	O
oxidation	O
of	O
Cys126	O
.	O

Thus	O
,	O
both	O
deamidation	O
and	O
oxidation	O
initiate	O
degradation	O
of	O
TPI	B-PRGE
from	O
different	O
species	O
.	O

To	O
explore	O
the	O
terminal	O
marking	O
in	O
other	O
avians	O
,	O
we	O
have	O
purified	O
the	O
turkey	O
TPI	B-PRGE
to	O
homogeneity	O
and	O
determined	O
its	O
characteristics	O
.	O

Although	O
the	O
molecular	O
properties	O
of	O
the	O
turkey	O
and	O
chicken	O
TPI	B-PRGE
were	O
very	O
similar	O
,	O
their	O
tolerances	O
to	O
temperature	O
,	O
oxidants	O
,	O
and	O
alkaline	O
pH	O
were	O
very	O
different	O
.	O

For	O
example	O
,	O
chicken	O
TPI	B-PRGE
was	O
inactivated	O
80	O
%	O
in	O
either	O
10	O
mM	O
oxidized	O
glutathione	O
or	O
H2O2	O
,	O
whereas	O
120	O
mM	O
GSSG	O
had	O
no	O
effect	O
on	O
turkey	O
TPI	B-PRGE
,	O
and	O
>	O
120	O
mM	O
H2O2	O
was	O
needed	O
for	O
80	O
%	O
inactivation	O
.	O

Under	O
alkaline	O
conditions	O
that	O
cause	O
rapid	O
deamidation	O
of	O
the	O
mammalian	O
TPI	B-PRGE
,	O
neither	O
avian	O
enzyme	O
deamidated	O
.	O

Chicken	O
TPI	B-PRGE
,	O
however	O
,	O
aggregated	O
.	O

Aggregation	O
was	O
reversed	O
by	O
2	O
-	O
mercaptoethanol	O
.	O

Under	O
prolonged	O
exposure	O
to	O
milder	O
conditions	O
the	O
turkey	O
enzyme	O
was	O
completely	O
inactivated	O
and	O
deamidated	O
at	O
Asn15	O
-	O
Gly	O
.	O

Thus	O
,	O
there	O
are	O
marked	O
differences	O
in	O
the	O
susceptibility	O
of	O
these	O
two	O
avian	O
enzymes	O
to	O
oxidation	O
and	O
deamidation	O
,	O
and	O
their	O
terminal	O
marking	O
mechanisms	O
appear	O
to	O
be	O
different	O
.	O

Effects	O
of	O
lovastatin	O
on	O
adenylyl	O
cyclase	O
activity	O
and	O
G	O
proteins	O
in	O
GH4C1	O
cells	O
.	O

We	O
studied	O
the	O
effect	O
of	O
lovastatin	O
,	O
a	O
cholesterol	O
lowering	O
drug	O
,	O
on	O
the	O
basal	O
state	O
of	O
G	O
-	O
proteins	O
in	O
GH4C1	O
cells	O
.	O

Our	O
data	O
show	O
that	O
the	O
addition	O
of	O
lovastatin	O
markedly	O
decreased	O
the	O
amount	O
of	O
the	O
alpha	O
-	O
subunits	O
of	O
the	O
Gs	O
and	O
Gi	O
-	O
proteins	O
in	O
the	O
plasma	O
membrane	O
.	O

The	O
decrease	O
of	O
alpha	O
s	O
was	O
correlated	O
with	O
a	O
decrease	O
in	O
adenylyl	O
cyclase	O
activity	O
,	O
and	O
both	O
effects	O
were	O
reverted	O
by	O
the	O
presence	O
of	O
mevalonate	O
.	O

As	O
the	O
attachment	O
of	O
G	O
protein	O
subunits	O
to	O
the	O
membrane	O
is	O
dependent	O
on	O
gamma	O
-	O
subunit	O
prenylation	O
,	O
we	O
assume	O
that	O
the	O
mechanism	O
through	O
which	O
lovastatin	O
exerts	O
its	O
effects	O
on	O
G	O
-	O
proteins	O
is	O
the	O
lack	O
of	O
mevalonate	O
for	O
the	O
synthesis	O
of	O
prenyl	O
residues	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
some	O
of	O
the	O
effects	O
of	O
lovastatin	O
are	O
mediated	O
through	O
changes	O
in	O
the	O
basal	O
state	O
of	O
G	O
-	O
protein	O
in	O
the	O
membrane	O
and	O
consequently	O
on	O
adenylyl	O
cyclase	O
activity	O
.	O

The	O
neuroendocrine	O
precursor	O
7B2	B-PRGE
is	O
a	O
sulfated	O
protein	O
proteolytically	O
processed	O
by	O
a	O
ubiquitous	O
furin	B-PRGE
-	O
like	O
convertase	O
.	O

The	O
neuroendocrine	O
granule	O
-	O
associated	O
protein	O
7B2	B-PRGE
,	O
unlike	O
many	O
other	O
neuroendocrine	O
precursor	O
proteins	O
stored	O
in	O
secretory	O
granules	O
,	O
carries	O
in	O
its	O
primary	O
structure	O
the	O
Arg	O
-	O
Xaa	O
-	O
Arg	O
/	O
Lys	O
-	O
Arg	O
processing	O
site	O
usually	O
found	O
in	O
constitutively	O
secreted	O
precursor	O
proteins	O
and	O
recognized	O
by	O
the	O
ubiquitously	O
expressed	O
convertase	O
,	O
furin	B-PRGE
.	O

pro7B2	B-PRGE
(	O
30	O
kDa	O
)	O
,	O
when	O
expressed	O
in	O
endocrine	O
(	O
AtT	O
-	O
20	O
,	O
PC12	O
,	O
and	O
GH4C1	O
)	O
or	O
non	O
-	O
endocrine	O
(	O
Ltk	O
-	O
)	O
cell	O
lines	O
using	O
recombinant	O
vaccinia	O
viruses	O
,	O
was	O
converted	O
to	O
a	O
23	O
-	O
kDa	O
form	O
.	O

Mutation	O
of	O
the	O
P4	O
Arg	O
to	O
Gly	O
completely	O
prevented	O
this	O
conversion	O
.	O

When	O
excess	O
pro7B2	B-PRGE
was	O
coexpressed	O
with	O
the	O
pro	O
-	O
protein	O
convertases	O
PC1	B-PRGE
,	O
PC2	B-PRGE
,	O
or	O
furin	B-PRGE
,	O
only	O
furin	B-PRGE
could	O
induce	O
complete	O
processing	O
.	O

In	O
addition	O
,	O
coexpression	O
of	O
pro7B2	B-PRGE
in	O
LoVo	O
cells	O
,	O
which	O
are	O
devoid	O
of	O
endogenous	O
furin	B-PRGE
activity	O
,	O
with	O
each	O
one	O
of	O
the	O
three	O
convertases	O
,	O
showed	O
that	O
only	O
furin	B-PRGE
was	O
able	O
to	O
induce	O
processing	O
of	O
this	O
precursor	O
.	O

pro7B2	B-PRGE
processing	O
in	O
AtT	O
-	O
20	O
was	O
completely	O
abolished	O
when	O
protein	O
transport	O
into	O
Golgi	O
compartments	O
was	O
blocked	O
by	O
cell	O
incubation	O
at	O
either	O
15	O
or	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
monensin	O
or	O
brefeldin	O
A	O
.	O

Furthermore	O
,	O
pulse	O
-	O
chase	O
experiments	O
in	O
the	O
presence	O
of	O
Na2	O
[	O
35S	O
]	O
SO4	O
showed	O
that	O
pro7B2	B-PRGE
is	O
Tyr	O
-	O
sulfated	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
before	O
it	O
is	O
processed	O
.	O

These	O
results	O
demonstrate	O
that	O
pro7B2	B-PRGE
is	O
first	O
processed	O
by	O
a	O
furin	B-PRGE
-	O
like	O
enzyme	O
within	O
the	O
trans	O
-	O
Golgi	O
network	O
into	O
a	O
23	O
-	O
kDa	O
form	O
that	O
is	O
then	O
sequestered	O
into	O
secretory	O
granules	O
.	O

Molecular	O
cloning	O
of	O
ras	O
and	O
rap	O
genes	O
from	O
Entamoeba	O
histolytica	O
.	O

To	O
better	O
understand	O
growth	O
regulation	O
in	O
the	O
protozoan	O
parasite	O
Entamoeba	O
histolytica	O
,	O
ameba	O
genes	O
homologous	O
to	O
the	O
ras	O
oncogene	O
and	O
rap	O
(	O
Krev	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
anti	O
-	O
oncogene	O
were	O
cloned	O
.	O

Two	O
putative	O
ameba	O
ras	O
genes	O
(	O
Ehras1	B-PRGE
and	O
Ehras2	B-PRGE
)	O
were	O
identified	O
,	O
which	O
contain	O
205	O
and	O
203	O
amino	O
acid	O
(	O
aa	O
)	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
respectively	O
.	O

The	O
Ehras1	B-PRGE
ORF	O
shows	O
an	O
91	O
%	O
positional	O
identity	O
with	O
that	O
of	O
Ehras2	B-PRGE
,	O
a	O
55	O
%	O
identity	O
with	O
Dictyostelium	O
discoideum	O
(	O
Dd	O
)	O
ras	B-PRGE
,	O
and	O
a	O
47	O
%	O
identity	O
with	O
human	O
(	O
Hs	O
)	O
ras	O
.	O

Two	O
ameba	O
rap	O
genes	O
(	O
Ehrap1	B-PRGE
and	O
Ehrap2	B-PRGE
)	O
were	O
identified	O
,	O
both	O
of	O
which	O
contain	O
184	O
-	O
aa	O
ORFs	O
.	O

The	O
Ehrap1	B-PRGE
ORF	O
shows	O
a	O
93	O
%	O
positional	O
identity	O
with	O
that	O
of	O
Ehrap2	B-PRGE
,	O
a	O
60	O
%	O
identity	O
with	O
Dd	O
rap	B-PRGE
,	O
a	O
61	O
%	O
identity	O
with	O
Hs	O
Krev	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
a	O
45	O
%	O
identity	O
with	O
that	O
of	O
Ehras1	B-PRGE
.	O

Conserved	O
aa	O
in	O
each	O
ameba	O
ras	O
and	O
rap	O
ORF	O
include	O
GTP	O
-	O
binding	O
sites	O
,	O
effector	O
site	O
,	O
site	O
of	O
ADP	O
-	O
ribosylation	O
by	O
Pseudomonas	O
exoenzyme	O
S	O
,	O
and	O
COOH	O
-	O
terminus	O
CAAX	O
.	O

As	O
all	O
Xs	O
=	O
Leu	O
or	O
Phe	O
,	O
ameba	O
ras	O
and	O
rap	O
proteins	O
may	O
be	O
gerenylgerenylated	O
and	O
not	O
farnesylated	O
.	O

Both	O
ras	O
and	O
rap	O
genes	O
are	O
transcribed	O
by	O
trophozoites	O
.	O

A	O
single	O
21	O
-	O
kDa	O
ameba	O
ras	O
protein	O
reacts	O
with	O
the	O
rat	O
Y13	O
-	O
259	O
anti	O
-	O
ras	O
monoclonal	O
antibody	O
,	O
which	O
is	O
located	O
on	O
the	O
cytosolic	O
side	O
of	O
the	O
plasma	O
membrane	O
.	O

These	O
are	O
the	O
first	O
ras	O
and	O
rap	O
genes	O
identified	O
from	O
a	O
protozoan	O
parasite	O
.	O

Isoprenylation	O
of	O
large	B-PRGE
hepatitis	I-PRGE
delta	I-PRGE
antigen	I-PRGE
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
hepatitis	O
delta	O
virus	O
assembly	O
.	O

Hepatitis	O
delta	O
virus	O
(	O
HDV	O
)	O
encodes	O
two	O
proteins	O
,	O
the	O
small	B-PRGE
hepatitis	I-PRGE
delta	I-PRGE
antigen	I-PRGE
(	O
SHDAg	B-PRGE
)	O
and	O
large	B-PRGE
hepatitis	I-PRGE
delta	I-PRGE
antigen	I-PRGE
(	O
LHDAg	B-PRGE
)	O
.	O

Both	O
proteins	O
are	O
identical	O
except	O
for	O
the	O
presence	O
of	O
additional	O
19	O
amino	O
acids	O
at	O
the	O
C	O
terminus	O
of	O
LHDAg	B-PRGE
.	O

While	O
SHDAg	B-PRGE
is	O
required	O
for	O
HDV	O
RNA	O
replication	O
,	O
LHDAg	B-PRGE
inhibits	O
replication	O
and	O
is	O
required	O
together	O
with	O
hepatitis	O
B	O
surface	O
antigen	O
for	O
the	O
assembly	O
of	O
HDV	O
.	O

The	O
C	O
-	O
terminal	O
last	O
4	O
amino	O
acids	O
of	O
LHDAg	B-PRGE
(	O
Cys	O
-	O
Arg	O
-	O
Pro	O
-	O
Gln	O
)	O
is	O
an	O
isoprenylation	O
motif	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
mutation	O
of	O
the	O
Cys	O
inhibited	O
the	O
assembly	O
of	O
HDV	O
.	O

In	O
order	O
to	O
discern	O
whether	O
this	O
effect	O
is	O
due	O
to	O
change	O
of	O
amino	O
acid	O
residue	O
or	O
abolition	O
of	O
isoprenylation	O
,	O
we	O
constructed	O
several	O
LHDAg	B-PRGE
mutants	O
of	O
the	O
terminal	O
three	O
amino	O
acid	O
residues	O
and	O
tested	O
their	O
abilities	O
to	O
be	O
packaged	O
with	O
HBsAg	B-PRGE
by	O
cotransfection	O
experiments	O
.	O

We	O
also	O
made	O
GST	O
-	O
fusion	O
proteins	O
of	O
these	O
mutants	O
and	O
tested	O
their	O
abilities	O
to	O
be	O
isoprenylated	O
in	O
rabbit	O
reticulocyte	O
lysate	O
system	O
.	O

We	O
found	O
that	O
some	O
,	O
but	O
not	O
all	O
,	O
of	O
the	O
substitutions	O
of	O
the	O
amino	O
acid	O
residues	O
other	O
than	O
the	O
Cys	O
also	O
inhibited	O
isoprenylation	O
and	O
that	O
the	O
status	O
of	O
isoprenylation	O
of	O
these	O
mutant	O
proteins	O
correlated	O
well	O
with	O
their	O
abilities	O
to	O
be	O
packaged	O
with	O
HBsAg	B-PRGE
into	O
virions	O
.	O

This	O
result	O
indicates	O
that	O
isoprenylation	O
,	O
rather	O
than	O
the	O
primary	O
amino	O
acid	O
sequence	O
,	O
is	O
required	O
for	O
LHDAg	B-PRGE
packaging	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
attachment	O
of	O
an	O
isoprenylation	O
motif	O
to	O
SHDAg	B-PRGE
did	O
not	O
enable	O
it	O
to	O
be	O
packaged	O
with	O
HBsAg	B-PRGE
and	O
that	O
the	O
deletions	O
of	O
any	O
5	O
amino	O
acids	O
in	O
the	O
last	O
15	O
amino	O
acids	O
(	O
amino	O
acids	O
196	O
to	O
210	O
)	O
unique	O
to	O
the	O
LHDAg	B-PRGE
abolished	O
the	O
packaging	O
ability	O
.	O

In	O
contrast	O
,	O
the	O
deletion	O
of	O
33	O
amino	O
acids	O
(	O
amino	O
acids	O
163	O
to	O
195	O
)	O
upstream	O
of	O
the	O
last	O
C	O
-	O
terminal	O
19	O
amino	O
acids	O
of	O
LHDAg	B-PRGE
did	O
not	O
interfere	O
with	O
its	O
packaging	O
ability	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
15	O
amino	O
acids	O
upstream	O
of	O
the	O
isoprenylation	O
site	O
of	O
LHDAg	B-PRGE
are	O
also	O
essential	O
for	O
HDV	O
assembly	O
,	O
and	O
a	O
large	O
portion	O
of	O
the	O
alleged	O
C	O
-	O
terminal	O
Pro	O
/	O
Gly	O
-	O
rich	O
region	O
(	O
amino	O
acids	O
146	O
to	O
195	O
)	O
is	O
not	O
required	O
for	O
the	O
assembly	O
process	O
.	O

Involvement	O
of	O
lysine	O
residues	O
of	O
goat	O
serum	B-PRGE
albumin	I-PRGE
in	O
high	O
-	O
affinity	O
binding	O
of	O
bilirubin	O
.	O

Four	O
maleylated	O
derivatives	O
of	O
goat	O
serum	B-PRGE
albumin	I-PRGE
having	O
percent	O
modification	O
as	O
40	O
%	O
,	O
46	O
%	O
,	O
84	O
%	O
and	O
98	O
%	O
were	O
prepared	O
using	O
varying	O
molar	O
ratio	O
of	O
maleic	O
anhydride	O
over	O
protein	O
.	O

These	O
preparations	O
were	O
found	O
to	O
be	O
pure	O
,	O
both	O
with	O
respect	O
to	O
size	O
and	O
charged	O
as	O
judged	O
by	O
gel	O
filtration	O
and	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Maleylation	O
caused	O
significant	O
change	O
in	O
protein	O
conformation	O
as	O
revealed	O
by	O
the	O
change	O
in	O
Stokes	O
radius	O
and	O
frictional	O
ratio	O
of	O
serum	B-PRGE
albumin	I-PRGE
,	O
from	O
3	O
.	O
46	O
nm	O
and	O
1	O
.	O
28	O
to	O
4	O
.	O
96	O
nm	O
and	O
1	O
.	O
79	O
,	O
respectively	O
,	O
upon	O
98	O
%	O
modification	O
.	O

Immunodiffusion	O
results	O
of	O
native	O
and	O
modified	O
albumins	B-PRGE
with	O
anti	O
-	O
goat	O
serum	B-PRGE
albumin	I-PRGE
antiserum	O
also	O
suggested	O
significant	O
conformational	O
changes	O
in	O
serum	B-PRGE
albumin	I-PRGE
upon	O
maleylation	O
.	O

About	O
88	O
%	O
reduction	O
in	O
bilirubin	O
binding	O
was	O
observed	O
after	O
modification	O
of	O
98	O
%	O
amino	O
groups	O
of	O
serum	B-PRGE
albumin	I-PRGE
as	O
studied	O
by	O
visible	O
difference	O
spectroscopy	O
at	O
pH	O
8	O
.	O
0	O
,	O
and	O
at	O
0	O
.	O
15	O
ionic	O
strength	O
.	O

Increase	O
in	O
ionic	O
strength	O
to	O
1	O
.	O
0	O
did	O
not	O
lead	O
to	O
any	O
significant	O
reversal	O
in	O
bilirubin	O
binding	O
.	O

These	O
results	O
prove	O
the	O
involvement	O
of	O
lysine	O
residues	O
in	O
bilirubin	O
-	O
albumin	B-PRGE
interaction	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
Schizosaccharomyces	O
pombe	O
YPT5	O
protein	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
analysis	O
of	O
processing	O
mutants	O
.	O

SpYPT5p	B-PRGE
is	O
a	O
member	O
of	O
the	O
rab	O
/	O
YPT	O
small	O
GTP	O
-	O
binding	O
protein	O
family	O
,	O
which	O
is	O
believed	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
intracellular	O
trafficking	O
.	O

The	O
protein	O
sequence	O
terminates	O
with	O
a	O
CXC	O
motif	O
,	O
and	O
in	O
our	O
previous	O
report	O
(	O
Newman	O
,	O
C	O
.	O
M	O
.	O
H	O
.	O
,	O
Giannakouros	O
,	O
T	O
.	O
,	O
Hancock	O
,	O
J	O
.	O
F	O
.	O
,	O
Fawell	O
,	O
E	O
.	O
H	O
.	O
,	O
Armstrong	O
,	O
J	O
.	O
,	O
and	O
Magee	O
,	O
A	O
.	O
I	O
.	O
(	O
1992	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
267	O
,	O
11329	O
-	O
11336	O
)	O
we	O
have	O
shown	O
that	O
SpYPT5p	B-PRGE
is	O
prenylated	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
where	O
geranylgeranylation	O
was	O
confirmed	O
,	O
and	O
carboxyl	O
-	O
methylated	O
.	O

In	O
order	O
to	O
dissect	O
the	O
role	O
of	O
prenylation	O
of	O
each	O
cysteine	O
,	O
we	O
have	O
generated	O
C	O
-	O
terminal	O
mutants	O
where	O
either	O
one	O
or	O
both	O
cysteine	O
(	O
s	O
)	O
were	O
replaced	O
by	O
serine	O
and	O
expressed	O
them	O
in	O
vitro	O
in	O
reticulocyte	O
lysates	O
and	O
in	O
vivo	O
in	O
transfected	O
COS	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
both	O
cysteines	O
of	O
the	O
CXC	O
motif	O
are	O
prenylated	O
but	O
that	O
the	O
rate	O
of	O
prenylation	O
of	O
the	O
two	O
cysteines	O
is	O
different	O
.	O

The	O
upstream	O
cysteine	O
was	O
found	O
to	O
be	O
preferentially	O
prenylated	O
in	O
reticulocyte	O
lysates	O
unless	O
cytosol	O
from	O
COS	O
cells	O
was	O
added	O
.	O

A	O
separate	O
activity	O
could	O
therefore	O
be	O
required	O
for	O
prenylation	O
of	O
the	O
second	O
cysteine	O
,	O
or	O
the	O
presence	O
of	O
an	O
additional	O
factor	O
is	O
needed	O
to	O
allow	O
accumulation	O
of	O
doubly	O
prenylated	O
SpYPT5p	B-PRGE
.	O

However	O
,	O
the	O
modification	O
of	O
the	O
upstream	O
cysteine	O
is	O
not	O
a	O
prerequisite	O
for	O
the	O
prenylation	O
of	O
the	O
other	O
.	O

Furthermore	O
,	O
gene	O
replacement	O
in	O
Schizosaccharomyces	O
pombe	O
revealed	O
that	O
each	O
cysteine	O
of	O
the	O
CXC	O
motif	O
can	O
individually	O
support	O
function	O
.	O

Carboxyl	O
methylation	O
occurred	O
only	O
on	O
protein	O
which	O
had	O
been	O
prenylated	O
on	O
the	O
C	O
-	O
terminal	O
cysteine	O
and	O
was	O
required	O
for	O
efficient	O
membrane	O
binding	O
in	O
vitro	O
.	O

Bet2p	B-PRGE
and	O
Mad2p	B-PRGE
are	O
components	O
of	O
a	O
prenyltransferase	O
that	O
adds	O
geranylgeranyl	O
onto	O
Ypt1p	B-PRGE
and	O
Sec4p	B-PRGE
.	O

Three	O
different	O
prenyltransferases	O
have	O
been	O
identified	O
in	O
yeast	O
and	O
higher	O
cells	O
,	O
the	O
farnesyltransferase	O
and	O
the	O
type	O
I	O
and	O
type	O
II	O
geranylgeranyltransferases	O
(	O
GGTase	O
)	O
.	O

The	O
farnesyltransferase	O
and	O
GGTase	O
-	O
I	O
modify	O
peptides	O
in	O
vitro	O
with	O
the	O
CAAX	O
(	O
C	O
,	O
Cys	O
;	O
A	O
,	O
aliphatic	O
residue	O
;	O
X	O
,	O
terminal	O
amino	O
acid	O
)	O
consensus	O
motif	O
.	O

These	O
enzymes	O
are	O
heterodimers	O
that	O
have	O
different	O
beta	O
-	O
subunits	O
and	O
a	O
shared	O
alpha	O
-	O
subunit	O
.	O

In	O
yeast	O
,	O
the	O
RAM2	B-PRGE
gene	O
encodes	O
this	O
alpha	O
-	O
subunit	O
.	O

RAM2	B-PRGE
is	O
also	O
homologous	O
to	O
MAD2	B-PRGE
,	O
a	O
yeast	O
gene	O
whose	O
product	O
has	O
been	O
implicated	O
in	O
the	O
feedback	O
control	O
of	O
mitosis	O
.	O

We	O
have	O
shown	O
that	O
Bet2p	B-PRGE
is	O
a	O
component	O
of	O
the	O
yeast	O
GGTase	O
-	O
II	O
(	O
refs	O
6	O
,	O
12	O
)	O
that	O
geranylgeranylates	O
Ypt1p	B-PRGE
,	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
that	O
mediates	O
transport	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
complex	O
.	O

Here	O
we	O
report	O
that	O
Mad2p	B-PRGE
is	O
a	O
component	O
of	O
this	O
enzyme	O
.	O

Bet2p	B-PRGE
forms	O
a	O
complex	O
with	O
Mad2p	B-PRGE
that	O
appears	O
to	O
bind	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
farnesyl	O
pyrophosphate	O
.	O

The	O
efficient	O
transfer	O
of	O
geranylgeranyl	O
onto	O
small	O
GTP	O
-	O
binding	O
proteins	O
requires	O
the	O
presence	O
of	O
an	O
additional	O
activity	O
.	O

Vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
carboxylase	I-PRGE
activity	O
,	O
prothrombin	B-PRGE
mRNA	O
,	O
and	O
prothrombin	B-PRGE
production	O
in	O
two	O
cultured	O
rat	O
hepatoma	O
cell	O
lines	O
.	O

The	O
presence	O
of	O
under	O
-	O
gamma	O
-	O
carboxylated	O
forms	O
of	O
plasma	O
prothrombin	B-PRGE
is	O
a	O
marker	O
for	O
human	O
primary	O
hepatocellular	O
carcinoma	O
.	O

A	O
rat	O
hepatoma	O
cell	O
line	O
(	O
7777	O
)	O
which	O
was	O
previously	O
shown	O
to	O
secrete	O
undercarboxylated	O
prothrombin	B-PRGE
when	O
grown	O
as	O
a	O
solid	O
tumor	O
has	O
now	O
been	O
grown	O
in	O
monolayer	O
culture	O
.	O

This	O
cell	O
line	O
has	O
a	O
decreased	O
activity	O
of	O
the	O
microsomal	O
vitamin	B-PRGE
K	I-PRGE
-	I-PRGE
dependent	I-PRGE
carboxylase	I-PRGE
when	O
compared	O
to	O
a	O
control	O
(	O
H4IIEC3	O
)	O
hepatoma	O
line	O
,	O
does	O
not	O
increase	O
intracellular	O
prothrombin	B-PRGE
concentrations	O
in	O
response	O
to	O
vitamin	O
K	O
depletion	O
,	O
and	O
secretes	O
undercarboxylated	O
prothrombin	B-PRGE
even	O
when	O
grown	O
in	O
vitamin	O
K	O
supplemented	O
media	O
.	O

Prothrombin	B-PRGE
gene	O
expression	O
in	O
the	O
7777	O
cell	O
line	O
,	O
as	O
measured	O
by	O
prothrombin	B-PRGE
mRNA	O
levels	O
,	O
was	O
not	O
altered	O
in	O
the	O
7777	O
cell	O
line	O
.	O

This	O
cell	O
line	O
appears	O
to	O
be	O
a	O
model	O
for	O
assessing	O
the	O
cellular	O
alterations	O
responsible	O
for	O
undercarboxylated	O
prothrombin	B-PRGE
excretion	O
by	O
human	O
hepatocellular	O
tumors	O
.	O

A	O
novel	O
N	O
-	O
terminal	O
motif	O
for	O
palmitoylation	O
of	O
G	O
-	O
protein	O
alpha	O
subunits	O
.	O

We	O
have	O
examined	O
the	O
post	O
-	O
translational	O
processing	O
of	O
G	O
alpha	O
subunits	O
expressed	O
endogenously	O
in	O
rat	O
PC12	O
and	O
NG108	O
-	O
15	O
rat	O
/	O
mouse	O
hybrid	O
cells	O
,	O
and	O
after	O
transfection	O
of	O
cDNA	O
expression	O
constructs	O
into	O
COS	O
cells	O
.	O

Thioester	O
-	O
linked	O
palmitoylation	O
of	O
alpha	B-PRGE
o	I-PRGE
,	O
alpha	B-PRGE
s	I-PRGE
,	O
alpha	B-PRGE
q	I-PRGE
/	O
alpha	B-PRGE
11	I-PRGE
and	O
alpha	B-PRGE
12	I-PRGE
has	O
been	O
detected	O
by	O
metabolic	O
labelling	O
with	O
[	O
3H	O
]	O
palmitate	O
and	O
immunoprecipitation	O
.	O

Palmitoylation	O
of	O
alpha	B-PRGE
o	I-PRGE
occurs	O
post	O
-	O
translationally	O
in	O
cells	O
treated	O
with	O
protein	O
-	O
synthesis	O
inhibitors	O
,	O
suggesting	O
possible	O
dynamic	O
acylation	O
.	O

Palmitoylation	O
of	O
the	O
C	O
-	O
terminal	O
CAAX	O
motif	O
has	O
been	O
excluded	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
alpha	B-PRGE
o	I-PRGE
has	O
been	O
used	O
to	O
implicate	O
the	O
site	O
of	O
modification	O
as	O
a	O
cysteine	O
residue	O
next	O
to	O
the	O
N	O
-	O
terminal	O
myristoylated	O
glycine	O
,	O
in	O
a	O
novel	O
protein	O
-	O
lipid	O
modification	O
motif	O
Met	O
-	O
Gly	O
-	O
Cys	O
.	O

The	O
non	O
-	O
palmitoylated	O
alpha	B-PRGE
o	I-PRGE
mutant	O
is	O
still	O
myristoylated	O
but	O
shows	O
reduced	O
membrane	O
binding	O
,	O
suggesting	O
that	O
reversible	O
palmitoylation	O
may	O
regulate	O
G	O
alpha	O
localization	O
and	O
function	O
.	O

cDNA	O
cloning	O
of	O
component	O
A	O
of	O
Rab	O
geranylgeranyl	O
transferase	O
and	O
demonstration	O
of	O
its	O
role	O
as	O
a	O
Rab	O
escort	O
protein	O
.	O

cDNA	O
cloning	O
of	O
component	O
A	O
of	O
rat	O
Rab	O
geranylgeranyl	O
transferase	O
confirms	O
identity	O
of	O
the	O
protein	O
with	O
the	O
human	O
choroideremia	B-PRGE
gene	O
product	O
and	O
its	O
resemblance	O
to	O
Rab3A	B-PRGE
guanine	I-PRGE
nucleotide	I-PRGE
dissociation	I-PRGE
inhibitor	I-PRGE
(	O
GDI	B-PRGE
)	O
,	O
which	O
binds	O
prenylated	O
Rabs	O
.	O

In	O
biochemical	O
assays	O
we	O
demonstrate	O
that	O
component	O
A	O
binds	O
unprenylated	O
Rab1A	B-PRGE
,	O
presents	O
it	O
to	O
the	O
catalytic	O
component	O
B	O
,	O
and	O
remains	O
bound	O
to	O
it	O
after	O
the	O
geranylgeranyl	O
transfer	O
reaction	O
.	O

In	O
the	O
absence	O
of	O
detergents	O
,	O
the	O
reaction	O
terminates	O
when	O
all	O
of	O
component	O
A	O
is	O
occupied	O
with	O
prenylated	O
Rab	O
.	O

Detergents	O
allow	O
multiple	O
rounds	O
of	O
catalysis	O
,	O
apparently	O
by	O
dissociating	O
the	O
component	O
A	O
-	O
Rab	O
complex	O
and	O
thus	O
allowing	O
recycling	O
of	O
component	O
A	O
.	O

Within	O
the	O
cell	O
,	O
component	O
A	O
may	O
be	O
regenerated	O
by	O
transferring	O
its	O
prenylated	O
Rab	O
to	O
a	O
protein	O
acceptor	O
,	O
such	O
as	O
Rab3A	B-PRGE
GDI	I-PRGE
.	O

In	O
view	O
of	O
its	O
function	O
in	O
escorting	O
Rab	O
proteins	O
during	O
and	O
presumably	O
after	O
the	O
prenyl	O
transfer	O
reaction	O
,	O
we	O
propose	O
to	O
rename	O
component	O
A	O
as	O
Rab	O
escort	O
protein	O
(	O
REP	O
)	O
.	O

A	O
genetic	O
defect	O
in	O
REP	O
underlies	O
human	O
choroideremia	B-PRGE
,	O
a	O
disease	O
of	O
retinal	O
degeneration	O
.	O

The	O
acylation	O
of	O
megakaryocyte	O
proteins	O
:	O
glycoprotein	B-PRGE
IX	I-PRGE
is	O
primarily	O
myristoylated	O
while	O
glycoprotein	O
Ib	O
is	O
palmitoylated	O
.	O

The	O
acylation	O
of	O
megakaryocyte	O
proteins	O
was	O
studied	O
with	O
special	O
emphasis	O
on	O
the	O
myristoylation	O
and	O
palmitoylation	O
of	O
the	O
glycoprotein	O
(	O
GP	O
)	O
Ib	O
complex	O
.	O

Guinea	O
pig	O
megakaryocytes	O
were	O
purified	O
and	O
separated	O
into	O
subpopulations	O
at	O
different	O
phases	O
of	O
maturation	O
.	O

Cells	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
myristate	O
,	O
[	O
3H	O
]	O
palmitate	O
,	O
or	O
[	O
3H	O
]	O
acetate	O
to	O
study	O
endogenous	O
protein	O
acylation	O
.	O

Cycloheximide	O
was	O
used	O
to	O
distinguish	O
between	O
cotranslational	O
and	O
posttranslational	O
acylation	O
and	O
hydroxylamine	O
to	O
distinguish	O
between	O
thioester	O
and	O
amide	O
linkages	O
.	O

After	O
incubations	O
,	O
delipidated	O
proteins	O
or	O
GPIb	O
complex	O
subunits	O
,	O
immunoprecipitated	O
with	O
PG	O
-	O
1	O
,	O
AN	O
-	O
51	O
or	O
FMC	O
-	O
25	O
monoclonal	O
antibody	O
,	O
were	O
separated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
assessed	O
by	O
fluorography	O
.	O

Radiolabeled	O
fatty	O
acids	O
bound	O
to	O
GPIX	B-PRGE
and	O
GPIb	O
were	O
also	O
analyzed	O
by	O
high	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
scintillation	O
spectrometry	O
.	O

With	O
[	O
3H	O
]	O
myristic	O
acid	O
and	O
[	O
3H	O
]	O
acetate	O
,	O
GPIX	B-PRGE
was	O
found	O
to	O
be	O
a	O
major	O
myristoylated	O
protein	O
in	O
megakaryocytes	O
and	O
CHRF	O
-	O
288	O
cells	O
.	O

Myristic	O
acid	O
was	O
linked	O
to	O
GPIX	B-PRGE
by	O
an	O
amide	O
bond	O
,	O
and	O
this	O
process	O
occurred	O
cotranslationally	O
.	O

With	O
[	O
3H	O
]	O
acetate	O
,	O
GPIb	O
was	O
primarily	O
palmitoylated	O
,	O
but	O
with	O
[	O
3H	O
]	O
myristate	O
,	O
GPIb	O
was	O
acylated	O
with	O
about	O
equal	O
mounts	O
of	O
myristic	O
acid	O
and	O
palmitic	O
acids	O
.	O

Both	O
fatty	O
acids	O
were	O
linked	O
to	O
GPIb	O
by	O
thioester	O
bonds	O
,	O
and	O
acylation	O
was	O
posttranslational	O
.	O

The	O
myristoylation	O
of	O
GPIX	B-PRGE
while	O
the	O
palmitoylation	O
of	O
GPIb	O
occurred	O
throughout	O
megakaryocyte	O
maturation	O
.	O

Myristoylation	O
and	O
palmitoylation	O
may	O
have	O
different	O
functions	O
relevant	O
to	O
the	O
assembly	O
of	O
the	O
GPIb	O
complex	O
in	O
megakaryocytes	O
.	O

The	O
inhibition	O
of	O
phosphoenolpyruvate	B-PRGE
carboxykinase	I-PRGE
following	O
in	O
vivo	O
chronic	O
phenobarbital	O
treatment	O
in	O
the	O
rat	O
is	O
due	O
to	O
a	O
post	O
-	O
translational	O
event	O
.	O

Chronic	O
treatment	O
of	O
rats	O
with	O
phenobarbital	O
has	O
been	O
reported	O
to	O
decrease	O
gluconeogenesis	O
in	O
rat	O
hepatocytes	O
by	O
a	O
50	O
%	O
inhibition	O
of	O
phosphoenolpyruvate	B-PRGE
(	I-PRGE
P	I-PRGE
-	I-PRGE
pyruvate	I-PRGE
)	I-PRGE
carboxykinase	I-PRGE
activity	O
[	O
Argaud	O
,	O
D	O
.	O
,	O
Halimi	O
,	O
S	O
.	O
,	O
Catelloni	O
,	O
F	O
.	O
&	O
Leverve	O
,	O
X	O
.	O
(	O
1991	O
)	O
Biochem	O
.	O
J	O
.	O
280	O
,	O
663	O
-	O
669	O
]	O
.	O

Contrary	O
to	O
the	O
current	O
knowledge	O
of	O
P	B-PRGE
-	I-PRGE
pyruvate	I-PRGE
carboxykinase	I-PRGE
regulation	O
,	O
we	O
failed	O
to	O
find	O
a	O
diminution	O
of	O
either	O
P	B-PRGE
-	I-PRGE
pyruvate	I-PRGE
carboxykinase	I-PRGE
protein	O
(	O
by	O
using	O
a	O
polyclonal	O
antibody	O
)	O
or	O
P	B-PRGE
-	I-PRGE
pyruvate	I-PRGE
carboxykinase	I-PRGE
mRNA	O
,	O
in	O
the	O
liver	O
of	O
rats	O
treated	O
with	O
phenobarbital	O
for	O
2	O
weeks	O
.	O

Kinetic	O
studies	O
of	O
P	B-PRGE
-	I-PRGE
pyruvate	I-PRGE
carboxykinase	I-PRGE
activity	O
,	O
measured	O
by	O
either	O
carboxylation	O
of	O
P	O
-	O
pyruvate	O
or	O
decarboxylation	O
of	O
oxaloacetate	O
,	O
revealed	O
a	O
decrease	O
in	O
both	O
V	O
(	O
max	O
)	O
and	O
Km	O
after	O
phenobarbital	O
treatment	O
,	O
whereas	O
the	O
nutritional	O
state	O
affected	O
only	O
the	O
V	O
(	O
max	O
)	O
,	O
as	O
expected	O
.	O

Assessment	O
of	O
P	B-PRGE
-	I-PRGE
pyruvate	I-PRGE
carboxykinase	I-PRGE
specificity	O
was	O
confirmed	O
by	O
the	O
full	O
inhibition	O
of	O
the	O
enzyme	O
with	O
its	O
specific	O
inhibitor	O
3	O
-	O
mercaptopicolinate	O
in	O
the	O
micromolar	O
range	O
.	O

P	B-PRGE
-	I-PRGE
Pyruvate	I-PRGE
carboxykinase	I-PRGE
,	O
purified	O
either	O
by	O
ammonium	O
sulfate	O
fractionation	O
or	O
by	O
immunoprecipitation	O
,	O
exhibited	O
a	O
similar	O
decrease	O
in	O
affinity	O
after	O
phenobarbital	O
treatment	O
.	O

Although	O
the	O
molecular	O
mass	O
does	O
not	O
appear	O
to	O
be	O
altered	O
,	O
the	O
pH	O
sensitivity	O
to	O
3	O
-	O
mercaptopicolinate	O
inhibition	O
and	O
the	O
enzyme	O
recovery	O
after	O
immunoprecipitation	O
both	O
seemed	O
to	O
be	O
affected	O
.	O

This	O
leads	O
us	O
to	O
propose	O
that	O
the	O
effect	O
of	O
chronic	O
phenobarbital	O
treatment	O
on	O
P	B-PRGE
-	I-PRGE
pyruvate	I-PRGE
carboxykinase	I-PRGE
activity	O
is	O
not	O
the	O
result	O
of	O
transcriptional	O
regulation	O
but	O
is	O
exerted	O
at	O
the	O
post	O
-	O
translational	O
level	O
.	O

Regulation	O
by	O
cAMP	O
of	O
post	O
-	O
translational	O
processing	O
and	O
subcellular	O
targeting	O
of	O
endothelial	B-PRGE
nitric	I-PRGE
-	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
(	O
type	O
3	O
)	O
in	O
cardiac	O
myocytes	O
.	O

Cardiac	O
myocytes	O
express	O
the	O
nitric	O
-	O
oxide	O
synthase	O
isoform	O
originally	O
identified	O
in	O
endothelial	O
cells	O
,	O
termed	O
eNOS	B-PRGE
or	O
NOS3	B-PRGE
,	O
where	O
it	O
plays	O
a	O
role	O
in	O
regulating	O
myocyte	O
responsiveness	O
to	O
both	O
adrenergic	O
and	O
muscarinic	O
cholinergic	O
autonomic	O
nervous	O
system	O
agonists	O
.	O

eNOS	B-PRGE
in	O
endothelial	O
cells	O
has	O
been	O
shown	O
to	O
undergo	O
extensive	O
post	O
-	O
translational	O
processing	O
,	O
and	O
in	O
cardiac	O
myocytes	O
as	O
well	O
as	O
endothelial	O
cells	O
,	O
eNOS	B-PRGE
has	O
been	O
shown	O
to	O
be	O
targeted	O
to	O
plasmalemmal	O
caveolae	O
,	O
a	O
process	O
that	O
is	O
dependent	O
on	O
myristoylation	O
and	O
palmitoylation	O
.	O

Other	O
post	O
-	O
translational	O
modifications	O
essential	O
for	O
the	O
correct	O
subcellular	O
targeting	O
of	O
eNOS	B-PRGE
have	O
not	O
been	O
described	O
previously	O
.	O

We	O
demonstrate	O
,	O
using	O
[	O
35S	O
]	O
methionine	O
pulse	O
-	O
chase	O
experiments	O
,	O
that	O
native	O
eNOS	B-PRGE
in	O
adult	O
rat	O
ventricular	O
myocytes	O
is	O
initially	O
translated	O
as	O
a	O
nonpalmitoylated	O
150	O
-	O
kDa	O
isoform	O
,	O
which	O
is	O
associated	O
with	O
cytosolic	O
and	O
intracellular	O
membrane	O
-	O
enriched	O
fractions	O
.	O

This	O
is	O
subsequently	O
processed	O
to	O
a	O
palmitoylated	O
135	O
-	O
kDa	O
isoform	O
,	O
which	O
is	O
found	O
only	O
in	O
a	O
sarcolemma	O
-	O
enriched	O
membrane	O
fraction	O
.	O

Forskolin	O
,	O
an	O
agent	O
that	O
elevates	O
intracellular	O
cAMP	O
,	O
rapidly	O
inhibited	O
processing	O
of	O
the	O
150	O
-	O
kDa	O
isoform	O
to	O
the	O
135	O
-	O
kDa	O
isoform	O
and	O
transport	O
of	O
eNOS	B-PRGE
to	O
the	O
sarcolemma	O
,	O
effects	O
paralleled	O
by	O
protein	O
kinase	O
A	O
-	O
dependent	O
phosphorylation	O
of	O
the	O
larger	O
eNOS	B-PRGE
isoform	O
.	O

Forskolin	O
also	O
decreased	O
palmitoylation	O
of	O
the	O
135	O
-	O
kDa	O
isoform	O
,	O
although	O
it	O
did	O
not	O
accelerate	O
depalmitoylation	O
of	O
sarcolemmal	O
eNOS	B-PRGE
,	O
as	O
determined	O
by	O
pulse	O
-	O
chase	O
experiments	O
with	O
[	O
3H	O
]	O
palmitate	O
.	O

Thus	O
,	O
post	O
-	O
translational	O
processing	O
of	O
a	O
150	O
-	O
kDa	O
isoform	O
of	O
myocyte	O
eNOS	B-PRGE
appears	O
to	O
be	O
necessary	O
for	O
intracellular	O
trafficking	O
of	O
the	O
enzyme	O
to	O
sarcolemmal	O
caveolae	O
.	O

Both	O
the	O
post	O
-	O
translational	O
processing	O
and	O
subcellular	O
targeting	O
of	O
eNOS	B-PRGE
appear	O
to	O
be	O
modified	O
by	O
changes	O
in	O
intracellular	O
cAMP	O
,	O
an	O
effect	O
that	O
may	O
have	O
important	O
implications	O
for	O
cardiac	O
myocyte	O
responsiveness	O
to	O
autonomic	O
agonists	O
in	O
vivo	O
.	O

Direct	O
demonstration	O
of	O
geranylgeranylation	O
and	O
farnesylation	O
of	O
Ki	B-PRGE
-	I-PRGE
Ras	I-PRGE
in	O
vivo	O
.	O

It	O
has	O
recently	O
been	O
reported	O
that	O
Ki	B-PRGE
-	I-PRGE
Ras	I-PRGE
protein	O
can	O
be	O
modified	O
in	O
vitro	O
by	O
farnesylation	O
or	O
geranylgeranylation	O
.	O

However	O
,	O
a	O
previous	O
analysis	O
of	O
Ki	B-PRGE
-	I-PRGE
Ras	I-PRGE
prenylation	O
in	O
vivo	O
found	O
only	O
farnesylated	O
Ki	B-PRGE
-	I-PRGE
Ras	I-PRGE
.	O

In	O
this	O
report	O
it	O
is	O
shown	O
that	O
under	O
normal	O
conditions	O
,	O
Ki	B-PRGE
-	I-PRGE
Ras	I-PRGE
is	O
farnesylated	O
in	O
vivo	O
and	O
when	O
cells	O
are	O
treated	O
with	O
the	O
farnesyl	O
transferase	O
inhibitors	O
B956	O
or	O
B957	O
,	O
farnesylation	O
is	O
inhibited	O
and	O
Ki	B-PRGE
-	I-PRGE
Ras	I-PRGE
becomes	O
geranylgeranylated	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

These	O
results	O
have	O
strong	O
implications	O
in	O
the	O
design	O
of	O
anticancer	O
drugs	O
based	O
on	O
inhibition	O
of	O
prenylation	O
.	O

The	O
alpha	B-PRGE
7	I-PRGE
integrin	I-PRGE
as	O
a	O
target	O
protein	O
for	O
cell	O
surface	O
mono	O
-	O
ADP	O
-	O
ribosylation	O
in	O
muscle	O
cells	O
.	O

A	O
membrane	B-PRGE
-	I-PRGE
associated	I-PRGE
arginine	I-PRGE
-	I-PRGE
specific	I-PRGE
mono	I-PRGE
-	I-PRGE
ADP	I-PRGE
-	I-PRGE
ribosyltransferase	I-PRGE
was	O
purified	O
215	O
,	O
000	O
-	O
fold	O
from	O
rabbit	O
skeletal	O
muscle	O
and	O
its	O
gene	O
was	O
isolated	O
from	O
a	O
skeletal	O
muscle	O
cDNA	O
library	O
.	O

The	O
enzyme	O
was	O
a	O
glycosylphosphatidyl	O
-	O
inositol	O
-	O
linked	O
protein	O
,	O
present	O
on	O
the	O
surface	O
of	O
differentiated	O
skeletal	O
muscle	O
myoblasts	O
(	O
myotubes	O
)	O
.	O

Following	O
incubation	O
of	O
cultured	O
,	O
intact	O
myotubes	O
with	O
[	O
adenylate	O
-	O
32P	O
]	O
NAD	O
and	O
analysis	O
by	O
SDS	O
-	O
PAGE	O
,	O
a	O
major	O
radiolabeled	O
protein	O
of	O
97	O
/	O
140	O
kDa	O
(	O
reduced	O
/	O
nonreduced	O
conditions	O
)	O
was	O
observed	O
.	O

It	O
was	O
identified	O
as	O
integrin	B-PRGE
alpha	I-PRGE
7	I-PRGE
based	O
on	O
its	O
size	O
,	O
binding	O
to	O
a	O
laminin	O
affinity	O
column	O
,	O
immunoprecipitation	O
with	O
a	O
monoclonal	O
antibody	O
,	O
and	O
partial	O
amino	O
acid	O
sequencing	O
.	O

Since	O
ADP	B-PRGE
-	I-PRGE
ribosylarginine	I-PRGE
hydrolase	I-PRGE
,	O
the	O
enzyme	O
responsible	O
for	O
cleavage	O
of	O
the	O
ADP	O
-	O
ribosylarginine	O
bond	O
and	O
a	O
component	O
with	O
the	O
transferase	O
of	O
a	O
putative	O
ADP	O
-	O
ribosylation	O
cycle	O
,	O
is	O
cytosolic	O
,	O
whereas	O
the	O
transferase	O
is	O
attached	O
via	O
a	O
GPI	O
-	O
anchor	O
to	O
the	O
cell	O
surface	O
,	O
the	O
processing	O
of	O
ADP	O
-	O
ribosylated	O
integrin	B-PRGE
alpha	I-PRGE
7	I-PRGE
was	O
investigated	O
.	O

32P	O
label	O
was	O
rapidly	O
removed	O
from	O
[	O
32P	O
]	O
ADP	O
-	O
ribosylated	O
integrin	B-PRGE
alpha	I-PRGE
7	I-PRGE
,	O
a	O
process	O
inhibited	O
by	O
free	O
ADP	O
-	O
ribose	O
or	O
p	O
-	O
nitrophenylthymidine	O
-	O
5	O
'	O
-	O
monophosphate	O
,	O
alternative	O
substrates	O
for	O
5	O
'	O
-	O
nucleotide	O
phosphodiesterase	O
.	O

The	O
processed	O
integrin	B-PRGE
alpha	I-PRGE
7	I-PRGE
was	O
not	O
susceptible	O
to	O
subsequent	O
ADP	O
-	O
ribosylation	O
,	O
although	O
the	O
amount	O
of	O
surface	O
integrin	B-PRGE
alpha	I-PRGE
7	I-PRGE
remained	O
constant	O
.	O

During	O
the	O
processing	O
,	O
no	O
loss	O
of	O
label	O
was	O
observed	O
from	O
integrin	B-PRGE
alpha	I-PRGE
7	I-PRGE
radiolabeled	O
with	O
[	O
14C	O
]	O
NAD	O
,	O
containing	O
14C	O
in	O
the	O
nicotinamide	O
-	O
proximal	O
ribose	O
,	O
consistent	O
with	O
a	O
degradation	O
of	O
the	O
ADP	O
-	O
ribose	O
moiety	O
by	O
a	O
cell	O
surface	O
5	O
'	O
-	O
nucleotide	O
phosphodiesterase	O
.	O

Thus	O
,	O
cell	O
surface	O
ADP	O
-	O
ribosylation	O
,	O
in	O
contrast	O
to	O
intracellular	O
ADP	O
-	O
ribosylation	O
,	O
is	O
not	O
readily	O
reversed	O
by	O
the	O
presently	O
known	O
ADP	B-PRGE
-	I-PRGE
ribosylarginine	I-PRGE
hydrolase	I-PRGE
and	O
seems	O
to	O
operate	O
outside	O
the	O
postulated	O
ADP	O
-	O
ribosylation	O
cycle	O
.	O

[	O
Isoprenylated	O
proteins	O
and	O
cell	O
proliferation	O
:	O
regulators	O
and	O
effectors	O
of	O
Ras	O
proteins	O
]	O

Ras	O
proteins	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
cellular	O
proliferation	O
.	O

They	O
are	O
189	O
amino	O
acid	O
monomeric	O
GTP	O
-	O
binding	O
proteins	O
that	O
cycle	O
between	O
an	O
inactive	O
GDP	O
-	O
bound	O
and	O
the	O
active	O
GTP	O
-	O
bound	O
state	O
,	O
and	O
carry	O
a	O
slow	O
intrinsic	O
GTPase	O
activity	O
.	O

Ras	O
proteins	O
are	O
activated	O
by	O
growth	O
promoting	O
signals	O
incoming	O
from	O
receptor	O
tyrosine	O
kinases	O
via	O
SH2	O
domain	O
and	O
SH3	O
domain	O
containing	O
adapter	O
proteins	O
and	O
the	O
Ras	O
exchange	O
factor	O
Sos	O
,	O
as	O
well	O
as	O
from	O
serpentine	O
receptors	O
via	O
the	O
beta	O
gamma	O
subunits	O
of	O
heterotrimeric	O
G	O
proteins	O
and	O
the	O
Ras	O
exchange	O
factor	O
Ras	B-PRGE
-	I-PRGE
GRF	I-PRGE
(	O
or	O
Cdc25	B-PRGE
)	O
.	O

Proteins	O
that	O
can	O
stimulate	O
the	O
GTPase	O
activity	O
of	O
Ras	O
(	O
GAPs	O
)	O
ensure	O
that	O
following	O
mitogenic	O
stimulations	O
,	O
they	O
return	O
to	O
their	O
inactive	O
GDP	O
-	O
bound	O
state	O
;	O
amongst	O
these	O
proteins	O
are	O
p120	B-PRGE
-	I-PRGE
GAP	I-PRGE
,	O
neurofibomin	B-PRGE
(	O
the	O
product	O
of	O
the	O
susceptibility	O
gene	O
to	O
type	O
I	O
neurofibromatosis	O
)	O
,	O
as	O
well	O
as	O
the	O
inositol	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
tetrakisphosphate	O
-	O
dependent	O
GAPIP4BF	B-PRGE
.	O

Several	O
effectors	O
have	O
been	O
identified	O
that	O
mediate	O
the	O
biological	O
effects	O
of	O
Ras	O
.	O

The	O
serine	O
/	O
threonine	O
kinase	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
as	O
well	O
as	O
the	O
closely	O
related	O
protein	O
B	B-PRGE
-	I-PRGE
Raf	I-PRGE
,	O
elicit	O
the	O
ERK	O
cascade	O
of	O
MAP	O
kinases	O
.	O

Phosphatidylinositol	O
-	O
3	O
-	O
OH	O
kinase	O
is	O
involved	O
in	O
the	O
activation	O
of	O
the	O
Rac	O
/	O
Rho	O
family	O
proteins	O
that	O
play	O
a	O
role	O
in	O
the	O
control	O
of	O
actin	O
polymerisation	O
,	O
as	O
well	O
as	O
in	O
growth	O
control	O
,	O
RalGDS	B-PRGE
,	O
RGL	O
and	O
Rlf	B-PRGE
,	O
are	O
responsible	O
for	O
the	O
activation	O
of	O
the	O
Ras	O
-	O
related	O
protein	O
Ral	B-PRGE
.	O

Recent	O
evidence	O
,	O
using	O
effector	O
domain	O
mutants	O
of	O
Ras	O
,	O
demonstrates	O
that	O
these	O
pathways	O
cooperate	O
to	O
elicit	O
the	O
growth	O
promoting	O
effects	O
of	O
Ras	O
proteins	O
.	O

Inhibition	O
of	O
the	O
prenylation	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
,	O
but	O
not	O
H	B-PRGE
-	I-PRGE
or	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
,	O
is	O
highly	O
resistant	O
to	O
CAAX	O
peptidomimetics	O
and	O
requires	O
both	O
a	O
farnesyltransferase	O
and	O
a	O
geranylgeranyltransferase	O
I	O
inhibitor	O
in	O
human	O
tumor	O
cell	O
lines	O
.	O

The	O
farnesyltransferase	O
(	O
FTase	O
)	O
inhibitor	O
FTI	O
-	O
277	O
is	O
highly	O
effective	O
at	O
blocking	O
oncogenic	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
but	O
not	O
K	B-PRGE
-	I-PRGE
Ras4B	I-PRGE
processing	O
and	O
signaling	O
.	O

While	O
inhibition	O
of	O
processing	O
and	O
signaling	O
of	O
oncogenic	O
K	B-PRGE
-	I-PRGE
Ras4B	I-PRGE
is	O
more	O
sensitive	O
to	O
the	O
geranylgeranyltransferase	O
I	O
(	O
GGTase	O
I	O
)	O
inhibitor	O
GGTI	O
-	O
286	O
than	O
it	O
is	O
to	O
FTI	O
-	O
277	O
in	O
K	B-PRGE
-	I-PRGE
Ras4B	I-PRGE
-	O
transformed	O
NIH3T3	O
cells	O
,	O
the	O
sensitivity	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
as	O
well	O
as	O
H	B-PRGE
-	I-PRGE
and	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
to	O
the	O
CAAX	O
peptidomimetics	O
in	O
human	O
tumor	O
cell	O
lines	O
is	O
not	O
known	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
panel	O
of	O
five	O
human	O
carcinoma	O
cell	O
lines	O
from	O
pancreatic	O
,	O
pulmonary	O
,	O
and	O
bladder	O
origins	O
all	O
express	O
H	B-PRGE
-	I-PRGE
,	O
N	B-PRGE
-	I-PRGE
,	O
and	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
,	O
and	O
their	O
respective	O
prenylation	O
sensitivities	O
to	O
the	O
FTase	O
and	O
GGTase	O
I	O
inhibitors	O
is	O
variable	O
.	O

In	O
all	O
of	O
the	O
cell	O
lines	O
investigated	O
,	O
the	O
prenylation	O
of	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
was	O
highly	O
sensitive	O
to	O
FTI	O
-	O
277	O
,	O
and	O
in	O
two	O
of	O
the	O
cell	O
lines	O
,	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
showed	O
slight	O
sensitivity	O
to	O
GGTI	O
-	O
298	O
,	O
an	O
analog	O
of	O
GGTI	O
-	O
286	O
.	O

Although	O
the	O
prenylation	O
of	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
was	O
also	O
sensitive	O
to	O
FTI	O
-	O
277	O
,	O
complete	O
inhibition	O
of	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
processing	O
even	O
at	O
high	O
concentrations	O
of	O
FTI	O
-	O
277	O
and	O
/	O
or	O
GGTI	O
-	O
298	O
was	O
never	O
achieved	O
.	O

The	O
prenylation	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
highly	O
resistant	O
to	O
FTI	O
-	O
277	O
and	O
GGTI	O
-	O
298	O
.	O

Most	O
significantly	O
,	O
treatment	O
of	O
human	O
tumor	O
cell	O
lines	O
with	O
both	O
inhibitors	O
was	O
required	O
for	O
inhibition	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
prenylation	O
.	O

In	O
one	O
cell	O
line	O
,	O
the	O
human	O
lung	O
adenocarcinoma	O
A	O
-	O
549	O
,	O
prenylation	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
was	O
highly	O
resistant	O
even	O
when	O
co	O
-	O
treated	O
with	O
both	O
inhibitors	O
.	O

Furthermore	O
,	O
soft	O
agar	O
experiments	O
demonstrated	O
that	O
in	O
all	O
the	O
human	O
tumor	O
cell	O
lines	O
tested	O
inhibition	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
prenylation	O
was	O
not	O
necessary	O
for	O
inhibition	O
of	O
anchorage	O
-	O
independent	O
growth	O
.	O

In	O
addition	O
,	O
although	O
GGTI	O
-	O
298	O
had	O
very	O
little	O
effect	O
on	O
soft	O
agar	O
growth	O
,	O
the	O
combination	O
of	O
FTI	O
-	O
277	O
and	O
GGTI	O
-	O
298	O
resulted	O
in	O
significant	O
growth	O
inhibition	O
.	O

Therefore	O
,	O
the	O
results	O
demonstrate	O
that	O
while	O
FTI	O
-	O
277	O
inhibits	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
and	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
processing	O
in	O
the	O
human	O
tumor	O
cell	O
lines	O
evaluated	O
,	O
inhibition	O
of	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
processing	O
requires	O
both	O
an	O
FTase	O
inhibitor	O
as	O
well	O
as	O
a	O
GGTase	O
I	O
inhibitor	O
,	O
and	O
that	O
inhibition	O
of	O
human	O
tumor	O
growth	O
in	O
soft	O
agar	O
does	O
not	O
require	O
inhibition	O
of	O
oncogenic	O
K	B-PRGE
-	I-PRGE
Ras	I-PRGE
processing	O
.	O

Pro108	O
is	O
important	O
for	O
folding	O
and	O
stabilization	O
of	O
adrenal	B-PRGE
ferredoxin	I-PRGE
,	O
but	O
does	O
not	O
influence	O
the	O
functional	O
properties	O
of	O
the	O
protein	O
.	O

The	O
truncated	O
mutant	O
Met	O
-	O
adrenodoxin	B-PRGE
-	O
(	O
4	O
-	O
107	O
)	O
-	O
peptide	O
of	O
bovine	O
adrenal	B-PRGE
ferredoxin	I-PRGE
was	O
expressed	O
as	O
apoprotein	O
in	O
Escherichia	O
coli	O
BL21	O
and	O
could	O
be	O
reconstituted	O
to	O
the	O
holoform	O
by	O
chemical	O
or	O
enzymatic	O
methods	O
.	O

The	O
reconstituted	O
protein	O
had	O
spectroscopic	O
,	O
functional	O
and	O
redox	O
properties	O
similar	O
to	O
the	O
Met	O
-	O
adrenodoxin	B-PRGE
-	O
(	O
4	O
-	O
108	O
)	O
-	O
peptide	O
of	O
adrenal	B-PRGE
ferredoxin	I-PRGE
,	O
into	O
which	O
the	O
cluster	O
was	O
inserted	O
upon	O
expression	O
in	O
the	O
same	O
Escherichia	O
coli	O
strain	O
.	O

Rate	O
of	O
in	O
vitro	O
cluster	O
insertion	O
into	O
the	O
Met	O
-	O
adrenodoxin	B-PRGE
-	O
(	O
4	O
-	O
107	O
)	O
apoprotein	O
was	O
much	O
lower	O
than	O
for	O
the	O
Met	O
-	O
adrenodoxin	B-PRGE
-	O
(	O
4	O
-	O
108	O
)	O
apoprotein	O
under	O
identical	O
conditions	O
.	O

Comparative	O
thermodynamic	O
studies	O
with	O
the	O
Met	O
-	O
adrenodoxin	B-PRGE
-	O
(	O
4	O
-	O
108	O
)	O
-	O
peptide	O
indicated	O
that	O
removal	O
of	O
Pro108	O
resulted	O
in	O
an	O
extensive	O
decrease	O
of	O
the	O
overall	O
stability	O
of	O
the	O
protein	O
in	O
either	O
oxidation	O
state	O
.	O

The	O
Met	O
-	O
adrenodoxin	B-PRGE
-	O
(	O
4	O
-	O
107	O
)	O
-	O
peptide	O
showed	O
a	O
higher	O
sensitivity	O
to	O
urea	O
denaturation	O
and	O
had	O
a	O
sensibly	O
lower	O
denaturation	O
temperature	O
,	O
44	O
.	O
8	O
degrees	O
C	O
,	O
compared	O
with	O
51	O
.	O
7	O
degrees	O
C	O
for	O
mutant	O
Met	O
-	O
adrenodoxin	B-PRGE
-	O
(	O
4	O
-	O
108	O
)	O
.	O

The	O
stability	O
of	O
the	O
reduced	O
state	O
of	O
both	O
mutants	O
is	O
slightly	O
lower	O
than	O
that	O
of	O
the	O
oxidized	O
state	O
indicating	O
that	O
this	O
protein	O
region	O
does	O
not	O
undergo	O
major	O
structural	O
changes	O
upon	O
reduction	O
.	O

A	O
novel	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
glycoprotein	I-PRGE
ligand	I-PRGE
-	I-PRGE
1	I-PRGE
monoclonal	O
antibody	O
recognizes	O
an	O
epitope	O
within	O
the	O
tyrosine	O
sulfate	O
motif	O
of	O
human	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
blocks	O
recognition	O
of	O
both	O
P	B-PRGE
-	I-PRGE
and	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

Interactions	O
between	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
glycoprotein	I-PRGE
ligand	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
mediate	O
the	O
earliest	O
"	O
rolling	O
"	O
of	O
leukocytes	O
on	O
the	O
lumenal	O
surface	O
of	O
endothelial	O
cells	O
at	O
sites	O
of	O
inflammation	O
.	O

Previously	O
,	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
has	O
been	O
shown	O
to	O
be	O
the	O
primary	O
mediator	O
of	O
interactions	O
between	O
neutrophils	O
and	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
but	O
studies	O
on	O
the	O
ability	O
of	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
mediate	O
interactions	O
between	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
other	O
subsets	O
of	O
leukocytes	O
have	O
yielded	O
variable	O
and	O
conflicting	O
results	O
.	O

A	O
novel	O
IgG	O
monoclonal	O
antibody	O
(	O
MoAb	O
)	O
to	O
human	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
generated	O
,	O
and	O
the	O
specificity	O
of	O
this	O
MoAb	O
was	O
confirmed	O
by	O
both	O
flow	O
cytometric	O
analysis	O
and	O
Western	O
blotting	O
of	O
cells	O
transfected	O
with	O
human	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

This	O
newly	O
developed	O
MoAb	O
,	O
KPL1	O
,	O
inhibited	O
interactions	O
between	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
expressing	O
COS	O
cells	O
and	O
either	O
HL60	O
cells	O
,	O
neutrophils	O
,	O
or	O
lymphocytes	O
.	O

Furthermore	O
,	O
KPL1	O
completely	O
inhibited	O
interactions	O
between	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
either	O
purified	O
CD4	B-PRGE
T	O
cells	O
or	O
neutrophils	O
in	O
a	O
flow	O
assay	O
under	O
physiological	O
conditions	O
,	O
but	O
had	O
no	O
effect	O
on	O
interactions	O
of	O
T	O
cells	O
or	O
neutrophils	O
with	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

In	O
addition	O
,	O
KPL1	O
blocked	O
interactions	O
between	O
lymphoid	O
cells	O
transfected	O
with	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
COS	O
cells	O
expressing	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
KPL1	O
epitope	O
was	O
mapped	O
to	O
a	O
site	O
within	O
a	O
consensus	O
tyrosine	O
sulfation	O
motif	O
of	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
previously	O
shown	O
to	O
be	O
essential	O
for	O
interaction	O
with	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
now	O
shown	O
to	O
be	O
essential	O
for	O
interaction	O
with	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
and	O
to	O
be	O
distinct	O
from	O
the	O
epitope	O
identified	O
by	O
the	O
PL1	O
function	O
blocking	O
anti	O
-	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
MoAb	O
.	O

Two	O
-	O
color	O
flow	O
cytometry	O
of	O
normal	O
leukocytes	O
showed	O
that	O
while	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
(	O
CD16	O
(	O
+	O
)	O
)	O
,	O
monocytes	O
,	O
CD4	B-PRGE
and	O
CD8	O
T	O
cells	O
,	O
and	O
alpha	O
/	O
beta	O
and	O
gamma	O
/	O
delta	O
T	O
cells	O
were	O
uniformly	O
positive	O
for	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
B	O
cells	O
expressed	O
low	O
levels	O
of	O
the	O
KPL1	O
epitope	O
.	O

This	O
low	O
level	O
of	O
KPL1	O
staining	O
was	O
also	O
observed	O
immunohistologically	O
in	O
germinal	O
centers	O
,	O
which	O
had	O
no	O
detectable	O
KPL1	O
staining	O
,	O
whereas	O
T	O
-	O
cell	O
areas	O
(	O
interfollicular	O
region	O
)	O
were	O
positive	O
for	O
KPL1	O
.	O

Interestingly	O
,	O
plasma	O
cells	O
in	O
situ	O
and	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
-	O
dependent	O
myeloma	O
cell	O
lines	O
were	O
KPL1	O
(	O
+	O
)	O
.	O

Thus	O
,	O
PSGL	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
expressed	O
on	O
essentially	O
all	O
blood	O
neutrophils	O
,	O
NK	O
cells	O
,	O
B	O
cells	O
,	O
T	O
cells	O
,	O
and	O
monocytes	O
.	O

Variation	O
in	O
tyrosine	O
sulfation	O
during	O
B	O
-	O
cell	O
differentiation	O
may	O
affect	O
the	O
ability	O
of	O
B	O
cells	O
to	O
interact	O
with	O
P	B-PRGE
-	I-PRGE
and	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

Modification	O
of	O
yeast	O
Cdc53p	B-PRGE
by	O
the	O
ubiquitin	B-PRGE
-	O
related	O
protein	O
rub1p	B-PRGE
affects	O
function	O
of	O
the	O
SCFCdc4	B-PRGE
complex	O
.	O

The	O
RUB1	B-PRGE
/	O
NEDD	B-PRGE
-	I-PRGE
8	I-PRGE
family	O
of	O
ubiquitin	B-PRGE
-	O
related	O
genes	O
is	O
widely	O
represented	O
among	O
eukaryotes	O
.	O

Here	O
we	O
report	O
that	O
Cdc53p	B-PRGE
in	O
Saccharomyces	O
cerevisiae	O
,	O
a	O
member	O
of	O
the	O
Cullin	O
family	O
of	O
proteins	O
,	O
is	O
stably	O
modified	O
by	O
the	O
covalent	O
attachment	O
of	O
a	O
single	O
Rub1p	B-PRGE
molecule	O
.	O

Two	O
genes	O
have	O
been	O
identified	O
that	O
are	O
required	O
for	O
Rub1p	B-PRGE
conjugation	O
to	O
Cdc53p	B-PRGE
.	O

The	O
first	O
gene	O
,	O
designated	O
ENR2	B-PRGE
,	O
encodes	O
a	O
protein	O
with	O
sequence	O
similarity	O
to	O
the	O
amino	O
-	O
terminal	O
half	O
of	O
the	O
ubiquitin	B-PRGE
-	O
activating	O
enzyme	O
.	O

By	O
analogy	O
with	O
Aos1p	B-PRGE
,	O
we	O
infer	O
that	O
Enr2p	B-PRGE
functions	O
in	O
a	O
bipartite	O
Rub1p	B-PRGE
-	O
activating	O
enzyme	O
.	O

The	O
second	O
gene	O
is	O
SKP1	B-PRGE
,	O
shown	O
previously	O
to	O
be	O
required	O
for	O
some	O
ubiquitin	B-PRGE
-	O
conjugation	O
events	O
.	O

A	O
deletion	O
allele	O
of	O
ENR2	B-PRGE
is	O
lethal	O
with	O
temperature	O
-	O
sensitive	O
alleles	O
of	O
cdc34	B-PRGE
and	O
enhances	O
the	O
phenotypes	O
of	O
cdc4	B-PRGE
,	O
cdc53	B-PRGE
,	O
and	O
skp1	B-PRGE
,	O
strongly	O
implying	O
that	O
Rub1p	B-PRGE
conjugation	O
to	O
Cdc53p	B-PRGE
is	O
required	O
for	O
optimal	O
assembly	O
or	O
function	O
of	O
the	O
E3	O
complex	O
SCFCdc4	B-PRGE
.	O

Consistent	O
with	O
this	O
model	O
,	O
both	O
enr2delta	B-PRGE
and	O
an	O
allele	O
of	O
Cdc53p	B-PRGE
that	O
is	O
not	O
Rub1p	B-PRGE
modified	O
,	O
render	O
cells	O
sensitive	O
to	O
alterations	O
in	O
the	O
levels	O
of	O
Cdc4p	B-PRGE
,	O
Cdc34p	B-PRGE
,	O
and	O
Cdc53p	B-PRGE
.	O

A	O
novel	O
calcium	O
-	O
independent	O
phospholipase	O
A2	O
,	O
cPLA2	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
that	O
is	O
prenylated	O
and	O
contains	O
homology	O
to	O
cPLA2	B-PRGE
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
membrane	O
-	O
bound	O
,	O
calcium	O
-	O
independent	O
PLA2	O
,	O
named	O
cPLA2	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

The	O
sequence	O
encodes	O
a	O
541	O
-	O
amino	O
acid	O
protein	O
containing	O
a	O
domain	O
with	O
significant	O
homology	O
to	O
the	O
catalytic	O
domain	O
of	O
the	O
85	O
-	O
kDa	O
cPLA2	B-PRGE
(	O
cPLA2	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

cPLA2	B-PRGE
-	I-PRGE
gamma	I-PRGE
does	O
not	O
contain	O
the	O
regulatory	O
calcium	O
-	O
dependent	O
lipid	O
binding	O
(	O
CaLB	O
)	O
domain	O
found	O
in	O
cPLA2	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

However	O
,	O
cPLA2	B-PRGE
-	I-PRGE
gamma	I-PRGE
does	O
contain	O
two	O
consensus	O
motifs	O
for	O
lipid	O
modification	O
,	O
a	O
prenylation	O
motif	O
(	O
-	O
CCLA	O
)	O
at	O
the	O
C	O
terminus	O
and	O
a	O
myristoylation	O
site	O
at	O
the	O
N	O
terminus	O
.	O

We	O
present	O
evidence	O
that	O
the	O
isoprenoid	O
precursor	O
[	O
3H	O
]	O
mevalonolactone	O
is	O
incorporated	O
into	O
the	O
prenylation	O
motif	O
of	O
cPLA2	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Interestingly	O
,	O
cPLA2	B-PRGE
-	I-PRGE
gamma	I-PRGE
demonstrates	O
a	O
preference	O
for	O
arachidonic	O
acid	O
at	O
the	O
sn	O
-	O
2	O
position	O
of	O
phosphatidylcholine	O
as	O
compared	O
with	O
palmitic	O
acid	O
.	O

cPLA2	B-PRGE
-	I-PRGE
gamma	I-PRGE
encodes	O
a	O
3	O
-	O
kilobase	O
message	O
,	O
which	O
is	O
highly	O
expressed	O
in	O
heart	O
and	O
skeletal	O
muscle	O
,	O
suggesting	O
a	O
specific	O
role	O
in	O
these	O
tissues	O
.	O

Identification	O
of	O
cPLA2	B-PRGE
-	I-PRGE
gamma	I-PRGE
reveals	O
a	O
newly	O
defined	O
family	O
of	O
phospholipases	O
A2	O
with	O
homology	O
to	O
cPLA2	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

A	O
practical	O
diagnostic	O
test	O
for	O
choroideremia	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
aimed	O
to	O
establish	O
a	O
practical	O
diagnostic	O
test	O
for	O
choroideremia	O
(	O
CHM	O
)	O
and	O
to	O
show	O
its	O
application	O
in	O
a	O
family	O
with	O
the	O
clinical	O
diagnosis	O
of	O
choroideremia	O
.	O

DESIGN	O
:	O
Case	O
series	O
.	O

PARTICIPANTS	O
:	O
Sixteen	O
males	O
from	O
13	O
families	O
with	O
clinically	O
documented	O
CHM	O
and	O
unaffected	O
normal	O
males	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

METHODS	O
:	O
Protein	O
extracted	O
from	O
either	O
leukocytes	O
or	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
lymphocytes	O
was	O
subjected	O
to	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Immunoblot	O
analysis	O
of	O
the	O
protein	O
was	O
performed	O
with	O
two	O
monoclonal	O
antibodies	O
,	O
one	O
against	O
the	O
CHM	B-PRGE
gene	O
product	O
,	O
Rab	B-PRGE
escort	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
REP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
and	O
the	O
other	O
against	O
the	O
alpha	O
-	O
subunit	O
of	O
farnesyl	O
transferase	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformation	O
polymorphism	O
analysis	O
using	O
primers	O
for	O
the	O
exons	O
of	O
the	O
CHM	B-PRGE
gene	O
.	O

Where	O
altered	O
mobility	O
of	O
the	O
DNA	O
fragments	O
was	O
detected	O
,	O
direct	O
sequencing	O
of	O
that	O
exon	O
was	O
compared	O
with	O
the	O
published	O
normal	O
sequence	O
.	O

RESULTS	O
:	O
The	O
authors	O
detected	O
REP	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
protein	O
samples	O
extracted	O
from	O
lymphoblastoid	O
cell	O
lines	O
from	O
female	O
carriers	O
but	O
not	O
from	O
CHM	O
males	O
.	O

The	O
authors	O
also	O
showed	O
the	O
absence	O
of	O
REP	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
the	O
peripheral	O
leukocytes	O
of	O
males	O
affected	O
with	O
CHM	O
.	O

In	O
one	O
male	O
who	O
lacked	O
REP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
direct	O
sequencing	O
of	O
exon	O
7	O
showed	O
a	O
cytosine	O
-	O
to	O
-	O
thymine	O
transition	O
mutation	O
(	O
Arg293X	O
)	O
in	O
the	O
CHM	B-PRGE
gene	O
.	O

CONCLUSIONS	O
:	O
The	O
clinical	O
diagnosis	O
of	O
CHM	O
can	O
be	O
confirmed	O
simply	O
by	O
immunoblot	O
analysis	O
with	O
anti	O
-	O
REP	B-PRGE
-	I-PRGE
1	I-PRGE
antibody	O
,	O
showing	O
the	O
absence	O
of	O
REP	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
in	O
peripheral	O
blood	O
samples	O
.	O

Because	O
all	O
known	O
mutations	O
in	O
the	O
CHM	B-PRGE
gene	O
create	O
stop	O
codons	O
that	O
truncate	O
the	O
protein	O
product	O
and	O
result	O
in	O
absence	O
of	O
REP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
the	O
authors	O
predict	O
that	O
most	O
patients	O
with	O
CHM	O
can	O
be	O
diagnosed	O
by	O
this	O
procedure	O
.	O

Mutations	O
in	O
orthologous	O
genes	O
in	O
human	O
spondyloepimetaphyseal	O
dysplasia	O
and	O
the	O
brachymorphic	O
mouse	O
.	O

The	O
osteochondrodysplasias	O
are	O
a	O
genetically	O
heterogeneous	O
group	O
of	O
disorders	O
affecting	O
skeletal	O
development	O
,	O
linear	O
growth	O
and	O
the	O
maintenance	O
of	O
cartilage	O
and	O
bone	O
.	O

We	O
have	O
studied	O
a	O
large	O
inbred	O
Pakistani	O
family	O
with	O
a	O
distinct	O
form	O
of	O
recessively	O
inherited	O
spondyloepimetaphyseal	O
dysplasia	O
(	O
SEMD	O
)	O
and	O
mapped	O
a	O
gene	O
associated	O
with	O
this	O
dwarfing	O
condition	O
to	O
chromosome	O
10q23	O
-	O
24	O
,	O
a	O
region	O
syntenic	O
with	O
the	O
locus	O
for	O
the	O
brachymorphic	O
mutation	O
on	O
mouse	O
chromosome	O
19	O
.	O

We	O
identified	O
two	O
orthologous	O
genes	O
,	O
ATPSK2	B-PRGE
and	O
Atpsk2	B-PRGE
,	O
encoding	O
novel	O
ATP	O
sulfurylase	O
/	O
APS	O
kinase	O
orthologues	O
in	O
the	O
respective	O
regions	O
of	O
the	O
human	O
and	O
mouse	O
genomes	O
.	O

We	O
characterized	O
a	O
nonsense	O
mutation	O
in	O
ATPSK2	B-PRGE
in	O
the	O
SEMD	O
family	O
and	O
a	O
missense	O
mutation	O
in	O
the	O
region	O
of	O
Atpsk2	B-PRGE
encoding	O
the	O
APS	O
kinase	O
activity	O
in	O
the	O
brachymorphic	O
mouse	O
.	O

ATP	O
sulfurylase	O
/	O
APS	O
kinase	O
catalyses	O
the	O
metabolic	O
activation	O
of	O
inorganic	O
sulfate	O
to	O
PAPS	O
,	O
the	O
universal	O
donor	O
for	O
post	O
-	O
translational	O
protein	O
sulfation	O
in	O
all	O
cell	O
types	O
.	O

The	O
cartilage	O
-	O
specificity	O
of	O
the	O
human	O
and	O
mouse	O
phenotypes	O
provides	O
further	O
evidence	O
of	O
the	O
critical	O
role	O
of	O
sulfate	O
activation	O
in	O
the	O
maturation	O
of	O
cartilage	O
extracellular	O
matrix	O
molecules	O
and	O
the	O
effect	O
of	O
defects	O
in	O
this	O
process	O
on	O
the	O
architecture	O
of	O
cartilage	O
and	O
skeletogenesis	O
.	O

Apoprotein	B-PRGE
B100	I-PRGE
has	O
a	O
prolonged	O
interaction	O
with	O
the	O
translocon	O
during	O
which	O
its	O
lipidation	O
and	O
translocation	O
change	O
from	O
dependence	O
on	O
the	O
microsomal	O
triglyceride	O
transfer	O
protein	O
to	O
independence	O
.	O

When	O
lipid	O
synthesis	O
is	O
limited	O
in	O
HepG2	O
cells	O
,	O
apoprotein	B-PRGE
B100	I-PRGE
(	O
apoB100	B-PRGE
)	O
is	O
not	O
secreted	O
but	O
rapidly	O
degraded	O
by	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
pathway	O
.	O

To	O
investigate	O
apoB100	B-PRGE
biosynthesis	O
and	O
secretion	O
further	O
,	O
the	O
physical	O
and	O
functional	O
states	O
of	O
apoB100	B-PRGE
destined	O
for	O
either	O
degradation	O
or	O
lipoprotein	O
assembly	O
were	O
studied	O
under	O
conditions	O
in	O
which	O
lipid	O
synthesis	O
,	O
proteasomal	O
activity	O
,	O
and	O
microsomal	O
triglyceride	O
transfer	O
protein	O
(	O
MTP	O
)	O
lipid	O
-	O
transfer	O
activity	O
were	O
varied	O
.	O

Cells	O
were	O
pretreated	O
with	O
a	O
proteasomal	O
inhibitor	O
(	O
which	O
remained	O
with	O
the	O
cells	O
throughout	O
the	O
experiment	O
)	O
and	O
radiolabeled	O
for	O
15	O
min	O
.	O

During	O
the	O
chase	O
period	O
,	O
labeled	O
apoB100	B-PRGE
remained	O
associated	O
with	O
the	O
microsomes	O
.	O

Furthermore	O
,	O
by	O
crosslinking	O
sec61beta	B-PRGE
to	O
apoB100	B-PRGE
,	O
we	O
showed	O
that	O
apoB100	B-PRGE
remained	O
close	O
to	O
the	O
translocon	O
at	O
the	O
same	O
time	O
apoB100	B-PRGE
-	O
ubiquitin	B-PRGE
conjugates	O
could	O
be	O
detected	O
.	O

When	O
lipid	O
synthesis	O
and	O
lipoprotein	O
assembly	O
/	O
secretion	O
were	O
stimulated	O
by	O
adding	O
oleic	O
acid	O
(	O
OA	O
)	O
to	O
the	O
chase	O
medium	O
,	O
apoB100	B-PRGE
was	O
deubiquitinated	O
,	O
and	O
its	O
interaction	O
with	O
sec61beta	B-PRGE
was	O
disrupted	O
,	O
signifying	O
completion	O
of	O
translocation	O
concomitant	O
with	O
the	O
formation	O
of	O
lipoprotein	O
particles	O
.	O

MTP	O
participates	O
in	O
apoB100	B-PRGE
translocation	O
and	O
lipoprotein	O
assembly	O
.	O

In	O
the	O
presence	O
of	O
OA	O
,	O
when	O
MTP	O
lipid	O
-	O
transfer	O
activity	O
was	O
inhibited	O
at	O
the	O
end	O
of	O
pulse	O
labeling	O
,	O
apoB100	B-PRGE
secretion	O
was	O
abolished	O
.	O

In	O
contrast	O
,	O
when	O
the	O
labeled	O
apoB100	B-PRGE
was	O
allowed	O
to	O
accumulate	O
in	O
the	O
cell	O
for	O
60	O
min	O
before	O
adding	O
OA	O
and	O
the	O
inhibitor	O
,	O
apoB100	B-PRGE
lipidation	O
and	O
secretion	O
were	O
no	O
longer	O
impaired	O
.	O

Overall	O
,	O
the	O
data	O
imply	O
that	O
during	O
most	O
of	O
its	O
association	O
with	O
the	O
endoplasmic	O
reticulum	O
,	O
apoB100	B-PRGE
is	O
close	O
to	O
or	O
within	O
the	O
translocon	O
and	O
is	O
accessible	O
to	O
both	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
and	O
lipoprotein	O
-	O
assembly	O
pathways	O
.	O

Furthermore	O
,	O
MTP	O
lipid	O
-	O
transfer	O
activity	O
seems	O
to	O
be	O
necessary	O
only	O
for	O
early	O
translocation	O
and	O
lipidation	O
events	O
.	O

Synthesis	O
and	O
characterization	O
of	O
photoreactive	O
insulin	B-PRGE
-	I-PRGE
like	I-PRGE
growth	I-PRGE
factor	I-PRGE
1	I-PRGE
derivatives	O
for	O
receptor	O
analysis	O
.	O

Recombinant	O
human	O
insulin	B-PRGE
-	I-PRGE
like	I-PRGE
growth	I-PRGE
factor	I-PRGE
1	I-PRGE
(	O
hIGF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
was	O
reacted	O
with	O
4	O
-	O
azidosalicylic	O
acid	O
(	O
Asa	O
)	O
to	O
synthesize	O
photoreactive	O
IGF	B-PRGE
-	I-PRGE
1	I-PRGE
derivatives	O
.	O

Depending	O
on	O
the	O
time	O
of	O
reaction	O
and	O
the	O
Asa	O
/	O
IGF	B-PRGE
-	I-PRGE
1	I-PRGE
ratio	O
,	O
a	O
mixture	O
of	O
mono	O
-	O
,	O
bis	O
-	O
,	O
and	O
trisacylated	O
derivatives	O
and	O
one	O
tetraacylated	O
derivative	O
was	O
produced	O
,	O
which	O
was	O
separated	O
by	O
reversed	O
-	O
phase	O
HPLC	O
.	O

HPLC	O
,	O
PAGE	O
,	O
and	O
MALDI	O
mass	O
spectrometry	O
were	O
used	O
to	O
determine	O
the	O
degree	O
of	O
the	O
acylation	O
and	O
location	O
of	O
the	O
photolabel	O
insertion	O
.	O

After	O
iodination	O
of	O
the	O
three	O
monoacylated	O
photoreactive	O
IGF	B-PRGE
-	I-PRGE
1	I-PRGE
derivatives	O
,	O
the	O
specific	O
labeling	O
of	O
the	O
receptor	O
could	O
be	O
proved	O
.	O

Together	O
with	O
a	O
comparative	O
investigation	O
in	O
which	O
B29	O
-	O
Asa	O
-	O
insulin	B-PRGE
was	O
used	O
,	O
the	O
results	O
suggest	O
corresponding	O
contact	O
areas	O
for	O
IGF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
insulin	B-PRGE
with	O
the	O
insulin	B-PRGE
receptor	I-PRGE
ectodomain	O
.	O

Cell	O
-	O
specific	O
glycoforms	O
of	O
sialoadhesin	B-PRGE
and	O
CD45	B-PRGE
are	O
counter	O
-	O
receptors	O
for	O
the	O
cysteine	O
-	O
rich	O
domain	O
of	O
the	O
mannose	O
receptor	O
.	O

We	O
previously	O
reported	O
that	O
CR	O
-	O
Fc	O
,	O
an	O
Fc	O
chimeric	O
protein	O
containing	O
the	O
cysteine	O
-	O
rich	O
(	O
CR	O
)	O
domain	O
of	O
the	O
mannose	O
receptor	O
,	O
binds	O
to	O
marginal	O
zone	O
metallophilic	O
macrophages	O
(	O
Mo	O
)	O
and	O
B	O
cell	O
areas	O
in	O
the	O
spleen	O
and	O
to	O
subcapsular	O
sinus	O
Mo	O
in	O
lymph	O
nodes	O
of	O
naive	O
mice	O
(	O
CR	O
-	O
Fc	O
(	O
+	O
)	O
cells	O
)	O
.	O

Several	O
CR	O
-	O
Fc	O
ligands	O
were	O
found	O
in	O
spleen	O
and	O
lymph	O
node	O
tissue	O
lysates	O
using	O
ligand	O
blots	O
.	O

In	O
this	O
paper	O
we	O
report	O
the	O
identification	O
of	O
two	O
of	O
these	O
ligands	O
as	O
sialoadhesin	B-PRGE
(	O
Sn	B-PRGE
)	O
,	O
an	O
Mo	O
-	O
specific	O
membrane	O
molecule	O
,	O
and	O
the	O
leukocyte	O
common	O
antigen	O
,	O
CD45	B-PRGE
.	O

CR	O
-	O
Fc	O
bound	O
selectively	O
to	O
Sn	B-PRGE
purified	O
from	O
spleen	O
and	O
lymph	O
nodes	O
and	O
to	O
two	O
low	O
molecular	O
weight	O
isoforms	O
of	O
CD45	B-PRGE
in	O
a	O
sugar	O
-	O
dependent	O
manner	O
.	O

CR	O
-	O
Fc	O
binding	O
and	O
non	O
-	O
binding	O
forms	O
of	O
Sn	B-PRGE
,	O
probably	O
derived	O
from	O
CR	O
-	O
Fc	O
(	O
+	O
)	O
and	O
CR	O
-	O
Fc	O
(	O
-	O
)	O
cells	O
respectively	O
,	O
were	O
selected	O
from	O
spleen	O
lysates	O
.	O

Analysis	O
of	O
the	O
glycan	O
pool	O
associated	O
with	O
the	O
CR	O
-	O
Fc	O
-	O
binding	O
form	O
revealed	O
the	O
presence	O
of	O
charged	O
structures	O
resistant	O
to	O
sialidase	O
,	O
absent	O
in	O
the	O
non	O
-	O
binding	O
form	O
,	O
that	O
could	O
correspond	O
to	O
sulfated	O
structures	O
.	O

These	O
results	O
confirm	O
the	O
identification	O
of	O
the	O
CR	O
region	O
of	O
the	O
mannose	O
receptor	O
as	O
a	O
lectin	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
same	O
glycoprotein	O
expressed	O
in	O
different	O
cells	O
of	O
the	O
same	O
organ	O
can	O
display	O
distinct	O
sugar	O
epitopes	O
that	O
determine	O
its	O
binding	O
properties	O
.	O

Disrupting	O
the	O
geranylgeranylation	O
at	O
the	O
C	O
-	O
termini	O
of	O
the	O
shrimp	O
Ras	B-PRGE
by	O
depriving	O
guanine	O
nucleotide	O
binding	O
at	O
the	O
N	O
-	O
terminal	O
.	O

In	O
order	O
to	O
assess	O
the	O
effects	O
of	O
guanine	O
nucleotide	O
binding	O
on	O
the	O
geranylgeranylation	O
at	O
the	O
CAAX	O
box	O
of	O
the	O
shrimp	O
Ras	B-PRGE
,	O
we	O
experimented	O
with	O
the	O
shrimp	O
Penaeus	O
japonicus	O
Ras	B-PRGE
(	O
S	O
-	O
Ras	B-PRGE
)	O
which	O
is	O
geranylgeranylated	O
at	O
the	O
C	O
-	O
termini	O
,	O
shares	O
85	O
%	O
homology	O
with	O
mammalian	O
K	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
-	I-PRGE
Ras	I-PRGE
protein	O
and	O
demonstrates	O
identity	O
in	O
the	O
guanine	O
nucleotide	O
binding	O
domains	O
(	O
Huang	O
C	O
-	O
F	O
,	O
Chuang	O
N	O
-	O
N	O
.	O
1999	O
.	O
J	O
Exp	O
Zool	O
283	O
:	O
510	O
-	O
521	O
)	O
.	O

Several	O
point	O
mutations	O
in	O
the	O
S	O
-	O
ras	B-PRGE
gene	O
were	O
generated	O
at	O
codons	O
12	O
(	O
G12V	O
)	O
,	O
61	O
(	O
Q61K	O
)	O
,	O
and	O
116	O
(	O
N116I	O
)	O
.	O

The	O
bacterially	O
expressed	O
mutant	O
S	O
-	O
Ras	B-PRGE
proteins	O
,	O
G12V	O
and	O
Q61K	O
,	O
were	O
bound	O
with	O
GTP	O
without	O
hydrolysis	O
.	O

In	O
contrast	O
,	O
the	O
mutant	O
S	O
-	O
Ras	B-PRGE
N116I	O
was	O
defective	O
in	O
its	O
ability	O
to	O
bind	O
any	O
guanine	O
nucleotides	O
.	O

Autoradiography	O
studies	O
showed	O
that	O
the	O
purified	O
shrimp	O
protein	O
geranylgeranyltransferase	B-PRGE
I	I-PRGE
(	O
Lin	O
R	O
-	O
S	O
,	O
Chuang	O
N	O
-	O
N	O
.	O
1998	O
.	O
J	O
Exp	O
Zool	O
281	O
:	O
565	O
-	O
573	O
)	O
was	O
unable	O
to	O
catalyze	O
the	O
transfer	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
-	O
geranylgeranylpyrophosphate	O
to	O
this	O
mutant	O
N116I	O
but	O
very	O
competently	O
caused	O
the	O
geranylgeranylation	O
of	O
GTP	O
-	O
locked	O
mutants	O
,	O
G12V	O
and	O
Q61K	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
geranylgeranylation	O
at	O
the	O
CAAX	O
box	O
of	O
the	O
shrimp	O
Ras	B-PRGE
protein	O
requires	O
the	O
proper	O
binding	O
of	O
guanine	O
nucleotide	O
at	O
its	O
N	O
-	O
terminal	O
region	O
.	O

J	O
.	O

Exp	O
.	O

Zool	O
.	O

286	O
:	O
441	O
-	O
449	O
,	O
2000	O
.	O

Akr1p	B-PRGE
and	O
the	O
type	O
I	O
casein	O
kinases	O
act	O
prior	O
to	O
the	O
ubiquitination	O
step	O
of	O
yeast	O
endocytosis	O
:	O
Akr1p	B-PRGE
is	O
required	O
for	O
kinase	O
localization	O
to	O
the	O
plasma	O
membrane	O
.	O

Ubiquitination	O
of	O
the	O
plasma	O
membrane	O
-	O
localized	O
yeast	O
a	B-PRGE
-	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
Ste3p	B-PRGE
)	O
triggers	O
a	O
rapid	O
,	O
ligand	O
-	O
independent	O
endocytosis	O
leading	O
to	O
its	O
vacuolar	O
degradation	O
.	O

This	O
report	O
identifies	O
two	O
mutants	O
that	O
block	O
uptake	O
by	O
blocking	O
ubiquitination	O
,	O
these	O
being	O
mutant	O
either	O
for	O
the	O
ankyrin	O
repeat	O
protein	O
Akr1p	B-PRGE
or	O
for	O
the	O
redundant	O
type	O
I	O
casein	O
kinases	O
Yck1p	B-PRGE
and	O
Yck2p	B-PRGE
.	O

While	O
no	O
obvious	O
defect	O
was	O
seen	O
for	O
wild	O
-	O
type	O
Ste3p	B-PRGE
phosphorylation	O
in	O
akr1	B-PRGE
or	O
yck	O
mutant	O
backgrounds	O
,	O
examination	O
of	O
the	O
Delta320	O
-	O
413	O
Ste3p	B-PRGE
deletion	O
mutant	O
phosphorylation	O
did	O
reveal	O
a	O
clear	O
defect	O
in	O
both	O
mutants	O
.	O

The	O
Delta320	O
-	O
413	O
deletion	O
removes	O
18	O
Ser	O
-	O
Thr	O
residues	O
(	O
possible	O
YCK	O
-	O
independent	O
phosphorylation	O
sites	O
)	O
yet	O
retains	O
the	O
15	O
Ser	O
-	O
Thr	O
residues	O
of	O
the	O
Ste3p	B-PRGE
PEST	O
-	O
like	O
ubiquitination	O
-	O
endocytosis	O
signal	O
.	O

Two	O
other	O
phenotypes	O
link	O
akr1	B-PRGE
and	O
yck	O
mutants	O
:	O
both	O
are	O
defective	O
in	O
phosphorylation	O
of	O
wild	O
-	O
type	O
alpha	B-PRGE
-	I-PRGE
factor	I-PRGE
receptor	I-PRGE
,	O
and	O
while	O
both	O
are	O
defective	O
for	O
Ste3p	B-PRGE
constitutive	O
internalization	O
,	O
both	O
remain	O
partially	O
competent	O
for	O
the	O
Ste3p	B-PRGE
ligand	O
-	O
dependent	O
uptake	O
mode	O
.	O

Yck1p	B-PRGE
-	O
Yck2p	B-PRGE
may	O
be	O
the	O
function	O
responsible	O
in	O
phosphorylation	O
of	O
the	O
PEST	O
-	O
like	O
ubiquitination	O
-	O
endocytosis	O
signal	O
.	O

Akr1p	B-PRGE
appears	O
to	O
function	O
in	O
localizing	O
Yck1p	B-PRGE
-	O
Yck2p	B-PRGE
to	O
the	O
plasma	O
membrane	O
,	O
a	O
localization	O
that	O
depends	O
on	O
prenylation	O
of	O
C	O
-	O
terminal	O
dicysteinyl	O
motifs	O
.	O

In	O
akr1Delta	B-PRGE
cells	O
,	O
Yck2p	B-PRGE
is	O
mislocalized	O
,	O
showing	O
a	O
diffuse	O
cytoplasmic	O
localization	O
identical	O
to	O
that	O
seen	O
for	O
a	O
Yck2p	B-PRGE
mutant	O
that	O
lacks	O
the	O
C	O
-	O
terminal	O
Cys	O
-	O
Cys	O
,	O
indicating	O
a	O
likely	O
Akr1p	B-PRGE
requirement	O
for	O
the	O
lipid	O
modification	O
of	O
Yck2p	B-PRGE
,	O
for	O
prenylation	O
,	O
or	O
possibly	O
for	O
palmitoylation	O
.	O

The	O
Drosophila	O
UBC9	B-PRGE
homologue	O
lesswright	B-PRGE
mediates	O
the	O
disjunction	O
of	O
homologues	O
in	O
meiosis	O
I	O
.	O

BACKGROUND	O
:	O
In	O
Saccharomyces	O
cerevisiae	O
and	O
other	O
organisms	O
,	O
the	O
UBC9	B-PRGE
(	O
ubiquitin	B-PRGE
-	I-PRGE
conjugating	I-PRGE
9	I-PRGE
)	O
protein	O
modifies	O
the	O
function	O
of	O
many	O
different	O
target	O
proteins	O
through	O
covalent	O
attachment	O
of	O
the	O
ubiquitin	O
-	O
like	O
protein	O
SMT	B-PRGE
-	I-PRGE
3	I-PRGE
/	O
SUMO	O
.	O

RESULTS	O
:	O
Using	O
a	O
second	O
-	O
site	O
suppression	O
screen	O
of	O
a	O
mutation	O
in	O
the	O
nod	O
locus	O
with	O
a	O
variable	O
meiotic	O
phenotype	O
,	O
we	O
have	O
identified	O
mutations	O
in	O
the	O
Drosophila	O
melanogaster	O
UBC9	B-PRGE
homologue	O
,	O
encoded	O
by	O
the	O
gene	O
lesswright	B-PRGE
(	O
lwr	B-PRGE
)	O
.	O
lwr	B-PRGE
mutations	O
dominantly	O
suppress	O
the	O
nondisjunction	O
and	O
cytological	O
defects	O
of	O
female	O
meiotic	O
mutations	O
that	O
affect	O
spindle	O
formation	O
.	O

The	O
lwr	B-PRGE
lethal	O
phenotype	O
is	O
rescued	O
by	O
a	O
Drosophila	O
UBC9	B-PRGE
/	O
lwr	B-PRGE
transgene	O
.	O

CONCLUSIONS	O
:	O
We	O
suggest	O
that	O
LWR	B-PRGE
mediates	O
the	O
dissociation	O
of	O
heterochromatic	O
regions	O
of	O
homologues	O
at	O
the	O
end	O
of	O
meiotic	O
prophase	O
I	O
.	O

Our	O
model	O
proposes	O
that	O
when	O
there	O
is	O
less	O
LWR	B-PRGE
protein	O
,	O
homologues	O
remain	O
together	O
longer	O
,	O
allowing	O
for	O
more	O
normal	O
spindle	O
formation	O
in	O
mutant	O
backgrounds	O
and	O
therefore	O
more	O
accurate	O
meiotic	O
chromosome	O
segregation	O
.	O

Solution	O
structure	O
of	O
the	O
lipoyl	O
domain	O
of	O
the	O
chimeric	O
dihydrolipoyl	O
dehydrogenase	O
P64K	B-PRGE
from	O
Neisseria	O
meningitidis	O
.	O

The	O
antigenic	O
P64K	B-PRGE
protein	O
from	O
the	O
pathogenic	O
bacterium	O
Neisseria	O
meningitidis	O
is	O
found	O
in	O
the	O
outer	O
membrane	O
of	O
the	O
cell	O
,	O
and	O
consists	O
of	O
two	O
parts	O
:	O
an	O
81	O
-	O
residue	O
N	O
-	O
terminal	O
region	O
and	O
a	O
482	O
-	O
residue	O
C	O
-	O
terminal	O
region	O
.	O

The	O
amino	O
-	O
acid	O
sequence	O
of	O
the	O
N	O
-	O
terminal	O
region	O
is	O
homologous	O
with	O
the	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	O
acyltransferase	O
(	O
E2	O
)	O
components	O
,	O
and	O
that	O
of	O
the	O
C	O
-	O
terminal	O
region	O
with	O
the	O
dihydrolipoyl	O
dehydrogenase	O
(	O
E3	O
)	O
components	O
,	O
of	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
multienzyme	O
complexes	O
.	O

The	O
two	O
parts	O
are	O
separated	O
by	O
a	O
long	O
linker	O
region	O
,	O
similar	O
to	O
the	O
linker	O
regions	O
in	O
the	O
E2	O
chains	O
of	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
complexes	O
,	O
and	O
it	O
is	O
likely	O
this	O
region	O
is	O
conformationally	O
flexible	O
.	O

A	O
subgene	O
encoding	O
the	O
P64K	B-PRGE
lipoyl	O
domain	O
was	O
created	O
and	O
over	O
-	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
product	O
was	O
capable	O
of	O
post	O
-	O
translational	O
modification	O
by	O
the	O
lipoate	B-PRGE
protein	I-PRGE
ligase	I-PRGE
but	O
not	O
aberrant	O
modification	O
by	O
the	O
biotin	B-PRGE
protein	I-PRGE
ligase	I-PRGE
of	O
E	O
.	O
coli	O
.	O

The	O
solution	O
structure	O
of	O
the	O
apo	O
-	O
domain	O
was	O
determined	O
by	O
means	O
of	O
heteronuclear	O
NMR	O
spectroscopy	O
and	O
found	O
to	O
be	O
a	O
flattened	O
beta	O
barrel	O
composed	O
of	O
two	O
four	O
-	O
stranded	O
antiparallel	O
beta	O
sheets	O
.	O

The	O
lysine	O
residue	O
that	O
becomes	O
lipoylated	O
is	O
in	O
an	O
exposed	O
beta	O
turn	O
that	O
,	O
from	O
a	O
[	O
1H	O
]	O
-	O
15N	O
heteronuclear	O
Overhauser	O
effect	O
experiment	O
,	O
appears	O
to	O
enjoy	O
substantial	O
local	O
motion	O
.	O

This	O
structure	O
of	O
a	O
lipoyl	O
domain	O
derived	O
from	O
a	O
dihydrolipoyl	O
dehydrogenase	O
resembles	O
that	O
of	O
lipoyl	O
domains	O
normally	O
found	O
as	O
part	O
of	O
the	O
dihydrolipoyl	O
acyltransferase	O
component	O
of	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
complexes	O
and	O
will	O
assist	O
in	O
furthering	O
the	O
understanding	O
of	O
its	O
function	O
in	O
a	O
multienzyme	O
complex	O
and	O
in	O
the	O
membrane	O
-	O
bound	O
P64K	B-PRGE
protein	O
itself	O
.	O

PARP	B-PRGE
-	I-PRGE
1	I-PRGE
modifies	O
the	O
effectiveness	O
of	O
p53	B-PRGE
-	O
mediated	O
DNA	O
damage	O
response	O
.	O

The	O
tumour	O
suppressor	O
protein	O
p53	B-PRGE
plays	O
a	O
key	O
role	O
in	O
the	O
cell	O
'	O
s	O
decision	O
to	O
arrest	O
the	O
cell	O
cycle	O
or	O
undergo	O
apoptosis	O
following	O
a	O
genotoxic	O
insult	O
.	O

p53	B-PRGE
is	O
stabilized	O
and	O
activated	O
after	O
DNA	O
damage	O
,	O
however	O
the	O
cascade	O
of	O
events	O
signalling	O
from	O
DNA	O
lesions	O
to	O
p53	B-PRGE
stabilization	O
and	O
activation	O
is	O
still	O
controversial	O
.	O

Poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
different	O
nuclear	O
acceptors	O
by	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
an	O
early	O
event	O
when	O
a	O
single	O
strand	O
DNA	O
lesion	O
is	O
produced	O
.	O

We	O
present	O
here	O
evidences	O
that	O
interplay	O
between	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
p53	B-PRGE
is	O
dependent	O
on	O
the	O
type	O
of	O
damage	O
induced	O
to	O
DNA	O
.	O

Primary	O
mouse	O
embryonic	O
fibroblasts	O
derived	O
from	O
parp	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
/	O
-	O
mice	O
exhibited	O
decreased	O
p53	B-PRGE
accumulation	O
and	O
activation	O
following	O
gamma	O
-	O
irradiation	O
compared	O
to	O
parp	B-PRGE
-	I-PRGE
1	I-PRGE
proficient	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
with	O
the	O
single	O
alkylating	O
agent	O
2	O
'	O
-	O
methyl	O
-	O
2	O
'	O
-	O
nitrose	O
-	O
urea	O
(	O
MNU	O
)	O
,	O
resulted	O
in	O
the	O
rapid	O
and	O
sustained	O
accumulation	O
and	O
activation	O
of	O
p53	B-PRGE
in	O
parp	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
deficient	O
cells	O
,	O
while	O
very	O
little	O
accumulation	O
was	O
observed	O
in	O
parp	B-PRGE
-	I-PRGE
1	I-PRGE
+	O
/	O
+	O
cells	O
.	O

After	O
IR	O
,	O
the	O
turnover	O
of	O
the	O
p53	B-PRGE
inhibitory	O
protein	O
MDM	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
perturbed	O
and	O
the	O
level	O
of	O
phosphorylation	O
of	O
p53	B-PRGE
at	O
serine	O
-	O
15	O
is	O
blunted	O
in	O
parp	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
/	O
-	O
cells	O
.	O

PARP	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
determinant	O
in	O
the	O
cytotoxic	O
response	O
to	O
alkylating	O
agents	O
but	O
only	O
partially	O
contributes	O
to	O
radiation	O
-	O
induced	O
cell	O
killing	O
,	O
as	O
determined	O
by	O
colony	O
forming	O
assay	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
PARP	B-PRGE
-	I-PRGE
1	I-PRGE
participates	O
in	O
the	O
p53	B-PRGE
response	O
following	O
irradiation	O
,	O
resides	O
upstream	O
of	O
p53	B-PRGE
and	O
indirectly	O
modulates	O
the	O
level	O
of	O
phosphorylation	O
of	O
key	O
substrates	O
in	O
this	O
pathway	O
while	O
treatment	O
with	O
MNU	O
results	O
in	O
an	O
enhanced	O
p53	B-PRGE
-	O
mediated	O
response	O
in	O
parp	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
null	O
cells	O
.	O

[	O
Monoclonal	O
antibodies	O
against	O
protein	O
Daxx	B-PRGE
and	O
its	O
localization	O
in	O
nuclear	O
domains	O
10	O
]	O

Nuclear	O
domains	O
10	O
(	O
ND10	O
)	O
were	O
first	O
detected	O
occasionally	O
using	O
antibodies	O
to	O
an	O
antigen	O
of	O
unknown	O
nature	O
(	O
Ascoli	O
,	O
Maul	O
,	O
1991	O
)	O
.	O

Further	O
on	O
it	O
was	O
shown	O
that	O
ND10	O
were	O
sites	O
of	O
locality	O
of	O
the	O
number	O
of	O
proteins	O
(	O
PML	B-PRGE
,	O
Sp	B-PRGE
100	I-PRGE
,	O
pRB	B-PRGE
)	O
(	O
Sterndorf	O
et	O
al	O
.	O
,	O
1992	O
;	O
Kamitani	O
et	O
al	O
.	O
,	O
1998	O
)	O
,	O
the	O
majority	O
of	O
which	O
are	O
modified	O
with	O
ubiquitin	B-PRGE
-	O
like	O
small	O
proteins	O
-	O
modifiers	O
(	O
SUMO	O
)	O
(	O
Ishov	O
,	O
Maul	O
,	O
1996	O
)	O
.	O

In	O
addition	O
,	O
it	O
was	O
shown	O
that	O
ND10	O
were	O
sites	O
of	O
primary	O
localization	O
,	O
transcription	O
and	O
replication	O
of	O
some	O
DNA	O
-	O
viruses	O
(	O
SV40	O
,	O
virus	O
of	O
simple	O
herpes	O
1	O
,	O
adenovirus	O
5	O
)	O
(	O
Ishov	O
,	O
Maul	O
,	O
1996	O
;	O
Ishov	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

Except	O
for	O
SV40	O
,	O
these	O
viruses	O
produce	O
proteins	O
able	O
to	O
modify	O
ND10	O
,	O
or	O
leading	O
to	O
degradation	O
of	O
ND10	O
-	O
associated	O
proteins	O
(	O
Maul	O
et	O
al	O
.	O
,	O
1993	O
;	O
Maul	O
,	O
Everett	O
,	O
1994	O
)	O
.	O

This	O
degradation	O
is	O
accompanied	O
with	O
protein	O
desumofication	O
and	O
,	O
later	O
,	O
with	O
hydrolysis	O
on	O
the	O
ubiquitin	B-PRGE
-	O
proteosomal	O
way	O
(	O
Everett	O
et	O
al	O
.	O
,	O
1998	O
,	O
1999	O
)	O
.	O

Cell	O
incubation	O
with	O
interferon	O
leads	O
to	O
augmentation	O
of	O
the	O
number	O
and	O
dimension	O
of	O
ND10	O
owing	O
to	O
increased	O
expression	O
of	O
Sp100	B-PRGE
and	O
PML	B-PRGE
(	O
Lavau	O
et	O
al	O
.	O
,	O
1995	O
;	O
Grotzinger	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O

In	O
all	O
,	O
these	O
data	O
make	O
it	O
possible	O
to	O
put	O
forward	O
a	O
hypothesis	O
that	O
ND10	O
may	O
represent	O
a	O
peculiar	O
cell	O
storage	O
(	O
"	O
d	O
e	O
p	O
o	O
t	O
"	O
)	O
of	O
proteins	O
regulated	O
according	O
to	O
the	O
"	O
accumulation	O
-	O
drop	O
"	O
principle	O
(	O
Ishov	O
et	O
al	O
.	O
,	O
1997	O
;	O
Maul	O
,	O
1998	O
)	O
.	O

However	O
,	O
this	O
hypothesis	O
requires	O
further	O
factual	O
grounds	O
.	O

The	O
SUMO	O
ubiquitin	B-PRGE
-	O
protein	O
isopeptide	O
ligase	O
family	O
member	O
Miz1	B-PRGE
/	O
PIASxbeta	B-PRGE
/	O
Siz2	B-PRGE
is	O
a	O
transcriptional	O
cofactor	O
for	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

We	O
have	O
shown	O
previously	O
that	O
a	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
-	O
related	O
protein	O
,	O
hMusTRD1	B-PRGE
/	I-PRGE
BEN	I-PRGE
,	O
represses	O
transcriptional	O
activity	O
of	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

The	O
repression	O
by	O
hMusTRD1	B-PRGE
/	I-PRGE
BEN	I-PRGE
was	O
hypothesized	O
to	O
occur	O
via	O
a	O
two	O
-	O
step	O
competition	O
mechanism	O
involving	O
a	O
cytoplasmic	O
shuttling	O
factor	O
and	O
a	O
nuclear	O
cofactor	O
required	O
for	O
transcriptional	O
activation	O
of	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

Employing	O
a	O
two	O
-	O
hybrid	O
approach	O
with	O
both	O
yeast	O
genomic	O
and	O
mouse	O
cDNA	O
libraries	O
in	O
parallel	O
,	O
we	O
have	O
identified	O
the	O
RING	O
-	O
like	O
zinc	O
finger	O
containing	O
Miz1	B-PRGE
/	O
PIASxbeta	B-PRGE
/	O
Siz2	B-PRGE
,	O
which	O
is	O
a	O
ubiquitin	B-PRGE
-	O
protein	O
isopeptide	O
ligase	O
in	O
the	O
SUMO	O
pathway	O
,	O
as	O
the	O
potential	O
nuclear	O
cofactor	O
that	O
interacts	O
with	O
both	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
hMusTRD1	B-PRGE
/	I-PRGE
BEN	I-PRGE
.	O

Our	O
conclusion	O
is	O
based	O
on	O
the	O
following	O
observations	O
.	O

First	O
,	O
the	O
interactions	O
are	O
biochemically	O
confirmed	O
in	O
mammalian	O
cells	O
where	O
Miz1	B-PRGE
/	O
mPIASxbeta	B-PRGE
interacts	O
with	O
both	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
hMusTRD1	B-PRGE
/	I-PRGE
BEN	I-PRGE
when	O
these	O
proteins	O
are	O
ectopically	O
co	O
-	O
expressed	O
.	O

Second	O
,	O
co	O
-	O
expression	O
of	O
a	O
nuclear	O
localization	O
signal	O
-	O
deficient	O
mutant	O
of	O
Miz1	B-PRGE
/	O
mPIASxbeta	B-PRGE
with	O
wild	O
type	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
fails	O
to	O
alter	O
the	O
subcellular	O
localization	O
of	O
the	O
former	O
.	O

Finally	O
,	O
ectopically	O
expressed	O
Miz1	B-PRGE
/	O
mPIASxbeta	B-PRGE
augments	O
the	O
transcriptional	O
activity	O
of	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
relieves	O
the	O
repression	O
exerted	O
by	O
a	O
mutant	O
hMusTRD1	B-PRGE
/	I-PRGE
BEN	I-PRGE
that	O
co	O
-	O
localized	O
with	O
TFII	B-PRGE
-	I-PRGE
I	I-PRGE
in	O
the	O
nucleus	O
.	O

Modulation	O
of	O
p120E4F	B-PRGE
transcriptional	O
activity	O
by	O
the	O
Gam1	B-PRGE
adenoviral	O
early	O
protein	O
.	O

Gam1	B-PRGE
,	O
an	O
early	O
adenoviral	O
CELO	O
protein	O
,	O
is	O
required	O
for	O
viral	O
replication	O
.	O

Consistent	O
with	O
its	O
ability	O
to	O
inhibit	O
histone	B-PRGE
deacetylation	O
by	O
HDAC1	B-PRGE
,	O
Gam1	B-PRGE
activates	O
transcription	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
the	O
cellular	O
transcription	O
factor	O
p120	B-PRGE
(	O
E4F	B-PRGE
)	O
as	O
a	O
Gam1	B-PRGE
interaction	O
partner	O
.	O

p120	B-PRGE
(	O
E4F	B-PRGE
)	O
is	O
a	O
low	O
-	O
abundance	O
transcription	O
factor	O
that	O
represses	O
the	O
adenovirus	O
E4	B-PRGE
promoter	O
.	O

Here	O
we	O
demonstrate	O
that	O
p120	B-PRGE
(	O
E4F	B-PRGE
)	O
interacts	O
with	O
HDAC1	B-PRGE
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
that	O
E4F	B-PRGE
-	O
mediated	O
transcriptional	O
repression	O
is	O
alleviated	O
by	O
the	O
HDAC	O
inhibitor	O
trichostatin	O
A	O
or	O
by	O
overexpressing	O
Gam1	B-PRGE
.	O

A	O
mutant	O
E4	B-PRGE
promoter	O
unresponsive	O
to	O
E4F	B-PRGE
-	O
mediated	O
transcriptional	O
repression	O
is	O
also	O
not	O
stimulated	O
by	O
Gam1	B-PRGE
.	O

Moreover	O
,	O
our	O
cofractionation	O
experiments	O
demonstrate	O
that	O
p120	B-PRGE
(	O
E4F	B-PRGE
)	O
,	O
HDAC1	B-PRGE
and	O
Gam1	B-PRGE
may	O
be	O
concomitantly	O
present	O
in	O
protein	O
complexes	O
.	O

We	O
conclude	O
that	O
Gam1	B-PRGE
activates	O
E4	B-PRGE
-	O
dependent	O
transcription	O
possibly	O
by	O
inactivating	O
HDAC1	B-PRGE
.	O

The	O
B	O
cell	O
-	O
specific	O
major	O
raft	O
protein	O
,	O
Raftlin	B-PRGE
,	O
is	O
necessary	O
for	O
the	O
integrity	O
of	O
lipid	O
raft	O
and	O
BCR	O
signal	O
transduction	O
.	O

Recent	O
evidence	O
indicates	O
that	O
membrane	O
microdomains	O
,	O
termed	O
lipid	O
rafts	O
,	O
have	O
a	O
role	O
in	O
B	O
-	O
cell	O
activation	O
as	O
platforms	O
for	O
B	O
-	O
cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
signal	O
initiation	O
.	O

To	O
gain	O
an	O
insight	O
into	O
the	O
possible	O
functioning	O
of	O
lipid	O
rafts	O
in	O
B	O
cells	O
,	O
we	O
applied	O
liquid	O
chromatography	O
electrospray	O
ionization	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
)	O
methodologies	O
to	O
the	O
identification	O
of	O
proteins	O
that	O
co	O
-	O
purified	O
with	O
lipid	O
rafts	O
of	O
Raji	O
cells	O
.	O

Among	O
these	O
raft	O
proteins	O
,	O
we	O
characterized	O
a	O
novel	O
protein	O
termed	O
Raftlin	B-PRGE
(	O
raft	B-PRGE
-	I-PRGE
linking	I-PRGE
protein	I-PRGE
)	O
.	O

Like	O
the	O
Src	O
family	O
kinase	O
,	O
Raftlin	B-PRGE
is	O
localized	O
exclusively	O
in	O
lipid	O
rafts	O
by	O
fatty	O
acylation	O
of	O
N	O
-	O
terminal	O
Gly2	O
and	O
Cys3	O
,	O
and	O
is	O
co	O
-	O
localized	O
with	O
BCR	O
before	O
and	O
after	O
BCR	O
stimulation	O
.	O

Disruption	O
of	O
the	O
Raftlin	B-PRGE
gene	O
in	O
the	O
DT40	O
B	O
-	O
cell	O
line	O
resulted	O
in	O
a	O
marked	O
reduction	O
in	O
the	O
quantity	O
of	O
lipid	O
raft	O
components	O
,	O
including	O
Lyn	B-PRGE
and	O
ganglioside	O
GM1	O
,	O
while	O
overexpression	O
of	O
Raftlin	B-PRGE
increased	O
the	O
content	O
of	O
raft	O
protein	O
.	O

Moreover	O
,	O
BCR	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
calcium	O
mobilization	O
were	O
impaired	O
by	O
the	O
lack	O
of	O
Raftlin	B-PRGE
and	O
actually	O
potentiated	O
by	O
overexpression	O
of	O
Raftlin	B-PRGE
.	O

These	O
data	O
suggest	O
that	O
Raftlin	B-PRGE
plays	O
a	O
pivotal	O
role	O
in	O
the	O
formation	O
and	O
/	O
or	O
maintenance	O
of	O
lipid	O
rafts	O
,	O
therefore	O
regulating	O
BCR	O
-	O
mediated	O
signaling	O
.	O

Molecular	O
evolution	O
of	O
the	O
Rab	B-PRGE
-	I-PRGE
escort	I-PRGE
-	I-PRGE
protein	I-PRGE
/	O
guanine	B-PRGE
-	I-PRGE
nucleotide	I-PRGE
-	I-PRGE
dissociation	I-PRGE
-	I-PRGE
inhibitor	I-PRGE
superfamily	O
.	O

Prenylation	O
of	O
Rab	O
GTPases	O
regulating	O
vesicle	O
traffic	O
by	O
Rab	O
geranylgeranyltransferase	O
(	O
RabGGTase	O
)	O
requires	O
a	O
complex	O
formed	O
by	O
the	O
association	O
of	O
newly	O
synthesized	O
Rab	O
proteins	O
with	O
Rab	B-PRGE
-	I-PRGE
escort	I-PRGE
-	I-PRGE
protein	I-PRGE
(	O
REP	B-PRGE
)	O
,	O
the	O
choroideremia	B-PRGE
-	O
gene	O
-	O
product	O
that	O
is	O
mutated	O
in	O
disease	O
,	O
leading	O
to	O
loss	O
of	O
vision	O
.	O

After	O
delivery	O
to	O
the	O
membrane	O
by	O
the	O
REP	B-PRGE
-	O
Rab	O
complex	O
,	O
subsequent	O
recycling	O
to	O
the	O
cytosol	O
requires	O
the	O
REP	B-PRGE
-	O
related	O
guanine	B-PRGE
-	I-PRGE
nucleotide	I-PRGE
-	I-PRGE
dissociation	I-PRGE
-	I-PRGE
inhibitor	I-PRGE
(	O
GDI	B-PRGE
)	O
.	O

Although	O
REP	B-PRGE
and	O
GDI	B-PRGE
share	O
common	O
Rab	O
-	O
binding	O
properties	O
,	O
GDI	B-PRGE
cannot	O
assist	O
in	O
Rab	O
prenylation	O
and	O
REP	B-PRGE
cannot	O
retrieve	O
Rab	O
proteins	O
from	O
the	O
membranes	O
.	O

We	O
have	O
now	O
isolated	O
REP	B-PRGE
mutant	O
proteins	O
that	O
are	O
able	O
to	O
partially	O
function	O
as	O
both	O
REP	B-PRGE
and	O
GDI	B-PRGE
.	O

These	O
results	O
provide	O
molecular	O
insight	O
into	O
the	O
functional	O
and	O
evolutionary	O
organization	O
of	O
the	O
REP	B-PRGE
/	O
GDI	B-PRGE
superfamily	O
.	O

Synthesis	O
of	O
functionalized	O
rab	O
GTPases	O
by	O
a	O
combination	O
of	O
solution	O
-	O
or	O
solid	O
-	O
phase	O
lipopeptide	O
synthesis	O
with	O
expressed	O
protein	O
ligation	O
.	O

Prenylated	O
proteins	O
with	O
non	O
-	O
native	O
functionalities	O
are	O
generally	O
very	O
difficult	O
to	O
obtain	O
by	O
recombinant	O
or	O
enzymatic	O
means	O
.	O

The	O
semisynthesis	O
of	O
preparative	O
amounts	O
of	O
prenylated	O
Rab	O
guanosine	O
triphosphatases	O
(	O
GTPases	O
)	O
from	O
recombinant	O
proteins	O
and	O
synthetic	O
prenylated	O
peptides	O
depends	O
largely	O
on	O
the	O
availability	O
of	O
functionalised	O
prenylated	O
peptides	O
corresponding	O
to	O
the	O
proteins	O
'	O
native	O
structure	O
or	O
modifications	O
thereof	O
.	O

Here	O
,	O
we	O
describe	O
and	O
compare	O
solution	O
-	O
phase	O
and	O
solid	O
-	O
phase	O
strategies	O
for	O
the	O
generation	O
of	O
peptides	O
corresponding	O
to	O
the	O
prenylated	O
C	O
terminus	O
of	O
Rab7	B-PRGE
GTPase	O
.	O

The	O
solid	O
-	O
phase	O
with	O
utilisation	O
of	O
a	O
hydrazide	O
linker	O
emerges	O
as	O
the	O
more	O
favourable	O
approach	O
.	O

It	O
allows	O
a	O
fast	O
and	O
practical	O
synthesis	O
of	O
pure	O
peptides	O
and	O
gives	O
a	O
high	O
degree	O
of	O
flexibility	O
in	O
their	O
modification	O
.	O

To	O
facilitate	O
the	O
analysis	O
of	O
semisynthetic	O
proteins	O
,	O
the	O
synthesised	O
peptides	O
were	O
equipped	O
with	O
a	O
fluorescent	O
group	O
.	O

Using	O
the	O
described	O
approach	O
,	O
we	O
introduced	O
fluorophores	O
at	O
several	O
different	O
positions	O
of	O
the	O
Rab7	B-PRGE
C	O
terminus	O
.	O

The	O
position	O
of	O
the	O
incorporated	O
fluorescent	O
groups	O
in	O
the	O
peptides	O
did	O
not	O
influence	O
the	O
protein	O
-	O
ligation	O
reaction	O
,	O
as	O
the	O
generated	O
peptides	O
could	O
be	O
ligated	O
onto	O
thioester	O
-	O
tagged	O
Rab7	B-PRGE
.	O

However	O
,	O
it	O
was	O
found	O
that	O
the	O
positioning	O
of	O
the	O
fluorescent	O
group	O
had	O
an	O
influence	O
on	O
the	O
functionality	O
of	O
the	O
Rab7	B-PRGE
proteins	O
;	O
analysis	O
of	O
the	O
interaction	O
of	O
the	O
semisynthetic	O
Rab7	B-PRGE
proteins	O
with	O
REP	O
(	O
Rab	O
escort	O
protein	O
)	O
and	O
GDI	O
(	O
guanosine	O
diphosphate	O
dissociation	O
inhibitor	O
)	O
molecules	O
revealed	O
that	O
modification	O
of	O
the	O
peptide	O
side	O
chains	O
or	O
of	O
the	O
C	O
-	O
terminal	O
isoprenoid	O
did	O
not	O
significantly	O
interfere	O
with	O
complex	O
formation	O
.	O

However	O
,	O
functionalisation	O
of	O
the	O
C	O
terminus	O
was	O
found	O
to	O
have	O
an	O
adverse	O
effect	O
on	O
complex	O
formation	O
and	O
stability	O
,	O
possibly	O
reflecting	O
low	O
structural	O
flexibility	O
of	O
the	O
Rab	O
GDI	O
/	O
REP	O
molecules	O
in	O
the	O
vicinity	O
of	O
the	O
lipid	O
-	O
binding	O
site	O
.	O

Application	O
of	O
protein	O
semisynthesis	O
for	O
the	O
construction	O
of	O
functionalized	O
posttranslationally	O
modified	O
rab	O
GTPases	O
.	O

Rab	O
GTPases	O
represent	O
a	O
family	O
of	O
key	O
membrane	O
traffic	O
regulators	O
in	O
eukaryotic	O
cells	O
.	O

To	O
exert	O
their	O
function	O
,	O
Rab	O
proteins	O
must	O
be	O
modified	O
with	O
one	O
or	O
two	O
geranylgeranyl	O
moieties	O
.	O

This	O
modification	O
enables	O
them	O
to	O
reversibly	O
associate	O
with	O
intracellular	O
membranes	O
.	O

In	O
vivo	O
the	O
newly	O
synthesized	O
Rab	O
proteins	O
are	O
recruited	O
by	O
Rab	O
escort	O
protein	O
(	O
REP	O
)	O
that	O
presents	O
them	O
to	O
the	O
Rab	O
geranylgeranyl	O
transferase	O
(	O
Rab	O
GGTase	O
)	O
,	O
which	O
transfers	O
one	O
or	O
two	O
geranylgeranyl	O
moieties	O
to	O
the	O
C	O
-	O
terminal	O
cysteines	O
.	O

Detailed	O
understanding	O
of	O
the	O
mechanism	O
of	O
prenylation	O
reaction	O
and	O
subsequent	O
membrane	O
delivery	O
of	O
Rab	O
proteins	O
to	O
the	O
target	O
membranes	O
were	O
hampered	O
by	O
lack	O
of	O
efficient	O
technologies	O
for	O
the	O
generation	O
of	O
preparative	O
amounts	O
of	O
prenylated	O
Rab	O
GTPases	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
approach	O
that	O
combines	O
recombinant	O
protein	O
production	O
,	O
chemical	O
synthesis	O
of	O
lipidated	O
peptides	O
with	O
precisely	O
designed	O
and	O
readily	O
alterable	O
structures	O
,	O
and	O
a	O
technique	O
for	O
peptide	O
-	O
to	O
-	O
protein	O
ligation	O
.	O

Using	O
this	O
approach	O
,	O
we	O
generated	O
a	O
number	O
of	O
semisynthetic	O
prenylated	O
Rab	O
GTPases	O
.	O

Some	O
of	O
the	O
proteins	O
were	O
also	O
supplemented	O
with	O
fluorophores	O
,	O
which	O
enabled	O
us	O
to	O
develop	O
a	O
fluorescence	O
-	O
based	O
in	O
vitro	O
prenylation	O
assay	O
.	O

The	O
approach	O
described	O
allows	O
production	O
of	O
preparative	O
amounts	O
of	O
prenylated	O
GTPases	O
,	O
which	O
was	O
demonstrated	O
by	O
generation	O
and	O
crystallization	O
of	O
a	O
monoprenylated	O
YPT1	B-PRGE
:	O
Rab	B-PRGE
GDI	I-PRGE
complex	O
.	O

Simple	O
histone	B-PRGE
acetylation	O
plays	O
a	O
complex	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

Eukaryotic	O
DNA	O
is	O
packaged	O
into	O
chromatin	O
by	O
histone	B-PRGE
proteins	O
,	O
which	O
assemble	O
the	O
DNA	O
into	O
an	O
organized	O
,	O
higher	O
-	O
order	O
structure	O
.	O

The	O
precise	O
organization	O
of	O
chromatin	O
is	O
essential	O
for	O
faithful	O
execution	O
of	O
DNA	O
-	O
mediated	O
reactions	O
such	O
as	O
transcription	O
,	O
DNA	O
replication	O
,	O
DNA	O
repair	O
and	O
DNA	O
recombination	O
.	O

The	O
organization	O
of	O
chromatin	O
is	O
considered	O
to	O
be	O
regulated	O
by	O
a	O
variety	O
of	O
post	O
-	O
translational	O
modifications	O
of	O
histones	B-PRGE
,	O
such	O
as	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
SUMOylation	O
and	O
poly	O
-	O
ADP	O
-	O
ribosylation	O
.	O

The	O
relationship	O
between	O
histone	B-PRGE
acetylation	O
and	O
gene	O
expression	O
was	O
first	O
observed	O
in	O
1964	O
.	O

Since	O
then	O
,	O
a	O
great	O
deal	O
of	O
evidence	O
has	O
accumulated	O
showing	O
that	O
not	O
only	O
transcription	O
but	O
other	O
DNA	O
-	O
mediated	O
reactions	O
also	O
are	O
regulated	O
by	O
histone	B-PRGE
acetylation	O
.	O

With	O
regard	O
to	O
the	O
putative	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
histone	B-PRGE
acetylation	O
regulates	O
the	O
flow	O
of	O
genetic	O
information	O
,	O
site	O
-	O
specific	O
modification	O
and	O
recognition	O
of	O
acetylated	O
histone	B-PRGE
/	O
DNA	O
complexes	O
have	O
been	O
postulated	O
.	O

Elucidation	O
of	O
the	O
downstream	O
effects	O
of	O
histone	B-PRGE
modification	O
,	O
as	O
well	O
as	O
the	O
identification	O
,	O
isolation	O
and	O
characterization	O
of	O
the	O
relevant	O
factors	O
involved	O
,	O
have	O
aided	O
in	O
our	O
understanding	O
of	O
the	O
mechanisms	O
of	O
regulation	O
of	O
DNA	O
activity	O
by	O
histones	B-PRGE
.	O

Currently	O
,	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
technologies	O
that	O
enable	O
genome	O
-	O
wide	O
analysis	O
are	O
allowing	O
insight	O
into	O
a	O
critical	O
and	O
interesting	O
question	O
in	O
eukaryotic	O
transcription	O
:	O
are	O
the	O
principles	O
that	O
govern	O
transcription	O
of	O
individual	O
gene	O
loci	O
applicable	O
to	O
the	O
genome	O
as	O
a	O
whole	O
?	O

Here	O
,	O
we	O
review	O
the	O
recent	O
progress	O
on	O
histone	B-PRGE
modifications	O
,	O
with	O
an	O
emphasis	O
on	O
the	O
role	O
of	O
histone	B-PRGE
acetylation	O
in	O
gene	O
expression	O
.	O

PIAS3	B-PRGE
induction	O
of	O
PRB	B-PRGE
sumoylation	O
represses	O
PRB	B-PRGE
transactivation	O
by	O
destabilizing	O
its	O
retention	O
in	O
the	O
nucleus	O
.	O

Progesterone	B-PRGE
receptor	I-PRGE
(	O
PR	B-PRGE
)	O
plays	O
a	O
critical	O
role	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
,	O
and	O
its	O
transcriptional	O
activity	O
is	O
known	O
to	O
be	O
modulated	O
by	O
cofactor	O
proteins	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
in	O
the	O
presence	O
of	O
progesterone	O
,	O
protein	B-PRGE
inhibitor	I-PRGE
of	I-PRGE
activated	I-PRGE
STAT	I-PRGE
-	I-PRGE
3	I-PRGE
(	O
PIAS3	B-PRGE
)	O
significantly	O
inhibited	O
the	O
PR	B-PRGE
transcriptional	O
activity	O
and	O
the	O
expression	O
of	O
progesterone	O
-	O
responsive	O
genes	O
.	O

Reduction	O
of	O
endogenous	O
PIAS3	B-PRGE
by	O
PIAS3	B-PRGE
small	O
-	O
interfering	O
RNA	O
enhanced	O
PR	B-PRGE
transactivation	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

PIAS3	B-PRGE
interacted	O
with	O
PR	B-PRGE
both	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
the	O
interaction	O
was	O
enhanced	O
by	O
progesterone	O
.	O

Furthermore	O
,	O
our	O
findings	O
suggested	O
that	O
PIAS3	B-PRGE
strongly	O
induced	O
PRB	B-PRGE
sumoylation	O
at	O
three	O
sites	O
,	O
Lys	O
-	O
7	O
,	O
Lys	O
-	O
388	O
and	O
Lys	O
-	O
531	O
.	O

In	O
addition	O
,	O
novel	O
roles	O
in	O
PRB	B-PRGE
nuclear	O
retention	O
and	O
transactivation	O
were	O
identified	O
for	O
these	O
sites	O
.	O

Our	O
data	O
also	O
suggested	O
that	O
PIAS3	B-PRGE
was	O
recruited	O
in	O
a	O
largely	O
hormone	O
-	O
dependent	O
manner	O
in	O
response	O
to	O
a	O
progesterone	O
-	O
responsive	O
promoter	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
PIAS3	B-PRGE
inhibited	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
PR	B-PRGE
and	O
influenced	O
its	O
nuclear	O
export	O
as	O
well	O
as	O
PR	B-PRGE
transactivation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
strongly	O
suggested	O
that	O
PIAS3	B-PRGE
played	O
an	O
important	O
physiological	O
role	O
in	O
PR	B-PRGE
function	O
.	O

Herpes	O
simplex	O
virus	O
protein	O
UL11	B-PRGE
but	O
not	O
UL51	B-PRGE
is	O
associated	O
with	O
lipid	O
rafts	O
.	O

The	O
UL11	B-PRGE
and	O
UL51	B-PRGE
gene	O
products	O
of	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
are	O
membrane	O
-	O
associated	O
tegument	O
proteins	O
that	O
are	O
incorporated	O
into	O
the	O
HSV	O
virion	O
.	O

UL11	B-PRGE
and	O
UL51	B-PRGE
are	O
conserved	O
throughout	O
the	O
herpesvirus	O
family	O
.	O

Both	O
UL11	B-PRGE
and	O
UL51	B-PRGE
,	O
either	O
singly	O
or	O
in	O
combination	O
,	O
are	O
involved	O
in	O
virion	O
envelopment	O
and	O
/	O
or	O
egress	O
.	O

Both	O
proteins	O
are	O
fatty	O
acylated	O
:	O
UL11	B-PRGE
is	O
both	O
acylated	O
by	O
myristoic	O
and	O
palmitoic	O
acids	O
and	O
UL51	B-PRGE
is	O
monoacylated	O
by	O
palmitoic	O
acid	O
.	O

Using	O
confocal	O
microscopy	O
and	O
sucrose	O
gradient	O
fractionations	O
in	O
transfected	O
or	O
HSV	O
-	O
infected	O
cells	O
,	O
we	O
found	O
that	O
HSV	O
-	O
2	O
UL11	B-PRGE
but	O
not	O
UL51	B-PRGE
was	O
associated	O
with	O
lipid	O
rafts	O
.	O

The	O
dual	O
acylation	O
of	O
UL11	B-PRGE
was	O
necessary	O
for	O
lipid	O
raft	O
association	O
,	O
as	O
mutations	O
in	O
the	O
myristoylation	O
or	O
palmitoylation	O
sites	O
prevented	O
lipid	O
raft	O
association	O
.	O

These	O
differences	O
in	O
lipid	O
raft	O
association	O
may	O
contribute	O
to	O
the	O
functional	O
differences	O
between	O
UL11	B-PRGE
and	O
UL51	B-PRGE
.	O

Localization	O
of	O
the	O
TIG3	B-PRGE
transglutaminase	O
interaction	O
domain	O
and	O
demonstration	O
that	O
the	O
amino	O
-	O
terminal	O
region	O
is	O
required	O
for	O
TIG3	B-PRGE
function	O
as	O
a	O
keratinocyte	O
differentiation	O
regulator	O
.	O

Tazarotene	B-PRGE
-	I-PRGE
induced	I-PRGE
gene	I-PRGE
3	I-PRGE
(	O
TIG3	B-PRGE
)	O
regulates	O
keratinocyte	O
terminal	O
differentiation	O
by	O
activating	O
type	B-PRGE
I	I-PRGE
transglutaminase	I-PRGE
(	O
TG1	B-PRGE
)	O
.	O

TIG3	B-PRGE
consists	O
of	O
an	O
amino	O
-	O
terminal	O
(	O
N	O
-	O
terminal	O
)	O
segment	O
,	O
that	O
encodes	O
several	O
conserved	O
motifs	O
,	O
and	O
a	O
carboxy	O
-	O
terminal	O
(	O
C	O
-	O
terminal	O
)	O
membrane	O
-	O
anchoring	O
domain	O
.	O

By	O
producing	O
a	O
series	O
of	O
truncation	O
mutants	O
that	O
remove	O
segments	O
of	O
the	O
N	O
-	O
terminal	O
region	O
,	O
and	O
monitoring	O
the	O
ability	O
of	O
each	O
mutant	O
to	O
co	O
-	O
precipitate	O
TG1	B-PRGE
,	O
function	O
as	O
a	O
TG1	B-PRGE
substrate	O
,	O
or	O
functionally	O
localize	O
with	O
TG1	O
in	O
cells	O
,	O
we	O
show	O
that	O
the	O
TIG3	B-PRGE
domain	O
that	O
interacts	O
with	O
TG1	B-PRGE
is	O
located	O
within	O
a	O
TIG3	B-PRGE
segment	O
spanning	O
amino	O
acids	O
112	O
-	O
164	O
.	O

Although	O
they	O
bind	O
TG1	B-PRGE
,	O
TIG3	B-PRGE
mutants	O
lacking	O
the	O
conserved	O
N	O
-	O
terminal	O
region	O
drive	O
apoptosis	O
-	O
like	O
cell	O
death	O
characterized	O
by	O
cell	O
rounding	O
,	O
membrane	O
blebbing	O
,	O
cytochrome	B-PRGE
c	I-PRGE
release	O
,	O
procaspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
cleavage	O
,	O
and	O
reduced	O
p53	B-PRGE
and	O
p21	B-PRGE
levels	O
.	O

Compared	O
with	O
TIG3	B-PRGE
,	O
these	O
truncated	O
mutants	O
have	O
an	O
increased	O
tendency	O
to	O
associate	O
with	O
membranes	O
.	O

A	O
mutant	O
lacking	O
the	O
C	O
-	O
terminal	O
membrane	O
-	O
anchoring	O
domain	O
is	O
inactive	O
.	O

These	O
findings	O
suggest	O
that	O
TIG3	B-PRGE
interaction	O
with	O
TG1	B-PRGE
does	O
not	O
require	O
the	O
N	O
-	O
terminal	O
conserved	O
domains	O
,	O
that	O
the	O
TIG3	B-PRGE
N	O
-	O
terminal	O
region	O
is	O
required	O
for	O
TIG3	B-PRGE
-	O
dependent	O
keratinocyte	O
differentiation	O
,	O
that	O
its	O
removal	O
converts	O
TIG3	B-PRGE
into	O
a	O
proapoptotic	O
protein	O
,	O
and	O
that	O
this	O
change	O
in	O
action	O
of	O
TIG3	B-PRGE
is	O
associated	O
with	O
an	O
intracellular	O
redistribution	O
.	O

Altered	O
pattern	O
of	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
expression	O
and	O
neddylation	O
in	O
human	O
lung	O
tumours	O
:	O
relationships	O
with	O
CAND1	B-PRGE
and	O
cyclin	B-PRGE
E	I-PRGE
protein	O
levels	O
.	O

The	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
is	O
the	O
scaffold	O
element	O
of	O
SCF	O
complexes	O
that	O
are	O
involved	O
in	O
the	O
proteasomal	O
degradation	O
of	O
numerous	O
proteins	O
regulating	O
cell	O
cycle	O
progression	O
.	O

Owing	O
to	O
this	O
central	O
role	O
in	O
cell	O
growth	O
control	O
,	O
aberrant	O
expression	O
of	O
the	O
components	O
of	O
SCF	O
is	O
thought	O
to	O
play	O
a	O
role	O
during	O
tumourigenesis	O
.	O

Nothing	O
is	O
known	O
about	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
human	O
tumours	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
its	O
status	O
in	O
a	O
series	O
of	O
128	O
human	O
lung	O
carcinomas	O
,	O
comprising	O
50	O
non	O
-	O
small	O
cell	O
lung	O
cancers	O
(	O
NSCLCs	O
;	O
29	O
squamous	O
cell	O
carcinomas	O
and	O
21	O
adenocarcinomas	O
)	O
and	O
78	O
neuroendocrine	O
(	O
NE	O
)	O
lung	O
tumours	O
(	O
24	O
typical	O
and	O
atypical	O
carcinoids	O
,	O
19	O
large	O
cell	O
NE	O
carcinomas	O
and	O
35	O
small	O
cell	O
lung	O
carcinomas	O
)	O
,	O
using	O
immunohistochemistry	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
an	O
altered	O
pattern	O
of	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
human	O
tumours	O
;	O
indeed	O
,	O
we	O
show	O
that	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
is	O
up	O
-	O
regulated	O
in	O
40	O
%	O
(	O
51	O
/	O
128	O
)	O
of	O
all	O
lung	O
tumours	O
as	O
compared	O
to	O
normal	O
lung	O
tissues	O
,	O
including	O
34	O
%	O
(	O
17	O
/	O
50	O
)	O
,	O
75	O
%	O
(	O
18	O
/	O
24	O
)	O
and	O
30	O
%	O
(	O
16	O
/	O
54	O
)	O
of	O
NSCLCs	O
,	O
carcinoids	O
and	O
high	O
grade	O
neuroendocrine	O
lung	O
carcinomas	O
,	O
respectively	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
high	O
levels	O
of	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
are	O
associated	O
with	O
a	O
low	O
KI67	O
proliferative	O
index	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
with	O
a	O
decrease	O
in	O
the	O
cyclin	B-PRGE
E	I-PRGE
oncoprotein	O
(	O
p	O
=	O
0	O
.	O
0003	O
)	O
,	O
one	O
of	O
the	O
major	O
targets	O
of	O
SCF	O
complexes	O
.	O

These	O
data	O
suggest	O
that	O
up	O
-	O
regulation	O
of	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
could	O
protect	O
cells	O
from	O
hyperproliferative	O
signals	O
through	O
cyclin	B-PRGE
E	I-PRGE
down	O
-	O
regulation	O
.	O

Cul	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
modified	O
by	O
neddylation	O
,	O
a	O
post	O
-	O
translational	O
modification	O
that	O
grafts	O
ubiquitin	B-PRGE
-	O
like	O
Nedd8	B-PRGE
/	O
Rub1	B-PRGE
residues	O
and	O
controls	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
neddylated	O
forms	O
of	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
are	O
specifically	O
expressed	O
in	O
high	O
-	O
grade	O
NE	O
lung	O
tumours	O
and	O
are	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
the	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
inhibitor	O
CAND1	B-PRGE
(	O
p	O
=	O
0	O
.	O
03	O
)	O
and	O
a	O
high	O
level	O
of	O
cyclin	B-PRGE
E	I-PRGE
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

These	O
data	O
support	O
the	O
notion	O
that	O
alterations	O
in	O
the	O
Cul	B-PRGE
-	I-PRGE
1	I-PRGE
neddylation	O
/	O
deneddylation	O
pathway	O
could	O
contribute	O
to	O
the	O
development	O
of	O
these	O
highly	O
aggressive	O
lung	O
tumours	O
.	O

Polyunsaturated	O
fatty	O
acids	O
block	O
platelet	O
-	O
activating	O
factor	O
-	O
induced	O
phosphatidylinositol	O
3	O
kinase	O
/	O
Akt	O
-	O
mediated	O
apoptosis	O
in	O
intestinal	O
epithelial	O
cells	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
causes	O
apoptosis	O
in	O
enterocytes	O
via	O
a	O
mechanism	O
that	O
involves	O
Bax	B-PRGE
translocation	O
to	O
mitochondria	O
,	O
followed	O
by	O
caspase	O
activation	O
and	O
DNA	O
fragmentation	O
.	O

Herein	O
we	O
report	O
that	O
,	O
in	O
rat	O
small	O
intestinal	O
epithelial	O
cells	O
(	O
IEC	O
-	O
6	O
)	O
,	O
these	O
downstream	O
apoptotic	O
effects	O
are	O
mediated	O
by	O
a	O
PAF	O
-	O
induced	O
inhibition	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
/	O
protein	O
kinase	O
B	O
(	O
Akt	O
)	O
signaling	O
pathway	O
.	O

Treatment	O
with	O
PAF	O
results	O
in	O
rapid	O
dephosphorylation	O
of	O
Akt	O
,	O
phosphoinositide	B-PRGE
-	I-PRGE
dependent	I-PRGE
kinase	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
the	O
YXXM	O
p85	B-PRGE
binding	O
motif	O
of	O
several	O
proteins	O
and	O
redistribution	O
of	O
Akt	O
-	O
pleckstrin	O
homology	O
domain	O
-	O
green	O
fluorescent	O
protein	O
,	O
i	O
.	O
e	O
.	O
,	O
an	O
in	O
vivo	O
phosphatidylinositol	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
-	O
trisphosphate	O
sensor	O
,	O
from	O
membrane	O
to	O
cytosol	O
.	O

The	O
proapoptotic	O
effects	O
of	O
PAF	O
were	O
inhibited	O
by	O
both	O
n	O
-	O
3	O
and	O
n	O
-	O
6	O
polyunsaturated	O
fatty	O
acids	O
but	O
not	O
by	O
a	O
saturated	O
fatty	O
acid	O
palmitate	O
.	O

Indomethacin	O
,	O
an	O
inhibitor	O
of	O
prostaglandin	O
biosynthesis	O
,	O
did	O
not	O
influence	O
the	O
baseline	O
or	O
PAF	O
-	O
induced	O
apoptosis	O
,	O
but	O
2	O
-	O
bromopalmitate	O
,	O
an	O
inhibitor	O
of	O
protein	O
palmitoylation	O
,	O
inhibited	O
all	O
of	O
the	O
proapoptotic	O
effects	O
of	O
PAF	O
.	O

Our	O
data	O
strongly	O
suggest	O
that	O
an	O
inhibition	O
of	O
the	O
PI	O
3	O
-	O
kinase	O
/	O
Akt	O
signaling	O
pathway	O
is	O
the	O
main	O
mechanism	O
of	O
PAF	O
-	O
induced	O
apoptosis	O
in	O
enterocytes	O
and	O
that	O
polyunsaturated	O
fatty	O
acids	O
block	O
this	O
mechanism	O
very	O
early	O
in	O
the	O
signaling	O
cascade	O
independently	O
of	O
any	O
effect	O
on	O
prostaglandin	O
synthesis	O
,	O
and	O
probably	O
directly	O
via	O
an	O
effect	O
on	O
protein	O
palmitoylation	O
.	O

Ubiquitylation	O
is	O
required	O
for	O
degradation	O
of	O
transmembrane	O
surface	O
proteins	O
in	O
trypanosomes	O
.	O

The	O
surface	O
of	O
Trypanosoma	O
brucei	O
is	O
dominated	O
by	O
glycosyl	O
-	O
phosphatidylinositol	O
(	O
GPI	O
)	O
-	O
anchored	O
proteins	O
,	O
and	O
endocytosis	O
is	O
clathrin	O
dependent	O
.	O

The	O
vast	O
majority	O
of	O
internalized	O
GPI	O
-	O
anchored	O
protein	O
is	O
efficiently	O
recycled	O
,	O
while	O
the	O
processes	O
by	O
which	O
transmembrane	O
domain	O
(	O
TMD	O
)	O
proteins	O
are	O
internalized	O
and	O
sorted	O
are	O
unknown	O
.	O

We	O
demonstrate	O
that	O
internalization	O
of	O
invariant	B-PRGE
surface	I-PRGE
glycoprotein	I-PRGE
(	I-PRGE
ISG	I-PRGE
)	I-PRGE
65	I-PRGE
,	O
a	O
trypanosome	O
TMD	O
protein	O
,	O
involves	O
ubiquitylation	O
and	O
also	O
requires	O
clathrin	O
.	O

We	O
find	O
a	O
hierarchical	O
requirement	O
for	O
cytoplasmic	O
lysine	O
residues	O
in	O
internalization	O
and	O
turnover	O
,	O
and	O
a	O
single	O
position	O
-	O
specific	O
lysine	O
is	O
sufficient	O
for	O
degradation	O
,	O
surface	O
removal	O
and	O
attachment	O
of	O
oligoubiquitin	B-PRGE
chains	O
.	O

Ubiquitylation	O
is	O
context	O
dependent	O
as	O
provision	O
of	O
additional	O
lysine	O
residues	O
by	O
C	O
-	O
terminal	O
fusion	O
of	O
neuronal	B-PRGE
precursor	I-PRGE
cell	I-PRGE
-	I-PRGE
expressed	I-PRGE
developmentally	I-PRGE
downregulated	I-PRGE
protein	I-PRGE
(	I-PRGE
NEDD	I-PRGE
)	I-PRGE
8	I-PRGE
fails	O
to	O
support	O
ubiquitylation	O
.	O

Attachment	O
of	O
NEDD8	B-PRGE
leads	O
to	O
degradation	O
by	O
a	O
second	O
ubiquitin	B-PRGE
-	O
independent	O
pathway	O
.	O

Moreover	O
,	O
degradation	O
of	O
ubiquitylated	O
or	O
NEDDylated	O
substrate	O
takes	O
place	O
in	O
an	O
acidic	O
compartment	O
and	O
is	O
proteosome	O
independent	O
.	O

Significantly	O
,	O
in	O
non	O
-	O
opisthokont	O
lineages	O
,	O
Rsp5p	B-PRGE
or	O
c	B-PRGE
-	I-PRGE
Cbl	I-PRGE
,	O
the	O
E3	O
ubiquitin	B-PRGE
ligases	O
acting	O
on	O
endocytic	O
cargo	O
,	O
are	O
absent	O
but	O
Uba1	B-PRGE
class	O
genes	O
are	O
present	O
and	O
are	O
required	O
for	O
cell	O
viability	O
and	O
ISG65	B-PRGE
ubiquitylation	O
.	O

Hence	O
,	O
ubiquitylation	O
is	O
an	O
evolutionarily	O
conserved	O
mechanism	O
for	O
internalization	O
of	O
surface	O
proteins	O
,	O
but	O
aspects	O
of	O
the	O
machinery	O
differ	O
substantially	O
between	O
the	O
major	O
eukaryotic	O
lineages	O
.	O

Innate	O
link	O
between	O
NF	O
-	O
kappaB	O
activity	O
and	O
ubiquitin	B-PRGE
-	O
like	O
modifiers	O
.	O

Among	O
the	O
several	O
signalling	O
pathways	O
regulated	O
by	O
ubiquitin	B-PRGE
and	O
ubiquitin	B-PRGE
-	O
like	O
proteins	O
,	O
the	O
one	O
activating	O
NF	O
-	O
kappaB	O
(	O
nuclear	O
factor	O
kappaB	O
)	O
is	O
certainly	O
one	O
of	O
the	O
best	O
characterized	O
.	O

The	O
regulation	O
of	O
the	O
activity	O
of	O
this	O
transcription	O
factor	O
by	O
members	O
of	O
the	O
ubiquitin	B-PRGE
family	O
occurs	O
at	O
various	O
levels	O
,	O
imposing	O
overlapping	O
controls	O
of	O
security	O
of	O
intriguing	O
complexity	O
.	O

The	O
formation	O
of	O
active	O
macromolecular	O
complexes	O
such	O
as	O
the	O
IKK	O
[	O
IkappaB	O
(	O
inhibitory	O
kappaB	O
)	O
kinase	O
]	O
complex	O
is	O
tightly	O
regulated	O
by	O
these	O
post	O
-	O
translational	O
modifications	O
probably	O
due	O
to	O
the	O
fact	O
that	O
many	O
signals	O
converge	O
on	O
this	O
signal	O
'	O
s	O
roundabout	O
.	O

An	O
additional	O
,	O
very	O
important	O
level	O
of	O
NF	O
-	O
kappaB	O
control	O
occurs	O
through	O
the	O
partial	O
or	O
total	O
proteolysis	O
of	O
precursor	O
and	O
inhibitor	O
molecules	O
exerted	O
by	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
pathway	O
.	O

Regulation	O
at	O
this	O
level	O
implicates	O
various	O
conjugating	O
and	O
de	O
-	O
conjugating	O
activities	O
for	O
ubiquitin	B-PRGE
,	O
SUMO	O
(	O
small	O
ubiquitin	B-PRGE
-	O
related	O
modifier	O
)	O
and	O
NEDD8	B-PRGE
.	O

Here	O
,	O
we	O
summarize	O
some	O
of	O
these	O
events	O
and	O
underline	O
the	O
importance	O
of	O
the	O
interconnecting	O
ubiquitin	B-PRGE
and	O
ubiquitin	B-PRGE
-	O
like	O
conjugating	O
pathways	O
that	O
determine	O
the	O
status	O
of	O
the	O
activity	O
of	O
this	O
critical	O
transcription	O
factor	O
.	O

Identification	O
of	O
G	O
protein	O
alpha	O
subunit	O
-	O
palmitoylating	O
enzyme	O
.	O

The	O
heterotrimeric	O
G	O
protein	O
alpha	O
subunit	O
(	O
Galpha	O
)	O
is	O
targeted	O
to	O
the	O
cytoplasmic	O
face	O
of	O
the	O
plasma	O
membrane	O
through	O
reversible	O
lipid	O
palmitoylation	O
and	O
relays	O
signals	O
from	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
to	O
its	O
effectors	O
.	O

By	O
screening	O
23	O
DHHC	O
motif	O
(	O
Asp	O
-	O
His	O
-	O
His	O
-	O
Cys	O
)	O
palmitoyl	O
acyl	O
-	O
transferases	O
,	O
we	O
identified	O
DHHC3	B-PRGE
and	O
DHHC7	B-PRGE
as	O
Galpha	O
palmitoylating	O
enzymes	O
.	O

DHHC3	B-PRGE
and	O
DHHC7	B-PRGE
robustly	O
palmitoylated	O
Galpha	B-PRGE
(	I-PRGE
q	I-PRGE
)	I-PRGE
,	O
Galpha	B-PRGE
(	I-PRGE
s	I-PRGE
)	I-PRGE
,	O
and	O
Galpha	B-PRGE
(	I-PRGE
i2	I-PRGE
)	I-PRGE
in	O
HEK293T	O
cells	O
.	O

Knockdown	O
of	O
DHHC3	B-PRGE
and	O
DHHC7	B-PRGE
decreased	O
Galpha	B-PRGE
(	I-PRGE
q	I-PRGE
/	O
11	B-PRGE
)	I-PRGE
palmitoylation	O
and	O
relocalized	O
it	O
from	O
the	O
plasma	O
membrane	O
into	O
the	O
cytoplasm	O
.	O

Photoconversion	O
analysis	O
revealed	O
that	O
Galpha	B-PRGE
(	I-PRGE
q	I-PRGE
)	I-PRGE
rapidly	O
shuttles	O
between	O
the	O
plasma	O
membrane	O
and	O
the	O
Golgi	O
apparatus	O
,	O
where	O
DHHC3	B-PRGE
specifically	O
localizes	O
.	O

Fluorescence	O
recovery	O
after	O
photobleaching	O
studies	O
showed	O
that	O
DHHC3	B-PRGE
and	O
DHHC7	B-PRGE
are	O
necessary	O
for	O
this	O
continuous	O
Galpha	B-PRGE
(	I-PRGE
q	I-PRGE
)	I-PRGE
shuttling	O
.	O

Furthermore	O
,	O
DHHC3	B-PRGE
and	O
DHHC7	B-PRGE
knockdown	O
blocked	O
the	O
alpha	B-PRGE
(	I-PRGE
1A	I-PRGE
)	I-PRGE
-	I-PRGE
adrenergic	I-PRGE
receptor	I-PRGE
/	O
Galpha	B-PRGE
(	I-PRGE
q	I-PRGE
/	O
11	B-PRGE
)	I-PRGE
-	O
mediated	O
signaling	O
pathway	O
.	O

Together	O
,	O
our	O
findings	O
revealed	O
that	O
DHHC3	B-PRGE
and	O
DHHC7	B-PRGE
regulate	O
GPCR	O
-	O
mediated	O
signal	O
transduction	O
by	O
controlling	O
Galpha	O
localization	O
to	O
the	O
plasma	O
membrane	O
.	O

Context	O
-	O
dependent	O
substrate	O
recognition	O
by	O
protein	O
farnesyltransferase	O
.	O

Prenylation	O
is	O
a	O
posttranslational	O
modification	O
whereby	O
C	O
-	O
terminal	O
lipidation	O
leads	O
to	O
protein	O
localization	O
to	O
membranes	O
.	O

A	O
C	O
-	O
terminal	O
"	O
Ca	O
(	O
1	O
)	O
a	O
(	O
2	O
)	O
X	O
"	O
sequence	O
has	O
been	O
proposed	O
as	O
the	O
recognition	O
motif	O
for	O
two	O
prenylation	O
enzymes	O
,	O
protein	O
farnesyltransferase	O
(	O
FTase	O
)	O
and	O
protein	O
geranylgeranyltransferase	O
type	O
I	O
.	O

To	O
define	O
the	O
parameters	O
involved	O
in	O
recognition	O
of	O
the	O
a	O
(	O
2	O
)	O
residue	O
,	O
we	O
performed	O
structure	O
-	O
activity	O
analysis	O
which	O
indicates	O
that	O
FTase	O
discriminates	O
between	O
peptide	O
substrates	O
based	O
on	O
both	O
the	O
hydrophobicity	O
and	O
steric	O
volume	O
of	O
the	O
side	O
chain	O
at	O
the	O
a	O
(	O
2	O
)	O
position	O
.	O

For	O
nonpolar	O
side	O
chains	O
,	O
the	O
dependence	O
of	O
the	O
reactivity	O
on	O
side	O
chain	O
volume	O
at	O
this	O
position	O
forms	O
a	O
pyramidal	O
pattern	O
with	O
a	O
maximal	O
activity	O
near	O
the	O
steric	O
volume	O
of	O
valine	O
.	O

This	O
discrimination	O
occurs	O
at	O
a	O
step	O
in	O
the	O
kinetic	O
mechanism	O
that	O
is	O
at	O
or	O
before	O
the	O
farnesylation	O
step	O
.	O

Furthermore	O
,	O
a	O
(	O
2	O
)	O
selectivity	O
is	O
also	O
affected	O
by	O
the	O
identity	O
of	O
the	O
adjacent	O
X	O
residue	O
,	O
leading	O
to	O
context	O
-	O
dependent	O
substrate	O
recognition	O
.	O

Context	O
-	O
dependent	O
a	O
(	O
2	O
)	O
selectivity	O
suggests	O
that	O
FTase	O
recognizes	O
the	O
sequence	O
downstream	O
of	O
the	O
conserved	O
cysteine	O
as	O
a	O
set	O
of	O
two	O
or	O
three	O
cooperative	O
,	O
interconnected	O
recognition	O
elements	O
as	O
opposed	O
to	O
three	O
independent	O
amino	O
acids	O
.	O

These	O
findings	O
expand	O
the	O
pool	O
of	O
proposed	O
FTase	O
substrates	O
in	O
cells	O
.	O

A	O
better	O
understanding	O
of	O
the	O
molecular	O
recognition	O
of	O
substrates	O
performed	O
by	O
FTase	O
will	O
aid	O
in	O
both	O
designing	O
new	O
FTase	O
inhibitors	O
as	O
therapeutic	O
agents	O
and	O
characterizing	O
proteins	O
involved	O
in	O
prenylation	O
-	O
dependent	O
cellular	O
pathways	O
.	O

Lysophosphatidic	B-PRGE
acid	I-PRGE
2	I-PRGE
receptor	I-PRGE
-	O
mediated	O
supramolecular	O
complex	O
formation	O
regulates	O
its	O
antiapoptotic	O
effect	O
.	O

The	O
G	O
protein	O
-	O
coupled	O
lysophosphatidic	B-PRGE
acid	I-PRGE
2	I-PRGE
(	I-PRGE
LPA	I-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
)	I-PRGE
receptor	I-PRGE
elicits	O
prosurvival	O
responses	O
to	O
prevent	O
and	O
rescue	O
cells	O
from	O
apoptosis	O
.	O

However	O
,	O
G	O
protein	O
-	O
coupled	O
signals	O
are	O
not	O
sufficient	O
for	O
the	O
full	O
protective	O
effect	O
of	O
LPA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
.	O

LPA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
differs	O
from	O
other	O
LPA	O
receptor	O
subtypes	O
in	O
the	O
C	O
-	O
terminal	O
tail	O
,	O
where	O
it	O
contains	O
a	O
zinc	O
finger	O
-	O
binding	O
motif	O
for	O
the	O
interactions	O
with	O
LIM	O
domain	O
-	O
containing	O
TRIP6	B-PRGE
and	O
proapoptotic	O
Siva	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
a	O
PDZ	O
-	O
binding	O
motif	O
through	O
which	O
it	O
complexes	O
with	O
the	O
NHERF2	B-PRGE
scaffold	O
protein	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
a	O
unique	O
CXXC	O
motif	O
of	O
LPA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
responsible	O
for	O
the	O
binding	O
to	O
TRIP6	B-PRGE
and	O
Siva	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
demonstrate	O
that	O
disruption	O
of	O
these	O
macromolecular	O
complexes	O
or	O
knockdown	O
of	O
TRIP6	B-PRGE
or	O
NHERF2	B-PRGE
expression	O
attenuates	O
LPA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
-	O
mediated	O
protection	O
from	O
chemotherapeutic	O
agent	O
-	O
induced	O
apoptosis	O
.	O

In	O
contrast	O
,	O
knockdown	O
of	O
Siva	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
enhances	O
this	O
effect	O
.	O

Furthermore	O
,	O
a	O
PDZ	O
-	O
mediated	O
direct	O
interaction	O
between	O
TRIP6	B-PRGE
and	O
NHERF2	B-PRGE
facilitates	O
their	O
interaction	O
with	O
LPA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
in	O
addition	O
to	O
G	O
protein	O
-	O
activated	O
signals	O
,	O
the	O
cooperation	O
embedded	O
in	O
the	O
LPA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
-	O
TRIP6	B-PRGE
-	O
NHERF2	B-PRGE
ternary	O
complex	O
provides	O
a	O
novel	O
ligand	O
-	O
dependent	O
signal	O
amplification	O
mechanism	O
that	O
is	O
required	O
for	O
LPA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
-	O
mediated	O
full	O
activation	O
of	O
antiapoptotic	O
signaling	O
.	O

A	O
functional	O
screen	O
implicates	O
microRNA	B-PRGE
-	I-PRGE
138	I-PRGE
-	O
dependent	O
regulation	O
of	O
the	O
depalmitoylation	O
enzyme	O
APT1	B-PRGE
in	O
dendritic	O
spine	O
morphogenesis	O
.	O

The	O
microRNA	O
pathway	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
synaptic	O
protein	O
synthesis	O
and	O
ultimately	O
in	O
dendritic	O
spine	O
morphogenesis	O
,	O
a	O
phenomenon	O
associated	O
with	O
long	O
-	O
lasting	O
forms	O
of	O
memory	O
.	O

However	O
,	O
the	O
particular	O
microRNAs	O
(	O
miRNAs	O
)	O
involved	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
identify	O
specific	O
miRNAs	O
that	O
function	O
at	O
synapses	O
to	O
control	O
dendritic	O
spine	O
structure	O
by	O
performing	O
a	O
functional	O
screen	O
.	O

One	O
of	O
the	O
identified	O
miRNAs	O
,	O
miR	B-PRGE
-	I-PRGE
138	I-PRGE
,	O
is	O
highly	O
enriched	O
in	O
the	O
brain	O
,	O
localized	O
within	O
dendrites	O
and	O
negatively	O
regulates	O
the	O
size	O
of	O
dendritic	O
spines	O
in	O
rat	O
hippocampal	O
neurons	O
.	O

miR	B-PRGE
-	I-PRGE
138	I-PRGE
controls	O
the	O
expression	O
of	O
acyl	B-PRGE
protein	I-PRGE
thioesterase	I-PRGE
1	I-PRGE
(	O
APT1	B-PRGE
)	O
,	O
an	O
enzyme	O
regulating	O
the	O
palmitoylation	O
status	O
of	O
proteins	O
that	O
are	O
known	O
to	O
function	O
at	O
the	O
synapse	O
,	O
including	O
the	O
alpha	O
(	O
13	O
)	O
subunits	O
of	O
G	O
proteins	O
(	O
Galpha	B-PRGE
(	I-PRGE
13	I-PRGE
)	I-PRGE
)	O
.	O

RNA	O
-	O
interference	O
-	O
mediated	O
knockdown	O
of	O
APT1	B-PRGE
and	O
the	O
expression	O
of	O
membrane	O
-	O
localized	O
Galpha	B-PRGE
(	I-PRGE
13	I-PRGE
)	I-PRGE
both	O
suppress	O
spine	O
enlargement	O
caused	O
by	O
inhibition	O
of	O
miR	B-PRGE
-	I-PRGE
138	I-PRGE
,	O
suggesting	O
that	O
APT1	B-PRGE
-	O
regulated	O
depalmitoylation	O
of	O
Galpha	B-PRGE
(	I-PRGE
13	I-PRGE
)	I-PRGE
might	O
be	O
an	O
important	O
downstream	O
event	O
of	O
miR	B-PRGE
-	I-PRGE
138	I-PRGE
function	O
.	O

Our	O
results	O
uncover	O
a	O
previously	O
unknown	O
miRNA	O
-	O
dependent	O
mechanism	O
in	O
neurons	O
and	O
demonstrate	O
a	O
previously	O
unrecognized	O
complexity	O
of	O
miRNA	O
-	O
dependent	O
control	O
of	O
dendritic	O
spine	O
morphogenesis	O
.	O

Four	O
flavonoids	O
from	O
Echinosophora	O
koreensis	O
and	O
their	O
effects	O
on	O
alcohol	O
metabolizing	O
enzymes	O
.	O

A	O
new	O
prenylated	O
dihydroflavonol	O
,	O
3	O
-	O
hydroxy	O
-	O
kenusanone	O
B	O
1	O
,	O
as	O
well	O
as	O
three	O
other	O
known	O
isoflavanones	O
,	O
sophoronol	O
2	O
,	O
sophoraisoflavanone	O
A	O
3	O
and	O
kenusanone	O
H	O
4	O
,	O
were	O
isolated	O
from	O
the	O
rhizomes	O
of	O
Echinosophora	O
koreensis	O
.	O

The	O
structures	O
of	O
these	O
compounds	O
were	O
elucidated	O
using	O
spectroscopic	O
analyses	O
that	O
included	O
extensive	O
2D	O
NMR	O
,	O
optical	O
rotation	O
spectrometry	O
and	O
mass	O
spectrometry	O
.	O

All	O
four	O
flavonoids	O
enhanced	O
the	O
activities	O
of	O
alcohol	O
metabolizing	O
enzymes	O
such	O
as	O
alcohol	O
dehydrogenase	O
(	O
ADH	O
)	O
and	O
aldehyde	O
dehydrogenase	O
(	O
ALDH	O
)	O
at	O
micromolar	O
concentrations	O
.	O

Sophoronol	O
2	O
showed	O
a	O
nine	O
-	O
fold	O
increased	O
activation	O
of	O
alcohol	O
dehydrogenase	O
and	O
aldehyde	O
dehydrogenase	O
than	O
a	O
negative	O
control	O
group	O
at	O
concentrations	O
of	O
100	O
microg	O
/	O
mL	O
and	O
50	O
microg	O
/	O
mL	O
,	O
respectively	O
.	O

This	O
study	O
suggests	O
that	O
prenylated	O
flavonoids	O
have	O
the	O
potential	O
to	O
prevent	O
'	O
hangovers	O
'	O
after	O
alcohol	O
intake	O
.	O

A	O
unique	O
lipoylation	O
system	O
in	O
the	O
Archaea	O
.	O

Lipoylation	O
in	O
Thermoplasma	O
acidophilum	O
requires	O
two	O
proteins	O
.	O

Members	O
of	O
the	O
2	O
-	O
oxoacid	O
dehydrogenase	O
multienzyme	O
complex	O
family	O
play	O
a	O
key	O
role	O
in	O
the	O
pathways	O
of	O
central	O
metabolism	O
.	O

Post	O
-	O
translational	O
lipoylation	O
of	O
the	O
dihydrolipoyl	O
acyltransferase	O
component	O
of	O
these	O
complexes	O
is	O
essential	O
for	O
their	O
activity	O
,	O
the	O
lipoyllysine	O
moiety	O
performing	O
the	O
transfer	O
of	O
substrates	O
and	O
intermediates	O
between	O
the	O
different	O
active	O
sites	O
within	O
these	O
multienzyme	O
systems	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
thermophilic	O
archaeon	O
,	O
Thermoplasma	O
acidophilum	O
,	O
has	O
a	O
four	O
-	O
gene	O
cluster	O
encoding	O
the	O
components	O
of	O
such	O
a	O
complex	O
,	O
which	O
,	O
when	O
recombinantly	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
can	O
be	O
assembled	O
into	O
an	O
active	O
multienzyme	O
in	O
vitro	O
.	O

Crucially	O
,	O
the	O
E	O
.	O
coli	O
host	O
carries	O
out	O
the	O
required	O
lipoylation	O
of	O
the	O
archaeal	O
dihydrolipoyl	O
acyltransferase	O
component	O
.	O

Because	O
active	O
2	O
-	O
oxoacid	O
dehydrogenase	O
multienzyme	O
complexes	O
have	O
never	O
been	O
detected	O
in	O
any	O
archaeon	O
,	O
the	O
question	O
arises	O
as	O
to	O
whether	O
Archaea	O
possess	O
a	O
functional	O
lipoylation	O
system	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
cloning	O
and	O
heterologous	O
expression	O
of	O
two	O
genes	O
from	O
Tp	O
.	O
acidophilum	O
whose	O
protein	O
products	O
together	O
show	O
significant	O
sequence	O
identity	O
with	O
the	O
single	O
lipoate	O
protein	O
ligase	O
enzyme	O
of	O
bacteria	O
.	O

We	O
demonstrate	O
that	O
both	O
recombinantly	O
expressed	O
Tp	O
.	O
acidophilum	O
proteins	O
are	O
required	O
for	O
lipoylation	O
of	O
the	O
acyltransferase	O
,	O
and	O
that	O
the	O
two	O
proteins	O
associate	O
together	O
to	O
carry	O
out	O
this	O
post	O
-	O
translational	O
modification	O
.	O

From	O
the	O
published	O
DNA	O
sequences	O
,	O
we	O
suggest	O
the	O
presence	O
of	O
functional	O
transcriptional	O
and	O
translational	O
regulatory	O
elements	O
,	O
and	O
furthermore	O
we	O
present	O
preliminary	O
evidence	O
that	O
lipoylation	O
occurs	O
in	O
vivo	O
in	O
Tp	O
.	O
acidophilum	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
lipoylation	O
machinery	O
in	O
the	O
Archaea	O
,	O
which	O
is	O
unique	O
in	O
that	O
the	O
catalytic	O
activity	O
is	O
dependent	O
on	O
two	O
separate	O
gene	O
products	O
.	O

Molecular	O
basis	O
of	O
canonical	O
and	O
bactericidal	O
autophagy	O
.	O

Autophagy	O
is	O
a	O
catabolic	O
process	O
by	O
which	O
cells	O
degrade	O
their	O
own	O
cytoplasmic	O
constituents	O
.	O

Cells	O
respond	O
to	O
the	O
stress	O
response	O
of	O
nutrient	O
deficiency	O
by	O
degrading	O
a	O
portion	O
of	O
their	O
cellular	O
components	O
to	O
produce	O
amino	O
acids	O
and	O
energy	O
.	O

Recently	O
,	O
it	O
became	O
evident	O
that	O
the	O
autophagic	O
machinery	O
is	O
also	O
involved	O
in	O
a	O
kind	O
of	O
innate	O
immune	O
system	O
.	O

Some	O
bacteria	O
that	O
invade	O
mammalian	O
cells	O
are	O
eventually	O
entrapped	O
in	O
an	O
autophagic	O
membrane	O
structure	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
current	O
understanding	O
of	O
three	O
of	O
the	O
basic	O
components	O
of	O
the	O
canonical	O
autophagy	O
machinery	O
-	O
LC3	O
,	O
the	O
Atg16L	O
complex	O
and	O
phosphatidylinositol	O
3	O
-	O
phosphate	O
(	O
PI3P	O
)	O
-	O
which	O
are	O
dynamically	O
associated	O
with	O
the	O
autophagic	O
structure	O
.	O

LC3	O
is	O
proposed	O
to	O
function	O
in	O
autophagosome	O
closure	O
,	O
whereas	O
the	O
Atg16L	O
complex	O
functions	O
as	O
an	O
E3	O
-	O
like	O
protein	O
in	O
ubiquitination	O
-	O
like	O
reactions	O
in	O
the	O
LC3	O
lipidation	O
system	O
.	O

PI3P	O
is	O
a	O
key	O
determinant	O
of	O
the	O
autophagic	O
membrane	O
.	O

Further	O
,	O
their	O
relation	O
to	O
bactericidal	O
autophagy	O
(	O
i	O
.	O
e	O
.	O
xenophagy	O
)	O
will	O
be	O
introduced	O
.	O

Three	O
-	O
dimensional	O
organization	O
of	O
promyelocytic	O
leukemia	O
nuclear	O
bodies	O
.	O

Promyelocytic	O
leukemia	O
nuclear	O
bodies	O
(	O
PML	O
-	O
NBs	O
)	O
are	O
mobile	O
subnuclear	O
organelles	O
formed	O
by	O
PML	B-PRGE
and	O
Sp100	B-PRGE
protein	O
.	O

They	O
have	O
been	O
reported	O
to	O
have	O
a	O
role	O
in	O
transcription	O
,	O
DNA	O
replication	O
and	O
repair	O
,	O
telomere	O
lengthening	O
,	O
cell	O
cycle	O
control	O
and	O
tumor	O
suppression	O
.	O

We	O
have	O
conducted	O
high	O
-	O
resolution	O
4Pi	O
fluorescence	O
laser	O
-	O
scanning	O
microscopy	O
studies	O
complemented	O
with	O
correlative	O
electron	O
microscopy	O
and	O
investigations	O
of	O
the	O
accessibility	O
of	O
the	O
PML	O
-	O
NB	O
subcompartment	O
.	O

During	O
interphase	O
PML	O
-	O
NBs	O
adopt	O
a	O
spherical	O
organization	O
characterized	O
by	O
the	O
assembly	O
of	O
PML	B-PRGE
and	O
Sp100	B-PRGE
proteins	O
into	O
patches	O
within	O
a	O
50	O
-	O
to	O
100	O
-	O
nm	O
-	O
thick	O
shell	O
.	O

This	O
spherical	O
shell	O
of	O
PML	B-PRGE
and	O
Sp100	B-PRGE
imposes	O
little	O
constraint	O
to	O
the	O
exchange	O
of	O
components	O
between	O
the	O
PML	O
-	O
NB	O
interior	O
and	O
the	O
nucleoplasm	O
.	O

Post	O
-	O
translational	O
SUMO	O
modifications	O
,	O
telomere	O
repeats	O
and	O
heterochromatin	B-PRGE
protein	I-PRGE
1	I-PRGE
were	O
found	O
to	O
localize	O
in	O
characteristic	O
patterns	O
with	O
respect	O
to	O
PML	B-PRGE
and	O
Sp100	B-PRGE
.	O

From	O
our	O
findings	O
,	O
we	O
derived	O
a	O
model	O
that	O
explains	O
how	O
the	O
three	O
-	O
dimensional	O
organization	O
of	O
PML	O
-	O
NBs	O
serves	O
to	O
concentrate	O
different	O
biological	O
activities	O
while	O
allowing	O
for	O
an	O
efficient	O
exchange	O
of	O
components	O
.	O

The	O
structure	O
of	O
dopamine	O
induced	O
alpha	B-PRGE
-	I-PRGE
synuclein	I-PRGE
oligomers	O
.	O

Inclusions	O
of	O
aggregated	O
alpha	B-PRGE
-	I-PRGE
synuclein	I-PRGE
(	O
alpha	B-PRGE
-	I-PRGE
syn	I-PRGE
)	O
in	O
dopaminergic	O
neurons	O
are	O
a	O
characteristic	O
histological	O
marker	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

In	O
vitro	O
,	O
alpha	B-PRGE
-	I-PRGE
syn	I-PRGE
in	O
the	O
presence	O
of	O
dopamine	O
(	O
DA	O
)	O
at	O
physiological	O
pH	O
forms	O
SDS	O
-	O
resistant	O
non	O
-	O
amyloidogenic	O
oligomers	O
.	O

We	O
used	O
a	O
combination	O
of	O
biophysical	O
techniques	O
,	O
including	O
sedimentation	O
velocity	O
analysis	O
,	O
small	O
angle	O
X	O
-	O
ray	O
scattering	O
(	O
SAXS	O
)	O
and	O
circular	O
dichroism	O
spectroscopy	O
to	O
study	O
the	O
characteristics	O
of	O
alpha	B-PRGE
-	I-PRGE
syn	I-PRGE
oligomers	O
formed	O
in	O
the	O
presence	O
of	O
DA	O
.	O

Our	O
SAXS	O
data	O
show	O
that	O
the	O
trimers	O
formed	O
by	O
the	O
action	O
of	O
DA	O
on	O
alpha	B-PRGE
-	I-PRGE
syn	I-PRGE
consist	O
of	O
overlapping	O
worm	O
-	O
like	O
monomers	O
,	O
with	O
no	O
end	O
-	O
to	O
-	O
end	O
associations	O
.	O

This	O
lack	O
of	O
structure	O
contrasts	O
with	O
the	O
well	O
-	O
established	O
,	O
extensive	O
beta	O
-	O
sheet	O
structure	O
of	O
the	O
amyloid	B-PRGE
fibril	O
form	O
of	O
the	O
protein	O
and	O
its	O
pre	O
-	O
fibrillar	O
oligomers	O
.	O

We	O
propose	O
on	O
the	O
basis	O
of	O
these	O
and	O
earlier	O
data	O
that	O
oxidation	O
of	O
the	O
four	O
methionine	O
residues	O
at	O
the	O
C	O
-	O
and	O
N	O
-	O
terminal	O
ends	O
of	O
alpha	B-PRGE
-	I-PRGE
syn	I-PRGE
molecules	O
prevents	O
their	O
end	O
-	O
to	O
-	O
end	O
association	O
and	O
stabilises	O
oligomers	O
formed	O
by	O
cross	O
linking	O
with	O
DA	O
-	O
quinone	O
/	O
DA	O
-	O
melanin	O
,	O
which	O
are	O
formed	O
as	O
a	O
result	O
of	O
the	O
redox	O
process	O
,	O
thus	O
inhibiting	O
formation	O
of	O
the	O
beta	O
-	O
sheet	O
structure	O
found	O
in	O
other	O
pre	O
-	O
fibrillar	O
forms	O
of	O
alpha	B-PRGE
-	I-PRGE
syn	I-PRGE
.	O

NEDD8	B-PRGE
-	O
targeting	O
drug	O
MLN4924	O
elicits	O
DNA	O
rereplication	O
by	O
stabilizing	O
Cdt1	B-PRGE
in	O
S	O
phase	O
,	O
triggering	O
checkpoint	O
activation	O
,	O
apoptosis	O
,	O
and	O
senescence	O
in	O
cancer	O
cells	O
.	O

MLN4924	O
is	O
a	O
first	O
-	O
in	O
-	O
class	O
experimental	O
cancer	O
drug	O
that	O
inhibits	O
the	O
NEDD8	B-PRGE
-	O
activating	O
enzyme	O
,	O
thereby	O
inhibiting	O
cullin	O
-	O
RING	O
E3	O
ubiquitin	B-PRGE
ligases	O
and	O
stabilizing	O
many	O
cullin	O
substrates	O
.	O

The	O
mechanism	O
by	O
which	O
MLN4924	O
inhibits	O
cancer	O
cell	O
proliferation	O
has	O
not	O
been	O
defined	O
,	O
although	O
it	O
is	O
accompanied	O
by	O
DNA	O
rereplication	O
and	O
attendant	O
DNA	O
damage	O
.	O

Here	O
we	O
show	O
that	O
stabilization	O
of	O
the	O
DNA	O
replication	O
factor	O
Cdt1	B-PRGE
,	O
a	O
substrate	O
of	O
cullins	B-PRGE
1	I-PRGE
and	O
4	B-PRGE
,	O
is	O
critical	O
for	O
MLN4924	O
to	O
trigger	O
DNA	O
rereplication	O
and	O
inhibit	O
cell	O
proliferation	O
.	O

Even	O
only	O
1	O
hour	O
of	O
exposure	O
to	O
MLN4924	O
,	O
which	O
was	O
sufficient	O
to	O
elevate	O
Cdt1	B-PRGE
for	O
4	O
-	O
5	O
hours	O
,	O
was	O
found	O
to	O
be	O
sufficient	O
to	O
induce	O
DNA	O
rereplication	O
and	O
to	O
activate	O
apoptosis	O
and	O
senescence	O
pathways	O
.	O

Cells	O
in	O
S	O
phase	O
were	O
most	O
susceptible	O
,	O
suggesting	O
that	O
MLN4924	O
will	O
be	O
most	O
toxic	O
on	O
highly	O
proliferating	O
cancers	O
.	O

Although	O
MLN4924	O
-	O
induced	O
cell	O
senescence	O
seems	O
to	O
be	O
dependent	O
on	O
induction	O
of	O
p53	B-PRGE
and	O
its	O
downstream	O
effector	O
p21	B-PRGE
(	O
Waf1	B-PRGE
)	O
,	O
we	O
found	O
that	O
p53	B-PRGE
(	O
-	O
/	O
-	O
)	O
and	O
p21	B-PRGE
(	O
-	O
/	O
-	O
)	O
cells	O
were	O
even	O
more	O
susceptible	O
than	O
wild	O
-	O
type	O
cells	O
to	O
MLN4924	O
.	O

Our	O
results	O
suggested	O
that	O
apoptosis	O
,	O
not	O
senescence	O
,	O
might	O
be	O
more	O
important	O
for	O
the	O
antiproliferative	O
effect	O
of	O
MLN4924	O
.	O

Furthermore	O
,	O
our	O
findings	O
show	O
that	O
transient	O
exposure	O
to	O
this	O
new	O
investigational	O
drug	O
should	O
be	O
useful	O
for	O
controlling	O
p53	B-PRGE
-	O
negative	O
cancer	O
cells	O
,	O
which	O
often	O
pose	O
significant	O
clinical	O
challenge	O
.	O

Mechanisms	O
of	O
metal	O
ion	O
incorporation	O
into	O
metalloproteins	O
.	O

Although	O
the	O
structure	O
and	O
function	O
of	O
protein	O
metallocenters	O
have	O
been	O
extensively	O
characterized	O
,	O
much	O
less	O
is	O
known	O
about	O
their	O
assembly	O
.	O

Here	O
,	O
I	O
describe	O
several	O
general	O
strategies	O
for	O
metallocenter	O
biosynthesis	O
and	O
provide	O
literature	O
precedents	O
for	O
each	O
mechanism	O
.	O

The	O
simplest	O
mechanism	O
involves	O
reversible	O
metal	O
ion	O
binding	O
to	O
amino	O
acid	O
ligands	O
of	O
the	O
apo	O
-	O
protein	O
.	O

In	O
a	O
variation	O
of	O
this	O
mechanism	O
,	O
the	O
apo	O
-	O
protein	O
first	O
must	O
be	O
phosphorylated	O
,	O
carboxylated	O
or	O
otherwise	O
covalently	O
modified	O
in	O
order	O
to	O
create	O
the	O
metal	O
ion	O
binding	O
site	O
.	O

Alternatively	O
,	O
passive	O
metal	O
ion	O
binding	O
may	O
require	O
the	O
presence	O
of	O
an	O
associated	O
compound	O
,	O
such	O
as	O
a	O
nucleotide	O
,	O
carbonate	O
or	O
inorganic	O
sulfide	O
,	O
which	O
is	O
co	O
-	O
incorporated	O
into	O
the	O
protein	O
along	O
with	O
the	O
metal	O
ion	O
.	O

In	O
addition	O
,	O
reversible	O
binding	O
may	O
occur	O
using	O
a	O
pre	O
-	O
formed	O
organometallic	O
cofactor	O
such	O
as	O
a	O
metal	O
-	O
tetrapyrrole	O
.	O

Electron	O
transfer	O
reactions	O
are	O
coupled	O
to	O
biosynthesis	O
of	O
certain	O
metallocenters	O
,	O
i	O
.	O
e	O
.	O
oxidation	O
or	O
reduction	O
of	O
the	O
metallocenter	O
or	O
apo	O
-	O
protein	O
may	O
be	O
required	O
prior	O
to	O
binding	O
,	O
or	O
once	O
bound	O
the	O
metallocenter	O
may	O
be	O
oxidatively	O
trapped	O
in	O
the	O
protein	O
.	O

An	O
effector	O
molecule	O
may	O
bind	O
to	O
apo	O
-	O
protein	O
to	O
open	O
up	O
or	O
stabilize	O
the	O
metallocenter	O
binding	O
site	O
,	O
then	O
after	O
the	O
metallocenter	O
is	O
incorporated	O
the	O
effector	O
molecule	O
dissociates	O
.	O

A	O
transferase	O
or	O
insertase	O
protein	O
first	O
may	O
bind	O
the	O
metallocenter	O
and	O
then	O
incorporate	O
it	O
into	O
the	O
appropriate	O
apo	O
-	O
protein	O
.	O

Finally	O
,	O
metal	O
cofactors	O
may	O
be	O
covalently	O
attached	O
to	O
proteins	O
.	O

Regardless	O
of	O
the	O
metallocenter	O
biosynthetic	O
mechanism	O
,	O
intracellular	O
metal	O
ion	O
concentrations	O
must	O
be	O
sufficient	O
;	O
hence	O
,	O
metal	O
ion	O
transport	O
systems	O
also	O
are	O
briefly	O
discussed	O
.	O

The	O
effect	O
of	O
sulfation	O
on	O
the	O
anticoagulant	O
and	O
antithrombin	B-PRGE
III	I-PRGE
-	O
binding	O
properties	O
of	O
a	O
heparin	O
fraction	O
with	O
low	O
affinity	O
for	O
antithrombin	B-PRGE
III	I-PRGE
.	O

Heparin	O
with	O
low	O
affinity	O
for	O
antithrombin	B-PRGE
III	I-PRGE
(	O
ATIII	B-PRGE
)	O
and	O
devoid	O
of	O
anticoagulant	O
activity	O
was	O
chemically	O
oversulfated	O
and	O
fractionated	O
by	O
affinity	O
for	O
ATIII	B-PRGE
.	O

The	O
oversulfated	O
material	O
showed	O
ATIII	B-PRGE
binding	O
properties	O
,	O
as	O
monitored	O
by	O
intrinsic	O
fluorescence	O
enhancement	O
of	O
ATIII	B-PRGE
.	O

The	O
fluorescence	O
increase	O
was	O
comparable	O
to	O
that	O
of	O
the	O
AT	B-PRGE
III	I-PRGE
high	O
affinity	O
fraction	O
of	O
native	O
heparin	O
.	O

The	O
estimated	O
dissociation	O
constants	O
however	O
,	O
showed	O
a	O
10	O
-	O
fold	O
weaker	O
binding	O
of	O
the	O
oversulfated	O
material	O
to	O
ATIII	B-PRGE
,	O
Kd	O
=	O
6	O
.	O
4	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
,	O
as	O
compared	O
to	O
native	O
heparin	O
,	O
Kd	O
=	O
0	O
.	O
63	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
.	O

Concomitant	O
with	O
the	O
binding	O
-	O
induced	O
allosteric	O
change	O
in	O
ATIII	B-PRGE
,	O
the	O
oversulfated	O
material	O
stimulated	O
the	O
ATIII	B-PRGE
-	O
thrombin	B-PRGE
and	O
ATIII	B-PRGE
-	O
factor	B-PRGE
Xa	I-PRGE
reactions	O
.	O

The	O
high	O
affinity	O
fractions	O
of	O
native	O
heparin	O
and	O
the	O
sulfated	O
material	O
were	O
almost	O
equally	O
effective	O
in	O
enhancing	O
the	O
rate	O
of	O
thrombin	B-PRGE
neutralization	O
by	O
ATIII	B-PRGE
.	O

However	O
,	O
a	O
3	O
-	O
fold	O
faster	O
rate	O
of	O
factor	B-PRGE
Xa	I-PRGE
inactivation	O
was	O
found	O
with	O
the	O
native	O
high	O
affinity	O
material	O
.	O

Acylation	O
and	O
carbamylation	O
of	O
equine	O
muscle	O
carbonic	O
anhydrase	O
(	O
CA	B-PRGE
-	I-PRGE
III	I-PRGE
)	O
upon	O
reaction	O
with	O
p	O
-	O
nitrophenyl	O
esters	O
and	O
carbamoyl	O
phosphate	O
.	O

Equine	O
muscle	O
carbonic	O
anhydrase	O
(	O
CA	B-PRGE
-	I-PRGE
III	I-PRGE
)	O
behaves	O
like	O
ubiquitin	O
in	O
undergoing	O
extensive	O
acylation	O
of	O
N	O
epsilon	O
-	O
lysine	O
residues	O
upon	O
reacting	O
with	O
p	O
-	O
nitrophenyl	O
esters	O
.	O

The	O
enzyme	O
undergoes	O
extensive	O
carbamoylation	O
of	O
lysine	O
residues	O
when	O
reacted	O
with	O
carbamoyl	O
phosphate	O
.	O

The	O
modification	O
of	O
from	O
6	O
to	O
7	O
lysine	O
residues	O
results	O
in	O
the	O
production	O
of	O
a	O
series	O
of	O
more	O
anodic	O
electrophoretic	O
components	O
.	O

The	O
derivatization	O
of	O
the	O
lysine	O
residues	O
leads	O
to	O
a	O
marked	O
decrease	O
in	O
the	O
enzyme	O
'	O
s	O
ability	O
to	O
hydrate	O
CO2	O
.	O

The	O
equine	O
CA	B-PRGE
-	I-PRGE
III	I-PRGE
possesses	O
both	O
acid	O
and	O
alkaline	O
phosphatase	O
activities	O
in	O
contrast	O
to	O
the	O
rabbit	O
which	O
possesses	O
only	O
the	O
former	O
type	O
.	O

Posttranslational	O
processing	O
of	O
human	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
glycoprotein	I-PRGE
(	O
human	O
fetuin	O
)	O
.	O

Evidence	O
for	O
the	O
production	O
of	O
a	O
phosphorylated	O
single	O
-	O
chain	O
form	O
by	O
hepatoma	O
cells	O
.	O

alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
glycoprotein	I-PRGE
(	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
)	O
is	O
a	O
major	O
protein	O
occurring	O
in	O
human	O
blood	O
and	O
calciferous	O
tissues	O
.	O

Due	O
to	O
extensive	O
sequence	O
identity	O
,	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
has	O
been	O
grouped	O
with	O
the	O
fetuins	O
,	O
a	O
family	O
of	O
proteins	O
that	O
occur	O
in	O
fetal	O
plasma	O
in	O
high	O
concentrations	O
.	O

Native	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
undergoes	O
a	O
series	O
of	O
posttranslational	O
modifications	O
including	O
proteolytic	O
processing	O
,	O
multiple	O
N	O
-	O
glycosylations	O
and	O
O	O
-	O
glycosylations	O
,	O
and	O
sulfation	O
of	O
the	O
carbohydrate	O
side	O
chains	O
.	O

Various	O
two	O
-	O
chain	O
forms	O
of	O
alpha	O
2	O
-	O
HS	O
have	O
been	O
prepared	O
from	O
human	O
plasma	O
,	O
however	O
,	O
the	O
single	O
-	O
chain	O
precursor	O
has	O
not	O
yet	O
been	O
isolated	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
biosynthesis	O
of	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
by	O
a	O
human	O
hepatoma	O
cell	O
line	O
,	O
HepG2	O
.	O

We	O
demonstrate	O
that	O
a	O
single	O
-	O
chain	O
form	O
and	O
the	O
two	O
-	O
chain	O
form	O
of	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
are	O
secreted	O
by	O
this	O
cell	O
line	O
.	O

The	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
forms	O
are	O
further	O
modified	O
by	O
phosphorylation	O
on	O
multiple	O
serine	O
residues	O
.	O

Mapping	O
studies	O
indicate	O
that	O
the	O
connecting	O
peptide	O
region	O
releasable	O
from	O
the	O
heavy	O
chain	O
of	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
contains	O
at	O
least	O
one	O
such	O
phosphorylation	O
site	O
.	O

Our	O
results	O
identify	O
proteolytic	O
trimming	O
and	O
/	O
or	O
phosphorylation	O
as	O
modifications	O
possibly	O
regulating	O
the	O
biological	O
effects	O
of	O
alpha	B-PRGE
2	I-PRGE
-	I-PRGE
HS	I-PRGE
and	O
the	O
homologous	O
fetuins	O
.	O

P	B-PRGE
-	I-PRGE
selectin	I-PRGE
is	O
acylated	O
with	O
palmitic	O
acid	O
and	O
stearic	O
acid	O
at	O
cysteine	O
766	O
through	O
a	O
thioester	O
linkage	O
.	O

We	O
report	O
that	O
the	O
adhesion	O
receptor	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
can	O
be	O
metabolically	O
labeled	O
with	O
[	O
3H	O
]	O
palmitic	O
acid	O
in	O
human	O
platelets	O
.	O

Analysis	O
of	O
alkaline	O
methanolysis	O
products	O
from	O
labeled	O
protein	O
demonstrated	O
that	O
the	O
radioactivity	O
associated	O
with	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
was	O
covalently	O
bound	O
palmitic	O
acid	O
.	O

[	O
3H	O
]	O
Palmitic	O
acid	O
was	O
cleaved	O
by	O
hydroxylamine	O
treatment	O
at	O
neutral	O
pH	O
and	O
by	O
reducing	O
agents	O
,	O
indicating	O
that	O
acylation	O
occurred	O
through	O
a	O
thioester	O
linkage	O
.	O

Both	O
stearic	O
acid	O
and	O
palmitic	O
acid	O
were	O
detected	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
analysis	O
of	O
alkaline	O
hydrolysates	O
of	O
purified	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

Deletion	O
or	O
mutation	O
of	O
Cys766	O
eliminated	O
[	O
3H	O
]	O
palmitic	O
acid	O
labeling	O
of	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
in	O
transfected	O
COS	O
-	O
7	O
cells	O
.	O

We	O
conclude	O
that	O
the	O
cytoplasmic	O
domain	O
of	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
is	O
acylated	O
at	O
Cys766	O
through	O
a	O
thioester	O
bond	O
.	O

Fatty	O
acid	O
acylation	O
may	O
regulate	O
intracellular	O
trafficking	O
or	O
other	O
functions	O
of	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

ADP	O
ribosylation	O
factor	O
and	O
a	O
14	O
-	O
kD	O
polypeptide	O
are	O
associated	O
with	O
heparan	O
sulfate	O
-	O
carrying	O
post	O
-	O
trans	O
-	O
Golgi	O
network	O
secretory	O
vesicles	O
in	O
rat	O
hepatocytes	O
.	O

Constitutive	O
secretory	O
vesicles	O
carrying	O
heparan	B-PRGE
sulfate	I-PRGE
proteoglycan	I-PRGE
(	O
HSPG	B-PRGE
)	O
were	O
identified	O
in	O
isolated	O
rat	O
hepatocytes	O
by	O
pulse	O
-	O
chase	O
experiments	O
with	O
[	O
35S	O
]	O
sulfate	O
and	O
purified	O
by	O
velocity	O
-	O
controlled	O
sucrose	O
gradient	O
centrifugation	O
followed	O
by	O
equilibrium	O
density	O
centrifugation	O
in	O
Nycodenz	O
.	O

Using	O
this	O
procedure	O
,	O
the	O
vesicles	O
were	O
separated	O
from	O
plasma	O
membranes	O
,	O
Golgi	O
,	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
,	O
ER	O
,	O
endosomes	O
,	O
lysosomes	O
,	O
transcytotic	O
vesicles	O
,	O
and	O
mitochondria	O
.	O

The	O
diameter	O
of	O
these	O
vesicles	O
was	O
approximately	O
100	O
-	O
200	O
nm	O
as	O
determined	O
by	O
electron	O
microscopy	O
.	O

A	O
typical	O
coat	O
structure	O
as	O
described	O
for	O
intra	O
-	O
Golgi	O
transport	O
vesicles	O
or	O
clathrin	O
-	O
coated	O
vesicles	O
could	O
not	O
be	O
seen	O
,	O
and	O
the	O
vesicles	O
were	O
not	O
associated	O
with	O
the	O
coat	O
protein	O
beta	B-PRGE
-	I-PRGE
COP	I-PRGE
.	O

Furthermore	O
,	O
the	O
vesicles	O
appear	O
to	O
represent	O
a	O
low	O
density	O
compartment	O
(	O
1	O
.	O
05	O
-	O
1	O
.	O
06	O
g	O
/	O
ml	O
)	O
.	O

Other	O
constitutively	O
secreted	O
proteins	O
(	O
rat	O
serum	B-PRGE
albumin	I-PRGE
,	O
apolipoprotein	B-PRGE
E	I-PRGE
,	O
and	O
fibrinogen	O
)	O
could	O
not	O
be	O
detected	O
in	O
purified	O
HSPG	B-PRGE
-	O
carrying	O
vesicles	O
,	O
but	O
banded	O
in	O
the	O
denser	O
fractions	O
of	O
the	O
Nycodenz	O
gradient	O
.	O

Moreover	O
,	O
during	O
pulse	O
-	O
chase	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
,	O
labeled	O
albumin	B-PRGE
did	O
not	O
appear	O
in	O
the	O
post	O
-	O
TGN	O
vesicle	O
fraction	O
carrying	O
HSPGs	B-PRGE
.	O

These	O
findings	O
indicate	O
sorting	O
of	O
HSPGs	B-PRGE
and	O
albumin	B-PRGE
into	O
different	O
types	O
of	O
constitutive	O
secretory	O
vesicles	O
in	O
hepatocytes	O
.	O

Two	O
proteins	O
were	O
found	O
to	O
be	O
tightly	O
associated	O
with	O
the	O
membranes	O
of	O
the	O
HSPG	B-PRGE
carrying	O
vesicles	O
:	O
a	O
member	O
of	O
the	O
ADP	O
ribosylation	O
factor	O
family	O
of	O
small	O
guanine	O
nucleotide	O
-	O
binding	O
proteins	O
and	O
an	O
unknown	O
14	O
-	O
kD	O
peripheral	O
membrane	O
protein	O
(	O
VAPP14	O
)	O
.	O

Concerning	O
the	O
secretory	O
pathway	O
,	O
we	O
conclude	O
from	O
these	O
results	O
that	O
ADP	O
ribosylation	O
factor	O
proteins	O
are	O
not	O
only	O
involved	O
in	O
vesicular	O
transport	O
from	O
the	O
ER	O
via	O
the	O
Golgi	O
to	O
the	O
TGN	O
,	O
but	O
also	O
in	O
vesicular	O
transport	O
from	O
the	O
TGN	O
to	O
the	O
plasma	O
membrane	O
.	O

Tyrosine	O
sulfation	O
of	O
varicella	O
-	O
zoster	O
virus	O
envelope	O
glycoprotein	O
gpl	B-PRGE
.	O

Sulfation	O
is	O
a	O
common	O
post	O
-	O
translational	O
modification	O
of	O
secreted	O
and	O
membrane	O
proteins	O
,	O
with	O
the	O
sulfate	O
attached	O
to	O
tyrosine	O
residues	O
or	O
to	O
glycan	O
side	O
-	O
chains	O
.	O

I	O
have	O
shown	O
that	O
varicella	O
-	O
zoster	O
virus	O
(	O
VZV	O
)	O
envelope	O
glycoproteins	O
gpI	B-PRGE
,	O
gpII	B-PRGE
,	O
and	O
gpIII	B-PRGE
can	O
be	O
labeled	O
with	O
[	O
35S	O
]	O
sulfate	O
.	O

The	O
predominant	O
VZV	O
glycoprotein	O
,	O
gpI	B-PRGE
,	O
was	O
shown	O
to	O
be	O
sulfated	O
on	O
asparagine	O
-	O
linked	O
glycans	O
and	O
on	O
tyrosine	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
tyrosine	O
sulfation	O
of	O
a	O
viral	O
envelope	O
glycoprotein	O
.	O

Examination	O
of	O
the	O
predicted	O
amino	O
acid	O
sequences	O
of	O
gpI	B-PRGE
from	O
the	O
Dumas	O
and	O
CP	O
-	O
5262	O
VZV	O
strains	O
revealed	O
the	O
presence	O
of	O
a	O
single	O
consensus	O
sequence	O
for	O
tyrosine	O
sulfation	O
of	O
tyr88	O
:	O
IWPRNDYDGFLEN	O
.	O

Consensus	O
sequences	O
are	O
also	O
present	O
in	O
the	O
homologues	O
of	O
gpI	B-PRGE
in	O
herpes	O
simplex	O
type	O
1	O
,	O
herpes	O
simplex	O
type	O
2	O
,	O
and	O
pseudorabies	O
virus	O
,	O
suggesting	O
that	O
tyrosine	O
sulfation	O
may	O
be	O
a	O
general	O
post	O
-	O
translational	O
modification	O
of	O
the	O
neurotropic	O
alphaherpesviruses	O
.	O

Posttranslational	O
regulation	O
of	O
nitrogenase	O
activity	O
by	O
anaerobiosis	O
and	O
ammonium	O
in	O
Azospirillum	O
brasilense	O
.	O

In	O
the	O
microaerophilic	O
diazotroph	O
Azospirillum	O
brasilense	O
,	O
the	O
addition	O
of	O
fixed	O
nitrogen	O
or	O
a	O
shift	O
to	O
anaerobic	O
conditions	O
leads	O
to	O
a	O
rapid	O
loss	O
of	O
nitrogenase	O
activity	O
due	O
to	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-PRGE
reductase	I-PRGE
.	O

The	O
product	O
of	O
draT	B-PRGE
(	O
DRAT	B-PRGE
)	O
is	O
shown	O
to	O
be	O
necessary	O
for	O
this	O
modification	O
,	O
and	O
the	O
product	O
of	O
draG	B-PRGE
(	O
DRAG	B-PRGE
)	O
is	O
shown	O
to	O
be	O
necessary	O
for	O
the	O
removal	O
of	O
the	O
modification	O
upon	O
removal	O
of	O
the	O
stimulus	O
.	O

DRAG	B-PRGE
and	O
DRAT	B-PRGE
are	O
themselves	O
subject	O
to	O
posttranslational	O
regulation	O
,	O
and	O
this	O
report	O
identifies	O
features	O
of	O
that	O
regulation	O
.	O

We	O
demonstrate	O
that	O
the	O
activation	O
of	O
DRAT	B-PRGE
in	O
response	O
to	O
an	O
anaerobic	O
shift	O
is	O
transient	O
but	O
that	O
the	O
duration	O
of	O
DRAT	B-PRGE
activation	O
in	O
response	O
to	O
added	O
NH4	O
+	O
varies	O
with	O
the	O
NH4	O
+	O
concentration	O
.	O

In	O
contrast	O
,	O
DRAG	B-PRGE
appears	O
to	O
be	O
continuously	O
active	O
under	O
conditions	O
favoring	O
nitrogen	O
fixation	O
.	O

Thus	O
,	O
the	O
activities	O
of	O
DRAG	B-PRGE
and	O
DRAT	B-PRGE
are	O
not	O
always	O
coordinately	O
regulated	O
.	O

Finally	O
,	O
our	O
experiments	O
suggest	O
the	O
existence	O
of	O
a	O
temporary	O
period	O
of	O
futile	O
cycling	O
during	O
which	O
DRAT	B-PRGE
and	O
DRAG	B-PRGE
are	O
simultaneously	O
adding	O
and	O
removing	O
ADP	O
-	O
ribose	O
from	O
dinitrogenase	B-PRGE
reductase	I-PRGE
,	O
immediately	O
following	O
the	O
addition	O
of	O
a	O
negative	O
stimulus	O
.	O

The	O
mevalonate	O
pathway	O
:	O
importance	O
in	O
mesangial	O
cell	O
biology	O
and	O
glomerular	O
disease	O
.	O

Products	O
of	O
intracellular	O
mevalonate	O
metabolism	O
are	O
critical	O
for	O
the	O
growth	O
and	O
proliferation	O
of	O
eukaryotic	O
cells	O
.	O

These	O
products	O
include	O
cholesterol	O
and	O
several	O
nonsterol	O
isoprenoids	O
.	O

The	O
isoprenoid	O
farnesyl	O
is	O
a	O
particularly	O
important	O
intermediate	O
in	O
the	O
mevalonate	O
pathway	O
.	O

Farnesyl	O
can	O
be	O
used	O
to	O
synthesize	O
cholesterol	O
and	O
can	O
also	O
bind	O
covalently	O
to	O
several	O
low	O
molecular	O
mass	O
GTP	O
-	O
binding	O
proteins	O
such	O
as	O
p21	B-PRGE
ras	I-PRGE
.	O

Farnesylated	O
p21	B-PRGE
ras	I-PRGE
may	O
be	O
critical	O
for	O
mitogenic	O
signalling	O
stimulated	O
by	O
growth	O
factors	O
such	O
as	O
platelet	O
-	O
derived	O
growth	O
factor	O
.	O

Inhibitors	O
of	O
the	O
enzyme	O
3	B-PRGE
-	I-PRGE
hydroxy	I-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
methylglutaryl	I-PRGE
coenzyme	I-PRGE
A	I-PRGE
reductase	I-PRGE
,	O
such	O
as	O
lovastatin	O
and	O
compactin	O
,	O
block	O
the	O
production	O
of	O
mevalonate	O
and	O
its	O
metabolites	O
.	O

These	O
agents	O
have	O
been	O
shown	O
to	O
inhibit	O
proliferation	O
of	O
many	O
cell	O
types	O
.	O

Recently	O
we	O
demonstrated	O
that	O
lovastatin	O
inhibited	O
proliferation	O
of	O
cultured	O
glomerular	O
mesangial	O
cells	O
.	O

Lovastatin	O
inhibition	O
was	O
overcome	O
by	O
the	O
simultaneous	O
addition	O
of	O
either	O
mevalonate	O
or	O
farnesol	O
,	O
but	O
not	O
by	O
exogenous	O
low	O
density	O
lipoprotein	O
cholesterol	O
.	O

These	O
results	O
suggested	O
that	O
farnesyl	O
is	O
critical	O
for	O
mesangial	O
cell	O
proliferation	O
.	O

In	O
several	O
experimental	O
models	O
of	O
renal	O
disease	O
,	O
chronic	O
lovastatin	O
administration	O
reduced	O
the	O
extent	O
of	O
glomerular	O
injury	O
.	O

The	O
beneficial	O
effects	O
of	O
lovastatin	O
have	O
been	O
attributed	O
to	O
lowering	O
of	O
circulating	O
lipid	O
and	O
lipoprotein	O
levels	O
.	O

In	O
view	O
of	O
recent	O
data	O
,	O
however	O
,	O
it	O
is	O
possible	O
that	O
lovastatin	O
may	O
act	O
to	O
reduce	O
glomerular	O
injury	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
a	O
direct	O
action	O
on	O
mesangial	O
cell	O
proliferation	O
.	O

Use	O
of	O
photoactivatable	O
peptide	O
substrates	O
of	O
Saccharomyces	O
cerevisiae	O
myristoyl	B-PRGE
-	I-PRGE
CoA	I-PRGE
:	I-PRGE
protein	I-PRGE
N	I-PRGE
-	I-PRGE
myristoyltransferase	I-PRGE
(	O
Nmt1p	B-PRGE
)	O
to	O
characterize	O
a	O
myristoyl	O
-	O
CoA	O
-	O
Nmt1p	B-PRGE
-	O
peptide	O
ternary	O
complex	O
and	O
to	O
provide	O
evidence	O
for	O
an	O
ordered	O
reaction	O
mechanism	O
.	O

Nmt1p	B-PRGE
(	O
EC	O
2	O
.	O
3	O
.	O
1	O
.	O
97	O
)	O
catalyzes	O
the	O
transfer	O
of	O
myristate	O
(	O
C14	O
:	O
0	O
)	O
from	O
coenzyme	O
A	O
to	O
the	O
N	O
-	O
terminal	O
glycine	O
residue	O
of	O
a	O
variety	O
of	O
eukaryotic	O
cellular	O
and	O
viral	O
proteins	O
.	O

Our	O
recent	O
studies	O
of	O
the	O
455	O
-	O
amino	O
acid	O
Saccharomyces	O
cerevisiae	O
acyltransferase	O
(	O
Nmt1p	B-PRGE
)	O
suggested	O
that	O
its	O
mechanism	O
of	O
catalysis	O
is	O
ordered	O
Bi	O
Bi	O
with	O
myristoyl	O
-	O
CoA	O
binding	O
occurring	O
prior	O
to	O
binding	O
of	O
peptide	O
and	O
release	O
of	O
CoA	O
occurring	O
prior	O
to	O
release	O
of	O
the	O
myristoyl	O
-	O
peptide	O
.	O

The	O
interaction	O
between	O
enzyme	O
and	O
peptide	O
has	O
now	O
been	O
examined	O
in	O
greater	O
detail	O
by	O
using	O
photoactivatable	O
octapeptide	O
substrates	O
containing	O
125I	O
-	O
labeled	O
azidosalicyclic	O
acid	O
attached	O
via	O
an	O
amide	O
bond	O
to	O
the	O
gamma	O
-	O
amino	O
group	O
of	O
a	O
diaminobutyrate	O
residue	O
located	O
at	O
position	O
2	O
or	O
the	O
epsilon	O
-	O
amino	O
group	O
of	O
a	O
lysine	O
residue	O
located	O
at	O
position	O
8	O
.	O

The	O
photopeptides	O
can	O
be	O
specifically	O
crosslinked	O
to	O
chymotryptic	O
fragments	O
of	O
Nmt1p	B-PRGE
in	O
the	O
presence	O
but	O
not	O
in	O
the	O
absence	O
of	O
a	O
nonhydrolyzable	O
myristoyl	O
-	O
CoA	O
analog	O
,	O
S	O
-	O
(	O
2	O
-	O
oxo	O
)	O
pentadecyl	O
-	O
CoA	O
.	O

Labeling	O
of	O
the	O
chymotryptic	O
fragments	O
is	O
markedly	O
reduced	O
when	O
GLYASKLS	O
,	O
a	O
high	O
-	O
affinity	O
substrate	O
derived	O
from	O
residues	O
2	O
-	O
9	O
of	O
S	O
.	O
cerevisiae	O
ADP	B-PRGE
-	I-PRGE
ribosylation	I-PRGE
factor	I-PRGE
2	I-PRGE
,	O
or	O
ALYASKLS	O
,	O
a	O
competitive	O
inhibitor	O
(	O
for	O
peptide	O
)	O
,	O
is	O
added	O
with	O
the	O
iodinated	O
photopeptide	O
.	O

These	O
findings	O
suggest	O
that	O
peptide	O
affinity	O
for	O
the	O
acyl	O
-	O
CoA	O
-	O
Nmt1p	B-PRGE
binary	O
complex	O
is	O
much	O
greater	O
than	O
it	O
is	O
for	O
apoNmt1p	B-PRGE
,	O
consistent	O
with	O
the	O
ordered	O
Bi	O
Bi	O
mechanism	O
ascribed	O
to	O
Nmt1p	B-PRGE
.	O

Finally	O
,	O
automated	O
sequential	O
Edman	O
degradation	O
of	O
these	O
chymotryptic	O
fragments	O
suggests	O
that	O
the	O
peptide	O
binding	O
domain	O
of	O
Nmt1p	B-PRGE
may	O
be	O
composed	O
of	O
elements	O
from	O
two	O
protease	O
-	O
resistant	O
domains	O
,	O
Arg42	O
-	O
Try219	O
and	O
Thr220	O
-	O
Leu455	O
.	O

Prenyl	O
modification	O
of	O
guanine	B-PRGE
nucleotide	I-PRGE
regulatory	I-PRGE
protein	I-PRGE
gamma	I-PRGE
2	I-PRGE
subunits	O
is	O
not	O
required	O
for	O
interaction	O
with	O
the	O
transducin	O
alpha	O
subunit	O
or	O
rhodopsin	B-PRGE
.	O

Guanine	O
nucleotide	O
-	O
binding	O
regulatory	O
protein	O
(	O
G	O
protein	O
)	O
beta	O
gamma	O
dimers	O
that	O
were	O
active	O
in	O
reconstitution	O
assays	O
were	O
produced	O
in	O
insect	O
cells	O
using	O
the	O
baculovirus	O
/	O
Sf9	O
insect	O
cell	O
expression	O
system	O
.	O

Sf9	O
cells	O
were	O
infected	O
either	O
singly	O
or	O
in	O
combination	O
with	O
recombinant	O
baculoviruses	O
containing	O
a	O
human	O
G	B-PRGE
-	I-PRGE
protein	I-PRGE
beta	I-PRGE
1	I-PRGE
gene	O
or	O
a	O
bovine	O
G	B-PRGE
-	I-PRGE
protein	I-PRGE
gamma	I-PRGE
2	I-PRGE
gene	O
.	O

It	O
was	O
possible	O
to	O
express	O
the	O
beta	B-PRGE
1	I-PRGE
and	O
gamma	B-PRGE
2	I-PRGE
gene	O
products	O
independently	O
of	O
each	O
other	O
in	O
this	O
system	O
,	O
as	O
determined	O
by	O
using	O
immunological	O
and	O
metabolic	O
labeling	O
techniques	O
.	O

Further	O
,	O
the	O
ability	O
of	O
recombinant	O
beta	O
and	O
/	O
or	O
gamma	O
chains	O
to	O
function	O
in	O
defined	O
biochemical	O
assays	O
of	O
beta	O
gamma	O
activity	O
was	O
assessed	O
for	O
membrane	O
extracts	O
and	O
supernatant	O
fractions	O
from	O
infected	O
Sf9	O
cells	O
.	O

Extracts	O
of	O
cells	O
expressing	O
beta	O
or	O
gamma	O
chain	O
alone	O
were	O
inactive	O
in	O
these	O
assays	O
,	O
whereas	O
those	O
from	O
cells	O
coinfected	O
with	O
beta	B-PRGE
1	I-PRGE
and	O
gamma	B-PRGE
2	I-PRGE
did	O
display	O
activity	O
.	O

These	O
assays	O
were	O
used	O
to	O
identify	O
recombinant	O
beta	O
gamma	O
dimer	O
migration	O
during	O
chromatographic	O
purification	O
,	O
and	O
the	O
recombinant	O
dimers	O
were	O
purified	O
to	O
near	O
homogeneity	O
.	O

Both	O
the	O
membrane	O
-	O
associated	O
and	O
soluble	O
beta	O
gamma	O
dimers	O
facilitated	O
rhodopsin	B-PRGE
-	O
catalyzed	O
guanosine	O
5	O
'	O
-	O
[	O
gamma	O
-	O
thio	O
]	O
triphosphate	O
binding	O
to	O
Gt	O
alpha	O
,	O
the	O
GTP	O
-	O
binding	O
subunit	O
of	O
the	O
retinal	O
G	O
protein	O
transducin	O
(	O
K0	O
.	O
5	O
of	O
13	O
+	O
/	O
-	O
2	O
and	O
36	O
+	O
/	O
-	O
5	O
nM	O
,	O
respectively	O
)	O
.	O

Both	O
recombinant	O
beta	O
gamma	O
dimers	O
also	O
facilitated	O
the	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
Gt	O
alpha	O
with	O
equal	O
potency	O
(	O
K0	O
.	O
5	O
of	O
9	O
+	O
/	O
-	O
1	O
and	O
10	O
+	O
/	O
-	O
3	O
nM	O
for	O
membrane	O
and	O
soluble	O
dimers	O
,	O
respectively	O
)	O
.	O

[	O
3H	O
]	O
Mevalonolactone	O
labeling	O
showed	O
that	O
the	O
gamma	O
2	O
subunits	O
of	O
membrane	O
-	O
associated	O
beta	O
gamma	O
dimers	O
incorporated	O
radiolabel	O
,	O
whereas	O
in	O
the	O
soluble	O
form	O
they	O
did	O
not	O
.	O

Thus	O
,	O
prenyl	O
modification	O
of	O
gamma	B-PRGE
2	I-PRGE
directs	O
the	O
membrane	O
association	O
of	O
the	O
beta	B-PRGE
1	I-PRGE
gamma	I-PRGE
2	I-PRGE
dimer	O
and	O
increases	O
its	O
apparent	O
affinity	O
for	O
receptor	O
,	O
but	O
it	O
is	O
not	O
required	O
for	O
the	O
functional	O
interaction	O
(	O
s	O
)	O
of	O
the	O
dimer	O
.	O

The	O
role	O
of	O
G	O
protein	O
methylation	O
in	O
the	O
function	O
of	O
a	O
geranylgeranylated	O
beta	O
gamma	O
isoform	O
.	O

The	O
gamma	O
subunit	O
of	O
heterotrimeric	O
G	O
proteins	O
is	O
isoprenylated	O
and	O
methylated	O
on	O
its	O
carboxyl	O
terminal	O
cysteine	O
residue	O
.	O

While	O
retinal	O
transducin	O
is	O
farnesylated	O
,	O
all	O
other	O
gamma	O
subunits	O
are	O
modified	O
by	O
geranylgeranylation	O
.	O

An	O
immobilized	O
form	O
of	O
pig	O
liver	O
esterase	O
(	O
iPLE	O
)	O
is	O
able	O
to	O
hydrolyze	O
the	O
methyl	O
ester	O
of	O
a	O
geranylgeranylated	O
beta	O
gamma	O
isoform	O
(	O
beta	B-PRGE
1	I-PRGE
gamma	B-PRGE
2	I-PRGE
)	O
.	O

Since	O
methylation	O
is	O
the	O
only	O
reversible	O
reaction	O
in	O
the	O
isoprenylation	O
pathway	O
,	O
it	O
could	O
be	O
a	O
site	O
of	O
regulation	O
of	O
G	O
protein	O
activity	O
.	O

With	O
both	O
the	O
methylated	O
and	O
demethylated	O
beta	B-PRGE
1	I-PRGE
gamma	B-PRGE
2	I-PRGE
now	O
available	O
,	O
the	O
role	O
of	O
methylation	O
for	O
a	O
geranylgeranylated	O
heterotrimeric	O
G	O
protein	O
may	O
be	O
addressed	O
.	O

Here	O
,	O
it	O
is	O
reported	O
that	O
methylation	O
has	O
no	O
effect	O
on	O
the	O
ability	O
of	O
beta	O
gamma	O
to	O
interact	O
with	O
an	O
alpha	O
subunit	O
,	O
as	O
probed	O
by	O
ADP	O
-	O
ribosylation	O
studies	O
with	O
pertussis	O
toxin	O
,	O
and	O
has	O
a	O
small	O
effect	O
(	O
less	O
than	O
2	O
-	O
fold	O
)	O
on	O
the	O
ability	O
of	O
geranylgeranylated	O
beta	O
gamma	O
to	O
activate	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	O
C	O
(	O
PIPLC	O
)	O
and	O
phosphoinositide	O
3	O
kinase	O
(	O
PI3K	O
)	O
.	O

In	O
binding	O
studies	O
,	O
demethylation	O
only	O
slightly	O
decreased	O
the	O
ability	O
of	O
beta	B-PRGE
1	I-PRGE
gamma	B-PRGE
2	I-PRGE
to	O
adhere	O
to	O
azolectin	O
vesicles	O
.	O

Therefore	O
,	O
methylation	O
of	O
heterotrimeric	O
G	O
proteins	O
appears	O
to	O
have	O
only	O
a	O
minor	O
effect	O
in	O
signal	O
transduction	O
processes	O
which	O
can	O
be	O
correlated	O
to	O
a	O
decrease	O
in	O
hydrophobicity	O
of	O
the	O
beta	O
gamma	O
subunit	O
.	O

Purification	O
of	O
a	O
protein	O
palmitoyltransferase	O
that	O
acts	O
on	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
protein	O
and	O
on	O
a	O
C	O
-	O
terminal	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
peptide	O
.	O

Mammalian	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
and	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
are	O
GTP	O
-	O
binding	O
proteins	O
that	O
must	O
be	O
post	O
-	O
translationally	O
lipidated	O
to	O
function	O
as	O
molecular	O
switches	O
in	O
signal	O
transduction	O
cascades	O
controlling	O
cell	O
growth	O
and	O
differentiation	O
.	O

These	O
proteins	O
contain	O
a	O
C	O
-	O
terminal	O
farnesyl	O
-	O
cysteine	O
alpha	O
-	O
methyl	O
ester	O
and	O
palmitoyl	O
groups	O
attached	O
to	O
nearby	O
cysteines	O
.	O

Data	O
is	O
presented	O
showing	O
that	O
rat	O
liver	O
microsomes	O
contain	O
an	O
enzyme	O
that	O
transfers	O
the	O
palmitoyl	O
group	O
from	O
palmitoyl	O
-	O
coenzyme	O
A	O
to	O
cysteine	O
residues	O
of	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
protein	O
and	O
of	O
a	O
synthetic	O
peptide	O
having	O
the	O
structure	O
of	O
the	O
C	O
terminus	O
of	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
.	O

This	O
protein	O
palmitoyltransferase	O
(	O
PPT	O
)	O
was	O
solubilized	O
from	O
membranes	O
and	O
purified	O
10	O
,	O
500	O
-	O
fold	O
to	O
apparent	O
homogeneity	O
with	O
an	O
overall	O
yield	O
of	O
10	O
%	O
.	O

On	O
an	O
SDS	O
gel	O
,	O
PPT	O
appears	O
as	O
two	O
proteins	O
of	O
molecular	O
masses	O
of	O
approximately	O
30	O
and	O
approximately	O
33	O
kDa	O
.	O

If	O
the	O
palmitoylation	O
sites	O
of	O
the	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
peptide	O
(	O
the	O
non	O
-	O
farnesylated	O
cysteine	O
)	O
or	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
protein	O
(	O
cysteines	O
181	O
and	O
184	O
)	O
are	O
changed	O
to	O
serine	O
,	O
palmitoylation	O
by	O
PPT	O
does	O
not	O
occur	O
.	O

Non	O
-	O
farnesylated	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
produced	O
in	O
bacteria	O
as	O
well	O
as	O
in	O
vitro	O
farnesylated	O
bacterial	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
are	O
not	O
substrates	O
for	O
PPT	O
nor	O
is	O
the	O
non	O
-	O
farnesylated	O
,	O
methylated	O
N	B-PRGE
-	I-PRGE
Ras	I-PRGE
peptide	O
.	O

These	O
results	O
suggest	O
,	O
but	O
do	O
not	O
prove	O
,	O
that	O
farnesylation	O
and	O
possibly	O
C	O
-	O
terminal	O
methylation	O
are	O
prerequisites	O
for	O
Ras	O
palmitoylation	O
.	O

PPT	O
shows	O
a	O
large	O
preference	O
for	O
palmitoyl	O
-	O
coenzyme	O
A	O
over	O
myristoyl	O
-	O
coenzyme	O
as	O
the	O
acyl	O
donor	O
.	O

Values	O
of	O
Km	O
for	O
palmitoyl	O
-	O
CoA	O
and	O
H	B-PRGE
-	I-PRGE
Ras	I-PRGE
are	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
and	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
3	O
microM	O
,	O
respectively	O
.	O

PPT	O
is	O
the	O
first	O
protein	O
palmitoyltransferase	O
to	O
be	O
purified	O
,	O
and	O
the	O
availability	O
of	O
pure	O
enzyme	O
should	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
function	O
and	O
regulation	O
of	O
Ras	O
palmitoylation	O
in	O
cells	O
.	O

Prenylated	O
isoforms	O
of	O
yeast	O
casein	O
kinase	O
I	O
,	O
including	O
the	O
novel	O
Yck3p	B-PRGE
,	O
suppress	O
the	O
gcs1	B-PRGE
blockage	O
of	O
cell	O
proliferation	O
from	O
stationary	O
phase	O
.	O

The	O
GCS1	B-PRGE
gene	O
of	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
mediate	O
the	O
resumption	O
of	O
cell	O
proliferation	O
from	O
the	O
starved	O
,	O
stationary	O
-	O
phase	O
state	O
.	O

Here	O
we	O
identify	O
yeast	O
genes	O
that	O
,	O
in	O
increased	O
dosages	O
,	O
overcome	O
the	O
growth	O
defect	O
of	O
gcs1	B-PRGE
delta	O
mutant	O
cells	O
.	O

Among	O
these	O
are	O
YCK1	B-PRGE
(	O
CK12	B-PRGE
)	O
and	O
YCK2	B-PRGE
(	O
CKI1	B-PRGE
)	O
,	O
encoding	O
membrane	O
-	O
associated	O
casein	O
kinase	O
I	O
,	O
and	O
YCK3	B-PRGE
,	O
encoding	O
a	O
novel	O
casein	O
kinase	O
I	O
isoform	O
.	O

Some	O
Yck3p	B-PRGE
gene	O
product	O
was	O
found	O
associated	O
with	O
the	O
plasma	O
membrane	O
,	O
like	O
Yck1p	B-PRGE
and	O
Yck2p	B-PRGE
,	O
but	O
most	O
confractionated	O
with	O
the	O
nucleus	O
,	O
like	O
another	O
yeast	O
casein	O
kinase	O
I	O
isoform	O
,	O
Hrr25p	B-PRGE
.	O

Genetic	O
studies	O
showed	O
that	O
YCK3	B-PRGE
and	O
HRR25	B-PRGE
constitute	O
an	O
essential	O
gene	O
family	O
and	O
that	O
Yck3p	B-PRGE
can	O
weakly	O
substitute	O
for	O
Yck1p	B-PRGE
-	O
Yck2p	B-PRGE
.	O

For	O
gcs1	B-PRGE
delta	O
suppression	O
,	O
both	O
a	O
protein	O
kinase	O
domain	O
and	O
a	O
C	O
-	O
terminal	O
prenylation	O
motif	O
were	O
shown	O
to	O
be	O
necessary	O
.	O

An	O
impairment	O
in	O
endocytosis	O
was	O
found	O
for	O
gcs1	B-PRGE
delta	O
mutant	O
cells	O
,	O
which	O
was	O
alleviated	O
by	O
an	O
increased	O
YCK2	B-PRGE
gene	O
dosage	O
.	O

The	O
ability	O
of	O
an	O
increased	O
casein	O
kinase	O
I	O
gene	O
dosage	O
to	O
suppress	O
the	O
effects	O
caused	O
by	O
the	O
absence	O
of	O
Gcs1p	B-PRGE
suggests	O
that	O
Gcs1p	B-PRGE
and	O
Yck1p	B-PRGE
-	O
Yck2p	B-PRGE
affect	O
parallel	O
pathways	O
.	O

Protection	O
against	O
Fas	B-PRGE
/	O
APO	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
and	O
tumor	O
necrosis	O
factor	O
-	O
mediated	O
cell	O
death	O
by	O
a	O
novel	O
protein	O
,	O
sentrin	B-PRGE
.	O

Fas	B-PRGE
/	O
APO	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
TNF	B-PRGE
receptor	I-PRGE
1	I-PRGE
share	O
a	O
common	O
signaling	O
motif	O
in	O
their	O
cytoplasmic	O
tail	O
called	O
the	O
"	O
death	O
domain	O
.	O
"	O
Using	O
the	O
death	O
domain	O
as	O
bait	O
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
several	O
death	O
domain	O
-	O
containing	O
proteins	O
that	O
participate	O
in	O
cell	O
death	O
signaling	O
have	O
been	O
identified	O
.	O

Here	O
we	O
report	O
the	O
isolation	O
of	O
a	O
novel	O
protein	O
,	O
sentrin	B-PRGE
,	O
which	O
interacts	O
with	O
Fas	B-PRGE
/	O
APO	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
TNF	B-PRGE
receptor	I-PRGE
1	I-PRGE
but	O
not	O
with	O
FADD	B-PRGE
/	O
MORT1	B-PRGE
or	O
CD40	B-PRGE
.	O

Two	O
-	O
hybrid	O
interaction	O
assays	O
reveal	O
that	O
sentrin	B-PRGE
associates	O
only	O
with	O
the	O
signal	O
-	O
competent	O
forms	O
of	O
Fas	B-PRGE
/	O
APO	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
TNF	B-PRGE
receptor	I-PRGE
1	I-PRGE
death	O
domains	O
.	O

Sentrin	B-PRGE
is	O
a	O
novel	O
protein	O
of	O
101	O
amino	O
acids	O
with	O
homology	O
to	O
ubiquitin	B-PRGE
,	O
Nedd8	B-PRGE
,	O
and	O
a	O
Saccharomyces	O
cerevisiae	O
protein	O
,	O
Smt3	B-PRGE
.	O

When	O
overexpressed	O
,	O
sentrin	B-PRGE
provides	O
protection	O
against	O
both	O
anti	O
-	O
Fas	B-PRGE
/	O
APO	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
TNF	O
-	O
induced	O
cell	O
death	O
.	O

Effect	O
of	O
insulin	B-PRGE
on	O
farnesyltransferase	O
activity	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
.	O

Activation	O
of	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
by	O
GTP	O
loading	O
is	O
a	O
critical	O
step	O
in	O
a	O
cascade	O
of	O
intracellular	O
insulin	B-PRGE
signaling	O
.	O

Farnesylation	O
of	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
protein	O
is	O
an	O
obligatory	O
event	O
that	O
facilitates	O
Ras	O
migration	O
to	O
the	O
plasma	O
membrane	O
and	O
subsequent	O
activation	O
.	O

Farnesyltransferase	O
(	O
FTase	O
)	O
is	O
a	O
ubiquitous	O
enzyme	O
that	O
catalyzes	O
the	O
lipid	O
modification	O
of	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
by	O
the	O
addition	O
of	O
farnesyl	O
to	O
the	O
C	O
-	O
terminal	O
"	O
CAAX	O
"	O
motif	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
FTase	O
activities	O
were	O
studied	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
in	O
response	O
to	O
insulin	B-PRGE
challenge	O
.	O

Insulin	B-PRGE
exerted	O
a	O
biphasic	O
stimulatory	O
effect	O
on	O
FTase	O
activity	O
measured	O
in	O
vitro	O
with	O
a	O
31	O
%	O
increase	O
at	O
5	O
min	O
and	O
a	O
130	O
%	O
increase	O
at	O
60	O
min	O
.	O

Insulin	B-PRGE
-	O
stimulated	O
farnesylation	O
of	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
pools	O
in	O
vivo	O
correlated	O
with	O
FTase	O
activity	O
seen	O
in	O
vitro	O
by	O
displaying	O
an	O
increase	O
in	O
farnesylated	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
from	O
40	O
%	O
of	O
total	O
cellular	O
Ras	O
in	O
control	O
cells	O
to	O
63	O
%	O
by	O
5	O
min	O
and	O
80	O
%	O
by	O
60	O
min	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
insulin	B-PRGE
-	O
treated	O
cells	O
.	O

Insulin	B-PRGE
challenge	O
of	O
3T3	O
-	O
L1	O
adipocytes	O
increased	O
incorporation	O
of	O
tritiated	O
mevalonic	O
acid	O
in	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
stimulated	O
a	O
2	O
-	O
fold	O
increase	O
in	O
phosphorylation	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
FTase	O
at	O
5	O
min	O
and	O
a	O
4	O
-	O
fold	O
increase	O
at	O
60	O
min	O
.	O

Caspase	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
Nedd	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
processing	O
and	O
death	O
of	O
trophic	O
factor	O
-	O
deprived	O
PC12	O
cells	O
and	O
sympathetic	O
neurons	O
occur	O
independently	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
CPP32	B-PRGE
)	O
-	O
like	O
activity	O
.	O

We	O
have	O
previously	O
shown	O
that	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
Nedd	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
is	O
required	O
for	O
apoptosis	O
induced	O
by	O
withdrawal	O
of	O
trophic	O
support	O
from	O
PC12	O
cells	O
and	O
sympathetic	O
neurons	O
.	O

Here	O
,	O
we	O
examine	O
the	O
relationship	O
of	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
processing	O
and	O
cell	O
death	O
to	O
induction	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
CPP32	B-PRGE
)	O
-	O
like	O
activity	O
in	O
PC12	O
cells	O
.	O

Caspase	B-PRGE
-	I-PRGE
2	I-PRGE
processing	O
,	O
at	O
a	O
site	O
tentatively	O
identified	O
as	O
D333	O
,	O
led	O
to	O
the	O
formation	O
of	O
an	O
N	O
-	O
terminal	O
37	O
kDa	O
product	O
.	O

This	O
processing	O
correlated	O
temporally	O
with	O
induction	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
activity	O
.	O

Agents	O
previously	O
shown	O
to	O
inhibit	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
activation	O
,	O
such	O
as	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
the	O
Cdk	O
inhibitor	O
flavopiridol	O
,	O
also	O
acted	O
upstream	O
of	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
processing	O
.	O

The	O
general	O
caspase	O
inhibitors	O
BAF	O
and	O
zVAD	O
-	O
FMK	O
inhibited	O
N	O
-	O
terminal	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
processing	O
.	O

In	O
contrast	O
,	O
the	O
more	O
selective	O
caspase	O
inhibitor	O
DEVD	O
-	O
FMK	O
inhibited	O
the	O
induction	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
activity	O
but	O
did	O
not	O
affect	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
processing	O
or	O
significantly	O
suppress	O
death	O
in	O
PC12	O
cells	O
or	O
sympathetic	O
neurons	O
.	O

This	O
indicates	O
that	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
activity	O
is	O
not	O
required	O
for	O
either	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
processing	O
or	O
apoptosis	O
in	O
this	O
paradigm	O
.	O

An	O
antisense	O
oligonucleotide	O
to	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
inhibited	O
cell	O
death	O
but	O
did	O
not	O
affect	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
activity	O
,	O
indicating	O
that	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
not	O
upstream	O
of	O
this	O
activity	O
and	O
that	O
activation	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
caspases	O
is	O
not	O
sufficient	O
for	O
death	O
.	O

Thus	O
,	O
in	O
our	O
paradigm	O
,	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
processing	O
and	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
activity	O
are	O
induced	O
independently	O
of	O
each	O
other	O
.	O

Moreover	O
,	O
although	O
death	O
requires	O
caspase	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
activity	O
is	O
neither	O
necessary	O
nor	O
sufficient	O
for	O
death	O
.	O
